text,label
guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of eatonlambert it is not indicated for treating myasthenia gravis the eatonlambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung but myography may be necessary to make the diagnosis,2
guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of eatonlambert it is not indicated for treating myasthenia gravis the eatonlambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung but myography may be necessary to make the diagnosis,1
parkinsons diseaseropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinsons diseasethe effectiveness of ropinirole hydrochloride tablets were demonstrated in randomized controlled trials in patients with early parkinsons disease who were not receiving concomitant ldopa therapy as well as in patients with advanced disease on concomitant ldopa see clinical pharmacology clinical trials restless legs syndromeropinirole hydrochloride tablets are indicated for the treatment of moderatetosevere primary restless legs syndrome rlskey diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with moderatetosevere rls,3
mirapexr pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinsons disease the effectiveness of mirapex tablets was demonstrated in randomized controlled trials in patients with early parkinsons disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa see clinical studiesmirapex tablets are indicated for the treatment of moderatetosevere primary restless legs syndrome rls key diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with symptoms of rls,3
mirapexr pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinsons disease the effectiveness of mirapex tablets was demonstrated in randomized controlled trials in patients with early parkinsons disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa see clinical studiesmirapex tablets are indicated for the treatment of moderatetosevere primary restless legs syndrome rls key diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with symptoms of rls,3
neupro is a dopamine agonist indicated for the treatment of parkinsons disease 11moderatetosevere primary restless legs syndrome 12neupro is indicated for the treatment of parkinsons diseaseneupro is indicated for the treatment of moderatetosevere primary restless legs syndrome,3
neupro is a dopamine agonist indicated for the treatment of parkinsons disease 11moderatetosevere primary restless legs syndrome 12neupro is indicated for the treatment of parkinsons diseaseneupro is indicated for the treatment of moderatetosevere primary restless legs syndrome,3
ilaris is an interleukin1b blocker indicated for the treatment of periodic fever syndromes cryopyrinassociated periodic syndromes caps familial cold autoinflammatory syndrome fcas 11mucklewells syndrome mws 11 tumor necrosis factor receptor associated periodic syndrome traps 11 hyperimmunoglobulin d syndrome hidsmevalonate kinase deficiency mkd11 familial mediterranean fever fmf11 active systemic juvenile idiopathic arthritis sjia 12 ilarisr cryopyrinassociated periodic syndromes capsilaris is indicated for the treatment of cryopyrinassociated periodic syndromes caps in adults and children 4 years of age and older including familial cold autoinflammatory syndrome fcas mucklewells syndrome mws tumor necrosis factor receptor tnf associated periodic syndrome traps ilaris is indicated for the treatment of tumor necrosis factor tnf receptor associated periodic syndrome traps in adult and pediatric patients hyperimmunoglobulin d syndrome hidsmevalonate kinase deficiency mkd ilaris is indicated for the treatment of hyperimmunoglobulin d hyperigd syndrome hidsmevalonate kinase deficiency mkd in adult and pediatric patients familial mediterranean fever fmf ilaris is indicated for the treatment of familial mediterranean fever fmf in adult and pediatric patientsilaris is indicated for the treatment of active systemic juvenile idiopathic arthritis sjia in patients aged 2 years and older,3
ilaris is an interleukin1b blocker indicated for the treatment of periodic fever syndromes cryopyrinassociated periodic syndromes caps familial cold autoinflammatory syndrome fcas 11mucklewells syndrome mws 11 tumor necrosis factor receptor associated periodic syndrome traps 11 hyperimmunoglobulin d syndrome hidsmevalonate kinase deficiency mkd11 familial mediterranean fever fmf11 active systemic juvenile idiopathic arthritis sjia 12 ilarisr cryopyrinassociated periodic syndromes capsilaris is indicated for the treatment of cryopyrinassociated periodic syndromes caps in adults and children 4 years of age and older including familial cold autoinflammatory syndrome fcas mucklewells syndrome mws tumor necrosis factor receptor tnf associated periodic syndrome traps ilaris is indicated for the treatment of tumor necrosis factor tnf receptor associated periodic syndrome traps in adult and pediatric patients hyperimmunoglobulin d syndrome hidsmevalonate kinase deficiency mkd ilaris is indicated for the treatment of hyperimmunoglobulin d hyperigd syndrome hidsmevalonate kinase deficiency mkd in adult and pediatric patients familial mediterranean fever fmf ilaris is indicated for the treatment of familial mediterranean fever fmf in adult and pediatric patientsilaris is indicated for the treatment of active systemic juvenile idiopathic arthritis sjia in patients aged 2 years and older,3
ropinirole extendedrelease tablets are contraindicated in patients known to have a hypersensitivityallergic reaction including urticaria angioedema rash pruritus to ropinirole or any of the excipientshistory of hypersensitivity allergic reaction including urticaria angioedema rash pruritus to ropinirole or to any of the excipients 4,2
ropinirole extendedrelease tablets are contraindicated in patients known to have a hypersensitivityallergic reaction including urticaria angioedema rash pruritus to ropinirole or any of the excipientshistory of hypersensitivity allergic reaction including urticaria angioedema rash pruritus to ropinirole or to any of the excipients 4,1
ropinirole extendedrelease tablets are contraindicated in patients known to have a hypersensitivityallergic reaction including urticaria angioedema rash pruritus to ropinirole or any of the excipientshistory of hypersensitivity allergic reaction including urticaria angioedema rash pruritus to ropinirole or to any of the excipients 4,3
ropinirole extendedrelease tablets are contraindicated in patients known to have a hypersensitivityallergic reaction including urticaria angioedema rash pruritus to ropinirole or any of the excipientshistory of hypersensitivity allergic reaction including urticaria angioedema rash pruritus to ropinirole or to any of the excipients 4,1
vraylar is contraindicated in patients with history of a hypersensitivity reaction to cariprazine reactions have ranged from rash pruritus urticaria and events suggestive of angioedema eg swollen tongue lip swelling face edema pharyngeal edema and swelling faceknown hypersensitivity to vraylar 4,2
vraylar is contraindicated in patients with history of a hypersensitivity reaction to cariprazine reactions have ranged from rash pruritus urticaria and events suggestive of angioedema eg swollen tongue lip swelling face edema pharyngeal edema and swelling faceknown hypersensitivity to vraylar 4,3
vraylar is contraindicated in patients with history of a hypersensitivity reaction to cariprazine reactions have ranged from rash pruritus urticaria and events suggestive of angioedema eg swollen tongue lip swelling face edema pharyngeal edema and swelling faceknown hypersensitivity to vraylar 4,0
ravicti is contraindicated in patients with known hypersensitivity to phenylbutyrate signs of hypersensitivity include wheezing dyspnea coughing hypotension flushing nausea and rashknown hypersensitivity to phenylbutyrate 4,2
ravicti is contraindicated in patients with known hypersensitivity to phenylbutyrate signs of hypersensitivity include wheezing dyspnea coughing hypotension flushing nausea and rashknown hypersensitivity to phenylbutyrate 4,2
rexulti is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components reactions have included rash facial swelling urticaria and anaphylaxisknown hypersensitivity to rexulti or any of its components 4,3
rexulti is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components reactions have included rash facial swelling urticaria and anaphylaxisknown hypersensitivity to rexulti or any of its components 4,1
pantoprazole sodium delayedrelease tablets are indicated forpantoprazole sodium delayedrelease tablet is a proton pump inhibitor indicated for the following shortterm treatment of erosive esophagitis associated with gastroesophageal reflux disease gerd 11maintenance of healing of erosive esophagitis 12pathological hypersecretory conditions including zollingerellison syndrome 13 pantoprazole sodium delayedrelease tablets are indicated in adults for the shortterm treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for those adult patients who have not healed after 8 weeks of treatment an additional 8week course of pantoprazole sodium delayedrelease tablets may be considered safety of treatment beyond 8 weeks in pediatric patients has not been establishedpediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals incs pantoprazole sodium delayedrelease tablets however due to wyeth pharmaceuticals incs marketing exclusivity rights this drug product is not labeled with that pediatric informationpantoprazole sodium delayedrelease tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd controlled studies did not extend beyond 12 monthspantoprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
pantoprazole sodium delayedrelease tablets are indicated forpantoprazole sodium delayedrelease tablet is a proton pump inhibitor indicated for the following shortterm treatment of erosive esophagitis associated with gastroesophageal reflux disease gerd 11maintenance of healing of erosive esophagitis 12pathological hypersecretory conditions including zollingerellison syndrome 13 pantoprazole sodium delayedrelease tablets are indicated in adults for the shortterm treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for those adult patients who have not healed after 8 weeks of treatment an additional 8week course of pantoprazole sodium delayedrelease tablets may be considered safety of treatment beyond 8 weeks in pediatric patients has not been establishedpediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals incs pantoprazole sodium delayedrelease tablets however due to wyeth pharmaceuticals incs marketing exclusivity rights this drug product is not labeled with that pediatric informationpantoprazole sodium delayedrelease tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd controlled studies did not extend beyond 12 monthspantoprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
pantoprazole sodium delayedrelease tablets are indicated forpantoprazole sodium delayedrelease tablet is a proton pump inhibitor indicated for the following shortterm treatment of erosive esophagitis associated with gastroesophageal reflux disease gerd 11maintenance of healing of erosive esophagitis 12pathological hypersecretory conditions including zollingerellison syndrome 13 pantoprazole sodium delayedrelease tablets are indicated in adults for the shortterm treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for those adult patients who have not healed after 8 weeks of treatment an additional 8week course of pantoprazole sodium delayedrelease tablets may be considered safety of treatment beyond 8 weeks in pediatric patients has not been establishedpediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals incs pantoprazole sodium delayedrelease tablets however due to wyeth pharmaceuticals incs marketing exclusivity rights this drug product is not labeled with that pediatric informationpantoprazole sodium delayedrelease tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd controlled studies did not extend beyond 12 monthspantoprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
esomeprazole magnesium delayedrelease capsule usp is a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 11risk reduction of nsaidassociated gastric ulcer 12 h pylori13 pathological hypersecretory conditions including zollingerellison syndrome 14 healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated for the shortterm treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayedrelease capsules may be considered in infants 1 month to less than 1 year esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment up to 6 weeks of erosive esophagitis due to acidmediated gerd maintenance of healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months symptomatic gastroesophageal reflux disease esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment 4 to 8 weeks of heartburn and other symptoms associated with gerd in adults and children 1 year or older esomeprazole magnesium delayedrelease capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 60 andor documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayedrelease capsules plus amoxicillin and clarithromycin esomeprazole magnesium delayedrelease capsules in combination with amoxicillin and clarithromycin are indicated for the treatment of patients with h pylori h pylorih pyloridosage and administration 2clinical studies 14in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 124esomeprazole magnesium delayedrelease capsule usp is indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
esomeprazole magnesium delayedrelease capsule usp is a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 11risk reduction of nsaidassociated gastric ulcer 12 h pylori13 pathological hypersecretory conditions including zollingerellison syndrome 14 healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated for the shortterm treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayedrelease capsules may be considered in infants 1 month to less than 1 year esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment up to 6 weeks of erosive esophagitis due to acidmediated gerd maintenance of healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months symptomatic gastroesophageal reflux disease esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment 4 to 8 weeks of heartburn and other symptoms associated with gerd in adults and children 1 year or older esomeprazole magnesium delayedrelease capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 60 andor documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayedrelease capsules plus amoxicillin and clarithromycin esomeprazole magnesium delayedrelease capsules in combination with amoxicillin and clarithromycin are indicated for the treatment of patients with h pylori h pylorih pyloridosage and administration 2clinical studies 14in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 124esomeprazole magnesium delayedrelease capsule usp is indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
esomeprazole magnesium delayedrelease capsule usp is a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 11risk reduction of nsaidassociated gastric ulcer 12 h pylori13 pathological hypersecretory conditions including zollingerellison syndrome 14 healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated for the shortterm treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayedrelease capsules may be considered in infants 1 month to less than 1 year esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment up to 6 weeks of erosive esophagitis due to acidmediated gerd maintenance of healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months symptomatic gastroesophageal reflux disease esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment 4 to 8 weeks of heartburn and other symptoms associated with gerd in adults and children 1 year or older esomeprazole magnesium delayedrelease capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 60 andor documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayedrelease capsules plus amoxicillin and clarithromycin esomeprazole magnesium delayedrelease capsules in combination with amoxicillin and clarithromycin are indicated for the treatment of patients with h pylori h pylorih pyloridosage and administration 2clinical studies 14in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 124esomeprazole magnesium delayedrelease capsule usp is indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
ranitidine tablets usp are indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets usp 150 mg twice daily 7treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets usp 150 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeksconcomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
ranitidine tablets usp are indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets usp 150 mg twice daily 7treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets usp 150 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeksconcomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
ranitidine tablets usp are indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets usp 150 mg twice daily 7treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets usp 150 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeksconcomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
ranitidine tablets usp are indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets usp 150 mg twice daily 7treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets usp 150 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeksconcomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
ranitidine tablets usp are indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets usp 150 mg twice daily 7treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets usp 150 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeksconcomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
famotidine is indicated in most adult patients heal within 4 weeks there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks short term treatment of active duodenal ulcercontrolled studies in adults have not extended beyond one year maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcermost adult patients heal within 6 weeks studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks short term treatment of active benign gastric ulcerfamotidine is indicated for short term treatment of patients with symptoms of gerd see famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy see short term treatment of gastroesophageal reflux disease gerdclinical pharmacology in adults clinical studiesclinical pharmacology in adults clinical studiestreatment of pathological hypersecretory conditions eg zollingerellison syndrome multiple endocrine adenomas see clinical pharmacology in adults clinical studies,3
famotidine is indicated in most adult patients heal within 4 weeks there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks short term treatment of active duodenal ulcercontrolled studies in adults have not extended beyond one year maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcermost adult patients heal within 6 weeks studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks short term treatment of active benign gastric ulcerfamotidine is indicated for short term treatment of patients with symptoms of gerd see famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy see short term treatment of gastroesophageal reflux disease gerdclinical pharmacology in adults clinical studiesclinical pharmacology in adults clinical studiestreatment of pathological hypersecretory conditions eg zollingerellison syndrome multiple endocrine adenomas see clinical pharmacology in adults clinical studies,3
famotidine is indicated in most adult patients heal within 4 weeks there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks short term treatment of active duodenal ulcercontrolled studies in adults have not extended beyond one year maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcermost adult patients heal within 6 weeks studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks short term treatment of active benign gastric ulcerfamotidine is indicated for short term treatment of patients with symptoms of gerd see famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy see short term treatment of gastroesophageal reflux disease gerdclinical pharmacology in adults clinical studiesclinical pharmacology in adults clinical studiestreatment of pathological hypersecretory conditions eg zollingerellison syndrome multiple endocrine adenomas see clinical pharmacology in adults clinical studies,3
famotidine is indicated in most adult patients heal within 4 weeks there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks short term treatment of active duodenal ulcercontrolled studies in adults have not extended beyond one year maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcermost adult patients heal within 6 weeks studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks short term treatment of active benign gastric ulcerfamotidine is indicated for short term treatment of patients with symptoms of gerd see famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy see short term treatment of gastroesophageal reflux disease gerdclinical pharmacology in adults clinical studiesclinical pharmacology in adults clinical studiestreatment of pathological hypersecretory conditions eg zollingerellison syndrome multiple endocrine adenomas see clinical pharmacology in adults clinical studies,3
11 healing of erosive or ulcerative gerd in adultsrabeprazole sodium delayedrelease tablets are indicated for shortterm 4 to 8 weeks treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease gerd for those patients who have not healed after 8 weeks of treatment an additional 8week course of rabeprazole sodium delayedrelease tablets may be considered12 maintenance of healing of erosive or ulcerative gerd in adultsrabeprazole sodium delayedrelease tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease gerd maintenance controlled studies do not extend beyond 12 months13 treatment of symptomatic gerd in adultsrabeprazole sodium delayedrelease tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks14 healing of duodenal ulcers in adultsrabeprazole sodium delayedrelease tablets are indicated for shortterm up to four weeks treatment in the healing and symptomatic relief of duodenal ulcers most patients heal within four weeks15 helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence in adultsrabeprazole sodium delayedrelease tablets in combination with amoxicillin and clarithromycin as a three drug regimen are indicated for the treatment of patients with h pylori infection and duodenal ulcer disease active or history within the past 5 years to eradicate h pylori eradication of h pylori has been shown to reduce the risk of duodenal ulcer recurrence see clinical studies 145 and dosage and administration 25in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 122 and the clarithromycin package insert clinical pharmacology 12216 treatment of pathological hypersecretory conditions including zollingerellison syndrome in adultsrabeprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome17 shortterm treatment of symptomatic gerd in adolescent patients 12 years of age and olderrabeprazole sodium delayedrelease tablets are indicated for the treatment of symptomatic gerd in adolescents 12 years of age and above for up to 8 weeks,3
11 healing of erosive or ulcerative gerd in adultsrabeprazole sodium delayedrelease tablets are indicated for shortterm 4 to 8 weeks treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease gerd for those patients who have not healed after 8 weeks of treatment an additional 8week course of rabeprazole sodium delayedrelease tablets may be considered12 maintenance of healing of erosive or ulcerative gerd in adultsrabeprazole sodium delayedrelease tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease gerd maintenance controlled studies do not extend beyond 12 months13 treatment of symptomatic gerd in adultsrabeprazole sodium delayedrelease tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks14 healing of duodenal ulcers in adultsrabeprazole sodium delayedrelease tablets are indicated for shortterm up to four weeks treatment in the healing and symptomatic relief of duodenal ulcers most patients heal within four weeks15 helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence in adultsrabeprazole sodium delayedrelease tablets in combination with amoxicillin and clarithromycin as a three drug regimen are indicated for the treatment of patients with h pylori infection and duodenal ulcer disease active or history within the past 5 years to eradicate h pylori eradication of h pylori has been shown to reduce the risk of duodenal ulcer recurrence see clinical studies 145 and dosage and administration 25in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 122 and the clarithromycin package insert clinical pharmacology 12216 treatment of pathological hypersecretory conditions including zollingerellison syndrome in adultsrabeprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome17 shortterm treatment of symptomatic gerd in adolescent patients 12 years of age and olderrabeprazole sodium delayedrelease tablets are indicated for the treatment of symptomatic gerd in adolescents 12 years of age and above for up to 8 weeks,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,0
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,2
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,0
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditionsprimary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation inpsoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases ofsystemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatmentseasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such asallergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management ofleukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosusto tide the patient over a critical period of the disease inulcerative colitis regional enteritis acute exacerbations of multiple sclerosistuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapytrichinosis with neurologic or myocardial involvement,3
propafenone hydrochloride is contraindicated in the following circumstances heart failurecardiogenic shocksinoatrial atrioventricular and intraventricular disorders of impulse generation or conduction eg sick sinus node syndrome av block in the absence of an artificial pacemakerknown brugada syndromebradycardiamarked hypotensionbronchospastic disorders or severe obstructive pulmonary diseasemarked electrolyte imbalance heart failure 4cardiogenic shock 4sinoatrial atrioventricular and intraventricular disorders of impulse generation or conduction in the absence of pacemaker 4known brugada syndrome 4bradycardia 4marked hypotension 4bronchospastic disorders and severe obstructive pulmonary disease 4marked electrolyte imbalance 4,0
esmolol hydrochloride injection is contraindicated in patients with severe sinus bradycardia may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52heart block greater than first degree second or thirddegree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52sick sinus syndrome may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52decompensated heart failure may worsen heart failure cardiogenic shock may precipitate further cardiovascular collapse and cause cardiac arrest iv administration of cardiodepressant calciumchannel antagonists eg verapamil and esmolol hydrochloride in close proximity ie while cardiac effects from the other are still present fatal cardiac arrests have occurred in patients receiving esmolol hydrochloride and intravenous verapamilpulmonary hypertension may precipitate cardiorespiratory compromisehypersensitivity reactions including anaphylaxis to esmolol or any of the inactive ingredients of the product crosssensitivity between beta blockers is possible severe sinus bradycardia 4heart block greater than first degree 4sick sinus syndrome 4decompensated heart failure 4cardiogenic shock 4coadministration of iv cardiodepressant calciumchannel antagonists eg verapamil in close proximity to esmolol hydrochloride 47pulmonary hypertension 4known hypersensitivity to esmolol 4,1
betoptic s ophthalmic suspension 025 is contraindicated in patients with sinus bradycardiagreater than a first degree atrioventricular blockcardiogenic shockpatients with overt cardiac failurehypersensitivity to any component of this product hypersensitivity to any component of this product 4sinus bradycardia second or third degree atrioventricular block overt cardiac failure and cardiogenic shock 4,3
diltiazem hydrochloride injection is contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker patients with second or thirddegree av block except in the presence of a functioning ventricular pacemaker patients with severe hypotension or cardiogenic shock patients who have demonstrated hypersensitivity to the drug intravenous diltiazem and intravenous betablockers should not be administered together or in close proximity within a few hours patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wpw syndrome or short pr syndrome as with other agents which slow av nodal conduction and do not prolong the refractoriness of the accessory pathway eg verapamil digoxin in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially lifethreatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection as such the initial use of diltiazem hydrochloride injection should be if possible in a setting where monitoring and resuscitation capabilities including dc cardioversiondefibrillation are present see overdosagepatients with ventricular tachycardia administration of other calcium channel blockers to patients with wide complex tachycardia qrs 012 seconds has resulted in hemodynamic deterioration and ventricular fibrillation it is important that an accurate pretreatment diagnosis distinguish wide complex qrs tachycardia of superventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection,0
diltiazem hydrochloride injection is contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker patients with second or thirddegree av block except in the presence of a functioning ventricular pacemaker patients with severe hypotension or cardiogenic shock patients who have demonstrated hypersensitivity to the drug intravenous diltiazem and intravenous betablockers should not be administered together or in close proximity within a few hours patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wpw syndrome or short pr syndrome as with other agents which slow av nodal conduction and do not prolong the refractoriness of the accessory pathway eg verapamil digoxin in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially lifethreatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection as such the initial use of diltiazem hydrochloride injection should be if possible in a setting where monitoring and resuscitation capabilities including dc cardioversiondefibrillation are present see overdosagepatients with ventricular tachycardia administration of other calcium channel blockers to patients with wide complex tachycardia qrs 012 seconds has resulted in hemodynamic deterioration and ventricular fibrillation it is important that an accurate pretreatment diagnosis distinguish wide complex qrs tachycardia of superventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection,3
mexiletine hydrochloride capsules are contraindicated in the presence of cardiogenic shock or preexisting second or thirddegree av block if no pacemaker is present,1
sotalol hydrochloride is contraindicated in patients with sinus bradycardia sick sinus syndrome second and third degree av block unless a functioning pacemaker is present congenital or acquired long qt syndromes cardiogenic shock or decompensated heart failure serum potassium 4 meql bronchial asthma or related bronchospastic conditions hypersensitivity to sotalolfor the treatment of afibafl sotalol hydrochloride is also contraindicated in patients with baseline qt interval 450 ms creatinine clearance 40 mlminfor the treatment of afibafl or ventricular arrhythmias sinus bradycardia 2 ndrd4 congenital or acquired long qt syndrome 4 serum potassium 4 meql 4 cardiogenic shock decompensated heart failure 4 bronchial asthma or related bronchospastic conditions 4 hypersensitivity to sotalol 4for the treatment of afibafl also contraindicated for qt interval 450 ms 4 creatine clearance 40 mlmin 4,3
bisoprolol fumarate tablets are contraindicated in patients with cardiogenic shock overt cardiac failure second or third degree av block and marked sinus bradycardia,1
verapamil hydrochloride injection is contraindicated in1 severe hypotension or cardiogenic shock2 second or thirddegree av block except in patients with a functioning artificial ventricular pacemaker3 sick sinus syndrome except in patients with a functioning artificial ventricular pacemaker4 severe congestive heart failure unless secondary to a supraventricular tachycardia amenable to verapamil therapy5 patients receiving intravenous betaadrenergic blocking drugs eg propranolol intravenous verapamil and intravenous betaadrenergic blocking drugs should not be administered in close proximity to each other within a few hours since both may have a depressant effect on myocardial contractility and av conduction6 patients with atrial flutter or atrial fibrillation and an accessory bypass tract eg wolff parkinsonwhite lownganonglevine syndromes are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered therefore the use of verapamil in these patients is contraindicated7 ventricular tachycardia administration of intravenous verapamil to patients with widecomplex ventricular tachycardia qrs 012 sec can result in marked hemodynamic deterioration and ventricular fibrillation proper pretherapy diagnosis and differentiation from widecomplex supraventricular tachycardia is imperative in the emergency room setting8 known hypersensitivity to verapamil hydrochloride,1
verapamil hydrochloride injection is contraindicated in1 severe hypotension or cardiogenic shock2 second or thirddegree av block except in patients with a functioning artificial ventricular pacemaker3 sick sinus syndrome except in patients with a functioning artificial ventricular pacemaker4 severe congestive heart failure unless secondary to a supraventricular tachycardia amenable to verapamil therapy5 patients receiving intravenous betaadrenergic blocking drugs eg propranolol intravenous verapamil and intravenous betaadrenergic blocking drugs should not be administered in close proximity to each other within a few hours since both may have a depressant effect on myocardial contractility and av conduction6 patients with atrial flutter or atrial fibrillation and an accessory bypass tract eg wolff parkinsonwhite lownganonglevine syndromes are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered therefore the use of verapamil in these patients is contraindicated7 ventricular tachycardia administration of intravenous verapamil to patients with widecomplex ventricular tachycardia qrs 012 sec can result in marked hemodynamic deterioration and ventricular fibrillation proper pretherapy diagnosis and differentiation from widecomplex supraventricular tachycardia is imperative in the emergency room setting8 known hypersensitivity to verapamil hydrochloride,1
quinidine is contraindicated in patients who are known to be allergic to it or who have a history of immune thrombocytopenia or have developed thrombocytopenic purpura during prior therapy with quinidine or quinine see warningsin the absence of a functioning artificial pacemaker quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker including patients in complete atrioventricular blockquinidine is also contraindicated in patients who like those with myasthenia gravis might be adversely affected by an anticholinergic agent,1
flecainide acetate tablets usp are contraindicated in patients with preexisting second or thirddegree av block or with right bundle branch block when associated with a left hemiblock bifascicular block unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur flecainide acetate tablets usp are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug,1
gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failurea history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugshad a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4history of mobitz type ii 2ndrd4baseline qtc interval 500 msec 4cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4hypersensitivity to fingolimod or its excipients 4,1
mayzent is contraindicated in patients who have a cyp2c933 genotype see use in specific populations 86 and clinical pharmacology 125in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iii or iv heart failurepresence of mobitz type ii seconddegree thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 53 patients with a cyp2c933 genotype 4in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure 4presence of mobitz type ii seconddegree thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker 4,0
carmustine for injection usp is indicated as palliative therapy as a single agent or in established combination therapy in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors multiple myeloma in combination with prednisone relapsed or refractory hodgkins lymphoma in combination with other approved drugs relapsed or refractory nonhodgkins lymphomas in combination with other approved drugscarmustine for injection usp is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors 1 multiple myelomain combination with prednisone 1relapsed or refractory hodgkins lymphoma in combination with other approved drugs 1relapsed or refractory nonhodgkins lymphomas in combination with other approved drugs 1,3
carmustine for injection usp is indicated as palliative therapy as a single agent or in established combination therapy in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors multiple myeloma in combination with prednisone relapsed or refractory hodgkins lymphoma in combination with other approved drugs relapsed or refractory nonhodgkins lymphomas in combination with other approved drugscarmustine for injection usp is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors 1 multiple myelomain combination with prednisone 1relapsed or refractory hodgkins lymphoma in combination with other approved drugs 1relapsed or refractory nonhodgkins lymphomas in combination with other approved drugs 1,3
carmustine for injection usp is indicated as palliative therapy as a single agent or in established combination therapy in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors multiple myeloma in combination with prednisone relapsed or refractory hodgkins lymphoma in combination with other approved drugs relapsed or refractory nonhodgkins lymphomas in combination with other approved drugscarmustine for injection usp is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors 1 multiple myelomain combination with prednisone 1relapsed or refractory hodgkins lymphoma in combination with other approved drugs 1relapsed or refractory nonhodgkins lymphomas in combination with other approved drugs 1,3
bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous tcell lymphoma in patients who are refractory to at least one prior systemic therapy bexarotene capsules are a retinoid indicated for the treatment of cutaneous manifestations of cutaneous tcell lymphoma in patients who are refractory to at least one prior systemic therapy 1,2
this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautionsallopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis andor nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mgday in male patients and 750 mgday in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks,3
this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautionsallopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis andor nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mgday in male patients and 750 mgday in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks,3
this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautionsallopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis andor nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mgday in male patients and 750 mgday in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks,3
revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 11mm as maintenance following autologous hematopoietic stem cell transplantation autohsct 11transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 12mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 13 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 14revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mmrevlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation autohsctrevlimid is indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalitiesrevlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomibrevlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 55,3
revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 11mm as maintenance following autologous hematopoietic stem cell transplantation autohsct 11transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 12mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 13 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 14revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mmrevlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation autohsctrevlimid is indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalitiesrevlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomibrevlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 55,1
revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 11mm as maintenance following autologous hematopoietic stem cell transplantation autohsct 11transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 12mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 13 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 14revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mmrevlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation autohsctrevlimid is indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalitiesrevlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomibrevlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 55,1
revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 11mm as maintenance following autologous hematopoietic stem cell transplantation autohsct 11transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 12mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 13 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 14revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mmrevlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation autohsctrevlimid is indicated for the treatment of patients with transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalitiesrevlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomibrevlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 55,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases11 minimal change nephrotic syndrome in pediatric patients12 limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been establishedcyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkins disease lymphocytic lymphoma nodular or diffuse mixedcell type lymphoma histiocytic lymphoma burkitts lymphomamultiple myelomaleukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stemcell leukemia cyclophosphamide for injection given during remission is effective in prolonging its durationmycosis fungoides advanced diseaseneuroblastoma disseminated diseaseadenocarcinoma of the ovaryretinoblastomacarcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugscyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of usethe safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established,3
arranon is indicated for the treatment of patients with tcell acute lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens this use is based on the induction of complete responses randomized trials demonstrating increased survival or other clinical benefit have not been conductedarranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with tcell acute lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens this use is based on the induction of complete responses randomized trials demonstrating increased survival or other clinical benefit have not been conducted 1,3
arranon is indicated for the treatment of patients with tcell acute lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens this use is based on the induction of complete responses randomized trials demonstrating increased survival or other clinical benefit have not been conductedarranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with tcell acute lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens this use is based on the induction of complete responses randomized trials demonstrating increased survival or other clinical benefit have not been conducted 1,3
arranon is indicated for the treatment of patients with tcell acute lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens this use is based on the induction of complete responses randomized trials demonstrating increased survival or other clinical benefit have not been conductedarranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with tcell acute lymphoblastic leukemia and tcell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens this use is based on the induction of complete responses randomized trials demonstrating increased survival or other clinical benefit have not been conducted 1,3
zolinza rzolinza is a histone deacetylase hdac inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous tcell lymphoma ctcl who have progressive persistent or recurrent disease on or following two systemic therapies 1,3
mozobilr mozobil a hematopoietic stem cell mobilizer is indicated in combination with granulocytecolony stimulating factor gcsf to mobilize hematopoietic stem cells hscs to the peripheral blood for collection and subsequent autologous transplantation in patients with nonhodgkins lymphoma and multiple myeloma 1,3
mozobilr mozobil a hematopoietic stem cell mobilizer is indicated in combination with granulocytecolony stimulating factor gcsf to mobilize hematopoietic stem cells hscs to the peripheral blood for collection and subsequent autologous transplantation in patients with nonhodgkins lymphoma and multiple myeloma 1,3
mozobilr mozobil a hematopoietic stem cell mobilizer is indicated in combination with granulocytecolony stimulating factor gcsf to mobilize hematopoietic stem cells hscs to the peripheral blood for collection and subsequent autologous transplantation in patients with nonhodgkins lymphoma and multiple myeloma 1,3
folotyn is indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl this indication is based on overall response rate clinical benefit such as improvement in progressionfree survival or overall survival has not been demonstrated folotyn is a folate analog metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl this indication is based on overall response rate clinical benefit such as improvement in progressionfree survival or overall survival has not been demonstrated 1,3
imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 11chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll 12chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion 13waldenstroms macroglobulinemia wm 14marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy 15chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 16imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyaccelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 141imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sllimbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletionimbruvica is indicated for the treatment of adult patients with waldenstroms macroglobulinemia wmimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapyaccelerated approval was granted for this indication based on overall response rate see clinical studies 144imbruvica is indicated for the treatment of adult patients with chronic graftversushost disease cgvhd after failure of one or more lines of systemic therapy,3
imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 11chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll 12chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion 13waldenstroms macroglobulinemia wm 14marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy 15chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 16imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyaccelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 141imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sllimbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletionimbruvica is indicated for the treatment of adult patients with waldenstroms macroglobulinemia wmimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapyaccelerated approval was granted for this indication based on overall response rate see clinical studies 144imbruvica is indicated for the treatment of adult patients with chronic graftversushost disease cgvhd after failure of one or more lines of systemic therapy,3
imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 11chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll 12chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion 13waldenstroms macroglobulinemia wm 14marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy 15chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 16imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyaccelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 141imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sllimbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletionimbruvica is indicated for the treatment of adult patients with waldenstroms macroglobulinemia wmimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapyaccelerated approval was granted for this indication based on overall response rate see clinical studies 144imbruvica is indicated for the treatment of adult patients with chronic graftversushost disease cgvhd after failure of one or more lines of systemic therapy,3
imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 11chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll 12chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion 13waldenstroms macroglobulinemia wm 14marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy 15chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 16imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapyaccelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 141imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sllimbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletionimbruvica is indicated for the treatment of adult patients with waldenstroms macroglobulinemia wmimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapyaccelerated approval was granted for this indication based on overall response rate see clinical studies 144imbruvica is indicated for the treatment of adult patients with chronic graftversushost disease cgvhd after failure of one or more lines of systemic therapy,3
alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc as detected by an fdaapproved testalecensa is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc as detected by an fdaapproved test 1,3
alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc as detected by an fdaapproved testalecensa is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alkpositive metastatic nonsmall cell lung cancer nsclc as detected by an fdaapproved test 1,3
glaucoma obstructive uropathy for example bladder neck obstruction due to prostatic hypertrophy obstructive disease of the gastrointestinal tract as in achalasia pyloroduodenal stenosis paralytic ileus intestinal atony of elderly or debilitated patients unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravis and myocardial ischemia,2
glaucoma obstructive uropathy for example bladder neck obstruction due to prostatic hypertrophy obstructive disease of the gastrointestinal tract as in achalasia pyloroduodenal stenosis paralytic ileus intestinal atony of elderly or debilitated patients unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravis and myocardial ischemia,3
loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipientsloperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhealoperamide hydrochloride is not recommended in infants below 24 months of ageloperamide hydrochloride should not be used as the primary therapy in patients with acute dysentery which is characterized by blood in stools and high fever in patients with acute ulcerative colitis in patients with bacterial enterocolitis caused by invasive organisms including salmonella shigella and campylobacter in patients with pseudomembranous colitis associated with the use of broadspectrum antibiotics,1
loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipientsloperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhealoperamide hydrochloride is not recommended in infants below 24 months of ageloperamide hydrochloride should not be used as the primary therapy in patients with acute dysentery which is characterized by blood in stools and high fever in patients with acute ulcerative colitis in patients with bacterial enterocolitis caused by invasive organisms including salmonella shigella and campylobacter in patients with pseudomembranous colitis associated with the use of broadspectrum antibiotics,1
do not initiate in patients with constipation 41history of chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment 42concomitant use of fluvoxamine 43 alosetron hydrochloride should not be initiatedsee warnings and precautions 51 alosetron hydrochloride is contraindicated in patients with a history of the following chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated fluvoxamine a known strong inhibitor of cyp1a2 has been shown to increase mean alosetron plasma concentrations auc approximately 6fold and prolong the halflife by approximately 3fold see drug interactions 71,2
cuvposa is contraindicated in patients with medical conditions that preclude anticholinergic therapy eg glaucoma paralytic ileus unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravis patients taking solid oral dosage forms of potassium chloride the passage of potassium chloride tablets through the gastrointestinal gi tract may be arrested or delayed with coadministration of cuvposa medical conditions that preclude anticholinergic therapy 4 concomitant use of solid oral dosage forms of potassium chloride 4,0
cuvposa is contraindicated in patients with medical conditions that preclude anticholinergic therapy eg glaucoma paralytic ileus unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravis patients taking solid oral dosage forms of potassium chloride the passage of potassium chloride tablets through the gastrointestinal gi tract may be arrested or delayed with coadministration of cuvposa medical conditions that preclude anticholinergic therapy 4 concomitant use of solid oral dosage forms of potassium chloride 4,1
history of hypersensitivity to clindamycin or other lincosamides 41 history of regional enteritis ulcerative colitis or a history of c difficile4251 do not administer clindesse to individuals with a history of hypersensitivity to clindamycin or other lincosamides reported reactions to other formulations of clindamycin include rashes urticaria erythema multiforme and anaphylactoid reactions see adverse reactions 62do not administer clindesse to patients with regional enteritis ulcerative colitis or a history of clostridium difficile,2
glaucoma obstructive uropathy eg bladder neck obstruction due to prostatic hypertrophy obstructive disease of the gastrointestinal tract eg pyloroduodenal stenosis paralytic ileus intestinal atony of the elderly or debilitated patient unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravismethscopolamine bromide 25 mg tabletsmethscopolamine bromide 5 mg tablets are contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs,0
glaucoma obstructive uropathy eg bladder neck obstruction due to prostatic hypertrophy obstructive disease of the gastrointestinal tract eg pyloroduodenal stenosis paralytic ileus intestinal atony of the elderly or debilitated patient unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravismethscopolamine bromide 25 mg tabletsmethscopolamine bromide 5 mg tablets are contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs,2
propafenone hydrochloride is indicated to prolong the time to recurrence of paroxysmal atrial fibrillationflutter paf associated with disabling symptoms in patients without structural heart diseaseprolong the time to recurrence of paroxysmal supraventricular tachycardia psvt associated with disabling symptoms in patients without structural heart diseasetreat documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are lifethreatening initiate treatment in the hospital usage considerations the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation af or in patients exclusively with atrial flutter or psvt has not been evaluated do not use propafenone hydrochloride tablets to control ventricular rate during afsome patients with atrial flutter treated with propafenone have developed 11 conduction producing an increase in ventricular rate concomitant treatment with drugs that increase the functional atrioventricular av nodal refractory period is recommendedthe use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluatedbecause of the proarrhythmic effects of propafenone hydrochloride its use with lesser ventricular arrhythmias is not recommended even if patients are symptomatic and any use of the drug should be reserved for patients in whom in the opinion of the physician the potential benefits outweigh the risksthe effect of propafenone on mortality has not been determined see boxed warningpropafenone hydrochloride is an antiarrhythmic indicated to prolong the time to recurrence of symptomatic atrial fibrillation af in patients with episodic most likely paroxysmal or persistent af who do not have structural heart disease 1prolong the time to recurrence of paroxysmal supraventricular tachycardia psvt associated with disabling symptoms in patients who do not have structural heart disease 1treat documented lifethreatening ventricular arrhythmias 1 usage considerations use in patients with permanent atrial fibrillation or with atrial flutter or psvt has not been evaluated do not use to control ventricular rate during atrial fibrillation 1in patients with atrial fibrillation and atrial flutter use propafenone hydrochloride with drugs that increase the atrioventricular nodal refractory period 1because of proarrhythmic effects use with lesser ventricular arrhythmias is not recommended even if patients are symptomatic 1the effect of propafenone on mortality has not been determined 1,1
11 supraventricular tachycardia or noncompensatory sinus tachycardiaesmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where in the physicians judgment the rapid heart rate requires specific intervention esmolol hydrochloride injection is intended for shortterm use 12 intraoperative and postoperative tachycardia and hypertensionesmolol hydrochloride injection is indicated for the shortterm treatment of tachycardia and hypertension that occur during induction and tracheal intubation during surgery on emergence from anesthesia and in the postoperative period when in the physicians judgment such specific intervention is considered indicatedesmolol hydrochloride injection is a beta adrenergic blocker indicated for the shortterm treatment of control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia 11control of perioperative tachycardia and hypertension 12,2
11 supraventricular tachycardia or noncompensatory sinus tachycardiaesmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where in the physicians judgment the rapid heart rate requires specific intervention esmolol hydrochloride injection is intended for shortterm use 12 intraoperative and postoperative tachycardia and hypertensionesmolol hydrochloride injection is indicated for the shortterm treatment of tachycardia and hypertension that occur during induction and tracheal intubation during surgery on emergence from anesthesia and in the postoperative period when in the physicians judgment such specific intervention is considered indicatedesmolol hydrochloride injection is a beta adrenergic blocker indicated for the shortterm treatment of control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia 11control of perioperative tachycardia and hypertension 12,3
in patients without structural heart disease flecainide is indicated for the prevention of paroxysmal supraventricular tachycardias psvt including atrioventricular nodal reentrant tachycardia atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms paroxysmal atrial fibrillationflutter paf associated with disabling symptoms flecainide is also indicated for the prevention of documented ventricular arrhythmias such as sustainedsustaineduse of flecainide for the treatment of sustained vt like other antiarrhythmics should be initiated in the hospital the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic because of the proarrhythmic effects of flecainide its use should be reserved for patients in whom in the opinion of the physician the benefits of treatment outweigh the risks flecainide should not be used in patients with recent myocardial infarction see boxed warningsuse of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended see boxed warningsas is the case for other antiarrhythmic agents there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death,2
in patients without structural heart disease flecainide is indicated for the prevention of paroxysmal supraventricular tachycardias psvt including atrioventricular nodal reentrant tachycardia atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms paroxysmal atrial fibrillationflutter paf associated with disabling symptoms flecainide is also indicated for the prevention of documented ventricular arrhythmias such as sustainedsustaineduse of flecainide for the treatment of sustained vt like other antiarrhythmics should be initiated in the hospital the use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic because of the proarrhythmic effects of flecainide its use should be reserved for patients in whom in the opinion of the physician the benefits of treatment outweigh the risks flecainide should not be used in patients with recent myocardial infarction see boxed warningsuse of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended see boxed warningsas is the case for other antiarrhythmic agents there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death,1
maintenance of normal sinus rhythm delay in afafl recurrence dofetilide capsules are indicated for the maintenance of normal sinus rhythm delay in time to recurrence of atrial fibrillationatrial flutter afafl in patients with atrial fibrillationatrial flutter of greater than one week duration who have been converted to normal sinus rhythm because dofetilide can cause life threatening ventricular arrhythmias it should be reserved for patients in whom atrial fibrillationatrial flutter is highly symptomatic in general antiarrhythmic therapy for atrial fibrillationatrial flutter aims to prolong the time in normal sinus rhythm recurrence is expected in some patients see clinical studies conversion of atrial fibrillationflutter dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation,3
ibutilide fumarate injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm patients with atrial arrhythmias of longer duration are less likely to respond to ibutilide fumarate injection the effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration,3
in adults digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation 1 in pediatric patients with heart failure digoxin increases myocardial contractilitydigoxin oral solution usp is indicated for the treatment of mild to moderate heart failure digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failurerelated hospitalizations and emergency care while having no effect on mortality where possible digoxin should be used with a diuretic and an angiotensinconverting enzyme inhibitor but an optimal order for starting these three drugs cannot be specifieddigoxin increases myocardial contractility in pediatric patients with heart failuredigoxin oral solution usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation digoxin should not be used for the treatment of multifocal atrial tachycardia,3
prophylaxis and treatment of venous thrombosis and its extension pulmonary embolism peprophylaxis and treatment of thromboembolic complications associated with atrial fibrillation af andor cardiac valve replacementreduction in the risk of death recurrent myocardial infarction mi and thromboembolic events such as stroke or systemic embolization after myocardial infarction limitations of use warfarin sodium tablets usp have no direct effect on an established thrombus nor does it reverse ischemic tissue damage once a thrombus has occurred however the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae warfarin sodium is indicated for prophylaxis and treatment of venous thrombosis and its extension pulmonary embolism 1 prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation andor cardiac valve replacement 1 reduction in the risk of death recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction 1 limitation of use warfarin sodium tablets usp has no direct effect on an established thrombus nor does it reverse ischemic tissue damage 1,3
prophylaxis and treatment of venous thrombosis and its extension pulmonary embolism peprophylaxis and treatment of thromboembolic complications associated with atrial fibrillation af andor cardiac valve replacementreduction in the risk of death recurrent myocardial infarction mi and thromboembolic events such as stroke or systemic embolization after myocardial infarction limitations of use warfarin sodium tablets usp have no direct effect on an established thrombus nor does it reverse ischemic tissue damage once a thrombus has occurred however the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae warfarin sodium is indicated for prophylaxis and treatment of venous thrombosis and its extension pulmonary embolism 1 prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation andor cardiac valve replacement 1 reduction in the risk of death recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction 1 limitation of use warfarin sodium tablets usp has no direct effect on an established thrombus nor does it reverse ischemic tissue damage 1,0
multaq is contraindicated in patients with permanent atrial fibrillation patients in whom normal sinus rhythm will not or cannot be restored see boxed warningwarnings and precautions 52symptomatic heart failure with recent decompensation requiring hospitalization or nyha class iv symptoms see boxed warningwarnings and precautions 51second or thirddegree atrioventricular av block or sick sinus syndrome except when used in conjunction with a functioning pacemakerbradycardia 50 bpm concomitant use of strong cyp3a inhibitors such as ketoconazole itraconazole voriconazole cyclosporine telithromycin clarithromycin nefazodone and ritonavir see drug interactions 72concomitant use of drugs or herbal products that prolong the qt interval and might increase the risk of torsade de pointes such as phenothiazine antipsychotics tricyclic antidepressants certain oral macrolide antibiotics and class i and iii antiarrhythmics liver or lung toxicity related to the previous use of amiodaroneqtc bazett interval 500 ms or pr interval 280 mssevere hepatic impairmentpregnancy category x multaq may cause fetal harm when administered to a pregnant woman multaq is contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to a fetus see use in specific populations 81nursing mothers see use in specific populations 83hypersensitivity to the active substance or to any of the excipients permanent af patients in whom normal sinus rhythm will not or cannot be restored boxed warning4recently decompensated heart failure requiring hospitalization or class iv heart failure boxed warning4second or thirddegree atrioventricular av block or sick sinus syndrome except when used in conjunction with a functioning pacemaker 4bradycardia 50 bpm 4concomitant use of a strong cyp3a inhibitor 4concomitant use of drugs or herbal products that prolong the qt interval and may induce torsade de pointes 4liver or lung toxicity related to the previous use of amiodarone 4severe hepatic impairment 4qtc bazett interval 500 ms 4pregnancy 481483hypersensitivity to the active substance or to any of the excipients 4,1
multaqrsee clinical studies 14multaq is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation af in patients in sinus rhythm with a history of paroxysmal or persistent af 114,3
eliquis is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 11for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients who have undergone hip or knee replacement surgery 12for the treatment of dvt and pe and for the reduction in the risk of recurrent dvt and pe following initial therapy 131415eliquis reliquis is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients who have undergone hip or knee replacement surgery eliquis is indicated for the treatment of dvteliquis is indicated for the treatment of pe eliquis is indicated to reduce the risk of recurrent dvt and pe following initial therapy,3
eliquis is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 11for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients who have undergone hip or knee replacement surgery 12for the treatment of dvt and pe and for the reduction in the risk of recurrent dvt and pe following initial therapy 131415eliquis reliquis is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients who have undergone hip or knee replacement surgery eliquis is indicated for the treatment of dvteliquis is indicated for the treatment of pe eliquis is indicated to reduce the risk of recurrent dvt and pe following initial therapy,0
savaysa is a factor xa inhibitor indicatedto reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf 11 limitation of use for nvafsavaysa should not be used in patients with creatinine clearance crcl 95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg 11savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 10 days of initial therapy with a parenteral anticoagulant 12savaysa is indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf limitation of use for nvafsavaysa should not be used in patients with crcl 95 mlmin because of an increased risk of ischemic stroke compared to warfarin seedosage and administration 21 warnings and precautions 51 clinical studies 141savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 10 days of initial therapy with a parenteral anticoagulant,3
savaysa is a factor xa inhibitor indicatedto reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf 11 limitation of use for nvafsavaysa should not be used in patients with creatinine clearance crcl 95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg 11savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 10 days of initial therapy with a parenteral anticoagulant 12savaysa is indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf limitation of use for nvafsavaysa should not be used in patients with crcl 95 mlmin because of an increased risk of ischemic stroke compared to warfarin seedosage and administration 21 warnings and precautions 51 clinical studies 141savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 10 days of initial therapy with a parenteral anticoagulant,3
savaysa is a factor xa inhibitor indicatedto reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf 11 limitation of use for nvafsavaysa should not be used in patients with creatinine clearance crcl 95 mlmin because of increased risk of ischemic stroke compared to warfarin at the highest dose studied 60 mg 11savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 10 days of initial therapy with a parenteral anticoagulant 12savaysa is indicated to reduce the risk of stroke and systemic embolism se in patients with nonvalvular atrial fibrillation nvaf limitation of use for nvafsavaysa should not be used in patients with crcl 95 mlmin because of an increased risk of ischemic stroke compared to warfarin seedosage and administration 21 warnings and precautions 51 clinical studies 141savaysa is indicated for the treatment of deep vein thrombosis dvt and pulmonary embolism pe following 5 to 10 days of initial therapy with a parenteral anticoagulant,3
fenoglide is contraindicated in patients with severe renal dysfunction including those receiving dialysis see clinical pharmacology 123fenoglide is contraindicated in patients with active liver disease including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities see warnings and precautions 51fenoglide is contraindicated in patients with gallbladder disease see warnings and precautions 52fenoglide is contraindicated in nursing mothers see use in specific populations 83fenoglide is contraindicated in patients who have a known hypersensitivity to fenofibrate such as severe skin rashes including stevensjohnson syndrome and toxic epidermal necrolysis see warnings and precautions 59 severe renal dysfunction including patients receiving dialysis 4123active liver disease 451gallbladder disease 452nursing mothers 483,1
fenoglide is contraindicated in patients with severe renal dysfunction including those receiving dialysis see clinical pharmacology 123fenoglide is contraindicated in patients with active liver disease including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities see warnings and precautions 51fenoglide is contraindicated in patients with gallbladder disease see warnings and precautions 52fenoglide is contraindicated in nursing mothers see use in specific populations 83fenoglide is contraindicated in patients who have a known hypersensitivity to fenofibrate such as severe skin rashes including stevensjohnson syndrome and toxic epidermal necrolysis see warnings and precautions 59 severe renal dysfunction including patients receiving dialysis 4123active liver disease 451gallbladder disease 452nursing mothers 483,1
isoproterenol hydrochloride injection is indicated for mild or transient episodes of heart block that do not require electric shock or pacemaker therapyfor serious episodes of heart block and adamsstokes attacks except when caused by ventricular tachycardia or fibrillation see contraindicationsfor use in cardiac arrest until electric shock or pacemaker therapy the treatments of choice is available see contraindicationsfor bronchospasm occurring during anesthesiaas an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock low cardiac output hypoperfusion states congestive heart failure and cardiogenic shock see warnings,3
potassium citrate extendedrelease tablets are contraindicated in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloride in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medication in patients with peptic ulcer disease because of its ulcerogenic potential in patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of potassium citrate extended release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate moreover the rise in urinary ph resulting from potassium citrate therapy might promote further bacterial growth in patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4 patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4 patients with peptic ulcer disease 4 patients with active urinary tract infection 4 patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4,1
potassium citrate extendedrelease tablets are contraindicated in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloride in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medication in patients with peptic ulcer disease because of its ulcerogenic potential in patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of potassium citrate extended release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate moreover the rise in urinary ph resulting from potassium citrate therapy might promote further bacterial growth in patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4 patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4 patients with peptic ulcer disease 4 patients with active urinary tract infection 4 patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4,1
endometrin is contraindicated in individuals with any of the following conditions previous allergic reactions to progesterone or any of the ingredients of endometrin see description 11see description 11 undiagnosed vaginal bleeding undiagnosed vaginal bleeding known missed abortion or ectopic pregnancyknown missed abortion or ectopic pregnancy liver diseaseliver disease known or suspected malignancy of the breast or genital organsknown or suspected malignancy of the breast or genital organs active arterial or venous thromboembolism or severe thrombophlebitis or a history of these eventsactive arterial or venous thromboembolism or severe thrombophlebitis or a history of these events previous allergic reactions to progesterone or any of the ingredients of endometrin vaginal insert 4undiagnosed vaginal bleeding 4known missed abortion or ectopic pregnancy 4liver disease 4known or suspected malignancy of the breast or genital organs 4active arterial or venous thromboembolism or severe thrombophlebitis or a history of these events 4,1
the use of liletta is contraindicated when one or more of the following conditions exist pregnancy or suspected pregnancyfor use as postcoital contraception emergency contraceptioncongenital or acquired uterine anomaly including fibroids that distorts the uterine cavity and would be incompatible with correct ius placementacute pelvic inflammatory disease pid or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy infected abortion in the past 3 monthsknown or suspected uterine or cervical neoplasia known or suspected breast cancer or other hormonesensitive cancer now or in the past uterine bleeding of unknown etiologyuntreated acute cervicitis or vaginitis including bacterial vaginosis known chlamydial or gonococcal cervical infection or other lower genital tract infections until infection is controlled acute liver disease or liver tumor benign or malignantconditions associated with increased susceptibility to pelvic infections see warnings and precautions 54a previously inserted ius that has not been removedhypersensitivity to any component of liletta see adverse reactions 62 pregnancy or suspected pregnancy 4use for postcoital contraception emergency contraception 4congenital or acquired uterine anomaly that distorts the uterine cavity and would be incompatible with correct ius placement 4acute pelvic inflammatory disease pid or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy 4infected abortion in the past 3 months 4known or suspected uterine or cervical neoplasia 4known or suspected breast cancer or other hormonesensitive cancer 4uterine bleeding of unknown etiology 4untreated acute cervicitis or vaginitis or other lower genital tract infections 4acute liver disease or liver tumor benign or malignant 4increased susceptibility to pelvic infections 4a previously inserted ius that has not been removed 4hypersensitivity to any component of liletta 4,1
the use of liletta is contraindicated when one or more of the following conditions exist pregnancy or suspected pregnancyfor use as postcoital contraception emergency contraceptioncongenital or acquired uterine anomaly including fibroids that distorts the uterine cavity and would be incompatible with correct ius placementacute pelvic inflammatory disease pid or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy infected abortion in the past 3 monthsknown or suspected uterine or cervical neoplasia known or suspected breast cancer or other hormonesensitive cancer now or in the past uterine bleeding of unknown etiologyuntreated acute cervicitis or vaginitis including bacterial vaginosis known chlamydial or gonococcal cervical infection or other lower genital tract infections until infection is controlled acute liver disease or liver tumor benign or malignantconditions associated with increased susceptibility to pelvic infections see warnings and precautions 54a previously inserted ius that has not been removedhypersensitivity to any component of liletta see adverse reactions 62 pregnancy or suspected pregnancy 4use for postcoital contraception emergency contraception 4congenital or acquired uterine anomaly that distorts the uterine cavity and would be incompatible with correct ius placement 4acute pelvic inflammatory disease pid or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy 4infected abortion in the past 3 months 4known or suspected uterine or cervical neoplasia 4known or suspected breast cancer or other hormonesensitive cancer 4uterine bleeding of unknown etiology 4untreated acute cervicitis or vaginitis or other lower genital tract infections 4acute liver disease or liver tumor benign or malignant 4increased susceptibility to pelvic infections 4a previously inserted ius that has not been removed 4hypersensitivity to any component of liletta 4,1
the use of liletta is contraindicated when one or more of the following conditions exist pregnancy or suspected pregnancyfor use as postcoital contraception emergency contraceptioncongenital or acquired uterine anomaly including fibroids that distorts the uterine cavity and would be incompatible with correct ius placementacute pelvic inflammatory disease pid or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy infected abortion in the past 3 monthsknown or suspected uterine or cervical neoplasia known or suspected breast cancer or other hormonesensitive cancer now or in the past uterine bleeding of unknown etiologyuntreated acute cervicitis or vaginitis including bacterial vaginosis known chlamydial or gonococcal cervical infection or other lower genital tract infections until infection is controlled acute liver disease or liver tumor benign or malignantconditions associated with increased susceptibility to pelvic infections see warnings and precautions 54a previously inserted ius that has not been removedhypersensitivity to any component of liletta see adverse reactions 62 pregnancy or suspected pregnancy 4use for postcoital contraception emergency contraception 4congenital or acquired uterine anomaly that distorts the uterine cavity and would be incompatible with correct ius placement 4acute pelvic inflammatory disease pid or endometritis or a history of pid unless there has been a subsequent intrauterine pregnancy 4infected abortion in the past 3 months 4known or suspected uterine or cervical neoplasia 4known or suspected breast cancer or other hormonesensitive cancer 4uterine bleeding of unknown etiology 4untreated acute cervicitis or vaginitis or other lower genital tract infections 4acute liver disease or liver tumor benign or malignant 4increased susceptibility to pelvic infections 4a previously inserted ius that has not been removed 4hypersensitivity to any component of liletta 4,1
paragardr pregnancy or suspicion of pregnancyabnormalities of the uterus resulting in distortion of the uterine cavityacute pelvic inflammatory disease or current behavior suggesting a high risk for pelvic inflammatory diseasepostpartum endometritis or postabortal endometritis in the past 3 monthsknown or suspected uterine or cervical malignancygenital bleeding of unknown etiologymucopurulent cervicitiswilsons diseaseallergy to any component of paragardra previously placed iud that has not been removed,0
paragardr pregnancy or suspicion of pregnancyabnormalities of the uterus resulting in distortion of the uterine cavityacute pelvic inflammatory disease or current behavior suggesting a high risk for pelvic inflammatory diseasepostpartum endometritis or postabortal endometritis in the past 3 monthsknown or suspected uterine or cervical malignancygenital bleeding of unknown etiologymucopurulent cervicitiswilsons diseaseallergy to any component of paragardra previously placed iud that has not been removed,0
biltricide is contraindicated in patients who previously have shown hypersensitivity to the drug or any of the excipients since parasite destruction within the eye may cause irreversible lesions ocular cysticercosis must not be treated with this compoundconcomitant administration with strong cytochrome p450 p450 inducers such as rifampin is contraindicated since therapeutically effective blood levels of praziquantel may not be achieved see precautionsdrug interactions in patients receiving rifampin who need immediate treatment for schistosomiasis alternative agents for schistosomiasis should be considered however if treatment with praziquantel is necessary rifampin should be discontinued 4 weeks before administration of praziquantel treatment with rifampin can then be restarted one day after completion of praziquantel treatment see precautionsdrug interactions,0
dermatitis herpetiformis dhleprosy all forms of leprosy except for cases of proven dapsone resistancemfd by taro pharmaceutical industries ltddist by taro pharmaceuticals usa increvised december 2018,3
dermatitis herpetiformis dhleprosy all forms of leprosy except for cases of proven dapsone resistancemfd by taro pharmaceutical industries ltddist by taro pharmaceuticals usa increvised december 2018,3
metastatic prostate cancernilutamide tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer stage d2for maximum benefit treatment with nilutamide tablets must begin on the same day as or on the day after surgical castration,3
mitoxantrone injection usp concentrate is indicated for reducing neurologic disability andor the frequency of clinical relapses in patients with secondary chronic progressive progressive relapsing or worsening relapsingremitting multiple sclerosis ie patients whose neurologic status is significantly abnormal between relapses mitoxantrone injection usp concentrate is not indicated in the treatment of patients with primary progressive multiple sclerosis the clinical patterns of multiple sclerosis in the studies were characterized as follows secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses and worsening relapsingremitting disease was characterized by clinical relapses resulting in a stepwise worsening of disability mitoxantrone injection usp concentrate in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormonerefractory prostate cancer mitoxantrone injection usp concentrate in combination with other approved drugs is indicated in the initial therapy of acute nonlymphocytic leukemia anll in adults this category includes myelogenous promyelocytic monocytic and erythroid acute leukemias,3
mitoxantrone injection usp concentrate is indicated for reducing neurologic disability andor the frequency of clinical relapses in patients with secondary chronic progressive progressive relapsing or worsening relapsingremitting multiple sclerosis ie patients whose neurologic status is significantly abnormal between relapses mitoxantrone injection usp concentrate is not indicated in the treatment of patients with primary progressive multiple sclerosis the clinical patterns of multiple sclerosis in the studies were characterized as follows secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses and worsening relapsingremitting disease was characterized by clinical relapses resulting in a stepwise worsening of disability mitoxantrone injection usp concentrate in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormonerefractory prostate cancer mitoxantrone injection usp concentrate in combination with other approved drugs is indicated in the initial therapy of acute nonlymphocytic leukemia anll in adults this category includes myelogenous promyelocytic monocytic and erythroid acute leukemias,3
mitoxantrone injection usp concentrate is indicated for reducing neurologic disability andor the frequency of clinical relapses in patients with secondary chronic progressive progressive relapsing or worsening relapsingremitting multiple sclerosis ie patients whose neurologic status is significantly abnormal between relapses mitoxantrone injection usp concentrate is not indicated in the treatment of patients with primary progressive multiple sclerosis the clinical patterns of multiple sclerosis in the studies were characterized as follows secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses and worsening relapsingremitting disease was characterized by clinical relapses resulting in a stepwise worsening of disability mitoxantrone injection usp concentrate in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormonerefractory prostate cancer mitoxantrone injection usp concentrate in combination with other approved drugs is indicated in the initial therapy of acute nonlymphocytic leukemia anll in adults this category includes myelogenous promyelocytic monocytic and erythroid acute leukemias,2
based on a review of this drug by the national academy of sciencesnational research andor other information the fda has classified the indications as follows for the relief of symptoms associated with cerebrovascular insufficiencyin peripheral vascular disease of arteriosclerosis obliterans thromboangitis obliterans buergers disease and raynauds disease final classification of the lessthaneffective indications requires further investigation,2
teniposide injection in combination with other approved anticancer agents is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia,3
teniposide injection in combination with other approved anticancer agents is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia,3
teniposide injection in combination with other approved anticancer agents is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia,3
clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in diseaserelated symptoms or increased survival with clofarabine injectionclofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in diseaserelated symptoms or increased survival with clofarabine injection 1,3
clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in diseaserelated symptoms or increased survival with clofarabine injectionclofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in diseaserelated symptoms or increased survival with clofarabine injection 1,3
clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in diseaserelated symptoms or increased survival with clofarabine injectionclofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in diseaserelated symptoms or increased survival with clofarabine injection 1,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 doxorubicin hcl for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma,3
iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph alliclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicatedtreatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 57 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 57,3
iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph alliclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicatedtreatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 57 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 57,3
iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph alliclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicatedtreatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 57 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 57,3
iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph alliclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicatedtreatment of adult patients with t315ipositive cml chronic phase accelerated phase or blast phase or t315ipositive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 57 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 57,3
rituxan rituximab is a cd20directed cytolytic antibody indicated for the treatment of adult patients with nonhodgkins lymphoma nhl 11 relapsed or refractory low grade or follicular cd20positive bcell nhl as a single agentpreviously untreated follicular cd20positive bcell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as singleagent maintenance therapynonprogressing including stable disease lowgrade cd20positive bcell nhl as a single agent after firstline cyclophosphamide vincristine and prednisone cvp chemotherapypreviously untreated diffuse large bcell cd20positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracyclinebased chemotherapy regimenschronic lymphocytic leukemia cll 12 previously untreated and previously treated cd20positive cll in combination with fludarabine and cyclophosphamide fcrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ra who have inadequate response to one or more tnf antagonist therapies 13granulomatosis with polyangiitis gpa wegeners granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 14moderate to severe pemphigus vulgaris pv in adult patients 15rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory lowgrade or follicular cd20positive bcell nhl as a single agentpreviously untreated follicular cd20positive bcell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as singleagent maintenance therapynonprogressing including stable disease lowgrade cd20positive bcell nhl as a single agent after firstline cyclophosphamide vincristine and prednisone cvp chemotherapypreviously untreated diffuse large bcell cd20positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracyclinebased chemotherapy regimensrituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd20positive cllrituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapiesrituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegeners granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris,3
rituxan rituximab is a cd20directed cytolytic antibody indicated for the treatment of adult patients with nonhodgkins lymphoma nhl 11 relapsed or refractory low grade or follicular cd20positive bcell nhl as a single agentpreviously untreated follicular cd20positive bcell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as singleagent maintenance therapynonprogressing including stable disease lowgrade cd20positive bcell nhl as a single agent after firstline cyclophosphamide vincristine and prednisone cvp chemotherapypreviously untreated diffuse large bcell cd20positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracyclinebased chemotherapy regimenschronic lymphocytic leukemia cll 12 previously untreated and previously treated cd20positive cll in combination with fludarabine and cyclophosphamide fcrheumatoid arthritis ra in combination with methotrexate in adult patients with moderatelyto severelyactive ra who have inadequate response to one or more tnf antagonist therapies 13granulomatosis with polyangiitis gpa wegeners granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 14moderate to severe pemphigus vulgaris pv in adult patients 15rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory lowgrade or follicular cd20positive bcell nhl as a single agentpreviously untreated follicular cd20positive bcell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as singleagent maintenance therapynonprogressing including stable disease lowgrade cd20positive bcell nhl as a single agent after firstline cyclophosphamide vincristine and prednisone cvp chemotherapypreviously untreated diffuse large bcell cd20positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracyclinebased chemotherapy regimensrituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd20positive cllrituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapiesrituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegeners granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris,3
mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic lymphocytic lymophoblastic leukemia as part of a combination regimen the response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient pediatric or adult mercaptopurine tablets are not effective prophylaxis or treatment of central nervous system leukemia mercaptopurine tablets are not effective in acute myelogenous leukemia chronic lymphatic leukemia the lymphomas including hodgkins disease or solid tumors,1
fludarabine phosphate injection is a nucleotide metabolic inhibitor indicated for the treatment of adult patients with bcell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylatingagent containing regimen benefit in treatmentnaive or nonrefractory cll patients is not established 11important limitations fludarabine phosphate should not be used in patients with severe renal impairment creatinine clearance less than 30 mlmin173 m2 57fludarabine phosphate injection is indicated for the treatment of adult patients with bcell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylatingagent containing regimen the safety and effectiveness of fludarabine phosphate injection in previously untreated or nonrefractory patients with cll have not been establishedfludarabine phosphate injection should not be used in patients with severe renal impairment creatinine clearance less than 30 mlmin173 m2see warnings and precautions 57,3
fludarabine phosphate injection is a nucleotide metabolic inhibitor indicated for the treatment of adult patients with bcell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylatingagent containing regimen benefit in treatmentnaive or nonrefractory cll patients is not established 11important limitations fludarabine phosphate should not be used in patients with severe renal impairment creatinine clearance less than 30 mlmin173 m2 57fludarabine phosphate injection is indicated for the treatment of adult patients with bcell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylatingagent containing regimen the safety and effectiveness of fludarabine phosphate injection in previously untreated or nonrefractory patients with cll have not been establishedfludarabine phosphate injection should not be used in patients with severe renal impairment creatinine clearance less than 30 mlmin173 m2see warnings and precautions 57,3
chronic lymphocytic leukemia cll arzerra ofatumumab is indicated in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabinebased therapy is considered inappropriate see clinical studies 141 in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll see clinical studies 142 for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll see clinical studies 143 for the treatment of patients with cll refractory to fludarabine and alemtuzumab see clinical studies 144arzerra ofatumumab is a cd20directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia cll 1 in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabinebased therapy is considered inappropriate in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cllfor extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll for the treatment of patients with cll refractory to fludarabine and alemtuzumab,3
bendamustine hydrochloride injection is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia cll efficacy relative to first line therapies other than chlorambucil has not been established 11indolent bcell nonhodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen 12bendamustine hydrochloride injection is indicated for the treatment of patients with chronic lymphocytic leukemia efficacy relative to first line therapies other than chlorambucil has not been establishedbendamustine hydrochloride injection is indicated for the treatment of patients with indolent bcell nonhodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen,3
gazyva obinutuzumab is a cd20directed cytolytic antibody and is indicated in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia 114in combination with bendamustine followed by gazyva monotherapy for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximabcontaining regimen 114in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma 114gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia see clinical studies 141gazyva in combination with bendamustine followed by gazyva monotherapy is indicated for the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximabcontaining regimen see clinical studies 142 gazyva in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission is indicated for the treatment of adult patients with previously untreated stage ii bulky iii or iv follicular lymphoma see clinical studies 142,3
zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia cll in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities 11relapsed follicular bcell nonhodgkin lymphoma fl in patients who have received at least two prior systemic therapies 12relapsed small lymphocytic lymphoma sll in patients who have received at least two prior systemic therapies 13 limitation of usezydelig is not indicated and is not recommended for firstline treatment of any patient 111213zydelig is not indicated and is not recommended in combination with bendamustine andor rituximab for the treatment of fl 12accelerated approval was granted for fl and sll based on overall response rate improvement in patient survival or disease related symptoms has not been established continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trialszydelig is indicated in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia cll for whom rituximab alone would be considered appropriate therapy due to other comorbidities limitation of usezydelig is not indicated and is not recommended for first line treatment of patients with cllzydelig is indicated for the treatment of patients with relapsed follicular bcell nonhodgkin lymphoma fl who have received at least two prior systemic therapiesaccelerated approval was granted for this indication based on overall response rate see clinical studies 142 limitation of usezydelig is not indicated and is not recommended for first line treatment of patients with fl zydelig is not indicated and is not recommended in combination with bendamustine andor rituximab for the treatment of flzydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma sll who have received at least two prior systemic therapiesaccelerated approval was granted for this indication based on overall response rate see clinical studies 143 limitation of usezydelig is not indicated and is not recommended for first line treatment of patients with sll,3
venclexta is a bcl2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll 11in combination with azacitidine or decitabine or lowdose cytarabine for the treatment of newlydiagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy12 venclexta is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll venclexta is indicated in combination with azacitidine or decitabine or lowdose cytarabine for the treatment of newlydiagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy this indication is approved under accelerated approval based on response rates see clinical studies 142,3
cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms otitis mediastreptococcus pneumoniae haemophilus influenzae streptococcus pyogenes note bhaemophilus influenzae in vitro lower respiratory tract infectionsstreptococcus pneumoniae haemophilus influenzaestreptococcus pyogenes note bhaemophilus influenzae in vitro pharyngitis and tonsillitisstreptococcus pyogenes note urinary tract infectionsescherichia coli proteus mirabilis klebsiella skin and skin structure infectionsstaphylococcus aureusstreptococcus pyogenesappropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclorto reduce the development of drugresistant bacteria and maintain the effectiveness of cefaclor for oral suspension and other antibacterial drugs cefaclor for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms otitis mediastreptococcus pneumoniae haemophilus influenzae streptococcus pyogenes note bhaemophilus influenzae in vitro lower respiratory tract infectionsstreptococcus pneumoniae haemophilus influenzaestreptococcus pyogenes note bhaemophilus influenzae in vitro pharyngitis and tonsillitisstreptococcus pyogenes note urinary tract infectionsescherichia coli proteus mirabilis klebsiella skin and skin structure infectionsstaphylococcus aureusstreptococcus pyogenesappropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclorto reduce the development of drugresistant bacteria and maintain the effectiveness of cefaclor for oral suspension and other antibacterial drugs cefaclor for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases urinary tract infections caused by e coli p mirabilisklebsiellaskin and skin structure infections caused by staphylococcistreptococcipharyngitis andor tonsillitis caused by streptococcus pyogenesnote only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever cefadroxil is generally effective in the eradication of streptococci from the oropharynx however data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available noteto reduce the development of drugresistant bacteria and maintain the effectiveness of cefadroxil capsules usp and other antibacterial drugs cefadroxil capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cedax ceftibuten is indicated for the treatment of individuals with mildtomoderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below see dosage and administration clinical studies acute bacterial exacerbations of chronic bronchitishaemophilus influenzaemoraxella catarrhalisstreptococcus pneumoniae note moraxella catarrhalis acute bacterial otitis mediahaemophilus influenzaemoraxella catarrhalisstreptococcus pyogenes note streptococcus pneumoniaeonlystreptococcus pneumoniae pharyngitis and tonsillitisstreptococcus pyogenes note streptococcus pyogenes,3
cedax ceftibuten is indicated for the treatment of individuals with mildtomoderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below see dosage and administration clinical studies acute bacterial exacerbations of chronic bronchitishaemophilus influenzaemoraxella catarrhalisstreptococcus pneumoniae note moraxella catarrhalis acute bacterial otitis mediahaemophilus influenzaemoraxella catarrhalisstreptococcus pyogenes note streptococcus pneumoniaeonlystreptococcus pneumoniae pharyngitis and tonsillitisstreptococcus pyogenes note streptococcus pyogenes,3
cedax ceftibuten is indicated for the treatment of individuals with mildtomoderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below see dosage and administration clinical studies acute bacterial exacerbations of chronic bronchitishaemophilus influenzaemoraxella catarrhalisstreptococcus pneumoniae note moraxella catarrhalis acute bacterial otitis mediahaemophilus influenzaemoraxella catarrhalisstreptococcus pyogenes note streptococcus pneumoniaeonlystreptococcus pneumoniae pharyngitis and tonsillitisstreptococcus pyogenes note streptococcus pyogenes,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration acute otitis mediastreptococcus pneumoniaestreptococcus pyogenes haemophilusinfluenzaemoraxella branhamella catarrhalis pharyngitis andor tonsillitisstreptococcus pyogenes note communityacquired pneumonias pneumoniaeh influenzae acute bacterial exacerbation of chronic bronchitiss pneumoniae h influenzaem catarrhalish influenzae acute uncomplicated urethral and cervical gonorrheaneisseria gonorrhoeae acute uncomplicated anorectal infections in womenneisseria gonorrhoeae noten gonorrhoeaen gonorrhoeae uncomplicated skin and skin structure infectionsstaphylococcus aureusstreptococcus pyogenes note dosage and administration acute maxillary sinusitishaemophilusinfluenzaestreptococcus pneumoniaemoraxella catarrhalis uncomplicated urinary tract infections cystitisescherichia coli klebsiellapneumoniae proteus mirabilisstaphylococcus saprophyticus note clinical studiesappropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime therapy may be instituted while awaiting the results of these studies once these results become available antimicrobial therapy should be adjusted accordinglyto reduce the development of drugresistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets usp and other antibacterial drugs cefpodoxime proxetil tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration acute otitis mediastreptococcus pneumoniaestreptococcus pyogenes haemophilusinfluenzaemoraxella branhamella catarrhalis pharyngitis andor tonsillitisstreptococcus pyogenes note communityacquired pneumonias pneumoniaeh influenzae acute bacterial exacerbation of chronic bronchitiss pneumoniae h influenzaem catarrhalish influenzae acute uncomplicated urethral and cervical gonorrheaneisseria gonorrhoeae acute uncomplicated anorectal infections in womenneisseria gonorrhoeae noten gonorrhoeaen gonorrhoeae uncomplicated skin and skin structure infectionsstaphylococcus aureusstreptococcus pyogenes note dosage and administration acute maxillary sinusitishaemophilusinfluenzaestreptococcus pneumoniaemoraxella catarrhalis uncomplicated urinary tract infections cystitisescherichia coli klebsiellapneumoniae proteus mirabilisstaphylococcus saprophyticus note clinical studiesappropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime therapy may be instituted while awaiting the results of these studies once these results become available antimicrobial therapy should be adjusted accordinglyto reduce the development of drugresistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets usp and other antibacterial drugs cefpodoxime proxetil tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration acute otitis mediastreptococcus pneumoniaestreptococcus pyogenes haemophilusinfluenzaemoraxella branhamella catarrhalis pharyngitis andor tonsillitisstreptococcus pyogenes note communityacquired pneumonias pneumoniaeh influenzae acute bacterial exacerbation of chronic bronchitiss pneumoniae h influenzaem catarrhalish influenzae acute uncomplicated urethral and cervical gonorrheaneisseria gonorrhoeae acute uncomplicated anorectal infections in womenneisseria gonorrhoeae noten gonorrhoeaen gonorrhoeae uncomplicated skin and skin structure infectionsstaphylococcus aureusstreptococcus pyogenes note dosage and administration acute maxillary sinusitishaemophilusinfluenzaestreptococcus pneumoniaemoraxella catarrhalis uncomplicated urinary tract infections cystitisescherichia coli klebsiellapneumoniae proteus mirabilisstaphylococcus saprophyticus note clinical studiesappropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime therapy may be instituted while awaiting the results of these studies once these results become available antimicrobial therapy should be adjusted accordinglyto reduce the development of drugresistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets usp and other antibacterial drugs cefpodoxime proxetil tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
temporarily relieves nasal congestion due to the common cold hay fever or other upper respiratory allergiestemporarily relieves sinus congestion and pressure,2
prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia prochlorperazine is effective for the shortterm treatment of generalized nonpsychotic anxiety however prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with nonpsychotic anxiety because certain risks associated with its use are not shared by common alternative treatments eg benzodiazepines when used in the treatment of nonpsychotic anxiety prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warningsthe effectiveness of prochlorperazine as treatment for nonpsychotic anxiety was established in 4week clinical studies of outpatients with generalized anxiety disorder this evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other nonpsychotic conditions in which anxiety or signs that mimic anxiety are found eg physical illness organic mental conditions agitated depression character pathologies etc prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation,1
prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia prochlorperazine is effective for the shortterm treatment of generalized nonpsychotic anxiety however prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with nonpsychotic anxiety because certain risks associated with its use are not shared by common alternative treatments eg benzodiazepines when used in the treatment of nonpsychotic anxiety prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warningsthe effectiveness of prochlorperazine as treatment for nonpsychotic anxiety was established in 4week clinical studies of outpatients with generalized anxiety disorder this evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other nonpsychotic conditions in which anxiety or signs that mimic anxiety are found eg physical illness organic mental conditions agitated depression character pathologies etc prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation,3
prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia prochlorperazine is effective for the shortterm treatment of generalized nonpsychotic anxiety however prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with nonpsychotic anxiety because certain risks associated with its use are not shared by common alternative treatments eg benzodiazepines when used in the treatment of nonpsychotic anxiety prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warningsthe effectiveness of prochlorperazine as treatment for nonpsychotic anxiety was established in 4week clinical studies of outpatients with generalized anxiety disorder this evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other nonpsychotic conditions in which anxiety or signs that mimic anxiety are found eg physical illness organic mental conditions agitated depression character pathologies etc prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation,3
prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia prochlorperazine is effective for the shortterm treatment of generalized nonpsychotic anxiety however prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with nonpsychotic anxiety because certain risks associated with its use are not shared by common alternative treatments eg benzodiazepines when used in the treatment of nonpsychotic anxiety prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warningsthe effectiveness of prochlorperazine as treatment for nonpsychotic anxiety was established in 4week clinical studies of outpatients with generalized anxiety disorder this evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other nonpsychotic conditions in which anxiety or signs that mimic anxiety are found eg physical illness organic mental conditions agitated depression character pathologies etc prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation,3
fluphenazine decanoate injection is a longacting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy eg chronic schizophrenicsfluphenazine decanoate injection has not been shown effective in the management of behavioral complications in patients with mental retardation,1
for the management of schizophreniatrifluoperazine hydrochloride tablets usp are effective for the shortterm treatment of generalized nonpsychotic anxiety however trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with nonpsychotic anxiety because certain risks associated with its use are not shared by common alternative treatments ie benzodiazepineswhen used in the treatment of nonpsychotic anxiety trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warningsthe effectiveness of trifluoperazine hydrochloride tablets as a treatment for nonpsychotic anxiety was established in a 4week clinical multicenter study of outpatients with generalized anxiety disorder dsmiii this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other nonpsychotic conditions in which anxiety or signs that mimic anxiety are found ie physical illness organic mental conditions agitated depression character pathologies etctrifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation,1
for the management of schizophreniatrifluoperazine hydrochloride tablets usp are effective for the shortterm treatment of generalized nonpsychotic anxiety however trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with nonpsychotic anxiety because certain risks associated with its use are not shared by common alternative treatments ie benzodiazepineswhen used in the treatment of nonpsychotic anxiety trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warningsthe effectiveness of trifluoperazine hydrochloride tablets as a treatment for nonpsychotic anxiety was established in a 4week clinical multicenter study of outpatients with generalized anxiety disorder dsmiii this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other nonpsychotic conditions in which anxiety or signs that mimic anxiety are found ie physical illness organic mental conditions agitated depression character pathologies etctrifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation,3
perphenazine tablets are indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults perphenazine tablets have not been shown effective for the management of behavioral complications in patients with mental retardation,1
perphenazine tablets are indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults perphenazine tablets have not been shown effective for the management of behavioral complications in patients with mental retardation,3
thiothixene capsules are effective in the management of schizophrenia thiothixene capsules have not been evaluated in the management of behavioral complications in patients with mental retardation,1
thiothixene capsules are effective in the management of schizophrenia thiothixene capsules have not been evaluated in the management of behavioral complications in patients with mental retardation,3
ergocalciferol capsules usp are indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia,3
ergocalciferol capsules usp are indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia,3
pantoprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6,2
pantoprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6,1
pantoprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6,1
pantoprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6,1
pantoprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6,2
procysbi is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and olderprocysbi is a cystinedepleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older 1,3
donepezil hydrochloride orally disintegrating tablets usp are an acetylcholinesterase inhibitor indicated for the treatment of dementia of the alzheimers type efficacy has been demonstrated in patients with mild moderate and severe alzheimers disease 1donepezil hydrochloride orally disintegrating tablets usp are indicated for the treatment of dementia of the alzheimers type efficacy has been demonstrated in patients with mild moderate and severe alzheimers disease,3
betaxolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic openangle glaucoma it may be used alone or in combination with other antiglaucoma drugsin clinical studies betaxolol hydrochloride ophthalmic solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months however caution should be used in treating patients with severe reactive airway disease or a history of asthma,3
betaxolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic openangle glaucoma it may be used alone or in combination with other antiglaucoma drugsin clinical studies betaxolol hydrochloride ophthalmic solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months however caution should be used in treating patients with severe reactive airway disease or a history of asthma,3
betaxolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic openangle glaucoma it may be used alone or in combination with other antiglaucoma drugsin clinical studies betaxolol hydrochloride ophthalmic solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months however caution should be used in treating patients with severe reactive airway disease or a history of asthma,3
travoprost ophthalmic solution usp 0004 is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertensiontravoprost ophthalmic solution usp 0004 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension 1,3
travoprost ophthalmic solution usp 0004 is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertensiontravoprost ophthalmic solution usp 0004 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension 1,2
brimonidine tartrate ophthalmic solution 02 is indicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients this loss of effect appears with a variable time of onset in each patient and should be closely monitored brimonidine tartrate ophthalmic solution 02 is an alpha adrenergic agonist indicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension 1,3
brimonidine tartrate ophthalmic solution 02 is indicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients this loss of effect appears with a variable time of onset in each patient and should be closely monitored brimonidine tartrate ophthalmic solution 02 is an alpha adrenergic agonist indicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension 1,2
carteolol hydrochloride ophthalmic solution 1 has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic openangle glaucoma and intraocular hypertension it may be used alone or in combination with other intraocular pressure lowering medications,3
carteolol hydrochloride ophthalmic solution 1 has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic openangle glaucoma and intraocular hypertension it may be used alone or in combination with other intraocular pressure lowering medications,3
latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertensionlatanoprost ophthalmic solution is a prostaglandin f2a analogue indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension 1,3
latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertensionlatanoprost ophthalmic solution is a prostaglandin f2a analogue indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension 1,3
methazolamide tablets usp is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit such as chronic openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where lowering the intraocular pressure is desired before surgery,3
methazolamide tablets usp is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit such as chronic openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where lowering the intraocular pressure is desired before surgery,3
dorzolamide hydrochloride ophthalmic solution 2 is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucomadorzolamide hydrochloride ophthalmic solution 2 is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma 1,3
dorzolamide hydrochloride ophthalmic solution 2 is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucomadorzolamide hydrochloride ophthalmic solution 2 is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or openangle glaucoma 1,3
bimatoprost ophthalmic solution 003 is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertensionbimatoprost ophthalmic solution 003 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension,3
bimatoprost ophthalmic solution 003 is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertensionbimatoprost ophthalmic solution 003 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension,2
pilocarpine hydrochloride can be used in the medical management of glaucoma especially openangle glaucoma in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine in acute closedangle glaucoma pilocarpine hydrochloride may be used alone or in combination with other cholinergic agents or carbonic anhydrase inhibitors to relieve tension prior to emergency surgerypatients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields the choice of concentration should be determined by the severity of the condition and the response of the patient pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination,3
levobunolol hcl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic openangle glaucoma or ocular hypertension,2
levobunolol hcl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic openangle glaucoma or ocular hypertension,3
tinidazole tablets is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in non pregnant adult women 1481tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalissee clinical studies 141tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalisg lambliasee clinical studies 142tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolyticasee clinical studies 143 144tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilusgardnerellasee use in specific populations 81 and clinical studies 145other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicansherpes simplexto reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
tinidazole tablets is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in non pregnant adult women 1481tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalissee clinical studies 141tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalisg lambliasee clinical studies 142tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolyticasee clinical studies 143 144tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilusgardnerellasee use in specific populations 81 and clinical studies 145other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicansherpes simplexto reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
tinidazole tablets is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in non pregnant adult women 1481tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalissee clinical studies 141tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalisg lambliasee clinical studies 142tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolyticasee clinical studies 143 144tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilusgardnerellasee use in specific populations 81 and clinical studies 145other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicansherpes simplexto reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
hypertensiontimolol maleate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics myocardial infarctiontimolol is indicated in patients who have survived the acute phase of myocardial infarction and are clinically stable to reduce cardiovascular mortality and the risk of reinfarction migrainetimolol is indicated for the prophylaxis of migraine headache,3
hypertensiontimolol maleate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics myocardial infarctiontimolol is indicated in patients who have survived the acute phase of myocardial infarction and are clinically stable to reduce cardiovascular mortality and the risk of reinfarction migrainetimolol is indicated for the prophylaxis of migraine headache,3
hypertensiontimolol maleate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics myocardial infarctiontimolol is indicated in patients who have survived the acute phase of myocardial infarction and are clinically stable to reduce cardiovascular mortality and the risk of reinfarction migrainetimolol is indicated for the prophylaxis of migraine headache,3
bisoprolol fumarate tablets usp are indicated in the management of hypertension they may be used alone or in combination with other antihypertensive agents,3
carvedilol is an alphabetaadrenergic blocking agent indicated for the treatment of mild to severe chronic heart failure 11left ventricular dysfunction following myocardial infarction in clinically stable patients 12hypertension 13carvedilol tablets are indicated for the treatment of mildtosevere chronic heart failure of ischemic or cardiomyopathic origin usually in addition to diuretics ace inhibitors and digitalis to increase survival and also to reduce the risk of hospitalization see drug interactions 74 and clinical studies 141carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40 with or without symptomatic heart failure see clinical studies 142carvedilol tablets are indicated for the management of essential hypertension see clinical studies 143144see drug interactions 72,3
carvedilol is an alphabetaadrenergic blocking agent indicated for the treatment of mild to severe chronic heart failure 11left ventricular dysfunction following myocardial infarction in clinically stable patients 12hypertension 13carvedilol tablets are indicated for the treatment of mildtosevere chronic heart failure of ischemic or cardiomyopathic origin usually in addition to diuretics ace inhibitors and digitalis to increase survival and also to reduce the risk of hospitalization see drug interactions 74 and clinical studies 141carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40 with or without symptomatic heart failure see clinical studies 142carvedilol tablets are indicated for the management of essential hypertension see clinical studies 143144see drug interactions 72,3
ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,3
ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,0
ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,3
ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,3
ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,3
ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,3
methyclothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionmethyclothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapymethyclothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome acute glomerulonephritis and chronic renal failurethe routine use of diuretics in an otherwise healthy pregnant woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathological causes or from the physiological and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathological causes just as they are in the absence of pregnancy see precautions pregnancy,3
methyclothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionmethyclothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapymethyclothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome acute glomerulonephritis and chronic renal failurethe routine use of diuretics in an otherwise healthy pregnant woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathological causes or from the physiological and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathological causes just as they are in the absence of pregnancy see precautions pregnancy,3
methyclothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionmethyclothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapymethyclothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome acute glomerulonephritis and chronic renal failurethe routine use of diuretics in an otherwise healthy pregnant woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathological causes or from the physiological and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathological causes just as they are in the absence of pregnancy see precautions pregnancy,3
isradipine capsules are indicated in the management of hypertension it may be used alone or concurrently with thiazidetype diuretics,3
diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure usage in pregnancythe routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy chlorthalidone is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions below dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother in the absence of cardiovascular disease but that is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort that is not relieved by rest in these cases a short course of diuretics may provide relief and be appropriate,3
diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure usage in pregnancythe routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy chlorthalidone is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions below dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother in the absence of cardiovascular disease but that is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort that is not relieved by rest in these cases a short course of diuretics may provide relief and be appropriate,3
diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionchlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure usage in pregnancythe routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy chlorthalidone is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions below dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother in the absence of cardiovascular disease but that is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort that is not relieved by rest in these cases a short course of diuretics may provide relief and be appropriate,3
because of the potential for serious adverse effects minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs at the present time use in milder degrees of hypertension is not recommended because the benefitrisk relationship in such patients has not been definedminoxidil reduced supine diastolic blood pressure by 20 mm hg or to 90 mm hg or less in approximately 75 of patients most of who had hypertension that could not be controlled by other drugs,3
hypertension toxemia pregnancy and hypersensitivity,0
hypertension toxemia pregnancy and hypersensitivity,3
nisoldipine extendedrelease tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents,3
prazosin hydrochloride capsules usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drugcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy prazosin hydrochloride capsules usp can be used alone or in combination with other antihypertensive drugs such as diuretics or betaadrenergic blocking agents,3
prazosin hydrochloride capsules usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drugcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy prazosin hydrochloride capsules usp can be used alone or in combination with other antihypertensive drugs such as diuretics or betaadrenergic blocking agents,0
prazosin hydrochloride capsules usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drugcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy prazosin hydrochloride capsules usp can be used alone or in combination with other antihypertensive drugs such as diuretics or betaadrenergic blocking agents,3
fosinopril sodium tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsfosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis see dosage and administrationin using fosinopril sodium consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that fosinopril sodium does not have a similar risk see warningsin considering use of fosinopril sodium it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema and intestinal angioedema,3
fosinopril sodium tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsfosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis see dosage and administrationin using fosinopril sodium consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that fosinopril sodium does not have a similar risk see warningsin considering use of fosinopril sodium it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema and intestinal angioedema,0
hypertensiontrandolapril tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazidein considering the use of trandolapril tablets it should be noted that in controlled trials ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedemawhen using trandolapril tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that trandolapril tablets do not have a similar risk see warnings,3
hypertensiontrandolapril tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazidein considering the use of trandolapril tablets it should be noted that in controlled trials ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedemawhen using trandolapril tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that trandolapril tablets do not have a similar risk see warnings,0
hypertensiontrandolapril tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazidein considering the use of trandolapril tablets it should be noted that in controlled trials ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedemawhen using trandolapril tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that trandolapril tablets do not have a similar risk see warnings,0
upstates metolazone tablets usp are indicated for the treatment of salt and water retention includingedema accompanying congestive heart failure metolazone tablets usp are also indicated for the treatment of hypertension alone or in combination with other antihypertensive drugs of a different class mykrox tablets a more rapidly available form of metolazone are intended for the treatment of new patients with mild to moderate hypertension a dose titration is necessary if mykrox tablets are to be substituted for upstates metolazone tablets usp in the treatment of hypertension see package circular for mykrox tablets ucbusage in pregnancythe routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy metolazone tablets usp are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy see precautions dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother in the absence of cardiovascular disease but which is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort which is not relieved by rest in these cases a short course of diuretics may be appropriate,0
benazepril hydrochloride tablets usp are indicated for the treatment of hypertension benazepril hydrochloride tablets may be used alone or in combination with thiazide diureticsin using benazepril consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk see warningsblack patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks,3
benazepril hydrochloride tablets usp are indicated for the treatment of hypertension benazepril hydrochloride tablets may be used alone or in combination with thiazide diureticsin using benazepril consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk see warningsblack patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks,1
innopran xlrcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mm hg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyinnopran xl is a beta adrenergic blocker indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1limitation of use innopran xl is not indicated for the treatment of hypertensive emergencies 1,3
innopran xlrcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mm hg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyinnopran xl is a beta adrenergic blocker indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1limitation of use innopran xl is not indicated for the treatment of hypertensive emergencies 1,0
innopran xlrcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mm hg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyinnopran xl is a beta adrenergic blocker indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1limitation of use innopran xl is not indicated for the treatment of hypertensive emergencies 1,0
innopran xlrcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mm hg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyinnopran xl is a beta adrenergic blocker indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1limitation of use innopran xl is not indicated for the treatment of hypertensive emergencies 1,3
enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additiveenalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trialsin clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trialsin using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warningsin considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,3
enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additiveenalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trialsin clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trialsin using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warningsin considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,0
enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additiveenalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trialsin clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trialsin using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warningsin considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,1
amiloride hcl tablets are indicated as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension to a help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic b prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop eg digitalized patients or patients with significant cardiac arrhythmias the use of potassiumconserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet amiloride hcl tablets have little additive diuretic or antihypertensive effect when added to a thiazide diureticamiloride hcl tablets should rarely be used alone it has weak compared with thiazides diuretic and antihypertensive effects used as single agents potassium sparing diuretics including amiloride hcl tablets result in an increased risk of hyperkalemia approximately 10 with amiloride amiloride hcl tablets should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes,3
labetalol hydrochloride tablets usp are indicated in the management of hypertension labetalol hydrochloride tablets usp may be used alone or in combination with other antihypertensive agents especially thiazide and loop diuretics,3
nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina effortassociated angina nicardipine hydrochloride capsules may be used alone or in combination with betablockers nicardipine hydrochloride capsules are indicated for the treatment of hypertension nicardipine hydrochloride capsules may be used alone or in combination with other antihypertensive drugs in administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect see dosage and administration,3
for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension,3
for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension,3
stable coronary artery diseaseperindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease such as antiplatelet antihypertensive or lipidlowering therapy hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension perindopril erbumine tablets may be used alone or given with other classes of antihypertensives especially thiazide diuretics when using perindopril erbumine tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to determine whether perindopril erbumine tablets has a similar potential see warningsin considering use of perindopril erbumine tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,3
stable coronary artery diseaseperindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease such as antiplatelet antihypertensive or lipidlowering therapy hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension perindopril erbumine tablets may be used alone or given with other classes of antihypertensives especially thiazide diuretics when using perindopril erbumine tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to determine whether perindopril erbumine tablets has a similar potential see warningsin considering use of perindopril erbumine tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,0
stable coronary artery diseaseperindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease such as antiplatelet antihypertensive or lipidlowering therapy hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension perindopril erbumine tablets may be used alone or given with other classes of antihypertensives especially thiazide diuretics when using perindopril erbumine tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to determine whether perindopril erbumine tablets has a similar potential see warningsin considering use of perindopril erbumine tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,3
stable coronary artery diseaseperindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease such as antiplatelet antihypertensive or lipidlowering therapy hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension perindopril erbumine tablets may be used alone or given with other classes of antihypertensives especially thiazide diuretics when using perindopril erbumine tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to determine whether perindopril erbumine tablets has a similar potential see warningsin considering use of perindopril erbumine tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,3
indapamide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive drugsindapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failurethe routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard see below precautionsdiuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy indapamide is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see below dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother in the absence of cardiovascular disease but which is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort which is not relieved by rest in these cases a short course of diuretics may provide relief and may be appropriate precautions,3
eprosartan mesylate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers,3
chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failurechlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertensionroutine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy,3
chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failurechlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertensionroutine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy,3
chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failurechlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertensionroutine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy,3
hypertensionquinapril hydrochloride tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsin using quinapril hydrochloride tablets consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk see warnings angioedema in black patientsblack patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks,3
hypertensionquinapril hydrochloride tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsin using quinapril hydrochloride tablets consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk see warnings angioedema in black patientsblack patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks,0
hypertensionquinapril hydrochloride tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsin using quinapril hydrochloride tablets consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk see warnings angioedema in black patientsblack patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks,0
pindolol tablets are indicated in the management of hypertension it may be used alone or concomitantly with other antihypertensive agents particularly with a thiazidetype diuretic,3
hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failurehydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertensionuse in pregnancyroutine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy dependent edema in pregnancy resulting from restriction of venous return by the gravid uterus is properly treated through elevation of the lower extremities and use of support stockings use of diuretics to lower intravascular volume in this instance is illogical and unnecessary during normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease however it may be associated with edema rarely generalized edema if such edema causes discomfort increased recumbency will often provide relief rarely this edema may cause extreme discomfort which is not relieved by rest in these instances a short course of diuretic therapy may provide relief and be appropriate,3
felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy felodipine extendedrelease tablets usp may be administered with other antihypertensive agents,3
felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy felodipine extendedrelease tablets usp may be administered with other antihypertensive agents,0
felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy felodipine extendedrelease tablets usp may be administered with other antihypertensive agents,0
felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy felodipine extendedrelease tablets usp may be administered with other antihypertensive agents,0
terazosin capsules usp are indicated for the treatment of symptomatic benign prostatic hyperplasia bph there is a rapid response with approximately 70 of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules usp the longterm effects of terazosin capsules usp on the incidence of surgery acute urinary obstruction or other complications of bph are yet to be determinedterazosin capsules usp are also indicated for the treatment of hypertension terazosin capsules usp can be used alone or in combination with other antihypertensive agents such as diuretics or betaadrenergic blocking agents,3
hypertensionacebutolol hydrochloride capsules usp are indicated for the management of hypertension in adults it may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics ventricular arrhythmiasacebutolol hydrochloride capsules usp are indicated in the management of ventricular premature beats it reduces the total number of premature beats as well as the number of paired and multiform ventricular ectopic beats and ront beats,3
captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,3
captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,0
captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,0
captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,1
captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,3
captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,3
nadolol tablets usp are indicated for the longterm management of patients with angina pectorisnadolol tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with nadolol tablets uspcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapynadolol tablets usp may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics,3
nadolol tablets usp are indicated for the longterm management of patients with angina pectorisnadolol tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with nadolol tablets uspcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapynadolol tablets usp may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics,0
nadolol tablets usp are indicated for the longterm management of patients with angina pectorisnadolol tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with nadolol tablets uspcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapynadolol tablets usp may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics,3
technetium tc 99m albumin aggregated injection should not be administered to patients with severe pulmonary hypertensionthe use of technetium tc 99m albumin aggregated injection is contraindicated in persons with a history of hypersensitivity reactions to products containing human serum albumin,2
cimetidine tablets are indicated inmost patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks see concomitant antacids should be given as needed for relief of pain however simultaneous administration of cimetidine tablets and antacids is not recommended since antacids have been reported to interfere with the absorption of cimetidine 1 shortterm treatment of active duodenal ulcerdosage and administration duodenal ulcerpatients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcerthere is no information concerning usefulness of treatment periods of longer than 8 weeks 3 shortterm treatment of active benign gastric ulcererosive esophagitis diagnosed by endoscopy treatment is indicated for 12 weeks for healing of lesions and control of symptoms the use of cimetidine tablets beyond 12 weeks has not been established see 4 erosive gastroesophageal reflux gerddosage and administration gerdie zollingerellison syndrome systemic mastocytosis multiple endocrine adenomas 5 the treatment of pathological hypersecretory conditions,3
cimetidine tablets are indicated inmost patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks see concomitant antacids should be given as needed for relief of pain however simultaneous administration of cimetidine tablets and antacids is not recommended since antacids have been reported to interfere with the absorption of cimetidine 1 shortterm treatment of active duodenal ulcerdosage and administration duodenal ulcerpatients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcerthere is no information concerning usefulness of treatment periods of longer than 8 weeks 3 shortterm treatment of active benign gastric ulcererosive esophagitis diagnosed by endoscopy treatment is indicated for 12 weeks for healing of lesions and control of symptoms the use of cimetidine tablets beyond 12 weeks has not been established see 4 erosive gastroesophageal reflux gerddosage and administration gerdie zollingerellison syndrome systemic mastocytosis multiple endocrine adenomas 5 the treatment of pathological hypersecretory conditions,3
cimetidine tablets are indicated inmost patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks see concomitant antacids should be given as needed for relief of pain however simultaneous administration of cimetidine tablets and antacids is not recommended since antacids have been reported to interfere with the absorption of cimetidine 1 shortterm treatment of active duodenal ulcerdosage and administration duodenal ulcerpatients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcerthere is no information concerning usefulness of treatment periods of longer than 8 weeks 3 shortterm treatment of active benign gastric ulcererosive esophagitis diagnosed by endoscopy treatment is indicated for 12 weeks for healing of lesions and control of symptoms the use of cimetidine tablets beyond 12 weeks has not been established see 4 erosive gastroesophageal reflux gerddosage and administration gerdie zollingerellison syndrome systemic mastocytosis multiple endocrine adenomas 5 the treatment of pathological hypersecretory conditions,3
cimetidine tablets are indicated inmost patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks see concomitant antacids should be given as needed for relief of pain however simultaneous administration of cimetidine tablets and antacids is not recommended since antacids have been reported to interfere with the absorption of cimetidine 1 shortterm treatment of active duodenal ulcerdosage and administration duodenal ulcerpatients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcerthere is no information concerning usefulness of treatment periods of longer than 8 weeks 3 shortterm treatment of active benign gastric ulcererosive esophagitis diagnosed by endoscopy treatment is indicated for 12 weeks for healing of lesions and control of symptoms the use of cimetidine tablets beyond 12 weeks has not been established see 4 erosive gastroesophageal reflux gerddosage and administration gerdie zollingerellison syndrome systemic mastocytosis multiple endocrine adenomas 5 the treatment of pathological hypersecretory conditions,3
nizatidineoral solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer in most patients the ulcer will heal within 4 weeksnizatidineoral solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg hs after healing of an active duodenal ulcer the consequences of continuous therapy with nizatidine for longer than 1 year are not knownnizatidine oral solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis including erosive and ulcerative esophagitis and associated heartburn due to gerdnizatidine oral solution is indicated for up to 8 weeks for the treatment of active benign gastric ulcer before initiating therapy care should be taken to exclude the possibility of malignant gastric ulcerationin pediatric patients nizatidine oral solution is indicated for ages 12 years and older nizatidine oral solution is indicated for up to 8 weeks for the treatment of endoscopically diagnosed esophagitis including erosive and ulcerative esophagitis and associated heartburn due to gerd,3
nizatidineoral solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer in most patients the ulcer will heal within 4 weeksnizatidineoral solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg hs after healing of an active duodenal ulcer the consequences of continuous therapy with nizatidine for longer than 1 year are not knownnizatidine oral solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis including erosive and ulcerative esophagitis and associated heartburn due to gerdnizatidine oral solution is indicated for up to 8 weeks for the treatment of active benign gastric ulcer before initiating therapy care should be taken to exclude the possibility of malignant gastric ulcerationin pediatric patients nizatidine oral solution is indicated for ages 12 years and older nizatidine oral solution is indicated for up to 8 weeks for the treatment of endoscopically diagnosed esophagitis including erosive and ulcerative esophagitis and associated heartburn due to gerd,3
fenoldopam injection is a dopaminergic agonist indicated 11 12fenoldopam is indicated for inhospital shortterm up to 48 hours management of severe hypertension when rapid but quickly reversible emergency reduction of blood pressure is clinically indicated including malignant hypertension with deteriorating endorgan function transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusionfenoldopam is indicated for inhospital shortterm up to 4 hours reduction in blood pressure see clinical pharmacology 122,3
fluvoxamine maleate extendedrelease capsules are a selective serotonin reuptake inhibitor ssri indicated for the treatment of obsessive compulsive disorder ocd 1efficacy was demonstrated in one 12week study with fluvoxamine maleate extendedrelease capsules in adults 141 two 10week studies with immediaterelease ir fluvoxamine tablets in adults and one 10week study with ir fluvoxamine tablets in children and adolescents 141 143 one maintenance study with ir fluvoxamine tablets 142fluvoxamine maleate extendedrelease capsules are indicated for the treatment of obsessive compulsive disorder ocd as defined in the dsmiv obsessive compulsive disorder is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are egodystonic andor repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable the obsessions or compulsions cause marked distress are timeconsuming or significantly interfere with social or occupational functioning the efficacy of fluvoxamine maleate extendedrelease capsules was demonstrated in one 12week trial in adults with fluvoxamine maleate extendedrelease capsules as well as in two 10week trials in adults and in one 10week trial in children and adolescents ages 8 to 17 years with immediaterelease fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsmiv or dsmiiir see clinical studies141 143the efficacy of fluvoxamine for longterm use was established in one maintenance study in adults with immediaterelease fluvoxamine tablets see clinical studies 142 dosage and administration24,3
clomipramine hydrochloride capsules usp is indicated for the treatment of obsessions and compulsions in patients with obsessivecompulsive disorder ocd the obsessions or compulsions must cause marked distress be timeconsuming or significantly interfere with social or occupational functioning in order to meet the dsmiiir circa 1989 diagnosis of ocdobsessions are recurrent persistent ideas thoughts images or impulses that are ego dystonic compulsions are repetitive purposeful and intentional behaviors performed in response to an obsession or in a stereotyped fashion and are recognized by the person as excessive or unreasonablethe effectiveness of clomipramine hydrochloride capsules usp for the treatment of ocd was demonstrated in multicenter placebocontrolled parallelgroup studies including two 10week studies in adults and one 8week study in children and adolescents 10 to 17 years of age patients in all studies had moderatetosevere ocd dsmiii with mean baseline ratings on the yalebrown obsessive compulsive scale ybocs ranging from 26 to 28 and a mean baseline rating of 10 on the nimh clinical global obsessive compulsive scale nimhoc patients taking cmi experienced a mean reduction of approximately 10 on the ybocs representing an average improvement on this scale of 35 to 42 among adults and 37 among children and adolescents cmitreated patients experienced a 35 unit decrement on the nimhoc patients on placebo showed no important clinical response on either scale the maximum dose was 250 mgday for most adults and 3 mgkgday up to 200 mg for all children and adolescentsthe effectiveness of clomipramine hydrochloride capsules usp for longterm use ie for more than 10 weeks has not been systematically evaluated in placebocontrolled trials the physician who elects to use clomipramine hydrochloride capsules usp for extended periods should periodically reevaluate the longterm usefulness of the drug for the individual patient see dosage and administration,3
stromectol is indicated for the treatment of the following infections strongyloidiasis of the intestinal tractstrongyloides stercoralisthis indication is based on clinical studies of both comparative and openlabel designs in which 64100 of infected patients were cured following a single 200mcgkg dose of ivermectin see clinical pharmacology clinical studies onchocerciasisonchocerca volvulusthis indication is based on randomized doubleblind placebocontrolled and comparative studies conducted in 1427 patients in onchocerciasisendemic areas of west africa the comparative studies used diethylcarbamazine citrate decc note stromectol has no activity against adult onchocerca volvulus,3
stromectol is indicated for the treatment of the following infections strongyloidiasis of the intestinal tractstrongyloides stercoralisthis indication is based on clinical studies of both comparative and openlabel designs in which 64100 of infected patients were cured following a single 200mcgkg dose of ivermectin see clinical pharmacology clinical studies onchocerciasisonchocerca volvulusthis indication is based on randomized doubleblind placebocontrolled and comparative studies conducted in 1427 patients in onchocerciasisendemic areas of west africa the comparative studies used diethylcarbamazine citrate decc note stromectol has no activity against adult onchocerca volvulus,3
colchicine tablets usp are an alkaloid indicated for prophylaxis and treatment of gout flares in adults 11familial mediterranean fever fmf in adults and children 4 years or older 12colchicine tablets usp are not an analgesic medication and should not be used to treat pain from other causescolchicine tablets usp are indicated for prophylaxis and the treatment of acute gout flares prophylaxis of gout flares treatment of gout flarescolchicine tablets usp are indicated in adults and children four years or older for treatment of familial mediterranean fever fmf,3
colchicine tablets usp are an alkaloid indicated for prophylaxis and treatment of gout flares in adults 11familial mediterranean fever fmf in adults and children 4 years or older 12colchicine tablets usp are not an analgesic medication and should not be used to treat pain from other causescolchicine tablets usp are indicated for prophylaxis and the treatment of acute gout flares prophylaxis of gout flares treatment of gout flarescolchicine tablets usp are indicated in adults and children four years or older for treatment of familial mediterranean fever fmf,3
acute critical illness 4children with praderwilli syndrome pws who are severely obese or have severe respiratory impairment reports of sudden death 4active malignancy 4hypersensitivity to somatropin or excipients 4active proliferative or severe nonproliferative diabetic retinopathy 4children with closed epiphysis 4 acute critical illnesstreatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery abdominal surgery or multiple accidental trauma or those with acute respiratory failure see warnings and precautions 51 praderwilli syndrome pws in children somatropin is contraindicated in patients with pws who are severely obese have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment there have been reports of sudden death when somatropin was used in such patients nutropin aq is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed pws see warnings and precautions 52 active malignancy in general somatropin is contraindicated in the presence of active malignancy any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin somatropin should be discontinued if there is evidence of recurrent activity since growth hormone deficiency ghd may be an early sign of the presence of a pituitary tumor or rarely other brain tumors the presence of such tumors should be ruled out prior to initiation of treatment somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor see warnings and precautions 53 hypersensitivity nutropin aq is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products see warnings and precautions 56 diabetic retinopathy somatropin is contraindicated in patients with active proliferative or severe nonproliferative diabetic retinopathy closed epiphysis somatropin should not be used for growth promotion in pediatric patients with closed epiphysis,0
acute critical illness 4children with praderwilli syndrome pws who are severely obese or have severe respiratory impairment reports of sudden death 4active malignancy 4hypersensitivity to somatropin or excipients 4active proliferative or severe nonproliferative diabetic retinopathy 4children with closed epiphysis 4 acute critical illnesstreatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery abdominal surgery or multiple accidental trauma or those with acute respiratory failure see warnings and precautions 51 praderwilli syndrome pws in children somatropin is contraindicated in patients with pws who are severely obese have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment there have been reports of sudden death when somatropin was used in such patients nutropin aq is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed pws see warnings and precautions 52 active malignancy in general somatropin is contraindicated in the presence of active malignancy any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin somatropin should be discontinued if there is evidence of recurrent activity since growth hormone deficiency ghd may be an early sign of the presence of a pituitary tumor or rarely other brain tumors the presence of such tumors should be ruled out prior to initiation of treatment somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor see warnings and precautions 53 hypersensitivity nutropin aq is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products see warnings and precautions 56 diabetic retinopathy somatropin is contraindicated in patients with active proliferative or severe nonproliferative diabetic retinopathy closed epiphysis somatropin should not be used for growth promotion in pediatric patients with closed epiphysis,0
condylox gel 05 is indicated for the topical treatment of anogenital warts external genital warts and perianal warts this product is not precautionsalthough anogenital warts have a characteristic appearance histopathologic confirmation should be obtained if there is any doubt of the diagnosis differentiating warts from squamous cell carcinoma and bowenoid papulosis is of particular concern squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with condylox gel 05,3
condylox gel 05 is indicated for the topical treatment of anogenital warts external genital warts and perianal warts this product is not precautionsalthough anogenital warts have a characteristic appearance histopathologic confirmation should be obtained if there is any doubt of the diagnosis differentiating warts from squamous cell carcinoma and bowenoid papulosis is of particular concern squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with condylox gel 05,1
condylox gel 05 is indicated for the topical treatment of anogenital warts external genital warts and perianal warts this product is not precautionsalthough anogenital warts have a characteristic appearance histopathologic confirmation should be obtained if there is any doubt of the diagnosis differentiating warts from squamous cell carcinoma and bowenoid papulosis is of particular concern squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with condylox gel 05,1
predialysis patientscalcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure ccr 15 to 55 mlmin not yet on dialysis in children the creatinine clearance value must be corrected for a surface area of 173 square meters a serum ipth level of 100 pgml is strongly suggestive of secondary hyperparathyroidismdialysis patientscalcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis in these patients calcitriol oral solution administration enhances calcium absorption reduces serum alkaline phosphatase levels and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralizationhypoparathyroidism patientscalcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism idiopathic hypoparathyroidism and pseudohypoparathyroidism,3
predialysis patientscalcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure ccr 15 to 55 mlmin not yet on dialysis in children the creatinine clearance value must be corrected for a surface area of 173 square meters a serum ipth level of 100 pgml is strongly suggestive of secondary hyperparathyroidismdialysis patientscalcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis in these patients calcitriol oral solution administration enhances calcium absorption reduces serum alkaline phosphatase levels and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralizationhypoparathyroidism patientscalcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism idiopathic hypoparathyroidism and pseudohypoparathyroidism,3
natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidismlimitations of use because of the potential risk of osteosarcoma natpara is recommended only for patients who cannot be wellcontrolled on calcium supplements and active forms of vitamin d alone see warnings and precautions 51natpara was not studied in patients with hypoparathyroidism caused by calciumsensing receptor mutationsnatpara was not studied in patients with acute postsurgical hypoparathyroidismnatpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidism 1 limitations of use because of the potential risk of osteosarcoma natpara is recommended only for patients who cannot be wellcontrolled on calcium supplements and active forms of vitamin d alone 51 natpara was not studied in patients with hypoparathyroidism caused by calciumsensing receptor mutations natpara was not studied in patients with acute postsurgical hypoparathyroidism,3
aminocaproic acid should not be used when there is evidence of an active intravascular clotting processwhen there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation dic this distinction must be made before administering aminocaproic acid injectionthe following tests can be applied to differentiate the two conditions platelet count is usually decreased in dic but normal in primary fibrinolysis protamine paracoagulation test is positive in dic a precipitate forms when protamine sulfate is dropped into citrated plasma the test is negative in the presence of primary fibrinolysis the euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in dicaminocaproic acid injection must not be used in the presence of dic without concomitant heparin,2
heparin sodium injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who for other reasons are at risk of developing thromboembolic disease atrial fibrillation with embolization treatment of acute and chronic consumptive coagulopathies disseminated intravascular coagulation prevention of clotting in arterial and cardiac surgery prophylaxis and treatment of peripheral arterial embolism anticoagulant use in blood transfusions extracorporeal circulation and dialysis procedures heparin sodium injection is an anticoagulant indicated for 1 prophylaxis and treatment of venous thrombosis and pulmonary embolism prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who for other reasons are at risk of developing thromboembolic disease atrial fibrillation with embolization treatment of acute and chronic consumptive coagulopathies disseminated intravascular coagulation prevention of clotting in arterial and cardiac surgery prophylaxis and treatment of peripheral arterial embolism use as an anticoagulant in blood transfusions extracorporeal circulation and dialysis procedures,3
for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachomaescherichia coli staphylococcus aureus streptococcus pneumoniae streptococcus viridans group haemophilus influenzae klebsiella species and enterobacter speciestopically applied sulfonamides do not provide adequate coverage against neisseria species serratia marcescens and pseudomonas aeruginosa a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs,3
spravato is contraindicated in patients with aneurysmal vascular disease including thoracic and abdominal aorta intracranial and peripheral arterial vessels or arteriovenous malformation see warnings and precautions 56history of intracerebral hemorrhage see warnings and precautions 56hypersensitivity to esketamine ketamine or any of the excipients aneurysmal vascular disease including thoracic and abdominal aorta intracranial and peripheral arterial vessels or arteriovenous malformation 4intracerebral hemorrhage 4hypersensitivity to esketamine ketamine or any of the excipients 4,2
for the management of manifestations of psychotic disorders for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance,3
for the management of manifestations of psychotic disorders for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance,3
for the management of manifestations of psychotic disorders for the treatment of schizophrenia to control nausea and vomiting for relief of restlessness and apprehension before surgery for acute intermittent porphyria as an adjunct in the treatment of tetanus to control the manifestations of the manic type of manicdepressive illness for relief of intractable hiccups for the treatment of severe behavioral problems in children 1 to 12 years of age marked by combativeness andor explosive hyperexcitable behavior out of proportion to immediate provocations and in the shortterm treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms impulsivity difficulty sustaining attention aggressivity mood lability and poor frustration tolerance,3
diazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticin acute alcohol withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor impending or acute delirium tremens and hallucinosisas an adjunct prior to endoscopic procedures if apprehension anxiety or acute stress reactions are present and to diminish the patients recall of the procedures see warningsdiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology such as inflammation of the muscles or joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis stiffman syndrome and tetanusinjectable diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizuresdiazepam is a useful premedication the intramuscular route is preferred for relief of anxiety and tension in patients who are to undergo surgical procedures intravenously prior to cardioversion for the relief of anxiety and tension and to diminish the patients recall of the procedure,2
diazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticin acute alcohol withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor impending or acute delirium tremens and hallucinosisas an adjunct prior to endoscopic procedures if apprehension anxiety or acute stress reactions are present and to diminish the patients recall of the procedures see warningsdiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology such as inflammation of the muscles or joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis stiffman syndrome and tetanusinjectable diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizuresdiazepam is a useful premedication the intramuscular route is preferred for relief of anxiety and tension in patients who are to undergo surgical procedures intravenously prior to cardioversion for the relief of anxiety and tension and to diminish the patients recall of the procedure,3
diazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticin acute alcohol withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor impending or acute delirium tremens and hallucinosisas an adjunct prior to endoscopic procedures if apprehension anxiety or acute stress reactions are present and to diminish the patients recall of the procedures see warningsdiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology such as inflammation of the muscles or joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis stiffman syndrome and tetanusinjectable diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizuresdiazepam is a useful premedication the intramuscular route is preferred for relief of anxiety and tension in patients who are to undergo surgical procedures intravenously prior to cardioversion for the relief of anxiety and tension and to diminish the patients recall of the procedure,3
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,0
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,3
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,3
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,2
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,3
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,3
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturateshypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanestheticlongterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depressionphenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,3
testosterone gel 162 is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired testicular failure due to conditions such as cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchiectomy klinefelters syndrome chemotherapy or toxic damage from alcohol or heavy metals these men usually have low serum testosterone concentrations and gonadotropins folliclestimulating hormone fsh luteinizing hormone lh above the normal rangehypogonadotropic hypogonadism congenital or acquired gonadotropin or luteinizing hormonereleasing hormone lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiation these men have low testosterone serum concentrations but have gonadotropins in the normal or low rangelimitations of use safety and efficacy of testosterone gel 162 in men with agerelated hypogonadism also referred to as lateonset hypogonadism have not been established safety and efficacy of testosterone gel 162 in males less than 18 years old have not been established seeuse in specific populations 84topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure seeindications and usage 1andclinical pharmacology 123testosterone gel 162 is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired 1hypogonadotropic hypogonadism congenital or acquired 1limitations of use safety and efficacy of testosterone gel 162 in men with agerelated hypogonadism have not been established 1safety and efficacy of testosterone gel 162 in males less than 18 years old have not been established 184topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure 1123,3
testosterone gel 162 is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired testicular failure due to conditions such as cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchiectomy klinefelters syndrome chemotherapy or toxic damage from alcohol or heavy metals these men usually have low serum testosterone concentrations and gonadotropins folliclestimulating hormone fsh luteinizing hormone lh above the normal rangehypogonadotropic hypogonadism congenital or acquired gonadotropin or luteinizing hormonereleasing hormone lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiation these men have low testosterone serum concentrations but have gonadotropins in the normal or low rangelimitations of use safety and efficacy of testosterone gel 162 in men with agerelated hypogonadism also referred to as lateonset hypogonadism have not been established safety and efficacy of testosterone gel 162 in males less than 18 years old have not been established seeuse in specific populations 84topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure seeindications and usage 1andclinical pharmacology 123testosterone gel 162 is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired 1hypogonadotropic hypogonadism congenital or acquired 1limitations of use safety and efficacy of testosterone gel 162 in men with agerelated hypogonadism have not been established 1safety and efficacy of testosterone gel 162 in males less than 18 years old have not been established 184topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure 1123,3
testosterone gel 162 is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired testicular failure due to conditions such as cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchiectomy klinefelters syndrome chemotherapy or toxic damage from alcohol or heavy metals these men usually have low serum testosterone concentrations and gonadotropins folliclestimulating hormone fsh luteinizing hormone lh above the normal rangehypogonadotropic hypogonadism congenital or acquired gonadotropin or luteinizing hormonereleasing hormone lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiation these men have low testosterone serum concentrations but have gonadotropins in the normal or low rangelimitations of use safety and efficacy of testosterone gel 162 in men with agerelated hypogonadism also referred to as lateonset hypogonadism have not been established safety and efficacy of testosterone gel 162 in males less than 18 years old have not been established seeuse in specific populations 84topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure seeindications and usage 1andclinical pharmacology 123testosterone gel 162 is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired 1hypogonadotropic hypogonadism congenital or acquired 1limitations of use safety and efficacy of testosterone gel 162 in men with agerelated hypogonadism have not been established 1safety and efficacy of testosterone gel 162 in males less than 18 years old have not been established 184topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure 1123,3
androxytmtesticular failure due to cryptorchidism bilateral torsion orchitis vanishing testis syndrome or orchidectomyidiopathic gonadotropin or luteinizing hormonereleasing hormone lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiation appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary however and are actually of primary importanceif the above conditions occur prior to puberty androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty androxytmsee warnings androxytm,3
in the treatment of parkinsonism rigidity and tremor relieved by the apparently selective depressant actionin the gastrointestinal tract to relieve pylorospasm hypertonicity of the small intestine and the hypermotility of the colonto relieve hypertonicity of the uterine muscleto relax the spasm of biliary and uretered colic and bronchial spasmto diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disordersto control the crying and laughing episodes in patients with brain lesionsin cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns stupor and neurological signsin the management of peptic ulcerin anesthesia to control excessive salivation and bronchial secretionsto control rhinorrhea of acute rhinitis or hay feveras an antidote for pilocarpine physostigmine isoflurophate choline esters certain species of aminata and in cases of anticholinesterase insecticide poisoningin poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases large doses of atropine relieve the muscarinelike symptoms and some of the centralnervoussystem manifestations adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate 08 mg intramuscularly if an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur nausea vomiting diarrhea pupillary constriction pulmonary edema fasciculations of eyelids and tongue jerky ocular movements and excessive sweating salivation and bronchial secretion atropine sulfate 2 mg should be given intramuscularly at hourly intervals until signs of atropinization are observed up to two or three times this dose 4 to 6 mg may be required in severe cases removing contaminated clothing washing the skin and commencing artificial respiration and supportive therapy are also indicated,2
in the treatment of parkinsonism rigidity and tremor relieved by the apparently selective depressant actionin the gastrointestinal tract to relieve pylorospasm hypertonicity of the small intestine and the hypermotility of the colonto relieve hypertonicity of the uterine muscleto relax the spasm of biliary and uretered colic and bronchial spasmto diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disordersto control the crying and laughing episodes in patients with brain lesionsin cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns stupor and neurological signsin the management of peptic ulcerin anesthesia to control excessive salivation and bronchial secretionsto control rhinorrhea of acute rhinitis or hay feveras an antidote for pilocarpine physostigmine isoflurophate choline esters certain species of aminata and in cases of anticholinesterase insecticide poisoningin poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases large doses of atropine relieve the muscarinelike symptoms and some of the centralnervoussystem manifestations adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate 08 mg intramuscularly if an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur nausea vomiting diarrhea pupillary constriction pulmonary edema fasciculations of eyelids and tongue jerky ocular movements and excessive sweating salivation and bronchial secretion atropine sulfate 2 mg should be given intramuscularly at hourly intervals until signs of atropinization are observed up to two or three times this dose 4 to 6 mg may be required in severe cases removing contaminated clothing washing the skin and commencing artificial respiration and supportive therapy are also indicated,0
parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations edemafurosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome furosemide is particularly useful when an agent with greater diuretic potential is desiredfurosemide is indicated as adjunctive therapy in acute pulmonary edema the intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edemaif gastrointestinal absorption is impaired or oral medication is not practical for any reason furosemide is indicated by the intravenous or intramuscular route parenteral use should be replaced with oral furosemide as soon as practical,3
parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations edemafurosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome furosemide is particularly useful when an agent with greater diuretic potential is desiredfurosemide is indicated as adjunctive therapy in acute pulmonary edema the intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edemaif gastrointestinal absorption is impaired or oral medication is not practical for any reason furosemide is indicated by the intravenous or intramuscular route parenteral use should be replaced with oral furosemide as soon as practical,3
parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations edemafurosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome furosemide is particularly useful when an agent with greater diuretic potential is desiredfurosemide is indicated as adjunctive therapy in acute pulmonary edema the intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edemaif gastrointestinal absorption is impaired or oral medication is not practical for any reason furosemide is indicated by the intravenous or intramuscular route parenteral use should be replaced with oral furosemide as soon as practical,3
ethacrynic acid tablets is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required treatment of the edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome shortterm management of ascites due to malignancy idiopathic edema and lymphedema shortterm management of hospitalized pediatric patients other than infants with congenital heart disease or the nephrotic syndrome intravenous ethacrynic acid sodium is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edema or when gastrointestinal absorption is impaired or oral medication is not practicable,3
ethacrynic acid tablets is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required treatment of the edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome shortterm management of ascites due to malignancy idiopathic edema and lymphedema shortterm management of hospitalized pediatric patients other than infants with congenital heart disease or the nephrotic syndrome intravenous ethacrynic acid sodium is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edema or when gastrointestinal absorption is impaired or oral medication is not practicable,3
ethacrynic acid tablets is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required treatment of the edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome shortterm management of ascites due to malignancy idiopathic edema and lymphedema shortterm management of hospitalized pediatric patients other than infants with congenital heart disease or the nephrotic syndrome intravenous ethacrynic acid sodium is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edema or when gastrointestinal absorption is impaired or oral medication is not practicable,3
ethacrynic acid tablets is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required treatment of the edema associated with congestive heart failure cirrhosis of the liver and renal disease including the nephrotic syndrome shortterm management of ascites due to malignancy idiopathic edema and lymphedema shortterm management of hospitalized pediatric patients other than infants with congenital heart disease or the nephrotic syndrome intravenous ethacrynic acid sodium is indicated when a rapid onset of diuresis is desired eg in acute pulmonary edema or when gastrointestinal absorption is impaired or oral medication is not practicable,3
hypersensitivity to hydralazine coronary artery disease mitral valvular rheumatic heart disease,3
hypersensitivity to hydralazine coronary artery disease mitral valvular rheumatic heart disease,3
ischemic heart disease coronary artery vasospasm or other significant underlying cardiovascular disease 41cerebrovascular syndromes eg history of stroke or tia 42peripheral vascular disease including ischemic bowel disease 43uncontrolled hypertension 44do not use almotriptan tablets within 24 hours of an ergotaminecontaining or ergottype medication or of another 5ht14546hemiplegic or basilar migraine 47known hypersensitivity to almotriptan tablets 48do not use almotriptan tablets in patients with ischemic heart disease angina pectoris history of myocardial infarction or documented silent ischemia or in patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings and precautions 51do not use almotriptan tablets in patients with cerebrovascular syndromes including but not limited to stroke of any type as well as transient ischemic attacks see warnings and precautions 53do not use almotriptan tablets in patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings and precautions 54because almotriptan tablets may increase blood pressure do not use almotriptan tablets in patients with uncontrolled hypertension see warnings and precautions 57do not use almotriptan tablets and ergotaminecontaining or ergotderived medications like dihydroergotamine ergotamine tartrate or methysergide within 24 hours of each other see drug interactions 71almotriptan tablets and other 5ht1see warnings and precautions 5152do not use almotriptan tablets in patients with hemiplegic or basilar migrainealmotriptan tablets are contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients,0
ischemic heart disease coronary artery vasospasm or other significant underlying cardiovascular disease 41cerebrovascular syndromes eg history of stroke or tia 42peripheral vascular disease including ischemic bowel disease 43uncontrolled hypertension 44do not use almotriptan tablets within 24 hours of an ergotaminecontaining or ergottype medication or of another 5ht14546hemiplegic or basilar migraine 47known hypersensitivity to almotriptan tablets 48do not use almotriptan tablets in patients with ischemic heart disease angina pectoris history of myocardial infarction or documented silent ischemia or in patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings and precautions 51do not use almotriptan tablets in patients with cerebrovascular syndromes including but not limited to stroke of any type as well as transient ischemic attacks see warnings and precautions 53do not use almotriptan tablets in patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings and precautions 54because almotriptan tablets may increase blood pressure do not use almotriptan tablets in patients with uncontrolled hypertension see warnings and precautions 57do not use almotriptan tablets and ergotaminecontaining or ergotderived medications like dihydroergotamine ergotamine tartrate or methysergide within 24 hours of each other see drug interactions 71almotriptan tablets and other 5ht1see warnings and precautions 5152do not use almotriptan tablets in patients with hemiplegic or basilar migrainealmotriptan tablets are contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients,2
rizatriptan benzoate tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51coronary artery vasospasm including prinzmetals angina see warnings and precautions 51history of stroke or transient ischemic attack tia see warnings and precautions 54peripheral vascular disease pvd see warnings and precautions 55ischemic bowel disease see warnings and precautions 55uncontrolled hypertension see warnings and precautions 58recent use ie within 24 hours of another 5ht 1 see drug interactions 7273hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75clinical pharmacology 123hypersensitivity to rizatriptan benzoate tablets angioedema and anaphylaxis seen see adverse reactions 62 history of ischemic heart disease or coronary artery vasospasm 4history of stroke or transient ischemic attack 4peripheral vascular disease 4ischemic bowel disease 4uncontrolled hypertension 4recent within 24 hours use of another 5ht 14hemiplegic or basilar migraine 4maoa inhibitor used in the past 2 weeks 4hypersensitivity to rizatriptan 4,2
rizatriptan benzoate tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51coronary artery vasospasm including prinzmetals angina see warnings and precautions 51history of stroke or transient ischemic attack tia see warnings and precautions 54peripheral vascular disease pvd see warnings and precautions 55ischemic bowel disease see warnings and precautions 55uncontrolled hypertension see warnings and precautions 58recent use ie within 24 hours of another 5ht 1 see drug interactions 7273hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75clinical pharmacology 123hypersensitivity to rizatriptan benzoate tablets angioedema and anaphylaxis seen see adverse reactions 62 history of ischemic heart disease or coronary artery vasospasm 4history of stroke or transient ischemic attack 4peripheral vascular disease 4ischemic bowel disease 4uncontrolled hypertension 4recent within 24 hours use of another 5ht 14hemiplegic or basilar migraine 4maoa inhibitor used in the past 2 weeks 4hypersensitivity to rizatriptan 4,2
to reduce the development of drugresistant bacteria and maintain the effectiveness of ertapenem and other antibacterial drugs ertapenem should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy see dosage and administration 2ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients 3 months of age and older for the treatment of the following moderate to severe infections caused by susceptible bacteria complicated intraabdominal infections 11complicated skin and skin structure infections including diabetic foot infections without osteomyelitis 12communityacquired pneumonia 13complicated urinary tract infections including pyelonephritis 14acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections 15ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery 16ertapenem for injection is indicated for the treatment of complicated intraabdominal infections due to escherichia coliclostridium clostridioformeeubacterium lentumpeptostreptococcus bacteroides fragilisbacteroides distasonisbacteroides ovatusbacteroides thetaiotaomicronbacteroides uniformisertapenem for injection is indicated for the treatment of complicated skin and skin structure infections including diabetic foot infections without osteomyelitis due to staphylococcus aureus streptococcus agalactiaestreptococcus pyogenesescherichia coliklebsiella pneumoniaeproteus mirabilisbacteroides fragilispeptostreptococcus porphyromonas asaccharolyticaprevotella biviasee clinical studies 14ertapenem for injection is indicated for the treatment of community acquired pneumonia due to streptococcus pneumoniae haemophilus influenzae moraxella catarrhalisertapenem for injection is indicated for the treatment of complicated urinary tract infections including pyelonephritis due to escherichia coliklebsiella pneumoniaeertapenem for injection is indicated for the treatment of acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecological infections due to streptococcus agalactiae escherichia colibacteroides fragilis porphyromonas asaccharolytica peptostreptococcus prevotella bivia ertapenem for injection is indicated for the prevention of surgical site infection following elective colorectal surgery,3
doripenem for injection is a penem antibacterial indicated in the treatment of the following infections caused by designated susceptible bacteria complicated intraabdominal infections 11complicated urinary tract infections including pyelonephritis 12to reduce the development of drugresistant bacteria and maintain the effectiveness of doripenem for injection and other antibacterial drugs doripenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria 13doripenem for injection is indicated as a single agent for the treatment of complicated intraabdominal infections caused by escherichia coli klebsiella pneumoniae pseudomonas aeruginosa bacteroides caccae bacteroides fragilis bacteroides thetaiotaomicron bacteroides uniformis bacteroides vulgatus streptococcus intermedius streptococcus constellatuspeptostreptococcus microsdoripenem for injection is indicated as a single agent for the treatment of complicated urinary tract infections including pyelonephritis caused by escherichia coliklebsiella pneumoniaeproteus mirabilispseudomonas aeruginosaacinetobacter baumanniito reduce the development of drugresistant bacteria and maintain the effectiveness of doripenem for injection and other antibacterial drugs doripenem for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting and modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy topical vaginal products should be considered treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease treatment of advanced androgendependent carcinoma of the prostate for palliation only prevention of postmenopausal osteoporosis when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and for whom nonestrogen medications are not considered to be appropriate see clinical studiesthe mainstays for decreasing the risk of postmenopausal osteoporosis are weightbearing exercise adequate calcium and vitamin d intake and when indicated pharmacologic therapy postmenopausal women require an average of 1500 mgday of elemental calcium therefore when not contraindicated calcium supplementation may be helpful for women with suboptimal dietary intake vitamin d supplementation of 400800 iuday may also be required to ensure adequate daily intake in postmenopausal women,3
treatment of moderate to severe vasomotor symptoms due to menopause treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy topical vaginal products should be considered treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease treatment of advanced androgendependent carcinoma of the prostate for palliation only prevention of postmenopausal osteoporosis when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and for whom nonestrogen medications are not considered to be appropriate see clinical studiesthe mainstays for decreasing the risk of postmenopausal osteoporosis are weightbearing exercise adequate calcium and vitamin d intake and when indicated pharmacologic therapy postmenopausal women require an average of 1500 mgday of elemental calcium therefore when not contraindicated calcium supplementation may be helpful for women with suboptimal dietary intake vitamin d supplementation of 400800 iuday may also be required to ensure adequate daily intake in postmenopausal women,3
reclast is a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis 1112treatment to increase bone mass in men with osteoporosis 13treatment and prevention of glucocorticoidinduced osteoporosis 14treatment of pagets disease of bone in men and women 15limitations of use16reclast is indicated for treatment of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis diagnosed by bone mineral density bmd or prevalent vertebral fracture reclast reduces the incidence of fractures hip vertebral and nonvertebral osteoporosisrelated fractures in patients at high risk of fracture defined as a recent lowtrauma hip fracture reclast reduces the incidence of new clinical fractures see clinical studies 141reclast is indicated for prevention of osteoporosis in postmenopausal women see clinical studies 142reclast is indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 143reclast is indicated for the treatment and prevention of glucocorticoidinduced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 75 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months see clinical studies144reclast is indicated for treatment of pagets disease of bone in men and women treatment is indicated in patients with pagets disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the agespecific normal reference range or those who are symptomatic or those at risk for complications from their disease see clinical studies 145 the safety and effectiveness of reclast for the treatment of osteoporosis is based on clinical data of three years duration the optimal duration of use has not been determined all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
reclast is a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis 1112treatment to increase bone mass in men with osteoporosis 13treatment and prevention of glucocorticoidinduced osteoporosis 14treatment of pagets disease of bone in men and women 15limitations of use16reclast is indicated for treatment of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis diagnosed by bone mineral density bmd or prevalent vertebral fracture reclast reduces the incidence of fractures hip vertebral and nonvertebral osteoporosisrelated fractures in patients at high risk of fracture defined as a recent lowtrauma hip fracture reclast reduces the incidence of new clinical fractures see clinical studies 141reclast is indicated for prevention of osteoporosis in postmenopausal women see clinical studies 142reclast is indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 143reclast is indicated for the treatment and prevention of glucocorticoidinduced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 75 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months see clinical studies144reclast is indicated for treatment of pagets disease of bone in men and women treatment is indicated in patients with pagets disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the agespecific normal reference range or those who are symptomatic or those at risk for complications from their disease see clinical studies 145 the safety and effectiveness of reclast for the treatment of osteoporosis is based on clinical data of three years duration the optimal duration of use has not been determined all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
oxandrolone tablets usp are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery chronic infections or severe trauma and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight to offset the protein catabolism associated with prolonged administration of corticosteroids and for the relief of the bone pain frequently accompanying osteoporosis see dosage and administration,2
estropipate tablets are indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy topical vaginal products should be considered treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure prevention of postmenopausal osteoporosis when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and for whom nonestrogen medications are not considered to be appropriatethe mainstays for decreasing the risk of postmenopausal osteoporosis are weightbearing exercise adequate calcium and vitamin d intake and when indicated pharmacologic therapy postmenopausal women require an average of 1500 mgday of elemental calcium therefore when not contraindicated calcium supplementation may be helpful for women with suboptimal dietary intake vitamin d supplementation of 400800 iuday may also be required to ensure adequate daily intake in postmenopausal women,3
ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women 11limitations of useoptimal duration of use has not been determined for patients at lowrisk for fracture consider drug discontinuation after 3 to 5 years of use 12ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis ibandronate sodium injection increases bone mineral density bmd and reduces the incidence of vertebral fractures see clinical studies 14 the safety and effectiveness of ibandronate sodium injection for the treatment of osteoporosis are based on clinical data of one year duration the optimal duration of use has not been determined all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
estradiol tablets usp is indicated in the 1treatment of moderate to severe vasomotor symptoms associated with the menopause 2treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy topical vaginal products should be considered 3 treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure 4 treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease 5 treatment of advanced androgendependent carcinoma of the prostate for palliation only 6 prevention of osteoporosis when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and for whom nonestrogen medications are not considered to be appropriate see clinical pharmacologyclinical studiesthe mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise adequate calcium and vitamin d intake and when indicated pharmacologic therapy postmenopausal women require an average of 1500 mgday of elemental calcium therefore when not contraindicated calcium supplementation may be helpful for women with suboptimal dietary intake vitamin d supplementation of 400800 iuday may also be required to ensure adequate daily intake in postmenopausal women,3
estradiol tablets usp is indicated in the 1treatment of moderate to severe vasomotor symptoms associated with the menopause 2treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy topical vaginal products should be considered 3 treatment of hypoestrogenism due to hypogonadism castration or primary ovarian failure 4 treatment of breast cancer for palliation only in appropriately selected women and men with metastatic disease 5 treatment of advanced androgendependent carcinoma of the prostate for palliation only 6 prevention of osteoporosis when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and for whom nonestrogen medications are not considered to be appropriate see clinical pharmacologyclinical studiesthe mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise adequate calcium and vitamin d intake and when indicated pharmacologic therapy postmenopausal women require an average of 1500 mgday of elemental calcium therefore when not contraindicated calcium supplementation may be helpful for women with suboptimal dietary intake vitamin d supplementation of 400800 iuday may also be required to ensure adequate daily intake in postmenopausal women,2
risedronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis 11 treatment to increase bone mass in men with osteoporosis 12treatment and prevention of glucocorticoidinduced osteoporosis 13treatment of pagets disease 14limitations of useoptimal duration of use has not been determined for patients at lowrisk for fracture consider drug discontinuation after 3 to 5 years of use 15risedronate sodium tablets usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis risedronate sodium tablets usp reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosisrelated fractures see clinical studies 141142risedronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosisrisedronate sodium tablets usp are indicated for the treatment and prevention of glucocorticoidinduced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment daily dosage of greater than or equal to 75 mg of prednisone or equivalent for chronic diseases patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin drisedronate sodium tablets usp are indicated for treatment of pagets disease of bone in men and women the optimal duration of use has not been determined the safety and effectiveness of risedronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of three years duration all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
prolia is a rank ligand rankl inhibitor indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture 11treatment to increase bone mass in men with osteoporosis at high risk for fracture 12treatment of glucocorticoidinduced osteoporosis in men and women at high risk for fracture 13treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer 14treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer 15prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy in postmenopausal women with osteoporosis prolia reduces the incidence of vertebral nonvertebral and hip fractures see clinical studies 141prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 142 prolia is indicated for the treatment of glucocorticoidinduced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 75 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months high risk of fracture is defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 143prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer in these patients prolia also reduced the incidence of vertebral fractures see clinical studies 144prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer see clinical studies 145,3
proleukinrproleukin is contraindicated in patients with an abnormal thallium stress test or abnormal pulmonary function tests and those with organ allografts retreatment with proleukin is contraindicated in patients who have experienced the following drugrelated toxicities while receiving an earlier course of therapy sustained ventricular tachycardia 5 beats cardiac arrhythmias not controlled or unresponsive to management chest pain with ecg changes consistent with angina or myocardial infarction cardiac tamponade intubation for 72 hours renal failure requiring dialysis 72 hours coma or toxic psychosis lasting 48 hours repetitive or difficult to control seizures bowel ischemiaperforation gi bleeding requiring surgery,3
pantoprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6 proton pump inhibitors ppis including pantoprazole sodium delayedrelease tablets are contraindicated in patients receiving rilpivirinecontaining products see drug interactions 7 patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles 4patients receiving rilpivirinecontaining products 4,1
patients with a history of hypersensitivity to rabeprazole 4ppis including rabeprazole sodium delayedrelease tablets are contraindicated in patients receiving rilpivirinecontaining products 47refer to the contraindications section of the prescribing information for clarithromycin and amoxicillin when administered in combination with rabeprazole 4 rabeprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to rabeprazole substituted benzimidazoles or to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6ppis including rabeprazole sodium delayedrelease tablets are contraindicated with rilpivirinecontaining products see drug interactions 7for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with rabeprazole sodium delayedrelease tablets refer to the contraindications,2
omeprazole delayedrelease capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm interstitial nephritis and urticaria omeprazole delayedrelease capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm interstitial nephritis and urticaria see warnings and precautions 526 proton pump inhibitors ppis including omeprazole are contraindicated in patients receiving rilpivirinecontaining products see drug interactions 7 for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with omeprazole refer to the section of their package inserts for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with omeprazole refer to the contraindications patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation 4patients receiving rilpivirinecontaining products 47refer to the contraindications section of the prescribing information for clarithromycin and amoxicillin when administered in combination with omeprazole 4,1
adasuve is contraindicated in patients with the following current diagnosis or history of asthma copd or other lung disease associated with bronchospasm see warnings and precautions 51acute respiratory symptoms or signs eg wheezing see warnings and precautions 51current use of medications to treat airways disease such as asthma or copd see warnings and precautions 51history of bronchospasm following adasuve treatment see warnings and precautions 51known hypersensitivity to loxapine or amoxapine serious skin reactions have occurred with oral loxapine and amoxapine current diagnosis or history of asthma chronic obstructive pulmonary disease copd or other lung disease associated with bronchospasm 4acute respiratory signssymptoms eg wheezing 4current use of medications to treat airways disease such as asthma or copd 4history of bronchospasm following adasuve treatment 4known hypersensitivity to loxapine or amoxapine 4,1
adasuve is contraindicated in patients with the following current diagnosis or history of asthma copd or other lung disease associated with bronchospasm see warnings and precautions 51acute respiratory symptoms or signs eg wheezing see warnings and precautions 51current use of medications to treat airways disease such as asthma or copd see warnings and precautions 51history of bronchospasm following adasuve treatment see warnings and precautions 51known hypersensitivity to loxapine or amoxapine serious skin reactions have occurred with oral loxapine and amoxapine current diagnosis or history of asthma chronic obstructive pulmonary disease copd or other lung disease associated with bronchospasm 4acute respiratory signssymptoms eg wheezing 4current use of medications to treat airways disease such as asthma or copd 4history of bronchospasm following adasuve treatment 4known hypersensitivity to loxapine or amoxapine 4,1
patients with hypersensitivity to salicylates or to any of the components of balsalazide disodium capsules or balsalazide metabolites hypersensitivity reactions may include but are not limited to the following anaphylaxis bronchospasm and skin reactionpatients with hypersensitivity to salicylates or to any of the components of balsalazide disodium capsules or balsalazide metabolites hypersensitivity reactions may include but are not limited to the following anaphylaxis bronchospasm and skin reaction 4,1
atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions eg angioedema bronchospasm throat tightness urticaria to atovaquone or any of the components of atovaquone oral suspensionknown serious allergichypersensitivity reaction eg angioedema bronchospasm throat tightness urticaria to atovaquone or any of the components of atovaquone oral suspension 4,1
metoclopramide tablets are contraindicated metoclopramide tablets are contraindicated in patients with a history of tardive dyskinesia td or a dystonic reaction to metoclopramide see warnings and precautions 51 52 when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide tablets may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide tablets may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor see warnings and precautions 55 in patients with epilepsy metoclopramide tablets may increase the frequency and severity of seizures in patients with epilepsy metoclopramide tablets may increase the frequency and severity of seizures see adverse reactions 6 in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm see adverse reactions 6 history of td or dystonic reaction to metoclopramide 4 when stimulation of gastrointestinal motility might be dangerous 4 pheochromocytoma catecholaminereleasing paragangliomas 4 epilepsy 4 hypersensitivity to metoclopramide 4,1
metoclopramide tablets are contraindicated metoclopramide tablets are contraindicated in patients with a history of tardive dyskinesia td or a dystonic reaction to metoclopramide see warnings and precautions 51 52 when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide tablets may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide tablets may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor see warnings and precautions 55 in patients with epilepsy metoclopramide tablets may increase the frequency and severity of seizures in patients with epilepsy metoclopramide tablets may increase the frequency and severity of seizures see adverse reactions 6 in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm see adverse reactions 6 history of td or dystonic reaction to metoclopramide 4 when stimulation of gastrointestinal motility might be dangerous 4 pheochromocytoma catecholaminereleasing paragangliomas 4 epilepsy 4 hypersensitivity to metoclopramide 4,0
neostigmine is contraindicated in patients with known hypersensitivity to neostigmine methylsulfate known hypersensitivity reactions have included urticaria angioedema erythema multiforme generalized rash facial swelling peripheral edema pyrexia flushing hypotension bronchospasm bradycardia and anaphylaxis peritonitis or mechanical obstruction of the urinary or intestinal tracts hypersensitivity to neostigmine 4peritonitis or mechanical obstruction of urinary or intestinal tracts 4,0
entyvio is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to entyvio or any of its excipients such as dyspnea bronchospasm urticaria flushing rash and increased heart rate see warnings and precautions 51adverse reactions 61patients who have had a known serious or severe hypersensitivity reaction to entyvio or any of its excipients 4,0
levalbuterol tartrate hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol racemic albuterol or any other component of levalbuterol tartrate hfa inhalation aerosol reactions have included urticaria angioedema rash bronchospasm anaphylaxis and oropharyngeal edemahypersensitivity to levalbuterol racemic albuterol or any other component of levalbuterol tartrate hfa inhalation aerosol 4,1
dyrenium triamterene is indicated in the treatment of edema associated with congestive heart failure cirrhosis of the liver and the nephrotic syndrome steroidinduced edema idiopathic edema and edema due to secondary hyperaldosteronism dyrenium may be used alone or with other diuretics either for its added diuretic effect or its potassiumsparing potential it also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism usage in pregnancyedema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy diuretics are indicated in pregnancy however see precautions,3
dyrenium triamterene is indicated in the treatment of edema associated with congestive heart failure cirrhosis of the liver and the nephrotic syndrome steroidinduced edema idiopathic edema and edema due to secondary hyperaldosteronism dyrenium may be used alone or with other diuretics either for its added diuretic effect or its potassiumsparing potential it also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism usage in pregnancyedema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy diuretics are indicated in pregnancy however see precautions,3
dyrenium triamterene is indicated in the treatment of edema associated with congestive heart failure cirrhosis of the liver and the nephrotic syndrome steroidinduced edema idiopathic edema and edema due to secondary hyperaldosteronism dyrenium may be used alone or with other diuretics either for its added diuretic effect or its potassiumsparing potential it also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism usage in pregnancyedema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy diuretics are indicated in pregnancy however see precautions,3
bumetanide tablets usp are indicated for the treatment of edema associated with congestive heart failure hepatic and renal disease including the nephrotic syndromealmost equal diuretic response occurs after oral and parenteral administration of bumetanide therefore if impaired gastrointestinal absorption is suspected or oral administration is not practical bumetanide should be given by the intramuscular or intravenous route successful treatment with bumetanide tablets usp following instances of allergic reactions to furosemide suggests a lack of crosssensitivitybumetanide is contraindicated in anuria although bumetanide tablets can be used to induce diuresis in renal insufficiency any marked increase in blood urea nitrogen or creatinine or the development of oliguria during therapy of patients with progressive renal disease is an indication for discontinuation of treatment with bumetanide tablets bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected bumetanide is contraindicated in patients hypersensitive to this drug,2
bumetanide tablets usp are indicated for the treatment of edema associated with congestive heart failure hepatic and renal disease including the nephrotic syndromealmost equal diuretic response occurs after oral and parenteral administration of bumetanide therefore if impaired gastrointestinal absorption is suspected or oral administration is not practical bumetanide should be given by the intramuscular or intravenous route successful treatment with bumetanide tablets usp following instances of allergic reactions to furosemide suggests a lack of crosssensitivitybumetanide is contraindicated in anuria although bumetanide tablets can be used to induce diuresis in renal insufficiency any marked increase in blood urea nitrogen or creatinine or the development of oliguria during therapy of patients with progressive renal disease is an indication for discontinuation of treatment with bumetanide tablets bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected bumetanide is contraindicated in patients hypersensitive to this drug,1
eletriptan hydrobromide tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52history of stroke transient ischemic attack tia or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54peripheral vascular disease see warnings and precautions 55ischemic bowel disease see warnings and precautions 55uncontrolled hypertension see warnings and precautions 58recent use ie within 24 hours of another 5hydroxytryptamine11see drug interactions 71hypersensitivity to eletriptan hydrobromide tablets angioedema and anaphylaxis seen see warnings and precautions 59recent use ie within at least 72 hours of the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir see drug interactions 72 and clinical pharmacology 123 history of coronary artery disease cad or coronary artery vasospasm 4wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4history of stroke transient ischemic attack or history or current evidence of hemiplegic or basilar migraine 4peripheral vascular disease 4ischemic bowel disease 4uncontrolled hypertension 4within 24 hours of treatment with another 5ht14hypersensitivity to eletriptan hydrobromide tablets angioedema and anaphylaxis seen 4within at least 72 hours of treatment with the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir 4,0
naratriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 agonist ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide see drug interactions 71 72 hypersensitivity to naratriptan angioedema and anaphylaxis seen see warnings and precautions 59 severe renal or hepatic impairment see use in specific populations 86 87 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 agonist eg another triptan or an ergotaminecontaining medication 4 hypersensitivity to naratriptan angioedema and anaphylaxis seen 4 severe renal or hepatic impairment 4,1
frovatriptan succinate tablets are contraindicated in patients with ischemic coronary artery disease cad eg angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54peripheral vascular disease see warnings and precautions 55ischemic bowel disease see warnings and precautions 55uncontrolled hypertension see warnings and precautions 58recent use ie within 24 hours of another 5ht1see drug interactions 7172hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen see warnings and precautions 59 history of coronary artery disease or coronary artery vasospasm 4wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4history of stroke transient ischemic attack or hemiplegic or basilar migraine 4peripheral vascular disease 4ischemic bowel disease 4uncontrolled hypertension 4recent within 24 hours use of treatment with another 5ht14hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen 4,1
frovatriptan succinate tablets are contraindicated in patients with ischemic coronary artery disease cad eg angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54peripheral vascular disease see warnings and precautions 55ischemic bowel disease see warnings and precautions 55uncontrolled hypertension see warnings and precautions 58recent use ie within 24 hours of another 5ht1see drug interactions 7172hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen see warnings and precautions 59 history of coronary artery disease or coronary artery vasospasm 4wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4history of stroke transient ischemic attack or hemiplegic or basilar migraine 4peripheral vascular disease 4ischemic bowel disease 4uncontrolled hypertension 4recent within 24 hours use of treatment with another 5ht14hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen 4,1
potassium supplements are contraindicatedin patients with hyperkalemia since a further increase in serumpotassium concentration in such patients can produce cardiacarrest hyperkalemia may complicate any of the following conditionschronic renal failure systemic acidosis such as diabetic acidosisacute dehydration extensive tissue breakdown as in severeburns adrenal insufficiency or the administration of a potassiumsparingdiuretic eg spironolactone triamterene amiloride see overdosagecontrolledrelease formulations of potassium chloride have producedesophageal ulceration in certain cardiac patients withesophageal compression due to an enlarged left atrium potassiumsupplementation when indicated in such patients should be givenas a liquid preparationall solid oral dosage forms of potassium chloride are contraindicatedin any patient in whom there is structural pathological eg diabeticgastroparesis or pharmacologic use of anticholinergicagents or other agents with anticholineric properties at sufficientdoses to exert anticholinergic effects cause for arrest or delay incapsule passage through the gastrointestinal tract,0
the use of metoclopramide tablets usp is recommended for adults only therapy should not exceed 12 weeks in durationsymptomatic gastroesophageal reflux metoclopramide tablets usp are indicated as shortterm 4 to 12 weeks therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapythe principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms if symptoms are confined to particular situations such as following the evening meal use of metoclopramide as single doses prior to the provocative situation should be considered rather than using the drug throughout the day healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12week trial using doses of 15 mg qid as there is no documented correlation between symptoms and healing of esophageal lesions patients with documented lesions should be monitored endoscopicallydiabetic gastroparesis diabetic gastric stasis metoclopramide tablets usp are indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis the usual manifestations of delayed gastric emptying eg nausea vomiting heartburn persistent fullness after meals and anorexia appear to respond to metoclopramide within different time intervals significant relief of nausea occurs early and continues to improve over a threeweek period relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more,2
bleomycin for injection should be considered a palliative treatment it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents squamous cell carcinomahead and neck including mouth tongue tonsil nasopharynx oropharynx sinus palate lip buccal mucosa gingivae epiglottis skin larynx penis cervix and vulva the response to bleomycin is poorer in patients with previously irradiated head and neck cancer lymphomashodgkins disease nonhodgkins lymphoma testicular carcinomaembryonal cell choriocarcinoma and teratocarcinomableomycin has also been shown to be useful in the management of malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions,3
bleomycin for injection should be considered a palliative treatment it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents squamous cell carcinomahead and neck including mouth tongue tonsil nasopharynx oropharynx sinus palate lip buccal mucosa gingivae epiglottis skin larynx penis cervix and vulva the response to bleomycin is poorer in patients with previously irradiated head and neck cancer lymphomashodgkins disease nonhodgkins lymphoma testicular carcinomaembryonal cell choriocarcinoma and teratocarcinomableomycin has also been shown to be useful in the management of malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions,3
bleomycin for injection should be considered a palliative treatment it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents squamous cell carcinomahead and neck including mouth tongue tonsil nasopharynx oropharynx sinus palate lip buccal mucosa gingivae epiglottis skin larynx penis cervix and vulva the response to bleomycin is poorer in patients with previously irradiated head and neck cancer lymphomashodgkins disease nonhodgkins lymphoma testicular carcinomaembryonal cell choriocarcinoma and teratocarcinomableomycin has also been shown to be useful in the management of malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions,3
bleomycin for injection should be considered a palliative treatment it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents squamous cell carcinomahead and neck including mouth tongue tonsil nasopharynx oropharynx sinus palate lip buccal mucosa gingivae epiglottis skin larynx penis cervix and vulva the response to bleomycin is poorer in patients with previously irradiated head and neck cancer lymphomashodgkins disease nonhodgkins lymphoma testicular carcinomaembryonal cell choriocarcinoma and teratocarcinomableomycin has also been shown to be useful in the management of malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions,3
ethyol amifostine is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer ethyol is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer where the radiation port includes a substantial portion of the parotid glands see clinical studiesfor the approved indications the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens or radiation therapy is altered by ethyol there are at present only limited data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings ethyol should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure or in patients receiving definitive radiotherapy except in the context of a clinical study see warnings,2
ethyol amifostine is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer ethyol is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer where the radiation port includes a substantial portion of the parotid glands see clinical studiesfor the approved indications the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens or radiation therapy is altered by ethyol there are at present only limited data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings ethyol should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure or in patients receiving definitive radiotherapy except in the context of a clinical study see warnings,3
omnitroper is a recombinant human growth hormone indicated for pediatric11 adult12omnitrope somatropin injection is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone ghomnitrope somatropin injection is indicated for the treatment of pediatric patients who have growth failure due to praderwilli syndrome pws the diagnosis of pws should be confirmed by appropriate genetic testing see contraindications 4252omnitrope somatropin injection is indicated for the treatment of growth failure in children born small for gestational age sga who fail to manifest catchup growth by age 2 yearsomnitrope somatropin injection is indicated for the treatment of growth failure associated with turner syndromeomnitrope somatropin injection is indicated for the treatment of idiopathic short stature iss also called nongrowth hormonedeficient short stature defined by height standard deviation score sds 225 and associated with growth rates unlikely to permit attainment of adult height in the normal range in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other meansomnitrope somatropin injection is indicated for the replacement of endogenous gh in adults with growth hormone deficiency ghd who meet either of the following two criteria patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults confirmation of the diagnosis of adult growth hormone deficiency in both,3
omnitroper is a recombinant human growth hormone indicated for pediatric11 adult12omnitrope somatropin injection is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone ghomnitrope somatropin injection is indicated for the treatment of pediatric patients who have growth failure due to praderwilli syndrome pws the diagnosis of pws should be confirmed by appropriate genetic testing see contraindications 4252omnitrope somatropin injection is indicated for the treatment of growth failure in children born small for gestational age sga who fail to manifest catchup growth by age 2 yearsomnitrope somatropin injection is indicated for the treatment of growth failure associated with turner syndromeomnitrope somatropin injection is indicated for the treatment of idiopathic short stature iss also called nongrowth hormonedeficient short stature defined by height standard deviation score sds 225 and associated with growth rates unlikely to permit attainment of adult height in the normal range in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other meansomnitrope somatropin injection is indicated for the replacement of endogenous gh in adults with growth hormone deficiency ghd who meet either of the following two criteria patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults confirmation of the diagnosis of adult growth hormone deficiency in both,3
guanidine is contraindicated in individuals with a history of intolerance or allergy to this drug,2
confirmed hypersensitivity to the active substance or to any of the excipients see warnings and precautions 53 and adverse reactions 62confirmed hypersensitivity to the active substance or to any of the excipients 4,3
betamethasone dipropionate ointment usp augmented 005 is contraindicated in patients who are hypersensitive to betamethasone dipropionate to other corticosteroids or to any ingredient in this preparation hypersensitivity to any component of this medicine 4,1
norpace and norpace cr are contraindicated in the presence of cardiogenic shock preexisting second or thirddegree av block if no pacemaker is present congenital qt prolongation or known hypersensitivity to the drug,1
carmustine for injection usp is contraindicated in patients with previous hypersensitivity to carmustine for injection usp or its componentshypersensitivity 4,0
history of hypersensitivity to mozobil see warnings and precautions 51 history of hypersensitivity to mozobil 4,2
ibutilide fumarate injection is contraindicated in patients who have previously demonstrated hypersensitivity to ibutilide fumarate or any of the other product components,1
nilandron tablets are contraindicated in patients with severe hepatic impairment baseline hepatic enzymes should be evaluated prior to treatment in patients with severe respiratory insufficiency in patients with hypersensitivity to nilutamide or any component of this preparation,2
mitoxantrone injection concentrate is contraindicated in patients who have demonstrated prior hypersensitivity to it,1
teniposide is generally contraindicated in patients who have demonstrated a previous hypersensitivity to teniposide andor polyoxyl 35 castor oil,3
cefadroxil is contraindicated in patients with known allergy to the cephalosporin group of antibiotics,1
cedax ceftibuten is contraindicated in patients with known allergy to the cephalosporin group of antibiotics,3
cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics,1
contraindicationspatients with allergy to these drugs or other analogues diclofenac patients with asthma like nsaids acetylsalicylic acid and other drugs which inhibit prostagladinsynthesis may precipitate attacks of asthma acute rhinitis or urticaria patients with active peptic ulcer,2
contraindicationspatients with allergy to these drugs or other analogues diclofenac patients with asthma like nsaids acetylsalicylic acid and other drugs which inhibit prostagladinsynthesis may precipitate attacks of asthma acute rhinitis or urticaria patients with active peptic ulcer,1
metopirone is contraindicated in patients with adrenal cortical insufficiency or hypersensitivity to metopirone or to any of its excipients,3
the use of procysbi is contraindicated in patients with a serious hypersensitivity reaction including anaphylaxis to penicillamine or cysteaminehypersensitivity to penicillamine or cysteamine 4,3
donepezil hydrochloride tablets are contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives 4,1
methyclothiazide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to this compound or other sulfonamidederived drugs,2
methyclothiazide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to this compound or other sulfonamidederived drugs,2
nisoldipine extendedrelease tablets are contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers,0
anuria hypersensitivity to any component of this product or to other sulfonamidederived drugs,2
prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia,1
see boxed warnings misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal antiinflammatory drugs nsaidsmisoprostol tablets should not be taken by anyone with a history of allergy to prostaglandins,0
hydroxyurea is contraindicated in patients with marked bone marrow depression ie leukopenia 2500 wbc or thrombocytopenia 100000 or severe anemiahydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation,2
hydroxyurea is contraindicated in patients with marked bone marrow depression ie leukopenia 2500 wbc or thrombocytopenia 100000 or severe anemiahydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation,2
hydroxyurea is contraindicated in patients with marked bone marrow depression ie leukopenia 2500 wbc or thrombocytopenia 100000 or severe anemiahydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation,1
podofilox topical solution 05 is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation,1
natpara is contraindicated in patients with a known hypersensitivity to any component of this product hypersensitivity reactions eg anaphylaxis angioedema and urticaria have occurred with natpara see warnings and precautions 56adverse reactions 63 hypersensitivity to any component of this product 4,1
do not use in patients with known hypersensitivity to phenothiazinesdo not use in comatose states or in the presence of large amounts of central nervous system depressants alcohol barbiturates narcotics etc,1
furosemide tablet is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide,2
furosemide tablet is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide,2
pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa chinese hamster ovary cell products or any component of the productpulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa chinese hamster ovary cell products or any component of the product 4,2
kineret is contraindicated in patients with known hypersensitivity to e coli53 known hypersensitivity to e coli4,2
actimmune is contraindicated in patients who develop or have known hypersensitivity to interferon gamma e coli known hypersensitivity to interferon gamma e coli4,2
myobloc is contraindicated in patients with a known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulationmyobloc is contraindicated for use in patients with infection at the proposed injection sites,1
the use of xolair is contraindicated in the followingsevere hypersensitivity reaction to xolair or any ingredient of xolair see warnings and precautions 51severe hypersensitivity reaction to xolair or any ingredient of xolair 451,1
albuminex 5 is contraindicated in patients with hypersensitivity to human albumin or any of the excipientssevere anemia or cardiac failure with normal or increased intravascular volume hypersensitivity to human albumin or the excipientssevere anemia or cardiac failure with normal or increased intravascular volume,2
albuminex 5 is contraindicated in patients with hypersensitivity to human albumin or any of the excipientssevere anemia or cardiac failure with normal or increased intravascular volume hypersensitivity to human albumin or the excipientssevere anemia or cardiac failure with normal or increased intravascular volume,2
betaseron is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta albumin human or any other component of the formulationhistory of hypersensitivity to natural or recombinant interferon beta albumin or mannitol 4,2
the administration of rgene 10 is contraindicated in persons having known hypersensitivity to any ingredient in this product,1
vascepa is contraindicated in patients with known hypersensitivity eg anaphylactic reaction to vascepa or any of its componentsvascepa is contraindicated in patients with known hypersensitivity eg anaphylactic reaction to vascepa or any of its components 4,0
gablofen is contraindicated in patients with a hypersensitivity to baclofen do not use gablofen for intravenous intramuscular subcutaneous or epidural administration hypersensitivity to baclofen 4 do not use gablofen for intravenous intramuscular subcutaneous or epidural administration 4,3
cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma known hypersensitivity to cevimeline and when miosis is undesirable eg in acute iritis and in narrowangle angleclosure glaucoma,2
cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma known hypersensitivity to cevimeline and when miosis is undesirable eg in acute iritis and in narrowangle angleclosure glaucoma,3
cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma known hypersensitivity to cevimeline and when miosis is undesirable eg in acute iritis and in narrowangle angleclosure glaucoma,1
caffeine citrate injection and caffeine citrate oral solution are contraindicated in patients who have demonstrated hypersensitivity to any of its components,2
torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide tablets or to povidonetorsemide tablets are contraindicated in patients who are anurictorsemide tablets are contraindicated in patients with hepatic comahypersensitivity to torsemide tablets or povidone anuria and hepatic coma 4,2
torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide tablets or to povidonetorsemide tablets are contraindicated in patients who are anurictorsemide tablets are contraindicated in patients with hepatic comahypersensitivity to torsemide tablets or povidone anuria and hepatic coma 4,3
omniscan is contraindicated in patients with chronic severe kidney disease glomerular filtration rate gfr 30 mlmin173m2prior hypersensitivity to omniscanpatients with chronic severe kidney disease gfr 30 mlmin173m24,1
oxiconazole nitrate cream is contraindicated in individuals who have shown hypersensitivity to any of their components,3
alclometasone dipropionate cream usp 005 is contraindicated in those patients with a history of hypersensitivity to any of the components in this preparation,2
hypersensitivity to benztropine mesylate tablets or to any component of the tabletsbecause of its atropinelike side effects this drug is contraindicated in pediatric patients under three years of age and should be used with caution in older pediatric patients,1
topical antifungal agents are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation,1
elixophyllin elixir theophylline oral solution usp is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product,1
pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium other bisphosphonates or mannitol reactions to pamidronate disodium injection and to mannitol have included anaphylaxishypersensitivity to pamidronate other bisphosphonates or mannitol 4,1
etomidate is contraindicated in patients who have shown hypersensitivity to it,3
ropivacaine hydrochloride injection is contraindicated in patients with a known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type,1
pyrazinamide is contraindicated in persons with severe hepatic damage who have shown hypersensitivity to it with acute gout,3
cetirizine hydrochloride oral solution usp is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine,1
cayston is contraindicated in patients with a known allergy to aztreonam do not administer to patients with a known allergy to aztreonam 4,2
eraxis is contraindicated in persons with known hypersensitivity to anidulafungin any component of eraxis or other echinocandins known hypersensitivity to anidulafungin any component of eraxis or other echinocandins 4,1
carafate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients,2
colestid granules and flavored colestid granules are contraindicated in those individuals who have shown hypersensitivity to any of its components,1
eszopiclone is contraindicated in patients with known hypersensitivity to eszopiclone hypersensitivity reactions include anaphylaxis and angioedema see warnings and precautions 52known hypersensitivity to eszopiclone 4,2
mupirocin ointment usp 2 is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp 2 known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp 2 4,1
should not be used in those persons showing hypersensitivity to any of the components of this preparation,3
a history of a previous hypersensitivity reaction to any of the penicillins is a contraindication ampicillin is also contraindicated in infections caused by penicillinaseproducing organisms,3
zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mildmoderate type 1 gaucher disease for whom enzyme replacement therapy is not a therapeutic option 11zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 gaucher disease for whom enzyme replacement therapy is not a therapeutic option eg due to allergy hypersensitivity or poor venous access,1
zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mildmoderate type 1 gaucher disease for whom enzyme replacement therapy is not a therapeutic option 11zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 gaucher disease for whom enzyme replacement therapy is not a therapeutic option eg due to allergy hypersensitivity or poor venous access,3
trifluridine ophthalmic solution 1 is contraindicated for patients who develop hypersensitivity reactions or chemical intolerance to trifluridine,2
gemcitabine for injection usp is contraindicated in patients with a known hypersensitivity to gemcitabine reactions include anaphylaxis see adverse reactions 61patients with a known hypersensitivity to gemcitabine 4,2
levothyroxine sodium is used for the following indicationshypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiterpituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancercontraindicationslevothyroxine is contraindicated in patients with untreated subclinical suppressed serum tsh level with normal t3 and t4 levels or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids see precautions levothyroxine sodium tablets usp is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets usp see description inactive ingredients,1
levothyroxine sodium is used for the following indicationshypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiterpituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancercontraindicationslevothyroxine is contraindicated in patients with untreated subclinical suppressed serum tsh level with normal t3 and t4 levels or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids see precautions levothyroxine sodium tablets usp is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets usp see description inactive ingredients,3
levothyroxine sodium is used for the following indicationshypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiterpituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancercontraindicationslevothyroxine is contraindicated in patients with untreated subclinical suppressed serum tsh level with normal t3 and t4 levels or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids see precautions levothyroxine sodium tablets usp is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets usp see description inactive ingredients,3
levothyroxine sodium is used for the following indicationshypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiterpituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancercontraindicationslevothyroxine is contraindicated in patients with untreated subclinical suppressed serum tsh level with normal t3 and t4 levels or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids see precautions levothyroxine sodium tablets usp is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets usp see description inactive ingredients,1
levothyroxine sodium is used for the following indicationshypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiterpituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancercontraindicationslevothyroxine is contraindicated in patients with untreated subclinical suppressed serum tsh level with normal t3 and t4 levels or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids see precautions levothyroxine sodium tablets usp is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets usp see description inactive ingredients,3
brevital is contraindicated in patients in whom general anesthesia is contraindicated in those with latent or manifest porphyria or in patients with a known hypersensitivity to barbiturates,1
brevital is contraindicated in patients in whom general anesthesia is contraindicated in those with latent or manifest porphyria or in patients with a known hypersensitivity to barbiturates,2
chlordiazepoxide hydrochloride capsule is contraindicated in patients with known hypersensitivity to the drug,2
rimantadine hydrochloride is contraindicated in patients with known hypersensitivity to drugs of the adamantane class including rimantadine and amantadine,1
dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations,0
cesamet is contraindicated in any patient who has a history of hypersensitivity to any cannabinoid,0
cefotaxime for injection is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium or the cephalosporin group of antibiotics,2
entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients,2
vancomycin is contraindicated in patients with known hypersensitivity to this antibiotic solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products,1
albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tabletspatients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets 4,1
panretinr gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product,2
hypersensitivity to the drug 41qt prolongation hypokalemia hypomagnesemia 42toremifene citrate tablets are contraindicated in patients with known hypersensitivity to the drugtoremifene should not be prescribed to patients with congenitalacquired qt prolongation long qt syndrome uncorrected hypokalemia or uncorrected hypomagnesemia,3
hypersensitivity to the drug 41qt prolongation hypokalemia hypomagnesemia 42toremifene citrate tablets are contraindicated in patients with known hypersensitivity to the drugtoremifene should not be prescribed to patients with congenitalacquired qt prolongation long qt syndrome uncorrected hypokalemia or uncorrected hypomagnesemia,3
hypersensitivity to the drug 41qt prolongation hypokalemia hypomagnesemia 42toremifene citrate tablets are contraindicated in patients with known hypersensitivity to the drugtoremifene should not be prescribed to patients with congenitalacquired qt prolongation long qt syndrome uncorrected hypokalemia or uncorrected hypomagnesemia,2
hypersensitivity to the drug 41qt prolongation hypokalemia hypomagnesemia 42toremifene citrate tablets are contraindicated in patients with known hypersensitivity to the drugtoremifene should not be prescribed to patients with congenitalacquired qt prolongation long qt syndrome uncorrected hypokalemia or uncorrected hypomagnesemia,1
finacea gel 15 is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation,2
propylthiouracil is contraindicated in the presence of hypersensitivity to the drug or any of the other product components and in nursing mothers because the drug is excreted in milk,2
nipent is contraindicated in patients who have demonstrated hypersensitivity to nipent,2
do not administer definity to patients with known or suspected hypersensitivity to perflutren see warnings and precautions 5do not administer definity to patients with known or suspected,3
cephalexin is contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugspatients with known h ypersensitivity to cephalexin or other m e mbers of the cephalosporin class of antibacterial drugs 4,2
halobetasol propionate ointment 005 is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation,3
prohance is contraindicated in patients with known allergic or hypersensitivity reactions to prohance see warnings and precautions 52allergic or hypersensitivity reactions to prohance 4,1
this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it,2
clorazepate dipotassium tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma,1
rayos is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy see adverse reactions 6 known hypersensitivity to prednisone or any excipients in the formulation 4 6,3
alimta is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed see adverse reactions 61history of severe hypersensitivity reaction to pemetrexed 4,1
vermoxtm chewable is contraindicated in persons with a known hypersensitivity to the drug or its excipients patients with a known hypersensitivity to the drug or its excipients 4,2
nystatin is contraindicated in patients with a history of hypersensitivity to nystatin or any of the suspension components,3
the injectable form of tiganr is contraindicated in pediatric patients and in patients with known hypersensitivity tothe injectable form of tiganr is contraindicated in pediatric patients and in patients with known hypersensitivity to,0
this product is contraindicated in those patients who have shown hypersensitivity to amphotericin b or any other component in the formulation unless in the opinion of the physician the condition requiring treatment is lifethreatening and amenable only to amphotericin b therapy,3
a hypersensitivity to any aminoglycoside is a contraindication to the use of tobramycin a history of hypersensitivity or serious toxic reactions to aminoglycosides may also contraindicate the use of any other aminoglycoside because of the known crosssensitivity of patients to drugs in this class,1
fludrocortisone acetate tablets corticosteroids are contraindicated in patients with systemic fungal infections and in those with a history of possible or known hypersensitivity to these agents,1
myocardial infarction history of myocardial infarction coronary insufficiency angina or other evidence suggestive of coronary artery disease hypersensitivity to phentolamine or related compounds,2
a history of a hypersensitivity anaphylactic reaction to any penicillin is a contraindication solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products,0
nedocromil sodium ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients,1
rocuronium bromide is contraindicated in patients known to have hypersensitivity eg anaphylaxis to rocuronium bromide or other neuromuscular blocking agents see warnings and precautions 52 hypersensitivity eg anaphylaxis to rocuronium bromide or other neuromuscular blocking agents 4,1
nateglinide tablets are contraindicated in patients with 1 known hypersensitivity to the drug or its inactive ingredients 2 type 1 diabetes 3 diabetic ketoacidosis this condition should be treated with insulin,3
naftifine hydrochloride cream usp 1 is contraindicated in individuals who have shown hypersensitivity to any of its components,1
modafinil tablets are contraindicated in patients with known hypersensitivity to modafinil or armodafinil or its inactive ingredients see warnings and precautions 51 52 53modafinil tablets are contraindicated in patients with known hypersensitivity to modafinil or armodafinil 4,3
this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines,1
irinotecan hydrochloride injection usp is contraindicated in patients with a known hypersensitivity to the drug or its excipients hypersensitivity to irinotecan hydrochloride injection usp or its excipients 4,3
methimazole is contraindicated in the presence of hypersensitivity to the drug and in nursing mothers because the drug is excreted in milk,2
etopophos is contraindicated in patients with a history of a severe hypersensitivity reaction to etoposide products see warnings and precautions 53hypersensitivity to etoposide products 453,1
alfentanil hcl injection is contraindicated in patients with hypersensitivity to alfentanil eg anaphylaxis see adverse reactions 6 hypersensitivity to alfentanil 4,1
contraindicated in persons showing hypersensitivity to any component of this preparation,3
use in patients with cardiac arrhythmias associated with tachycardia is contraindicated although rare immediate hypersensitivity reactions can occur therefore metaproterenol sulfate syrup is contraindicated in patients with a history of hypersensitivity to any of its components,3
propofol injectable emulsion is contraindicated in patients with a known hypersensitivity to propofol injectable emulsion or any of propofol injectable emulsion components propofol injectable emulsion is contraindicated in patients with allergies to eggs egg products soybeans or soy products,1
tolazamide is contraindicated in patients with known hypersensitivity or allergy to the drugdiabetic ketoacidosis with or without coma this condition should be treated with insulintype i diabetes as sole therapy,2
tolazamide is contraindicated in patients with known hypersensitivity or allergy to the drugdiabetic ketoacidosis with or without coma this condition should be treated with insulintype i diabetes as sole therapy,3
topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparationsuse of cordran tape is not recommended for lesions exuding serum or in intertriginous areas,1
dacarbazine for injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past,1
hypersensitivity to any of the ingredients,2
sirolimus oral solution is contraindicated in patients with a hypersensitivity to sirolimus see warnings and precautions 54 hypersensitivity to sirolimus 4,1
emtriva is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the productsemtriva is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products 4,1
the use of valchlor is contraindicated in patients with known severe hypersensitivity to mechlorethamine hypersensitivity reactions including anaphylaxis have occurred with topical formulations of mechlorethaminesevere hypersensitivity to mechlorethamine 4,3
tiagabine hydrochloride tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients,3
conditions where a fall in blood pressure may be undesirable hypersensitivity to the drug or any of its components,0
isoniazid is contraindicated in patients who develop severe hypersensitivity reactions including druginduced hepatitis previous isoniazidassociated hepatic injury severe adverse reactions to isoniazid such as drug fever chills arthritis and acute liver disease of any etiology,2
isoniazid is contraindicated in patients who develop severe hypersensitivity reactions including druginduced hepatitis previous isoniazidassociated hepatic injury severe adverse reactions to isoniazid such as drug fever chills arthritis and acute liver disease of any etiology,1
isoniazid is contraindicated in patients who develop severe hypersensitivity reactions including druginduced hepatitis previous isoniazidassociated hepatic injury severe adverse reactions to isoniazid such as drug fever chills arthritis and acute liver disease of any etiology,2
mepivacaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amidetype or to other components of mepivacaine solutions,2
apraclonidine ophthalmic solution is contraindicated in patients with hypersensitivity to apraclonidine or any other component of this medication as well as systemic clonidine it is also contraindicated in patients receiving monoamine oxidase inhibitors mao inhibitors,1
methyldopa is contraindicated in patients with active hepatic disease such as acute hepatitis and active cirrhosis with liver disorders previously associated with methyldopa therapy see warnings with hypersensitivity to any component of this product on therapy with monoamine oxidase mao inhibitors,2
methyldopa is contraindicated in patients with active hepatic disease such as acute hepatitis and active cirrhosis with liver disorders previously associated with methyldopa therapy see warnings with hypersensitivity to any component of this product on therapy with monoamine oxidase mao inhibitors,2
dopamine hydrochloride should not be used in patients with pheochromocytomadopamine hydrochloride should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillationsolutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products,1
gabapentin capsules are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients known hypersensitivity to gabapentin or its ingredients 4,3
valganciclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction eg anaphylaxis to valganciclovir ganciclovir or any component of the formulation see adverse reactions 61hypersensitivity to valganciclovir or ganciclovir 4,0
active uveal inflammationmost cases of angleclosure glaucoma without iridectomy due to the possibility of increasing angle blockhypersensitivity to the active or inactive ingredients,3
active uveal inflammationmost cases of angleclosure glaucoma without iridectomy due to the possibility of increasing angle blockhypersensitivity to the active or inactive ingredients,3
active uveal inflammationmost cases of angleclosure glaucoma without iridectomy due to the possibility of increasing angle blockhypersensitivity to the active or inactive ingredients,0
glipizide is contraindicated in patients with known hypersensitivity to glipizide or any of the products ingredients known hypersensitivity to glipizide or any of the products ingredients 4 hypersensitivity to sulfonamide derivatives 4,1
a history of clinically significant hypersensitivity to streptomycin is a contraindication to its use clinically significant hypersensitivity to other aminoglycosides may contraindicate the use of streptomycin because of the known crosssensitivity of patients to drugs in this class,2
oravig is contraindicated in patients with known hypersensitivity eg anaphylaxis to miconazole milk protein concentrate or any other component of the productknown hypersensitivity to miconazole milk protein concentrate or any other component of the product 4,1
econazole nitrate cream 1 is contraindicated in individuals who have shown hypersensitivity to any of its ingredients,1
prednicarbate cream 01 emollient is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparations,1
mycamine is contraindicated in persons with known hypersensitivity to micafungin any component of mycamine or other echinocandinsmycamine is contraindicated in persons with known hypersensitivity to micafungin sodium any component of mycamine or other echinocandins 4,0
factive is contraindicated in patients with a history of hypersensitivity to gemifloxacin fluoroquinolone antibiotic agents or any of the product components,3
contraindicationsofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin to other quinolones or to any of the components in this medication,1
matulane is contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration due consideration of this possible state should be given to each patient who has leukopenia thrombocytopenia or anemia,2
matulane is contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration due consideration of this possible state should be given to each patient who has leukopenia thrombocytopenia or anemia,1
matulane is contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration due consideration of this possible state should be given to each patient who has leukopenia thrombocytopenia or anemia,3
evzio is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredientshypersensitivity to naloxone hydrochloride 4,2
fomepizole injection should not be administered to patients with a documented serious hypersensitivity reaction to fomepizole injection or other pyrazoles,1
ketamine hydrochloride is contraindicated in those in whom a significant elevation of blood pressure would constitute a serious hazard and in those who have shown hypersensitivity to the drug,1
tykerb is contraindicated in patients with known severe hypersensitivity eg anaphylaxis to this product or any of its componentsknown severe hypersensitivity eg anaphylaxis to this product or any of its components 4,2
ocular or periocular infections 41hypersensitivity 42lucentis is contraindicated in patients with ocular or periocular infectionslucentis is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in lucentis hypersensitivity reactions may manifest as severe intraocular inflammation,2
chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantixhistory of serious hypersensitivity or skin reactions to chantix 4,2
levemir is contraindicated in patients with hypersensitivity to levemir or any of its excipients reactions have included anaphylaxis see warnings and precautions 55 and adverse reactions 61 do not use in patients with hypersensitivity to levemir or any of its excipients 4,3
vecuronium bromide is contraindicated in patients known to have a hypersensitivity to it,2
paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it it is also contraindicated in intestinal obstruction,3
paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it it is also contraindicated in intestinal obstruction,1
cholestyramine for oral suspension usp light powder is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown hypersensitivity to any of its components,3
afinitorafinitor disperz is contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives see warnings and precautions 53clinically significant hypersensitivity to everolimus or to other rapamycin derivatives 4,3
molindone hydrochloride tablets are contraindicated in severe central nervous system depression alcohol barbiturates narcotics etc or comatose states and in patients with known hypersensitivity to the drug,2
miochole is contraindicated in persons with a known hypersensitivity to any component of this product,1
hypersensitivity to acetic acid otic solution or any of the ingredients perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal,0
panhematin is contraindicated in patients with known hypersensitivity to this drugdo not use in patients with known hypersensitivity to panhematin 4,3
hydro 35 foam should not be used by persons who have a known hypersensitivity to urea or any of the listed ingredients,3
ethamolin injection should not be administered to subjects with a known hypersensitivity to ethanolamine oleic acid or ethanolamine oleate,0
ammonium lactate lotion 12 is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients,1
bepreve is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients see adverse reactions 62hypersensitivity to any component of this product 4,1
permethrin cream 5 ww is contraindicated in patients with known hypersensitivity to any of its components to any synthetic pyrethroid or pyrethrin,3
picatorrsee adverse reactions 62known hypersensitivity to ingenol mebutate or any component of the formulation 4,2
eucrisa is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation see warnings and precautions 5 1known hypersensitivity to crisaborole or any component of the formulation 4,1
methsuximide should not be used in patients with a history of hypersensitivity to succinimides,3
glatiramer acetate injection is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol known hypersensitivity to glatiramer acetate or mannitol 4,3
otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation see adverse reactions 61known hypersensitivity to apremilast or any excipients in formulation 4,0
stelararsee warnings and precautions 55clinically significant hypersensitivity to ustekinumab or to any of the excipients 4,3
cablivi is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumabyhdp or to any of the excipients hypersensitivity reactions have included urticaria see adverse reactions 61previous severe hypersensitivity reaction to caplacizumabyhdp or any of the excipients 4,2
cablivi is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumabyhdp or to any of the excipients hypersensitivity reactions have included urticaria see adverse reactions 61previous severe hypersensitivity reaction to caplacizumabyhdp or any of the excipients 4,2
history of a serious hypersensitivity reaction to alogliptincontaining products such as anaphylaxis angioedema or severe cutaneous adverse reactionshistory of a serious hypersensitivity reaction to alogliptincontaining products such as anaphylaxis angioedema or severe cutaneous adverse reactions 4,3
dalvance is contraindicated in patients with known hypersensitivity to dalbavancin no data are available on crossreactivity between dalbavancin and other glycopeptides including vancomycin hypersensitivity to dalbavancin 4,2
northera is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients see warnings and precautions 54history of hypersensitivity to the drug or its ingredients 4,1
actemra is contraindicated in patients with known hypersensitivity to actemra see warnings and precautions 55 actemra is contraindicated in patients with known hypersensitivity to actemra 4,3
onglyza is contraindicated in patients with a history of a serious hypersensitivity reaction to onglyza such as anaphylaxis angioedema or exfoliative skin conditions see warnings and precautions 54 and adverse reactions 62 4,1
onglyza is contraindicated in patients with a history of a serious hypersensitivity reaction to onglyza such as anaphylaxis angioedema or exfoliative skin conditions see warnings and precautions 54 and adverse reactions 62 4,1
perjeta is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipientsperjeta is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients 4,0
armodafinil tablets are contraindicated in patients with known hypersensitivity to modafinil or armodafinil or their inactive ingredients see warnings and precautions 515253armodafinil tablets are contraindicated in patients with known hypersensitivity to modafinil or armodafinil 4,1
cinqair is contraindicated in patients who have known hypersensitivity to reslizumab or any of its excipients see warnings and precautions 51known hypersensitivity to reslizumab or any of its excipients 4,2
nucala should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulationhistory of hypersensitivity to mepolizumab or excipients in the formulation 4,1
bosulif is contraindicated in patients with a history of hypersensitivity to bosulif reactions have included anaphylaxis in the bosulif singleagent cancer studies anaphylactic shock occurred in less than 02 of treated patientshypersensitivity to bosulif 4,1
pradaxa is contraindicated in patients with active pathological bleeding see warnings and precautions 5161history of a serious hypersensitivity reaction to pradaxa eg anaphylactic reaction or anaphylactic shock see adverse reactions 61 active pathological bleeding 4history of serious hypersensitivity reaction to pradaxa 4,3
contraindicated in the presence of an anatomically narrow angle or in narrow angle glaucoma or in persons who have shown hypersensitivity to any component of this preparation,2
ganirelix acetate injection is contraindicated under the following conditions known hypersensitivity to ganirelix acetate or to any of its components including dry natural rubberlatex see how suppliedknown hypersensitivity to gnrh or any other gnrh analogknown or suspected pregnancy see precautions,2
hypersensitivity to any component of this product,0
nevanac 01 is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal antiinflammatory drugs nsaidshypersensitivity to any of the ingredients in the formula or to other nonsteroidal antiinflammatory drugs nsaids,1
the use of varithena is contraindicated in patients with known allergy to polidocanol see warnings and precautions 51acute thromboembolic disease known allergy to polidocanol 4acute thromboembolic disease 4,2
contraindicationshypersensitivity to this product,2
datscan is contraindicated in patients with known hypersensitivity to the active substance or to any of the excipients or to iodineknown hypersensitivity to the active substance or to any of the excipients or to iodine 4,3
cosentyx is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients see warnings and precautions 54serious hypersensitivity reaction to secukinumab or to any of the excipients 4,3
severe hypersensitivity reaction to siltuximab or any of the excipients in sylvant see warnings and precautions 53severe hypersensitivity reaction to siltuximab or any of the excipients in sylvant 4,1
blincyto is contraindicated in patients with known hypersensitivity to blinatumomab or to any component of the product formulationknown hypersensitivity to blinatumomab or to any component of the product formulation 4,2
epidiolex is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product see description 11 and warnings and precautions 54hypersensitivity to cannabidiol or any of the ingredients in epidiolex 4,3
mesna injection is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients see warnings and precautions 51 known hypersensitivity to mesna or to any of the excipients including benzyl alcohol 4,1
vizamyl is contraindicated in patients with a history of hypersensitivity reaction to vizamyl polysorbate 80 or any other inactive ingredient in vizamyl see warnings and precautions 51known hypersensitivity to vizamyl or any excipient including polysorbate 80 4,0
lovaza is contraindicated in patients with known hypersensitivity eg anaphylactic reaction to lovaza or any of its componentslovaza is contraindicated in patients with known hypersensitivity eg anaphylactic reaction to lovaza or any of its components 4,1
allergenic extracts should not be used if the patient has asthma cardiovascular disease emphysema diabetes bleeding diathesis or pregnancy unless a specific diagnosis of type 1 allergic disease is made based on skin testing and the benefits of treatment outweigh the risks of an adverse reaction during testing or treatment allergenic extracts are not indicated for use in patients who are not clinically allergic or who are not skin reactive to an allergen allergenic extracts should be discontinued or the concentration of potency substantially reduced in patients who experience unacceptable adverse reactions,3
atryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins known hypersensitivity to goat and goat milk proteins 4,2
contraindicated in persons with primary glaucoma or a tendency toward glaucoma eg narrow anterior chamber angle and in those persons showing hypersensitivity to any component of this preparation,3
contraindicated in persons with primary glaucoma or a tendency toward glaucoma eg narrow anterior chamber angle and in those persons showing hypersensitivity to any component of this preparation,1
yupelri is contraindicated in patients with hypersensitivity to revefenacin or any component of this productyupelri is contraindicated in patients with hypersensitivity to revefenacin or any component of this product 4,1
baxdela is contraindicated in patients with known hypersensitivity to delafloxacin or any of the fluoroquinolone class of antibacterial drugs or any of the components of baxdela see warnings and precautions 56known hypersensitivity to baxdela or other fluoroquinolones 456,1
piqray is contraindicated in patients with severe hypersensitivity to it or any of its components see warnings and precautions 51severe hypersensitivity to piqray or to any of its components 4,2
fasenra is contraindicated in patients who have known hypersensitivity to benralizumab or any of its excipients see warnings and precautions 51known hypersensitivity to benralizumab or excipients 4,1
radicava is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product hypersensitivity reactions and anaphylactic reactions have occurred see warningsand precautions 5152 4,0
zemdri is contraindicated in patients with known hypersensitivity to any aminoglycoside see warnings and precautions 55zemdri is contraindicated in patients with known hypersensitivity to any aminoglycoside 454,3
atracurium besylate is contraindicated in patients known to have a hypersensitivity to it use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol,1
adefovir dipivoxil tablets are contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the productadefovir dipivoxil tablets are contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product 4,1
known hypersensitivity to sodium ferric gluconate or any of its componentsknown hypersensitivity to sodium ferric gluconate or any of its inactive components 4,3
xofluza is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredientsxofluza is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients 4,3
ilumya is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients see warnings and precautions 51serious hypersensitivity reaction to tildrakizumab or to any of the excipients 4,0
hypersensitivity to the active ingredient or to any component of the product see warnings and precautions 51hypersensitivity to the active ingredient or any component of this product 4,2
neonates and patients with a history of hypersensitivity to dimenhydrinate or its components diphenhydramine or 8chlorotheophylline should not be treated with dimenhydrinate note,3
known hypersensitivity to rose bengal,0
mometasone furoate lotion mometasone furoate topical solution usp 01 is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation,1
hypersensitivity 41hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product a preliminary skin test for hypersensitivity to amphadasearar,2
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,1
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,3
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,1
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,3
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,1
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,1
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,3
amphotericin b for injection usp should be administered primarily to patients with progressive potentially lifethreatening fungal infections this potent drug should not be used to treat noninvasive fungal infections such as oral thrush vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil countsamphotericin b for injection usp is specifically intended to treat potentially lifethreatening fungal infections aspergillosis cryptococcosis torulosis north american blastomycosis systemic candidiasis coccidioidomycosis histoplasmosis zygomycosis including mucormycosis due to susceptible species of the genera absidiamucorrhizopusconidiobolusbasidiobolusamphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis but it is not the drug of choice as primary therapy,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,1
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
griseofulvin tablets usp are indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy hair and nails namelytinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note prior to initiating treatment appropriate specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosisgriseofulvin tablets usp are not bacterial infectionscandidiasis moniliasishistoplasmosisactinomycosissporotrichosischromoblastomycosiscoccidioidomycosisnorth american blastomycosiscryptococcosis torulosistinea versicolornocardiosisthe use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone,3
equetro is a mood stabilizer indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder 11indicated for the treatment of the pain associated with trigeminal neuralgia 12an antiepileptic drug aed indicated for the treatment of partial seizures with complex symptomatology generalized tonicclonic seizures and mixed seizures 13equetro is indicated for treatment of patients with acute manic or mixed episodes associated with bipolar i disorder see clinical studies 141equetro is indicated in the treatment of the pain associated with trigeminal neuralgia beneficial results have also been reported in glossopharyngeal neuralgia this drug is not a simple analgesic and should not be used for the relief of trivial aches or painsequetro is indicated for the treatment of partial seizures with complex symptomatology eg psychomotor temporal lobe generalized tonicclonic seizures grand mal and mixed seizure patterns which include the seizure types listed here or other partial or generalized seizures limitations of usageequetro is not indicated for the treatment of absence seizures petit malcarbamazepine has been associated with increased frequency of generalized convulsions in these patients,3
equetro is a mood stabilizer indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder 11indicated for the treatment of the pain associated with trigeminal neuralgia 12an antiepileptic drug aed indicated for the treatment of partial seizures with complex symptomatology generalized tonicclonic seizures and mixed seizures 13equetro is indicated for treatment of patients with acute manic or mixed episodes associated with bipolar i disorder see clinical studies 141equetro is indicated in the treatment of the pain associated with trigeminal neuralgia beneficial results have also been reported in glossopharyngeal neuralgia this drug is not a simple analgesic and should not be used for the relief of trivial aches or painsequetro is indicated for the treatment of partial seizures with complex symptomatology eg psychomotor temporal lobe generalized tonicclonic seizures grand mal and mixed seizure patterns which include the seizure types listed here or other partial or generalized seizures limitations of usageequetro is not indicated for the treatment of absence seizures petit malcarbamazepine has been associated with increased frequency of generalized convulsions in these patients,3
hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,3
hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,3
hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,2
hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,2
hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,3
propylthiouracil is indicated in patients with graves disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole,3
liothyronine sodium tablets are an ltriiodothyronine t3 indicated for hypothyroidism as replacement in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 11pituitary thyrotropin thyroidstimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer 12thyroid suppression test as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy 13 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients 1 not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis 1 liothyronine sodium tablets are indicated as a replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy limitations of use liothyronine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium tablets may induce hyperthyroidism see warnings and precautions 54liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis,1
liothyronine sodium tablets are an ltriiodothyronine t3 indicated for hypothyroidism as replacement in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 11pituitary thyrotropin thyroidstimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer 12thyroid suppression test as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy 13 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients 1 not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis 1 liothyronine sodium tablets are indicated as a replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy limitations of use liothyronine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium tablets may induce hyperthyroidism see warnings and precautions 54liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis,3
liothyronine sodium tablets are an ltriiodothyronine t3 indicated for hypothyroidism as replacement in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 11pituitary thyrotropin thyroidstimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer 12thyroid suppression test as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy 13 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients 1 not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis 1 liothyronine sodium tablets are indicated as a replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy limitations of use liothyronine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium tablets may induce hyperthyroidism see warnings and precautions 54liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis,3
liothyronine sodium tablets are an ltriiodothyronine t3 indicated for hypothyroidism as replacement in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 11pituitary thyrotropin thyroidstimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer 12thyroid suppression test as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy 13 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients 1 not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis 1 liothyronine sodium tablets are indicated as a replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of welldifferentiated thyroid cancer liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy limitations of use liothyronine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium tablets may induce hyperthyroidism see warnings and precautions 54liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis,1
loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,3
loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,3
loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,3
loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,3
loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,3
since the pharmacologic and clinical actions of haloperidol decanoate injection 50 mg ml and haloperidol decanoate injection 100 mgml are attributed to haloperidol usp as the active medication contraindications warnings and additional information are those of haloperidol usp modified only to reflect the prolonged action haloperidol is contraindicated in patients with severe toxic central nervous system depression or comatose states from any cause hypersensitivity to this drug hypersensitivity reactions have included anaphylactic reaction and angioedema see warnings hypersensitivity reactions and adverse reactions parkinsons disease see warnings neurological adverse reactions in patients with parkinsons disease or dementia with lewy bodies dementia with lewy bodies see warnings neurological adverse reactions in patients with parkinsons disease or dementia with lewy bodies,2
since the pharmacologic and clinical actions of haloperidol decanoate injection 50 mg ml and haloperidol decanoate injection 100 mgml are attributed to haloperidol usp as the active medication contraindications warnings and additional information are those of haloperidol usp modified only to reflect the prolonged action haloperidol is contraindicated in patients with severe toxic central nervous system depression or comatose states from any cause hypersensitivity to this drug hypersensitivity reactions have included anaphylactic reaction and angioedema see warnings hypersensitivity reactions and adverse reactions parkinsons disease see warnings neurological adverse reactions in patients with parkinsons disease or dementia with lewy bodies dementia with lewy bodies see warnings neurological adverse reactions in patients with parkinsons disease or dementia with lewy bodies,1
ixinity coagulation factor ix recombinant is a human blood coagulation factor indicated in adults and children 12 years of age with hemophilia b for control and prevention of bleeding episodes perioperative managementixinity is not indicated for induction of immune tolerance in patients with hemophilia bixinity coagulation factor ix recombinant is a human blood coagulation factor indicated in adults and children 12 years of age with hemophilia b for control and prevention of bleeding episodes perioperative management 1ixinity is not indicated for induction of immune tolerance in patients with hemophilia b,3
nipent is indicated as singleagent treatment for both untreated and alphainterferonrefractory hairy cell leukemia patients with active disease as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms,3
nipent is indicated as singleagent treatment for both untreated and alphainterferonrefractory hairy cell leukemia patients with active disease as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms,3
nipent is indicated as singleagent treatment for both untreated and alphainterferonrefractory hairy cell leukemia patients with active disease as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms,3
nipent is indicated as singleagent treatment for both untreated and alphainterferonrefractory hairy cell leukemia patients with active disease as defined by clinically significant anemia neutropenia thrombocytopenia or diseaserelated symptoms,3
neupogen is a leukocyte growth factor indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever 11reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia aml 12reduce the duration of neutropenia and neutropeniarelated clinical sequelae eg febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation bmt 13mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis 14reduce the incidence and duration of sequelae of severe neutropenia eg fever infections oropharyngeal ulcers in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia 15increase survival in patients acutely exposed to myelosuppressive doses of radiation hematopoietic syndrome of acute radiation syndrome 16neupogen is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever see clinical studies 141neupogen is indicated for reducing the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia aml see clinical studies 142neupogen is indicated to reduce the duration of neutropenia and neutropeniarelated clinical sequelae eg febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation see clinical studies 143neupogen is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis see clinical studies 144neupogen is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia eg fever infections oropharyngeal ulcers in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia see clinical studies 145neupogen is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation see clinical studies 146,2
clozapine orally disintegrating tablets are an atypical antipsychotic indicated for treatmentresistant schizophrenia efficacy was established in an activecontrolled study 11141reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder efficacy was established in an activecontrolled study 12142clozapine orally disintegrating tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment because of the risks of severe neutropenia and of seizure associated with their use clozapine orally disintegrating tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment see warnings and precautions 5155the effectiveness of clozapine orally disintegrating tablets in treatmentresistant schizophrenia was demonstrated in a 6week randomized doubleblind activecontrolled study comparing clozapine orally disintegrating tablets and chlorpromazine in patients who had failed other antipsychotics see clinical studies 141clozapine orally disintegrating tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior based on history and recent clinical state suicidal behavior refers to actions by a patient that put himherself at risk for death the effectiveness of clozapine orally disintegrating tablets in reducing the risk of recurrent suicidal behavior was demonstrated over a twoyear treatment period in the intersepttm trial see clinical studies 142,1
clozapine orally disintegrating tablets are an atypical antipsychotic indicated for treatmentresistant schizophrenia efficacy was established in an activecontrolled study 11141reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder efficacy was established in an activecontrolled study 12142clozapine orally disintegrating tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment because of the risks of severe neutropenia and of seizure associated with their use clozapine orally disintegrating tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment see warnings and precautions 5155the effectiveness of clozapine orally disintegrating tablets in treatmentresistant schizophrenia was demonstrated in a 6week randomized doubleblind activecontrolled study comparing clozapine orally disintegrating tablets and chlorpromazine in patients who had failed other antipsychotics see clinical studies 141clozapine orally disintegrating tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior based on history and recent clinical state suicidal behavior refers to actions by a patient that put himherself at risk for death the effectiveness of clozapine orally disintegrating tablets in reducing the risk of recurrent suicidal behavior was demonstrated over a twoyear treatment period in the intersepttm trial see clinical studies 142,3
mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquinesusceptible strains of p falciparumplasmodium vivaxp ovalep malariaenotep vivaxmefloquine hydrochloride tablets are indicated for the prophylaxis of p falciparump vivaxp falciparum,3
primaquine phosphate is indicated for the radical cure prevention of relapse of vivax malaria,3
clotrimazole lozenges are indicated for the local treatment of oropharyngeal candidiasis the diagnoses should be confirmed by a koh smear andor culture prior to treatmentclotrimazole lozenges are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation there are no data from adequate and wellcontrolled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence see dosage and administration,2
marqibo is a vinca alkaloid indicated for the treatment of adult patients with philadelphia chromosomenegative ph acute lymphoblastic leukemia all in second or greater relapse or whose disease has progressed following two or more antileukemia therapies this indication is based on overall response rate clinical benefit such as improvement in overall survival has not been verified 11marqiboar,3
marqibo is a vinca alkaloid indicated for the treatment of adult patients with philadelphia chromosomenegative ph acute lymphoblastic leukemia all in second or greater relapse or whose disease has progressed following two or more antileukemia therapies this indication is based on overall response rate clinical benefit such as improvement in overall survival has not been verified 11marqiboar,3
daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia myelogenous monocytic erythroid of adults and for remission induction in acute lymphocytic leukemia of children and adults,3
daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia myelogenous monocytic erythroid of adults and for remission induction in acute lymphocytic leukemia of children and adults,3
bosulif is indicated for the treatment of adult patients with newlydiagnosed chronic phase cp philadelphia chromosomepositive chronic myelogenous leukemia ph cml this indication is approved under accelerated approval based on molecular and cytogenetic response rates see clinical studies 141 chronic phase accelerated phase ap or blast phase bp ph cml with resistance or intolerance to prior therapybosulif is a kinase inhibitor indicated for the treatment of adult patients with newlydiagnosed chronic phase ph chronic myelogenous leukemia cml this indication is approved under accelerated approval based on molecular and cytogenetic response rates continued approval for this indication may be contingent upon verification and confirmation of clinical benefit in an ongoing longterm follow up trial 1 14chronic accelerated or blast phase ph cml with resistance or intolerance to prior therapy 1,3
cytarabine injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia of adults and pediatric patients it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia intrathecal administration of cytarabine injection preservative free preparations only is indicated in the prophylaxis and treatment of meningeal leukemia,3
cytarabine injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia of adults and pediatric patients it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia intrathecal administration of cytarabine injection preservative free preparations only is indicated in the prophylaxis and treatment of meningeal leukemia,3
idarubicin hydrochloride injection usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia aml in adults this includes frenchamericanbritish fab classifications m1 through m7,3
idarubicin hydrochloride injection usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia aml in adults this includes frenchamericanbritish fab classifications m1 through m7,3
decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups decitabine for injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes mds including previously treated and untreated de novo and secondary mds of all frenchamericanbritish subtypes refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia and intermediate1 intermediate2 and highrisk international prognostic scoring system groups,3
tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase 11adult patients with chronic phase cp and accelerated phase ap ph cml resistant to or intolerant to prior therapy that included imatinib 12pediatric patients greater than or equal to 1 year of age with ph cmlcp resistant or intolerant to prior tyrosinekinase inhibitor tki therapy 13 tasigna nilotinib is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phasetasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase philadelphia chromosome positive chronic myelogenous leukemia ph cml resistant or intolerant to prior therapy that included imatinib tasigna is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase philadelphia chromosome positive chronic myeloid leukemia ph cml with resistance or intolerance to prior tyrosinekinase inhibitor tki therapy,3
oxiconazole nitrate cream is indicated for the topical treatment of the following dermal infections tinea pedis tinea cruris and tinea corporis due to trichophyton rubrum trichophytonmentagrophytes epidermophyton floccosum malassezia furfur dosage and administration clinical studiesoxiconazole nitrate cream may be used in pediatric patients for tinea corporis tinea cruris tinea pedis and tinea pityriasis versicolor however these indications for which oxiconazole nitrate cream has been shown to be effective rarely occur in children below the age of 12,3
naftifine hydrochloride cream usp 2 is indicated for the treatment of interdigital tinea pedis tinea cruris and tinea corporis caused by the organism trichophyton rubrumnaftifine hydrochloride cream usp 2 is an allylamine antifungal indicated for the treatment of interdigital tinea pedis tinea cruris and tinea corporis caused by the organism trichophyton rubrum1,3
ecoza econazole nitrate topical foam 1 is indicated for the treatment of interdigital tinea pedis caused by trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum ecoza is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by trichophyton rubrum trichophyton mentagrophytes epidermophyton floccosum 1,3
ertaczortrichophyton rubrumtrichophyton mentagrophytes epidermophyton floccosum clinical studies 14ertaczo cream 2 is an azole antifungal indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older caused by trichophyton rubrum trichophyton mentagrophytesepidermophyton floccosum1,3
luzu luliconazole cream 1 is indicated for the topical treatment of interdigital tinea pedis tinea cruris and tinea corporis caused by the organisms trichophyton rubrumepidermophyton floccosumluzu luliconazole cream 1 is an azole antifungal indicated for the topical treatment of interdigital tinea pedis tinea cruris and tinea corporis caused by the organisms trichophyton rubrumepidermophyton floccosum1,3
except for the treatment of wilsons disease or certain patients with cystinuria use of penicillamine during pregnancy is contraindicated see warningsalthough breast milk studies have not been reported in animals or humans mothers on therapy with penicillamine should not nurse their infants patients with a history of penicillaminerelated aplastic anemia or agranulocytosis should not be restarted on penicillamine see warningsadverse reactionsbecause of its potential for causing renal damage penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency,1
except for the treatment of wilsons disease or certain patients with cystinuria use of penicillamine during pregnancy is contraindicated see warningsalthough breast milk studies have not been reported in animals or humans mothers on therapy with penicillamine should not nurse their infants patients with a history of penicillaminerelated aplastic anemia or agranulocytosis should not be restarted on penicillamine see warningsadverse reactionsbecause of its potential for causing renal damage penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency,3
mebendazole tablets are indicated for the treatment of enterobius vermicularistrichuris trichiuraascaris lumbricoidesancylostoma duodenalenecator americanusefficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time degree of infection and helminth strains efficacy rates derived from various studies are shown in the table below pinworm enterobiasiswhipworm trichuriasiscommon roundworm ascariasishookworm cure rates95689896 egg reduction939999,3
mebendazole tablets are indicated for the treatment of enterobius vermicularistrichuris trichiuraascaris lumbricoidesancylostoma duodenalenecator americanusefficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time degree of infection and helminth strains efficacy rates derived from various studies are shown in the table below pinworm enterobiasiswhipworm trichuriasiscommon roundworm ascariasishookworm cure rates95689896 egg reduction939999,0
mebendazole tablets are indicated for the treatment of enterobius vermicularistrichuris trichiuraascaris lumbricoidesancylostoma duodenalenecator americanusefficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time degree of infection and helminth strains efficacy rates derived from various studies are shown in the table below pinworm enterobiasiswhipworm trichuriasiscommon roundworm ascariasishookworm cure rates95689896 egg reduction939999,3
bumetanide is contraindicated in anuria although bumetanide tablets can be used to induce diuresis in renal insufficiency any marked increase in blood urea nitrogen or creatinine or the development of oliguria during therapy of patients with progressive renal disease is an indication for discontinuation of treatment with bumetanide tablets bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected bumetanide is contraindicated in patients hypersensitive to this drug,1
to reduce the development of drugresistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy suppression of intestinal bacterianeomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel eg preoperative preparation of the bowel it is given concomitantly with erythromycin entericcoated base see dosage and administration hepatic coma portalsystemic encephalopathyneomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammoniaforming bacteria in the intestinal tract the subsequent reduction in blood ammonia has resulted in neurologic improvement,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy suppression of intestinal bacterianeomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel eg preoperative preparation of the bowel it is given concomitantly with erythromycin entericcoated base see dosage and administration hepatic coma portalsystemic encephalopathyneomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammoniaforming bacteria in the intestinal tract the subsequent reduction in blood ammonia has resulted in neurologic improvement,3
pamidronate disodium for injection usp in conjunction with adequate hydration is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases patients who have either epidermoid or nonepidermoid tumors respond to treatment with pamidronate disodium for injection usp vigorous saline hydration an integral part of hypercalcemia therapy should be initiated promptly and an attempt should be made to restore the urine output to about 2 lday throughout treatment mild or asymptomatic hypercalcemia may be treated with conservative measures ie saline hydration with or without loop diuretics patients should be hydrated adequately throughout the treatment but overhydration especially in those patients who have cardiac failure must be avoided diuretic therapy should not be employed prior to correction of hypovolemia the safety and efficacy of pamidronate disodium for injection usp in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions has not been establishedpamidronate disodium for injection usp is indicated for the treatment of patients with moderate to severe pagets disease of bone the effectiveness of pamidronate disodium for injection usp was demonstrated primarily in patients with serum alkaline phosphatase 3 times the upper limit of normal pamidronate disodium for injection usp therapy in patients with pagets disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by 50 in at least 50 of patients and by 30 in at least 80 of patients pamidronate disodium for injection usp therapy has also been effective in reducing these biochemical markers in patients with pagets disease who failed to respond or no longer responded to other treatments pamidronate disodium for injection usp is indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma the pamidronate disodium for injection usp treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy however overall evidence of clinical benefit has been demonstrated see clinical pharmacologyosteolytic bone metastases of breast cancer and osteolytic lesions of multiple myelomaclinical trials,3
pamidronate disodium for injection usp in conjunction with adequate hydration is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases patients who have either epidermoid or nonepidermoid tumors respond to treatment with pamidronate disodium for injection usp vigorous saline hydration an integral part of hypercalcemia therapy should be initiated promptly and an attempt should be made to restore the urine output to about 2 lday throughout treatment mild or asymptomatic hypercalcemia may be treated with conservative measures ie saline hydration with or without loop diuretics patients should be hydrated adequately throughout the treatment but overhydration especially in those patients who have cardiac failure must be avoided diuretic therapy should not be employed prior to correction of hypovolemia the safety and efficacy of pamidronate disodium for injection usp in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions has not been establishedpamidronate disodium for injection usp is indicated for the treatment of patients with moderate to severe pagets disease of bone the effectiveness of pamidronate disodium for injection usp was demonstrated primarily in patients with serum alkaline phosphatase 3 times the upper limit of normal pamidronate disodium for injection usp therapy in patients with pagets disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by 50 in at least 50 of patients and by 30 in at least 80 of patients pamidronate disodium for injection usp therapy has also been effective in reducing these biochemical markers in patients with pagets disease who failed to respond or no longer responded to other treatments pamidronate disodium for injection usp is indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma the pamidronate disodium for injection usp treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy however overall evidence of clinical benefit has been demonstrated see clinical pharmacologyosteolytic bone metastases of breast cancer and osteolytic lesions of multiple myelomaclinical trials,3
pamidronate disodium for injection usp in conjunction with adequate hydration is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases patients who have either epidermoid or nonepidermoid tumors respond to treatment with pamidronate disodium for injection usp vigorous saline hydration an integral part of hypercalcemia therapy should be initiated promptly and an attempt should be made to restore the urine output to about 2 lday throughout treatment mild or asymptomatic hypercalcemia may be treated with conservative measures ie saline hydration with or without loop diuretics patients should be hydrated adequately throughout the treatment but overhydration especially in those patients who have cardiac failure must be avoided diuretic therapy should not be employed prior to correction of hypovolemia the safety and efficacy of pamidronate disodium for injection usp in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions has not been establishedpamidronate disodium for injection usp is indicated for the treatment of patients with moderate to severe pagets disease of bone the effectiveness of pamidronate disodium for injection usp was demonstrated primarily in patients with serum alkaline phosphatase 3 times the upper limit of normal pamidronate disodium for injection usp therapy in patients with pagets disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by 50 in at least 50 of patients and by 30 in at least 80 of patients pamidronate disodium for injection usp therapy has also been effective in reducing these biochemical markers in patients with pagets disease who failed to respond or no longer responded to other treatments pamidronate disodium for injection usp is indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma the pamidronate disodium for injection usp treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy however overall evidence of clinical benefit has been demonstrated see clinical pharmacologyosteolytic bone metastases of breast cancer and osteolytic lesions of multiple myelomaclinical trials,3
calcipotriene cream 0005 is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation it should not be used by patients with demonstrated hypercalcemia or evidence of vitamin d toxicity calcipotriene cream 0005 should not be used on the face,3
male patients with carcinoma of the breast or with known or suspected carcinoma of the prostatecarcinoma of the breast in females with hypercalcemia androgenic anabolic steroids may stimulate osteolytic resorption of bonespregnancy because of masculinization of the fetusnephrosis or the nephrotic phase of nephritis,2
calcium gluconate in sodium chloride injection is contraindicated inhyperca lce mia ne ona te s 28 day s of a ge or y oun ger rece iving cef tr iax one see warnings and precautions 52 hypercalcemia 4 neonates 28 days of age or younger receiving ceftriaxone 4,1
elaprase is indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and olderin patients 16 months to 5 years of age no data are available to demonstrate improvement in diseaserelated symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and olderthe safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age see use in specific populations 84elaprase is a hydrolytic lysosomal glycosaminoglycan gagspecific enzyme indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in diseaserelated symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age 1,3
naglazyme galsulfase is indicated for patients with mucopolysaccharidosis vi mps vi maroteauxlamy syndrome naglazyme has been shown to improve walking and stairclimbing capacitynaglazyme is a hydrolytic lysosomal glycosaminoglycan gagspecific enzyme indicated for patients with mucopolysaccharidosis vi mps vi maroteauxlamy syndrome naglazyme has been shown to improve walking and stairclimbing capacity 1,3
aldurazyme raldurazyme has been shown to improve pulmonary function and walking capacity aldurazyme has not been evaluated for effects on the central nervous system manifestations of the disorderaldurazyme is a hydrolytic lysosomal glycosaminoglycan gagspecific enzyme indicated for patients with hurler and hurlerscheie forms of mucopolysaccharidosis i mps i and for patients with the scheie form who have moderate to severe symptoms the risks and benefits of treating mildly affected patients with the scheie form have not been established aldurazyme has been shown to improve pulmonary function and walking capacity aldurazyme has not been evaluated for effects on the central nervous system manifestations of the disorder 1,3
enter section text here treatment of schizophrenia in adults 11alone or in combination with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adults 12due to janssen pharmaceuticals corporations marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia or bipolar mania 1112treatment of irritability associated with autistic disorder in children and adolescents aged 516 years 13 risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia see clinical studies 141adolescentsdue to janssen pharmaceuticals corporations marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia pediatric use information for the treatment of pediatric patients with schizophrenia 13 to 17 years of age is approved for janssen pharmaceuticals corporations risperidone drug products risperidone tablets are indicated for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 142due to janssen pharmaceuticals corporations marketing exclusivity rights this drug product is not labeled for use in pediatric patients with bipolar mania pediatric use information for the treatment of pediatric patients with bipolar mania 10 to 17 years of age is approved for janssen pharmaceuticals corporations risperidone drug productscombination therapy adultsthe combination of risperidone with lithium or valproate is indicated for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder see clinical studies 143 risperidone tablets are indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 516 years including symptoms of aggression towards others deliberate selfinjuriousness temper tantrums and quickly changing moods see clinical studies 144,3
enter section text here treatment of schizophrenia in adults 11alone or in combination with lithium or valproate for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adults 12due to janssen pharmaceuticals corporations marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia or bipolar mania 1112treatment of irritability associated with autistic disorder in children and adolescents aged 516 years 13 risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia see clinical studies 141adolescentsdue to janssen pharmaceuticals corporations marketing exclusivity rights this drug product is not labeled for use in pediatric patients with schizophrenia pediatric use information for the treatment of pediatric patients with schizophrenia 13 to 17 years of age is approved for janssen pharmaceuticals corporations risperidone drug products risperidone tablets are indicated for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 142due to janssen pharmaceuticals corporations marketing exclusivity rights this drug product is not labeled for use in pediatric patients with bipolar mania pediatric use information for the treatment of pediatric patients with bipolar mania 10 to 17 years of age is approved for janssen pharmaceuticals corporations risperidone drug productscombination therapy adultsthe combination of risperidone with lithium or valproate is indicated for the shortterm treatment of acute manic or mixed episodes associated with bipolar i disorder see clinical studies 143 risperidone tablets are indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 516 years including symptoms of aggression towards others deliberate selfinjuriousness temper tantrums and quickly changing moods see clinical studies 144,3
severe glucose6phosphate dehydrogenase g6pd deficiency see warningspregnant women see warnings usage in pregnancyprimaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia such as rheumatoid arthritis and lupus erythematosus the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrowbecause quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine the use of quinacrine in patients receiving primaquine is contraindicated similarly primaquine should not be administered to patients who have received quinacrine recently as toxicity is increased,3
vinblastine sulfate is contraindicated in patients who have significant granulocytopenia unless this is a result of the disease being treated it should not be used in the presence of bacterial infections such infections must be brought under control prior to the initiation of therapy with vinblastine sulfate,1
vexolr 1 rimexolone ophthalmic suspension is indicated for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis,3
vexolr 1 rimexolone ophthalmic suspension is indicated for the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis,3
eraxis is indicated for use in adults for the treatment of the following fungal infections listed below specimens for fungal culture and other relevant laboratory studies including histopathology should be obtained prior to therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies known however once these results become available antifungal therapy should be adjusted accordinglyanidulafungin is an echinocandin antifungal indicated in adults for the treatment of candidemia and other forms of candida11esophageal candidiasis 12limitations of use has not been studied in endocarditis osteomyelitis and meningitis due to candida13eraxis is indicated for the treatment of candidemia and the following candidasee clinical studies 141 clinical pharmacology microbiology 124eraxis is indicated for the treatment of esophageal candidiasis see clinical studies 142 table 10eraxis has not been studied in endocarditis osteomyelitis and meningitis due to candida,3
caspofungin acetate for injection is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for 1 candida1 1 1caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile neutropenic adult and pediatric patients 3 months of age and older see clinical studies141145caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections intraabdominal abscesses peritonitis and pleural space infections in adult and pediatric patients 3 months of age and older see clinical studies142145 limitations of usecaspofungin acetate for injection has not been studied in endocarditis osteomyelitis and meningitis due to candidacaspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients 3 months of age and older see clinical studies143145 limitations of usecaspofungin acetate for injection has not been approved for the treatment of oropharyngeal candidiasis opc in the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis patients with concomitant opc had higher relapse rate of the opc see clinical studies143caspofungin acetate for injection is indicated for the treatment of invasive aspergillosis in adult and pediatric patients 3 months of age and older who are refractory to or intolerant of other therapies see clinical studies144145 limitations of usecaspofungin acetate for injection has not been studied as initial therapy for invasive aspergillosis,3
caspofungin acetate for injection is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for 1 candida1 1 1caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile neutropenic adult and pediatric patients 3 months of age and older see clinical studies141145caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections intraabdominal abscesses peritonitis and pleural space infections in adult and pediatric patients 3 months of age and older see clinical studies142145 limitations of usecaspofungin acetate for injection has not been studied in endocarditis osteomyelitis and meningitis due to candidacaspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients 3 months of age and older see clinical studies143145 limitations of usecaspofungin acetate for injection has not been approved for the treatment of oropharyngeal candidiasis opc in the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis patients with concomitant opc had higher relapse rate of the opc see clinical studies143caspofungin acetate for injection is indicated for the treatment of invasive aspergillosis in adult and pediatric patients 3 months of age and older who are refractory to or intolerant of other therapies see clinical studies144145 limitations of usecaspofungin acetate for injection has not been studied as initial therapy for invasive aspergillosis,3
fluconazole is indicated for the treatment of vaginal candidiasis vaginal yeast infections due to candidaoropharyngeal and esophageal candidiasis in open noncomparative studies of relatively small numbers of patients fluconazole was also effective for the treatment of urinary tract infections peritonitis and systemic infections including candidemia disseminated candidiasis and pneumonia candidacandidacryptococcal meningitis before prescribing fluconazole for aids patients with cryptococcal meningitis please see section studies comparing fluconazole to amphotericin b in nonhiv infected patients have not been conducted clinical studiesfluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy andor radiation therapyspecimens for fungal culture and other relevant laboratory studies serology histopathology should be obtained prior to therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antiinfective therapy should be adjusted accordingly,3
voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis 11candidemia in nonneutropenics and other deep tissue candida12esophageal candidiasis 13serious fungal infections caused by scedosporium apiospermumfusariumfusarium solani14 voriconazole tablets is indicated in adults and pediatric patients 2 years of age and older for the treatment of invasive apergillosis ia in clinical trials the majority of isolates recovered were aspergillus fumigatus there was a small number of cases of cultureproven disease due to species of aspergillus other than a fumigatus see clinical studies 141145microbiology 124 voriconazole tablets is indicated in adults and pediatric patients 2 years of age and older for the treatment of candidemia in nonneutropenic patients and the following candida infections disseminated infections in skin and infections in abdomen kidney bladder wall and wounds see clinical studies 142145microbiology 124 voriconazole tablets is indicated in adults and pediatric patients 2 years of age and older for the treatment of esophageal candidiasis ec in adults and pediatric patients 2 years of age and older see clinical studies 143145microbiology 124 voriconazole tablets is indicated for the treatment of serious fungal infections caused by scedosporium apiospermum asexual form of pseudallescheria boydii and fusarium spp including fusarium solani in adults and pediatric patients 2 years of age and older intolerant of or refractory to other therapy see clinical studies 144microbiology 124specimens for fungal culture and other relevant laboratory studies including histopathology should be obtained prior to therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly,3
voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with invasive aspergillosis 11candidemia in nonneutropenics and other deep tissue candida12esophageal candidiasis 13serious fungal infections caused by scedosporium apiospermumfusariumfusarium solani14 voriconazole tablets is indicated in adults and pediatric patients 2 years of age and older for the treatment of invasive apergillosis ia in clinical trials the majority of isolates recovered were aspergillus fumigatus there was a small number of cases of cultureproven disease due to species of aspergillus other than a fumigatus see clinical studies 141145microbiology 124 voriconazole tablets is indicated in adults and pediatric patients 2 years of age and older for the treatment of candidemia in nonneutropenic patients and the following candida infections disseminated infections in skin and infections in abdomen kidney bladder wall and wounds see clinical studies 142145microbiology 124 voriconazole tablets is indicated in adults and pediatric patients 2 years of age and older for the treatment of esophageal candidiasis ec in adults and pediatric patients 2 years of age and older see clinical studies 143145microbiology 124 voriconazole tablets is indicated for the treatment of serious fungal infections caused by scedosporium apiospermum asexual form of pseudallescheria boydii and fusarium spp including fusarium solani in adults and pediatric patients 2 years of age and older intolerant of or refractory to other therapy see clinical studies 144microbiology 124specimens for fungal culture and other relevant laboratory studies including histopathology should be obtained prior to therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly,3
probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis as an adjuvant to therapy with penicillin or with ampicillin methicillin oxacillin cloxacillin or nafcillin for elevation and prolongation of plasma levels by whatever route the antibiotic is given,3
probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis as an adjuvant to therapy with penicillin or with ampicillin methicillin oxacillin cloxacillin or nafcillin for elevation and prolongation of plasma levels by whatever route the antibiotic is given,3
carefully consider the potential benefits and risks of indomethacin extendedrelease capsules usp 75 mg and other treatment options before deciding to use indomethacin extendedrelease capsules usp 75 mg use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsindomethacin extendedrelease capsules usp 75 mg has been found effective in active stages of the following1 moderate to severe rheumatoid arthritis including acute flares of chronic disease2 moderate to severe ankylosing spondylitis3 moderate to severe osteoarthritis4 acute painful shoulder bursitis andor tendinitisindomethacin extendedrelease capsules usp 75 mg are not recommended for the treatment of acute gouty arthritisindomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effectsthe use of indomethacin in conjunction with aspirin or other salicylates is not recommended controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone furthermore in one of these clinical studies the incidence of gastrointestinal side effects was significantly increased with combined therapy see precautions drug interactions,1
carefully consider the potential benefits and risks of indomethacin extendedrelease capsules usp 75 mg and other treatment options before deciding to use indomethacin extendedrelease capsules usp 75 mg use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsindomethacin extendedrelease capsules usp 75 mg has been found effective in active stages of the following1 moderate to severe rheumatoid arthritis including acute flares of chronic disease2 moderate to severe ankylosing spondylitis3 moderate to severe osteoarthritis4 acute painful shoulder bursitis andor tendinitisindomethacin extendedrelease capsules usp 75 mg are not recommended for the treatment of acute gouty arthritisindomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effectsthe use of indomethacin in conjunction with aspirin or other salicylates is not recommended controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone furthermore in one of these clinical studies the incidence of gastrointestinal side effects was significantly increased with combined therapy see precautions drug interactions,3
carefully consider the potential benefits and risks of indomethacin extendedrelease capsules usp 75 mg and other treatment options before deciding to use indomethacin extendedrelease capsules usp 75 mg use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsindomethacin extendedrelease capsules usp 75 mg has been found effective in active stages of the following1 moderate to severe rheumatoid arthritis including acute flares of chronic disease2 moderate to severe ankylosing spondylitis3 moderate to severe osteoarthritis4 acute painful shoulder bursitis andor tendinitisindomethacin extendedrelease capsules usp 75 mg are not recommended for the treatment of acute gouty arthritisindomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effectsthe use of indomethacin in conjunction with aspirin or other salicylates is not recommended controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone furthermore in one of these clinical studies the incidence of gastrointestinal side effects was significantly increased with combined therapy see precautions drug interactions,3
carefully consider the potential benefits and risks of indomethacin extendedrelease capsules usp 75 mg and other treatment options before deciding to use indomethacin extendedrelease capsules usp 75 mg use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsindomethacin extendedrelease capsules usp 75 mg has been found effective in active stages of the following1 moderate to severe rheumatoid arthritis including acute flares of chronic disease2 moderate to severe ankylosing spondylitis3 moderate to severe osteoarthritis4 acute painful shoulder bursitis andor tendinitisindomethacin extendedrelease capsules usp 75 mg are not recommended for the treatment of acute gouty arthritisindomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effectsthe use of indomethacin in conjunction with aspirin or other salicylates is not recommended controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone furthermore in one of these clinical studies the incidence of gastrointestinal side effects was significantly increased with combined therapy see precautions drug interactions,3
carefully consider the potential benefits and risks of indomethacin extendedrelease capsules usp 75 mg and other treatment options before deciding to use indomethacin extendedrelease capsules usp 75 mg use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsindomethacin extendedrelease capsules usp 75 mg has been found effective in active stages of the following1 moderate to severe rheumatoid arthritis including acute flares of chronic disease2 moderate to severe ankylosing spondylitis3 moderate to severe osteoarthritis4 acute painful shoulder bursitis andor tendinitisindomethacin extendedrelease capsules usp 75 mg are not recommended for the treatment of acute gouty arthritisindomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effectsthe use of indomethacin in conjunction with aspirin or other salicylates is not recommended controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone furthermore in one of these clinical studies the incidence of gastrointestinal side effects was significantly increased with combined therapy see precautions drug interactions,3
carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningssulindac tablets usp are indicated for acute or longterm use in the relief of signs and symptoms of the following osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis acute gouty arthritis the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,2
carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningssulindac tablets usp are indicated for acute or longterm use in the relief of signs and symptoms of the following osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis acute gouty arthritis the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,2
carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningssulindac tablets usp are indicated for acute or longterm use in the relief of signs and symptoms of the following osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis acute gouty arthritis the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,2
carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningssulindac tablets usp are indicated for acute or longterm use in the relief of signs and symptoms of the following osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis acute gouty arthritis the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,2
carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningssulindac tablets usp are indicated for acute or longterm use in the relief of signs and symptoms of the following osteoarthritis rheumatoid arthritis ankylosing spondylitis acute painful shoulder acute subacromial bursitissupraspinatus tendinitis acute gouty arthritis the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,3
loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies,2
alosetron hydrochloride is indicated only for women with severe diarrheapredominant irritable bowel syndrome ibs who have chronic ibs symptoms generally lasting 6 months or longer had anatomic or biochemical abnormalities of the gastrointestinal tract excluded and not responded adequately to conventional therapy diarrheapredominant ibs is severe if it includes diarrhea and one or more of the following frequent and severe abdominal paindiscomfort frequent bowel urgency or fecal incontinence disability or restriction of daily activities due to ibs because of infrequent but serious gastrointestinal adverse reactions associated with alosetron hydrochloride the indication is restricted to those patients for whom the benefittorisk balance is most favorable clinical studies have not been performed to adequately confirm the benefits of alosetron hydrochloride in men alosetron hydrochloride is a selective serotonin 5ht 3 chronic ibs symptoms generally lasting 6 months or longer had anatomic or biochemical abnormalities of the gastrointestinal tract excluded and not responded adequately to conventional therapy 1severe ibs includes diarrhea and 1 or more of the following frequent and severe abdominal paindiscomfort frequent bowel urgency or fecal incontinence disability or restriction of daily activities due to ibs 1,3
alosetron hydrochloride is indicated only for women with severe diarrheapredominant irritable bowel syndrome ibs who have chronic ibs symptoms generally lasting 6 months or longer had anatomic or biochemical abnormalities of the gastrointestinal tract excluded and not responded adequately to conventional therapy diarrheapredominant ibs is severe if it includes diarrhea and one or more of the following frequent and severe abdominal paindiscomfort frequent bowel urgency or fecal incontinence disability or restriction of daily activities due to ibs because of infrequent but serious gastrointestinal adverse reactions associated with alosetron hydrochloride the indication is restricted to those patients for whom the benefittorisk balance is most favorable clinical studies have not been performed to adequately confirm the benefits of alosetron hydrochloride in men alosetron hydrochloride is a selective serotonin 5ht 3 chronic ibs symptoms generally lasting 6 months or longer had anatomic or biochemical abnormalities of the gastrointestinal tract excluded and not responded adequately to conventional therapy 1severe ibs includes diarrhea and 1 or more of the following frequent and severe abdominal paindiscomfort frequent bowel urgency or fecal incontinence disability or restriction of daily activities due to ibs 1,3
all diuretics including ethacrynic acid are contraindicated in anuria if increasing electrolyte imbalance azotemia andor oliguria occur during treatment of severe progressive renal disease the diuretic should be discontinued in a few patients this diuretic has produced severe watery diarrhea if this occurs it should be discontinued and not used again until further experience in infants is accumulated therapy with oral ethacrynic acid is contraindicated hypersensitivity to any component of this product,1
acromegalyoctreotide acetate injection is indicated to reduce blood levels of growth hormone and igfi somatomedin c in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection pituitary irradiation and bromocriptine mesylate at maximally tolerated doses the goal is to achieve normalization of growth hormone and igfi somatomedin c levels see dosage and administrationimprovement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection these trials were not optimally designed to detect such effects carcinoid tumorsoctreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the diseaseoctreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases vasoactive intestinal peptide tumors vipomasoctreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with vipsecreting tumors octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases,3
acromegalyoctreotide acetate injection is indicated to reduce blood levels of growth hormone and igfi somatomedin c in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection pituitary irradiation and bromocriptine mesylate at maximally tolerated doses the goal is to achieve normalization of growth hormone and igfi somatomedin c levels see dosage and administrationimprovement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection these trials were not optimally designed to detect such effects carcinoid tumorsoctreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the diseaseoctreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases vasoactive intestinal peptide tumors vipomasoctreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with vipsecreting tumors octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapyxifaxan is a rifamycin antibacterial indicated for the treatment of patients 12 years of age with travelers diarrhea td caused by noninvasive strains of escherichia coli 11reduction in risk of overt hepatic encephalopathy he recurrence in patients 18 years of age 12 limitations of use td do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli 11 xifaxan 200 mg is indicated for the treatment of patients 12 years of age with travelers diarrhea caused by noninvasive strains of escherichia coli see warningsand precautions 5clinical pharmacology 124 clinicalstudies141 limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli xifaxan 550 mg is indicated for reduction in risk of overt hepatic encephalopathy he recurrence in patients 18 years of age in the trials of xifaxan for he 91 of the patients were using lactulose concomitantly differences in the treatment effect of those patients not using lactulose concomitantly could not be assessed xifaxan has not been studied in patients with meld model for endstage liver disease scores 25 and only 86 of patients in the controlled trial had meld scores over 19 there is increased systemic exposure in patients with more severe hepatic dysfunction see warnings and precautions 5487123,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapyxifaxan is a rifamycin antibacterial indicated for the treatment of patients 12 years of age with travelers diarrhea td caused by noninvasive strains of escherichia coli 11reduction in risk of overt hepatic encephalopathy he recurrence in patients 18 years of age 12 limitations of use td do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli 11 xifaxan 200 mg is indicated for the treatment of patients 12 years of age with travelers diarrhea caused by noninvasive strains of escherichia coli see warningsand precautions 5clinical pharmacology 124 clinicalstudies141 limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli xifaxan 550 mg is indicated for reduction in risk of overt hepatic encephalopathy he recurrence in patients 18 years of age in the trials of xifaxan for he 91 of the patients were using lactulose concomitantly differences in the treatment effect of those patients not using lactulose concomitantly could not be assessed xifaxan has not been studied in patients with meld model for endstage liver disease scores 25 and only 86 of patients in the controlled trial had meld scores over 19 there is increased systemic exposure in patients with more severe hepatic dysfunction see warnings and precautions 5487123,3
enter section text here concomitant use of meperidine tramadol methadone or propoxyphene 414243azilect is contraindicated for use with meperidine serious adverse reactions have been precipitated with concomitant use of meperidine eg demerol and other tradenames and mao inhibitors maois including selective maob inhibitors these adverse reactions are often described as serotonin syndrome a potentially serious condition which can result in death typical clinical signs and symptoms include behavioral and cognitivemental status changes eg confusion hypomania hallucinations agitation delirium headache and coma autonomic effects eg syncope shivering sweating high feverhyperthermia hypertension hypotension tachycardia nausea diarrhea and somatic effects eg muscular rigidity myoclonus muscle twitching hyperreflexia manifested by clonus and tremor at least 14 days should elapse between discontinuation of azilect and initiation of treatment with meperidineazilect should not be used with the antitussive agent dextromethorphan the combination of mao inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior azilect is also contraindicated for use with st johns wort and cyclobenzaprine a tricyclic muscle relaxant azilect should not be administered along with any other mao inhibitor selective or nonselective because of the increased risk of nonselective mao inhibition that may lead to a hypertensive crisis at least 14 days should elapse between discontinuation of azilect and initiation of treatment with any mao inhibitor,1
viberzi viberzi is a muopioid receptor agonist indicated in adults for the treatment of irritable bowel syndrome with diarrhea ibsd 1,3
viberzi viberzi is a muopioid receptor agonist indicated in adults for the treatment of irritable bowel syndrome with diarrhea ibsd 1,3
a patients exhibiting idiosyncratic reactions to psoralen compoundsb patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances diseases associated with photosensitivity include lupus erythematosus porphyria cutanea tarda erythropoietic protoporphyria variegate porphyria xeroderma pigmentosum and albinismc patients with melanoma or with a history of melanomad patients with invasive squamous cell carcinomase patients with aphakia because of the significantly increased risk of retinal damage due to the absence of lenses,2
proglycemr adults inoperable islet cell adenoma or carcinoma or extrapancreatic malignancyinfants and children leucine sensitivity islet cell hyperplasia nesidioblastosis extrapancreatic malignancy islet cell adenoma or adenomatosis proglycemrproglycemrr,3
proglycemr adults inoperable islet cell adenoma or carcinoma or extrapancreatic malignancyinfants and children leucine sensitivity islet cell hyperplasia nesidioblastosis extrapancreatic malignancy islet cell adenoma or adenomatosis proglycemrproglycemrr,3
proglycemr adults inoperable islet cell adenoma or carcinoma or extrapancreatic malignancyinfants and children leucine sensitivity islet cell hyperplasia nesidioblastosis extrapancreatic malignancy islet cell adenoma or adenomatosis proglycemrproglycemrr,3
proglycemr adults inoperable islet cell adenoma or carcinoma or extrapancreatic malignancyinfants and children leucine sensitivity islet cell hyperplasia nesidioblastosis extrapancreatic malignancy islet cell adenoma or adenomatosis proglycemrproglycemrr,3
pernicious anemia both uncomplicated and accompanied by nervous system involvement dietary deficiency of vitamin b1212 malabsorption of vitamin b121212 inadequate secretion of intrinsic factor resulting from lesions that destroy the gastric mucosa ingestion of corrosives extensive neoplasia and a number of conditions associated with a variable degree of gastric atrophy such as multiple sclerosis certain endocrine disorders iron deficiency and subtotal gastrectomy total gastrectomy always produces vitamin b12structural lesions leading to vitamin b12 competition for vitamin b12the fish tapeworm diphyllobothrium latum absorbs huge quantities of vitamin b1212 inadequate utilization of vitamin b12 for the schilling test,0
pernicious anemia both uncomplicated and accompanied by nervous system involvement dietary deficiency of vitamin b1212 malabsorption of vitamin b121212 inadequate secretion of intrinsic factor resulting from lesions that destroy the gastric mucosa ingestion of corrosives extensive neoplasia and a number of conditions associated with a variable degree of gastric atrophy such as multiple sclerosis certain endocrine disorders iron deficiency and subtotal gastrectomy total gastrectomy always produces vitamin b12structural lesions leading to vitamin b12 competition for vitamin b12the fish tapeworm diphyllobothrium latum absorbs huge quantities of vitamin b1212 inadequate utilization of vitamin b12 for the schilling test,3
nascobal is indicated for vitamin b1212treatment of adult patients with dietary druginduced or malabsorptionrelated vitamin b12prevention of vitamin b1212 limitations of use nascobal should not be used for the vitamin b12in patients with correctible or temporary causes of vitamin b1212the effectiveness of nascobal in patients with active symptoms of nasal congestion allergic rhinitis or upper respiratory infection has not been determined treatment with nascobal should be deferred until symptoms have subsidednascobal is a vitamin b12 vitamin b12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin b12 therapy and who have no nervous system involvement1treatment of adult patients with dietary druginduced or malabsorptionrelated vitamin b12 deficiency not due to pernicious anemia 1prevention of vitamin b12 deficiency in adult patients with vitamin b12 requirements in excess of normal 1limitations of use should not be used for the vitamin b12 absorption test schilling test 1in patients with correctible or temporary causes of vitamin b12 deficiency the benefit of continued longterm use following correction of vitamin b121in patients with active symptoms of nasal congestion allergic rhinitis or upper respiratory infection effectiveness has not been established 1,3
nascobal is indicated for vitamin b1212treatment of adult patients with dietary druginduced or malabsorptionrelated vitamin b12prevention of vitamin b1212 limitations of use nascobal should not be used for the vitamin b12in patients with correctible or temporary causes of vitamin b1212the effectiveness of nascobal in patients with active symptoms of nasal congestion allergic rhinitis or upper respiratory infection has not been determined treatment with nascobal should be deferred until symptoms have subsidednascobal is a vitamin b12 vitamin b12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin b12 therapy and who have no nervous system involvement1treatment of adult patients with dietary druginduced or malabsorptionrelated vitamin b12 deficiency not due to pernicious anemia 1prevention of vitamin b12 deficiency in adult patients with vitamin b12 requirements in excess of normal 1limitations of use should not be used for the vitamin b12 absorption test schilling test 1in patients with correctible or temporary causes of vitamin b12 deficiency the benefit of continued longterm use following correction of vitamin b121in patients with active symptoms of nasal congestion allergic rhinitis or upper respiratory infection effectiveness has not been established 1,1
methazolamide tablets therapy is contraindicated in situations in which sodium andor potassium serum levels are depressed in cases of marked kidney or liver disease or dysfunction in adrenal gland failure and in hyperchloremic acidosis in patients with cirrhosis use may precipitate the development of hepatic encephalopathylongterm administration of methazolamide is contraindicated in patients with angleclosure glaucoma since organic closure of the angle may occur in spite of lowered intraocular pressure,1
methazolamide tablets therapy is contraindicated in situations in which sodium andor potassium serum levels are depressed in cases of marked kidney or liver disease or dysfunction in adrenal gland failure and in hyperchloremic acidosis in patients with cirrhosis use may precipitate the development of hepatic encephalopathylongterm administration of methazolamide is contraindicated in patients with angleclosure glaucoma since organic closure of the angle may occur in spite of lowered intraocular pressure,1
methazolamide tablets therapy is contraindicated in situations in which sodium andor potassium serum levels are depressed in cases of marked kidney or liver disease or dysfunction in adrenal gland failure and in hyperchloremic acidosis in patients with cirrhosis use may precipitate the development of hepatic encephalopathylongterm administration of methazolamide is contraindicated in patients with angleclosure glaucoma since organic closure of the angle may occur in spite of lowered intraocular pressure,1
methazolamide tablets therapy is contraindicated in situations in which sodium andor potassium serum levels are depressed in cases of marked kidney or liver disease or dysfunction in adrenal gland failure and in hyperchloremic acidosis in patients with cirrhosis use may precipitate the development of hepatic encephalopathylongterm administration of methazolamide is contraindicated in patients with angleclosure glaucoma since organic closure of the angle may occur in spite of lowered intraocular pressure,3
hypersensitivity to acetazolamide or any excipients in the formulation since acetazolamide is a sulfonamide derivative cross sensitivity between acetazolamide sulfonamides and other sulfonamide derivatives is possible acetazolamide therapy is contraindicated in situations in which sodium andor potassium blood serum levels are depressed in cases of marked kidney and liver disease or dysfunction in suprarenal gland failure and in hyperchloremic acidosis it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy longterm administration of acetazolamide is contraindicated in patients with chronic noncongestive angleclosure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure,3
flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitis urethrotrigonitis flavoxate hydrochloride tablets are not indicated for definitive treatment but are compatible with drugs used for the treatment of urinary tract infections,2
flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitis urethrotrigonitis flavoxate hydrochloride tablets are not indicated for definitive treatment but are compatible with drugs used for the treatment of urinary tract infections,2
flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitis urethrotrigonitis flavoxate hydrochloride tablets are not indicated for definitive treatment but are compatible with drugs used for the treatment of urinary tract infections,2
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastaticlimitation of use12adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16afinitorrafinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of usesee clinical studies 142afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenibafinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgeryafinitor and afinitor disperzr afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,1
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastaticlimitation of use12adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16afinitorrafinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of usesee clinical studies 142afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenibafinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgeryafinitor and afinitor disperzr afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastaticlimitation of use12adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16afinitorrafinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of usesee clinical studies 142afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenibafinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgeryafinitor and afinitor disperzr afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastaticlimitation of use12adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16afinitorrafinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of usesee clinical studies 142afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenibafinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgeryafinitor and afinitor disperzr afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
11 chronic kidney disease stages 3 and 4paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stages 3 and 4 pediatric use information for patients 10 to 16 years of age is approved for abbvie incs zemplar paricalcitol capsules however due to abbvie incs marketing exclusivity rights this drug product is not labeled with that pediatric information 12 chronic kidney disease stage 5 pediatric use information for patients 10 to 16 years of age is approved for abbvie incs zemplar paricalcitol capsules however due to abbvie incs marketing exclusivity rights this drug product is not labeled with that pediatric information paricalcitol is a vitamin d analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stages 3 and 4 11,3
11 chronic kidney disease stages 3 and 4paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stages 3 and 4 pediatric use information for patients 10 to 16 years of age is approved for abbvie incs zemplar paricalcitol capsules however due to abbvie incs marketing exclusivity rights this drug product is not labeled with that pediatric information 12 chronic kidney disease stage 5 pediatric use information for patients 10 to 16 years of age is approved for abbvie incs zemplar paricalcitol capsules however due to abbvie incs marketing exclusivity rights this drug product is not labeled with that pediatric information paricalcitol is a vitamin d analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stages 3 and 4 11,3
11 chronic kidney disease stages 3 and 4paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stages 3 and 4 pediatric use information for patients 10 to 16 years of age is approved for abbvie incs zemplar paricalcitol capsules however due to abbvie incs marketing exclusivity rights this drug product is not labeled with that pediatric information 12 chronic kidney disease stage 5 pediatric use information for patients 10 to 16 years of age is approved for abbvie incs zemplar paricalcitol capsules however due to abbvie incs marketing exclusivity rights this drug product is not labeled with that pediatric information paricalcitol is a vitamin d analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease ckd stages 3 and 4 11,3
for adjunctive treatment of edema due to congestive heart failure druginduced edema centrencephalic epilepsies petit mal unlocalized seizures chronic simple openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where delay of surgery is desired in order to lower intraocular pressure acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent,3
for adjunctive treatment of edema due to congestive heart failure druginduced edema centrencephalic epilepsies petit mal unlocalized seizures chronic simple openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where delay of surgery is desired in order to lower intraocular pressure acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent,3
transderm scop is contraindicated in the following populations patients with angle closure glaucoma see adverse reactions 6persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system see drug interactions 7description 11 patients with angle closure glaucoma 462persons who are hypersensitive to scopolamine or to other belladonna alkaloids 47,0
transderm scop is contraindicated in the following populations patients with angle closure glaucoma see adverse reactions 6persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system see drug interactions 7description 11 patients with angle closure glaucoma 462persons who are hypersensitive to scopolamine or to other belladonna alkaloids 47,1
parenteral sedatives hypnotics for the shortterm treatment of insomnia since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacologypreanesthetics anticonvulsant in anesthetic doses in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia meningitis tetanus and toxic reactions to strychnine or local anesthetics,2
parenteral sedatives hypnotics for the shortterm treatment of insomnia since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacologypreanesthetics anticonvulsant in anesthetic doses in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia meningitis tetanus and toxic reactions to strychnine or local anesthetics,3
hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules uncontrolled hypertension and sensitivity to any ergot alkaloids in patients being treated for hyperprolactinemia bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed see precautions hyperprolactinemic states in the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma see precautions hyperprolactinemic statesand a patient experiences a hypertensive disorder of pregnancy the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy when bromocriptine is being used to treat acromegaly prolactinoma or parkinsons disease in patients who subsequently become pregnant a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn if it is continued the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy including eclampsia preeclampsia or pregnancyinduced hypertension unless withdrawal of bromocriptine is considered to be medically contraindicatedthe drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated if the drug is used in the postpartum period the patient should be observed with caution,3
hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules uncontrolled hypertension and sensitivity to any ergot alkaloids in patients being treated for hyperprolactinemia bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed see precautions hyperprolactinemic states in the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma see precautions hyperprolactinemic statesand a patient experiences a hypertensive disorder of pregnancy the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy when bromocriptine is being used to treat acromegaly prolactinoma or parkinsons disease in patients who subsequently become pregnant a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn if it is continued the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy including eclampsia preeclampsia or pregnancyinduced hypertension unless withdrawal of bromocriptine is considered to be medically contraindicatedthe drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated if the drug is used in the postpartum period the patient should be observed with caution,3
patients with known hypersensitivity to azithromycin erythromycin any macrolide or ketolide antibacterial drug 41patients with a history of cholestatic jaundicehepatic dysfunction associated with prior use of azithromycin 42azithromycin for injection is contraindicated in patients with known hypersensitivity to azithromycin erythromycin any macrolide or ketolide drugsazithromycin for injection is contraindicated in patients with a history of cholestatic jaundicehepatic dysfunction associated with prior use of azithromycin,1
hypersensitivity to clarithromycin or any macrolide drug 41cisapride pimozide lovastatinsimvastatin ergotaminedihydroergotamine 424546history of cholestatic jaundicehepatic dysfunction with use of clarithromycin 43colchicine in renal or hepatic impairment 44 hypersensitivity to clarithromycin or any macrolide drug 41cisapride pimozide lovastatinsimvastatin ergotaminedihydroergotamine 424546history of cholestatic jaundicehepatic dysfunction with use of clarithromycin 43colchicine in renal or hepatic impairment 44clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin erythromycin or any of the macrolide antibacterial drugs see warnings and precautions 51concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated see drug interactions 7there have been postmarketing reports of drug interactions when clarithromycin is coadministered with cisapride or pimozide resulting in cardiac arrhythmias qt prolongation ventricular tachycardia ventricular fibrillation and torsades de pointesclarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycinconcomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairmentdo not use clarithromycin tablets concomitantly with hmgcoa reductase inhibitors statins that are extensively metabolized by cyp3a4 lovastatin or simvastatin due to the increased risk of myopathy including rhabdomyolysis see warnings and precautions 54drug interactions 7concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated see drug interactions 7for information about contraindications of other drugs indicated in combination with clarithromycin tablets refer to their full prescribing information contraindications section,1
thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry major symptoms related to the nervous system or wet major symptoms related to the cardiovascular system variety thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary as in wernickes encephalopathy infantile beriberi with acute collapse cardiovascular disease due to thiamine deficiency or neuritis of pregnancy if vomiting is severe it is also indicated when giving iv dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia nausea vomiting or malabsorption thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption because multiple vitamins should usually be given,3
thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry major symptoms related to the nervous system or wet major symptoms related to the cardiovascular system variety thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary as in wernickes encephalopathy infantile beriberi with acute collapse cardiovascular disease due to thiamine deficiency or neuritis of pregnancy if vomiting is severe it is also indicated when giving iv dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia nausea vomiting or malabsorption thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption because multiple vitamins should usually be given,3
juxtapid is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a lowfat diet and other lipidlowering treatments including ldl apheresis where available to reduce lowdensity lipoprotein cholesterol ldlc total cholesterol tc apolipoprotein b apo b and nonhighdensity lipoprotein cholesterol nonhdlc in patients with homozygous familial hypercholesterolemia hofh 1 limitations of use the safety and effectiveness of juxtapid have not been established in patients with hypercholesterolemia who do not have hofh including those with heterozygous familial hypercholesterolemia hefh 1the effect of juxtapid on cardiovascular morbidity and mortality has not been determined 1juxtapid is indicated as an adjunct to a lowfat diet and other lipidlowering treatments including ldl apheresis where available to reduce lowdensity lipoprotein cholesterol ldlc total cholesterol tc apolipoprotein b apo b and nonhighdensity lipoprotein cholesterol nonhdlc in patients with homozygous familial hypercholesterolemia hofh limitations of use the safety and effectiveness of juxtapid have not been established in patients with hypercholesterolemia who do not have hofh including those with heterozygous familial hypercholesterolemia hefhthe effect of juxtapid on cardiovascular morbidity and mortality has not been determined,3
addyir flibanserin tablets are indicated for the treatment of premenopausal women with acquired generalized hypoactive sexual desire disorder hsdd as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to acquired hsdd refers to hsdd that develops in a patient who previously had no problems with sexual desire generalized hsdd refers to hsdd that occurs regardless of the type of stimulation situation or partner limitations of use addyi is indicated for the treatment of premenopausal women with acquired generalized hypoactive sexual desire disorder hsdd as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to 1 limitations of use 1 1,3
assisted reproductive technologycrinone 8 is indicated for progesterone supplementation or replacement as part of an assisted reproductive technology art treatment for infertile women with progesterone deficiency secondary amenorrheacrinone 4 is indicated for the treatment of secondary amenorrhea crinone 8 is indicated for use in women who have failed to respond to treatment with crinone 4,3
bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactinsecreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately onehalf of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifestedbromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been establisheddata are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopacarbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy,3
bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactinsecreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately onehalf of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifestedbromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been establisheddata are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopacarbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy,2
bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactinsecreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately onehalf of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifestedbromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been establisheddata are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopacarbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy,3
bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactinsecreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately onehalf of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifestedbromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been establisheddata are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopacarbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy,3
bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactinsecreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately onehalf of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifestedbromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been establisheddata are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopacarbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy,3
hypersensitivity to bethanechol chloride tablets hyperthyroidism peptic ulcer latent or active bronchial asthma pronounced bradycardia or hypotension vasomotor instability coronary artery disease epilepsy and parkinsonism bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question or in the presence of mechanical obstruction when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful as following recent urinary bladder surgery gastrointestinal resection and anastomosis or when there is possible gastrointestinal obstruction in bladder neck obstruction spastic gastrointestinal disturbances acute inflammatory lesions of the gastrointestinal tract or peritonitis or in marked vagotonia,0
hypersensitivity to bethanechol chloride tablets hyperthyroidism peptic ulcer latent or active bronchial asthma pronounced bradycardia or hypotension vasomotor instability coronary artery disease epilepsy and parkinsonism bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question or in the presence of mechanical obstruction when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful as following recent urinary bladder surgery gastrointestinal resection and anastomosis or when there is possible gastrointestinal obstruction in bladder neck obstruction spastic gastrointestinal disturbances acute inflammatory lesions of the gastrointestinal tract or peritonitis or in marked vagotonia,0
chloroquine phosphate is indicated for the treatment of uncomplicated malaria due to susceptible strains of p falciparum pmalariae p ovale and pvivaxprophylaxis of malaria in geographic areas where resistance to chloroquine is not presenttreatment of extraintestinal amebiasischloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites do not use chloroquine phosphate tablets for the treatment of complicated malaria highgrade parasitemia andor complications eg cerebral malaria or acute renal failuredo not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs resistance to chloroquine phosphate tablets is widespread in p falciparum pvivaxconcomitant therapy with an 8aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of pvivaxpovale,3
chloroquine phosphate is indicated for the treatment of uncomplicated malaria due to susceptible strains of p falciparum pmalariae p ovale and pvivaxprophylaxis of malaria in geographic areas where resistance to chloroquine is not presenttreatment of extraintestinal amebiasischloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites do not use chloroquine phosphate tablets for the treatment of complicated malaria highgrade parasitemia andor complications eg cerebral malaria or acute renal failuredo not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs resistance to chloroquine phosphate tablets is widespread in p falciparum pvivaxconcomitant therapy with an 8aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of pvivaxpovale,3
strensiqrstrensiqr is a tissue nonspecific alkaline phosphatase indicated for the treatment of patients with perinatalinfantile and juvenileonset hypophosphatasia hpp 1,3
indications and usagebuspirone hydrochloride tablets are indicated for the management of anxiety disorders or the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticthe efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder gad many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study with an average symptom duration of 6 months generalized anxiety disorder 30002 is described in the american psychiatric associations diagnostic and statistical manual lll1 as follows generalized persistent anxiety of at least 1 month continual duration manifested by symptoms from three of the four following categories motor tension shakiness jitteriness jumpiness trembling tension muscle aches fatigability inability to relax eyelid twitch furrowed brow strained face fidgeting restlessness easy startle autonomic hyperactivity sweating heart pounding or racing cold clammy hands dry mouth dizziness lightheadedness paresthesias tingling in hands or feet upset stomach hot or cold spells frequent urination diarrhea discomfort in the pit of the stomach lump in the throat flushing pallor high resting pulse and respiration rate apprehensive expectation anxiety worry fear rumination and anticipation of misfortune to self or others vigilance and scanning hyperattentiveness resulting in distractibility difficulty in concentrating insomnia feeling on edge irritability impatiencethe above symptoms would not be due to another mental disorder such as a depressive disorder or schizophrenia however mild depressive symptoms are common in gadthe effectiveness of buspirone in longterm use that is for more than 3 to 4 weeks has not been demonstrated in controlled trials there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad however in a study of longterm use 264 patients were treated with buspirone for 1 year without ill effect therefore the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient,3
escitalopram is a selective serotonin reuptake inhibitor ssri indicated for acute and maintenance treatment of major depressive disorder mdd in adults and adolescents aged 12 to 17 years 11acute treatment of generalized anxiety disorder gad in adults 12escitalopram is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age see clinical studies 141a major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least five of the following nine symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideationescitalopram is indicated for the acute treatment of generalized anxiety disorder gad in adults see clinical studies 142generalized anxiety disorder dsmiv is characterized by excessive anxiety and worry apprehensive expectation that is persistent for at least six months and which the person finds difficult to control it must be associated with at least three of the following symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension and sleep disturbance,3
northera is indicated for the treatment of orthostatic dizziness lightheadedness or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension noh caused by primary autonomic failure parkinsons disease pd multiple system atrophy and pure autonomic failure dopamine betahydroxylase deficiency and nondiabetic autonomic neuropathy effectiveness beyond 2 weeks of treatment has not been established the continued effectiveness of northera should be assessed periodicallynorthera is indicated for the treatment of orthostatic dizziness lightheadedness or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension noh caused by primary autonomic failure parkinsons disease pd multiple system atrophy and pure autonomic failure dopamine betahydroxylase deficiency and nondiabetic autonomic neuropathy effectiveness beyond 2 weeks of treatment has not been established the continued effectiveness of northera should be assessed periodically 1,3
azilect rasagiline tablets is indicated for the treatment of the signs and symptoms of idiopathic parkinsons disease as initial monotherapy and as adjunct therapy to levodopathe effectiveness of azilect was demonstrated in patients with early parkinsons disease who were receiving azilect as monotherapy and who were not receiving any concomitant dopaminergic therapy the effectiveness of azilect as adjunct therapy was demonstrated in patients with parkinsons disease who were treated with levodopa azilect is indicated for the treatment of the signs and symptoms of idiopathic parkinsons disease as initial monotherapy and as adjunct therapy to levodopa 1,3
carbidopa tablets are indicated for use with carbidopalevodopa or with levodopa in the treatment of the symptoms of idiopathic parkinsons disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication andor manganese intoxicationcarbidopa tablets are for use with carbidopalevodopa in patients for whom the dosage of carbidopalevodopa provides less than adequate daily dosage usually 70 mg daily of carbidopacarbidopa tablets are for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medicationcarbidopa tablets are used with carbidopalevodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting more rapid dosage titration and with a somewhat smoother response however patients with markedly irregular onoff responses to levodopa have not been shown to benefit from the addition of carbidopasince carbidopa prevents the reversal of levodopa effects caused by pyridoxine supplemental pyridoxine vitamin b6 can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopalevodopaalthough the administration of carbidopa tablets permits control of parkinsonism and parkinsons disease with much lower doses of levodopa there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting permitting more rapid titration and providing a somewhat smoother response to levodopacertain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently this was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system carbidopa has not been shown to enhance the intrinsic efficacy of levodopain deciding whether to give carbidopa tablets with carbidopalevodopa or with levodopa to patients who have nausea andor vomiting the physician should be aware that while many patients may be expected to improve some may not since one cannot predict which patients are likely to improve this can only be determined by a trial of therapy it should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone about half the patients with nausea andor vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial,2
carbidopa tablets are indicated for use with carbidopalevodopa or with levodopa in the treatment of the symptoms of idiopathic parkinsons disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication andor manganese intoxicationcarbidopa tablets are for use with carbidopalevodopa in patients for whom the dosage of carbidopalevodopa provides less than adequate daily dosage usually 70 mg daily of carbidopacarbidopa tablets are for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medicationcarbidopa tablets are used with carbidopalevodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting more rapid dosage titration and with a somewhat smoother response however patients with markedly irregular onoff responses to levodopa have not been shown to benefit from the addition of carbidopasince carbidopa prevents the reversal of levodopa effects caused by pyridoxine supplemental pyridoxine vitamin b6 can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopalevodopaalthough the administration of carbidopa tablets permits control of parkinsonism and parkinsons disease with much lower doses of levodopa there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting permitting more rapid titration and providing a somewhat smoother response to levodopacertain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently this was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system carbidopa has not been shown to enhance the intrinsic efficacy of levodopain deciding whether to give carbidopa tablets with carbidopalevodopa or with levodopa to patients who have nausea andor vomiting the physician should be aware that while many patients may be expected to improve some may not since one cannot predict which patients are likely to improve this can only be determined by a trial of therapy it should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone about half the patients with nausea andor vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial,2
tolcapone tablets usp is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic parkinsons disease because of the risk of potentially fatal acute fulminant liver failure tolcapone tablets usp should ordinarily be used in patients with parkinsons disease on ldopacarbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies because of the risk of liver injury and because tolcapone tablets usp when it is effective provides an observable symptomatic benefit the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment should be withdrawn from tolcapone tablets uspthe effectiveness of tolcapone tablets usp was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearingoff phenomena as well as in patients who did not experience such phenomena see clinical pharmacologyclinical studies,2
apokyn apomorphine hydrochloride injection is indicated for the acute intermittent treatment of hypomobility off episodes endofdose wearing off and unpredictable onoff episodes in patients with advanced parkinsons disease apokyn has been studied as an adjunct to other medications see clinical studies 14apokyn is a nonergoline dopamine agonist indicated for the acute intermittent treatment of hypomobility off episodes endofdose wearing off and unpredictable onoff episodes associated with advanced parkinsons disease 1,3
inbrija is indicated for the intermittent treatment of off episodes in patients with parkinsons disease treated with carbidopalevodopainbrija is an aromatic amino acid indicated for the intermittent treatment of off episodes in patients with parkinsons disease treated with carbidopalevodopa 1,3
vasceparvascepa is an ethyl ester of eicosapentaenoic acid epa indicated as an adjunct to diet to reduce triglyceride tg levels in adult patients with severe 500 mgdl hypertriglyceridemia 1limitations of use the effect of vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined 1the effect of vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined 1 usage considerations attempts should be made to control any medical problems such as diabetes mellitus hypothyroidism and alcohol intake that may contribute to lipid abnormalities medications known to exacerbate hypertriglyceridemia such as beta blockers thiazides estrogens should be discontinued or changed if possible prior to consideration of tglowering drug therapylimitations of usethe effect of vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determinedthe effect of vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined,1
cephalexin is a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria respiratory tract infection 11otitis media 12skin and skin structure infections 13bone infections 1 4genitourinary tract infections 15to reduce the development of drugresistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria 16cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae streptococcuspyogenescephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcuspneumoniae haemophilus infl uenz ae staphylococcus aureus streptococcuspyogenes mo raxella catarrhaliscephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following grampositive bacteria staphylococcus aureusstreptococcus pyogenescephalexin is indicated for the treat ment of bone infections caused by susceptible isolates of staphylococcusaureus proteus mi rabiliscephalexin is indicated for the treatment of genitourinary tract infections including acute prostatitis caused by susceptible isolates of escheric hia c oli proteus mirabilis klebsiella pneumonia eto reduce the development of drugresistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information is available this information should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
kalbitorr kalbitor is a plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema hae in patients 12 years of age and older 1,3
endometriosisdanazol capsules are indicated for the treatment of endometriosis amenable to hormonal management fibrocystic breast diseasemost cases of symptomatic fibrocystic breast disease may be treated by simple measures eg padded brassieres and analgesicsin infrequent patients symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function danazol capsules are usually effective in decreasing nodularity pain and tenderness it should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy hereditary angioedemadanazol capsules are indicated for the prevention of attacks of angioedema of all types cutaneous abdominal laryngeal in males and females,3
endometriosisdanazol capsules are indicated for the treatment of endometriosis amenable to hormonal management fibrocystic breast diseasemost cases of symptomatic fibrocystic breast disease may be treated by simple measures eg padded brassieres and analgesicsin infrequent patients symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function danazol capsules are usually effective in decreasing nodularity pain and tenderness it should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy hereditary angioedemadanazol capsules are indicated for the prevention of attacks of angioedema of all types cutaneous abdominal laryngeal in males and females,3
endometriosisdanazol capsules are indicated for the treatment of endometriosis amenable to hormonal management fibrocystic breast diseasemost cases of symptomatic fibrocystic breast disease may be treated by simple measures eg padded brassieres and analgesicsin infrequent patients symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function danazol capsules are usually effective in decreasing nodularity pain and tenderness it should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy hereditary angioedemadanazol capsules are indicated for the prevention of attacks of angioedema of all types cutaneous abdominal laryngeal in males and females,3
firazyrrfirazyr is a bradykinin b2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema hae in adults 18 years of age and older 1,3
firazyrrfirazyr is a bradykinin b2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema hae in adults 18 years of age and older 1,3
pulmozymerin cf patients with an fvc 40 of predicted daily administration of pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibioticspulmozyme is a recombinant dnase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis cf patients to improve pulmonary function 1,3
albendazole is indicated for the treatment of the following infections neurocysticercosistaenia soliumlesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrastenhanced computerized tomography clinical studies in patients with lesions of this type demonstrate a 74 to 88 reduction in number of cysts 40 to 70 of albendazoletreated patients showed resolution of all active cysts hydatid diseaseechinococcus granulosusthis indication is based on combined clinical studies which demonstrated noninfectious cyst contents in approximately 80 to 90 of patients given albendazole for 3 cycles of therapy of 28 days each see dosage and administrationnote when medically feasible surgery is considered the treatment of choice for hydatid disease when administering albendazole in the pre or postsurgical setting optimal killing of cyst contents is achieved when 3 courses of therapy have been givennote the efficacy of albendazole in the therapy of alveolar hydatid disease caused by echinococcus multilocularis,3
flucytosine is indicated only in the treatment of serious infections caused by susceptible strains of candida cryptococcus candidasepticemia endocarditis and urinary system infections have been effectively treated with flucytosine limited trials in pulmonary infections justify the use of flucytosine cryptococcusmeningitis and pulmonary infections have been treated effectively studies in septicemias and urinary tract infections are limited but good responses have been reportedflucytosine should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine see microbiology,3
flucytosine is indicated only in the treatment of serious infections caused by susceptible strains of candida cryptococcus candidasepticemia endocarditis and urinary system infections have been effectively treated with flucytosine limited trials in pulmonary infections justify the use of flucytosine cryptococcusmeningitis and pulmonary infections have been treated effectively studies in septicemias and urinary tract infections are limited but good responses have been reportedflucytosine should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine see microbiology,3
noxafil is an azole antifungal agent indicated forinjection delayedrelease tablets and oral suspension prophylaxis of invasive aspergilluscandida11oral suspension treatment of oropharyngeal candidiasis opc including opc refractory ropc to itraconazole andor fluconazole 12noxafilraspergilluscandidanoxafil injection is indicated in patients 18 years of age and oldernoxafil delayedrelease tablets and oral suspension are indicated in patients 13 years of age and oldernoxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to itraconazole andor fluconazole,3
durlaza is contraindicated in patients with a hypersensitivity to nonsteroidal antiinflammatory drugs nsaidsin patients with the syndrome of asthma rhinitis and nasal polyps durlaza may cause severe urticaria angioedema or bronchospasm hypersensitivity to nonsteroidal antiinflammatory drug products 4asthma rhinitis and nasal polyps 4,3
durlaza is contraindicated in patients with a hypersensitivity to nonsteroidal antiinflammatory drugs nsaidsin patients with the syndrome of asthma rhinitis and nasal polyps durlaza may cause severe urticaria angioedema or bronchospasm hypersensitivity to nonsteroidal antiinflammatory drug products 4asthma rhinitis and nasal polyps 4,1
durlaza is contraindicated in patients with a hypersensitivity to nonsteroidal antiinflammatory drugs nsaidsin patients with the syndrome of asthma rhinitis and nasal polyps durlaza may cause severe urticaria angioedema or bronchospasm hypersensitivity to nonsteroidal antiinflammatory drug products 4asthma rhinitis and nasal polyps 4,2
granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity eg anaphylaxis shortness of breath hypotension urticaria to the drug or to any of its components hypersensitivity to granisetron hydrochloride injection or to any of its components 4,2
fulvestrant injection is contraindicated in patients with a known hypersensitivity to the drug or to any of its components hypersensitivity reactions including urticaria and angioedema have been reported in association with fulvestrant see adverse reactions 62 hypersensitivity 4,1
fulvestrant injection is contraindicated in patients with a known hypersensitivity to the drug or to any of its components hypersensitivity reactions including urticaria and angioedema have been reported in association with fulvestrant see adverse reactions 62 hypersensitivity 4,3
hypersensitivity to brivaracetam or any of the inactive ingredients in briviact bronchospasm and angioedema have occurred see warnings and precautions 54hypersensitivity to brivaracetam or any of the inactive ingredients in briviact 4,1
history of a serious hypersensitivity reaction to sitagliptin such as anaphylaxis or angioedema see warnings and precautions 55 adverse reactions 62history of a serious hypersensitivity reaction to sitagliptin such as anaphylaxis or angioedema 5562,2
do not use forteo in patients with hypersensitivity to teriparatide or to any of its excipients reactions have included angioedema and anaphylaxis see adverse reactions 62 patients with hypersensitivity to teriparatide or to any of its excipients 4,3
tecfidera is contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of tecfidera reactions have included anaphylaxis and angioedema see warnings and precautions 51known hypersensitivity to dimethyl fumarate or any of the excipients of tecfidera 4,2
ascorbic acid is recommended for the prevention and treatment of scurvy its parenteral administration is desirable for patients with an acute deficiency or for those whose absorption of orally ingested ascorbic acid is uncertainsymptoms of mild deficiency may include faulty bone and tooth development gingivitis bleeding gums and loosened teeth febrile states chronic illness and infection pneumonia whooping cough tuberculosis diphtheria sinusitis rheumatic fever etc increases the need for ascorbic acid hemovascular disorders burns delayed fracture and wound healing are indications for an increase in the daily intake,0
ascorbic acid is recommended for the prevention and treatment of scurvy its parenteral administration is desirable for patients with an acute deficiency or for those whose absorption of orally ingested ascorbic acid is uncertainsymptoms of mild deficiency may include faulty bone and tooth development gingivitis bleeding gums and loosened teeth febrile states chronic illness and infection pneumonia whooping cough tuberculosis diphtheria sinusitis rheumatic fever etc increases the need for ascorbic acid hemovascular disorders burns delayed fracture and wound healing are indications for an increase in the daily intake,3
bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty ptca 11undergoing percutaneous coronary intervention pci with provisional use of glycoprotein iibiiia inhibitor gpi as in the replace2 study 12with or at risk of heparininduced thrombocytopenia hit or heparininduced thrombocytopenia and thrombosis syndrome hitts undergoing pci 12bivalirudin for injection is intended for use with aspirin 13 limitation of usesafety and effectiveness not established in patients with acute coronary syndromes who are not undergoing ptca or pci 14bivalirudin for injection is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty ptca bivalirudin for injection with provisional use of glycoprotein iibiiia inhibitor gpi as listed in the replace2 trial see clinical studies 141 bivalirudin for injection is indicated for patients with or at risk of heparin induced thrombocytopenia hit or heparin induced thrombocytopenia and thrombosis syndrome hitts undergoing pcibivalirudin for injection in these indications is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin see dosage and administration 21clinical studies 141the safety and effectiveness of bivalirudin for injection have not been established in patients with acute coronary syndromes who are not undergoing ptca or pci,0
bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty ptca 11undergoing percutaneous coronary intervention pci with provisional use of glycoprotein iibiiia inhibitor gpi as in the replace2 study 12with or at risk of heparininduced thrombocytopenia hit or heparininduced thrombocytopenia and thrombosis syndrome hitts undergoing pci 12bivalirudin for injection is intended for use with aspirin 13 limitation of usesafety and effectiveness not established in patients with acute coronary syndromes who are not undergoing ptca or pci 14bivalirudin for injection is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty ptca bivalirudin for injection with provisional use of glycoprotein iibiiia inhibitor gpi as listed in the replace2 trial see clinical studies 141 bivalirudin for injection is indicated for patients with or at risk of heparin induced thrombocytopenia hit or heparin induced thrombocytopenia and thrombosis syndrome hitts undergoing pcibivalirudin for injection in these indications is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin see dosage and administration 21clinical studies 141the safety and effectiveness of bivalirudin for injection have not been established in patients with acute coronary syndromes who are not undergoing ptca or pci,3
premarin therapy is contraindicated in individuals with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of breast cancer except in appropriately selected patients being treated for metastatic disease known or suspected estrogendependent neoplasia active dvt pe or a history of these conditions active arterial thromboembolic disease for example stroke and mi or a history of these conditions known anaphylactic reaction or angioedema with premarin known liver impairment or disease known protein c protein s or antithrombin deficiency or other known thrombophilic disorders known or suspected pregnancy undiagnosed abnormal genital bleeding 4known suspected or history of breast cancer except in appropriately selected patients being treated for metastatic diseases 452known or suspected estrogendependent neoplasia 452active dvt pe or a history of these conditions 451active arterial thromboembolic disease for example stroke and mi or a history of these conditions 451known anaphylactic reaction or angioedema with premarin 57known liver impairment or disease 4512known protein c protein s or antithrombin deficiency or other known thrombophilic disorders 4known or suspected pregnancy 481,1
do not use hydroxyprogesterone caproate injection in women with any of the following conditions current or history of thrombosis or thromboembolic disordersknown or suspected breast cancer other hormonesensitive cancer or history of these conditionsundiagnosed abnormal vaginal bleeding unrelated to pregnancycholestatic jaundice of pregnancyliver tumors benign or malignant or active liver diseaseuncontrolled hypertension current or history of thrombosis or thromboembolic disorders 4known or suspected breast cancer other hormonesensitive cancer or history of these conditions 4undiagnosed abnormal vaginal bleeding unrelated to pregnancy 4cholestatic jaundice of pregnancy 4liver tumors benign or malignant or active liver disease 4uncontrolled hypertension 4,1
do not use hydroxyprogesterone caproate injection in women with any of the following conditions current or history of thrombosis or thromboembolic disordersknown or suspected breast cancer other hormonesensitive cancer or history of these conditionsundiagnosed abnormal vaginal bleeding unrelated to pregnancycholestatic jaundice of pregnancyliver tumors benign or malignant or active liver diseaseuncontrolled hypertension current or history of thrombosis or thromboembolic disorders 4known or suspected breast cancer other hormonesensitive cancer or history of these conditions 4undiagnosed abnormal vaginal bleeding unrelated to pregnancy 4cholestatic jaundice of pregnancy 4liver tumors benign or malignant or active liver disease 4uncontrolled hypertension 4,3
implanon should not be used in women who have known or suspected pregnancy current or past history of thrombosis or thromboembolic disorders liver tumors benign or malignant or active liver disease undiagnosed abnormal genital bleeding known or suspected breast cancer personal history of breast cancer or other progestinsensitive cancer now or in the past allergic reaction to any of the components of implanon see adverse reactions 6 known or suspected pregnancy 4 current or past history of thrombosis or thromboembolic disorders 4 54 liver tumors benign or malignant or active liver disease 4 57 undiagnosed abnormal genital bleeding 4 52 known or suspected breast cancer personal history of breast cancer or other progestinsensitive cancer now or in the past 4 56 allergic reaction to any of the components of implanon 4 6,0
implanon should not be used in women who have known or suspected pregnancy current or past history of thrombosis or thromboembolic disorders liver tumors benign or malignant or active liver disease undiagnosed abnormal genital bleeding known or suspected breast cancer personal history of breast cancer or other progestinsensitive cancer now or in the past allergic reaction to any of the components of implanon see adverse reactions 6 known or suspected pregnancy 4 current or past history of thrombosis or thromboembolic disorders 4 54 liver tumors benign or malignant or active liver disease 4 57 undiagnosed abnormal genital bleeding 4 52 known or suspected breast cancer personal history of breast cancer or other progestinsensitive cancer now or in the past 4 56 allergic reaction to any of the components of implanon 4 6,0
soltamox is contraindicated in patients with known hypersensitivity eg angioedema serious skin reactions to tamoxifen or any other soltamox ingredient see adverse reactions 62soltamox is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis see warnings and precautions 52drug interactions 72 known hypersensitivity to tamoxifen or any other soltamox ingredient 4in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis 4,2
soltamox is contraindicated in patients with known hypersensitivity eg angioedema serious skin reactions to tamoxifen or any other soltamox ingredient see adverse reactions 62soltamox is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis see warnings and precautions 52drug interactions 72 known hypersensitivity to tamoxifen or any other soltamox ingredient 4in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis 4,1
testosterone gel is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate see warnings and precautions 51 adverse reactions 61 and nonclinical toxicology 131testosterone gel is contraindicated in women who are or may become pregnant or who are breastfeeding testosterone gel may cause fetal harm when administered to a pregnant woman testosterone gel may cause serious adverse reactions in nursing infants exposure of a female fetus or nursing infant to androgens may result in varying degrees of virilization pregnant women or those who may become pregnant need to be aware of the potential for transfer of testosterone from men treated with testosterone gel if a pregnant woman is exposed to testosterone gel she should be apprised of the potential hazard to the fetus see warnings and precautions 52 and use in specific populations 81 83 men with carcinoma of the breast or known or suspected prostate cancer 4 51 pregnant or breast feeding women testosterone may cause fetalneonatal harm 4 81 83,1
known or suspected pregnancy there is no indication for norethindrone acetate in pregnancy see precautions undiagnosed vaginal bleeding known suspected or history of cancer of the breast active deep vein thrombosis pulmonary embolism or history of these conditions active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction impaired liver function or liver disease as a diagnostic test for pregnancy hypersensitivity to any of the drug components,0
cenestin should not be used in women with any of the following conditions undiagnosed abnormal genital bleedingknown suspected or history of cancer of the breastknown or suspected estrogendependent neoplasiaactive deep vein thrombosis pulmonary embolism or a history of these conditionsactive or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarctionliver dysfunction or diseasecenestin therapy should not be used in patients with known hypersensitivity to its ingredientsknown or suspected pregnancy there is no indication for cenestin in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,1
menest should not be used in women with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease known or suspected estrogendependent neoplasia active deep vein thrombosis pulmonary embolism or a history of these conditions active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction liver dsyfunction or disease menest should not be used in patients with known hypersensitivity to its ingredients known or suspected pregnancy there is no indication for menest in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,0
diazepam tablets usp are contraindicated in patients with a known hypersensitivity to this drug and because of lack of sufficient clinical experience in pediatric patients under 6 months of age diazepam is also contraindicated in patients with myasthenia gravis severe respiratory insufficiency severe hepatic insufficiency and sleep apnea syndrome it may be used in patients with openangle glaucoma who are receiving appropriate therapy but is contraindicated in acute narrowangle glaucoma,1
this product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucomathis product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine this product should not be used in those persons showing hypersensitivity to any component of this preparation,0
trihexyphenidyl hcl is contraindicated in patients with hypersensitivity to trihexyphenidyl hcl or to any of the tablet ingredients trihexyphenidyl hcl is also contraindicated in patients with narrow angle glaucoma blindness after longterm use due to narrow angle glaucoma has been reported,1
epinephrine is contraindicated in patients with known hypersensitivity to sympathomimetic amines in patients with angle closure glaucoma and patients in shock nonanaphylactic it should not be used in patients anesthetized with agents such as cyclopropane or halothane as these may sensitize the heart to the arrhythmic action of sympathomimetic drugs addition of epinephrine to local anesthetics for injection of certain areas eg fingers toes ears etc is contraindicated because of danger that vasoconstriction may result in sloughing of tissueexcept as diluted for admixture with local anesthetics to reduce absorption and prolong action epinephrine should not ordinarily be used in those cases where vasopressor drugs may be contraindicated eg in thyrotoxicosis diabetes in obstetrics when maternal blood pressure is in excess of 13080 and in hypertension and other cardiovascular disorders,1
lorazepam injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle polyethylene glycol propylene glycol and benzyl alcohol in patients with acute narrowangle glaucoma or in patients with sleep apnea syndrome it is also contraindicated in patients with severe respiratory insufficiency except in those patients requiring relief of anxiety andor diminished recall of events while being mechanically ventilated the use of lorazepam injection intraarterially is contraindicated because as with other injectable benzodiazepines inadvertent intraarterial injection may produce arteriospasm resulting in gangrene which may require amputation see warningslorazepam injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol see warnings precautions pediatric use,2
lorazepam injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle polyethylene glycol propylene glycol and benzyl alcohol in patients with acute narrowangle glaucoma or in patients with sleep apnea syndrome it is also contraindicated in patients with severe respiratory insufficiency except in those patients requiring relief of anxiety andor diminished recall of events while being mechanically ventilated the use of lorazepam injection intraarterially is contraindicated because as with other injectable benzodiazepines inadvertent intraarterial injection may produce arteriospasm resulting in gangrene which may require amputation see warningslorazepam injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol see warnings precautions pediatric use,0
history of cardiovascular disease eg coronary artery disease stroke arrhythmias congestive heart failure uncontrolled hypertension during or within 14 days following the administration of monoamine oxidase inhibitors hyperthyroidism glaucoma agitated states history of drug abuse pregnancy see use in specific populations 81nursing see use in specific populations 83known hypersensitivity or idiosyncrasy to the sympathomimetic amines history of cardiovascular disease eg coronary artery disease stroke arrhythmias congestive heart failure uncontrolled hypertension 4during or within 14 days following the administration of monoamine oxidase inhibitors 4hyperthyroidism 4glaucoma 4agitated states 4history of drug abuse 4pregnancy 481nursing 483known hypersensitivity or idiosyncrasy to the sympathomimetic amines 4,2
trospium chloride tablets are contraindicated in patients with urinary retentiongastric retentionuncontrolled narrowangle glaucomaknown hypersensitivity to the drug or its ingredients angioedema rash and anaphylactic reaction have been reported trospium chloride tablets are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma and in patients who are at risk for these conditions 4patients with known hypersensitivity 4,1
topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparationuse of topical corticosteroids including diflorasone diacetate emollient cream may increase the risk of posterior subcapsular cataracts and glaucoma cataracts have been reported in postmarketing experience with the use of topical diflorasone diacetate products glaucoma with possible damage to the optic nerve and increased intraocular pressure have been reported in postmarketing experience with the use of topical dermal corticosteroids avoid contact of diflorasone diacetate emollient cream with eyes advise patients to report any visual symptoms,2
known hypersensitivity to the product 41marked anxiety tension or agitation 42glaucoma 43tics or a family history or diagnosis of tourettes syndrome 44do not use methylphenidate hydrochloride extendedrelease tablets in patients currently using or within 2 weeks of using an mao inhibitor 45hypersensitivity reactions such as angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate hydrochloride extendedrelease tablets therefore methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product see adverse reactions 66methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients with glaucoma methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 64methylphenidate hydrochloride extendedrelease tablets are contraindicated during treatment with monoamine oxidase mao inhibitors and also within a minimum of 14 days following discontinuation of a mao inhibitor hypertensive crises may result see drug interactions 71,3
tolterodine tartrate extendedrelease capsules are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma tolterodine tartrate extendedrelease capsulesare also contraindicated in patients with known hypersensitivity to the drug or its ingredients or to fesoterodine fumarate extendedrelease tablets which like tolterodine tartrate extendedrelease capsules are metabolized to 5hydroxymethyl tolterodine see warnings and precautions 525354tolterodine tartrate extendedrelease capsules are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma tolterodine tartrate extendedrelease capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients or to fesoterodine fumarate extendedrelease tablets which like tolterodine tartrate extendedrelease capsules are metabolized to 5hydroxymethyl tolterodine 4,2
oxybutynin chloride usp is contraindicated in patients with urinary retention gastric retention and other severe decreased gastrointestinal motility conditions uncontrolled narrowangle glaucomaoxybutynin chloride extendedrelease tablets usp are also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product there have been reports of hypersensitivity reactions including anaphylaxis and angiodema urinary retention 4gastric retention 4uncontrolled narrow angle glaucoma 4known hypersensitivity to oxybutynin chloride usp oxybutynin or any component of oxybutynin chloride extendedrelease tablets usp 4,1
hypersensitivity to doxepin hydrochloride inactive ingredients or other dibenzoxepines 41 coadministration with monoamine oxidase inhibitors maois do not administer if patient is taking maois or has used maois within the past two weeks 42 untreated narrow angle glaucoma or severe urinary retention 43silenor is contraindicated in individuals who have shown hypersensitivity to doxepin hcl any of its inactive ingredients or other dibenzoxepinesserious side effects and even death have been reported following the concomitant use of certain drugs with mao inhibitors do not administer silenor if patient is currently on maois or has used maois within the past two weeks the exact length of time may vary depending on the particular maoi dosage and duration of treatmentsilenor is contraindicated in individuals with untreated narrow angle glaucoma or severe urinary retention,0
orphenadrine citrate extendedrelease tablets are contraindicated in patients with glaucoma pyloric or duodenal obstruction stenosing peptic ulcers prostatic hypertrophy or obstruction of the bladder neck cardiospasm megaesophagus and myasthenia gravis orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug,3
orphenadrine citrate extendedrelease tablets are contraindicated in patients with glaucoma pyloric or duodenal obstruction stenosing peptic ulcers prostatic hypertrophy or obstruction of the bladder neck cardiospasm megaesophagus and myasthenia gravis orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug,0
ocular or periocular infections 41glaucoma 42torn or ruptured posterior lens capsule 43hypersensitivity 44 ozurdex r ozurdex r ozurdexrozurdexr ozurdex rsee adverse reactions 6,2
advanced arteriosclerosis symptomatic cardiovascular disease moderate to severe hypertension hyperthyroidism known hypersensitivity or idiosyncrasy to the sympathomimetic amines glaucomaagitated statespatients with a history of drug abuseknown hypersensitivity or idiosyncrasy to amphetaminein patients known to be hypersensitive to amphetamine or other components of dextroamphetamine sulfate extendedrelease capsules hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products see adverse reactionspatients taking monoamine oxidase inhibitors maois or within 14 days of stopping maois including maois such as linezolid or intravenous methylene blue because of an increased risk of hypertensive crisis see warnings and drug interactions,0
known hypersensitivity or idiosyncratic reactions to sympathomimeticsadvanced arteriosclerosis symptomatic cardiovascular disease moderate and severe hypertension hyperthyroidism and glaucomahighly nervous or agitated patientspatients with a history of drug abusepatients taking other cns stimulants including monoamine oxidase inhibitorstolerance to the anorectic effect of phendimetrazine develops within a few weeks when this occurs its use should be discontinued the maximum recommended dose should not be exceededuse of phendimetrazine tartrate within 14 days following the administration of monoamine oxidase inhibitors may result in a hypertensive crisisabrupt cessation of administration following prolonged high dosage results in extreme fatigue and depression because of the effect on the central nervous system phendimetrazine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle the patient should therefore be cautioned accordingly,2
vesicare is contraindicated in patients with urinary retention see warnings and precautions52gastric retention see warnings and precautions53uncontrolled narrowangle glaucoma see warnings and precautions54in patients who have demonstrated hypersensitivity to the drug see adverse reactions62 urinary retention 452gastric retention 453uncontrolled narrowangle glaucoma 454in patients who have demonstrated hypersensitivity to the drug 462,1
use of monoamine oxidase inhibitors concomitantly or in close temporal proximity 41use in patients with uncontrolled narrowangle glaucoma 42concomitant use of savella in patients taking monoamine oxidase inhibitors maois is contraindicated in patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor maoi there have been reports of serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability with possible rapid fluctuations of vital signs and mental status changes that include extreme agitation progressing to delirium and coma these reactions have also been reported in patients who have recently discontinued serotonin reuptake inhibitors and have been started on an maoi some cases presented with features resembling neuroleptic malignant syndrome the effects of combined use of savella and maois have not been evaluated in humans therefore it is recommended that savella should not be used in combination with an maoi or within 14 days of discontinuing treatment with an maoi similarly at least 5 days should be allowed after stopping savella before starting an maoi see dosage and administration 2552in clinical trials savella was associated with an increased risk of mydriasis mydriasis has been reported with other dual reuptake inhibitors of norepinephrine and serotonin therefore do not use savella in patients with uncontrolled narrowangle glaucoma,3
agitation marked anxiety and tension 41 known hypersensitivity to methylphenidate or product components 42 glaucoma 43 history of motor tics or a family history or diagnosis of tourettes syndrome 44 during or within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor maoi 45dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product hypersensitivity reactions including angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate see adverse reactions 6566dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with glaucomadexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 61dexmethylphenidate hcl extendedrelease capsules are contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor hypertensive crises may result,1
agitation marked anxiety and tension 41 known hypersensitivity to methylphenidate or product components 42 glaucoma 43 history of motor tics or a family history or diagnosis of tourettes syndrome 44 during or within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor maoi 45dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product hypersensitivity reactions including angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate see adverse reactions 6566dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with glaucomadexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 61dexmethylphenidate hcl extendedrelease capsules are contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor hypertensive crises may result,1
fesoterodine fumarate extendedrelease tablets are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma fesoterodine fumarate is also contraindicated in patients with known hypersensitivity to the drug or its ingredients or to tolterodine tartrate tablets or tolterodine tartrate extendedrelease capsules 4fesoterodine fumarate extendedrelease tablets are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma fesoterodine fumarate extendedrelease tablets are also contraindicated in patients with known hypersensitivity to the drug or its ingredients or to tolterodine tartrate tablets or tolterodine tartrate extendedrelease capsules seeclinicalpharmacology121,1
mekinist is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1121mekinist is indicated in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1121the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 1221the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 1321the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 1421 limitations of use15 mekinistrsee dosage and administration 21 22 mekinist is indicated in combination with dabrafenib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 mekinist is indicated in combination with dabrafenib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 mekinist is indicated in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 mekinist is not indicated for treatment of patients with melanoma who have progressed on prior brafinhibitor therapy see clinical studies 145,3
mekinist is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1121mekinist is indicated in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1121the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 1221the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 1321the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 1421 limitations of use15 mekinistrsee dosage and administration 21 22 mekinist is indicated in combination with dabrafenib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 mekinist is indicated in combination with dabrafenib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 mekinist is indicated in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 mekinist is not indicated for treatment of patients with melanoma who have progressed on prior brafinhibitor therapy see clinical studies 145,3
tafinlar is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test 1121tafinlar is indicated in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1221the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 1321the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 1421the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 1521 limitations of use 1652 tafinlarrsee dosage and administration 21 22 tafinlar is indicated in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test see dosage and administration 21 22 tafinlar is indicated in combination with trametinib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 tafinlar is indicated in combination with trametinib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 tafinlar is indicated in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 tafinlar is not indicated for treatment of patients with wildtype braf melanoma wildtype braf nsclc or wildtype braf atc see warnings and precautions 52,3
tafinlar is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test 1121tafinlar is indicated in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1221the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 1321the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 1421the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 1521 limitations of use 1652 tafinlarrsee dosage and administration 21 22 tafinlar is indicated in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test see dosage and administration 21 22 tafinlar is indicated in combination with trametinib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 tafinlar is indicated in combination with trametinib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 tafinlar is indicated in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 tafinlar is not indicated for treatment of patients with wildtype braf melanoma wildtype braf nsclc or wildtype braf atc see warnings and precautions 52,3
tafinlar is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fdaapproved test 1121tafinlar is indicated in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 1221the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 1321the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 1421the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 1521 limitations of use 1652 tafinlarrsee dosage and administration 21 22 tafinlar is indicated in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test see dosage and administration 21 22 tafinlar is indicated in combination with trametinib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 tafinlar is indicated in combination with trametinib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 tafinlar is indicated in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 tafinlar is not indicated for treatment of patients with wildtype braf melanoma wildtype braf nsclc or wildtype braf atc see warnings and precautions 52,3
lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer dtc 11in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior antiangiogenic therapy 12for the firstline treatment of patients with unresectable hepatocellular carcinoma hcc 13lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior antiangiogenic therapy lenvima is indicated for the firstline treatment of patients with unresectable hepatocellular carcinoma hcc,3
lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer dtc 11in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior antiangiogenic therapy 12for the firstline treatment of patients with unresectable hepatocellular carcinoma hcc 13lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior antiangiogenic therapy lenvima is indicated for the firstline treatment of patients with unresectable hepatocellular carcinoma hcc,3
lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer dtc 11in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior antiangiogenic therapy 12for the firstline treatment of patients with unresectable hepatocellular carcinoma hcc 13lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodinerefractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior antiangiogenic therapy lenvima is indicated for the firstline treatment of patients with unresectable hepatocellular carcinoma hcc,3
erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test receiving firstline maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 11firstline treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 12 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 11erlotinib tablets are not recommended for use in combination with platinumbased chemotherapy 11erlotinib tablets are indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test receiving firstline maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 141143limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 141142erlotinib tablets are not recommended for use in combination with platinumbased chemotherapy see clinical studies 144erlotinib tablets in combination with gemcitabine are indicated for the firstline treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 145,3
erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test receiving firstline maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 11firstline treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 12 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 11erlotinib tablets are not recommended for use in combination with platinumbased chemotherapy 11erlotinib tablets are indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test receiving firstline maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 141143limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 141142erlotinib tablets are not recommended for use in combination with platinumbased chemotherapy see clinical studies 144erlotinib tablets in combination with gemcitabine are indicated for the firstline treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 145,3
fosphenytoin sodium injection usp is indicated for the treatment of generalized tonicclonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery fosphenytoin sodium injection usp can also be substituted shortterm for oral phenytoin fosphenytoin sodium injection usp should be used only when oral phenytoin administration is not possible see dosage and administration 24 precautions 52fosphenytoin sodium injection usp is indicated for the treatment of generalized tonicclonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery fosphenytoin sodium injection usp can also be substituted as shortterm use for oral phenytoin fosphenytoin sodium injection usp should be used only when oral phenytoin administration is not possible 1,3
zonisamide capsules usp are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsyzonisamide capsules usp are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy,3
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection componentsdoxapram should not be used in patients with epilepsy or other convulsive disordersdoxapram is contraindicated in patients with proven or suspected pulmonary embolismdoxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansiondoxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,2
levetiracetam injection is indicated for adjunctive therapy as an alternative when oral administration is temporarily not feasible in the treatment of partial onset seizures in patients 1 month of age and older with epilepsy 11 myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy 12 primary generalized tonicclonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy 13levetiracetam injection usp is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy levetiracetam injection usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible levetiracetam injection usp is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy levetiracetam injection usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible levetiracetam injection usp is indicated as adjunctive therapy in the treatment of primary generalized tonicclonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy levetiracetam injection usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible,3
levetiracetam injection is indicated for adjunctive therapy as an alternative when oral administration is temporarily not feasible in the treatment of partial onset seizures in patients 1 month of age and older with epilepsy 11 myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy 12 primary generalized tonicclonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy 13levetiracetam injection usp is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy levetiracetam injection usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible levetiracetam injection usp is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy levetiracetam injection usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible levetiracetam injection usp is indicated as adjunctive therapy in the treatment of primary generalized tonicclonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy levetiracetam injection usp is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible,3
miglitol tablets are contraindicated in patients with diabetic ketoacidosis inflammatory bowel disease colonic ulceration or partial intestinal obstruction and in patients predisposed to intestinal obstruction chronic intestinal diseases associated with marked disorders of digestion or absorption or with conditions that may deteriorate as a result of increased gas formation in the intestine hypersensitivity to the drug or any of its components,2
glyburide tablets are contraindicated in patients with known hypersensitivity the drug or any of its excipientsdiabetic ketoacidosis with or without coma this condition should be treated with insulintype i diabetes mellitusconcomitant administration of bosentan warnings special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin this warning is based on the study conducted by the university group diabetes program ugdp a longterm prospective clinical trial designed to evaluate the effectiveness of glucoselowering drugs in preventing or delaying vascular complications in patients with noninsulindependent diabetes the study involved 823 patients who were randomly assigned to one of four treatment groups ugdp reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide 15 grams per day had a rate of cardiovascular mortality approximately 2 12 times that of patients treated with diet alone a significant increase in total mortality was not observed but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality thus limiting the opportunity for the study to show an increase in overall mortality despite controversy regarding the interpretation of these results the findings of the ugdp study provide an adequate basis for this warning the patient should be informed of the potential risks and advantages of glyburide tablets and of alternative modes of therapy although only one drug in the sulfonylurea class tolbutamide was included in this study it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class in view of their close similarities in mode of action and chemical structure,1
glyburide tablets are contraindicated in patients with known hypersensitivity the drug or any of its excipientsdiabetic ketoacidosis with or without coma this condition should be treated with insulintype i diabetes mellitusconcomitant administration of bosentan warnings special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin this warning is based on the study conducted by the university group diabetes program ugdp a longterm prospective clinical trial designed to evaluate the effectiveness of glucoselowering drugs in preventing or delaying vascular complications in patients with noninsulindependent diabetes the study involved 823 patients who were randomly assigned to one of four treatment groups ugdp reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide 15 grams per day had a rate of cardiovascular mortality approximately 2 12 times that of patients treated with diet alone a significant increase in total mortality was not observed but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality thus limiting the opportunity for the study to show an increase in overall mortality despite controversy regarding the interpretation of these results the findings of the ugdp study provide an adequate basis for this warning the patient should be informed of the potential risks and advantages of glyburide tablets and of alternative modes of therapy although only one drug in the sulfonylurea class tolbutamide was included in this study it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class in view of their close similarities in mode of action and chemical structure,0
proleukinrproleukin is indicated for the treatment of adults with metastatic melanomacareful patient selection is mandatory prior to the administration of proleukin see contraindications warnings precautionsevaluation of clinical studies to date reveals that patients with more favorable ecog performance status ecog ps 0 at treatment initiation respond better to proleukin with a higher response rate and lower toxicity see clinical pharmacology clinical studies adverse reactionsexperience in patients with ecog ps 1 is extremely limited,3
dacarbazine for injection usp is indicated in the treatment of metastatic malignant melanoma in addition dacarbazine for injection usp is also indicated for hodgkins disease as a secondline therapy when used in combination with other effective agents,3
sylatrontmsylatron is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy 1,3
uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable for the safe and effective use of allopurinol see allopurinol prescribing informationuloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable 1for the safe and effective use of allopurinol see allopurinol prescribing information limitations of useuloric is not recommended for the treatment of asymptomatic hyperuricemia 1 limitations of useuloric is not recommended for the treatment of asymptomatic hyperuricemia,3
zurampic is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone see clinical studies 14zurampic is a urat1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone 1limitations of use zurampic is not recommended for the treatment of asymptomatic hyperuricemia 11zurampic should not be used as monotherapy 1151zurampic is not recommended for the treatment of asymptomatic hyperuricemiazurampic should not be used as monotherapy see warnings and precautions 51,3
vpriv is indicated for longterm enzyme replacement therapy ert for patients with type 1 gaucher diseasevpriv is a hydrolytic lysosomal glucocerebrosidespecific enzyme indicated for longterm enzyme replacement therapy ert for patients with type 1 gaucher disease 1,3
cerdelga is indicated for the longterm treatment of adult patients with gaucher disease type 1 gd1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fdacleared test see dosage and administration 21cerdelga is a glucosylceramide synthase inhibitor indicated for the longterm treatment of adult patients with gaucher disease type 1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fdacleared test 1 limitations of use cyp2d6 ultrarapid metabolizers may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect 1a specific dosage cannot be recommended for cyp2d6 indeterminate metabolizers 1 limitations of use patients who are cyp2d6 ultrarapid metabolizers urms may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect see clinical studies 14a specific dosage cannot be recommended for those patients whose cyp2d6 genotype cannot be determined indeterminate metabolizers see clinical studies 14,3
hypersensitivity to any component of this medicationactive liver disease or unexplained persistent elevations of serum transaminases see warningsconcomitant administration with strong cyp3a4 inhibitors eg itraconazole ketoconazole posaconazole voriconazole hiv protease inhibitors boceprevir telaprevir erythromycin clarithromycin telithromycin nefazodone and cobicistatcontaining products see warnings myopathyrhabdomyolysispregnancy and lactation see precautions pregnancy and nursing mothers atherosclerosis is a chronic process and the discontinuation of lipidlowering drugs during pregnancy should have little impact on the outcome of longterm therapy of primary hypercholesterolemia moreover cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development including synthesis of steroids and cell membranes because of the ability of inhibitors of hmgcoa reductase such as lovastatin to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway lovastatin is contraindicated during pregnancy and in nursing mothers lovastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive if the patient becomes pregnant while taking this drug lovastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus see precautions pregnancy,3
hypersensitivity to any component of this medication 4active liver disease or unexplained persistent elevations in serum transaminases 452women who are pregnant or may become pregnant 481nursing mothers 483lescol and lescol xl are contraindicated in patients with hypersensitivity to any component of this medicationlescol and lescol xl are contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases see warnings and precautions 52lescol and lescol xl are contraindicated in women who are pregnant or may become pregnant serum cholesterol and triglycerides increase during normal pregnancy and cholesterol or cholesterol derivatives are essential for fetal development lescol and lescol xl may cause fetal harm when administered to pregnant women atherosclerosis is a chronic process and the discontinuation of lipidlowering drugs during pregnancy should have little impact on the outcome of longterm therapy of primary hypercholesterolemialescol and lescol xl should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards if the patient becomes pregnant while taking this drug lescol and lescol xl should be discontinued and the patient should be apprised of the potential hazard to the fetus see use in specific populations 81fluvastatin is secreted into the breast milk of animals and because hmgcoa reductase inhibitors have the potential to cause serious adverse reactions in nursing infants women who require treatment with lescol or lescol xl should be advised not to breastfeed their infants see use in specific populations 83,0
yondelisrsee clinical studies 14yondelis is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracyclinecontaining regimen 1,3
yondelisrsee clinical studies 14yondelis is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracyclinecontaining regimen 1,3
baclofen injection intrathecal is indicated for use in the management of severe spasticity patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump for spasticity of spinal cord origin chronic infusion of baclofen injection intrathecal via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy or those who experience intolerable cns side effects at effective doses patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy baclofen injection intrathecal is intended for use by the intrathecal route in single bolus test doses via spinal catheter or lumbar puncture and for chronic use only in implantable pumps approved by the fda specifically for the administration of baclofen injection intrathecal into the intrathecal space evidence supporting the efficacy of baclofen injection intrathecal was obtained in randomized controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of baclofen injection intrathecal to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis baclofen injection intrathecal was superior to placebo on both principal outcome measures employed change from baseline in the ashworth rating of spasticity and the frequency of spasmsthe efficacy of baclofen injection intrathecal was investigated in three controlled clinical trials two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury the first study a randomized controlled crossover trial of 51 patients with cerebral palsy provided strong statistically significant results baclofen injection intrathecal was superior to placebo in reducing spasticity as measured by the ashworth scale a second crossover study was conducted in 11 patients with spasticity arising from brain injury despite the small sample size the study yielded a nearly significant test statistic p 0066 and provided directionally favorable results the last study however did not provide data that could be reliably analyzed baclofen injection intrathecal therapy may be considered an alternative to destructive neurosurgical procedures prior to implantation of a device for chronic intrathecal infusion of baclofen injection intrathecal patients must show a response to baclofen injection intrathecal in a screening trial see dosage and administration,3
baclofen injection intrathecal is indicated for use in the management of severe spasticity patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump for spasticity of spinal cord origin chronic infusion of baclofen injection intrathecal via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy or those who experience intolerable cns side effects at effective doses patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy baclofen injection intrathecal is intended for use by the intrathecal route in single bolus test doses via spinal catheter or lumbar puncture and for chronic use only in implantable pumps approved by the fda specifically for the administration of baclofen injection intrathecal into the intrathecal space evidence supporting the efficacy of baclofen injection intrathecal was obtained in randomized controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of baclofen injection intrathecal to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis baclofen injection intrathecal was superior to placebo on both principal outcome measures employed change from baseline in the ashworth rating of spasticity and the frequency of spasmsthe efficacy of baclofen injection intrathecal was investigated in three controlled clinical trials two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury the first study a randomized controlled crossover trial of 51 patients with cerebral palsy provided strong statistically significant results baclofen injection intrathecal was superior to placebo in reducing spasticity as measured by the ashworth scale a second crossover study was conducted in 11 patients with spasticity arising from brain injury despite the small sample size the study yielded a nearly significant test statistic p 0066 and provided directionally favorable results the last study however did not provide data that could be reliably analyzed baclofen injection intrathecal therapy may be considered an alternative to destructive neurosurgical procedures prior to implantation of a device for chronic intrathecal infusion of baclofen injection intrathecal patients must show a response to baclofen injection intrathecal in a screening trial see dosage and administration,3
cyclobenzaprine hydrochloride extendedrelease capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions improvement is manifested by relief of muscle spasm and its associated signs and symptoms namely pain tenderness and limitation of motion limitations of use cyclobenzaprine hydrochloride extendedrelease capsules should be used only for short periods up to two or three weeks because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warrantedcyclobenzaprine hydrochloride extendedrelease capsules have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsycyclobenzaprine hydrochloride extendedrelease capsules are a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions 1 limitations of use cyclobenzaprine hydrochloride extendedrelease capsules should be used only for short periods up to 2 or 3 weeks 1 cyclobenzaprine hydrochloride extendedrelease capsules have not been found effective in the treatment of spasticity or cerebral palsy 1,1
dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders eg spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disordersif improvement occurs it will ordinarily occur within the dosage titration see dosage and administrationoccasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsule therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impressiona decision to continue the administration of dantrolene sodium capsules on a longterm basis is justified if introduction of the drug into the patients regimen produces a significant reduction in painful andor disabling spasticity such as clonus or permits a significant reduction in the intensity andor degree of nursing care required or rids the patient of any annoying manifestation of spasticity considered important by the patient himselforal dantrolene sodium capsules are also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia andor surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodiumoral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia,3
dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders eg spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disordersif improvement occurs it will ordinarily occur within the dosage titration see dosage and administrationoccasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsule therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impressiona decision to continue the administration of dantrolene sodium capsules on a longterm basis is justified if introduction of the drug into the patients regimen produces a significant reduction in painful andor disabling spasticity such as clonus or permits a significant reduction in the intensity andor degree of nursing care required or rids the patient of any annoying manifestation of spasticity considered important by the patient himselforal dantrolene sodium capsules are also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia andor surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodiumoral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia,2
administration is contraindicated in patients with any of the following hypersensitivity to cycloserine epilepsy depression severe anxiety or psychosis severe renal insufficiency excessive concurrent use of alcohol,2
chlordiazepoxide hcl capsules usp are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety withdrawal symptoms of acute alcoholism and preoperative apprehension and anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticthe effectiveness of chlordiazepoxide hcl capsules usp in long term use that is more than 4 months has not been assessed by systematic clinical studies the physician should periodically reassess the usefulness of the drug for the individual patient,2
clorazepate dipotassium tablets usp are indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticclorazepate dipotassium tablets usp are indicated as adjunctive therapy in the management of partial seizuresthe effectiveness of clorazepate dipotassium tablets usp in longterm management of anxiety that is more than 4 months has not been assessed by systematic clinical studies longterm studies in epileptic patients however have shown continued therapeutic activity the physician should reassess periodically the usefulness of the drug for the individual patientclorazepate dipotassium tablets usp are indicated for the symptomatic relief of acute alcohol withdrawal,2
oxazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticanxiety associated with depression is also responsive to oxazepam therapythis product has been found particularly useful in the management of anxiety tension agitation and irritability in older patientsalcoholics with acute tremulousness inebriation or with anxiety associated with alcohol withdrawal are responsive to therapythe effectiveness of oxazepam in longterm use that is more than 4 months has not been assessed by systematic clinical studies the physician should periodically reassess the usefulness of the drug for the individual patient,3
lorazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety or anxiety associated with depressive symptoms anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticthe effectiveness of lorazepam in longterm use that is more than 4 months has not been assessed by systematic clinical studies the physician should periodically reassess the usefulness of the drug for the individual patient note the manufacturers complete drug information can be found at the following fda sitehttpdailymednlmnihgovdailymedlookupcfmsetidad2a063350fe4180b743c1e49fc110c6,3
doxepin hydrochloride capsules usp are recommended for the treatment of psychoneurotic patients with depression andor anxiety depression andor anxiety associated with alcoholism not to be taken concomitantly with alcohol depression andor anxiety associated with organic disease the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly psychotic depressive disorders with associated anxiety including involutional depression and manicdepressive disorders the target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety tension depression somatic symptoms and concerns sleep disturbances guilt lack of energy fear apprehension and worryclinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient owing to lack of clinical experience in the pediatric population doxepin hydrochloride capsules are not recommended for use in children under 12 years of age,3
meprobamate tablets are indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic the effectiveness of meprobamate tablets in longterm use that is more than 4 months has not been assessed by systematic clinical studies the physician should periodically reassess the usefulness of the drug for the individual patient,2
amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions it is indicated for depression accompanied by anxiety or agitation,3
the total management of anxiety tension and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems it has also been recommended for the management of anxiety associated with organic disturbances as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay such as in asthma chronic urticarial and pruritushydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated the acutely disturbed or hysterical patientthe acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremensas pre and postoperative and pre and postpartum adjunctive medication to permit reduction in narcotic dosage allay anxiety and control emesishydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting excluding nausea and vomiting of pregnancy see contraindictionsin prepartum states the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent the effectiveness of hydroxyzine in long term use that is more than 4 months has not been assessed by systematic clinical studies the physician should reassess periodically the usefulness of the drug for the individual patient,3
phenelzine sulfate tablets usp has been found to be effective in depressed patients clinically characterized as atypical nonendogenous or neurotic these patients often have mixed anxiety and depression and phobic or hypochondriacal features there is less conclusive evidence of its usefulness with severely depressed patients with endogenous featuresphenelzine sulfate tablets should rarely be the first antidepressant drug used rather it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions,3
marplan is indicated for the treatment of depression because of its potentially serious side effects marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patientsthe efficacy of marplan in the treatment of depression was established in 6week controlled trials of depressed outpatients these patients had symptoms that corresponded to the dsmiv category of major depressive disorder however they often also had signs and symptoms of anxiety anxious mood panic andor phobic symptoms see clinical pharmacologya major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least five of the following nine symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration and a suicide attempt or suicidal ideationthe antidepressant effectiveness of marplan in hospitalized depressed patients or in endogenomorphically retarded and delusionally depressed patients has not been adequately studiedthe effectiveness of marplan in longterm use that is for more than 6 weeks has not been systematically evaluated in controlled trials therefore the physician who elects to use marplan for extended periods should periodically evaluate the longterm usefulness of the drug for the individual patient,3
ocrevus is contraindicated in patients with active hbv infection see dosage and administration 26warnings and precautions 52a history of lifethreatening infusion reaction to ocrevus see warnings and precautions 51 active hepatitis b virus infection 4history of lifethreatening infusion reaction to ocrevus 4,1
pegasys is contraindicated in patients with known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis or stevensjohnson syndrome to alpha interferons including pegasys or any of its componentsautoimmune hepatitishepatic decompensation childpugh score greater than 6 class b and c in cirrhotic patients before treatmenthepatic decompensation with childpugh score greater than or equal to 6 in cirrhotic chc patients coinfected with hiv before treatmentpegasys is contraindicated in neonates and infants because it contains benzyl alcohol benzyl alcohol is associated with an increased incidence of neurologic and other complications which are sometimes fatal in neonates and infantswhen pegasys is used in combination with other hcv antiviral drugs the contraindications applicable to those agents are applicable to combination therapies pegasys combination treatment with ribavirin is contraindicated in women who are pregnant and men whose female partners are pregnant see warnings and precautions 51use in specific populations 81refer to the prescribing information of the other hcv antiviral drugs including ribavirin for a list of their contraindications autoimmune hepatitis 4hepatic decompensation in patients with cirrhosis 4use in neonatesinfants 4known hypersensitivity reactions such as urticaria angioedema bronchoconstriction and anaphylaxis to alpha interferons or any component of the product 4 additional contraindications for use with other hcv antiviral drugs when used in combination with other hcv antiviral drugs all contraindications also apply to pegasys combination therapy 4ribavirin is contraindicated in pregnant women and men whose female partners are pregnant 481,1
pegasys is contraindicated in patients with known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis or stevensjohnson syndrome to alpha interferons including pegasys or any of its componentsautoimmune hepatitishepatic decompensation childpugh score greater than 6 class b and c in cirrhotic patients before treatmenthepatic decompensation with childpugh score greater than or equal to 6 in cirrhotic chc patients coinfected with hiv before treatmentpegasys is contraindicated in neonates and infants because it contains benzyl alcohol benzyl alcohol is associated with an increased incidence of neurologic and other complications which are sometimes fatal in neonates and infantswhen pegasys is used in combination with other hcv antiviral drugs the contraindications applicable to those agents are applicable to combination therapies pegasys combination treatment with ribavirin is contraindicated in women who are pregnant and men whose female partners are pregnant see warnings and precautions 51use in specific populations 81refer to the prescribing information of the other hcv antiviral drugs including ribavirin for a list of their contraindications autoimmune hepatitis 4hepatic decompensation in patients with cirrhosis 4use in neonatesinfants 4known hypersensitivity reactions such as urticaria angioedema bronchoconstriction and anaphylaxis to alpha interferons or any component of the product 4 additional contraindications for use with other hcv antiviral drugs when used in combination with other hcv antiviral drugs all contraindications also apply to pegasys combination therapy 4ribavirin is contraindicated in pregnant women and men whose female partners are pregnant 481,1
pegasys is contraindicated in patients with known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis or stevensjohnson syndrome to alpha interferons including pegasys or any of its componentsautoimmune hepatitishepatic decompensation childpugh score greater than 6 class b and c in cirrhotic patients before treatmenthepatic decompensation with childpugh score greater than or equal to 6 in cirrhotic chc patients coinfected with hiv before treatmentpegasys is contraindicated in neonates and infants because it contains benzyl alcohol benzyl alcohol is associated with an increased incidence of neurologic and other complications which are sometimes fatal in neonates and infantswhen pegasys is used in combination with other hcv antiviral drugs the contraindications applicable to those agents are applicable to combination therapies pegasys combination treatment with ribavirin is contraindicated in women who are pregnant and men whose female partners are pregnant see warnings and precautions 51use in specific populations 81refer to the prescribing information of the other hcv antiviral drugs including ribavirin for a list of their contraindications autoimmune hepatitis 4hepatic decompensation in patients with cirrhosis 4use in neonatesinfants 4known hypersensitivity reactions such as urticaria angioedema bronchoconstriction and anaphylaxis to alpha interferons or any component of the product 4 additional contraindications for use with other hcv antiviral drugs when used in combination with other hcv antiviral drugs all contraindications also apply to pegasys combination therapy 4ribavirin is contraindicated in pregnant women and men whose female partners are pregnant 481,1
zinbryta is contraindicated in patients with preexisting hepatic disease or hepatic impairment including alt or ast at least 2 times the uln because zinbryta could exacerbate existing liver dysfunction see dosage and administration 2351a history of autoimmune hepatitis or other autoimmune condition involving the liver see warnings and precautions 51a history of hypersensitivity to daclizumab or any other components of the formulation use in such patients may result in anaphylaxis or lifethreatening multiorgan hypersensitivity see warnings and precautions 54 preexisting hepatic disease or hepatic impairment including alt or ast at least 2 times the uln 4history of autoimmune hepatitis or other autoimmune condition involving the liver 4history of hypersensitivity to daclizumab or any other component of the formulation 4,2
motegritytm is indicated for the treatment of chronic idiopathic constipation cic in adultsmotegritytm is a serotonin4 5ht411,3
amitiza is a chloride channel activator indicated for treatment of chronic idiopathic constipation in adults 11treatment of opioidinduced constipation in adults with chronic noncancer pain 12treatment of irritable bowel syndrome with constipation in women 18 years old 13 limitations of use effectiveness of amitiza in the treatment of opioidinduced constipation in patients taking diphenylheptane opioids eg methadone has not been established 1142amitiza is indicated for the treatment of chronic idiopathic constipation in adults r amitizais indicated for the treatment ofopioidinduced constipation oic in adults with chronic noncancer pain limitations of use effectiveness ofamitizain the treatment ofopioidinduced constipation in patients takingdiphenylheptaneopioidseg methadone has not been established see clinical studies 142amitiza is indicated for the treatment of irritable bowel syndrome with constipation ibsc in women 18 years old,3
amitiza is a chloride channel activator indicated for treatment of chronic idiopathic constipation in adults 11treatment of opioidinduced constipation in adults with chronic noncancer pain 12treatment of irritable bowel syndrome with constipation in women 18 years old 13 limitations of use effectiveness of amitiza in the treatment of opioidinduced constipation in patients taking diphenylheptane opioids eg methadone has not been established 1142amitiza is indicated for the treatment of chronic idiopathic constipation in adults r amitizais indicated for the treatment ofopioidinduced constipation oic in adults with chronic noncancer pain limitations of use effectiveness ofamitizain the treatment ofopioidinduced constipation in patients takingdiphenylheptaneopioidseg methadone has not been established see clinical studies 142amitiza is indicated for the treatment of irritable bowel syndrome with constipation ibsc in women 18 years old,3
linzessr is indicated in adults for the treatment of irritable bowel syndrome with constipation ibsc chronic idiopathic constipation ciclinzess is a guanylate cyclasec agonist indicated in adults for treatment of irritable bowel syndrome with constipation ibsc 1chronic idiopathic constipation cic 1,3
linzessr is indicated in adults for the treatment of irritable bowel syndrome with constipation ibsc chronic idiopathic constipation ciclinzess is a guanylate cyclasec agonist indicated in adults for treatment of irritable bowel syndrome with constipation ibsc 1chronic idiopathic constipation cic 1,3
capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer 11 patients with dukes c colon cancer metastatic colorectal cancer 11 firstline as monotherapy when treatment with fluoropyrimidine therapy alone is preferred metastatic breast cancer 12 in combination with docetaxel after failure of prior anthracyclinecontaining therapy as monotherapy in patients resistant to both paclitaxel and an anthracyclinecontaining regimen capecitabine tablets usp is indicated as a single agent for adjuvant treatment in patients with dukes c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred capecitabine was noninferior to 5 fluorouracil and leucovorin 5fulv for diseasefree survival dfs physicians should consider results of combination chemotherapy trials which have shown improvement in dfs and os when prescribing singleagent capecitabine in the adjuvant treatment of dukes c colon cancercapecitabine tablets usp are indicated as firstline treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred combination chemotherapy has shown a survival benefit compared to 5fulv alone a survival benefit over 5fulv has not been demonstrated with capecitabine tablets monotherapy use of capecitabine tablets usp instead of 5fulv in combinations has not been adequately studied to assure safety or preservation of the survival advantage capecitabine tablets usp in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracyclinecontaining chemotherapy capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracyclinecontaining chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated eg patients who have received cumulative doses of 400 mgm2 of doxorubicin or doxorubicin equivalents resistance is defined as progressive disease while on treatment with or without an initial response or relapse within 6 months of completing treatment with an anthracyclinecontaining adjuvant regimen,3
capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer 11 patients with dukes c colon cancer metastatic colorectal cancer 11 firstline as monotherapy when treatment with fluoropyrimidine therapy alone is preferred metastatic breast cancer 12 in combination with docetaxel after failure of prior anthracyclinecontaining therapy as monotherapy in patients resistant to both paclitaxel and an anthracyclinecontaining regimen capecitabine tablets usp is indicated as a single agent for adjuvant treatment in patients with dukes c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred capecitabine was noninferior to 5 fluorouracil and leucovorin 5fulv for diseasefree survival dfs physicians should consider results of combination chemotherapy trials which have shown improvement in dfs and os when prescribing singleagent capecitabine in the adjuvant treatment of dukes c colon cancercapecitabine tablets usp are indicated as firstline treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred combination chemotherapy has shown a survival benefit compared to 5fulv alone a survival benefit over 5fulv has not been demonstrated with capecitabine tablets monotherapy use of capecitabine tablets usp instead of 5fulv in combinations has not been adequately studied to assure safety or preservation of the survival advantage capecitabine tablets usp in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracyclinecontaining chemotherapy capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracyclinecontaining chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated eg patients who have received cumulative doses of 400 mgm2 of doxorubicin or doxorubicin equivalents resistance is defined as progressive disease while on treatment with or without an initial response or relapse within 6 months of completing treatment with an anthracyclinecontaining adjuvant regimen,3
jakafi is a kinase inhibitor indicated for treatment of patients with intermediate or highrisk myelofibrosis including primary myelofibrosis postpolycythemia vera myelofibrosis and postessential thrombocythemia myelofibrosis 11polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 12jakafi is indicated for treatment of patients with intermediate or highrisk myelofibrosis mf including primary mf postpolycythemia vera mf and postessential thrombocythemia mfjakafi is indicated for treatment of patients with polycythemia vera pv who have had an inadequate response to or are intolerant of hydroxyurea,3
in patients who are hypersensitive to the drug or its ingredients phenazopyridine is contraindicated in patients with renal insufficiency severe liver disease severe hepatitis or pyelonephritis of pregnancy it should be used cautiously in the presence of gi disturbances,2
gynazole 1r butoconazole nitrate vaginal cream usp 2 is indicated for the local treatment of vulvovaginal candidiasis infections caused by candidaclinical studies note precautions pregnancy,3
miconazole nitrate vaginal suppositories usp 200 mg are indicated for the local treatment of vulvovaginal candidiasis moniliasis effectiveness in pregnancy has not been established as miconazole nitrate is effective only for candidal vulvovaginitis the diagnosis should be confirmed by koh smear andor cultures other pathogens commonly associated with vulvovaginitis trichomonas haemophilus vaginalis gardnerella,3
terconazole vaginal cream 04 is indicated for the local treatment of vulvovaginal candidiasis moniliasis as terconazole vaginal cream 04 is effective only for vulvovaginitis caused by the genus candida the diagnosis should be confirmed by koh smears andor cultures,3
sulfadiazine tablets usp are indicated in the following conditionschancroidtrachomainclusion conjunctivitisnocardiosisurinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coliklebsiellaenterobacterstaphylococcus aureusproteus mirabilisp vulgaristoxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethaminemalaria due to chloroquineresistant strains of plasmodium falciparumprophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groupsmeningococcal meningitis when the organism has been demonstrated to be susceptibleacute otitis media due to haemophilus influenzaeprophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzaeimportant notes in vitrocurrently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infectionswide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
sulfadiazine tablets usp are indicated in the following conditionschancroidtrachomainclusion conjunctivitisnocardiosisurinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coliklebsiellaenterobacterstaphylococcus aureusproteus mirabilisp vulgaristoxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethaminemalaria due to chloroquineresistant strains of plasmodium falciparumprophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groupsmeningococcal meningitis when the organism has been demonstrated to be susceptibleacute otitis media due to haemophilus influenzaeprophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzaeimportant notes in vitrocurrently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infectionswide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
pulmonary hypertension advanced arteriosclerosis hyperthyroidism known hypersensitivity or idiosyncrasy to the sympathomimetic amines glaucoma severe hypertension see precautionsagitated statespatients with a history of drug abuseuse in combination with other anorectic agents is contraindicatedduring or within 14 days following the administration of monoamine oxidase inhibitors hypertensive crises may result,1
gilenya is indicated for the treatment of relapsing forms of multiple sclerosis ms in patients 10 years of age and oldergilenya is a sphingosine 1phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis ms in patients 10 years of age and older 1,3
rebif interferon beta1a is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disabilityrebif is an interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability 1,3
extavia interferon beta1b is indicated for the treatment of relapsing forms of multiple sclerosis ms to reduce the frequency of clinical exacerbations patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have magnetic resonance imaging mri features consistent with msextavia is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis ms to reduce the frequency of clinical exacerbations patients with ms in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have mri features consistent with ms 1,3
glatiramer acetate injection is indicated for the treatment of patients with relapsing forms of multiple sclerosis glatiramer acetate injection is indicated for the treatment of patients with relapsingforms of multiple sclerosis 1,3
mavenclad is indicated for the treatment of relapsing forms of multiple sclerosis ms to include relapsingremitting disease and active secondary progressive disease in adults because of its safety profile use of mavenclad is generally recommended for patients who have had an inadequate response to or are unable to tolerate an alternate drug indicated for the treatment of ms see warnings and precautions 5mavenclad is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis ms to include relapsingremitting disease and active secondary progressive disease in adults because of its safety profile use of mavenclad is generally recommended for patients who have had an inadequate response to or are unable to tolerate an alternate drug indicated for the treatment of ms see warnings and precautions 51 limitations of usemavenclad is not recommended for use in patients with clinically isolated syndrome cis because of its safety profile see warnings and precautions 51 limitations of usemavenclad is not recommended for use in patients with clinically isolated syndrome cis because of its safety profile see warnings and precautions 5,3
tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 1151 crohns disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohns disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnfa 12important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnfa 12tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 51tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohns disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnfa tysabri should not be used in combination with immunosuppressants eg 6mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnfa see warnings and precautions 51,3
dalfampridine extendedrelease tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis ms this was demonstrated by an increase in walking speed see clinical studies 14 dalfampridine extendedrelease tablets are a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis ms this was demonstrated by an increase in walking speed 114,3
teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosisteriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis 1,3
hypersensitivityceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone any of its excipients or to any other cephalosporin patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone see warnings hypersensitivity neonates premature neonatesceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks gestational age chronological age hyperbilirubinemic neonates hyperbilirubinemic neonates should not be treated with ceftriaxone for injection ceftriaxone can displace bilirubin from its binding to serum albumin leading to a risk of bilirubin encephalopathy in these patients neonates requiring calcium containing iv solutionsceftriaxone for injection is contraindicated in neonates 28 days if they require or are expected to require treatment with calciumcontaining iv solutions including continuous calcium containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxonecalcium see clinical pharmacologywarnings dosage and administrationcases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium containing fluidsin some of these cases the same intravenous infusion line was used for both ceftriaxone for injection and calciumcontaining fluids and in some a precipitate was observed in the intravenous infusion line there have been no similar reports in patients other than neonates lidocaineintravenous administration of ceftriaxone solutions containing lidocaine is contraindicated when lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection exclude all contraindications to lidocaine refer to the prescribing information of lidocaine,3
topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy as a single agent 11 patients with small cell lung cancer slsc platinumsensitive disease who progressed at least 60 days after initiation of firstline chemotherapy as a single agent 12 patients with stage ivb recurrent or persistent cervical cancer which is not amenable to curative treatment in combination with cisplatin 13topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with small cell lung cancer sclc with platinumsensitive disease who progressed at least 60 days after initiation of firstline chemotherapy topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage ivb recurrent or persistent cervical cancer of the cervix not amenable to curative treatment,3
topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy as a single agent 11 patients with small cell lung cancer slsc platinumsensitive disease who progressed at least 60 days after initiation of firstline chemotherapy as a single agent 12 patients with stage ivb recurrent or persistent cervical cancer which is not amenable to curative treatment in combination with cisplatin 13topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with small cell lung cancer sclc with platinumsensitive disease who progressed at least 60 days after initiation of firstline chemotherapy topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage ivb recurrent or persistent cervical cancer of the cervix not amenable to curative treatment,3
topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy as a single agent 11 patients with small cell lung cancer slsc platinumsensitive disease who progressed at least 60 days after initiation of firstline chemotherapy as a single agent 12 patients with stage ivb recurrent or persistent cervical cancer which is not amenable to curative treatment in combination with cisplatin 13topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with small cell lung cancer sclc with platinumsensitive disease who progressed at least 60 days after initiation of firstline chemotherapy topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage ivb recurrent or persistent cervical cancer of the cervix not amenable to curative treatment,3
somatuline depot is a somatostatin analog indicated for the longterm treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery andor radiotherapy 11the treatment of adult patients with unresectable well or moderatelydifferentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors gepnets to improve progressionfree survival 12the treatment of adults with carcinoid syndrome when used it reduces the frequency of shortacting somatostatin analog rescue therapy 13somatuline depot is indicated for the longterm treatment of acromegalic patients who have had an inadequate response to surgery andor radiotherapy or for whom surgery andor radiotherapy is not an optionthe goal of treatment in acromegaly is to reduce growth hormone gh and insulin growth factor1 igf1 levels to normalsomatuline depot is indicated for the treatment of adult patients with unresectable well or moderately differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors gepnets to improve progressionfree survivalsomatuline depot is indicated for the treatment of adults with carcinoid syndrome when used it reduces the frequency of shortacting somatostatin analog rescue therapy,3
somavert is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy or for whom these therapies are not appropriate the goal of treatment is to normalize serum insulinlike growth factori igfi levelssomavert is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy or for whom these therapies are not appropriate the goal of treatment is to normalize serum insulinlike growth factori igfi levels1,3
signifor lar is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery andor for whom surgery is not an option 11patients with cushings disease for whom pituitary surgery is not an option or has not been curative 12signifor lar is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery andor for whom surgery is not an option signifor lar is indicated for the treatment of patients with cushings disease for whom pituitary surgery is not an option or has not been curative,3
alomider lodoxamide tromethamine ophthalmic solution 01 is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis vernal conjunctivitis and vernal keratitis,3
imiquimod cream is indicated for the topical treatment of clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses ak on the face or scalp in immunocompetent adults 11 biopsyconfirmed primary superficial basal cell carcinoma sbcc in immunocompetent adults maximum tumor diameter of 20 cm on trunk neck or extremities excluding hands and feet only when surgical methods are medically less appropriate and patient followup can be reasonably assured 12 external genital and perianal wartscondyloma acuminata in patients 12 years old or older 13limitations of use efficacy was not demonstrated for molluscum contagiosum in children aged 212 1484imiquimod cream is indicated for the topical treatment of clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adultsimiquimod cream is indicated for the topical treatment of biopsyconfirmed primary superficial basal cell carcinoma sbcc in immunocompetent adults with a maximum tumor diameter of 20 cm located on the trunk excluding anogenital skin neck or extremities excluding hands and feet only when surgical methods are medically less appropriate and patient followup can be reasonably assuredthe histological diagnosis of superficialimiquimod cream is indicated for the treatment of external genital and perianal wartscondyloma acuminata in patients 12 years old and olderimiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy see use in specific populations84the safety and efficacy of imiquimod cream in immunosuppressed patients have not been establishedimiquimod cream should be used with caution in patients with preexisting autoimmune conditionsthe efficacy and safety of imiquimod cream have not been established for patients with basal cell nevus syndrome or xeroderma pigmentosum,3
imiquimod cream is indicated for the topical treatment of clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses ak on the face or scalp in immunocompetent adults 11 biopsyconfirmed primary superficial basal cell carcinoma sbcc in immunocompetent adults maximum tumor diameter of 20 cm on trunk neck or extremities excluding hands and feet only when surgical methods are medically less appropriate and patient followup can be reasonably assured 12 external genital and perianal wartscondyloma acuminata in patients 12 years old or older 13limitations of use efficacy was not demonstrated for molluscum contagiosum in children aged 212 1484imiquimod cream is indicated for the topical treatment of clinically typical nonhyperkeratotic nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adultsimiquimod cream is indicated for the topical treatment of biopsyconfirmed primary superficial basal cell carcinoma sbcc in immunocompetent adults with a maximum tumor diameter of 20 cm located on the trunk excluding anogenital skin neck or extremities excluding hands and feet only when surgical methods are medically less appropriate and patient followup can be reasonably assuredthe histological diagnosis of superficialimiquimod cream is indicated for the treatment of external genital and perianal wartscondyloma acuminata in patients 12 years old and olderimiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy see use in specific populations84the safety and efficacy of imiquimod cream in immunosuppressed patients have not been establishedimiquimod cream should be used with caution in patients with preexisting autoimmune conditionsthe efficacy and safety of imiquimod cream have not been established for patients with basal cell nevus syndrome or xeroderma pigmentosum,3
erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiationerivedger1,3
erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiationerivedger1,3
odomzo sonidegib is indicated for the treatment of adult patients with locally advanced basal cell carcinoma bcc that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapyodomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma bcc that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy 1,3
odomzo sonidegib is indicated for the treatment of adult patients with locally advanced basal cell carcinoma bcc that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapyodomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma bcc that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy 1,3
ridaura auranofin is indicated in the management of adults with active classical or definite rheumatoid arthritis ara criteria who have had an insufficient therapeutic response to or are intolerant of an adequate trial of full doses of one or more nonsteroidal antiinflammatory drugs ridaura should be added to a comprehensive baseline program including nondrug therapiesunlike antiinflammatory drugs ridaura does not produce an immediate response therapeutic effects may be seen after three to four months of treatment although improvement has not been seen in some patients before six monthswhen cartilage and bone damage has already occurred gold cannot reverse structural damage to joints caused by previous disease the greatest potential benefit occurs in patients with active synovitis particularly in its early stagein controlled clinical trials comparing ridaura with injectable gold ridaura was associated with fewer dropouts due to adverse reactions while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect physicians should consider these findings when deciding on the use of ridaura in patients who are candidates for chrysotherapy,3
ridaura auranofin is indicated in the management of adults with active classical or definite rheumatoid arthritis ara criteria who have had an insufficient therapeutic response to or are intolerant of an adequate trial of full doses of one or more nonsteroidal antiinflammatory drugs ridaura should be added to a comprehensive baseline program including nondrug therapiesunlike antiinflammatory drugs ridaura does not produce an immediate response therapeutic effects may be seen after three to four months of treatment although improvement has not been seen in some patients before six monthswhen cartilage and bone damage has already occurred gold cannot reverse structural damage to joints caused by previous disease the greatest potential benefit occurs in patients with active synovitis particularly in its early stagein controlled clinical trials comparing ridaura with injectable gold ridaura was associated with fewer dropouts due to adverse reactions while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect physicians should consider these findings when deciding on the use of ridaura in patients who are candidates for chrysotherapy,3
ridaura auranofin is indicated in the management of adults with active classical or definite rheumatoid arthritis ara criteria who have had an insufficient therapeutic response to or are intolerant of an adequate trial of full doses of one or more nonsteroidal antiinflammatory drugs ridaura should be added to a comprehensive baseline program including nondrug therapiesunlike antiinflammatory drugs ridaura does not produce an immediate response therapeutic effects may be seen after three to four months of treatment although improvement has not been seen in some patients before six monthswhen cartilage and bone damage has already occurred gold cannot reverse structural damage to joints caused by previous disease the greatest potential benefit occurs in patients with active synovitis particularly in its early stagein controlled clinical trials comparing ridaura with injectable gold ridaura was associated with fewer dropouts due to adverse reactions while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect physicians should consider these findings when deciding on the use of ridaura in patients who are candidates for chrysotherapy,3
history of hypersensitivity to rifaximin rifamycin antimicrobial agents or any of the components of xifaxan 41 xifaxan is contraindicated in patients with a hypersensitivity to rifaximin any of the rifamycin antimicrobial agents or any of the components in xifaxan hypersensitivity reactions have included exfoliative dermatitis angioneurotic edema and anaphylaxis see adverse reactions 62,1
ridaura auranofin is contraindicated in patients with a history of any of the following goldinduced disorders anaphylactic reactions necrotizing enterocolitis pulmonary fibrosis exfoliative dermatitis bone marrow aplasia or other severe hematologic disorders,1
pimecrolimus cream 1 is indicated as secondline therapy for the shortterm and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable pimecrolimus cream 1 is not indicated for use in children less than 2 years of age warnings and precautions 51use in specific populations 84pimecrolimus cream 1 is a calcineurin inhibitor immunosuppressant indicated as secondline therapy for the shortterm and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable 1,3
pimecrolimus cream 1 is indicated as secondline therapy for the shortterm and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable pimecrolimus cream 1 is not indicated for use in children less than 2 years of age warnings and precautions 51use in specific populations 84pimecrolimus cream 1 is a calcineurin inhibitor immunosuppressant indicated as secondline therapy for the shortterm and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised adults and children 2 years of age and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable 1,3
lindane shampoo is contraindicated in premature infants and individuals with known uncontrolled seizure disorderslindane shampoo is contraindicated for premature infants because their skin may be more permeable than that of full term infants and their liver enzymes may not be sufficiently developed to metabolize lindanelindane shampoo is also contraindicated for patients with crusted norwegian scabies and other skin conditions eg atopic dermatitis psoriasis that may increase systemic absorption of the druglindane shampoo is contraindicated for patients with known uncontrolled seizure disorders and for individuals with a known sensitivity to the product or any of its components,0
this product is a liquid antiseborrheic antifungal preparation useful for the treatment of seborrheic dermatitis of the scalp dandruff and tinea versicolor urea hydrates and is useful for conditions such as dry scalp,3
rivastigmine tartrate capsules are contraindicated in patients with known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation see description 11a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing see warnings and precautions 52isolated cases of generalized skin reactions have been described in postmarketing experience see adverse reactions 62 known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation 4history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing 4 52,0
rivastigmine tartrate capsules are contraindicated in patients with known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation see description 11a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing see warnings and precautions 52isolated cases of generalized skin reactions have been described in postmarketing experience see adverse reactions 62 known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation 4history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing 4 52,3
rivastigmine tartrate capsules are contraindicated in patients with known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation see description 11a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing see warnings and precautions 52isolated cases of generalized skin reactions have been described in postmarketing experience see adverse reactions 62 known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation 4history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing 4 52,0
allergy to any component of tubersol or an anaphylactic or other allergic reaction to a previous test of tuberculin ppd is a contraindication to the use of tubersol see descriptionhow suppliedtubersol should not be administered to persons who have had a severe reaction eg necrosis blistering anaphylactic shock or ulcerations to a previous tstpersons with documented active tuberculosis or a clear history of treatment for tb infection or disease 10persons with extensive burns or eczema,0
ofev is indicated for the treatment of idiopathic pulmonary fibrosis ipfofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis ipf 1,3
ofev is indicated for the treatment of idiopathic pulmonary fibrosis ipfofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis ipf 1,3
pindolol tablets are contraindicated in 1 bronchial asthma 2 overt cardiac failure 3 cardiogenic shock 4 second and third degree heart block 5 severe bradycardia see warnings,2
nadolol tablets are contraindicated in bronchial asthma sinus bradycardia and greater than first degree conduction block cardiogenic shock and overt cardiac failure see warnings,2
xolair is an antiige antibody indicated for moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids 11 chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite h1 antihistamine treatment 12limitations of use not indicated for other allergic conditions or other forms of urticaria 1112 not indicated for acute bronchospasm or status asthmaticus 1153xolair is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroidsxolair has been shown to decrease the incidence of asthma exacerbations in these patients limitations of use xolair is not indicated for the relief of acute bronchospasm or status asthmaticusxolair is not indicated for treatment of other allergic conditionsxolair is indicated for the treatment of adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite h1 antihistamine treatment limitation of usexolair is not indicated for treatment of other forms of urticaria,3
intravenous theophylline is indicated as an adjunct to inhaled beta2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases eg emphysema and chronic bronchitis,2
intravenous theophylline is indicated as an adjunct to inhaled beta2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases eg emphysema and chronic bronchitis,3
montelukast sodium tablets are a leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma in patients 2 years of age and older 11acute prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older 12relief of symptoms of allergic rhinitis ar seasonal allergic rhinitis sar in patients 2 years of age and older and perennial allergic rhinitis par in patients 2 years of age and older 13montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older montelukast sodium is indicated for prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older pediatric use information for patients ages 6 to 14 years of age for acute prevention of exerciseinduced bronchoconstriction eib is approved for merck sharp dohme corps montelukast tablet products however due to merck sharp dohme corps marketing exclusivity rights this drug product is not labeled with that pediatric informationmontelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older,3
montelukast sodium tablets are a leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma in patients 2 years of age and older 11acute prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older 12relief of symptoms of allergic rhinitis ar seasonal allergic rhinitis sar in patients 2 years of age and older and perennial allergic rhinitis par in patients 2 years of age and older 13montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older montelukast sodium is indicated for prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older pediatric use information for patients ages 6 to 14 years of age for acute prevention of exerciseinduced bronchoconstriction eib is approved for merck sharp dohme corps montelukast tablet products however due to merck sharp dohme corps marketing exclusivity rights this drug product is not labeled with that pediatric informationmontelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older,2
metaproterenol sulfate tablets are indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm which may occur in association with bronchitis and emphysema,3
cromolyn sodium inhalation solution usp is a prophylactic agent indicated in the management of patients with bronchial asthmain patients whose symptoms are sufficiently frequent to require a continuous program of medication cromolyn sodium inhalation solution usp is given by inhalation on a regular daily basis see dosage and administrationin patients who develop acute bronchoconstriction in response to exposure to exercise toluene diisocyanate environmental pollutants etc cromolyn sodium should be given shortly before exposure to the precipitating factor see dosage and administration,3
ephedrine sulfate injection usp is indicated in the treatment of allergic disorders such as bronchial asthma the drug has long been used as a pressor agent particularly during spinal anesthesia when hypotension frequently occurs in stokesadams syndrome with complete heart block ephedrine has a value similar to that of epinephrine it is indicated as a central nervous system stimulant in narcolepsy and depressive states it is also used in myasthenia gravis,3
ephedrine sulfate injection usp is indicated in the treatment of allergic disorders such as bronchial asthma the drug has long been used as a pressor agent particularly during spinal anesthesia when hypotension frequently occurs in stokesadams syndrome with complete heart block ephedrine has a value similar to that of epinephrine it is indicated as a central nervous system stimulant in narcolepsy and depressive states it is also used in myasthenia gravis,3
ephedrine sulfate injection usp is indicated in the treatment of allergic disorders such as bronchial asthma the drug has long been used as a pressor agent particularly during spinal anesthesia when hypotension frequently occurs in stokesadams syndrome with complete heart block ephedrine has a value similar to that of epinephrine it is indicated as a central nervous system stimulant in narcolepsy and depressive states it is also used in myasthenia gravis,3
pyridostigmine bromide extendedrelease tablets are contraindicated in mechanical intestinal or urinary obstruction and particular caution should be used in its administration to patients with bronchial asthma care should be observed in the use of atropine for counteracting side effects as discussed below,1
zafirlukast tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older,3
relenza an influenza neuraminidase inhibitor is indicated for treatment of influenza prophylaxis of influenza important limitations on use of relenza not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease 51 not proven effective for treatment in individuals with underlying airways disease 13prophylaxis in nursing home residents 13 not a substitute for annual influenza vaccination 13 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 13relenzarrelenza is indicated for prophylaxis of influenza in adults and pediatric patients 5 years of age and older relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease such as asthma or chronic obstructive pulmonary disease due to risk of serious bronchospasm see warnings and precautions 51relenza has not been proven effective for treatment of influenza in individuals with underlying airways diseaserelenza has not been proven effective for prophylaxis of influenza in the nursing home settingrelenza is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease controls immunization practices advisory committee influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenzathere is no evidence for efficacy of zanamivir in any illness caused by agents other than influenza virus a and bpatients should be advised that the use of relenza for treatment of influenza has not been shown to reduce the risk of transmission of influenza to others,1
relenza an influenza neuraminidase inhibitor is indicated for treatment of influenza prophylaxis of influenza important limitations on use of relenza not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease 51 not proven effective for treatment in individuals with underlying airways disease 13prophylaxis in nursing home residents 13 not a substitute for annual influenza vaccination 13 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 13relenzarrelenza is indicated for prophylaxis of influenza in adults and pediatric patients 5 years of age and older relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease such as asthma or chronic obstructive pulmonary disease due to risk of serious bronchospasm see warnings and precautions 51relenza has not been proven effective for treatment of influenza in individuals with underlying airways diseaserelenza has not been proven effective for prophylaxis of influenza in the nursing home settingrelenza is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease controls immunization practices advisory committee influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenzathere is no evidence for efficacy of zanamivir in any illness caused by agents other than influenza virus a and bpatients should be advised that the use of relenza for treatment of influenza has not been shown to reduce the risk of transmission of influenza to others,1
relenza an influenza neuraminidase inhibitor is indicated for treatment of influenza prophylaxis of influenza important limitations on use of relenza not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease 51 not proven effective for treatment in individuals with underlying airways disease 13prophylaxis in nursing home residents 13 not a substitute for annual influenza vaccination 13 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 13relenzarrelenza is indicated for prophylaxis of influenza in adults and pediatric patients 5 years of age and older relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease such as asthma or chronic obstructive pulmonary disease due to risk of serious bronchospasm see warnings and precautions 51relenza has not been proven effective for treatment of influenza in individuals with underlying airways diseaserelenza has not been proven effective for prophylaxis of influenza in the nursing home settingrelenza is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease controls immunization practices advisory committee influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenzathere is no evidence for efficacy of zanamivir in any illness caused by agents other than influenza virus a and bpatients should be advised that the use of relenza for treatment of influenza has not been shown to reduce the risk of transmission of influenza to others,3
terbutaline sulfate injection usp is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema,3
terbutaline sulfate injection usp is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema,3
spiriva respimat is an anticholinergic indicated for the longterm oncedaily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd and for reducing copd exacerbations 11the longterm oncedaily maintenance treatment of asthma in patients 6 years of age and older 12limitation of use not indicated for relief of acute bronchospasm 111251spiriva respimat tiotropium bromide is indicated for the longterm oncedaily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema spiriva respimat is indicated to reduce exacerbations in copd patientsimportant limitation of usespiriva respimat is a bronchodilator indicated for the longterm oncedaily maintenance treatment of asthma in patients 6 years of age and olderimportant limitation of use,3
tradjenta is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin such as anaphylaxis angioedema exfoliative skin conditions urticaria or bronchial hyperreactivity see warnings and precautions 54 and adverse reactions 61history of hypersensitivity reaction to linagliptin such as anaphylaxis angioedema exfoliative skin conditions urticaria or bronchial hyperreactivity 4,0
all laba are contraindicated in patients with asthma without use of a longterm asthma control medication see warnings and precautions 51all laba are contraindicated in patients with asthma without use of a longterm asthma control medication 412,1
ribavirin capsules may cause birth defects andor death of the exposed fetus ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant see warningsprecautionsinformation for patients pregnancy category xribavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsulepatients with autoimmune hepatitis must not be treated with combination ribavirinintron a therapy because using these medicines can make the hepatitis worsepatients with hemoglobinopathies eg thalassemia major sicklecell anemia should not be treated with ribavirin capsulescombination ribavirin capsulesintron a therapy must not be used by females who are pregnant or by males whose female partners are pregnant extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsulesintron a therapy combination ribavirin capsulesintron a therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded significant teratogenic andor embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted these effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules if pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops physicians are encouraged to report such cases by calling the ribavirin pregnancy registry at 18005932214 see boxed contraindications and warnings see warningsribavirin capsules in combination with intron a injection is contraindicated in patients with a history of hypersensitivity to ribavirin andor alpha interferon or any component of the capsule andor injectionpatients with autoimmune hepatitis must not be treated with combination ribavirin capsulesintron a therapy,3
zoladex is a gonadotropin releasing hormone gnrh agonist indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate 11palliative treatment of advanced carcinoma of the prostate 12the management of endometriosis 13use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding 14use in the palliative treatment of advanced breast cancer in pre and perimenopausal women 15zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2bt4 stage b2c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 21141zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 22142zoladex is indicated for the management of endometriosis including pain relief and reduction of endometriotic lesions for the duration of therapy experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months see dosage and administration 23143zoladex is indicated for use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding see dosage and administration 24144zoladex is indicated for use in the palliative treatment of advanced breast cancer in pre and perimenopausal women the estrogen and progesterone receptor values may help to predict whether zoladex therapy is likely to be beneficial see dosage and administration 26121145the automatic safety feature of the syringe aids in the prevention of needlestick injury,3
zoladex is a gonadotropin releasing hormone gnrh agonist indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate 11palliative treatment of advanced carcinoma of the prostate 12the management of endometriosis 13use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding 14use in the palliative treatment of advanced breast cancer in pre and perimenopausal women 15zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2bt4 stage b2c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 21141zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 22142zoladex is indicated for the management of endometriosis including pain relief and reduction of endometriotic lesions for the duration of therapy experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months see dosage and administration 23143zoladex is indicated for use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding see dosage and administration 24144zoladex is indicated for use in the palliative treatment of advanced breast cancer in pre and perimenopausal women the estrogen and progesterone receptor values may help to predict whether zoladex therapy is likely to be beneficial see dosage and administration 26121145the automatic safety feature of the syringe aids in the prevention of needlestick injury,3
zoladex is a gonadotropin releasing hormone gnrh agonist indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate 11palliative treatment of advanced carcinoma of the prostate 12the management of endometriosis 13use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding 14use in the palliative treatment of advanced breast cancer in pre and perimenopausal women 15zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2bt4 stage b2c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 21141zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 22142zoladex is indicated for the management of endometriosis including pain relief and reduction of endometriotic lesions for the duration of therapy experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months see dosage and administration 23143zoladex is indicated for use as an endometrialthinning agent prior to endometrial ablation for dysfunctional uterine bleeding see dosage and administration 24144zoladex is indicated for use in the palliative treatment of advanced breast cancer in pre and perimenopausal women the estrogen and progesterone receptor values may help to predict whether zoladex therapy is likely to be beneficial see dosage and administration 26121145the automatic safety feature of the syringe aids in the prevention of needlestick injury,1
for endometriosis see reverse sidesynarel is indicated for treatment of central precocious puberty cppthe diagnosis of central precocious puberty cppfor central precocious puberty see reverse sidesynarel is indicated for management of endometriosis including pain relief and reduction of endometriotic lesions experience with synarel for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months,3
cleviprex is contraindicated in patients with allergy to soy or eggs 41defective lipid metabolism 42severe aortic stenosis 43cleviprex is contraindicated in patients with allergies to soybeans soy products eggs or egg products cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia lipoid nephrosis or acute pancreatitis if it is accompanied by hyperlipidemiacleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery,2
tegsedi is contraindicated in patients with platelet count below 100 x 109see warnings and precautions 51history of acute glomerulonephritis caused by tegsedi see warnings and precautions 52history of a hypersensitivity reaction to tegsedi see warnings and precautions 57 platelet count less than 100 x 109451history of acute glomerulonephritis caused by tegsedi 452patients with a history of a hypersensitivity reaction to tegsedi 457,1
indications based on a review of this drug by the national academy of sciences national research council andor other information fda has classified the indications as follows effective management of nausea and vomiting and dizziness associated with motion sickness possibly effective management of vertigo associated with diseases affecting the vestibular system final classification of the less than effective indications required further investigation,3
scopolamine transdermal system is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with scopolamine transdermal system is indicated in adults for prevention of nausea and vomiting associated with motion sickness see clinical studies 141scopolamine transdermal system is indicated in adults for prevention of nausea and vomiting associated with recovery from anesthesia andor opiate analgesia and surgery see clinical studies 142,3
promethazine hydrochloride injection is indicated for the following conditions amelioration of allergic reactions to blood or plasmain anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlledfor other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicatedfor sedation and relief of apprehension and to produce light sleep from which the patient can be easily arousedactive treatment of motion sicknessprevention and control of nausea and vomiting associated with certain types of anesthesia and surgeryas an adjunct to analgesics for the control of postoperative painpreoperative postoperative and obstetric during labor sedationintravenously in special surgical situations such as repeated bronchoscopy ophthalmic surgery and poorrisk patients with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia,3
diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients other than premature infants and neonates for the following conditions when diphenhydramine hydrochloride in the oral form is impractical antihistaminic for amelioration of allergic reactions to blood or plasma in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated motion sicknessfor active treatment of motion sickness antiparkinsonismfor use in parkinsonism when oral therapy is impossible or contraindicated as follows parkinsonism in the elderly who are unable to tolerate more potent agents mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents,3
priftin is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis tb caused by mycobacterium tuberculosis11 priftin is indicated for the treatment of latent tuberculosis infection ltbi caused by m tuberculosis 12 see limitations of use 1112priftinar mycobacterium tuberculosissee dosage and administration 21clinical studies 141 limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatmentpriftin should not be used once weekly in the continuation phase regimen in combination with isoniazid inh in hivinfected patients with active pulmonary tuberculosis because of a higher rate of failure andor relapse with rifampin rifresistant organisms see warnings and precautions 53 clinical studies 141priftin has not been studied as part of the initial phase treatment regimen in hivinfected patients with active pulmonary tuberculosispriftin is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by mycobacterium tuberculosissee clinical studies 142 limitations of use active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection priftin must always be used in combination with isoniazid as a 12week onceweekly regimen for the treatment of latent tuberculosis infection see dosage and administration 22clinical studies 142 priftin in combination with isoniazid is not recommended for individuals presumed to be exposed to rifamycinresistant or isoniazidresistant m tuberculosis,3
ethambutol hci is indicated for the treatment of pulmonary tuberculosis it should not be used as the sole antituberculous drug but should be used in conjunction with at least one other antituberculous drug selection of the companion drug should be based on clinical experience considerations of comparative safety and appropriate in vitro susceptibility studies in patients who have not received previous antituberculous therapy ie initial treatment the most frequently used regimens have been the following ethambutol hci plus isoniazid ethambutol hci plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy mycobacterial resistance to other drugs used in initial therapy is frequent consequently in such retreatment patients ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies antituberculous drugs used with ethambutol hci have included cycloserine ethionamide pyrazinamide viomycin and other drugs isoniazid aminosalicylic acid and streptomycin have also been used in multiple drug regimens alternating drug regimens have also been utilized,3
sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adults 18 years and older with pulmonary multidrug resistant tuberculosis mdrtb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dotthis indication is approved under accelerated approval based on time to sputum culture conversion see clinical studies 14sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults 18 years and older with pulmonary multidrug resistant tuberculosis mdrtb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot 121this indication is approved under accelerated approval based on time to sputum culture conversion continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 114 limitations of use114 limitations of use do not use sirturo for the treatment of latent infection due to mycobacterium tuberculosisdrugsensitive tuberculosisextrapulmonary tuberculosisinfections caused by nontuberculous mycobacteriathe safety and efficacy of sirturo in the treatment of hiv infected patients with mdrtb have not been established as clinical data are limited see clinical studies 14,3
carefully consider the potential benefits and risks of naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsnaproxen as naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension is indicated for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritisnaproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patients weightnaproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated for relief of the signs and symptoms of tendonitis for relief of the signs and symptoms of bursitis for relief of the signs and symptoms of acute gout for the management of pain for the management of primary dysmenorrheaecnaprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxencontaining products see clinical pharmacology dosage and administration,3
carefully consider the potential benefits and risks of naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsnaproxen as naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension is indicated for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritisnaproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patients weightnaproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated for relief of the signs and symptoms of tendonitis for relief of the signs and symptoms of bursitis for relief of the signs and symptoms of acute gout for the management of pain for the management of primary dysmenorrheaecnaprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxencontaining products see clinical pharmacology dosage and administration,2
carefully consider the potential benefits and risks of naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsnaproxen as naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension is indicated for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritisnaproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patients weightnaproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated for relief of the signs and symptoms of tendonitis for relief of the signs and symptoms of bursitis for relief of the signs and symptoms of acute gout for the management of pain for the management of primary dysmenorrheaecnaprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxencontaining products see clinical pharmacology dosage and administration,2
known hypersensitivity to the active substancedeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney see warnings,3
mitomycin for injection usp is not recommended as singleagent primary therapy it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed mitomycin is not recommended to replace appropriate surgery andor radiotherapy,3
tepadina thiotepa is an alkylating drug indicated to reduce the risk of graft rejection when used in conjunction with highdose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor stem cell transplantation hsct for pediatric patients with class 3 betathalassemia 11 14for treatment of adenocarcinoma of the breast or ovary 12for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities 13for treatment of superficial papillary carcinoma of the urinary bladder 14tepadina is indicated to reduce the risk of graft rejection when used in conjunction with highdose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor stem cell transplantation hsct for pediatric patients with class 3 betathalassemia see clinical studies 14tepadina is indicated for treatment of adenocarcinoma of the breast or ovarytepadina is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavitiestepadina is indicated for treatment of superficial papillary carcinoma of the urinary bladder,3
etoposide injection usp is indicated in the management of the following neoplasmsetoposide injection usp in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical chemotherapeutic and radiotherapeutic therapyadequate data on the use of etoposide capsules in the treatment of testicular cancer are not availableetoposide injection usp andor capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer,3
cosmegen is an actinomycin indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen 11adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen 12adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen 13adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen 14postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen 15adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion 16cosmegen is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimencosmegen is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion,3
cosmegen is an actinomycin indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen 11adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen 12adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen 13adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen 14postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen 15adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion 16cosmegen is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimencosmegen is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion,3
cosmegen is an actinomycin indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen 11adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen 12adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen 13adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen 14postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen 15adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion 16cosmegen is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimencosmegen is indicated for the treatment of postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimencosmegen is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion,3
ifosfamide for injection is indicated for use in combination with certain other approved antineoplastic agents for thirdline chemotherapy of germ cell testicular cancer it should be used in combination with mesna for prophylaxis of hemorrhagic cystitisifosfamide for injection is an alkylating drug indicated for use in combination with certain other approved antineoplastic agents for thirdline chemotherapy of germ cell testicular cancer it should be used in combination with mesna for prophylaxis of hemorrhagic cystitis 1,3
irinotecan hydrochloride injection is indicated as a component of firstline therapy in combination with 5 fluorouracil 5fu and leucovorin lv for patients with metastatic carcinoma of the colon or rectumirinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracilbased therapyirinotecan hydrochloride injection is a topoisomerase inhibitor indicated for firstline therapy in combination with 5fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum 1patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracilbased therapy 1,3
pregnancy 4181use of simvastatin or lovastatin and cyp3a substrates with narrow therapeutic range 42concurrent longterm corticosteroid use 43women with history of unexplained vaginal bleeding 44women with endometrial hyperplasia with atypia or endometrial carcinoma 44korlym is contraindicated in women who are pregnant pregnancy must be excluded before the initiation of treatment with korlym or if treatment is interrupted for more than 14 days in females of reproductive potential nonhormonal contraceptives should be used during and one month after stopping treatment in all women of reproductive potential see use in specific populations 88korlym is contraindicated in patients taking simvastatin lovastatin and cyp3a substrates with narrow therapeutic ranges such as cyclosporine dihydroergotamine ergotamine fentanyl pimozide quinidine sirolimus and tacrolimus due to an increased risk of adverse events see drug interactions 71123korlym is contraindicated in patients who require concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses eg immunosuppression after organ transplantation because korlym antagonizes the effect of glucocorticoids korlym is contraindicated in the following women with a history of unexplained vaginal bleeding women with endometrial hyperplasia with atypia or endometrial carcinoma korlym is contraindicated in patients with prior hypersensitivity reactions to mifepristone or to any of the product components,1
valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of bcgrefractory carcinoma in situ valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of bcgrefractory carcinoma in situ 1,3
nexavar is a kinase inhibitor indicated for the treatment of 11 12 13nexavarrnexavar is indicated for the treatment of patients with advanced renal cell carcinoma rccnexavar is indicated for the treatment of patients with locally recurrent or metastatic progressive differentiated thyroid carcinoma dtc that is refractory to radioactive iodine treatment,3
nexavar is a kinase inhibitor indicated for the treatment of 11 12 13nexavarrnexavar is indicated for the treatment of patients with advanced renal cell carcinoma rccnexavar is indicated for the treatment of patients with locally recurrent or metastatic progressive differentiated thyroid carcinoma dtc that is refractory to radioactive iodine treatment,3
lysodren is indicated for the treatment of patients with inoperable functional or nonfunctional adrenal cortical carcinomalysodren is an adrenal cytotoxic agent indicated for the treatment of inoperable functional or nonfunctional adrenal cortical carcinoma 1,3
emcyt capsules are indicated in the palliative treatment of patients with metastatic andor progressive carcinoma of the prostate,3
sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 11the treatment of advanced renal cell carcinoma rcc 12the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 13the treatment of progressive welldifferentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 14sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylatesutent is indicated for the treatment of advanced renal cell carcinomasutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomysutent is indicated for the treatment of progressive welldifferentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease,3
sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 11the treatment of advanced renal cell carcinoma rcc 12the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 13the treatment of progressive welldifferentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 14sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylatesutent is indicated for the treatment of advanced renal cell carcinomasutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomysutent is indicated for the treatment of progressive welldifferentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease,3
sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 11the treatment of advanced renal cell carcinoma rcc 12the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 13the treatment of progressive welldifferentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 14sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylatesutent is indicated for the treatment of advanced renal cell carcinomasutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomysutent is indicated for the treatment of progressive welldifferentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease,3
temsirolimus injection is indicated for the treatment of advanced renal cell carcinomatemsirolimus injection is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma 1,3
temsirolimus injection is indicated for the treatment of advanced renal cell carcinomatemsirolimus injection is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma 1,3
votrientrvotrient is indicated for the treatment of patients with advanced soft tissue sarcoma sts who have received prior chemotherapy limitations of usevotrient is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma 1advanced soft tissue sarcoma who have received prior chemotherapy 1 limitations of use,3
votrientrvotrient is indicated for the treatment of patients with advanced soft tissue sarcoma sts who have received prior chemotherapy limitations of usevotrient is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma 1advanced soft tissue sarcoma who have received prior chemotherapy 1 limitations of use,3
stivarga is a kinase inhibitor indicated for the treatment of patients with 11 12 stivarga is indicated for the treatment of patients with metastatic colorectal cancer crc who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf therapy and if ras wild type an antiegfr therapystivarga is indicated for the treatment of patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor gist who have been previously treated with imatinib mesylate and sunitinib malatestivarga is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib,3
stivarga is a kinase inhibitor indicated for the treatment of patients with 11 12 stivarga is indicated for the treatment of patients with metastatic colorectal cancer crc who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antivegf therapy and if ras wild type an antiegfr therapystivarga is indicated for the treatment of patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor gist who have been previously treated with imatinib mesylate and sunitinib malatestivarga is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib,3
medullary thyroid carcinomatanzeum is contraindicated in patients with a personal or family history of medullary thyroid carcinoma mtc or in patients with multiple endocrine neoplasia syndrome type 2 men 2 see warnings and precautions 51 hypersensitivitytanzeum is contraindicated in patients with a prior serious hypersensitivity reaction to albiglutide or to any of the product components serious hypersensitivity reactions including angioedema have been reported with tanzeum see warnings and precautions 54 4 454,1
temozolomide capsules are an alkylating drug indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme gbm concomitantly with radiotherapy and then as maintenance treatment 11refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine 12temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatmenttemozolomide capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma ie patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine,3
temozolomide capsules are an alkylating drug indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme gbm concomitantly with radiotherapy and then as maintenance treatment 11refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine 12temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatmenttemozolomide capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma ie patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine,3
bronchial asthma a history of bronchial asthma severe chronic obstructive pulmonary disease 415153sinus bradycardia second or third degree atrioventricular block overt cardiac failure cardiogenic shock 4252hypersensitivity to any component of this product 43timolol maleate ophthalmic solution is contraindicated in patients with bronchial asthma a history of bronchial asthma severe chronic obstructive pulmonary disease see warnings and precautions5153timolol maleate ophthalmic solution is contraindicated in patients with sinus bradycardia second or third degree atrioventricular block overt cardiac failure see warnings and precautions52timolol maleate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past,0
carteolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma or severe chronic obstructive pulmonary disease see warningswarnings,0
levobunolol hcl ophthalmic solution is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma or severe chronic obstructive pulmonary disease see warningswarnings,1
striverdi respimat inhalation spray is a longacting beta2 11important limitations striverdi respimat is not indicated to treat acute deterioration of copd 12striverdi respimat is not indicated to treat asthma 12striverdi respimat is a longacting beta2striverdi respimat is not indicated to treat acute deteriorations of copd see warnings and precautions 52striverdi respimat is not indicated to treat asthma the safety and effectiveness of striverdi respimat in asthma have not been established,1
serevent diskus is a laba indicated for treatment of asthma in patients aged 4 years and older 11prevention of exerciseinduced bronchospasm eib in patients aged 4 years and older 12maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd 13important limitation not indicated for the relief of acute bronchospasm 11 13 serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a longterm asthma control medication such as an inhaled corticosteroid in patients aged 4 years and older with reversible obstructive airway disease including patients with symptoms of nocturnal asthma laba such as salmeterol the active ingredient in serevent diskus increase the risk of asthmarelated death see warnings and precautions 51see contraindications 4 pediatric and adolescent patients important limitation of use serevent diskus is also indicated for prevention of exerciseinduced bronchospasm eib in patients aged 4 years and older use of serevent diskus as a single agent for the prevention of eib may be clinically indicated in patients who do not have persistent asthma in patients with persistent asthma use of serevent diskus for the prevention of eib may be clinically indicated but the treatment of asthma should include a longterm asthma control medication such as an inhaled corticosteroidserevent diskus is indicated for the longterm twicedaily morning and evening administration in the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including emphysema and chronic bronchitis important limitation of use,3
serevent diskus is a laba indicated for treatment of asthma in patients aged 4 years and older 11prevention of exerciseinduced bronchospasm eib in patients aged 4 years and older 12maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd 13important limitation not indicated for the relief of acute bronchospasm 11 13 serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a longterm asthma control medication such as an inhaled corticosteroid in patients aged 4 years and older with reversible obstructive airway disease including patients with symptoms of nocturnal asthma laba such as salmeterol the active ingredient in serevent diskus increase the risk of asthmarelated death see warnings and precautions 51see contraindications 4 pediatric and adolescent patients important limitation of use serevent diskus is also indicated for prevention of exerciseinduced bronchospasm eib in patients aged 4 years and older use of serevent diskus as a single agent for the prevention of eib may be clinically indicated in patients who do not have persistent asthma in patients with persistent asthma use of serevent diskus for the prevention of eib may be clinically indicated but the treatment of asthma should include a longterm asthma control medication such as an inhaled corticosteroidserevent diskus is indicated for the longterm twicedaily morning and evening administration in the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including emphysema and chronic bronchitis important limitation of use,3
brovana inhalation solution is a longacting beta22 longterm twice daily morning and evening administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema 11important limitations of use brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease 1252brovana inhalation solution is not indicated to treat asthma 12brovana arformoterol tartrate inhalation solution is indicated for the longterm twice daily morning and evening maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema brovana inhalation solution is for use by nebulization only brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease see warnings and precautions 52brovana inhalation solution is not indicated to treat asthma the safety and effectiveness of brovana inhalation solution in asthma have not been established,2
tudorzar pressairr aclidinium bromide inhalation powder is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease copdtudorza pressair is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease copd 1,3
incruse ellipta is indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysemaincruse ellipta is an anticholinergic indicated for the longterm oncedaily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd 1,3
fluocinolone acetonide 001 topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients 11 topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks 12 limitations of use apply the least amount to cover affected areas discontinue when disease is controlled 13 do not use in the diaper area 13 do not use on the face axillae or groin 136284fluocinolone acetonide 001 topical oil is indicated for the topical treatment of atopic dermatitis in adult patientsfluocinolone acetonide 001 topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks safety and effectiveness in pediatric patients younger than 3 months of age have not been establishedapply the least amount of fluocinolone acetonide 001 topical oil needed to cover the affected areas as with other corticosteroids fluocinolone acetonide 001 topical oil should be discontinued when control of disease is achieved contact the physician if no improvement is seen within 2 weeksfluocinolone acetonide 001 topical oil should not be applied to the diaper area diapers or plastic pants may constitute occlusive usefluocinolone acetonide 001 topical oil should not be used on the face axillae or groin unless directed by the physician application to intertriginous areas should be avoided due to the increased risk of local adverse reactions see adverse reactions 6 and use in specific populations 84,3
lamotrigine tablets are indicated for epilepsyadjunctive therapy in patients aged 2 years and older partialonset seizuresprimary generalized tonicclonic seizuresgeneralized seizures of lennoxgastaut syndrome 11 epilepsymonotherapy in patients aged 16 years and older11 bipolar disorder12 limitations of use treatment of acute manic or mixed episodes is not recommended effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established adjunctive therapy lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older partialonset seizuresprimary generalized tonicclonic pgtc seizuresgeneralized seizures of lennoxgastaut syndrome monotherapy lamotrigine tablets are indicated for conversion to monotherapy in adults aged 16 years and older with partialonset seizures who are receiving treatment with carbamazepine phenytoin phenobarbital primidone or valproate as the single antiepileptic drug aed safety and effectiveness of lamotrigine tablets have not been established 1 as initial monotherapy 2 for conversion to monotherapy from aeds other than carbamazepine phenytoin phenobarbital primidone or valproate or 3 for simultaneous conversion to monotherapy from 2 or more concomitant aeds lamotrigine tablets are indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in patients treated for acute mood episodes with standard therapy see clinical studies lamotrigine tablets are indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in patients treated for acute mood episodes with standard therapy see clinical studies 141 limitations of use treatment of acute manic or mixed episodes is not recommended effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been establishedtreatment of acute manic or mixed episodes is not recommended effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established,3
lithium carbonate extendedrelease tablets are indicated in the treatment of manic episodes of bipolar disorder bipolar disorder manic dsmiv is equivalent to manic depressive illness manic in the older dsmii terminology lithium carbonate extendedrelease tablets are also indicated as a maintenance treatment for individuals with a diagnosis of bipolar disorder maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occurtypical symptoms of mania include pressure of speech motor hyperactivity reduced need for sleep flight of ideas grandiosity elation poor judgment aggressiveness and possibly hostility when given to a patient experiencing a manic episode lithium may produce a normalization of symptomatology within 1 to 3 weeks,3
riluzole tablets usp is indicated for the treatment of amyotrophic lateral sclerosis alsriluzole tablets usp is indicated for the treatment of amyotrophic lateral sclerosis als 1,3
ticlopidine hydrochloride tablets usp are indicated to reduce the risk of thrombotic stroke fatal or nonfatal in patients who have experienced stroke precursors and in patients who have had a completed thrombotic stroke because ticlopidine is associated with a risk of lifethreatening blood dyscrasias including thrombotic thrombocytopenic purpura ttp neutropeniaagranulocytosis and aplastic anemia see and ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy boxed warningwarningsas adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation see clinical trials,0
leucovorin calcium for injection rescue is indicated after highdose methotrexate therapy in osteosarcoma leucovorin calcium for injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists leucovorin calcium for injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible leucovorin calcium for injection is also indicated for use in combination with 5fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer leucovorin calcium for injection should not be mixed in the same infusion as 5fluorouracil because a precipitate may form,3
halaven is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting 11unresectable or metastatic liposarcoma who have received a prior anthracyclinecontaining regimen 12halaven is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting see clinical studies 141halaven is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclinecontaining regimen see clinical studies 142,3
nitroglycerin lingual aerosol is indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery diseasenitroglycerin lingual aerosol is a nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease 1,2
isosorbide dinitrate sublingual tablets are indicated for the prevention and treatment of angina pectoris due to coronary artery disease however because the onset of action of sublingual isdn is significantly slower than that of sublingual nitroglycerin sublingual isdn is not the drug of first choice for abortion of an acute anginal episode,3
dipyridamole injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately in a study of about 1100 patients who underwent coronary arteriography and dipyridamole injection assisted thallium imaging the results of both tests were interpreted blindly and the sensitivity and specificity of the dipyridamole thallium study in predicting the angiographic outcome were calculated the sensitivity of the dipyridamole test true positive dipyridamole divided by the total number of patients with positive angiography was about 85 the specificity true negative divided by the number of patients with negative angiograms was about 50in a subset of patients who had exercise thallium imaging as well as dipyridamole thallium imaging sensitivity and specificity of the two tests were almost identical,3
isosorbide mononitrate tablets usp are indicated for the prevention and treatment of angina pectoris due to coronary artery disease the onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode,3
vinblastine sulfate injection is indicated in the palliative treatment of the following i frequently responsive malignancies generalized hodgkins disease stages iii and iv ann arbor modification of rye staging system lymphocytic lymphoma nodular and diffuse poorly and well differentiatedhistiocytic lymphomamycosis fungoides advanced stages advanced carcinoma of the testiskaposis sarcomaletterersiwe disease histiocytosis x ii less frequently responsive malignancies choriocarcinoma resistant to other chemotherapeutic agentscarcinoma of the breast unresponsive to appropriate endocrine surgery and hormonal therapycurrent principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents for enhanced therapeutic effect without additive toxicity agents with different doselimiting clinical toxicities and different mechanisms of action are generally selected therefore although vinblastine sulfate is effective as a single agent in the aforementioned indications it is usually administered in combination with other antineoplastic drugs such combination therapy produces a greater percentage of response than does a singleagent regimen these principles have been applied for example in the chemotherapy of hodgkins diseasevinblastine sulfate has been shown to be one of the most effective single agents for the treatment of hodgkins disease advanced hodgkins disease has also been successfully treated with several multipledrug regimens that included vinblastine sulfate patients who had relapses after treatment with the mopp program mechlorethamine hydrochloride nitrogen mustard vincristine sulfate prednisone and procarbazinehave likewise responded to combinationdrug therapy that included vinblastine sulfate a protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced hodgkins disease advanced testicular germinalcell cancers embryonal carcinoma teratocarcinoma and choriocarcinoma are sensitive to vinblastine sulfate alone but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents the effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin this schedule permits more cells to be arrested during metaphase the stage of the cell cycle in which bleomycin is active,3
vinblastine sulfate injection is indicated in the palliative treatment of the following i frequently responsive malignancies generalized hodgkins disease stages iii and iv ann arbor modification of rye staging system lymphocytic lymphoma nodular and diffuse poorly and well differentiatedhistiocytic lymphomamycosis fungoides advanced stages advanced carcinoma of the testiskaposis sarcomaletterersiwe disease histiocytosis x ii less frequently responsive malignancies choriocarcinoma resistant to other chemotherapeutic agentscarcinoma of the breast unresponsive to appropriate endocrine surgery and hormonal therapycurrent principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents for enhanced therapeutic effect without additive toxicity agents with different doselimiting clinical toxicities and different mechanisms of action are generally selected therefore although vinblastine sulfate is effective as a single agent in the aforementioned indications it is usually administered in combination with other antineoplastic drugs such combination therapy produces a greater percentage of response than does a singleagent regimen these principles have been applied for example in the chemotherapy of hodgkins diseasevinblastine sulfate has been shown to be one of the most effective single agents for the treatment of hodgkins disease advanced hodgkins disease has also been successfully treated with several multipledrug regimens that included vinblastine sulfate patients who had relapses after treatment with the mopp program mechlorethamine hydrochloride nitrogen mustard vincristine sulfate prednisone and procarbazinehave likewise responded to combinationdrug therapy that included vinblastine sulfate a protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced hodgkins disease advanced testicular germinalcell cancers embryonal carcinoma teratocarcinoma and choriocarcinoma are sensitive to vinblastine sulfate alone but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents the effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin this schedule permits more cells to be arrested during metaphase the stage of the cell cycle in which bleomycin is active,3
vinblastine sulfate injection is indicated in the palliative treatment of the following i frequently responsive malignancies generalized hodgkins disease stages iii and iv ann arbor modification of rye staging system lymphocytic lymphoma nodular and diffuse poorly and well differentiatedhistiocytic lymphomamycosis fungoides advanced stages advanced carcinoma of the testiskaposis sarcomaletterersiwe disease histiocytosis x ii less frequently responsive malignancies choriocarcinoma resistant to other chemotherapeutic agentscarcinoma of the breast unresponsive to appropriate endocrine surgery and hormonal therapycurrent principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents for enhanced therapeutic effect without additive toxicity agents with different doselimiting clinical toxicities and different mechanisms of action are generally selected therefore although vinblastine sulfate is effective as a single agent in the aforementioned indications it is usually administered in combination with other antineoplastic drugs such combination therapy produces a greater percentage of response than does a singleagent regimen these principles have been applied for example in the chemotherapy of hodgkins diseasevinblastine sulfate has been shown to be one of the most effective single agents for the treatment of hodgkins disease advanced hodgkins disease has also been successfully treated with several multipledrug regimens that included vinblastine sulfate patients who had relapses after treatment with the mopp program mechlorethamine hydrochloride nitrogen mustard vincristine sulfate prednisone and procarbazinehave likewise responded to combinationdrug therapy that included vinblastine sulfate a protocol using cyclophosphamide in place of nitrogen mustard and vinblastine sulfate instead of vincristine sulfate is an alternative therapy for previously untreated patients with advanced hodgkins disease advanced testicular germinalcell cancers embryonal carcinoma teratocarcinoma and choriocarcinoma are sensitive to vinblastine sulfate alone but better clinical results are achieved when vinblastine sulfate is administered concomitantly with other antineoplastic agents the effect of bleomycin is significantly enhanced if vinblastine sulfate is administered six to eight hours prior to the administration of bleomycin this schedule permits more cells to be arrested during metaphase the stage of the cell cycle in which bleomycin is active,3
paclitaxel injection usp is indicated as firstline and subsequent therapy for the treatment of advanced carcinoma of the ovary as firstline therapy paclitaxel injection usp is indicated in combination with cisplatinpaclitaxel injection usp is indicated for the adjuvant treatment of nodepositive breast cancer administered sequentially to standard doxorubicincontaining combination chemotherapy in the clinical trial there was an overall favorable effect on diseasefree and overall survival in the total population of patients with receptorpositive and receptornegative tumors but the benefit has been specifically demonstrated by available data median followup 30 months only in the patients with estrogen and progesterone receptornegative tumors see clinical studies breast carcinomapaclitaxel injection usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy prior therapy should have included an anthracycline unless clinically contraindicatedpaclitaxel injection usp in combination with cisplatin is indicated for the firstline treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery andor radiation therapypaclitaxel injection usp is indicated for the secondline treatment of aidsrelated kaposis sarcoma,3
paclitaxel injection usp is indicated as firstline and subsequent therapy for the treatment of advanced carcinoma of the ovary as firstline therapy paclitaxel injection usp is indicated in combination with cisplatinpaclitaxel injection usp is indicated for the adjuvant treatment of nodepositive breast cancer administered sequentially to standard doxorubicincontaining combination chemotherapy in the clinical trial there was an overall favorable effect on diseasefree and overall survival in the total population of patients with receptorpositive and receptornegative tumors but the benefit has been specifically demonstrated by available data median followup 30 months only in the patients with estrogen and progesterone receptornegative tumors see clinical studies breast carcinomapaclitaxel injection usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy prior therapy should have included an anthracycline unless clinically contraindicatedpaclitaxel injection usp in combination with cisplatin is indicated for the firstline treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery andor radiation therapypaclitaxel injection usp is indicated for the secondline treatment of aidsrelated kaposis sarcoma,3
sotradecol sodium tetradecyl sulfate injection is contraindicated in previous hypersensitivity reactions to the drug in acute superficial thrombophlebitis valvular or deep vein incompetence huge superficial veins with wide open communications to deeper veins phlebitis migrans acute cellulitis allergic conditions acute infections varicosities caused by abdominal and pelvic tumors unless the tumor has been removed bedridden patients such uncontrolled systemic diseases as diabetes toxic hyperthyroidism tuberculosis asthma neoplasm sepsis blood dyscrasias and acute respiratory or skin diseases,1
flavoxate hcl tablets are contraindicated in patients who have any of the following obstructive conditions pyloric or duodenal obstruction obstructive intestinal lesions or ileus achalasia gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract,1
prostin e2 vaginal suppository is indicated for the termination of pregnancy from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual periodprostin e2 is also indicated for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual periodprostin e2 is indicated in the management of nonmetastatic gestational trophoblastic disease benign hydatidiform mole,3
pentoxifylline extendedrelease tablets usp are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs pentoxifylline extendedrelease tablets can improve function and symptoms but is not intended to replace more definitive therapy such as surgical bypass or removal of arterial obstructions when treating peripheral vascular disease,3
cilostazol tablets usp are indicated for the reduction of symptoms of intermittent claudication as demonstrated by an increased walking distancecilostazol tablets usp are a phosphodiesterase iii inhibitor pde iii inhibitor indicated for the reduction of symptoms of intermittent claudication as demonstrated by an increased walking distance 1,2
intravenous adenosine injection usp is indicated for the followingconversion to sinus rhythm of paroxysmal supraventricular tachycardia psvt including that associated with accessory bypass tracts wolffparkinsonwhite syndrome when clinically advisable appropriate vagal maneuvers eg valsalva maneuver should be attempted prior to adenosine injection usp administrationit is important to be sure the adenosine injection usp solution actually reaches the systemic circulation see dosage and administrationadenosine injection usp does not convert atrial flutter atrial fibrillation or ventricular tachycardia to normal sinus rhythm in the presence of atrial flutter or atrial fibrillation a transient modest slowing of ventricular response may occur immediately following adenosine injection usp administration,3
panhematin is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women after initial carbohydrate therapy is known or suspected to be inadequate limitations of use see dosage and administration 21 panhematin is a hemin for injection indicated for amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women after initial carbohydrate therapy is known or suspected to be inadequate 1 limitations of use 1 1,2
carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate acute intermittent porphyria 4hypersensitivity reactions to a carbamate such as meprobamate 4,1
gemcitabine for injection is a nucleoside metabolic inhibitor indicated in combination with carboplatin for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy 11 in combination with paclitaxel for firstline treatment of metastatic breast cancer after failure of prior anthracyclinecontaining adjuvant chemotherapy unless anthracyclines were clinically contraindicated 12in combination with cisplatin for the treatment of nonsmall cell lung cancer 13as a single agent for the treatment of pancreatic cancer 14 gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapygemcitabine for injection in combination with paclitaxel is indicated for the firstline treatment of patients with metastatic breast cancer after failure of prior anthracyclinecontaining adjuvant chemotherapy unless anthracyclines were clinically contraindicatedgemcitabine for injection is indicated in combination with cisplatin for the firstline treatment of patients with inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancergemcitabine for injection is indicated as firstline treatment for patients with locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas gemcitabine for injection is indicated for patients previously treated with 5fu,3
gemcitabine for injection is a nucleoside metabolic inhibitor indicated in combination with carboplatin for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapy 11 in combination with paclitaxel for firstline treatment of metastatic breast cancer after failure of prior anthracyclinecontaining adjuvant chemotherapy unless anthracyclines were clinically contraindicated 12in combination with cisplatin for the treatment of nonsmall cell lung cancer 13as a single agent for the treatment of pancreatic cancer 14 gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinumbased therapygemcitabine for injection in combination with paclitaxel is indicated for the firstline treatment of patients with metastatic breast cancer after failure of prior anthracyclinecontaining adjuvant chemotherapy unless anthracyclines were clinically contraindicatedgemcitabine for injection is indicated in combination with cisplatin for the firstline treatment of patients with inoperable locally advanced stage iiia or iiib or metastatic stage iv nonsmall cell lung cancergemcitabine for injection is indicated as firstline treatment for patients with locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas gemcitabine for injection is indicated for patients previously treated with 5fu,3
alimtar in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic nonsquamous nsclc with no egfr or alk genomic tumor aberrations 11in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer nsclc 11as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous nsclc whose disease has not progressed after four cycles of platinumbased firstline chemotherapy 11as a single agent for the treatment of patients with recurrent metastatic nonsquamous nsclc after prior chemotherapy 11limitations of use11initial treatment in combination with cisplatin of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery 12alimtar in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer nsclc as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous nsclc whose disease has not progressed after four cycles of platinumbased firstline chemotherapy as a single agent for the treatment of patients with recurrent metastatic nonsquamous nsclc after prior chemotherapy limitations of usesee clinical studies 141alimta is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery,3
alimtar in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic nonsquamous nsclc with no egfr or alk genomic tumor aberrations 11in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer nsclc 11as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous nsclc whose disease has not progressed after four cycles of platinumbased firstline chemotherapy 11as a single agent for the treatment of patients with recurrent metastatic nonsquamous nsclc after prior chemotherapy 11limitations of use11initial treatment in combination with cisplatin of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery 12alimtar in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer nsclc as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous nsclc whose disease has not progressed after four cycles of platinumbased firstline chemotherapy as a single agent for the treatment of patients with recurrent metastatic nonsquamous nsclc after prior chemotherapy limitations of usesee clinical studies 141alimta is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery,3
iressa is indicated for the firstline treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test see clinical studies 14limitation of use safety and efficacy of iressa have not been established in patients with metastatic nsclc whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations see clinical studies 14iressa is a tyrosine kinase inhibitor indicated for the firstline treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test 1limitation of use safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 l858r substitution mutations 1,3
vinorelbine injection usp is indicated in combination with cisplatin for firstline treatment of patients with locally advanced or metastatic nonsmall cell lung cancer nsclcas a single agent for the treatment of patients with metastatic nsclc vinorelbine injection usp is a vinca alkaloid indicated in combination with cisplatin for firstline treatment of patients with locally advanced or metastatic nonsmall cell lung cancer nsclc 1 as a single agent for firstline treatment of patients with metastatic nsclc 1,3
docetaxel injection is a microtubule inhibitor indicated for breast cancer bc single agent for locally advanced or metastatic bc after chemotherapy failure and with doxorubicin and cyclophosphamide as adjuvant treatment of operable nodepositive bc 11nonsmall cell lung cancer nsclc single agent for locally advanced or metastatic nsclc after platinum therapy failure and with cisplatin for unresectable locally advanced or metastatic untreated nsclc 12hormone refractory prostate cancer hrpc with prednisone in androgen independent hormone refractory metastatic prostate cancer 13gastric adenocarcinoma gc with cisplatin and fluorouracil for untreated advanced gc including the gastroesophageal junction 14squamous cell carcinoma of the head and neck cancer scchn with cisplatin and fluorouracil for induction treatment of locally advanced scchn 15docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapydocetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancerdocetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapydocetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable locally advanced or metastatic nonsmall cell lung cancer who have not previously received chemotherapy for this condition docetaxel injection in combination with prednisone is indicated for the treatment of patients with androgen independent hormone refractory metastatic prostate cancer docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction who have not received prior chemotherapy for advanced disease docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck scchn,3
cyramzar as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinumcontaining chemotherapy 11in combination with docetaxel for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to receiving cyramza 12in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 13as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 400 ngml and have been treated with sorafenib 14cyramzarcyramza in combination with docetaxel is indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with disease progression on or after platinumbased chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine,3
portrazzatm is an epidermal growth factor receptor egfr antagonist indicated in combination with gemcitabine and cisplatin for firstline treatment of patients with metastatic squamous nonsmall cell lung cancer 11limitation of use portrazza is not indicated for treatment of nonsquamous nonsmall cell lung cancer 1256142portrazzatm is indicated in combination with gemcitabine and cisplatin for firstline treatment of patients with metastatic squamous nonsmall cell lung cancer portrazza is not indicated for treatment of nonsquamous nonsmall cell lung cancer see warnings and precautions 56142,3
korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery limitations of use korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to cushings syndrome korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery 1 important limitations of use,3
korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery limitations of use korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to cushings syndrome korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery 1 important limitations of use,2
korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery limitations of use korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to cushings syndrome korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery 1 important limitations of use,3
do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease possibly due to routine immunization patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease,0
do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease possibly due to routine immunization patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease,0
do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying condition possibly due to routine immunization children with nephrotic syndrome should not receive injections due to immunization exacerbating nephrotic diseases allergenic extracts are not intended for diagnosing patients who do not manifest immediate hypersensitivity reactions to the allergenic extract when skin tested,0
do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying condition possibly due to routine immunization children with nephrotic syndrome should not receive injections due to immunization exacerbating nephrotic diseases allergenic extracts are not intended for diagnosing patients who do not manifest immediate hypersensitivity reactions to the allergenic extract when skin tested,1
do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease possibly due to routine immunization patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease,1
inlyta is indicated for the treatment of advanced renal cell carcinoma rcc after failure of one prior systemic therapyinlyta is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy 1,3
cabometyx is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma rcc 11patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib 12cabometyx is indicated for the treatment of patients with advanced renal cell carcinoma rcc cabometyx is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib,3
fluorescitersee warnings and precautions 51adverse reactions 6fluorescein sodium can induce serious intolerance reactions these reactions of intolerance are always unpredictable but they are more frequent in patients who have previously experienced an adverse reaction after fluorescein injection symptoms other than nausea and vomiting or in patients with history of allergy such as food or drug induced urticaria asthma eczema allergic rhinitisdetailed questioning of each patient is recommended before the angiography to evaluate any prior history of allergyfluoresciter41,0
cetirizine hydrochloride syrup is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites animal dander and molds in children 6 to 23 months of age symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus and tearing cetirizine hydrochloride syrup is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months to 5 years of age it significantly reduces the occurrence severity and duration of hives and significantly reduces pruritus,2
desloratadine is a histamine1 h1 receptor antagonist indicated for seasonal allergic rhinitis perennial allergic rhinitis chronic idiopathic urticariadesloratadine tablets are indicated for the relief of the nasal and nonnasal symptoms of seasonal allergic rhinitis in patients 12 years of age and olderdesloratadine tablets are indicated for the relief of the nasal and nonnasal symptoms of perennial allergic rhinitis in patients 12 years of age and olderdesloratadine tablets are indicated for the symptomatic relief of pruritus reduction in the number of hives and size of hives in patients with chronic idiopathic urticaria 12 years of age and older,3
azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and olderazelastine hydrochloride nasal spray is an h1receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older 1,2
azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and olderazelastine hydrochloride nasal spray is an h1receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older 1,2
clemastine fumarate tablets 134 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and lacrimationclemastine fumarate tablets 268 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and lacrimation clemastine fumarate tablets 268 mg are also indicated for the relief of mild uncomplicated allergic skin manifestations of urticaria and angioedemait should be noted that clemastine fumarate is indicated for the dermatologic indications at the 268 mg dosage level only,2
perennial and seasonal allergic rhinitis newborn or premature infants nursing mothers other conditions pediatric patientsoverdosage cns depressants activities requiring mental alertness general information for patients drug interactions carcinogenesis mutagenesis impairment of fertility pregnancypregnancy category b nursing mothers pediatric use geriatric useadverse reactions which have been reported with the use of antihistamines are as followscentral nervous system integumentary special senses cardiovascular hematologic genitourinary respiratory miscellaneousantihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in pediatric patients also atropinelike signs and symptoms dry mouth fixed dilated pupils flushing etc as well as gastrointestinal symptoms may occur50dosage should be individualized according to the needs and the response of the patient pediatric patientsage 2 to 6 years age 7 to 14 years adultscyproheptadine hydrochloride tablets usp 4 mg are available as white to offwhite round convex tablets engraved it above bisect and 68 below bisect on one side with other side is plain containing 4 mg of cyproheptadine hcl packaged in bottles of 100 and 1000 tabletspharmacist dispense in a wellclosed container as defined in the usp with a childresistant closure as requiredmanufactured forusa,1
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies runny nose sneezing itchy watery eyes itching of the nose or throat,2
karbinal er extendedrelease oral suspension is an h1 seasonal and perennial allergic rhinitisvasomotor rhinitisallergic conjunctivitis due to inhalant allergens and foodsmild uncomplicated allergic skin manifestations of urticaria and angioedemadermatographismas therapy for anaphylactic reactions adjunctiveamelioration of the severity of allergic reactions to blood or plasmakarbinal er carbinoxamine maleate extendedrelease oral suspension is an h1 seasonal and perennial allergic rhinitis 1vasomotor rhinitis 1allergic conjunctivitis due to inhalant allergens and foods 1mild uncomplicated allergic skin manifestations of urticaria and angioedema 1dermatographism 1as therapy for anaphylactic reactions adjunctive1amelioration of the severity of allergic reactions to blood or plasma 1,3
karbinal er extendedrelease oral suspension is an h1 seasonal and perennial allergic rhinitisvasomotor rhinitisallergic conjunctivitis due to inhalant allergens and foodsmild uncomplicated allergic skin manifestations of urticaria and angioedemadermatographismas therapy for anaphylactic reactions adjunctiveamelioration of the severity of allergic reactions to blood or plasmakarbinal er carbinoxamine maleate extendedrelease oral suspension is an h1 seasonal and perennial allergic rhinitis 1vasomotor rhinitis 1allergic conjunctivitis due to inhalant allergens and foods 1mild uncomplicated allergic skin manifestations of urticaria and angioedema 1dermatographism 1as therapy for anaphylactic reactions adjunctive1amelioration of the severity of allergic reactions to blood or plasma 1,3
karbinal er extendedrelease oral suspension is an h1 seasonal and perennial allergic rhinitisvasomotor rhinitisallergic conjunctivitis due to inhalant allergens and foodsmild uncomplicated allergic skin manifestations of urticaria and angioedemadermatographismas therapy for anaphylactic reactions adjunctiveamelioration of the severity of allergic reactions to blood or plasmakarbinal er carbinoxamine maleate extendedrelease oral suspension is an h1 seasonal and perennial allergic rhinitis 1vasomotor rhinitis 1allergic conjunctivitis due to inhalant allergens and foods 1mild uncomplicated allergic skin manifestations of urticaria and angioedema 1dermatographism 1as therapy for anaphylactic reactions adjunctive1amelioration of the severity of allergic reactions to blood or plasma 1,3
mometasone furoate monohydrate nasal spray is a corticosteroid indicated for1 treatment of nasal symptoms of allergic rhinitis in patients 2 years of age 112 treatment of nasal congestion associated with seasonal allergic rhinitis in patients 2 years of age 123 prophylaxis of seasonal allergic rhinitis in patients 12 years of age 134 treatment of nasal polyps in patients 18 years of age 14mometasone furoate monohydrate nasal spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis in adults and pediatric patients 2 years of age and oldermometasone furoate monohydrate nasal spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis in adults and pediatric patients 2 years of age and oldermometasone furoate monohydrate nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and oldermometasone furoate monohydrate nasal spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older,2
fexofenadine hydrochloride is an h1receptor antagonist indicated for relief of symptoms associated with seasonal allergic rhinitis in patients 6 years of age and older 11 treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in patients 6 years of age and older 12fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 of age and older,2
omnaris nasal spray is a corticosteroid indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults and adolescents 12 years of age and older 1112omnaris nasal spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older omnaris nasal spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older,3
enter section text herelevocetirizine dihydrochloride tablets are a histamine h1 the relief of symptoms associated with seasonal and perennial allergic rhinitis 1112the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria 13levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older pediatric use information in pediatric patients age 2 to 5 years with seasonal allergic rhinitis is approved for ucb incs levocetirizine dihydrochloride drug product however due to ucb incs marketing exclusivity rights this drug product is not labeled for such use in those pediatric patientslevocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older pediatric use information in pediatric patients age 6 months to 5 years with perennial allergic rhinitis is approved for ucb incs levocetirizine dihydrochloride drug product however due to ucb incs marketing exclusivity rights this drug product is not labeled for such use in those pediatric patientslevocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older pediatric use information in pediatric patients age 6 months to 5 years with chronic idiopathic urticaria is approved for ucb incs levocetirizine dihydrochloride drug product however due to ucb incs marketing exclusivity rights this drug product is not labeled for such use in those pediatric patients,2
trifluridine ophthalmic solution 1 trifluridine ophthalmic solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2,3
trifluridine ophthalmic solution 1 trifluridine ophthalmic solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2,3
januvia is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 11 januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis 12januvia has not been studied in patients with a history of pancreatitis 1251januvia1see clinical studies 14januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings januvia has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia see warnings and precautions 51,1
januvia is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 11 januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis 12januvia has not been studied in patients with a history of pancreatitis 1251januvia1see clinical studies 14januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings januvia has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia see warnings and precautions 51,3
tradjenta is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 11important limitations of use should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis 12has not been studied in patients with a history of pancreatitis 12tradjenta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 141tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settingstradjenta has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using tradjenta see warnings and precautions 51,1
tradjenta is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 11important limitations of use should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis 12has not been studied in patients with a history of pancreatitis 12tradjenta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 141tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settingstradjenta has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using tradjenta see warnings and precautions 51,3
chenodiol is contraindicated in the presence of know hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis primary biliary cirrhosis or sclerosing cholangitits see warnings a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye radiopaque stones or gallstone complications or compelling reasons for gallbladder surgery including unremitting acute cholecystitis cholangitis biliary obstruction gallstone pancreatitis or biliary gastrointestinal fistula pregnancy category xchenodiol may cause fetal harm when administered to a pregnant woman serious hepatic renal and adrenal lesions occurred in fetuses of female rhesus monkeys given 60 to 90 mgkgday 4 to 6 times the maximum recommended human dose mrhd from day 21 to day 45 of pregnancy hepatic lesions also occurred in neonatal baboons whose mothers had received 18 to 38 mgkg 1 to 2 times the mrhd all during pregnancy fetal malformations were not observed neither fetal liver damage nor fetal abnormalities occurred in reproduction studies in rats and hamsters no human data are available at this time chenodiol is contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus,0
acarbose tablets are contraindicated in patients with known hypersensitivity to the drug acarbose tablets are also contraindicated in patients with diabetic ketoacidosis or cirrhosis acarbose tablets are also contraindicated in patients with inflammatory bowel disease colonic ulceration partial intestinal obstruction or in patients predisposed to intestinal obstruction in addition acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine,2
streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below mycobacterium tuberculosis the advisory council for the elimination of tuberculosis the american thoracic society and the center for disease control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid inh rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of inh or rifampin resistance is very low the need for a fourth drug should be reassessed when the results of susceptibility testing are known in the past when the national rate of primary drug resistance to isoniazid was known to be less than 4 and was either stable or declining therapy with two and three drug regimens was considered adequate if community rates of inh resistance are currently less than 4 an initial treatment regimen with less than four drugs may be considered streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance the management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant hiv infection additional consultation from experts in the treatment of tuberculosis may be desirable in those settings nontuberculosis infections the use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents pasteurella pestis francisella tularensis brucella calymmatobacterium granulomatis h ducreyi h influenzae k pneumoniae ecoli proteus a aerogenes k pneumoniae and enterococcus faecalis streptococcus enterococcus faecalis gramnegative bacillary bacteremia concomitantly with another antibacterial agentto reduce the development of drugresistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,0
mavenclad is contraindicated in patients with current malignancy see warnings and precautions 51in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception during mavenclad dosing and for 6 months after the last dose in each treatment course may cause fetal harm see warnings and precautions 52use in specific populations 8183in patients infected with the human immunodeficiency virus hiv see warnings and precautions 54in patients with active chronic infections eg hepatitis or tuberculosis see warnings and precautions 54in patients with a history of hypersensitivity to cladribine see warnings and precautions 58in women intending to breastfeed on a mavenclad treatment day and for 10 days after the last dose see use in specific populations 82 patients with current malignancy 4pregnant women and women and men of reproductive potential who do not plan to use effective contraception during mavenclad dosing and for 6 months after the last dose in each treatment course 483hiv infection 4active chronic infections eg hepatitis or tuberculosis 4history of hypersensitivity to cladribine 458women intending to breastfeed on a mavenclad treatment day and for 10 days after the last dose 482,1
nebupent is indicated for the prevention of pneumocystis jirovecii a history of one or more episodes of pjpii a peripheral cd4 t4 helperinducer lymphocyte count less than or equal to 200mm3these indications are based on the results of an 18month randomized doseresponse trial in high risk hivinfected patients and on existing epidemiological data from natural history studiesthe patient population of the controlled trial consisted of 408 patients 237 of whom had a history of one or more episodes of pjp the remaining patients without a history of pjp included 55 patients with kaposis sarcoma and 116 patients with other aids diagnoses arc or asymptomatic hiv infection patients were randomly assigned to receive nebupent via the respirgardrthe results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of nebupent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeksno doseresponse was observed for reduction in overall mortality however mortality from pjp was low in all three dosage groups,3
nebupent is indicated for the prevention of pneumocystis jirovecii a history of one or more episodes of pjpii a peripheral cd4 t4 helperinducer lymphocyte count less than or equal to 200mm3these indications are based on the results of an 18month randomized doseresponse trial in high risk hivinfected patients and on existing epidemiological data from natural history studiesthe patient population of the controlled trial consisted of 408 patients 237 of whom had a history of one or more episodes of pjp the remaining patients without a history of pjp included 55 patients with kaposis sarcoma and 116 patients with other aids diagnoses arc or asymptomatic hiv infection patients were randomly assigned to receive nebupent via the respirgardrthe results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of nebupent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeksno doseresponse was observed for reduction in overall mortality however mortality from pjp was low in all three dosage groups,3
invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv infection the twice daily administration of invirase in combination with ritonavir is supported by safety data from the maxcmin 1 study see table 6 table 1in a randomized doubleblind clinical study nv14256 in zidovudineexperienced hivinfected patients invirase in combination with zalcitabine was shown to be superior to either invirase or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to aidsdefining events or death furthermore in a randomized study actg229nv14255 patients with advanced hiv infection with history of prolonged zidovudine treatment and who were given invirase 600 mg three times daily zidovudine zalcitabine experienced greater increases in cd4 cell counts as compared to those who received invirase zidovudine or zalcitabine zidovudine it should be noted that hiv treatment regimens that were used in these initial clinical studies of invirase are no longer considered standard of caresaquinavir gel capsule 1000 mg twice daily coadministered with ritonavir 100 mg twice daily was studied in a heterogeneous population of 148 hivinfected patients maxcmin 1 study at baseline 42 were treatment naive and 106 were treatment experienced of which 52 had an hiv rna level 400 copiesml at baseline results showed that 91148 61 subjects achieved andor sustained an hiv rna level 400 copiesml at the completion of 48 weeks,3
invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv infection the twice daily administration of invirase in combination with ritonavir is supported by safety data from the maxcmin 1 study see table 6 table 1in a randomized doubleblind clinical study nv14256 in zidovudineexperienced hivinfected patients invirase in combination with zalcitabine was shown to be superior to either invirase or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to aidsdefining events or death furthermore in a randomized study actg229nv14255 patients with advanced hiv infection with history of prolonged zidovudine treatment and who were given invirase 600 mg three times daily zidovudine zalcitabine experienced greater increases in cd4 cell counts as compared to those who received invirase zidovudine or zalcitabine zidovudine it should be noted that hiv treatment regimens that were used in these initial clinical studies of invirase are no longer considered standard of caresaquinavir gel capsule 1000 mg twice daily coadministered with ritonavir 100 mg twice daily was studied in a heterogeneous population of 148 hivinfected patients maxcmin 1 study at baseline 42 were treatment naive and 106 were treatment experienced of which 52 had an hiv rna level 400 copiesml at baseline results showed that 91148 61 subjects achieved andor sustained an hiv rna level 400 copiesml at the completion of 48 weeks,3
alendronate sodium is a bisphosphonate indicated for treatment and prevention of osteoporosis in postmenopausal women 1112treatment to increase bone mass in men with osteoporosis 13treatment of glucocorticoidinduced osteoporosis 14treatment of pagets disease of bone 15limitations of useoptimal duration of use has not been determined for patients at lowrisk for fracture consider drug discontinuation after 3 to 5 years of use 16alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets increase bone mass and reduce the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 141alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis see clinical studies 142alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 143alendronate sodium tablets are indicated for the treatment of glucocorticoidinduced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 75 mg or greater of prednisone and who have low bone mineral density see clinical studies 144alendronate sodium tablets are indicated for the treatment of pagets disease of bone in men and women treatment is indicated in patients with pagets disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 145the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium tablets for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
paliperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia 11 adults efficacy was established in three 6week trials and one maintenance trial 141adolescents ages 12 to 17 efficacy was established in one 6week trial 141treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers andor antidepressants 12 efficacy was established in two 6week trials in adult patients 142paliperidone extendedrelease tablets are indicated for the treatment of schizophrenia see clinical studies 141the efficacy of paliperidone in schizophrenia was established in three 6week trials in adults and one 6week trial in adolescents as well as one maintenance trial in adultspaliperidone extendedrelease tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers andor antidepressant therapy see clinical studies 142the efficacy of paliperidone in schizoaffective disorder was established in two 6week trials in adults,3
paliperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia 11 adults efficacy was established in three 6week trials and one maintenance trial 141adolescents ages 12 to 17 efficacy was established in one 6week trial 141treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers andor antidepressants 12 efficacy was established in two 6week trials in adult patients 142paliperidone extendedrelease tablets are indicated for the treatment of schizophrenia see clinical studies 141the efficacy of paliperidone in schizophrenia was established in three 6week trials in adults and one 6week trial in adolescents as well as one maintenance trial in adultspaliperidone extendedrelease tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers andor antidepressant therapy see clinical studies 142the efficacy of paliperidone in schizoaffective disorder was established in two 6week trials in adults,3
vraylarr is indicated for the treatment of schizophrenia in adults see clinical studies 141acute treatment of manic or mixed episodes associated with bipolar i disorder in adults see clinical studies 142vraylar is an atypical antipsychotic indicated for the treatment of schizophrenia in adults 1acute treatment of manic or mixed episodes associated with bipolar i disorder in adults 1,3
rexulti is indicated for adjunctive treatment of major depressive disorder mdd see clinical studies 141treatment of schizophrenia see clinical studies 142rexulti is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder mdd 1141treatment of schizophrenia 1142,3
adasuve psychomotor agitation is defined in dsmiv as excessive motor activity associated with a feeling of inner tension patients experiencing agitation often manifest behaviors that interfere with their care eg threatening behaviors escalating or urgently distressing behavior selfexhausting behavior leading clinicians to the use of rapidly absorbed antipsychotic medications to achieve immediate control of the agitation see clinical studies 14the efficacy of adasuve was established in one study of acute agitation in patients with schizophrenia and one study of acute agitation in patients with bipolar i disorder see clinical studies 14 limitations of useas part of the adasuve rems program to mitigate the risk of bronchospasm adasuve must be administered only in an enrolled healthcare facility see warnings and precautions 52adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults efficacy was demonstrated in 2 trials in acute agitation one in schizophrenia and one in bipolar i disorder 114 limitations of useadasuve must be administered only in an enrolled healthcare facility 1,3
molindone hydrochloride tablets usp are indicated for the management of schizophrenia the efficacy of molindone hydrochloride tablets usp in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects,3
fanaptrsee clinical studies 14when deciding among the alternative treatments available for this condition the prescriber should consider the finding that fanaptsee warnings and precautions 52patients must be titrated to an effective dose of fanaptsee dosage and administration 21 and clinical studies 14the effectiveness of fanapt in longterm use that is for more than 6 weeks has not been systematically evaluated in controlled trials therefore the physician who elects to use fanapt for extended periods should periodically reevaluate the longterm usefulness of the drug for the individual patient see dosage and administration 23fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults 114,3
saphris is indicated for schizophrenia in adults see clinical studies 141bipolar i disorder see clinical studies 142 acute monotherapy of manic or mixed episodes in adults and pediatric patients 10 to 17 years of age adjunctive treatment to lithium or valproate in adults maintenance monotherapy treatment in adults saphris is an atypical antipsychotic indicated for 1 schizophrenia in adults bipolar i disorder acute monotherapy treatment of manic or mixed episodes in adults and pediatric patients 10 to 17 years of age adjunctive treatment to lithium or valproate in adults maintenance monotherapy treatment in adults,3
latuda is indicated for latuda is indicated for treatment of adult and adolescent patients 13 to 17 years with schizophrenia see clinical studies 141 monotherapy treatment of adult and pediatric patients 10 to 17 years with major depressive episode associated with bipolar i disorder bipolar depression see clinical studies 142142adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar i disorder bipolar depression see clinical studies 142latuda is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and adolescents 13 to 17 years 1141depressive episode associated with bipolar i disorder bipolar depression in adults and pediatric patients 10 to 17 years as monotherapy 1142depressive episode associated with bipolar i disorder bipolar depression in adults as adjunctive therapy with lithium or valproate 1142,3
lindane shampoo is indicated for the treatment of head lice infestations of pediculosis humanis capitispthirus pubis cannot tolerate other approved therapies orhave failed treatment with other approved therapieslindane shampoo should be used in the context of an overall lice management program that includes visual inspection to ensure that the patient is currently infested with live lice empty egg casings or nits can remain on hair shaft long after true infestationmanual removal of nits using a comb designed for this purpose andor individual removal with tweezers followed by close examination of the hair and scalpevaluation and treatment of sexual contacts simultaneously sexual contacts should be prescribed lindane shampoo only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapiesall recently worn clothing underwear pajamas used sheets pillowcases and towels should be washed in very hot water or drycleanedcaregivers applying this product to patients should wear gloves less permeable to lindane such as nitrile latex with neoprene or sheer vinyl and thoroughly clean hands after application natural latex gloves should be avoided because they are more permeable to lindanelindane shampoo does not prevent infestation or reinfestation and should not be used to ward off a possible infestation,3
in accordance with the statements in the warning box the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drugto reduce the development of drugresistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
rayaldee is a vitamin d3 limitations of userayaldee is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with endstage renal disease on dialysis rayaldee31 limitations of use rayaldee1,1
injectable midazolam in contraindicated in patients with a known hypersensitivity to the drug benzodiazepines are contraindicated in patients with acute narrowangle glaucoma benzodiazepines may be used in patiens with openangle glaucoma only if they are receiving appropriate therapy measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam patients with glaucoma have not been studiedmidazolam injection is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form midazoalm injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol see warnings precautions pediatric use,1
lipiodol is contraindicated in patients with hypersensitivity to lipiodol hyperthyroidism traumatic injuries recent hemorrhage or bleeding hysterosalpingographylipiodol hysterosalpingography is contraindicated in pregnancy acute pelvic inflammatory disease marked cervical erosion endocervicitis and intrauterine bleeding in the immediate preor postmenstrual phase or within 30 days of curettage or conization lymphographylipiodol lymphography is contraindicated in patients with a right to left cardiac shunt advanced pulmonary disease tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction previous surgery interrupting the lymphatic system radiation therapy to the examined area selective hepatic intraarterial use patients with hcc lipiodol use is contraindicated in areas of the liver where the bile ducts are dilated unless external biliary drainage was performed before injection hypersensitivity to lipiodol hyperthyroidism traumatic injuries recent hemorrhage or bleeding lipiodol hysterosalpingography is contraindicated in lipiodol lymphography is contraindicated in lipiodol selective hepatic intraarterial injection is contraindicated in,3
quinine sulfate is contraindicated in patients with the following prolongation of qt interval 4glucose6phosphate dehydrogenase g6pd deficiency 4myasthenia gravis 4known hypersensitivity to quinine mefloquine or quinidine 4optic neuritis 4quinine sulfate is contraindicated in patients with the following prolonged qt interval one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline who received quinine sulfate intravenously for p falciparum see warnings and precautions 53 glucose6phosphate dehydrogenase g6pd deficiency hemolysis can occur in patients with g6pd deficiency receiving quinine known hypersensitivity reactions to quinine these include but are not limited to the following see warnings and precautions 56 thrombocytopenia idiopathic thrombocytopenia purpura itp and thrombotic thrombocytopenic purpura ttp hemolytic uremic syndrome hus blackwater fever acute intravascular hemolysis hemoglobinuria and hemoglobinemia known hypersensitivity to mefloquine or quinidine crosssensitivity to quinine has been documented see warnings and precautions 56 myasthenia gravis quinine has neuromuscular blocking activity and may exacerbate muscle weakness optic neuritis quinine may exacerbate active optic neuritis see adverse reactions 6,2
cefotetan for injection usp and dextrose injection usp is contraindicated in patients with a known allergy to the cephalosporin group of antibiotics and in those individuals who have experienced a cephalosporin associated hemolytic anemiasolutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products,3
durlaza is indicated to reduce the risk of death and myocardial infarction mi in patients with chronic coronary artery disease such as patients with a history of mi or unstable angina pectoris or with chronic stable anginareduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack limitation of usedurlaza is a nonsteroidal antiinflammatory drug indicated to reduce the risk of death and myocardial infarction mi in patients with chronic coronary artery disease such as patients with a history of mi or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack 1 limitation of use1 4,0
activase is a tissue plasminogen activator tpa indicated for the treatment of acute ischemic stroke ais 11acute myocardial infarction ami to reduce mortality and incidence of heart failure 12limitation of use in ami12acute massive pulmonary embolism pe for lysis 13activase is indicated for the treatment of acute ischemic strokeexclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment see contraindications 41activase is indicated for use in acute myocardial infarction ami for the reduction of mortality and reduction of the incidence of heart failure limitation of useactivase is indicated for the lysis of acute massive pulmonary embolism defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segmentsacute pulmonary emboli accompanied by unstable hemodynamics eg failure to maintain blood pressure without supportive measures,3
activase is a tissue plasminogen activator tpa indicated for the treatment of acute ischemic stroke ais 11acute myocardial infarction ami to reduce mortality and incidence of heart failure 12limitation of use in ami12acute massive pulmonary embolism pe for lysis 13activase is indicated for the treatment of acute ischemic strokeexclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment see contraindications 41activase is indicated for use in acute myocardial infarction ami for the reduction of mortality and reduction of the incidence of heart failure limitation of useactivase is indicated for the lysis of acute massive pulmonary embolism defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segmentsacute pulmonary emboli accompanied by unstable hemodynamics eg failure to maintain blood pressure without supportive measures,3
activase is a tissue plasminogen activator tpa indicated for the treatment of acute ischemic stroke ais 11acute myocardial infarction ami to reduce mortality and incidence of heart failure 12limitation of use in ami12acute massive pulmonary embolism pe for lysis 13activase is indicated for the treatment of acute ischemic strokeexclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment see contraindications 41activase is indicated for use in acute myocardial infarction ami for the reduction of mortality and reduction of the incidence of heart failure limitation of useactivase is indicated for the lysis of acute massive pulmonary embolism defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segmentsacute pulmonary emboli accompanied by unstable hemodynamics eg failure to maintain blood pressure without supportive measures,3
retavase is indicated for use in acute stelevation myocardial infarction stemi to reduce the risk of death and heart failure limitation of useretavase is a tissue plasminogen activator tpa indicated for treatment of acute stelevation myocardial infarction stemi to reduce the risk of death and heart failure 1 limitation of use1,3
clopidogrel tablets are a p2y 12 acute coronary syndrome for patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi clopidogrel tablets have been shown to reduce the rate of myocardial infarction mi and stroke 11for patients with stelevation myocardial infarction stemi clopidogrel tablets have been shown to reduce the rate of mi and stroke 11recent mi recent stroke or established peripheral arterial disease clopidogrel tablets have been shown to reduce the rate of mi and stroke 12 clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirin in patients with established peripheral arterial disease or with a history of recent myocardial infarction mi or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke,0
clopidogrel tablets are a p2y 12 acute coronary syndrome for patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi clopidogrel tablets have been shown to reduce the rate of myocardial infarction mi and stroke 11for patients with stelevation myocardial infarction stemi clopidogrel tablets have been shown to reduce the rate of mi and stroke 11recent mi recent stroke or established peripheral arterial disease clopidogrel tablets have been shown to reduce the rate of mi and stroke 12 clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirin in patients with established peripheral arterial disease or with a history of recent myocardial infarction mi or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke,3
clopidogrel tablets are a p2y 12 acute coronary syndrome for patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi clopidogrel tablets have been shown to reduce the rate of myocardial infarction mi and stroke 11for patients with stelevation myocardial infarction stemi clopidogrel tablets have been shown to reduce the rate of mi and stroke 11recent mi recent stroke or established peripheral arterial disease clopidogrel tablets have been shown to reduce the rate of mi and stroke 12 clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirin in patients with established peripheral arterial disease or with a history of recent myocardial infarction mi or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke,3
enoxaparin sodium injection usp is a low molecular weight heparin lmwh indicated for prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery knee replacement surgery or medical patients with severely restricted mobility during acute illness 11inpatient treatment of acute dvt with or without pulmonary embolism 12outpatient treatment of acute dvt without pulmonary embolism 12prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction mi 13treatment of acute stsegment elevation myocardial infarction stemi managed medically or with subsequent percutaneous coronary intervention pci 14enoxaparin sodium injection usp is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 141in patients undergoing hip replacement surgery during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness enoxaparin sodium injection usp is indicated for the inpatient treatmentwith or without pulmonary embolismthe outpatient treatmentwithout pulmonary embolismenoxaparin sodium injection usp is indicated for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin enoxaparin sodium injection usp when administered concurrently with aspirin has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute stsegment elevation myocardial infarction stemi receiving thrombolysis and being managed medically or with percutaneous coronary intervention pci,3
enoxaparin sodium injection usp is a low molecular weight heparin lmwh indicated for prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery knee replacement surgery or medical patients with severely restricted mobility during acute illness 11inpatient treatment of acute dvt with or without pulmonary embolism 12outpatient treatment of acute dvt without pulmonary embolism 12prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction mi 13treatment of acute stsegment elevation myocardial infarction stemi managed medically or with subsequent percutaneous coronary intervention pci 14enoxaparin sodium injection usp is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 141in patients undergoing hip replacement surgery during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness enoxaparin sodium injection usp is indicated for the inpatient treatmentwith or without pulmonary embolismthe outpatient treatmentwithout pulmonary embolismenoxaparin sodium injection usp is indicated for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin enoxaparin sodium injection usp when administered concurrently with aspirin has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute stsegment elevation myocardial infarction stemi receiving thrombolysis and being managed medically or with percutaneous coronary intervention pci,3
enoxaparin sodium injection usp is a low molecular weight heparin lmwh indicated for prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery knee replacement surgery or medical patients with severely restricted mobility during acute illness 11inpatient treatment of acute dvt with or without pulmonary embolism 12outpatient treatment of acute dvt without pulmonary embolism 12prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction mi 13treatment of acute stsegment elevation myocardial infarction stemi managed medically or with subsequent percutaneous coronary intervention pci 14enoxaparin sodium injection usp is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 141in patients undergoing hip replacement surgery during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness enoxaparin sodium injection usp is indicated for the inpatient treatmentwith or without pulmonary embolismthe outpatient treatmentwithout pulmonary embolismenoxaparin sodium injection usp is indicated for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin enoxaparin sodium injection usp when administered concurrently with aspirin has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute stsegment elevation myocardial infarction stemi receiving thrombolysis and being managed medically or with percutaneous coronary intervention pci,3
effient is a p2y12 patients with unstable angina or nonstelevation myocardial infarction nstemi 11 patients with stelevation myocardial infarction stemi when managed with either primary or delayed pci 11effienttm is indicated to reduce the rate of thrombotic cardiovascular cv events including stent thrombosis in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci as follows patients with unstable angina ua or nonstelevation myocardial infarction nstemi patients with stelevation myocardial infarction stemi when managed with primary or delayed pci effient has been shown to reduce the rate of a combined endpoint of cardiovascular death nonfatal myocardial infarction mi or nonfatal stroke compared to clopidogrel the difference between treatments was driven predominantly by mi with no difference on strokes and little difference on cv death see clinical studies 14it is generally recommended that antiplatelet therapy be administered promptly in the management of acs because many cardiovascular events occur within hours of initial presentation in the clinical trial that established the efficacy of effient effient and the control drug were not administered to uanstemi patients until coronary anatomy was established for the small fraction of patients that required urgent cabg after treatment with effient the risk of significant bleeding was substantial see warnings and precautions 52,3
effient is a p2y12 patients with unstable angina or nonstelevation myocardial infarction nstemi 11 patients with stelevation myocardial infarction stemi when managed with either primary or delayed pci 11effienttm is indicated to reduce the rate of thrombotic cardiovascular cv events including stent thrombosis in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci as follows patients with unstable angina ua or nonstelevation myocardial infarction nstemi patients with stelevation myocardial infarction stemi when managed with primary or delayed pci effient has been shown to reduce the rate of a combined endpoint of cardiovascular death nonfatal myocardial infarction mi or nonfatal stroke compared to clopidogrel the difference between treatments was driven predominantly by mi with no difference on strokes and little difference on cv death see clinical studies 14it is generally recommended that antiplatelet therapy be administered promptly in the management of acs because many cardiovascular events occur within hours of initial presentation in the clinical trial that established the efficacy of effient effient and the control drug were not administered to uanstemi patients until coronary anatomy was established for the small fraction of patients that required urgent cabg after treatment with effient the risk of significant bleeding was substantial see warnings and precautions 52,3
effient is a p2y12 patients with unstable angina or nonstelevation myocardial infarction nstemi 11 patients with stelevation myocardial infarction stemi when managed with either primary or delayed pci 11effienttm is indicated to reduce the rate of thrombotic cardiovascular cv events including stent thrombosis in patients with acute coronary syndrome acs who are to be managed with percutaneous coronary intervention pci as follows patients with unstable angina ua or nonstelevation myocardial infarction nstemi patients with stelevation myocardial infarction stemi when managed with primary or delayed pci effient has been shown to reduce the rate of a combined endpoint of cardiovascular death nonfatal myocardial infarction mi or nonfatal stroke compared to clopidogrel the difference between treatments was driven predominantly by mi with no difference on strokes and little difference on cv death see clinical studies 14it is generally recommended that antiplatelet therapy be administered promptly in the management of acs because many cardiovascular events occur within hours of initial presentation in the clinical trial that established the efficacy of effient effient and the control drug were not administered to uanstemi patients until coronary anatomy was established for the small fraction of patients that required urgent cabg after treatment with effient the risk of significant bleeding was substantial see warnings and precautions 52,3
fragmin is a low molecular weight heparin lmwh indicated for prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction 11 prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery or medical patients with severely restricted mobility during acute illness 12 extended treatment of symptomatic venous thromboembolism vte to reduce the recurrence in patients with cancer in these patients the fragmin therapy begins with the initial vte treatment and continues for six months 13 limitations of usefragmin is not indicated for the acute treatment of vtefragmin injection is indicated for the prophylaxis of ischemic complications in unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin therapy see clinical studies 141fragmin is also indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing hip replacement surgery see clinical studies 142 in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 143 in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness see clinical studies 144fragmin is also indicated for the extended treatment of symptomatic venous thromboembolism vte proximal dvt andor pe to reduce the recurrence of vte in patients with cancer in these patients the fragmin therapy begins with the initial vte treatment and continues for six months see clinical studies 145 limitations of usefragmin is not indicated for the acute treatment of vte,3
fragmin is a low molecular weight heparin lmwh indicated for prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction 11 prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery or medical patients with severely restricted mobility during acute illness 12 extended treatment of symptomatic venous thromboembolism vte to reduce the recurrence in patients with cancer in these patients the fragmin therapy begins with the initial vte treatment and continues for six months 13 limitations of usefragmin is not indicated for the acute treatment of vtefragmin injection is indicated for the prophylaxis of ischemic complications in unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin therapy see clinical studies 141fragmin is also indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing hip replacement surgery see clinical studies 142 in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 143 in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness see clinical studies 144fragmin is also indicated for the extended treatment of symptomatic venous thromboembolism vte proximal dvt andor pe to reduce the recurrence of vte in patients with cancer in these patients the fragmin therapy begins with the initial vte treatment and continues for six months see clinical studies 145 limitations of usefragmin is not indicated for the acute treatment of vte,3
ticagrelor tablets are indicated to reduce the rate of cardiovascular death myocardial infarction and stroke in patients with acute coronary syndrome acs or a history of myocardial infarction mi for at least the first 12 months following acs it is superior to clopidogrel ticagrelor tablets also reduce the rate of stent thrombosis in patients who have been stented for treatment of acs see clinical studies 141ticagrelor tablets are a p2y12ticagrelor tablets also reduce the rate of stent thrombosis in patients who have been stented for treatment of acs 1,3
ticagrelor tablets are indicated to reduce the rate of cardiovascular death myocardial infarction and stroke in patients with acute coronary syndrome acs or a history of myocardial infarction mi for at least the first 12 months following acs it is superior to clopidogrel ticagrelor tablets also reduce the rate of stent thrombosis in patients who have been stented for treatment of acs see clinical studies 141ticagrelor tablets are a p2y12ticagrelor tablets also reduce the rate of stent thrombosis in patients who have been stented for treatment of acs 1,3
invokanar as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of major adverse cardiovascular events cardiovascular death nonfatal myocardial infarction and nonfatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease cvdinvokana is a sodiumglucose cotransporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis 1 limitations of useinvokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis,3
invokanar as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of major adverse cardiovascular events cardiovascular death nonfatal myocardial infarction and nonfatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease cvdinvokana is a sodiumglucose cotransporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis 1 limitations of useinvokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis,3
zontivity is a proteaseactivated receptor1 par1 antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or with peripheral arterial disease pad zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death mi stroke and urgent coronary revascularization 11zontivity ar,2
hypersensitivity to probenecidchildren under 2 years of agenot recommended in persons with known blood dyscrasias or uric acid kidney stonestherapy with probenecid should not be started until an acute gouty attack has subsided,2
clonazepam orally disintegrating tablets are useful alone or as an adjunct in the treatment of the lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures in patients with absence seizures petit mal who have failed to respond to succinimides clonazepam orally disintegrating tablets may be usefulin some studies up to 30 of patients have shown a loss of anticonvulsant activity often within 3 months of administration in some cases dosage adjustment may reestablish efficacyclonazepam orally disintegrating tablets are indicated for the treatment of panic disorder with or without agoraphobia as defined in dsmv panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks worry about the implications or consequences of the attacks andor a significant change in behavior related to the attacksthe efficacy of clonazepam orally disintegrating tablets was established in two 6 to 9week trials in panic disorder patients whose diagnoses corresponded to the dsmiiir category of panic disorder see clinical pharmacology clinical trialspanic disorder dsmv is characterized by recurrent unexpected panic attacks ie a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 10 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 10 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushesthe effectiveness of clonazepam orally disintegrating tablets in longterm use that is for more than 9 weeks has not been systematically studied in controlled clinical trials the physician who elects to use clonazepam orally disintegrating tablets for extended periods should periodically reevaluate the longterm usefulness of the drug for the individual patient see dosage and administration,3
clonazepam orally disintegrating tablets are useful alone or as an adjunct in the treatment of the lennoxgastaut syndrome petit mal variant akinetic and myoclonic seizures in patients with absence seizures petit mal who have failed to respond to succinimides clonazepam orally disintegrating tablets may be usefulin some studies up to 30 of patients have shown a loss of anticonvulsant activity often within 3 months of administration in some cases dosage adjustment may reestablish efficacyclonazepam orally disintegrating tablets are indicated for the treatment of panic disorder with or without agoraphobia as defined in dsmv panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks worry about the implications or consequences of the attacks andor a significant change in behavior related to the attacksthe efficacy of clonazepam orally disintegrating tablets was established in two 6 to 9week trials in panic disorder patients whose diagnoses corresponded to the dsmiiir category of panic disorder see clinical pharmacology clinical trialspanic disorder dsmv is characterized by recurrent unexpected panic attacks ie a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 10 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 10 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushesthe effectiveness of clonazepam orally disintegrating tablets in longterm use that is for more than 9 weeks has not been systematically studied in controlled clinical trials the physician who elects to use clonazepam orally disintegrating tablets for extended periods should periodically reevaluate the longterm usefulness of the drug for the individual patient see dosage and administration,3
hypersensitivity to any component of this product these adverse reactions may manifest as an anaphylactic reaction urticaria facial andor tongue swelling or pruritus discontinue cyclobenzaprine hydrochloride extendedrelease capsules if a hypersensitivity reaction is suspected concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine or structurally similar tricyclic antidepressants concomitantly with mao inhibitor drugs during the acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failurehyperthyroidism hypersensitivity to any component of this product 4concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation 4during acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure 4hyperthyroidism 4,0
noctiva is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia hyponatremia or a history of hyponatremia see warnings and precautions 51polydipsiaprimary nocturnal enuresis see use in specific populations 84concomitant use with loop diuretics see warnings and precautions 51concomitant use with systemic or inhaled glucocorticoids see warnings and precautions 5171renal impairment with an estimated glomerular filtration rate egfr below 50 mlmin173 m2see use in specific populations 86known or suspected syndrome of inappropriate antidiuretic hormone siadh secretionduring illnesses that can cause fluid or electrolyte imbalance such as gastroenteritis saltwasting nephropathies or systemic infectionnoctiva is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition congestive heart failure new york heart association class ii to iv see warnings and precautions 52uncontrolled hypertension hyponatremia or a history of hyponatremia 4polydipsia 4primary nocturnal enuresis 4concomitant use with loop diuretics or systemic or inhaled glucocorticoids 4estimated glomerular filtration rate below 50 mlmin173 m24syndrome of inappropriate antidiuretic hormone secretion siadh 4during illnesses that can cause fluid or electrolyte imbalance 4new york heart association nyha class iiiv congestive heart failure 4uncontrolled hypertension 4,1
cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iiiiv congestive heart failure cilostazol tablets usp are contraindicated in patients with congestive heart failure of any severity cilostazol tablets usp are contraindicated in patients with haemostatic disorders or active pathologic bleeding such as bleeding peptic ulcer and intracranial bleeding cilostazol tablets usp inhibit platelet aggregation in a reversible manner cilostazol tablets usp are contraindicated in patients with known or suspected hypersensitivity to any of its components,0
helps loosen phlegm mucus and thin bronchial secretions to rid the bronchial passageways of bothersome mucus drain bronchial tubes and make coughs more productive helps loosen phlegm and thin bronchial secretions in patients with stable chronic bronchitis,2
factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below see dosage and administration clinical studies acute bacterial exacerbation of chronic bronchitis abecb streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalisbecause fluoroquinolones including factive have been associated with serious adverse reactions see warnings communityacquired pneumonia streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis mycoplasma pneumoniae chlamydia pneumoniae klebsiella pneumoniaemdrsp multidrug resistant streptococcus pneumoniaestreptococcus pneumoniaeto reduce the development of drugresistant bacteria and maintain the effectiveness of factive and other antibacterial drugs factive should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cefditoren pivoxil is indicated for the treatment of mild to moderate infections in adults and adolescents 12 years of age or older which are caused by susceptible strains of the designated microorganisms in the conditions listed below acute bacterial exacerbation of chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis communityacquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis pharyngitistonsillitis streptococcus pyogenesstreptococcus pyogenes streptococcus pyogenes uncomplicated skin and skinstructure infections staphylococcus aureus streptococcus pyogenesto reduce the development of drugresistant bacteria and maintain the effectiveness of cefditoren pivoxil and other antibacterial drugs cefditoren pivoxil should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
nedocromil sodium ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis,3
olopatadine hydrochloride ophthalmic solution usp 02 is indicated for the treatment of ocular itching associated with allergic conjunctivitis olopatadine hydrochloride ophthalmic solution usp 02 is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis 1,3
milnacipran hcl tablets are indicated for the management of fibromyalgia milnacipran hcl tablets are not approved for use in pediatric patients see use in specific populations 84 milnacipran hcl tablets are a selective serotonin and norepinephrine reuptake inhibitor snri indicated for the management of fibromyalgia 1milnacipran hcl tablets are not approved for use in pediatric patients 1,3
lyrica is indicated forlyrica is indicated for management of neuropathic pain associated with diabetic peripheral neuropathy management of postherpetic neuralgia adjunctive therapy for the treatment of partial onset seizures in patients 4 years of age and older management of fibromyalgia management of neuropathic pain associated with spinal cord injurylyrica is indicated for neuropathic pain associated with diabetic peripheral neuropathy dpn 1postherpetic neuralgia phn 1adjunctive therapy for the treatment of partial onset seizures in patients 4 years of age and older 1fibromyalgia 1neuropathic pain associated with spinal cord injury 1,3
panretinr gel is indicated for topical treatment of cutaneous lesions in patients with aidsrelated kaposis sarcoma panretinr gel is not indicated when systemic antiks therapy is required eg more than 10 new ks lesions in the prior month symptomatic lymphedema symptomatic pulmonary ks or symptomatic visceral involvement there is no experience to date using panretinr gel with systemic antiks treatment,2
concomitant use of venclexta with strongsee dosage and administration 2471concomitant use with strong cyp3a inhibitors at initiation and during rampup phase in patients with cllsll is contraindicated 24471,1
subsys is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to aroundtheclock opioid therapy for their underlying persistent cancer painpatients considered opioid tolerant are those who are taking for one week or longer aroundtheclock medicine consisting of at least 60 mg of oral morphine per day at least 25 mcg of transdermal fentanyl per hour at least 30 mg of oral oxycodone per day at least 8 mg of oral hydromorphone per day or at least 25 mg oral oxymorphone per day or at least 60mg oral hydrocodone per day or an equianalgesic dose of another opioid daily for a week or longer patients must remain on aroundtheclock opioids when taking subsys limitations of use not for use in opioid nontolerant patientsnot for use in the management of acute or postoperative pain including headachemigraine dental pain or in the emergency room see contraindications 4as part of the transmucosal immediaterelease fentanyl tirf rems access program subsys may be dispensed only to outpatients enrolled in the program see warnings and precautions 57subsys is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to aroundtheclock opioid therapy for their underlying persistent cancer pain 1patients considered opioid tolerant are those who are taking for one week or longer aroundtheclock medicine consisting of at least 60 mg of oral morphine per day at least 25 mcg of transdermal fentanyl per hour at least 30 mg of oral oxycodone per day at least 8 mg of oral hydromorphone per day at least 25 mg oral oxymorphone per day at least 60 mg oral hydrocodone per day or an equianalgesic dose of another opioid daily for a week or longer patients must remain on aroundtheclock opioids when taking subsys limitations of use1 not for use in opioid nontolerant patientsnot for use in the management of acute or postoperative pain including headachemigraine dental pain or in the emergency roomas a part of the transmucosal immediaterelease fentanyl tirf rems access program subsys may be dispensed only to outpatients enrolled in the program see warnings and precautions 57,1
prostin vr pediatric sterile solution is indicated for palliative not definitive therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival such congenital heart defects include pulmonary atresia pulmonary stenosis tricuspid atresia tetralogy of fallot interruption of the aortic arch coarctation of the aorta or transposition of the great vessels with or without other defectsin infants with restricted pulmonary blood flow the increase in blood oxygenation is inversely proportional to pretreatment po222prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care,3
retinoids may cause fetal harm when administered to a pregnant womanin rats tazarotene 005 gel administered topically2topically2de024h2024h2as with other retinoids when tazarotene was given orallyde024h2024h2in a study of the effect of oral tazarotene on fertility and early embryonic development in rats decreased number of implantation sites decreased litter size decreased numbers of live fetuses and decreased fetal body weights all classic developmental effects of retinoids were observed when female rats were administered 2 mgkgday from 15 days before mating through gestation day 7 a low incidence of retinoidrelated malformations at that dose was reported to be related to treatment this dose produced an aucde024h2024h2systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated in patients treated topically over sufficient body surface area exposure could be in the same order of magnitude as in these orally treated animals although there may be less systemic exposure in the treatment of acne of the face alone due to less surface area for application tazarotene is a teratogenic substance and it is not known what level of exposure is required for teratogenicity in humans see clinical pharmacology pharmacokineticsthere were thirteen reported pregnancies in patients who participated in clinical trials for topical tazarotene nine of the patients were found to have been treated with topical tazarotene and the other four had been treated with vehicle one of the patients who was treated with tazarotene cream elected to terminate the pregnancy for nonmedical reasons unrelated to treatment the other eight pregnant women who were inadvertently exposed to topical tazarotene during clinical trials subsequently delivered apparently healthy babies as the exact timing and extent of exposure in relation to the gestation times are not certain the significance of these findings is unknowntazoracrrrprecautions pregnancy teratogenic effectstazoracar,0
pyridoxine hydrochloride injection is effective for the treatment of pyridoxine deficiency as seen in the following inadequate dietary intake druginduced deficiency as from isoniazid inh or oral contraceptivesinborn errors of metabolism eg vitamin b66the parenteral route is indicated when oral administration is not feasible as in anorexia nausea and vomiting and preoperative and postoperative conditions it is also indicated when gastrointestinal absorption is impaired,3
rgene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for hgh can be of diagnostic usefulness it can be used as a diagnostic aid in such conditions as panhypopituitarism pituitary dwarfism chromophobe adenoma postsurgical craniopharyngioma hypophysectomy pituitary trauma acromegaly gigantism and problems of growth and statureif the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for hgh a test with rgene 10 is advisable to confirm the negative response this can be done after a waiting period of one day as patients may not respond to rgene 10 arginine hydrochloride injection usp during the first test the unresponsive patient should be tested again to confirm the negative result a second test can be performed after a waiting period of one day some patients who respond to rgene 10 do not respond to insulin and vice versa the rate of false positive responses for rgene 10 is approximately 32 and the rate of false negatives is approximately 27,3
cabergoline tablets usp are indicated for the treatment of hyperprolactinemic disorders either idiopathic or due to pituitary adenomas,3
enbrel is a tumor necrosis factor tnf blocker indicated for the treatment of rheumatoid arthritis ra 11polyarticular juvenile idiopathic arthritis jia in patients aged 2 years or older 12psoriatic arthritis psa 13ankylosing spondylitis as 14plaque psoriasis pso in patients 4 years or older 15enbrel is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis ra enbrel can be initiated in combination with methotrexate mtx or used aloneenbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis jia in patients ages 2 and olderenbrel is indicated for reducing signs and symptoms inhibiting the progression of structural damage of active arthritis and improving physical function in patients with psoriatic arthritis psa enbrel can be used with or without methotrexateenbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis asenbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy,2
enbrel is a tumor necrosis factor tnf blocker indicated for the treatment of rheumatoid arthritis ra 11polyarticular juvenile idiopathic arthritis jia in patients aged 2 years or older 12psoriatic arthritis psa 13ankylosing spondylitis as 14plaque psoriasis pso in patients 4 years or older 15enbrel is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis ra enbrel can be initiated in combination with methotrexate mtx or used aloneenbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis jia in patients ages 2 and olderenbrel is indicated for reducing signs and symptoms inhibiting the progression of structural damage of active arthritis and improving physical function in patients with psoriatic arthritis psa enbrel can be used with or without methotrexateenbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis asenbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy,3
imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 11 juvenile idiopathic arthritis jia 12 psoriatic arthritis psa 13 ankylosing spondylitis as 14 adult crohns disease cd 15 ulcerative colitis uc 16 plaque psoriasis ps 17imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other nonbiologic diseasemodifying antirheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 30 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with nonbiologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohns disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6mercaptopurine 6mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 147imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular followup visits with a physician see boxed warning5,3
imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 11 juvenile idiopathic arthritis jia 12 psoriatic arthritis psa 13 ankylosing spondylitis as 14 adult crohns disease cd 15 ulcerative colitis uc 16 plaque psoriasis ps 17imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other nonbiologic diseasemodifying antirheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 30 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with nonbiologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohns disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6mercaptopurine 6mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 147imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular followup visits with a physician see boxed warning5,3
imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 11 juvenile idiopathic arthritis jia 12 psoriatic arthritis psa 13 ankylosing spondylitis as 14 adult crohns disease cd 15 ulcerative colitis uc 16 plaque psoriasis ps 17imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other nonbiologic diseasemodifying antirheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 30 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with nonbiologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohns disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6mercaptopurine 6mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 147imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular followup visits with a physician see boxed warning5,3
imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 11 juvenile idiopathic arthritis jia 12 psoriatic arthritis psa 13 ankylosing spondylitis as 14 adult crohns disease cd 15 ulcerative colitis uc 16 plaque psoriasis ps 17imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other nonbiologic diseasemodifying antirheumatic drugs dmards imraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and 30 kg 66 lbs imraldi can be used alone or in combination with methotrexate imraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with nonbiologic dmards imraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis imraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohns disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab imraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6mercaptopurine 6mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 147imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular followup visits with a physician see boxed warning5,3
celecoxib is indicatedcelecoxib is a nonsteroidal antiinflammatory drug indicated for osteoarthritis oa 11rheumatoid arthritis ra 12juvenile rheumatoid arthritis jra in patients 2 years and older 13ankylosing spondylitis as 14acute pain ap 15primary dysmenorrhea pd 16for the management of the signs and symptoms of oa see clinical studies 141for the management of the signs and symptoms of ra see clinical studies 142for the management of the signs and symptoms of jra in patients 2 years and older see clinical studies 143for the management of the signs and symptoms of as see clinical studies 144for the management of acute pain in adults see clinical studies 145for the management of primary dysmenorrhea see clinical studies 145,3
celecoxib is indicatedcelecoxib is a nonsteroidal antiinflammatory drug indicated for osteoarthritis oa 11rheumatoid arthritis ra 12juvenile rheumatoid arthritis jra in patients 2 years and older 13ankylosing spondylitis as 14acute pain ap 15primary dysmenorrhea pd 16for the management of the signs and symptoms of oa see clinical studies 141for the management of the signs and symptoms of ra see clinical studies 142for the management of the signs and symptoms of jra in patients 2 years and older see clinical studies 143for the management of the signs and symptoms of as see clinical studies 144for the management of acute pain in adults see clinical studies 145for the management of primary dysmenorrhea see clinical studies 145,3
celecoxib is indicatedcelecoxib is a nonsteroidal antiinflammatory drug indicated for osteoarthritis oa 11rheumatoid arthritis ra 12juvenile rheumatoid arthritis jra in patients 2 years and older 13ankylosing spondylitis as 14acute pain ap 15primary dysmenorrhea pd 16for the management of the signs and symptoms of oa see clinical studies 141for the management of the signs and symptoms of ra see clinical studies 142for the management of the signs and symptoms of jra in patients 2 years and older see clinical studies 143for the management of the signs and symptoms of as see clinical studies 144for the management of acute pain in adults see clinical studies 145for the management of primary dysmenorrhea see clinical studies 145,3
simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 11active psoriatic arthritis psa alone or in combination with methotrexate 12active ankylosing spondylitis as 13moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 14 inducing and maintaining clinical responseimproving endoscopic appearance of the mucosa during inductioninducing clinical remissionachieving and sustaining clinical remission in induction responderssimponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritissimponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritissimponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 144,3
simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 11active psoriatic arthritis psa alone or in combination with methotrexate 12active ankylosing spondylitis as 13moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 14 inducing and maintaining clinical responseimproving endoscopic appearance of the mucosa during inductioninducing clinical remissionachieving and sustaining clinical remission in induction responderssimponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritissimponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritissimponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 144,3
simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 11active psoriatic arthritis psa alone or in combination with methotrexate 12active ankylosing spondylitis as 13moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 14 inducing and maintaining clinical responseimproving endoscopic appearance of the mucosa during inductioninducing clinical remissionachieving and sustaining clinical remission in induction responderssimponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritissimponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritissimponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 144,3
simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 11active psoriatic arthritis psa alone or in combination with methotrexate 12active ankylosing spondylitis as 13moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 14 inducing and maintaining clinical responseimproving endoscopic appearance of the mucosa during inductioninducing clinical remissionachieving and sustaining clinical remission in induction responderssimponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritissimponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritissimponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 144,3
leflunomide is indicated in adults for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms to inhibit structural damage as evidenced by xray erosions and joint space narrowingto improve physical function see clinical studiesaspirin nonsteroidal antiinflammatory agents andor low dose corticosteroids may be continued during treatment with leflunomide see precautions drug interactions nsaids warnings immunosuppression potentialbone marrow suppression,3
leflunomide is indicated in adults for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms to inhibit structural damage as evidenced by xray erosions and joint space narrowingto improve physical function see clinical studiesaspirin nonsteroidal antiinflammatory agents andor low dose corticosteroids may be continued during treatment with leflunomide see precautions drug interactions nsaids warnings immunosuppression potentialbone marrow suppression,3
carefully consider the potential benefits and risks of ibuprofen oral suspension and other treatment options before deciding to use ibuprofen oral suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings in pediatric patients ibuprofen oral suspension is indicated for reduction of fever in patients aged 6 months up to 2 years of agefor relief of mild to moderate pain in patients aged 6 months up to 2 years of age for relief of signs and symptoms of juvenile arthritis in adults ibuprofen oral suspension is indicated for treatment of primary dysmenorrheafor relief of the signs and symptoms of rheumatoid arthritis and osteoarthritissince there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin the combination cannot be recommended see precautionsdrug interactions,3
kineret is an interleukin1 receptor antagonist indicated for rheumatoid arthritis ra reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards 11 cryopyrinassociated periodic syndromes caps treatment of neonatalonset multisystem inflammatory disease nomid 12kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis ra in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards kineret can be used alone or in combination with dmards other than tumor necrosis factor tnf blocking agents see warnings and precautions 52kineret is indicated for the treatment of neonatalonset multisystem inflammatory disease nomid,3
malariahydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p falciparump malariaep ovalep vivaxhydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported limitations of use in malaria hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malariahydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of plasmodium clinical pharmacology microbiologyplasmodium hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurshydroxychloroquine sulfate tablets do not prevent relapses of p vivax p ovale p vivax p ovale clinical pharmacology microbiologyprior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria consult the centers for disease control and prevention cdc malaria website httpwwwcdcgovmalaria lupus erythematosushydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults rheumatoid arthritishydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults,3
malariahydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p falciparump malariaep ovalep vivaxhydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported limitations of use in malaria hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malariahydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of plasmodium clinical pharmacology microbiologyplasmodium hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurshydroxychloroquine sulfate tablets do not prevent relapses of p vivax p ovale p vivax p ovale clinical pharmacology microbiologyprior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria consult the centers for disease control and prevention cdc malaria website httpwwwcdcgovmalaria lupus erythematosushydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults rheumatoid arthritishydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults,3
malariahydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p falciparump malariaep ovalep vivaxhydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported limitations of use in malaria hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malariahydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of plasmodium clinical pharmacology microbiologyplasmodium hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurshydroxychloroquine sulfate tablets do not prevent relapses of p vivax p ovale p vivax p ovale clinical pharmacology microbiologyprior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria consult the centers for disease control and prevention cdc malaria website httpwwwcdcgovmalaria lupus erythematosushydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults rheumatoid arthritishydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults,3
actemrar rheumatoid arthritis ra 11 adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more diseasemodifying antirheumatic drugs dmards giant cell arteritis gca 12 adult patients with giant cell arteritis polyarticular juvenile idiopathic arthritis pjia 13 patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis systemic juvenile idiopathic arthritis sjia 14 patients 2 years of age and older with active systemic juvenile idiopathic arthritis cytokine release syndrome crs 15 adults and pediatric patients 2 years of age and older with chimeric antigen receptor car t cellinduced severe or lifethreatening cytokine release syndromeactemraractemraractemraractemraractemrar,3
cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney liver and heart allogeneic transplants cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroidscyclosporine capsules usp modified are indicated for the treatment of patients with severe active rheumatoid arthritis where the disease has not adequately responded to methotrexate cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alonecyclosporine capsules usp modified are indicated for the treatment of adult nonimmunocompromised patients with severe ie extensive andor disabling recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy eg puva retinoids or methotrexate or in patients for whom other systemic therapies are contraindicated or cannot be toleratedwhile rebound rarely occurs most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment,3
cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney liver and heart allogeneic transplants cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroidscyclosporine capsules usp modified are indicated for the treatment of patients with severe active rheumatoid arthritis where the disease has not adequately responded to methotrexate cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alonecyclosporine capsules usp modified are indicated for the treatment of adult nonimmunocompromised patients with severe ie extensive andor disabling recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy eg puva retinoids or methotrexate or in patients for whom other systemic therapies are contraindicated or cannot be toleratedwhile rebound rarely occurs most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment,3
cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney liver and heart allogeneic transplants cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroidscyclosporine capsules usp modified are indicated for the treatment of patients with severe active rheumatoid arthritis where the disease has not adequately responded to methotrexate cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alonecyclosporine capsules usp modified are indicated for the treatment of adult nonimmunocompromised patients with severe ie extensive andor disabling recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy eg puva retinoids or methotrexate or in patients for whom other systemic therapies are contraindicated or cannot be toleratedwhile rebound rarely occurs most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment,3
carefully consider the potential benefits and risks of nabumetone tablets usp and other treatment options before deciding to use nabumetone tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings nabumetone tablets usp are indicated for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,2
carefully consider the potential benefits and risks of nabumetone tablets usp and other treatment options before deciding to use nabumetone tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings nabumetone tablets usp are indicated for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,2
carefully consider the potential benefits and risks of tolmetin sodium capsules usp and other treatment options before deciding to use tolmetin sodium capsules use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningstolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis tolmetin sodium capsules are indicated in the treatment of acute flares and the longterm management of the chronic diseasetolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age see precautions pediatric usedosage and administration,2
carefully consider the potential benefits and risks of tolmetin sodium capsules usp and other treatment options before deciding to use tolmetin sodium capsules use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningstolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis tolmetin sodium capsules are indicated in the treatment of acute flares and the longterm management of the chronic diseasetolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age see precautions pediatric usedosage and administration,2
piroxicam capsule is indicated for relief of the signs and symptoms of osteoarthritisfor relief of the signs and symptoms of rheumatoid arthritispiroxicam capsuleis a nonste roidal anti infla mmato ry d rug indicated for relief of the signs and sy mpt o ms of osteoarthritis oa 1relief of the signs and sy mpto ms of rheu m atoid arthritis ra 1,2
fenoprofen calcium usp is indicated for relief of mild to moderate pain in adultsrelief of the signs and symptoms of rheumatoid arthritesrelief of the signs and symptoms of osteoarthritisfenoprofen calcium usp is a nonsteroidal antiinflammatory drug indicated for relief of mild to moderate pain in adults 1relief of the signs and symptoms of rheumatoid arthritis 1relief of the signs and symptoms of osteoarthritis 1,2
carefully consider the potential benefits and risks of flurbiprofen tablets and other treatment options before deciding to use flurbiprofen tablets use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsflurbiprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,2
carefully consider the potential benefits and risks of etodolac extendedrelease tablets usp and other treatment options before deciding to use etodolac extendedrelease tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsetodolac extendedrelease tablets usp are indicated for relief of signs and symptoms of juvenile arthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,2
carefully consider the potential benefits and risks of etodolac extendedrelease tablets usp and other treatment options before deciding to use etodolac extendedrelease tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsetodolac extendedrelease tablets usp are indicated for relief of signs and symptoms of juvenile arthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,2
sulfasalazine delayed release tablets are indicated a b c d1sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites eg patients experiencing nausea and vomiting with the first few doses of the drug or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effectsin patients with rheumatoid arthritis or juvenile rheumatoid arthritis rest and physiotherapy as indicated should be continued unlike antiinflammatory drugs sulfasalazine delayed release tablets do not produce an immediate response concurrent treatment with analgesics andor nonsteroidal antiinflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent,3
sulfasalazine delayed release tablets are indicated a b c d1sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites eg patients experiencing nausea and vomiting with the first few doses of the drug or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effectsin patients with rheumatoid arthritis or juvenile rheumatoid arthritis rest and physiotherapy as indicated should be continued unlike antiinflammatory drugs sulfasalazine delayed release tablets do not produce an immediate response concurrent treatment with analgesics andor nonsteroidal antiinflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent,3
qmiiz odt is a nonsteroidal antiinflammatory drug indicated for osteoarthritis in adults oa 11rheumatoid arthritis in adults ra 12juvenile rheumatoid arthritis jra pauciarticular and polyarticular course in pediatric patients who weigh greater than or equal to 60 kg 13qmiiz odt is indicated for relief of the signs and symptoms of osteoarthritis in adults see clinical studies 141qmiiz odt is indicated for relief of the signs and symptoms of rheumatoid arthritis in adults see clinical studies 141qmiiz odt is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in pediatric patients who weigh greater than or equal to 60 kg see dosage and administration 24142,3
carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsdiflunisal tablets are indicated for acute or longterm use for symptomatic treatment of the following1 mild to moderate pain2 osteoarthritis3 rheumatoid arthritis,3
osteoarthritis rheumatoid arthritis and acute painful shouldercholine magnesium trisalicylate liquid is effective and generally well tolerated and is logical choice whenever salicylate treatment is indicated it is particularly suitable when a onceaday or bid dosage regimen is important to patient compliance when gastrointestinal intolerance to aspirin is encountered when gastrointestinal microbleeding or hematologic effects of aspirin are considered a patient hazard and when interference or the risk of interference with normal platelet function by aspirin or by propionic acid derivatives is considered to be clinically undesirable use of choline magnesium trisalicylate liquid is appropriate when a liquid dosage form is preferred as in the elderly patientthe efficacy of choline magnesium trisalicylate liquid has not been studied in those patients who are designated by the american rheumatism association as belonging in analgesic and antipyretic action in children,3
oxaprozin tablets are indicated for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of juvenile rheumatoid arthritis oxaprozin is a nonsteroidal antiinflammatory drug indicated for relief of signs and symptoms of osteoarthritis oa 1 relief of signs and symptoms of rheumatoid arthritis ra 1relief of signs and symptoms of juvenile rheumatoid arthritis jra 1,2
oxaprozin tablets are indicated for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of juvenile rheumatoid arthritis oxaprozin is a nonsteroidal antiinflammatory drug indicated for relief of signs and symptoms of osteoarthritis oa 1 relief of signs and symptoms of rheumatoid arthritis ra 1relief of signs and symptoms of juvenile rheumatoid arthritis jra 1,2
azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptomsazathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation experience with over 16000 transplants shows a 5year patient survival of 35 to 55 but this is dependent on donor match for hla antigens antidonor or antibcell alloantigen antibody and other variables the effect of azathioprine tablets on these variables has not been tested in controlled trialsazathioprine tablets usp are indicated for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms aspirin nonsteroidal antiinflammatory drugs andor low dose glucocorticoids may be continued during treatment with azathioprine tablets the combined use of azathioprine tablets with disease modifying antirheumatic drugs dmards has not been studied for either added benefit or unexpected adverse effects the use of azathioprine tablets with these agents cannot be recommended,3
azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptomsazathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation experience with over 16000 transplants shows a 5year patient survival of 35 to 55 but this is dependent on donor match for hla antigens antidonor or antibcell alloantigen antibody and other variables the effect of azathioprine tablets on these variables has not been tested in controlled trialsazathioprine tablets usp are indicated for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms aspirin nonsteroidal antiinflammatory drugs andor low dose glucocorticoids may be continued during treatment with azathioprine tablets the combined use of azathioprine tablets with disease modifying antirheumatic drugs dmards has not been studied for either added benefit or unexpected adverse effects the use of azathioprine tablets with these agents cannot be recommended,3
carefully consider the potential benefits and risks of ketoprofen immediaterelease capsules and ketoprofen extendedrelease capsules before deciding to use ketoprofen immediaterelease capsules and ketoprofen extendedrelease capsules use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsketoprofen immediaterelease capsules and ketoprofen extendedrelease capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritisketoprofen extendedrelease capsules are not recommended for treatment of acute pain because of its extendedrelease characteristics see clinical pharmacology pharmacokineticsketoprofen immediaterelease capsules are indicated for the management of pain ketoprofen immediaterelease capsules are also indicated for treatment of primary dysmenorrhea,2
carefully consider the potential benefits and risks of salsalate tablets usp and other treatment options before deciding to use salsalate tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis osteoarthritis and related rheumatic disorder warnings,2
carefully consider the potential benefits and risks of salsalate tablets usp and other treatment options before deciding to use salsalate tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis osteoarthritis and related rheumatic disorder warnings,2
xeljanzxeljanz xr is a janus kinase jak inhibitor rheumatoid arthritis limitations of use1 psoriatic arthritis limitations of use1 ulcerative colitis limitations of use1 rheumatoid arthritis xeljanzxeljanz xr is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate it may be used as monotherapy or in combination with methotrexate or other nonbiologic diseasemodifying antirheumatic drugs dmards limitations of use use of xeljanzxeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended psoriatic arthritis xeljanzxeljanz xr is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other diseasemodifying antirheumatic drugs dmards limitations of use use of xeljanzxeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended ulcerative colitis xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis uc limitations of use use of xeljanz in combination with biological therapies for uc or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended,3
unituxin dinutuximab is indicated in combination with granulocytemacrophage colonystimulating factor gmcsf interleukin2 il2 and 13cisretinoic acid ra for the treatment of pediatric patients with highrisk neuroblastoma who achieve at least a partial response to prior firstline multiagent multimodality therapy see clinical studies 14unituxin is a gd2binding monoclonal antibody indicated in combination with granulocytemacrophage colonystimulating factor gmcsf interleukin2 il2 and 13cisretinoic acid ra for the treatment of pediatric patients with highrisk neuroblastoma who achieve at least a partial response to prior firstline multiagent multimodality therapy 1,3
neomycin sulfate oral preparations are contraindicated in the presence of intestinal obstruction and in individuals with a history of hypersensitivity to the drugpatients with a history of hypersensitivity or serious toxic reaction to other aminoglycosides may have a crosssensitivity to neomycin neomycin sulfate oral preparations are contraindicated in patients with inflammatory or ulcerative gastrointestinal disease because of the potential for enhanced gastrointestinal absorption of neomycin,1
methimazole is indicated in the medical treatment of hyperthyroidism longterm therapy may lead to remission of the disease methimazole may be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy methimazole is also used when thyroidectomy is contraindicated or not advisable,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapymeropenem for injection is useful as presumptive therapy in the indicated condition eg intraabdominal infections prior to the identification of the causative organisms because of its broad spectrum of bactericidal activityfor information regarding use in pediatric patients see indications and usage 111213 dosage and administration 23 adverse reactions 61 clinical pharmacology 123meropenem for injection is a penem antibacterial indicated as single agent therapy for the treatment of complicated skin and skin structure infections adult patients and pediatric patients 3 months of age and older only 11 complicated intraabdominal infections adult and pediatric patients 12 bacterial meningitis pediatric patients 3 months of age and older only 13to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteriameropenem for injection is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes streptococcus agalactiaeenterococcus faecalis pseudomonas aeruginosa escherichia coli proteus mirabilis bacteroides fragilispeptostreptococcus meropenem for injection is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci escherichia coli klebsiella pneumoniae pseudomonas aeruginosa bacteroides fragilis b thetaiotaomicronpeptostreptococcus meropenem for injection is indicated as a single agent therapy for the treatment of bacterial meningitis caused by streptococcus pneumoniaethe efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of streptococcus pneumoniae has not been establishedneisseria meningitidismeropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapymeropenem for injection is useful as presumptive therapy in the indicated condition eg intraabdominal infections prior to the identification of the causative organisms because of its broad spectrum of bactericidal activityfor information regarding use in pediatric patients see indications and usage 111213 dosage and administration 23 adverse reactions 61 clinical pharmacology 123meropenem for injection is a penem antibacterial indicated as single agent therapy for the treatment of complicated skin and skin structure infections adult patients and pediatric patients 3 months of age and older only 11 complicated intraabdominal infections adult and pediatric patients 12 bacterial meningitis pediatric patients 3 months of age and older only 13to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteriameropenem for injection is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes streptococcus agalactiaeenterococcus faecalis pseudomonas aeruginosa escherichia coli proteus mirabilis bacteroides fragilispeptostreptococcus meropenem for injection is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci escherichia coli klebsiella pneumoniae pseudomonas aeruginosa bacteroides fragilis b thetaiotaomicronpeptostreptococcus meropenem for injection is indicated as a single agent therapy for the treatment of bacterial meningitis caused by streptococcus pneumoniaethe efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of streptococcus pneumoniae has not been establishedneisseria meningitidismeropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis,3
tamiflu is an influenza neuraminidase inhibitor indicated for treatment of influenza in patients 1 year and older who have been symptomatic for no more than 2 days 11prophylaxis of influenza in patients 1 year and older 12 important limitations of use efficacy not established in patients who begin therapy after 48 hours of symptoms 13not a substitute for annual influenza vaccination 13no evidence of efficacy for illness from agents other than influenza viruses types a and b 13consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 13tamiflu is indicated for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 daystamiflu is indicated for the prophylaxis of influenza in patients 1 year and olderthe following points should be considered before initiating treatment or prophylaxis with tamiflu efficacy of tamiflu in patients who begin treatment after 48 hours of symptoms has not been establishedtamiflu is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practicesthere is no evidence for efficacy of tamiflu in any illness caused by agents other than influenza viruses types a and binfluenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use tamiflu,3
rapivab is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than two days 1 limitations of use efficacy based on clinical trials in which the predominant influenza virus type was influenza a a limited number of subjects infected with influenza b virus were enrolled 1consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use 1efficacy could not be established in patients with serious influenza requiring hospitalization 1 limitations of use efficacy of rapivab is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza a virus a limited number of subjects infected with influenza b virus were enrolled influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rapivab see microbiology 124the efficacy of rapivab could not be established in patients with serious influenza requiring hospitalization see clinical studies 143,3
otezla an inhibitor of phosphodiesterase 4 pde4 is indicated for the treatment of adult patients with active psoriatic arthritis 11patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy 12otezla is indicated for the treatment of adult patients with active psoriatic arthritisotezla is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,3
otezla an inhibitor of phosphodiesterase 4 pde4 is indicated for the treatment of adult patients with active psoriatic arthritis 11patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy 12otezla is indicated for the treatment of adult patients with active psoriatic arthritisotezla is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,3
otezla an inhibitor of phosphodiesterase 4 pde4 is indicated for the treatment of adult patients with active psoriatic arthritis 11patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy 12otezla is indicated for the treatment of adult patients with active psoriatic arthritisotezla is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,3
indications and usageneoplastic diseasemethotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destuens and hydatidiform molemethotrexate is used in maintenance therapy in combination with other chemotherapeutic agentsmethotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage nonhodgkins lymphomaspsoriasismethotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by biopsy andor after dermatologic consultation it is important that a psoriasis flare is not due to an undiagnosed concomitant disease affecting immune responsesrheumatoid arthritis including polyarticularcourse juvenile rheumatoid arthritismethotrexate is indicated in the management of selected adults with severs active rheumatoid arthritis acr criteria or children with active polyarticularcourse juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of firstline therapy including full dose nonsteroidal antiinflammatory agents nsaidsaspirin nsaids andor low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions steroids may be reduced gradually in patients who respond to methotrexate combined use of methotrexate with gold penicilamine hydroxychloroquine sulfasalazine or cytotoxic agents has not been studied any may increase the incidence of adverse effects rest and physiotherapy as indicated should be continued,3
indications and usageneoplastic diseasemethotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destuens and hydatidiform molemethotrexate is used in maintenance therapy in combination with other chemotherapeutic agentsmethotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage nonhodgkins lymphomaspsoriasismethotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by biopsy andor after dermatologic consultation it is important that a psoriasis flare is not due to an undiagnosed concomitant disease affecting immune responsesrheumatoid arthritis including polyarticularcourse juvenile rheumatoid arthritismethotrexate is indicated in the management of selected adults with severs active rheumatoid arthritis acr criteria or children with active polyarticularcourse juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of firstline therapy including full dose nonsteroidal antiinflammatory agents nsaidsaspirin nsaids andor low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions steroids may be reduced gradually in patients who respond to methotrexate combined use of methotrexate with gold penicilamine hydroxychloroquine sulfasalazine or cytotoxic agents has not been studied any may increase the incidence of adverse effects rest and physiotherapy as indicated should be continued,3
indications and usageneoplastic diseasemethotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destuens and hydatidiform molemethotrexate is used in maintenance therapy in combination with other chemotherapeutic agentsmethotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage nonhodgkins lymphomaspsoriasismethotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by biopsy andor after dermatologic consultation it is important that a psoriasis flare is not due to an undiagnosed concomitant disease affecting immune responsesrheumatoid arthritis including polyarticularcourse juvenile rheumatoid arthritismethotrexate is indicated in the management of selected adults with severs active rheumatoid arthritis acr criteria or children with active polyarticularcourse juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of firstline therapy including full dose nonsteroidal antiinflammatory agents nsaidsaspirin nsaids andor low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions steroids may be reduced gradually in patients who respond to methotrexate combined use of methotrexate with gold penicilamine hydroxychloroquine sulfasalazine or cytotoxic agents has not been studied any may increase the incidence of adverse effects rest and physiotherapy as indicated should be continued,3
altabaxr2staphylococcus aureusstreptococcus pyogenes see clinical studies 14to reduce the development of drugresistant bacteria and maintain the effectiveness of altabax and other antibacterial drugs altabax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteriaaltabax a pleuromutilin antibacterial is indicated for the topical treatment of impetigo due to staphylococcus aureusstreptococcus pyogenes1,3
famciclovir a prodrug of penciclovir is a nucleoside analog dna polymerase inhibitor indicated for immunocompetent adult patients 11 herpes labialis cold sores treatment of recurrent episodes genital herpes treatment of recurrent episodes suppressive therapy of recurrent episodes herpes zoster shingles hivinfected adult patients 12 treatment of recurrent episodes of orolabial or genital herpes limitation of use 13the efficacy and safety of famciclovir have not been established for patients 18 years of age immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in hivinfected patients black and african american patients with recurrent genital herpes herpes labialis cold sores genital herpesrecurrent episodes suppressive therapy herpes zoster shingles recurrent orolabial or genital herpes famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in hivinfected adults the efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been establishedthe efficacy and safety of famciclovir tablets have not been established for patients 18 years of age patients with first episode of genital herpes patients with ophthalmic zoster immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in hivinfected patients black and african american patients with recurrent genital herpes,3
famciclovir tablets a prodrug of penciclovir is a nucleoside analog dna polymerase inhibitor indicated for immunocompetent adult patients11 herpes labialis cold sores treatment of recurrent episodesgenital herpes treatment of recurrent episodes suppressive therapy of recurrent episodes herpes zoster shingles hivinfected adult patients12 treatment of recurrent episodes of orolabial or genital herpes limitation of use13the efficacy and safety of famciclovir tablets has not been established for patients 18 years of age immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in hivinfected patientsblack and african american patients with recurrent genital herpes herpes labialis cold sores genital herpes recurrent episodes suppressive therapy herpes zoster shingles recurrent orolabial or genital herpesthe efficacy and safety of famciclovir tablets have not been established for patients 18 years of age patients with first episode of genital herpes patients with ophthalmic zoster immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in hivinfected patientsblack and african american patients with recurrent genital herpes,3
myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly establishedmyleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation,1
busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia busulfan injection is an alkylating drug indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia cml 1,3
tabloid brand thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias however it is not recommended for use during maintenance therapy or similar longterm continuous treatments due to the high risk of liver toxicity see warnings and adverse reactions the response to this agent depends upon the age of the patient younger patients faring better than older and whether thioguanine is used in previously treated or previously untreated patients reliance upon thioguanine alone is seldom justified for initial remission induction of acute nonlymphocytic leukemias because combination chemotherapy including thioguanine results in more frequent remission induction and longer duration of remission than thioguanine alonetabloid brand thioguanine is not effective in chronic lymphocytic leukemia hodgkins lymphoma multiple myeloma or solid tumors although thioguanine is one of several agents with activity in the treatment of the chronic phase of chronic myelogenous leukemia more objective responses are observed with myleranr,3
lotemax ointment as with other ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures lotemax ointment as with other ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures 4,3
vexolr 1 rimexolone ophthalmic suspension is contraindicated in epithelial herpes simplex keratitis dendritic keratitis vaccinia varicella and most other viral diseases of the cornea and conjunctiva mycobacterial infection of the eye fungal diseases of the eye acute purulent untreated infections which like other diseases caused by microorganisms may be masked or enhanced by the presence of the steroid and in those persons with hypersensitivity to any component of the formulation,1
ocular or periocular infections 41hypersensitivity 42yutiq is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis dendritic keratitis vaccinia varicella mycobacterial infections and fungal diseases yutiq is contraindicated in patients with known hypersensitivity to any components of this product,2
prednisolone acetate ophthalmic suspension 1 is contraindicated in acute untreated purulent ocular infections in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures prednisolone acetate ophthalmic suspension 1 is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids,0
immunocompromised patients 41pregnant patients 42imlygic is a live attenuated herpes simplex virus and may cause lifethreatening disseminated herpetic infection in patients who are immunocompromised do not administer imlygic to immunocompromised patients including those with a history of primary or acquired immunodeficient states leukemia lymphoma aids or other clinical manifestations of infection with human immunodeficiency viruses and those on immunosuppressive therapy see nonclinical toxicology 132do not administer imlygic to pregnant patients,2
lotemax as with other ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures lotemax is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids,3
gleostine is an alkylating drug indicated for the treatment of patients with 1 1gleostine is indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical andor radiotherapeutic procedures gleostine is indicated as a component of combination chemotherapy for the treatment of patients with hodgkins lymphoma whose disease has progressed following initial chemotherapy,3
adcetris is a cd30directed antibodydrug conjugate indicated for treatment of adult patients with previously untreated stage iii or iv classical hodgkin lymphoma chl in combination with doxorubicin vinblastine and dacarbazine 11classical hodgkin lymphoma chl at high risk of relapse or progression as postautologous hematopoietic stem cell transplantation autohsct consolidation 12classical hodgkin lymphoma chl after failure of autohsct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not autohsct candidates 13previously untreated systemic anaplastic large cell lymphoma salcl or other cd30expressing peripheral tcell lymphomas ptcl including angioimmunoblastic tcell lymphoma and ptcl not otherwise specified in combination with cyclophosphamide doxorubicin and prednisone 14systemic anaplastic large cell lymphoma salcl after failure of at least one prior multiagent chemotherapy regimen15primary cutaneous anaplastic large cell lymphoma pcalcl or cd30expressing mycosis fungoides mf who have received prior systemic therapy 16 adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv chl in combination with doxorubicin vinblastine and dacarbazine adcetris is indicated for the treatment of adult patients with chl at high risk of relapse or progression as postautologous hematopoietic stem cell transplantation autohsct consolidation adcetris is indicated for the treatment of adult patients with chl after failure of autohsct or after failure of at least two prior multiagent chemotherapy regimens in patients who are not autohsct candidates adcetris is indicated for the treatment of adult patients with previously untreated salcl or other cd30expressing ptcl including angioimmunoblastic tcell lymphoma and ptcl not otherwise specified in combination with cyclophosphamide doxorubicin and prednisoneadcetris is indicated for the treatment of adult patients with salcl after failure of at least one prior multiagent chemotherapy regimenadcetris is indicated for the treatment of adult patients with pcalcl or cd30expressing mf who have received prior systemic therapy,3
balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older safety and effectiveness of balsalazide beyond 8 weeks in children ages 5 to 17 years and 12 weeks in adults have not been established balsalazide is a locally acting aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older 1safety and effectiveness of balsalazide beyond 8 weeks in children ages 5 to 17 years and 12 weeks in adults have not been established 1,3
entyvio is an integrin receptor antagonist indicated for adult ulcerative colitis uc 11 adult patients with moderately to severely active uc who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids inducing and maintaining clinical responseinducing and maintaining clinical remissionimproving endoscopic appearance of the mucosaachieving corticosteroidfree remission adult crohns disease cd 12 adult patients with moderately to severely active cd who have had an inadequate response with lost response to or were intolerant to a tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids achieving clinical responseachieving clinical remissionachieving corticosteroidfree remissionentyvio vedolizumab is indicated for inducing and maintaining clinical responseinducing and maintaining clinical remissionimproving the endoscopic appearance of the mucosa andachieving corticosteroidfree remissionin adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroidsentyvio vedolizumab is indicated for achieving clinical response achieving clinical remission andachieving corticosteroidfree remissionin adult patients with moderately to severely active crohns disease who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids,3
olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine,3
mesalamine delayedrelease capsules is an aminosalicylate indicated for treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older 11maintenance of remission of ulcerative colitis in adults 12mesalamine delayedrelease capsules is indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and oldermesalamine delayedrelease capsules is indicated for the maintenance of remission of ulcerative colitis in adults,3
praluent is contraindicated in patients with a history of a serious hypersensitivity reaction to praluent reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization see warnings and precautions 51history of a serious hypersensitivity reaction to praluent 4,3
valchlor is an alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoidestype cutaneous tcell lymphoma in patients who have received prior skindirected therapy valchlor is an alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoidestype cutaneous tcell lymphoma in patients who have received prior skindirected therapy 1,3
antepartum use of pitocin is contraindicated in any of the following circumstances where there is significant cephalopelvic disproportionin unfavorable fetal positions or presentations such as transverse lies which are undeliverable without conversion prior to deliveryin obstetrical emergencies where the benefittorisk ratio for either the fetus or the mother favors surgical interventionin fetal distress where delivery is not imminentwhere adequate uterine activity fails to achieve satisfactory progresswhere the uterus is already hyperactive or hypertonicin cases where vaginal delivery is contraindicated such as invasive cervical carcinoma active herpes genitalis total placenta previa vasa previa and cord presentation or prolapse of the cordin patients with hypersensitivity to the drug,1
vibativ is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria complicated skin and skin structure infections csssi 11hospitalacquired and ventilatorassociated bacterial pneumonia habpvabp caused by susceptible isolates of staphylococcus aureus12to reduce the development of drugresistant bacteria and maintain the effectiveness of vibativ and other antibacterial drugs vibativ should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria vibativ is indicated for the treatment of adult patients with complicated skin and skin structure infections csssi caused by susceptible isolates of the following grampositive microorganisms staphylococcus aureusstreptococcus pyogenesstreptococcus agalactiaestreptococcus anginosuss anginosus s intermediuss constellatusenterococcus faecalisvibativ is indicated for the treatment of adult patients with hospitalacquired and ventilatorassociated bacterial pneumonia habpvabp caused by susceptible isolates of staphylococcus aureuscombination therapy may be clinically indicated if the documented or presumed pathogens include gramnegative organisms appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to telavancin vibativ may be initiated as empiric therapy before results of these tests are known to reduce the development of drugresistant bacteria and maintain the effectiveness of vibativ and other antibacterial drugs vibativ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
selenium sulfide 23 shampoo is a liquid antiseborrheic antifungal preparation useful for the treatment of seborrheic dermatitis of the scalp dandruff and tinea versicolor urea hydrates and is useful for conditions such as dry scalp,3
eptifibatide injection is a platelet aggregation inhibitor indicated for treatment of acute coronary syndrome acs managed medically or with percutaneous coronary intervention pci 11treatment of patients undergoing pci including intracoronary stenting 12eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction mi in patients with acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those undergoing percutaneous coronary intervention pcieptifibatide injection is indicated to decrease the rate of a combined endpoint of death new mi or need for urgent intervention in patients undergoing pci including those undergoing intracoronary stenting see clinical studies 141142,3
abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary interventionin patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hourssafety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been establishedabciximab is intended for use with aspirin and heparin and has been studied only in that setting as described in clinical studies,3
azelaic acid gel 15 is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated azelaic acid gel 15 is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated 1,3
rhofadetm cream is indicated for the topical treatment of persistent facial erythema associated with rosacea in adultsrhofadetm1a1,3
calcipotriene topical solution 0005 scalp solution is indicated for the topical treatment of chronic moderately severe psoriasis of the scalp the safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established,3
photochemotherapy methoxsalen with long wave uva radiation is indicated for the symptomatic control of severe recalcitrant disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy methoxsalen capsules usp soft gelatin capsules are intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation,3
acitretin capsules usp are indicated for the treatment of severe psoriasis in adults because of significant adverse effects associated with its use acitretin capsules usp should be prescribed only by those knowledgeable in the systemic use of retinoids in females of reproductive potential acitretin capsules usp should be reserved for nonpregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments see boxed contraindications and warnings most patients experience relapse of psoriasis after discontinuing therapy subsequent courses when clinically indicated have produced efficacy results similar to the initial course of therapy,3
trientine hydrochloride capsule is indicated in the treatment of patients with wilsons disease who are intolerant of penicillamine clinical experience with trientine hydrochloride capsule is limited and alternate dosing regimens have not been wellcharacterized all endpoints in determining an individual patients dose have not been well defined trientine hydrochloride capsule and penicillamine cannot be considered interchangeable trientine hydrochloride capsule should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effectsunlike penicillamine trientine hydrochloride capsule is not recommended in cystinuria or rheumatoid arthritis the absence of a sulfhydryl moiety renders it incapable of binding cystine and therefore it is of no use in cystinuria in 15 patients with rheumatoid arthritis trientine hydrochloride capsule was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatmenttrientine hydrochloride capsule is not indicated for treatment of biliary cirrhosis,3
lucentis is indicated for the treatment of patients withlucentis a vascular endothelial growth factor vegf inhibitor is indicated for the treatment of patients with neovascular wet agerelated macular degeneration amd 11macular edema following retinal vein occlusion rvo 12diabetic macular edema dme 13diabetic retinopathy dr 14myopic choroidal neovascularization mcnv 15,3
lucentis is indicated for the treatment of patients withlucentis a vascular endothelial growth factor vegf inhibitor is indicated for the treatment of patients with neovascular wet agerelated macular degeneration amd 11macular edema following retinal vein occlusion rvo 12diabetic macular edema dme 13diabetic retinopathy dr 14myopic choroidal neovascularization mcnv 15,3
modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy obstructive sleep apnea and shift work disorder in osa modafinil tablets are indicated as an adjunct to standard treatments for the underlying obstruction if continuous positive airway pressure cpap is the treatment of choice for a patient a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating modafinil tablets if modafinil tablets are used adjunctively with cpap the encouragement of and periodic assessment of cpap compliance is necessary in all cases careful attention to the diagnosis and treatment of the underlying sleep disorders is of utmost importance prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness the effectiveness of modafinil in longterm use greater than 9 weeks in narcolepsy clinical trials and 12 weeks in osa and swd clinical trials has not been systematically evaluated in placebocontrolled trials the physician who elects to prescribe modafinil tablets for an extended time in patients with narcolepsy osa or swd should periodically reevaluate longterm usefulness for the individual patient,3
nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea osa narcolepsy or shift work disorder swdin osa nuvigil is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction if continuous positive airway pressure cpap is the treatment of choice for a patient a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating nuvigil for excessive sleepiness if nuvigil is used adjunctively with cpap the encouragement of and periodic assessment of cpap compliance is necessary in all cases careful attention to the diagnosis and treatment of the underlying sleep disorders is of utmost importance prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepinessthe effectiveness of nuvigil in longterm use greater than 12 weeks has not been systematically evaluated in placebocontrolled trials the physician who elects to prescribe nuvigil for an extended time in patients should periodically reevaluate longterm usefulness for the individual patientnuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with treated obstructive sleep apnea osa narcolepsy or shift work disorder swd 1,3
dextroamphetamine sulfate extendedrelease capsules are indicated in narcolepsy attention deficit disorder with hyperactivity as an integral part of a total treatment program that typically includes other measures psychological educational social for patients ages 6 years to 16 years with this syndrome a diagnosis of attention deficit hyperactivity disorder adhd dsmiv implies the presence of the hyperactiveimpulsive or inattentive symptoms that caused impairment and were present before age 7 years the symptoms must cause clinically significant impairment eg in social academic or occupational functioning and be present in 2 or more settings eg school or work and at home the symptoms must not be better accounted for by another mental disorder for the inattentive type at least 6 of the following symptoms must have persisted for at least 6 months lack of attention to detailscareless mistakes lack of sustained attention poor listener failure to follow through on tasks poor organization avoids tasks requiring sustained mental effort loses things easily distracted forgetful for the hyperactiveimpulsive type at least 6 of the following symptoms must have persisted for at least 6 months fidgetingsquirming leaving seat inappropriate runningclimbing difficulty with quiet activities on the go excessive talking blurting answers cant wait turn intrusive the combined type requires both inattentive and hyperactiveimpulsive criteria to be met special diagnostic considerations specific etiology of this syndrome is unknown and there is no single diagnostic test adequate diagnosis requires the use of medical and special psychological educational and social resources learning may or may not be impaired the diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of dsmiv characteristics need for comprehensive treatment program dextroamphetamine sulfate extendedrelease is indicated as an integral part of a total treatment program for adhd that may include other measures psychological educational social for patients with this syndrome drug treatment may not be indicated for all patients with this syndrome stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors andor other primary psychiatric disorders including psychosis appropriate educational placement is essential and psychosocial intervention is often helpful when remedial measures alone are insufficient the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the patients symptoms,3
xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness eds in patients 7 years of age and older with narcolepsyxyrem is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness eds in patients 7 years of age and older with narcolepsy 1,3
benlysta belimumab is indicated for the treatment of patients aged 5 years and older with active autoantibodypositive systemic lupus erythematosus sle who are receiving standard therapy limitations of usethe efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situationsbenlysta is a blymphocyte stimulator blysspecific inhibitor indicated for the treatment of patients aged 5 years and older with active autoantibodypositive systemic lupus erythematosus who are receiving standard therapy 1limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations 1,3
ibandronate sodium tablets are contraindicated in patients with the following conditions abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia see warnings and precautions 51inability to stand or sit upright for at least 60 minutes see dosage and administration 22 and warnings and precautions 51hypocalcemia see warnings and precautions 52known hypersensitivity to ibandronate sodium tablets or to any of its excipients cases of anaphylaxis have been reported see adverse reactions 62 abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia 4 51inability to stand or sit upright for at least 60 minutes 4 51 hypocalcemia 4 hypersensitivity to ibandronate sodium tablets 4,1
actonel is contraindicated in patients with the following conditions abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia see warnings and precautions 51inability to stand or sit upright for at least 30 minutes see dosage and administration 2 warnings and precautions 51hypocalcemia seewarnings and precautions 52known hypersensitivity to actonel or any of its excipients angioedema generalized rash bullous skin reactions stevensjohnson syndrome and toxic epidermal necrolysis have been reported seeadverse reactions 62 abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia 451inability to stand or sit upright for at least 30 minutes 451hypocalcemia 452known hypersensitivity to any component of this product 462,1
paromomycin sulfate is indicated for intestinal amebiasisacute and chronic noteit is not effective in extraintestinal amebiasis management of hepatic comaas adjunctive therapyto reduce the development of drugresistant bacteria and maintain the effectiveness of paromomycin sulfate capsules and other antibacterial drugs paromomycin sulfate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cystadane is a methylating agent indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are 1 cystathionine betasynthase cbs deficiency510methylenetetrahydrofolate reductase mthfr deficiencycobalamin cofactor metabolism cbl defect cystadaner betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels included within the category of homocystinuria are cystathionine betasynthase cbs deficiency510methylenetetrahydrofolate reductase mthfr deficiencycobalamin cofactor metabolism cbl defect,3
thiola rcystine stones typically occur in approximately 10000 persons in the united states who are homozygous for cystinuria these persons excrete abnormal amounts of cystine in urine of over 250 mgg creatinine as well as excessive amounts of other dibasic amino acids lysine arginine and ornithine in addition they show varying intestinal transport defects for these same amino acids the stone formation is the result of poor aqueous solubility of cystinesince there are no known inhibitors of the crystallization of cystine the stone formation is determined primarily by the urinary supersaturation of cystine thus cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit cystine solubility in urine is phdependent and ranges from 170300 mgliter at ph 5 190400 mgliter at ph 7 and 220500 mgliter at ph 75the goal of therapy is to reduce urinary cystine concentration below its solubility limit it may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentrationunfortunately the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria urinary cystine exceeding 500 mgday in such patients dpenicillamine has been used as an additional therapy like thiola tmhowever dpenicillamine treatment is frequently accompanied by adverse reactions such as dermatologic complications hypersensitivity reactions hematologic abnormalities and renal disturbances thiola ar,3
nityrtm is indicated for the treatment of patients with hereditary tyrosinemia type 1 ht1 in combination with dietary restriction of tyrosine and phenylalaninenityr is a hydroxyphenylpyruvate dioxygenase inhibitor indicated for the treatment of hereditary tyrosinemia type 1 ht1 in combination with dietary restriction of tyrosine and phenylalanine,3
urocitr in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloridein patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medicationin patients with peptic ulcer disease because of its ulcerogenic potentialin patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of urocitrrin patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4patients with peptic ulcer disease 4patients with active urinary tract infection 4patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4,0
afrezzar afrezzar1important limitations of use in patients with type 1 diabetes must use with a longacting insulin 1not recommended for the treatment of diabetic ketoacidosis 1not recommended in patients who smoke 1 limitations of use afrezza is not a substitute for longacting insulin afrezza must be used in combination with longacting insulin in patients with type 1 diabetes mellitusafrezza is not recommended for the treatment of diabetic ketoacidosis see warning and precautions 56the safety and efficacy of afrezza in patients who smoke have not been established the use of afrezza is not recommended in patients who smoke or who have recently stopped smoking,3
afrezzar afrezzar1important limitations of use in patients with type 1 diabetes must use with a longacting insulin 1not recommended for the treatment of diabetic ketoacidosis 1not recommended in patients who smoke 1 limitations of use afrezza is not a substitute for longacting insulin afrezza must be used in combination with longacting insulin in patients with type 1 diabetes mellitusafrezza is not recommended for the treatment of diabetic ketoacidosis see warning and precautions 56the safety and efficacy of afrezza in patients who smoke have not been established the use of afrezza is not recommended in patients who smoke or who have recently stopped smoking,3
levemir is indicated to improve glycemic control in adults and children with diabetes mellitus important limitations of use levemir is not recommended for the treatment of diabetic ketoacidosis intravenous rapidacting or shortacting insulin is the preferred treatment for this condition levemir is a longacting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus 1important limitations of use not recommended for treating diabetic ketoacidosis use intravenous rapidacting or shortacting insulin instead,3
novolog mix 7030 is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus important limitations of use in premix insulins such as novolog mix 7030 the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments novolog mix 7030 is an insulin analog indicated to improve glycemic control in patients with diabetes mellitusimportant limitations of use in premix insulins such as novolog mix 7030 the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments 1,3
apidra is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitusapidra is a rapidacting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus 1,3
chlorpropamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,3
nateglinide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus limitations of use nateglinide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosisnateglinide is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 limitation of use1,3
tolazamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,3
glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with noninsulindependent diabetes mellitus niddm type ii formerly known as maturityonset diabetes after an adequate trial of dietary therapy has proved unsatisfactoryin initiating treatment for noninsulindependent diabetes diet should be emphasized as the primary form of treatment caloric restriction and weight loss are essential in the obese diabetic patient proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia the importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possibleif this treatment program fails to reduce symptoms andor blood glucose the use of an oral sulfonylurea or insulin should be considered use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint furthermore loss of blood glucose control on diet alone also may be transient thus requiring only shortterm administration of glipizideduring maintenance programs glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved judgements should be based on regular clinical and laboratory evaluationsin considering the use of glipizide in asymptomatic patients it should be recognized that controlling the blood glucose in noninsulindependent diabetes has not been definitely established to be effective in preventing the longterm cardiovascular or neural complications of diabetes,2
byetta is a glucagonlike peptide1 glp1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus important limitations of use not a substitute for insulin byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis 12concurrent use with prandial insulin has not been studied and cannot be recommended 12has not been studied in patients with a history of pancreatitis consider other antidiabetic therapies in patients with a history of pancreatitis 12byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusbyetta is not a substitute for insulin byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis as it would not be effective in these settingsthe concurrent use of byetta with prandial insulin has not been studied and cannot be recommendedbased on postmarketing data byetta has been associated with acute pancreatitis including fatal and nonfatal hemorrhagic or necrotizing pancreatitis byetta has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using byetta other antidiabetic therapies should be considered in patients with a history of pancreatitis,2
alogliptin tablets are a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 11 14important limitations of use not for treatment of type 1 diabetes or diabetic ketoacidosis 11 alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14 important limitations of use alogliptin tablets are not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis as it would not be effective in these settings,3
onglyza is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings 1114 12 12 51onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings see clinical studies 14onglyza should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis as it would not be effective in these settingsonglyza has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using onglyza see warnings and precautions 51,3
acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,3
metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitusmetformin hydrochloride extendedrelease tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusmetformin hydrochloride tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus 1metformin hydrochloride extendedrelease tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1,3
miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,3
glyburide tablets usp micronized are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,3
tanzeum is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14 limitations of use see warnings and precautions 51 see warnings and precautions 52 see adverse reactions 61 tanzeum is a glp1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1limitations of use 151 152 1 1 1,3
glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies141glimepiride is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 11 important limitations of use not for treating type 1 diabetes mellitus or diabetic ketoacidosis 11 glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis as it would not be effective in these settings,3
tolbutamide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulindependent diabetes mellitus type ii whose hyperglycemia cannot be controlled by diet alonein initiating treatment for noninsulindependent diabetes diet should be emphasized as the primary form of treatment caloric restriction and weight loss are essential in the obese diabetic patient proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia the importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possibleif this treatment program fails to reduce symptoms andor blood glucose the use of an oral sulfonylurea or insulin should be considered use of tolbutamide tablets must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint furthermore loss of blood glucose control on diet alone may be transient thus requiring only shortterm administration of tolbutamide tabletsduring maintenance programs tolbutamide tablets should be discontinued if satisfactory lowering of blood glucose is no longer achieved judgments should be based on regular clinical and laboratory evaluationsin considering the use of tolbutamide tablets in asymptomatic patients it should be recognized that controlling the blood glucose in noninsulin dependent diabetes has not been definitely established to be effective in preventing the longterm cardiovascular or neural complications of diabetes,3
monotherapy and combination therapy pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings see clinical studies 14 important limitations of use pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis as it would not be effective in these settings use caution in patients with liver disease see warnings and precautions 53pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferatoractivated receptor ppar gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings 114 important limitations of use not for treatment of type 1 diabetes or diabetic ketoacidosis 1,3
farxiga dapagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14farxiga is a sodiumglucose cotransporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 limitation of use 11farxiga is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis,3
jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusto reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease limitations of usejardiance is a sodiumglucose cotransporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusto reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use1,3
adlyxin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus adlyxin is a glucagonlike peptide1 glp1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 limitations of use1 has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis consider other antidiabetic therapies in patients with a history of pancreatitisnot for treatment of type 1 diabetes or diabetic ketoacidosishas not been studied in combination with short acting insulinhas not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis limitations of use adlyxin has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis consider other antidiabetic therapies in patients with a history of pancreatitis see warnings and precautions 52adlyxin is not a substitute for insulin adlyxin is not indicated for use in patients with type 1 diabetes mellitus or for treatment of diabetic ketoacidosis the concurrent use of adlyxin with short acting insulin has not been studied and is not recommended adlyxin has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis,3
qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required hypersensitivity to any of the ingredients of this preparation contraindicates its use,1
ursodiol capsules will not dissolve calcified cholesterol stones radiopaque stones or radiolucent bile pigment stones hence patients with such stones are not candidates for ursodiol capsules therapypatients with compelling reasons for cholecystectomy including unremitting acute cholecystitis cholangitis biliary obstruction gallstone pancreatitis or biliarygastrointestinal fistula are not candidates for ursodiol capsules therapyallergy to bile acids,0
ampicillin for injection usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions respiratory tract infectionstreptococcus pneumoniae staphylococcus aureush influenzae bacterial meningitis septicemia and endocarditisstreptococcus sppe coli proteus mirabilis and salmonella spp urinary tract infections e coliroteus mirabilis gastrointestinal infections salmonella typhisalmonella sppshigella sppbacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed therapy may be instituted prior to obtaining results of susceptibility testingit is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms a change to oral ampicillin may be made as soon as appropriateto reduce the development of drugresistant bacteria and maintain the effectiveness of ampicillin for injection usp and other antibacterial drugs ampicillin for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapyindicated surgical procedures should be performed,3
evomela is an alkylating drug indicated for 11 12evomela is indicated for use as a highdose conditioning treatment prior to hematopoietic progenitor stem cell transplantation in patients with multiple myelomaevomela is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate,3
bortezomib for injection is a proteasome inhibitor indicated for treatment of patients with multiple myeloma 11treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy 12bortezomib for injection is indicated for the treatment of patients with multiple myeloma bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy,3
thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma mm 11thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enl 12thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma mm see clinical studies 141thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum enlthalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence see clinical studies 142,3
empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitorempliciti is a slamf7directed immunostimulatory antibody indicated in 1 1,3
farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival see clinical studies 141farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1,3
kyprolis is a proteasome inhibitor that is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy 114as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy 114 kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapykyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy,3
pomalyst is a thalidomide analogue indicated in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy 11pomalyst in combination with dexamethasone is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy,3
darzalex is indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantin combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitoras monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are doublerefractory to a pi and an immunomodulatory agentdarzalex is a cd38directed cytolytic antibody indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantin combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapyin combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitoras monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are doublerefractory to a pi and an immunomodulatory agent 1,3
ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapyninlaro is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy 1,3
gatifloxacin ophthalmic solution 05 is a topical fluoroquinolone antiinfective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms haemophilus influenzae staphylococcus aureus staphylococcus epidermidis streptococcus mitis streptococcus oralis streptococcus pneumoniaeefficacy for this organism was studied in fewer than 10 infections 1gatifloxacin ophthalmic solution 05 is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms aerobic grampositive bacteria staphylococcus aureus staphylococcus epidermidis streptococcus mitis streptococcus oralis streptococcus pneumoniae aerobic gramnegative bacteria haemophilus influenzae,3
besivancetm besifloxacin ophthalmic suspension 06 is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteriacdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivariusefficacy for this organism was studied in fewer than 10 infectionsbesivancetm besifloxacin ophthalmic suspension 06 is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteriacdc coryneform group g corynebacterium pseudodiphtheriticum corynebacterium striatum haemophilus influenzae moraxella lacunata staphylococcus aureus staphylococcus epidermidis staphylococcus hominis staphylococcus lugdunensis streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivariusefficacy for this organism was studied in fewer than 10 infections 1,3
chlorpropamide tablets are contraindicated in patients with known hypersensitivity to any component of this medicine type 1 diabetes mellitus diabetic ketoacidosis with or without coma this condition should be treated with insulin,1
lantus is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitusimportant limitations of use lantus is not recommended for the treatment of diabetic ketoacidosis intravenous shortacting insulin is the preferred treatment for this conditionlantus is a long acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus 1important limitations of use not recommended for treating diabetic ketoacidosis use intravenous shortacting insulin instead,3
dicyclomine hydrochloride injection is an antispasmodic and anticholinergic antimuscarinic agent indicated for the treatment of functional bowelirritable bowel syndrome 1dicyclomine hydrochloride injection is indicated for the treatment of patients with functional bowelirritable bowel syndrome,3
oncaspar is an asparagine specific enzyme indicated as a component of a multiagent chemotherapeutic regimen for treatment of pediatric and adult patients with firstline acute lymphoblastic leukemia 11acute lymphoblastic leukemia and hypersensitivity to asparaginase 12oncasparr is indicated as a component of a multiagent chemotherapeutic regimen for the firstline treatment of pediatric and adult patients with alloncaspar is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and adult patients with all and hypersensitivity to native forms of lasparaginase,3
xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reducedcalorie diet xenical is also indicated to reduce the risk for weight regain after prior weight loss xenical is indicated for obese patients with an initial body mass index bmi 30 kgm 22 table 1 table 1 body mass index bmi kgm 2conversion factors weight in lbs 22 weight in kilograms kg height in inches x 00254 height in meters m 1 foot 12 inches xenical is a reversible inhibitor of gastrointestinal lipases indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reducedcalorie diet 1xenical is also indicated to reduce the risk for weight regain after prior weight loss 1,3
methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures psychological educational social for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms moderate to severe distractibility short attention span hyperactivity emotional lability and impulsivity the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin nonlocalizing soft neurological signs learning disability and abnormal eeg may or may not be present and a diagnosis of central nervous system dysfunction may or may not be warranted as a shortterm ie a few weeks adjunct in a regimen of weight reduction based on caloric restriction for patients in whom obesity is refractory to alternative therapy eg repeated diets group programs and other drugs the limited usefulness of methamphetamine hydrochloride tablets see clinical pharmacology,3
pregnancy 41use with cyclosporine a 42use with glyburide 43hypersensitivity 44use of bosentan tablets is contraindicated in females who are or may become pregnant to prevent pregnancy females of reproductive potential must use two reliable forms of contraception during treatment and for one month after stopping bosentan tablets see boxed warning527281coadministration of cyclosporine a and bosentan resulted in markedly increased plasma concentrations of bosentan therefore concomitant use of bosentan tablets and cyclosporine a is contraindicated see cytochrome p450 drug interactions 71an increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan therefore coadministration of glyburide and bosentan tablets is contraindicated see cytochrome p450 drug interactions 71bosentan tablets are contraindicated in patients who are hypersensitive to bosentan or any component of the product observed reactions include drug reaction with eosinophilia and systemic symptoms dress anaphylaxis rash and angioedema see adverse reactions 6211,1
for the treatment of severe hypoglycemiaglucagon is indicated as a treatment for severe hypoglycemia low blood sugar which may occur in patients with diabetes mellitus because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient supplementary carbohydrate should be given as soon as possible especially to a pediatric patient for use as a diagnostic aidglucagon is indicated as a diagnostic aid in the radiologic examination of the stomach duodenum small bowel and colon when diminished intestinal motility would be advantageousglucagon is as effective for this examination as are the anticholinergic drugs however as use of glucagon in combination with anticholinergic drugs may result in increased side effects the use of glucagon in combination with anticholinergic drugs is not recommended,3
nplate is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia itp who have had an insufficient response to corticosteroids immunoglobulins or splenectomy pediatric patients 1 year of age and older with itp for at least 6 months who have had an insufficient response to corticosteroids immunoglobulins or splenectomy limitations of use nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome mds or any cause of thrombocytopenia other than chronic itp see warnings and precautions 51 nplate should be used only in patients with itp whose degree of thrombocytopenia and clinical condition increases the risk for bleeding see warnings and precautions 52 nplate should not be used in an attempt to normalize platelet counts see warnings and precautions 52 nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia itp who have had an insufficient response to corticosteroids immunoglobulins or splenectomy pediatric patients 1 year of age and older with itp for at least 6 months who have had an insufficient response to corticosteroids immunoglobulins or splenectomy limitations of use nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome mds or any cause of thrombocytopenia other than chronic itp nplate should be used only in patients with itp whose degree of thrombocytopenia and clinical condition increases the risk for bleeding nplate should not be used in an attempt to normalize platelet counts 1,3
patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4 patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4 patients with peptic ulcer disease 4 patients with active urinary tract infection 4 patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4 potassium citrate extendedrelease tablets are contraindicated in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloride in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medication in patients with peptic ulcer disease because of its ulcerogenic potential in patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of potassium citrate extendedrelease tablet to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate moreover the rise in urinary ph resulting from potassium citrate extendedrelease tablet therapy might promote further bacterial growth in patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia,1
valsartan tablets are an angiotensin ii receptor blocker arb indicated for hypertension 11 heart failure 12 valsartan tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets valsartan tablets are indicated for the treatment of heart failure nyha class iiiv in a controlled clinical trial valsartan tablets significantly reduced hospitalizations for heart failure there is no evidence that valsartan tablets provides added benefits when it is used with an adequate dose of an ace inhibitor see clinical studies 142,3
dactinomycin for injection is an actinomycin indicated for the treatment of 11 12 13 14 15 16 dactinomycin for injection is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion,3
metronidazole topical lotion is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea a controlled clinical study was conducted in 144 patients with moderate to severe rosacea in which metronidazole topical lotion was compared with its vehicle applications were made twice daily for 12 weeks during which patients were instructed to avoid spicy foods thermally hot foods and drinks alcoholic beverages and caffeine patients were also provided samples of a soapless cleansing lotion and if requested a moisturizer metronidazole topical lotion was significantly more effective than its vehicle in mean percent reduction of inflammatory lesions associated with rosacea and in the investigators global assessment of improvement the results of the mean percent reduction in inflammatory lesion counts from baseline after 12 weeks of treatment and the investigators global assessment of improvement at week 12 are presented in the following table efficacy outcomes at week 12 mean percent reduction in inflammatory lesion counts from baseline metronidazole vehicle lotion 55 20 investigators global assessment of improvement percent change from baseline worse no change minimal improvement definite improvement marked improvement clear metronidazole topical lotion n65 5 12 11 32 32 8 vehicle lotion n60 15 27 23 15 20 0 the scale is based on the following definitions worse exacerbation of either erythema or quantitative assessment of papules andor pustules no change condition remains the same minimal improvement slight improvement in the quantitative assessment of papules andor pustules andor slight improvement in erythema definite improvement more pronounced improvement in the quantitative assessment of papules andor pustules andor more pronounced improvement in erythema marked improvement obvious improvement in the quantitative assessment of papules andor pustules andor obvious improvement in erythema clear no papules or pustules and minimal residual or no erythema,3
hypersensitivity 41 women 42 pregnancy 43 81 bicalutamide tablets usp are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablets components hypersensitivity reactions including angioneurotic edema and urticaria have been reported see adverse reactions 62 bicalutamide tablets usp have no indication for women and should not be used in this population bicalutamide tablets usp may cause fetal harm when administered to a pregnant woman bicalutamide tablets usp are contraindicated in women including those who are or may become pregnant there are no studies in pregnant women using bicalutamide tablets usp if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be appraised of the potential hazard to the fetus see use in specific populations 81,1
adenosine is contraindicated in patients with second or thirddegree av block except in patients with a functioning artificial pacemaker see warnings and precautions 52 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker see warnings and precautions 52 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma see warnings and precautions 53 known hypersensitivity to adenosine see warnings and precautions 57 second or thirddegree av block except in patients with a functioning artificial pacemaker 4 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker 4 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma 4 known hypersensitivity to adenosine 4,1
neoplastic diseases methotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destruens and hydatidiform mole methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage nonhodgkins lymphomas psoriasis methotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by biopsy andor after dermatologic consultation rheumatoid arthritis including polyarticularcourse juvenile rheumatoid arthritis methotrexate is indicated in the management of selected adults with severe active rheumatoid arthritis acr criteria or children with active polyarticularcourse juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of firstline therapy including full dose nonsteroidal antiinflammatory agents nsaids aspirin nsaids andor low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions,3
caverject impulse should not be used in men who have a known hypersensitivity to the drug see adverse reactions 61 in men who have conditions that predispose them to priapism such as sickle cell anemia or sickle cell trait multiple myeloma or leukemia see warnings and precautions 51 for the treatment of erectile dysfunction in men with fibrotic conditions of the penis such as anatomical deformation angulation cavernosal fibrosis or peyronies disease see warnings and precautions 52 in men with penile implants known hypersensitivity to the drug 4 men who have conditions that predispose them to priapism such as sickle cell anemia or sickle cell trait multiple myeloma or leukemia 4 treatment of erectile dysfunction in men with fibrotic conditions of the penis such as anatomical deformation angulation cavernosal fibrosis or peyronies disease 4 men with penile implants 4,1
epinephrine is contraindicated in patients with known hypersensitivity to sympathomimetic amines in patients with angle closure glaucoma and patients in shock nonanaphylactic it should not be used in patients anesthetized with agents such as cyclopropane or halothane as these may sensitize the heart to the arrhythmic action of sympathomimetic drugs addition of epinephrine to local anesthetics for injection of certain areas eg fingers toes ears etc is contraindicated because of danger that vasoconstriction may result in sloughing of tissue except as diluted for admixture with local anesthetics to reduce absorption and prolong action epinephrine should not ordinarily be used in those cases where vasopressor drugs may be contraindicated eg in thyrotoxicosis diabetes in obstetrics when maternal blood pressure is in excess of 13080 and in hypertension and other cardiovascular disorders,1
cortef tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of leukemias and lymphomas in adults to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,3
actonel is a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis 11 treatment to increase bone mass in men with osteoporosis 12 treatment and prevention of glucocorticoidinduced osteoporosis 13 treatment of pagets disease 14 actonel is indicated for the treatment and prevention of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis actonel reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosisrelated fractures see clinical studies 141 142 actonel is indicated for treatment to increase bone mass in men with osteoporosis actonel is indicated for the treatment and prevention of glucocorticoidinduced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment daily dosage of 75 mg prednisone or equivalent for chronic diseases patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d actonel is indicated for treatment of pagets disease of bone in men and women,3
the use of maois intended to treat psychiatric disorders with norpramin or within 14 days of stopping treatment with norpramin is contraindicated because of an increased risk of serotonin syndrome the use of norpramin within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated see warnings dosage and administration starting norpramin in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome see warnings dosage and administration norpramin is contraindicated in the acute recovery period following myocardial infarction it should not be used in those who have shown prior hypersensitivity to the drug crosssensitivity between this and other dibenzazepines is a possibility,1
omnitroper is a recombinant human growth hormone indicated for pediatric 11 adult 12 omnitrope somatropin injection is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone gh omnitrope somatropin injection is indicated for the treatment of pediatric patients who have growth failure due to praderwilli syndrome pws the diagnosis of pws should be confirmed by appropriate genetic testing see contraindications 42 52 omnitrope somatropin injection is indicated for the treatment of growth failure in children born small for gestational age sga who fail to manifest catchup growth by age 2 years omnitrope somatropin injection is indicated for the treatment of growth failure associated with turner syndrome omnitrope somatropin injection is indicated for the treatment of idiopathic short stature iss also called nongrowth hormonedeficient short stature defined by height standard deviation score sds 225 and associated with growth rates unlikely to permit attainment of adult height in the normal range in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means omnitrope somatropin injection is indicated for the replacement of endogenous gh in adults with growth hormone deficiency ghd who meet either of the following two criteria patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults confirmation of the diagnosis of adult growth hormone deficiency in both,3
acute critical illness treatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery abdominal surgery or multiple accidental trauma or those with acute respiratory failure see warnings and precautions 51 praderwilli syndrome in children somatropin is contraindicated in patients with praderwilli syndrome who are severely obese have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment there have been reports of sudden death when somatropin was used in such patients see warnings and precautions 52 active malignancy in general somatropin is contraindicated in the presence of active malignancy any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin somatropin should be discontinued if there is evidence of recurrent activity since ghd may be an early sign of the presence of a pituitary tumor or rarely other brain tumors the presence of such tumors should be ruled out prior to initiation of treatment somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor see warnings and precautions 53 hypersensitivity omnitrope is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products see warnings and precautions 56 diabetic retinopathy somatropin is contraindicated in patients with active proliferative or severe nonproliferative diabetic retinopathy closed epiphyses somatropin should not be used for growth promotion in pediatric patients with closed epiphyses 4 4 4 4 4 4 4,1
irbesartan tablets are angiotensin ii receptor blocker arb indicated for treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 11 treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes an elevated serum creatinine and proteinuria 12 irbesartan tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular cv events primarily strokes and myocardial infarction these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension an elevated serum creatinine and proteinuria 300 mgday in this population irbesartan tablets reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or endstage renal disease need for dialysis or renal transplantation see clinical studies 142,3
1 endocrine disorders congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases systemic lupus erythematosus acute rheumatic carditis systemic dermatomyositis polymyositis 4 dermatologic diseases bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions 6 ophthalmic diseases allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia 7 respiratory diseases loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8 hematologic disorders secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases leukemias and lymphomas in adults acute leukemia of childhood 10 edematous states 11 gastrointestinal diseases ulcerative colitis regional enteritis 12 nervous system 13 miscellaneous trichinosis with neurologic or myocardial involvement,3
1 endocrine disorders congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3 collagen diseases systemic lupus erythematosus acute rheumatic carditis systemic dermatomyositis polymyositis 4 dermatologic diseases bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis 5 allergic states seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions 6 ophthalmic diseases allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia 7 respiratory diseases loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8 hematologic disorders secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases leukemias and lymphomas in adults acute leukemia of childhood 10 edematous states 11 gastrointestinal diseases ulcerative colitis regional enteritis 12 nervous system 13 miscellaneous trichinosis with neurologic or myocardial involvement,3
brineura is contraindicated in patients with any sign or symptom of acute unresolved localized infection on or around the device insertion site eg cellulitis or abscess or suspected or confirmed cns infection eg cloudy csf or positive csf gram stain or meningitis see warnings and precautions 51 any acute intraventricular access devicerelated complication eg leakage extravasation of fluid or device failure see warnings and precautions 52 ventriculoperitoneal shunts any sign or symptom of acute or unresolved localized infection on or around the device insertion site eg cellulitis or abscess or suspected or confirmed cns infection eg cloudy csf or positive csf gram stain or meningitis 4 any acute intraventricular access devicerelated complication eg leakage extravasation of fluid or device failure 4 patients with ventriculoperitoneal shunts 4,1
imatinib mesylate is a kinase inhibitor indicated for the treatment of 11 12 13 15 16 17 18 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis accelerated phase or in chronic phase after failure of interferonalpha therapy adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all adult patients with myelodysplasticmyeloproliferative diseases associated with pdgfr plateletderived growth factor receptor gene rearrangements as determined with an fdaapproved test see dosage and administration 26 adult patients with aggressive systemic mastocytosis without the d816v ckit mutation as determined with an fdaapproved test see dosage and administration 27 adult patients with hypereosinophilic syndrome andor chronic eosinophilic leukemia who have the fip1l1pdgfra fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes andor cel who are fip1l1pdgfra fusion kinase negative or unknown adult patients with unresectable recurrent andor metastatic dermatofibrosarcoma protuberans,3
visipaque is indicated in for visipaque injection is a radiographic contrast agent indicated for the following intraarterial procedures 11 adults and pediatric patients 12 years of age and over intraarterial digital subtraction angiography 270 and 320 mg iodineml angiocardiography left ventriculography and selective coronary arteriography peripheral arteriography visceral arteriography and cerebral arteriography 320 mg iodineml pediatric patients less than 12 years of age angiocardiography cerebral arteriography and visceral arteriography 320 mg iodineml intravenous procedures 12 adults and pediatric patients 12 years of age and over computed tomography ct imaging head and body 270 and 320 mg iodineml excretory urography 270 and 320 mg iodineml peripheral venography 270 mg iodineml coronary computed tomography angiography ccta to assist diagnostic evaluation of patients with suspected coronary artery disease 320 mg iodineml pediatric patients less than 12 years of age ct imaging of the head and body 270 mg iodineml excretory urography 270 mg iodineml adult and pediatric patients 12 years of age and older 270 and 320 mg iodineml intraarterial digital subtraction angiography iadsa 320 mg iodineml angiocardiography left ventriculography and selective coronary arteriography peripheral arteriography visceral arteriography and cerebral arteriography pediatric patients less than 12 years of age 320 mg iodineml angiocardiography cerebral arteriography and visceral arteriography adult and pediatric patients 12 years of age and older 270 and 320 mg iodineml ct imaging of the head and body 270 and 320 mg iodineml excretory urography 270 mg iodineml peripheral venography 320 mg iodineml coronary computed tomography angiography ccta to assist in the diagnostic evaluation of patients with suspected coronary artery disease pediatric patients less than 12 years of age 270 mg iodineml ct imaging of the head and body 270 mg iodineml excretory urography,3
thyroid hormone drugs are indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis this category includes cretinism myxedema and ordinary hypothyroidism in patients of any age pediatric patients adults the elderly or state including pregnancy primary hypothyroidism resulting from functional deficiency primary atrophy partial or total absence of thyroid gland or the effects of surgery radiation or drugs with or without the presence of goiter and secondary pituitary or tertiary hypothalamic hypothyroidism see warnings as pituitary thyroidstimulating hormone tsh suppressants in the treatment or prevention of various types of euthyroid goiters including thyroid nodules subacute or chronic lymphocytic thyroiditis hashimotos and multinodular goiter as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy liothyronine sodium tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef,3
baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis particularly for the relief of flexor spasms and concomitant pain clonus and muscular rigidity patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders the efficacy of baclofen in stroke cerebral palsy and parkinsons disease has not been established and therefore it is not recommended for these conditions,2
caverject impulse should not be used in men who have a known hypersensitivity to the drug see adverse reactions 61 in men who have conditions that predispose them to priapism such as sickle cell anemia or sickle cell trait multiple myeloma or leukemia see warnings and precautions 51 for the treatment of erectile dysfunction in men with fibrotic conditions of the penis such as anatomical deformation angulation cavernosal fibrosis or peyronies disease see warnings and precautions 52 in men with penile implants known hypersensitivity to the drug 4 men who have conditions that predispose them to priapism such as sickle cell anemia or sickle cell trait multiple myeloma or leukemia 4 treatment of erectile dysfunction in men with fibrotic conditions of the penis such as anatomical deformation angulation cavernosal fibrosis or peyronies disease 4 men with penile implants 4,1
prednisone tablets usp are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia 2 rheumatic disorders as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus 4 dermatologic diseases pemphigus 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers 7 respiratory diseases symptomatic sarcoidosis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults 10 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,2
losartan potassium tablets are an angiotensin ii receptor blocker arb indicated for treatment of hypertension to lower blood pressure in adults and children greater than 6 years old lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 11 reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy there is evidence that this benefit does not apply to black patients 12 treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension 13 losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular cv events primarily strokes and myocardial infarction these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan losartan potassium tablets may be administered with other antihypertensive agents losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy but there is evidence that this benefit does not apply to black patients see use in specific populations 86 clinical pharmacology 123 losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria urinary albumin to creatinine ratio 300 mgg in patients with type 2 diabetes and a history of hypertension in this population losartan potassium tablets reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease need for dialysis or renal transplantation see clinical studies 143,3
methotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destruens and hydatidiform mole in acute lymphocytic leukemia methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents methotrexate is also indicated in the treatment of meningeal leukemia methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage nonhodgkins lymphomas methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapsefree survival in patients with nonmetastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor methotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by biopsy andor after dermatologic consultation methotrexate is indicated in the management of selected adults with severe active rheumatoid arthritis acr criteria or children with active polyarticularcourse juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of firstline therapy including full dose nonsteroidal antiinflammatory agents nsaids aspirin nsaids andor low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of ofloxacin tablets usp and other antibacterial drugs ofloxacin tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy dosage and administration acute bacterial exacerbations of chronic bronchitis abecb haemophilus influenzae streptococcus pneumonia because fluoroquinolones including ofloxacin have been associated with serious adverse reactions see warnings communityacquired pneumonia haemophilus influenzae streptococcus pneumonia staphylococcus aureus streptococcus pyogenes proteus mirabilis neisseria gonorrhoeae warnings chlamydia trachomatis warnings chlamydia trachomatis neisseria gonorrhoeae warnings chlamydia trachomatis neisseria gonorrhoeae warnings citrobacter diversus enterobacter aerogenes escherichia coli klebsiella pneumoniae proteus mirabilis pseudomonas aeruginosa warnings escherichia coli klebsiella pneumoniae proteus mirabilis citrobacter diversus pseudomonas aeruginosa prostatitis escherichia coli appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin usp therapy with ofloxacin usp may be initiated before results of these tests are known once results become available appropriate therapy should be continued pseudomonas aeruginosa,3
venlafaxine hydrochloride extendedrelease capsules are a serotonin and norepinephrine reuptake inhibitor snri indicated for the treatment of major depressive disorder mdd social anxiety disorder sad generalized anxiety disorder gad panic disorder pd venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of major depressive disorder mdd efficacy was established in three shortterm 4 8 and 12 weeks and two longterm maintenance trials venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of generalized anxiety disorder gad efficacy was established in two 8week and two 26week placebocontrolled trials venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of social anxiety disorder sad also known as social phobia efficacy was established in four 12week and one 26week placebocontrolled trials venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of panic disorder pd with or without agoraphobia efficacy was established in two 12week placebocontrolled trials,3
venlafaxine hydrochloride extendedrelease capsules are a serotonin and norepinephrine reuptake inhibitor snri indicated for the treatment of major depressive disorder mdd social anxiety disorder sad generalized anxiety disorder gad panic disorder pd venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of major depressive disorder mdd efficacy was established in three shortterm 4 8 and 12 weeks and two longterm maintenance trials venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of generalized anxiety disorder gad efficacy was established in two 8week and two 26week placebocontrolled trials venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of social anxiety disorder sad also known as social phobia efficacy was established in four 12week and one 26week placebocontrolled trials venlafaxine hydrochloride extendedrelease capsules are indicated for the treatment of panic disorder pd with or without agoraphobia efficacy was established in two 12week placebocontrolled trials,3
amoxicillin is indicated in the treatment of infections due to susceptible only blactamasenegative strains of the designated microorganisms in the conditions listed below infections of the ear nose and throat streptococcus s pneumoniae staphylococcus h influenzae infections of the genitourinary tract e coli p mirabilis e faecalis infections of the skin and skin structure streptococcus staphylococcus e coli infections of the lower respiratory tract streptococcus s pneumoniae staphylococcus h influenzae gonorrhea acute uncomplicated anogenital and urethral infections n gonorrhoeae h pylori amoxicillinclarithromycinlansoprazole amoxicillin in combination with clarithromycin plus lansoprazole as triple therapy is indicated for the treatment of patients with h pylori h pylori h pylori clinical studies dosage and administration amoxicillinlansoprazole amoxicillin in combination with lansoprazole delayedrelease capsules as dual therapy is indicated for the treatment of patients with h pylori who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected h pylori clinical studies dosage and administration to reduce the development of drugresistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy indicated surgical procedures should be performed,3
hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents angina pectoris metoprolol tartrate tablets are indicated in the longterm treatment of angina pectoris myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol oral metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or alternatively oral treatment can begin within 3 to 10 days of the acute event see dosage and administration contraindications warnings,3
glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with noninsulindependent diabetes mellitus niddm type ii formerly known as maturityonset diabetes after an adequate trial of dietary therapy has proved unsatisfactory in initiating treatment for noninsulindependent diabetes diet should be emphasized as the primary form of treatment caloric restriction and weight loss are essential in the obese diabetic patient proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia the importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible if this treatment program fails to reduce symptoms andor blood glucose the use of an oral sulfonylurea or insulin should be considered use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint furthermore loss of blood glucose control on diet alone also may be transient thus requiring only shortterm administration of glipizide during maintenance programs glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved judgements should be based on regular clinical and laboratory evaluations in considering the use of glipizide in asymptomatic patients it should be recognized that controlling the blood glucose in noninsulindependent diabetes has not been definitely established to be effective in preventing the longterm cardiovascular or neural complications of diabetes,3
to reduce the development of drugresistant bacteria and maintain effectiveness of doxycycline capsules usp and other antibacterial drugs doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy doxycycline is indicated for the treatment of the following infections rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae mycoplasma pneumoniae chlamydia trachomatis chlamydophila psittaci chlamydia trachomatis chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum borrelia recurrentis doxycycline is also indicated for the treatment of infections caused by the following gramnegative microorganisms chancroid caused by haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis klebsiella granulomatis because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline culture and susceptibility testing are recommended doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug escherichia coli acinetobacter haemophilus influenzae klebsiella doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug upper respiratory infections caused by streptococcus pneumoniae bacillus anthracis bacillus anthracis when penicillin is contraindicated doxycycline is an alternative drug in the treatment of the following infections uncomplicated gonorrhea caused by neisseria gonorrhoeae treponema pallidum treponema pallidum subspecies pertenue listeria monocytogenes fusobacterium fusiforme actinomyces israelii clostridium in acute intestinal amebiasis doxycycline may be a useful adjunct to amebicides in severe acne doxycycline may be useful adjunctive therapy,3
note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligrampermilligram basis see clinical pharmacology cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and wellcontrolled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen pharyngitistonsillitis note acute bacterial otitis media impetigo to reduce the development of drugresistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligrampermilligram basis see clinical pharmacology cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and wellcontrolled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen pharyngitistonsillitis note acute bacterial otitis media impetigo to reduce the development of drugresistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
nexplanon should not be used in women who have known or suspected pregnancy current or past history of thrombosis or thromboembolic disorders liver tumors benign or malignant or active liver disease undiagnosed abnormal genital bleeding known or suspected breast cancer personal history of breast cancer or other progestinsensitive cancer now or in the past allergic reaction to any of the components of nexplanon see adverse reactions 6 known or suspected pregnancy 4 current or past history of thrombosis or thromboembolic disorders 4 54 liver tumors benign or malignant or active liver disease 4 57 undiagnosed abnormal genital bleeding 4 52 known or suspected breast cancer personal history of breast cancer or other progestinsensitive cancer now or in the past 4 56 allergic reaction to any of the components of nexplanon 4 6,1
androgel 162 is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired testicular failure due to conditions such as cryptorchidism bilateral torsion orchitis vanishing testis syndrome orchiectomy klinefelters syndrome chemotherapy or toxic damage from alcohol or heavy metals these men usually have low serum testosterone concentrations and gonadotropins folliclestimulating hormone fsh luteinizing hormone lh above the normal range hypogonadotropic hypogonadism congenital or acquired gonadotropin or luteinizing hormonereleasing hormone lhrh deficiency or pituitaryhypothalamic injury from tumors trauma or radiation these men have low testosterone serum concentrations but have gonadotropins in the normal or low range limitations of use safety and efficacy of androgel 162 in men with agerelated hypogonadism also referred to as lateonset hypogonadism have not been established safety and efficacy of androgel 162 in males less than 18 years old have not been established see use in specific populations 84 topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure see indications and usage 1 123 androgel 162 is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenital or acquired 1 hypogonadotropic hypogonadism congenital or acquired 1 limitations of use safety and efficacy of androgel 162 in men with agerelated hypogonadism have not been established 1 safety and efficacy of androgel 162 in males less than 18 years old have not been established 1 84 topical testosterone products may have different doses strengths or application instructions that may result in different systemic exposure 1 123,3
sotalol hydrochloridesotalol hydrochloride af is contraindicated in patients with sinus bradycardia sick sinus syndrome second and third degree av block unless a functioning pacemaker is present congenital or acquired long qt syndromes cardiogenic shock or decompensated heart failure serum potassium 4 meql bronchial asthma or related bronchospastic conditions hypersensitivity to sotalol for the treatment of afibafl sotalol hydrochloridesotalol hydrochloride af is also contraindicated in patients with baseline qt interval 450 ms creatinine clearance 40 mlmin for the treatment of afibafl or ventricular arrythmias sinus bradycardia 2 nd rd 4 congenital or acquired long qt syndrome 4 serum potassium 4 meql4 cardiogenic shock decompensated heart failure 4 bronchial asthma or related bronchospastic conditions 4 hypersensitivity to sotalol 4 for the treatment of afibafl also contraindicated for qt interval 450 ms 4 creatine clearance 40 mlmin 4,1
rabeprazole sodium delayedrelease tablets are a proton pump inhibitor ppi indicated in adults for 11 12 13 14 helicobacter pylori 15 16 in adolescent patients 12 years of age and older for 17 rabeprazole sodium delayedrelease tablets are indicated for shortterm 4 to 8 weeks treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease gerd for those patients who have not healed after 8 weeks of treatment an additional 8week course of rabeprazole sodium delayedrelease tablets may be considered rabeprazole sodium delayedrelease tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease gerd maintenance controlled studies do not extend beyond 12 months rabeprazole sodium delayedrelease tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks rabeprazole sodium delayedrelease tablets are indicated for shortterm up to four weeks treatment in the healing and symptomatic relief of duodenal ulcers most patients heal within four weeks rabeprazole sodium delayedrelease tablets in combination with amoxicillin and clarithromycin as a three drug regimen are indicated for the treatment of patients with h pylori h pylori h pylori in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 122 rabeprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome rabeprazole sodium delayedrelease tablets are indicated for the treatment of symptomatic gerd in adolescents 12 years of age and above for up to 8 weeks,3
baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis particularly for the relief of flexor spasms and concomitant pain clonus and muscular rigidity patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders the efficacy of baclofen in stroke cerebral palsy and parkinsons disease has not been established and therefore it is not recommended for these conditions,1
history of coronary artery disease cad or coronary vasospasm 4 symptomatic wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 monoamine oxidase maoa inhibitor used in past 2 weeks 4 known hypersensitivity to zolmitriptan 4 zolmitriptan orally disintegrating tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia other significant underlying cardiovascular disease or c warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent use of a maoa inhibitor that is within 2 weeks see drug interactions 72 123 known hypersensitivity to zolmitriptan angioedema and anaphylaxis seen see adverse reactions 62,1
hypersensitivity to desvenlafaxine succinate venlafaxine hydrochloride or any excipients in the desvenlafaxine formulation 4 serotonin syndrome and maois 4 hypersensitivity to desvenlafaxine succinate venlafaxine hydrochloride or to any excipients in the desvenlafaxine formulation angioedema has been reported in patients treated with desvenlafaxine see adverse reactions 61 the use of maois intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine is contraindicated because of an increased risk of serotonin syndrome the use of desvenlafaxine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated see dosage and administration 27 warnings and precautions 52 starting desvenlafaxine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome see dosage and administration 28 warnings and precautions 52,0
acthar gel is contraindicated for intravenous administration acthar gel is contraindicated where congenital infections are suspected in infants administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension primary adrenocortical insufficiency adrenocortical hyperfunction or sensitivity to proteins of porcine origin acthar gel should never be given intravenously acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension or sensitivity to proteins of porcine origin administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in children under 2 years of age with suspected congenital infections 4 treatment of conditions listed within the indications and usage section is contraindicated when they are accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction 4,1
acthar gel is contraindicated for intravenous administration acthar gel is contraindicated where congenital infections are suspected in infants administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension primary adrenocortical insufficiency adrenocortical hyperfunction or sensitivity to proteins of porcine origin acthar gel should never be given intravenously acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension or sensitivity to proteins of porcine origin administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in children under 2 years of age with suspected congenital infections 4 treatment of conditions listed within the indications and usage section is contraindicated when they are accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction 4,1
acthar gel is contraindicated for intravenous administration acthar gel is contraindicated where congenital infections are suspected in infants administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension primary adrenocortical insufficiency adrenocortical hyperfunction or sensitivity to proteins of porcine origin acthar gel should never be given intravenously acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension or sensitivity to proteins of porcine origin administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in children under 2 years of age with suspected congenital infections 4 treatment of conditions listed within the indications and usage section is contraindicated when they are accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction 4,1
acthar gel is contraindicated for intravenous administration acthar gel is contraindicated where congenital infections are suspected in infants administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension primary adrenocortical insufficiency adrenocortical hyperfunction or sensitivity to proteins of porcine origin acthar gel should never be given intravenously acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension or sensitivity to proteins of porcine origin administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in children under 2 years of age with suspected congenital infections 4 treatment of conditions listed within the indications and usage section is contraindicated when they are accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction 4,1
acthar gel is contraindicated for intravenous administration acthar gel is contraindicated where congenital infections are suspected in infants administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension primary adrenocortical insufficiency adrenocortical hyperfunction or sensitivity to proteins of porcine origin acthar gel should never be given intravenously acthar gel is contraindicated in patients with scleroderma osteoporosis systemic fungal infections ocular herpes simplex recent surgery history of or the presence of a peptic ulcer congestive heart failure uncontrolled hypertension or sensitivity to proteins of porcine origin administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of acthar gel acthar gel is contraindicated in children under 2 years of age with suspected congenital infections 4 treatment of conditions listed within the indications and usage section is contraindicated when they are accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction 4,1
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,3
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,2
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,3
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,3
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,3
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,3
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,3
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,2
acthar gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age 11 acthar gel is indicated for the treatment of exacerbations of multiple sclerosis in adults 12 acthar gel may be used for the following disorders and diseases rheumatic collagen dermatologic allergic states ophthalmic respiratory and edematous state 13 19 acthar gel repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age acthar gel repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults controlled clinical trials have shown acthar gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis however there is no evidence that it affects the ultimate outcome or natural history of the disease as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis severe erythema multiforme stevensjohnson syndrome serum sickness severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis iritis iridocyclitis diffuse posterior uveitis and choroiditis optic neuritis chorioretinitis anterior segment inflammation symptomatic sarcoidosis to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus,2
indapamide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive drugs indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure usage in pregnancy the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard see precautions diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy indapamide is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions,3
linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below linezolid is not indicated for the treatment of gramnegative infections it is critical that specific gramnegative therapy be initiated immediately if a concomitant gramnegative pathogen is documented or suspected see warnings and precautions 54 linezolid is an oxazolidinoneclass antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible grampositive bacteria nosocomial pneumonia 11 11 12 12 enterococcus faecium 13 to reduce the development of drugresistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs linezolid should be used only to treat infections that are proven or strongly suspected to be caused by bacteria 14 nosocomial pneumonia staphylococcus aureus streptococcus pneumoniae see clinical studies 14 communityacquired pneumonia streptococcus pneumoniae staphylococcus aureus see clinical studies 14 complicated skin and skin structure infections including diabetic foot infections without concomitant osteomyelitis staphylococcus aureus streptococcus pyogenes streptococcus agalactiae see clinical studies 14 uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes see clinical studies 14 vancomycinresistant enterococcus faecium see clinical studies 14 to reduce the development of drugresistant bacteria and maintain the effectiveness of linezolid and other antibacterial drugs linezolid should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy the safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials,3
hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules uncontrolled hypertension and sensitivity to any ergot alkaloids in patients being treated for hyperprolactinemia bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed see precautions hyperprolactinemic states in the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma see precautions hyperprolactinemic statesand a patient experiences a hypertensive disorder of pregnancy the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy when bromocriptine is being used to treat acromegaly prolactinoma or parkinsons disease in patients who subsequently become pregnant a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn if it is continued the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy including eclampsia preeclampsia or pregnancyinduced hypertension unless withdrawal of bromocriptine is considered to be medically contraindicated the drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated if the drug is used in the postpartum period the patient should be observed with caution,1
cefepime for injection usp is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms see also precautions pediatric use dosage and administration pneumonia streptococcus pneumoniae pseudomonas aeruginosa klebsiella pneumoniae enterobacter empiric therapy for febrile neutropenic patients clinical studies uncomplicated and complicated urinary tract infections including pyelonephritis escherichia coli klebsiella pneumoniae escherichia coli klebsiella pneumoniae proteus mirabilis uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes complicated intraabdominal infections escherichia coli pseudomonas aeruginosa klebsiella pneumoniae enterobacter bacteroides fragilis clinical studies to reduce the development of drugresistant bacteria and maintain the effectiveness of cefepime for injection usp and other antibacterial drugs cefepime for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
serevent diskus is a laba indicated for treatment of asthma in patients aged 4 years and older 11 prevention of exerciseinduced bronchospasm eib in patients aged 4 years and older 12 maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd 13 important limitation not indicated for the relief of acute bronchospasm 11 13 serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a longterm asthma control medication such as an inhaled corticosteroid in patients aged 4 years and older with reversible obstructive airway disease including patients with symptoms of nocturnal asthma laba such as salmeterol the active ingredient in serevent diskus increase the risk of asthmarelated death see warnings and precautions 51 see contraindications 4 pediatric and adolescent patients important limitation of use serevent diskus is also indicated for prevention of exerciseinduced bronchospasm eib in patients aged 4 years and older use of serevent diskus as a single agent for the prevention of eib may be clinically indicated in patients who do not have persistent asthma in patients with persistent asthma use of serevent diskus for the prevention of eib may be clinically indicated but the treatment of asthma should include a longterm asthma control medication such as an inhaled corticosteroid serevent diskus is indicated for the longterm twicedaily morning and evening administration in the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease copd including emphysema and chronic bronchitis important limitation of use,3
methotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destruens and hydatidiform mole methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage nonhodgkins lymphomas methotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by biopsy andor after dermatologic consultation methotrexate is indicated in the management of selected adults with severe active rheumatoid arthritis acr criteria or children with active polyarticularcourse juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of firstline therapy including full dose nonsteroidal antiinflammatory agents nsaids aspirin nsaids andor low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions,3
propafenone hydrochloride extendedrelease capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation af in patients with episodic most likely paroxysmal or persistent af who do not have structural heart disease usage considerations the use of propafenone hydrochloride extendedrelease capsules in patients with permanent af or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia psvt has not been evaluated do not use propafenone hydrochloride extendedrelease capsules to control ventricular rate during af some patients with atrial flutter treated with propafenone have developed 11 conduction producing an increase in ventricular rate concomitant treatment with drugs that increase the functional atrioventricular av nodal refractory period is recommended the effect of propafenone on mortality has not been determined see boxed warning propafenone hydrochloride extendedrelease capsules are an antiarrhythmic indicated to prolong the time to recurrence of symptomatic atrial fibrillation af in patients with episodic most likely paroxysmal or persistent af who do not have structural heart disease 1 usage considerations use in patients with permanent atrial fibrillation or with atrial flutter or paroxysmal supraventricular tachycardia psvt has not been evaluated do not use to control ventricular rate during atrial fibrillation 1 in patients with atrial fibrillation and atrial flutter use propafenone hydrochloride extendedrelease capsules with drugs that increase the atrioventricular nodal refractory period 1 the effect of propafenone on mortality has not been determined 1,3
flector patch is contraindicated in the following patients known hypersensitivity eg anaphylactic reactions and serious skin reactions to diclofenac or any components of the drug product see warnings and precautions 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids severe sometimes fatal anaphylactic reactions to nsaids have been reported in such patients see warnings and precautions 57 58 in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51 flector patch is contraindicated for use on nonintact or damaged skin resulting from any etiology including exudative dermatitis eczema infection lesions burns or wounds known hypersensitivity to diclofenac or any components of the drug product 4 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 4 in the setting of cabg surgery 4 for use on nonintact or damaged skin 4,1
miacalcin synthetic injection is a calcitonin indicated for the following conditions 11 12 13 limitations of use 14 53 miacalcin injection is indicated for the treatment of symptomatic pagets disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable eg patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies miacalcin injection is indicated for the early treatment of hypercalcemic emergencies along with other appropriate agents when a rapid decrease in serum calcium is required until more specific treatment of the underlying disease can be accomplished it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents miacalcin injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause the evidence of efficacy for calcitonin salmon injection is based on increases in total body calcium observed in clinical trials fracture reduction efficacy has not been demonstrated miacalcin injection should be reserved for patients for whom alternative treatments are not suitable eg patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies due to the possible association between malignancy and calcitonin salmon use the need for continued therapy should be reevaluated on a periodic basis see warnings and precautions 53,3
miacalcin synthetic injection is a calcitonin indicated for the following conditions 11 12 13 limitations of use 14 53 miacalcin injection is indicated for the treatment of symptomatic pagets disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable eg patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies miacalcin injection is indicated for the early treatment of hypercalcemic emergencies along with other appropriate agents when a rapid decrease in serum calcium is required until more specific treatment of the underlying disease can be accomplished it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents miacalcin injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause the evidence of efficacy for calcitonin salmon injection is based on increases in total body calcium observed in clinical trials fracture reduction efficacy has not been demonstrated miacalcin injection should be reserved for patients for whom alternative treatments are not suitable eg patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies due to the possible association between malignancy and calcitonin salmon use the need for continued therapy should be reevaluated on a periodic basis see warnings and precautions 53,3
noctiva is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia hyponatremia or a history of hyponatremia see warnings and precautions 51 polydipsia primary nocturnal enuresis see use in specific populations 84 concomitant use with loop diuretics see warnings and precautions 51 concomitant use with systemic or inhaled glucocorticoids see warnings and precautions 51 71 renal impairment with an estimated glomerular filtration rate egfr below 50 mlmin173 m 2 see use in specific populations 86 known or suspected syndrome of inappropriate antidiuretic hormone siadh secretion during illnesses that can cause fluid or electrolyte imbalance such as gastroenteritis saltwasting nephropathies or systemic infection noctiva is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition congestive heart failure new york heart association class ii to iv see warnings and precautions 52 uncontrolled hypertension hyponatremia or a history of hyponatremia 4 polydipsia 4 primary nocturnal enuresis 4 concomitant use with loop diuretics or systemic or inhaled glucocorticoids 4 estimated glomerular filtration rate below 50 mlmin173 m 2 4 syndrome of inappropriate antidiuretic hormone secretion siadh 4 during illnesses that can cause fluid or electrolyte imbalance 4 new york heart association nyha class iiiv congestive heart failure 4 uncontrolled hypertension 4,1
noctiva is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia hyponatremia or a history of hyponatremia see warnings and precautions 51 polydipsia primary nocturnal enuresis see use in specific populations 84 concomitant use with loop diuretics see warnings and precautions 51 concomitant use with systemic or inhaled glucocorticoids see warnings and precautions 51 71 renal impairment with an estimated glomerular filtration rate egfr below 50 mlmin173 m 2 see use in specific populations 86 known or suspected syndrome of inappropriate antidiuretic hormone siadh secretion during illnesses that can cause fluid or electrolyte imbalance such as gastroenteritis saltwasting nephropathies or systemic infection noctiva is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition congestive heart failure new york heart association class ii to iv see warnings and precautions 52 uncontrolled hypertension hyponatremia or a history of hyponatremia 4 polydipsia 4 primary nocturnal enuresis 4 concomitant use with loop diuretics or systemic or inhaled glucocorticoids 4 estimated glomerular filtration rate below 50 mlmin173 m 2 4 syndrome of inappropriate antidiuretic hormone secretion siadh 4 during illnesses that can cause fluid or electrolyte imbalance 4 new york heart association nyha class iiiv congestive heart failure 4 uncontrolled hypertension 4,1
genotropin is a recombinant human growth hormone indicated for pediatric 11 adult 12 genotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone genotropin is indicated for the treatment of pediatric patients who have growth failure due to praderwilli syndrome pws the diagnosis of pws should be confirmed by appropriate genetic testing see contraindications 4 genotropin is indicated for the treatment of growth failure in children born small for gestational age sga who fail to manifest catchup growth by age 2 years genotropin is indicated for the treatment of growth failure associated with turner syndrome genotropin is indicated for the treatment of idiopathic short stature iss also called nongrowth hormonedeficient short stature defined by height standard deviation score sds 225 and associated with growth rates unlikely to permit attainment of adult height in the normal range in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means genotropin is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria adult onset ao childhood onset co patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults according to current standards confirmation of the diagnosis of adult growth hormone deficiency in both,3
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate pravastatin sodium tablets are an hmgcoa reductase inhibitor statin indicated as an adjunctive therapy to diet to 11 11 12 12 12 12 limitations of use fredrickson 13 in hypercholesterolemic patients without clinically evident coronary heart disease chd pravastatin sodium tablets are indicated to in patients with clinically evident chd pravastatin sodium tablets are indicated to pravastatin sodium tablets are indicated fredrickson 1 fredrickson fredrickson 1 2 pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons fredrickson,3
revlimid is a thalidomide analogue indicated for the treatment of adult patients with multiple myeloma mm in combination with dexamethasone 11 mm as maintenance following autologous hematopoietic stem cell transplantation autohsct 11 transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 12 mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 13 previously treated follicular lymphoma fl in combination with a rituximab product 14 previously treated marginal zone lymphoma mzl in combination with a rituximab product 15 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 14 revlimid in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma mm revlimid is indicated as maintenance therapy in adult patients with mm following autologous hematopoietic stem cell transplantation autohsct revlimid is indicated for the treatment of adult patients with transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is indicated for the treatment of adult patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib revlimid in combination with a rituximab product is indicated for the treatment of adult patients with previously treated follicular lymphoma fl revlimid in combination with a rituximab product is indicated for the treatment of adult patients with previously treated marginal zone lymphoma mzl revlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 55,3
revlimid is a thalidomide analogue indicated for the treatment of adult patients with multiple myeloma mm in combination with dexamethasone 11 mm as maintenance following autologous hematopoietic stem cell transplantation autohsct 11 transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 12 mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 13 previously treated follicular lymphoma fl in combination with a rituximab product 14 previously treated marginal zone lymphoma mzl in combination with a rituximab product 15 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 14 revlimid in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma mm revlimid is indicated as maintenance therapy in adult patients with mm following autologous hematopoietic stem cell transplantation autohsct revlimid is indicated for the treatment of adult patients with transfusiondependent anemia due to low or intermediate1risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is indicated for the treatment of adult patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib revlimid in combination with a rituximab product is indicated for the treatment of adult patients with previously treated follicular lymphoma fl revlimid in combination with a rituximab product is indicated for the treatment of adult patients with previously treated marginal zone lymphoma mzl revlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 55,1
alprazolam orally disintegrating tablets usp is a benzodiazepine indicated for 11 14 12 the efficacy of alprazolam in the treatment of panic disorder was established in 2 shortterm placebocontrolled trials 14 alprazolam orally disintegrating tablets usp is indicated for the treatment of generalized anxiety disorder the efficacy of alprazolam in the treatment of generalized anxiety disorder was demonstrated in 5 shortterm placebocontrolled trials see clinical studies 141 alprazolam is also indicated for the treatment of panic disorder with or without agoraphobia the efficacy of alprazolam in the treatment of panic disorder was established in 2 shortterm placebocontrolled trials see clinical studies 142 demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months in duration for generalized anxiety disorder and 4 to 10 weeks duration for panic disorder however patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit the physician should periodically reassess the usefulness of the drug for the individual patient,3
use of monoamine oxidase inhibitors concomitantly or in close temporal proximity 41 use in patients with uncontrolled narrowangle glaucoma 42 concomitant use of savella in patients taking monoamine oxidase inhibitors maois is contraindicated in patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor maoi there have been reports of serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability with possible rapid fluctuations of vital signs and mental status changes that include extreme agitation progressing to delirium and coma these reactions have also been reported in patients who have recently discontinued serotonin reuptake inhibitors and have been started on an maoi some cases presented with features resembling neuroleptic malignant syndrome the effects of combined use of savella and maois have not been evaluated in humans therefore it is recommended that savella should not be used in combination with an maoi or within 14 days of discontinuing treatment with an maoi similarly at least 5 days should be allowed after stopping savella before starting an maoi see dosage and administration 25 52 in clinical trials savella was associated with an increased risk of mydriasis mydriasis has been reported with other dual reuptake inhibitors of norepinephrine and serotonin therefore do not use savella in patients with uncontrolled narrowangle glaucoma,1
ezetimibe is contraindicated in the following conditions the combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels women who are pregnant or may become pregnant because statins decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol ezetimibe in combination with a statin may cause fetal harm when administered to pregnant women additionally there is no apparent benefit to therapy during pregnancy and safety in pregnant women has not been established if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy see use in specific populations 81 nursing mothers because statins may pass into breast milk and because statins have the potential to cause serious adverse reactions in nursing infants women who require ezetimibe treatment in combination with a statin should be advised not to nurse their infants see use in specific populations 83 patients with a known hypersensitivity to any component of this product hypersensitivity reactions including anaphylaxis angioedema rash and urticaria have been reported with ezetimibe see adverse reactions 62 statin contraindications apply when ezetimibe is used with a statin active liver disease which may include unexplained persistent elevations in hepatic transaminase levels 4 52 women who are pregnant or may become pregnant 4 81 nursing mothers 4 83 known hypersensitivity to product components 4 62,1
history of coronary artery disease cad or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or history or current evidence of hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 within 24 hours of treatment with another 5ht 1 4 hypersensitivity to eletriptan hydrobromide angioedema and anaphylaxis seen 4 within at least 72 hours of treatment with the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir 4 eletriptan hydrobromide is contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5hydroxytryptamine1 5ht 1 71 hypersensitivity to eletriptan hydrobromide angioedema and anaphylaxis seen see warnings and precautions 59 recent use ie within at least 72 hours of the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir see drug interactions 72 123,1
dotti is contraindicated in women with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of breast cancer known or suspected estrogendependent neoplasia active dvt pe or a history of these conditions active arterial thromboembolic disease for example stroke and mi or a history of these conditions known anaphylactic reaction or angioedema or hypersensitivity with dotti known liver impairment or disease known protein c protein s or antithrombin deficiency or other known thrombophilic disorders known or suspected pregnancy undiagnosed abnormal genital bleeding 4 52 known suspected or history of breast cancer 4 52 known or suspected estrogendependent neoplasia 4 52 active dvt pe or a history of these conditions 4 51 active arterial thromboembolic disease for example stroke and mi or a history of these conditions 4 51 known anaphylactic reaction or angioedema or hypersensitivity with dotti 4 515 known liver impairment or disease 4 510 known protein c protein s or antithrombin deficiency or other known thrombophilic disorders 4 known or suspected pregnancy 4 81,1
ischemic heart disease coronary artery vasospasm or other significant underlying cardiovascular disease 41 cerebrovascular syndromes eg history of stroke or tia 42 peripheral vascular disease including ischemic bowel disease 43 uncontrolled hypertension 44 do not use almotriptan malate within 24 hours of an ergotaminecontaining or ergottype medication or of another 5ht 1 45 46 hemiplegic or basilar migraine 47 known hypersensitivity to almotriptan malate 48 do not use almotriptan malate in patients with ischemic heart disease angina pectoris history of myocardial infarction or documented silent ischemia or in patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings and precautions 51 do not use almotriptan malate tablets in patients with cerebrovascular syndromes including but not limited to stroke of any type as well as transient ischemic attacks see warnings and precautions 53 do not use almotriptan malate tablets in patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings and precautions 54 because almotriptan malate may increase blood pressure do not use almotriptan malate tablets in patients with uncontrolled hypertension see warnings and precautions 57 do not use almotriptan malate tablets and ergotaminecontaining or ergotderived medications like dihydroergotamine ergotamine tartrate or methysergide within 24 hours of each other see drug interactions 71 almotriptan malate tablets and other 5ht 1 see warnings and precautions 51 52 do not use almotriptan malate tablets in patients with hemiplegic or basilar migraine almotriptan malate tablets are contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients,1
to reduce the development of drugresistant bacteria and maintain the effectiveness of azithromycin for injection usp azithromycin for injection usp is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated susceptible bacteria communityacquired pneumonia in adults 11 pelvic inflammatory disease 12 to reduce the development of drugresistant bacteria and maintain the effectiveness of azithromycin for injection usp and other antibacterial drugs azithromycin for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria due to chlamydophila pneumoniae haemophilus influenzae legionella pneumophila moraxella catarrhalis mycoplasma pneumoniae staphylococcus aureus streptococcus pneumoniae due to chlamydia trachomatis neisseria gonorrhoeae mycoplasma hominis see dosage and administration 2,3
41 42 43 44 1 45 46 47 48 do not use almotriptan tablets almotriptan malate in patients with ischemic heart disease angina pectoris history of myocardial infarction or documented silent ischemia or in patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings and precautions 51 do not use almotriptan tablets in patients with cerebrovascular syndromes including but not limited to stroke of any type as well as transient ischemic attacks see warnings and precautions 53 do not use almotriptan tablets in patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings and precautions 54 because almotriptan may increase blood pressure do not use almotriptan tablets in patients with uncontrolled hypertension see warnings and precautions 57 do not use almotriptan tablets and ergotaminecontaining or ergotderived medications like dihydroergotamine ergotamine tartrate or methysergide within 24 hours of each other see drug interactions 71 almotriptan tablets and other 5ht 1 see warnings and precautions 51 52 do not use almotriptan tablets in patients with hemiplegic or basilar migraine almotriptan tablets are contraindicated in patients with known hypersensitivity to almotriptan or any of their inactive ingredients,1
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate ezetimibe is an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated totalc ldlc apo b and nonhdlc in patients with primary hyperlipidemia alone or in combination with an hmgcoa reductase inhibitor statin 11 reduce elevated totalc ldlc apo b and nonhdlc in patients with mixed hyperlipidemia in combination with fenofibrate 11 reduce elevated totalc and ldlc in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin 12 reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia 13 limitations of use 14 the effect of ezetimibe on cardiovascular morbidity and mortality has not been determined ezetimibe has not been studied in fredrickson type i iii iv and v dyslipidemias monotherapy combination therapy with hmg coa reductase inhibitors statins combination therapy with fenofibrate the combination of ezetimibe and atorvastatin or simvastatin is indicated for the reduction of elevated totalc and ldlc levels in patients with hofh as an adjunct to other lipidlowering treatments eg ldl apheresis or if such treatments are unavailable ezetimibe tablets are indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias,3
zolmitriptan is contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia other significant underlying cardiovascular disease or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent use of a maoa inhibitor that is within 2 weeks see drug interactions 72 clinical pharmacology 123 known hypersensitivity to zolmitriptan tablets angioedema and anaphylaxis seen see adverse reactions 62 history of coronary artery disease cad or coronary vasospasm 4 symptomatic wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 monamine oxidase maoa inhibitor used in past 2 weeks 4 known hypersensitivity to zolmitriptan tablets 4,1
premarin therapy is contraindicated in individuals with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of breast cancer except in appropriately selected patients being treated for metastatic disease known or suspected estrogendependent neoplasia active dvt pe or a history of these conditions active arterial thromboembolic disease for example stroke and mi or a history of these conditions known anaphylactic reaction or angioedema with premarin known liver impairment or disease known protein c protein s or antithrombin deficiency or other known thrombophilic disorders known or suspected pregnancy undiagnosed abnormal genital bleeding 4 known suspected or history of breast cancer except in appropriately selected patients being treated for metastatic diseases 4 52 known or suspected estrogendependent neoplasia 4 52 active dvt pe or a history of these conditions 4 51 active arterial thromboembolic disease for example stroke and mi or a history of these conditions 4 51 known anaphylactic reaction or angioedema with premarin 57 known liver impairment or disease 4 512 known protein c protein s or antithrombin deficiency or other known thrombophilic disorders 4 known or suspected pregnancy 4 81,1
premarin therapy is contraindicated in individuals with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of breast cancer except in appropriately selected patients being treated for metastatic disease known or suspected estrogendependent neoplasia active dvt pe or a history of these conditions active arterial thromboembolic disease for example stroke and mi or a history of these conditions known anaphylactic reaction or angioedema with premarin known liver impairment or disease known protein c protein s or antithrombin deficiency or other known thrombophilic disorders known or suspected pregnancy undiagnosed abnormal genital bleeding 4 known suspected or history of breast cancer except in appropriately selected patients being treated for metastatic diseases 4 52 known or suspected estrogendependent neoplasia 4 52 active dvt pe or a history of these conditions 4 51 active arterial thromboembolic disease for example stroke and mi or a history of these conditions 4 51 known anaphylactic reaction or angioedema with premarin 57 known liver impairment or disease 4 512 known protein c protein s or antithrombin deficiency or other known thrombophilic disorders 4 known or suspected pregnancy 4 81,1
sirolimus is an mtor inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged 13 years receiving renal transplants 11 11 11 12 143 sirolimus is an mtor inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis 13 sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants in patients at low to moderateimmunologic risk see dosage and administration 22 in patients at highimmunologic risk see dosage and administration 23 clinical studies 143 cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal those who are dialysisdependent those with serum creatinine 45 mgdl black patients patients of multiorgan transplants secondary transplants or those with high levels of panelreactive antibodies see clinical studies 142 in patients at highimmunologic risk see clinical studies 143 in pediatric patients see adverse reactions 65 clinical studies 146 the safety and efficacy of de novo see warnings and precautions 512 the safety and efficacy of conversion from calcineurin inhibitors to sirolimus see clinical studies 144 sirolimus is indicated for the treatment of patients with lymphangioleiomyomatosis lam,3
nucynta tablets are contraindicated in patients with significant respiratory depression see warnings and precautions 52 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 55 known or suspected gastrointestinal obstruction including suspected paralytic ileus see warnings and precautions 510 hypersensitivity to tapentadol eg anaphylaxis angioedema or to any other ingredients of the product see adverse reactions 62 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days see drug interactions 7 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 hypersensitivity to tapentadol 4 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days 4,1
metronidazole tablets usp are indicated for the treatment of t vaginalis metronidazole tablets usp are indicated in the treatment of asymptomatic t vaginalis t vaginalis metronidazole tablets usp are indicated in the treatment of acute intestinal amebiasis amebic dysentery and amebic liver abscess in amebic liver abscess metronidazole tablets usp therapy does not obviate the need for aspiration or drainage of pus metronidazole tablets usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria indicated surgical procedures should be performed in conjunction with metronidazole tablets usp therapy in a mixed aerobic and anaerobic infection antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets usp intraabdominal infections bacteroides b fragilis b fragilis b distasonis b ovatus b thetaiotaomicron b vulgatus clostridium eubacterium peptococcus peptostreptococcus skin and skin structure infections bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium gynecologic infections including endometritis endomyometritis tuboovarian abscess and postsurgical vaginal cuff infection caused by bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium bacterial septicemia bacteroides b fragilis clostridium bone and joint infections bacteroides b fragilis central nervous system cns infections including meningitis and brain abscess caused by bacteroides b fragilis lower respiratory tract infections including pneumonia empyema and lung abscess caused by bacteroides b fragilis endocarditis bacteroides b fragilis to reduce the development of drugresistant bacteria and maintain the effectiveness of metronidazole tablets usp and other antibacterial drugs metronidazole tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
follistim r in women for follistim aq cartridge is a gonadotropin indicated in women for induction of ovulation and pregnancy in anovulatory infertile women in whom the cause of infertility is functional and not due to primary ovarian failure 11 pregnancy in normal ovulatory women undergoing controlled ovarian stimulation as part of an in vitro fertilization ivf or intracytoplasmic sperm injection icsi cycle 12 in men for induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism hh in whom the cause of infertility is not due to primary testicular failure 13 prior to initiation of treatment with follistim aq cartridge women should have a complete gynecologic and endocrinologic evaluation primary ovarian failure should be excluded the possibility of pregnancy should be excluded tubal patency should be demonstrated the fertility status of the male partner should be evaluated prior to initiation of treatment with follistim aq cartridge women should have a complete gynecologic and endocrinologic evaluation and diagnosis of cause of infertility the possibility of pregnancy should be excluded the fertility status of the male partner should be evaluated in men for prior to initiation of treatment with follistim aq cartridge men should have a complete medical and endocrinologic evaluation hypogonadotropic hypogonadism should be confirmed and primary testicular failure should be excluded serum testosterone levels should be normalized with human chorionic gonadotropin hcg treatment the fertility status of the female partner should be evaluated,3
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions seasonal or perennial allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,3
when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intramuscular use of depomedrol sterile aqueous suspension is indicated as follows allergic states dermatologic diseases endocrine disorders gastrointestinal diseases hematologic disorders miscellaneous neoplastic diseases nervous system ophthalmic diseases renal diseases respiratory diseases rheumatic disorders see warnings depomedrol is indicated as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis of osteoarthritis depomedrol is indicated for intralesional use in alopecia areata discoid lupus erythematosus keloids localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus neurodermatitis and psoriatic plaques necrobiosis lipoidica diabeticorum depomedrol also may be useful in cystic tumors of an aponeurosis or tendon ganglia,2
amantadine hydrochloride capsules usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus amantadine hydrochloride capsules usp are also indicated in the treatment of parkinsonism and druginduced extrapyramidal reactions influenza a prophylaxis following vaccination during an influenza a outbreak amantadine hydrochloride capsules usp prophylaxis should be considered for the 2 to 4week time period required to develop an antibody response influenza a treatment there is no clinical evidence indicating that amantadine hydrochloride capsules usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules usp amantadine hydrochloride capsules usp is not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules usp parkinsons diseasesyndrome druginduced extrapyramidal reactions,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
methylprednisolone tablets usp are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis symptomatic sarcoidosis berylliosis loefflers syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
indomethacin extendedrelease capsules are contraindicated in the following patients known hypersensitivity eg anaphylactic reactions and serious skin reactions to indomethacin or any components of the drug product see warnings and precautions 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids severe sometimes fatal anaphylactic reactions to nsaids have been reported in such patients see warnings and precautions 57 58 in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51 known hypersensitivity to indomethacin or any components of the drug product 4 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 4 in the setting of cabg surgery 4,1
paroxetine capsules are indicated for the treatment of moderate to severe vasomotor symptoms vms associated with menopause limitation of use paroxetine capsules are not indicated for the treatment of any psychiatric condition paroxetine capsules contain a lower dose of paroxetine than that used to treat depression obsessive compulsive disorder panic disorder generalized anxiety disorder social anxiety disorder and posttraumatic stress disorder the safety and efficacy of this lower dose of paroxetine in paroxetine capsules have not been established for any psychiatric condition patients who require paroxetine for treatment of a psychiatric condition should discontinue paroxetine capsules and initiate a paroxetinecontaining medication that is indicated for such use paroxetine is a selective serotonin reuptake inhibitor ssri indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause vms 1 limitation of use 1,3
tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae hemophilus influenzae lower respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae mycoplasma pneumoniae klebsiellasp skin and soft tissue infections caused by streptococcus pyogenes staphylococcus aureaus staphylococcal infections caused by rickettsia including rocky mountain spotted fever typhus group infections q fever rickettsialpox psittacosis of ornithosis caused by chlamydia psittaci infections caused by chlamydia trachomatis granuloma inquinale caused by calymmatobacterium granulomatis relapsing fever caused by borrelia bartonellosis caused by bartonella bacilliformis chancroid caused by hemophilus ducreyi tularemia caused by francisella tularensis plaque caused by yersinia pestis cholera caused by vibrio cholerae brucellosis caused by brucella infections due to campylobacter fetus as adjunctive therapy in intestinal amebiasis caused by entamoeba histolytica urinary tract infections caused by susceptible strains of escherichia coli klebsiella other infections caused by susceptible gramnegative organisms such as e coli enterobacter aerogenes shigella acinetobacter klebsiella bacteroides in severe acne adjunctive therapy with tetracycline may be useful when penicillin is contraindicated tetracyclines are alternative drugs in the treatment of the following infections syphilis and yaws caused by treponema pallidumand pertenue vincents infection caused by fusobacterium fusiforme infections caused by neisseria gonorrhoeae anthrax caused by bacillus anthracis infections due to listeria monocytogenes actinomycosis caused by actinomyces infections due to clostridium,3
tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below upper respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae hemophilus influenzae lower respiratory tract infections caused by streptococcus pyogenes streptococcus pneumoniae mycoplasma pneumoniae klebsiellasp skin and soft tissue infections caused by streptococcus pyogenes staphylococcus aureaus staphylococcal infections caused by rickettsia including rocky mountain spotted fever typhus group infections q fever rickettsialpox psittacosis of ornithosis caused by chlamydia psittaci infections caused by chlamydia trachomatis granuloma inquinale caused by calymmatobacterium granulomatis relapsing fever caused by borrelia bartonellosis caused by bartonella bacilliformis chancroid caused by hemophilus ducreyi tularemia caused by francisella tularensis plaque caused by yersinia pestis cholera caused by vibrio cholerae brucellosis caused by brucella infections due to campylobacter fetus as adjunctive therapy in intestinal amebiasis caused by entamoeba histolytica urinary tract infections caused by susceptible strains of escherichia coli klebsiella other infections caused by susceptible gramnegative organisms such as e coli enterobacter aerogenes shigella acinetobacter klebsiella bacteroides in severe acne adjunctive therapy with tetracycline may be useful when penicillin is contraindicated tetracyclines are alternative drugs in the treatment of the following infections syphilis and yaws caused by treponema pallidumand pertenue vincents infection caused by fusobacterium fusiforme infections caused by neisseria gonorrhoeae anthrax caused by bacillus anthracis infections due to listeria monocytogenes actinomycosis caused by actinomyces infections due to clostridium,3
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate in patients with chd or multiple risk factors for chd atorvastatin calcium tablets can be started simultaneously with diet atorvastatin calcium tablets are hmgcoa reductase inhibitor indicated as an adjunct therapy to diet to limitations of use atorvastatin calcium tablets have not been studied in fredrickson in adult patients without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as age smoking hypertension low hdlc or a family history of early coronary heart disease atorvastatin calcium tablets are indicated to in adult patients with type 2 diabetes and without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as retinopathy albuminuria smoking or hypertension atorvastatin calcium tablets are indicated to in adult patients with clinically evident coronary heart disease atorvastatin calcium tablets are indicated to atorvastatin calcium tablets are indicated fredrickson fredrickson fredrickson atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons fredrickson,3
capecitabine tablets are a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer 11 metastatic colorectal cancer 11 metastatic breast cancer 12 capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with dukes c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred capecitabine tablets were noninferior to 5fluorouracil and leucovorin 5fulv for diseasefree survival dfs physicians should consider results of combination chemotherapy trials which have shown improvement in dfs and os when prescribing singleagent capecitabine tablets in the adjuvant treatment of dukes c colon cancer capecitabine tablets are indicated as firstline treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred combination chemotherapy has shown a survival benefit compared to 5fulv alone a survival benefit over 5fulv has not been demonstrated with capecitabine tablets monotherapy use of capecitabine tablets instead of 5 fulv in combinations has not been adequately studied to assure safety or preservation of the survival advantage capecitabine tablets in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracyclinecontaining chemotherapy capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracyclinecontaining chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated eg patients who have received cumulative doses of 400 mgm 2,3
azithromycin tablets are indicated for the treatment of patients with mild to moderate infections pneumonia see warnings dosage and administration acute bacterial exacerbations of chronic obstructive pulmonary disease haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae acute bacterial sinusitis haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae communityacquired pneumonia chlamydia pneumoniae haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate note azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following pharyngitistonsillitis streptococcus pyogenes streptococcus pyogenes streptococcus pyogenes uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes streptococcus agalactiae urethritis and cervicitis chlamydia trachomatis neisseria gonorrhoeae genital ulcer disease haemophilus ducreyi see precautionspediatric use clinical studies in pediatric patients acute otitis media haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae dosage and administration communityacquired pneumonia chlamydia pneumoniae haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae dosage and administration note azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following pharyngitistonsillitis streptococcus pyogenes dosage and administration streptococcus pyogenes,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of bicillin cr 900300 and other antibacterial drugs bicillin cr 900300 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy bicillin cr 900300 is indicated in the treatment of infections as described below that are susceptible to serum levels characteristic of this particular dosage form therapy should be guided by bacteriological studies including susceptibility testing and by clinical response bicillin cr 900300 is indicated in the treatment of the following in pediatric patients moderately severe to severe infections of the upperrespiratory tract scarlet fever erysipelas and skin and softtissue infections due to susceptible streptococci note streptococci in groups a c g h l and m are very susceptible to penicillin g other groups including group d enterococci are resistant penicillin g sodium or potassium is recommended for streptococcal infections with bacteremia moderately severe pneumonia and otitis media due to susceptible streptococcus pneumoniae note severe pneumonia empyema bacteremia pericarditis meningitis peritonitis and arthritis of pneumococcal etiology are better treated with penicillin g sodium or potassium during the acute stage when high sustained serum levels are required penicillin g sodium or potassium either im or iv should be used this drug should not be used in the treatment of venereal diseases including syphilis gonorrhea yaws bejel and pinta,3
venlafaxine hydrochloride tablets are indicated for the treatment of major depressive disorder the efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsmiii or dsmiiir category of major depression and in a 4week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia see clinical trials a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning nearly every day for at least 2 weeks it should include at least 4 of the following 8 symptoms change in appetite change in sleep psychomotor agitation or retardation loss of interest in usual activities or decrease in sexual drive increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration and a suicide attempt or suicidal ideation the efficacy of venlafaxine extendedrelease capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebocontrolled trial the efficacy of venlafaxine hydrochloride in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebocontrolled trial see clinical trials,3
agitation marked anxiety and tension 41 known hypersensitivity to methylphenidate or product components 42 glaucoma 43 history of motor tics or a family history or diagnosis of tourettes syndrome 44 during or within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor maoi 45 dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product hypersensitivity reactions including angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate see adverse reactions 65 66 dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with glaucoma dexmethylphenidate hcl extendedrelease capsules are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 61 dexmethylphenidate hcl extendedrelease capsules are contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor hypertensive crises may result,1
relenza an influenza neuraminidase inhibitor is indicated for treatment of influenza prophylaxis of influenza important limitations on use of relenza not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease 51 not proven effective for treatment in individuals with underlying airways disease 13 prophylaxis in nursing home residents 13 not a substitute for annual influenza vaccination 13 consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza 13 relenza r relenza is indicated for prophylaxis of influenza in adults and pediatric patients 5 years of age and older relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease such as asthma or chronic obstructive pulmonary disease due to risk of serious bronchospasm see warnings and precautions 51 relenza has not been proven effective for treatment of influenza in individuals with underlying airways disease relenza has not been proven effective for prophylaxis of influenza in the nursing home setting relenza is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease controls immunization practices advisory committee influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use relenza there is no evidence for efficacy of zanamivir in any illness caused by agents other than influenza virus a and b patients should be advised that the use of relenza for treatment of influenza has not been shown to reduce the risk of transmission of influenza to others,3
erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test receiving firstline maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 11 firstline treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 12 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 11 erlotinib tablets are not recommended for use in combination with platinumbased chemotherapy 11 erlotinib tablets are indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fdaapproved test receiving firstline maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 141 143 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 141 142 erlotinib tablets are not recommended for use in combination with platinumbased chemotherapy see clinical studies 144 erlotinib tablets in combination with gemcitabine are indicated for the firstline treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 145,3
serotonin syndrome and maois do not use maois intended to treat psychiatric disorders with duloxetine delayedrelease capsules or within 5 days of stopping treatment with duloxetine delayedrelease capsules do not use duloxetine delayedrelease capsules within 14 days of stopping an maoi intended to treat psychiatric disorders in addition do not start duloxetine delayedrelease capsules in a patient who is treated with linezolid or intravenous methylene blue 41 use in patients with uncontrolled narrowangle glaucoma 42 the use of maois intended to treat psychiatric disorders with duloxetine delayedrelease capsules or within 5 days of stopping treatment with duloxetine delayedrelease capsules is contraindicated because of an increased risk of serotonin syndrome the use of duloxetine delayedrelease capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated see dosage and administration 25 warnings and precautions 54 starting duloxetine delayedrelease capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome see dosage and administration 26 warnings and precautions 54 in clinical trials duloxetine delayedrelease capsule use was associated with an increased risk of mydriasis therefore its use should be avoided in patients with uncontrolled narrowangle glaucoma see warnings and precautions 513,1
allergic reactions to organic nitrates are extremely rare but they do occur nitroglycerin is contraindicated in patients who are allergic to it allergy to the adhesives used in nitroglycerin patches has also been reported and it similarly constitutes a contraindication to the use of this product do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors such as sildenafil tadalafil or vardenafil for erectile dysfunction or pulmonary arterial hypertension concomitant use can cause severe drops in blood pressure do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat concomitant use can cause hypotension,1
in patients with symptomatic atrial fibrillationflutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response quinidine sulfate is indicated as a means of restoring normal sinus rhythm if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time see then quinidine sulfate should be discontinued dosage and administration chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillationflutter generally patients who have had previous episodes of atrial fibrillationflutter that were so frequent and poorly tolerated as to outweigh in the judgment of the physician and the patient the risks of prophylactic therapy with quinidine sulfate the increased risk of death should specifically be considered quinidine sulfate should be used only after alternative measures use of other drugs to control the ventricular rate have been found to be inadequate eg in patients with histories of frequent symptomatic episodes of atrial fibrillationflutter the goal of therapy should be an increase in the average time between episodes in most patients the tachyarrhythmia during therapy and a single recurrence should not be interpreted as therapeutic failure will recur quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are lifethreatening because of the proarrhythmic effects of quinidine its use with ventricular arrhythmias of lesser severity is generally not recommended and treatment of patients with asymptomatic ventricular premature contractions should be avoided where possible therapy should be guided by the results of programmed electrical stimulation andor holter monitoring with exercise antiarrhythmic drugs including quinidine sulfate have not been shown to enhance survival in patients with ventricular arrhythmias quinidine sulfate is also indicated in the treatment of lifethreatening malaria plasmodium falciparum,3
in patients with symptomatic atrial fibrillationflutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response quinidine sulfate is indicated as a means of restoring normal sinus rhythm if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time see then quinidine sulfate should be discontinued dosage and administration chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillationflutter generally patients who have had previous episodes of atrial fibrillationflutter that were so frequent and poorly tolerated as to outweigh in the judgment of the physician and the patient the risks of prophylactic therapy with quinidine sulfate the increased risk of death should specifically be considered quinidine sulfate should be used only after alternative measures use of other drugs to control the ventricular rate have been found to be inadequate eg in patients with histories of frequent symptomatic episodes of atrial fibrillationflutter the goal of therapy should be an increase in the average time between episodes in most patients the tachyarrhythmia during therapy and a single recurrence should not be interpreted as therapeutic failure will recur quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are lifethreatening because of the proarrhythmic effects of quinidine its use with ventricular arrhythmias of lesser severity is generally not recommended and treatment of patients with asymptomatic ventricular premature contractions should be avoided where possible therapy should be guided by the results of programmed electrical stimulation andor holter monitoring with exercise antiarrhythmic drugs including quinidine sulfate have not been shown to enhance survival in patients with ventricular arrhythmias quinidine sulfate is also indicated in the treatment of lifethreatening malaria plasmodium falciparum,3
relpax tablets should not be given to patients with ischemic heart disease eg angina pectoris history of myocardial infarction or documented silent ischemia or to patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings relpax tablets should not be given to patients with cerebrovascular syndromes including but not limited to strokes of any type as well as transient ischemic attacks see warnings relpax tablets should not be given to patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings because relpax tablets may increase blood pressure it should not be given to patients with uncontrolled hypertension see warnings relpax tablets should not be administered to patients with hemiplegic or basilar migraine relpax tablets should not be used within 24 hours of treatment with another 5ht 1 relpax tablets should not be used in patients with known hypersensitivity to eletriptan or any of its inactive ingredients relpax tablets should not be given to patients with severe hepatic impairment,1
hypertension lisinopril tablet is indicated for the treatment of hypertension it may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents heart failure lisinopril tablet is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis acute myocardial infarction lisinopril tablet is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction to improve survival patients should receive as appropriate the standard recommended treatments such as thrombolytics aspirin and beta blockers in using lisinopril tablet consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that lisinopril tablet does not have a similar risk see warnings in considering the use of lisinopril tablet it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients see warnings anaphylactoid and possibly related reactions,3
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,1
rabeprazole sodium delayedrelease tablets are a proton pump inhibitor ppi indicated in adults for helicobacter pylori in adolescent patients 12 years of age and older for rabeprazole sodium delayedrelease tablets are indicated for shortterm 4 to 8 weeks treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease gerd for those patients who have not healed after 8 weeks of treatment an additional 8week course of rabeprazole sodium delayedrelease tablets may be considered rabeprazole sodium delayedrelease tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease gerd maintenance controlled studies do not extend beyond 12 months rabeprazole sodium delayedrelease tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks rabeprazole sodium delayedrelease tablets are indicated for shortterm up to four weeks treatment in the healing and symptomatic relief of duodenal ulcers most patients heal within four weeks rabeprazole sodium delayedrelease tablets in combination with amoxicillin and clarithromycin as a three drug regimen are indicated for the treatment of patients with h pylori h pylori h pylori in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 122 rabeprazole sodium delayedrelease tablets are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome rabeprazole sodium delayedrelease tablets are indicated for the treatment of symptomatic gerd in adolescents 12 years of age and above for up to 8 weeks,2
foradil aerolizer is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a longterm asthma control medication such as an inhaled corticosteroid in adults and children 5 years of age and older with reversible obstructive airways disease including patients with symptoms of nocturnal asthma longacting beta 2 available data from controlled clinical trials suggest that laba increase the risk of asthmarelated hospitalization in pediatric and adolescent patients see warnings for pediatric and adolescent patients with asthma who require addition of a laba to an inhaled corticosteroid a fixeddose combination product containing both an inhaled corticosteroid and laba should ordinarily be used to ensure adherence with both drugs in cases where use of a separate longterm asthma control medication eg inhaled corticosteroid and laba is clinically indicated appropriate steps must be taken to ensure adherence with both treatment components if adherence cannot be assured a fixeddose combination product containing both an inhaled corticosteroid and laba is recommended foradil aerolizer is also indicated for the acute prevention of exerciseinduced bronchospasm eib in adults and children 5 years of age and older when administered on an occasional asneeded basis use of foradil aerolizer as a single agent for the prevention of exerciseinduced bronchospasm may be clinically indicated in patients who do not have persistent asthma in patients with persistent asthma use of foradil aerolizer for the prevention of exerciseinduced bronchospasm may be clinically indicated but the treatment of asthma should include a longterm asthma control medication such as an inhaled corticosteroid foradil aerolizer is indicated for the longterm twice daily morning and evening administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease including chronic bronchitis and emphysema,3
nitrofurantoin capsules usp monohydratemacrocrystals are indicated only for the treatment of acute uncomplicated urinary tract infections acute cystitis caused by susceptible strains of escherichia coli staphylococcus saprophyticus nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses to reduce the development of drugresistant bacteria and maintain the effectiveness of nitrofurantoin capsules usp monohydratemacrocrystals and other antibacterial drugs nitrofurantoin capsules usp monohydratemacrocrystals should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections consequently many patients who are treated with nitrofurantoin capsules usp monohydratemacrocrystals are predisposed to persistence or reappearance of bacteriuria see clinical studies,3
valacyclovir hydrochloride tablets are a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hivinfected patients reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis limitations of use 13 the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode recurrent episodes suppressive therapy reduction of transmission sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis labeling describing use of valacyclovir hcl in pediatric patients with chickenpox ages 2 to 18 years is approved for glaxosmithklines valtrexr caplets however due to glaxosmithklines marketing exclusivity rights a description of that pediatric use is not approved for this valacyclovir hcl tablet product the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection labeling describing use of valacyclovir hcl in pediatric patients with chickenpox ages of 2 to 18 years is approved for glaxosmithklines valtrex r,3
tinidazole tablets is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in nonpregnant adult women 14 81 tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis see clinical studies 141 tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalis g lamblia see clinical studies 142 tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolytica see clinical studies 143 144 tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilus gardnerella see use in specific populations 81 145 other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicans herpes simplex to reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
fluoxetine capsules are indicated for the treatment of acute and maintenance treatment of major depressive disorder see clinical studies 141 acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder ocd see clinical studies 142 acute and maintenance treatment of bingeeating and vomiting behaviors in patients with moderate to severe bulimia nervosa see clinical studies 143 acute treatment of panic disorder with or without agoraphobia see clinical studies 144 fluoxetine capsules and olanzapine in combination are indicated for the treatment of acute treatment of depressive episodes associated with bipolar i disorder treatment resistant depression major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder or the treatment of treatment resistant depression r fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for acute and maintenance treatment of major depressive disorder mdd 1 acute and maintenance treatment of obsessive compulsive disorder ocd 1 acute and maintenance treatment of bulimia nervosa 1 acute treatment of panic disorder with or without agoraphobia 1 fluoxetine capsules and olanzapine in combination for treatment of acute depressive episodes associated with bipolar i disorder 1 treatment resistant depression 1,3
irbesartan tablets are angiotensin ii receptor blocker arb indicated for treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 11 treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes an elevated serum creatinine and proteinuria 12 irbesartan tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular cv events primarily strokes and myocardial infarction these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension an elevated serum creatinine and proteinuria 300 mgday in this population irbesartan tablets reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or endstage renal disease need for dialysis or renal transplantation see clinical studies 142,3
diuretics such as chlorthalidone tablets usp are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension chlorthalidone tablets usp are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy chlorthalidone tablets usp has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy chlorthalidone is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions,3
metronidazole tablets usp are indicated for the treatment of t vaginalis metronidazole tablets usp are indicated in the treatment of asymptomatic t vaginalis t vaginalis metronidazole tablets usp are indicated in the treatment of acute intestinal amebiasis amebic dysentery and amebic liver abscess in amebic liver abscess metronidazole tablets usp therapy does not obviate the need for aspiration or drainage of pus metronidazole tablets usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria indicated surgical procedures should be performed in conjunction with metronidazole tablets usp therapy in a mixed aerobic and anaerobic infection antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets usp intraabdominal infections bacteroides b fragilis b fragilis b distasonis b ovatus b thetaiotaomicron b vulgatus clostridium eubacterium peptococcus peptostreptococcus skin and skin structure infections bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium gynecologic infections including endometritis endomyometritis tuboovarian abscess and postsurgical vaginal cuff infection caused by bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium bacterial septicemia bacteroides b fragilis clostridium bone and joint infections bacteroides b fragilis central nervous system cns infections including meningitis and brain abscess caused by bacteroides b fragilis lower respiratory tract infections including pneumonia empyema and lung abscess caused by bacteroides b fragilis endocarditis bacteroides b fragilis to reduce the development of drugresistant bacteria and maintain the effectiveness of metronidazole tablets usp and other antibacterial drugs metronidazole tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
captopril tablets usp are indicated for the treatment of hypertension in using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warnings captopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinations captopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additive captopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatment left ventricular dysfunction after myocardial infarction diabetic nephropathy in considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,3
captopril tablets usp are indicated for the treatment of hypertension in using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warnings captopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinations captopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additive captopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatment left ventricular dysfunction after myocardial infarction diabetic nephropathy in considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligrampermilligram basis see clinical pharmacology cefuroxime axetil tablets cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below pharyngitistonsillitis caused by streptococcus pyogenes acute bacterial otitis media caused by streptococcus pneumoniae haemophilus influenzae including betalactamaseproducing strains moraxella catarrhalis including betalactamaseproducing strains or streptococcus pyogenes acute bacterial maxillary sinusitis caused by streptococcus pneumoniae or haemophilus influenzae nonbetalactamaseproducing strains only see clinical studies acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by streptococcus pneumoniae haemophilus influenzae betalactamase negative strains or haemophilus parainfluenzae betalactamase negative strains see dosage and administration clinical studies uncomplicated skin and skinstructure infections caused by staphylococcus aureus including betalactamaseproducing strains or streptococcus pyogenes uncomplicated urinary tract infections caused by escherichia coli or klebsiella pneumoniae uncomplicated gonorrhea urethral and endocervical caused by penicillinaseproducing and nonpenicillinaseproducing strains of neisseria gonorrhoeae and uncomplicated gonorrhea rectal in females caused by nonpenicillinaseproducing strains of neisseria gonorrhoeae early lyme disease erythema migrans caused by borrelia burgdorferi contraindications cefuroxime axetil products are contraindicated in patients with known allergy to the cephalosporin group of antibiotics,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligrampermilligram basis see clinical pharmacology cefuroxime axetil tablets cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below pharyngitistonsillitis caused by streptococcus pyogenes acute bacterial otitis media caused by streptococcus pneumoniae haemophilus influenzae including betalactamaseproducing strains moraxella catarrhalis including betalactamaseproducing strains or streptococcus pyogenes acute bacterial maxillary sinusitis caused by streptococcus pneumoniae or haemophilus influenzae nonbetalactamaseproducing strains only see clinical studies acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by streptococcus pneumoniae haemophilus influenzae betalactamase negative strains or haemophilus parainfluenzae betalactamase negative strains see dosage and administration clinical studies uncomplicated skin and skinstructure infections caused by staphylococcus aureus including betalactamaseproducing strains or streptococcus pyogenes uncomplicated urinary tract infections caused by escherichia coli or klebsiella pneumoniae uncomplicated gonorrhea urethral and endocervical caused by penicillinaseproducing and nonpenicillinaseproducing strains of neisseria gonorrhoeae and uncomplicated gonorrhea rectal in females caused by nonpenicillinaseproducing strains of neisseria gonorrhoeae early lyme disease erythema migrans caused by borrelia burgdorferi contraindications cefuroxime axetil products are contraindicated in patients with known allergy to the cephalosporin group of antibiotics,3
pregnant women and men whose female partners are pregnant 4 51 81 hemoglobinopathies 4 coadministration with didanosine 4 71 ribavirin in combination with peginterferon alfa2a is contraindicated in patients with autoimmune hepatitis 4 hepatic decompensation in cirrhotic patients 4 53 ribavirin is contraindicated in women who are pregnant ribavirin may cause fetal harm when administered to a pregnant woman ribavirin is contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus see warnings and precautions 51 81 patient counseling information 17 men whose female partners are pregnant patients with hemoglobinopathies eg thalassemia major or sicklecell anemia in combination with didanosine reports of fatal hepatic failure as well as peripheral neuropathy pancreatitis and symptomatic hyperlactatemialactic acidosis have been reported in clinical trials see drug interactions 71 ribavirin and peginterferon alfa2a combination therapy is contraindicated in patients with autoimmune hepatitis hepatic decompensation childpugh score greater than 6 class b and c in cirrhotic chc monoinfected patients before treatment see warnings and precautions 53 hepatic decompensation childpugh score greater than or equal to 6 in cirrhotic chc patients coinfected with hiv before treatment see warnings and precautions 53,0
alfuzosin hydrochloride is contraindicated for use in patients with moderate or severe hepatic impairment childspugh categories b and c since alfuzosin blood levels are increased in these patients see use in specific populations 87 clinical pharmacology 123 with potent cyp3a4 inhibitors such as ketoconazole itraconazole and ritonavir since alfuzosin blood levels are increased see drug interactions 71 clinical pharmacology 123 in patients with known hypersensitivity such as urticaria and angioedema to alfuzosinhydrochloride or any component of alfuzosin hydrochloride tablets see adverse reactions 62 moderate or severe hepatic impairment 4 87 123 coadministration with potent cyp3a4 inhibitors egketoconazole itraconazole ritonavir 4 54 71 123 known hypersensitivity eg urticaria or angioedema to alfuzosin or any of the ingredients 4 62,1
capecitabine tablets are a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer 11 patients with dukes c colon cancer metastatic colorectal cancer 11 firstline as monotherapy when treatment with fluoropyrimidine therapy alone is preferred metastatic breast cancer 12 in combination with docetaxel after failure of prior anthracycline containing therapy as monotherapy in patients resistant to both paclitaxel and an anthracyclinecontaining regimen capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with dukes c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred capecitabine tablets are noninferior to 5fluorouracil and leucovorin 5fulv for diseasefree survival dfs physicians should consider results of combination chemotherapy trials which have shown improvement in dfs and os when prescribing singleagent capecitabine tablets in the adjuvant treatment of dukes c colon cancer capecitabine tablets are indicated as firstline treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred combination chemotherapy has shown a survival benefit compared to 5fulv alone a survival benefit over 5fulv has not been demonstrated with capecitabine tablets monotherapy use of capecitabine tablets instead of 5fulv in combinations has not been adequately studied to assure safety or preservation of the survival advantage capecitabine tablets in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracyclinecontaining chemotherapy capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracyclinecontaining chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated eg patients who have received cumulative doses of 400 mgm 2,3
bupropionhydrochloride extendedrelease tablets sr are contraindicated in patients with a seizure disorder bupropion hydrochloride extendedrelease tablets sr arecontraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediaterelease formulation of bupropion see warnings and precautions 53 bupropionhydrochloride extendedrelease tablets sr arecontraindicated in patients undergoing abrupt discontinuation of alcohol benzodiazepines barbiturates and antiepileptic drugs see warnings and precautions 53 73 the use of maois intended to treat psychiatric disorders concomitantly with bupropion hydrochloride extendedrelease tablets sr or within 14 days of discontinuing treatment with bupropion hydrochloride extendedrelease tablets sr are contraindicated there is an increased risk of hypertensive reactions when bupropion hydrochloride extendedrelease tablets sr are used concomitantly with maois the use of bupropion hydrochloride extendedrelease tablets sr within 14 days of discontinuing treatment with an maoi is also contraindicated starting bupropion hydrochloride extendedrelease tablets sr in a patient treated with reversible maois such as linezolid or intravenous methylene blue is contraindicated see dosage and administration 24 25 54 76 bupropion hydrochloride extendedrelease tablets sr are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extendedrelease tablets sr anaphylactoidanaphylactic reactions and stevensjohnson syndrome have been reported see warnings and precautions,1
therapy appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g therapy with penicillin g potassium for injection usp may be indicated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below however once these results become available appropriate therapy should be continued clinical indication infecting organism septicemia empyema pneumonia pericarditis endocarditis meningitis streptococcus pyogenes bhemolytic streptococcus other bhemolytic streptococci including groups chgl and m streptococcus pneumoniae staphylococcus anthrax bacillus anthracis actinomycosis cervicofacial disease and thoracic and abdominal disease actinomyces israelii botulism adjunctive therapy to antitoxin gas gangrene and tetanus adjunctive therapy to human tetanus immune globulin clostridium species diphtheria adjunctive therapy to antitoxin and prevention of the carrier state corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis severe infections of the oropharynx vincents lower respiratory tract and genital area fusobacterium spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae penicillinsusceptible syphilis congenital and neurosyphilis treponema pallidum meningococcal meningitis and or septicemia neisseria meningitidis gramnegative bacillary infections bacteremias penicillin g is not the drug of choice in the treatment of gramnegative bacillary infections gram enterobacteriaceae,3
xarelto is a factor xa inhibitor indicated 11 12 13 14 15 16 xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation there are limited data on the relative effectiveness of xarelto and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is wellcontrolled see clinical studies 141 xarelto is indicated for the treatment of deep vein thrombosis dvt xarelto is indicated for the treatment of pulmonary embolism pe xarelto is indicated for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months xarelto is indicated for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery xarelto in combination with aspirin is indicated to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad,3
xarelto is a factor xa inhibitor indicated 11 12 13 14 15 16 xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation there are limited data on the relative effectiveness of xarelto and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is wellcontrolled see clinical studies 141 xarelto is indicated for the treatment of deep vein thrombosis dvt xarelto is indicated for the treatment of pulmonary embolism pe xarelto is indicated for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months xarelto is indicated for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery xarelto in combination with aspirin is indicated to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad,3
morphine sulfate is indicated for the relief of severe pain it is used preoperatively to sedate the patient and allay apprehension facilitate anesthesia induction and reduce anesthetic dosage it is likewise effective in the control of postoperative pain the use of morphine for the relief of pain should be reserved for the more severe manifestations of pain as in myocardial infarctionsevere injuries or in severe chronic pain associated with terminal cancer after all nonnarcotic analgesics have failed effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem intermittent administration of intramuscular morphine may be effective however the mode of therapy has significant limitations morphine has a short plasma halflife of 25 to 30 hours therefore frequent administration every 1 to 2 hours often becomes necessary to control severe pain associated with cancer tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia the higher morphine doses produce significant and often lifethreatening side effects see adverse reactions continuous iv infusion of morphine see dosage and administration in addition to analgesia the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure morphine is also used in the therapy of dyspnea associated with acute left ventricular failure and pulmonary edema care must be taken to avoid inducing respiratory depression in such patients for openheart surgery especially in high risk patients with cardiac disease some anesthesiologists use morphine to produce anesthesia,2
morphine sulfate is indicated for the relief of severe pain it is used preoperatively to sedate the patient and allay apprehension facilitate anesthesia induction and reduce anesthetic dosage it is likewise effective in the control of postoperative pain the use of morphine for the relief of pain should be reserved for the more severe manifestations of pain as in myocardial infarctionsevere injuries or in severe chronic pain associated with terminal cancer after all nonnarcotic analgesics have failed effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem intermittent administration of intramuscular morphine may be effective however the mode of therapy has significant limitations morphine has a short plasma halflife of 25 to 30 hours therefore frequent administration every 1 to 2 hours often becomes necessary to control severe pain associated with cancer tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia the higher morphine doses produce significant and often lifethreatening side effects see adverse reactions continuous iv infusion of morphine see dosage and administration in addition to analgesia the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure morphine is also used in the therapy of dyspnea associated with acute left ventricular failure and pulmonary edema care must be taken to avoid inducing respiratory depression in such patients for openheart surgery especially in high risk patients with cardiac disease some anesthesiologists use morphine to produce anesthesia,2
osphena is contraindicated in women with any of the following conditions undiagnosed abnormal genital bleeding known or suspected estrogendependent neoplasia active dvt pulmonary embolism pe or a history of these conditions active arterial thromboembolic disease for example stroke and myocardial infarction mi or a history of these conditions hypersensitivity for example angioedema urticaria rash pruritus to osphena or any ingredients osphena is contraindicated in women who are or may become pregnant osphena may cause fetal harm when administered to a pregnant woman ospemifene was embryofetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures and embryofetal lethal in rabbits at 10 times the clinical exposure based on mgm 2 undiagnosed abnormal genital bleeding 4 known or suspected estrogendependent neoplasia 4 52 active dvt pulmonary embolism pe or a history of these conditions 4 51 active arterial thromboembolic disease for example stroke and myocardial infarction mi or a history of these conditions 4 51 hypersensitivity for example angioedema urticaria rash pruritus to osphena or any ingredients 4 known or suspected pregnancy 4 81,1
osphena is contraindicated in women with any of the following conditions undiagnosed abnormal genital bleeding known or suspected estrogendependent neoplasia active dvt pulmonary embolism pe or a history of these conditions active arterial thromboembolic disease for example stroke and myocardial infarction mi or a history of these conditions hypersensitivity for example angioedema urticaria rash pruritus to osphena or any ingredients osphena is contraindicated in women who are or may become pregnant osphena may cause fetal harm when administered to a pregnant woman ospemifene was embryofetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures and embryofetal lethal in rabbits at 10 times the clinical exposure based on mgm 2 undiagnosed abnormal genital bleeding 4 known or suspected estrogendependent neoplasia 4 52 active dvt pulmonary embolism pe or a history of these conditions 4 51 active arterial thromboembolic disease for example stroke and myocardial infarction mi or a history of these conditions 4 51 hypersensitivity for example angioedema urticaria rash pruritus to osphena or any ingredients 4 known or suspected pregnancy 4 81,1
osphena is contraindicated in women with any of the following conditions undiagnosed abnormal genital bleeding known or suspected estrogendependent neoplasia active dvt pulmonary embolism pe or a history of these conditions active arterial thromboembolic disease for example stroke and myocardial infarction mi or a history of these conditions hypersensitivity for example angioedema urticaria rash pruritus to osphena or any ingredients osphena is contraindicated in women who are or may become pregnant osphena may cause fetal harm when administered to a pregnant woman ospemifene was embryofetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures and embryofetal lethal in rabbits at 10 times the clinical exposure based on mgm 2 undiagnosed abnormal genital bleeding 4 known or suspected estrogendependent neoplasia 4 52 active dvt pulmonary embolism pe or a history of these conditions 4 51 active arterial thromboembolic disease for example stroke and myocardial infarction mi or a history of these conditions 4 51 hypersensitivity for example angioedema urticaria rash pruritus to osphena or any ingredients 4 known or suspected pregnancy 4 81,1
women with active thromboembolic disease or a history or intrinsic risk of thrombosis or thromboembolism including retinal vein or artery occlusion 41 hypersensitivity to tranexamic acid 42 do not prescribe tranexamic acid tablets to women who are known to have the following conditions active thromboembolic disease eg deep vein thrombosis pulmonary embolism or cerebral thrombosis a history of thrombosis or thromboembolism including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism eg thrombogenic valvular disease thrombogenic cardiac rhythm disease or hypercoagulopathy venous and arterial thrombosis or thromboembolism as well as cases of retinal artery and retinal vein occlusions have been reported with tranexamic acid do not prescribe tranexamic acid tablets to women with known hypersensitivity to tranexamic acid see warnings and precautions 52 adverse reactions 61,1
simvastatin is an hmgcoa reductase inhibitor statin indicated as an adjunctive therapy to diet to 11 12 12 12 12 13 limitations of use simvastatin has not been studied in fredrickson types i and v dyslipidemias 14 therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate in patients with coronary heart disease chd or at high risk of chd simvastatin tablets usp can be started simultaneously with diet in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease simvastatin tablets usp are indicated to simvastatin tablets usp are indicated to simvastatin tablets usp are indicated as an adjunct to diet to reduce totalc ldlc and apo b levels in adolescent boys and girls who are at least one year postmenarche 1017 years of age with hefh if after an adequate trial of diet therapy the following findings are present the minimum goal of treatment in pediatric and adolescent patients is to achieve a mean ldlc 130 mgdl the optimal age at which to initiate lipidlowering therapy to decrease the risk of symptomatic adulthood cad has not been determined simvastatin tablets usp have not been studied in conditions where the major abnormality is elevation of chylomicrons ie hyperlipidemia fredrickson types i and v,3
to reduce the development of drug resistant bacteria and maintain the effectiveness of suprax cefixime chewable tablets and other antibacterial drugs suprax cefixime chewable tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antimicrobial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy suprax cefixime chewable tablets are indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms uncomplicated urinary tract infections escherichia coli proteus mirabilis otitis media haemophilus influenzae moraxella branhamella catarrhalis s pyogenes note otitis media streptococcus pneumoniae clinical studies pharyngitis and tonsillitis s pyogenes note penicillin is the usual drug of choice in the treatment of s pyogenes s pyogenes acute bronchitis acute exacerbations of chronic bronchitis streptococcus pneumoniae haemophilus influenzae uncomplicated gonorrhea neisseria gonorrhoeae appropriate cultures and susceptibility studies should be performed to determine the causative organism and its susceptibility to cefixime however therapy may be started while awaiting the results of these studies therapy should be adjusted if necessary once these results are known efficacy for this organism in this organ system was studied in fewer than 10 infections,3
because abciximab may increase the risk of bleeding abciximab is contraindicated in the following clinical situations active internal bleeding recent within six weeks gastrointestinal gi or genitourinary gu bleeding of clinical significance history of cerebrovascular accident cva within two years or cva with a significant residual neurological deficit bleeding diathesis administration of oral anticoagulants within seven days unless prothrombin time is 12 times control thrombocytopenia 100000 cellsml recent within six weeks major surgery or trauma intracranial neoplasm arteriovenous malformation or aneurysm severe uncontrolled hypertension presumed or documented history of vasculitis use of intravenous dextran before pci or intent to use it during an intervention abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins,1
because abciximab may increase the risk of bleeding abciximab is contraindicated in the following clinical situations active internal bleeding recent within six weeks gastrointestinal gi or genitourinary gu bleeding of clinical significance history of cerebrovascular accident cva within two years or cva with a significant residual neurological deficit bleeding diathesis administration of oral anticoagulants within seven days unless prothrombin time is 12 times control thrombocytopenia 100000 cellsml recent within six weeks major surgery or trauma intracranial neoplasm arteriovenous malformation or aneurysm severe uncontrolled hypertension presumed or documented history of vasculitis use of intravenous dextran before pci or intent to use it during an intervention abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins,1
because abciximab may increase the risk of bleeding abciximab is contraindicated in the following clinical situations active internal bleeding recent within six weeks gastrointestinal gi or genitourinary gu bleeding of clinical significance history of cerebrovascular accident cva within two years or cva with a significant residual neurological deficit bleeding diathesis administration of oral anticoagulants within seven days unless prothrombin time is 12 times control thrombocytopenia 100000 cellsml recent within six weeks major surgery or trauma intracranial neoplasm arteriovenous malformation or aneurysm severe uncontrolled hypertension presumed or documented history of vasculitis use of intravenous dextran before pci or intent to use it during an intervention abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins,1
amlodipine besylate tablets usp is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension 11 coronary artery disease 12 chronic stable angina vasospastic angina prinzmetals or variant angina angiographically documented coronary artery disease in patients without heart failure or an ejection fraction 40 amlodipine besylate tablets usp are indicated for the treatment of hypertension it may be used alone or in combination with other antihypertensive agents chronic stable angina amlodipine besylate tablets usp are indicated for the symptomatic treatment of chronic stable angina amlodipine besylate tablets may be used alone or in combination with other antianginal agents vasospastic angina prinzmetals or variant angina amlodipine besylate tablets usp are indicated for the treatment of confirmed or suspected vasospastic angina amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction 40 amlodipine besylate is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure,3
premarin vaginal cream therapy should not be used in women with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of breast cancer known or suspected estrogendependent neoplasia active dvt pe or a history of these conditions active arterial thromboembolic disease for example stroke and mi or a history of these conditions known anaphylactic reaction or angioedema to premarin vaginal cream known liver dysfunction or disease known protein c protein s or antithrombin deficiency or other known thrombophilic disorders known or suspected pregnancy undiagnosed abnormal genital bleeding 4 known suspected or history of breast cancer 4 53 known or suspected estrogendependent neoplasia 4 53 active dvt pe or a history of these conditions 4 52 active arterial thromboembolic disease for example stroke and mi or a history of these conditions 4 52 known anaphylactic reaction or angioedema to premarin vaginal cream 516 517 known liver dysfunction or disease 4 510 known protein c protein s or antithrombin deficiency or other known thrombophilic disorders 4 known or suspected pregnancy 4 81,1
imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of 11 12 13 15 16 17 18 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis accelerated phase or in chronic phase after failure of interferonalpha therapy adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all adult patients with myelodysplasticmyeloproliferative diseases associated with pdgfr plateletderived growth factor receptor gene rearrangements as determined with an fdaapproved test see dosage and administration 26 adult patients with aggressive systemic mastocytosis without the d816v ckit mutation as determined with an fdaapproved test see dosage and administration 27 adult patients with hypereosinophilic syndrome andor chronic eosinophilic leukemia who have the fip1l1pdgfra fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes andor cel who are fip1l1pdgfra fusion kinase negative or unknown adult patients with unresectable recurrent andor metastatic dermatofibrosarcoma protuberans,3
imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of 11 12 13 15 16 17 18 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis accelerated phase or in chronic phase after failure of interferonalpha therapy adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all adult patients with myelodysplasticmyeloproliferative diseases associated with pdgfr plateletderived growth factor receptor gene rearrangements as determined with an fdaapproved test see dosage and administration 26 adult patients with aggressive systemic mastocytosis without the d816v ckit mutation as determined with an fdaapproved test see dosage and administration 27 adult patients with hypereosinophilic syndrome andor chronic eosinophilic leukemia who have the fip1l1pdgfra fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes andor cel who are fip1l1pdgfra fusion kinase negative or unknown adult patients with unresectable recurrent andor metastatic dermatofibrosarcoma protuberans,3
bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty ptca 11 undergoing percutaneous coronary intervention pci with provisional use of glycoprotein iibiiia inhibitor gpi as in the replace2 study 12 with or at risk of heparininduced thrombocytopenia hit or heparininduced thrombocytopenia and thrombosis syndrome hitts undergoing pci 12 bivalirudin for injection is intended for use with aspirin 13 limitation of use safety and effectiveness not established in patients with acute coronary syndromes who are not undergoing ptca or pci 14 bivalirudin for injection is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty ptca bivalirudin for injection with provisional use of glycoprotein iibiiia inhibitor gpi as listed in the replace2 trial see clinical studies 141 bivalirudin for injection is indicated for patients with or at risk of heparin induced thrombocytopenia hit or heparin induced thrombocytopenia and thrombosis syndrome hitts undergoing pci bivalirudin in these indications is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin see dosage and administration 21 clinical studies 141 the safety and effectiveness of bivalirudin for injection have not been established in patients with acute coronary syndromes who are not undergoing ptca or pci,3
perjeta is a her2neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with her2positive metastatic breast cancer mbc who have not received prior antiher2 therapy or chemotherapy for metastatic disease 11 use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with her2positive locally advanced inflammatory or early stage breast cancer either greater than 2 cm in diameter or node positive as part of a complete treatment regimen for early breast cancer 12 22 142 adjuvant treatment of patients with her2positive early breast cancer at high risk of recurrence 12 22 143 perjeta is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with her2positive metastatic breast cancer who have not received prior antiher2 therapy or chemotherapy for metastatic disease see dosage and administration 22 clinical studies 141 perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with her2positive locally advanced inflammatory or early stage breast cancer either greater than 2 cm in diameter or node positive as part of a complete treatment regimen for early breast cancer see dosage and administration 22 clinical studies 142 the adjuvant treatment of patients with her2positive early breast cancer at high risk of recurrence see dosage and administration 22 clinical studies 143,3
clobetasol propionate topical spray 005 is a corticosteroid indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20 body surface area bsa in patients 18 years of age or older 11 limitations of use do not use on the face axillae or groin 12 do not use if atrophy is present at the treatment site 12 do not use for rosacea or perioral dermatitis 12 clobetasol propionate topical spray 005 is a superhigh potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20 body surface area bsa in patients 18 years of age or older the total dosage should not exceed 50 g 59 ml or 2 fl oz per week do not use more than 26 sprays per application or 52 sprays per day treatment should be limited to 4 consecutive weeks patients should be instructed to use clobetasol propionate topical spray 005 for the minimum amount of time necessary to achieve the desired results see dosage and administration 2 use in patients under 18 years of age is not recommended because safety has not been established and because numerically high rates of hpa axis suppression were seen with other clobetasol propionate topical formulations clobetasol propionate topical spray 005 should not be used on the face axillae or groin clobetasol propionate topical spray 005 should not be used if there is atrophy at the treatment site clobetasol propionate topical spray 005 should not be used in the treatment of rosacea or perioral dermatitis,1
frova is contraindicated in patients with ischemic coronary artery disease cad eg angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke s ee warnings and precautions 54 peripheral vascular disease s ee warnings and precautions 55 ischemic bowel disease s ee warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 71 72 hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen s ee warnings and precautions 59 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of treatment with another 5ht 1 4 hypersensitivity to frova angioedema and anaphylaxis seen 4,1
to reduce the development of drugresistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs azithromycin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications see dosage and administration 2 11 adult patients acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae 12 pediatric patients see use in specific populations 84 and clinical studies 142 acute otitis media 6 months of age caused by haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae 13 limitations of use azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following patients with cystic fibrosis,3
cephalexin capsules usp are indicated for the treatment of the following infections when caused by susceptibile strains of the designated microorganisms respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including the prophylaxis of rheumatic fever cephalexin is generally effective in the eradication of streptococci from the nasopharynx however substantial data estabilishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present otitis media due to streptococcus pneumoniae haemophilus influenzae staphylococcus aureus streptococcus pyogenes and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus andor streptococcus pyogenes bone infections caused by staphylococcus aureus andor proteus mirabilis genitourinary tract infections including acute prostatitis caused by escherichia coli proteus mirabilis and klebsiella pneumoniae note culture and susceptibility tests should be initiated prior to and during therapy renal function studies should be performed when indicated to reduce the development of drugresistant bacteria and maintain the effectiveness of cephalexin capsules usp and other antibacterial drugs cephalexin capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of erythrocin r r erythrocin r upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae h influenzae lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes streptococcus pneumoniae listeriosis caused by listeria monocytogenes respiratory tract infections due to mycoplasma pneumoniae skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes staphylococcus aureus pertussis whooping cough caused by bordetella pertussis diphtheria infections due to corynebacterium diphtheriae erythrasma in the treatment of infections due to corynebacterium minutissimum intestinal amebiasis caused by entamoeba histolytica acute pelvic inflammatory disease caused by neisseria gonorrhoeae n gonorrhoeae erythromycins are indicated for treatment of the following infections caused by chlamydia trachomatis chlamydia trachomatis when tetracyclines are contraindicated or not tolerated erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum primary syphilis caused by treponema pallidum legionnaires disease caused by legionella pneumophila in vitro penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever treatment of streptococcus pyogenes infections of the upper respiratory tract eg tonsillitis or pharyngitis 1 penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever in patients who are allergic to penicillin and sulfonamides oral erythromycin is recommended by the american heart association in the longterm prophylaxis of streptococcal pharyngitis for the prevention of recurrent attacks of rheumatic fever 1,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated anorectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies,3
do not initiate in patients with constipation 41 history of chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment 42 concomitant use of fluvoxamine 43 alosetron hydrochloride should not be initiated see warnings and precautions 51 alosetron hydrochloride is contraindicated in patients with a history of the following chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated fluvoxamine a known strong inhibitor of cyp1a2 has been shown to increase mean alosetron plasma concentrations auc approximately 6fold and prolong the halflife by approximately 3fold see drug interactions 71,1
fluoxetine is indicated for the treatment of acute and maintenance treatment of major depressive disorder see clinical studies 141 acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder ocd see clinical studies 142 acute and maintenance treatment of bingeeating and vomiting behaviors in patients with moderate to severe bulimia nervosa see clinical studies 143 acute treatment of panic disorder with or without agoraphobia see clinical studies 144 fluoxetine and olanzapine in combination is indicated for the treatment of acute treatment of depressive episodes associated with bipolar i disorder fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder r fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for acute and maintenance treatment of major depressive disorder mdd 1 acute and maintenance treatment of obsessive compulsive disorder ocd 1 acute and maintenance treatment of bulimia nervosa 1 acute treatment of panic disorder with or without agoraphobia 1 fluoxetine capsules and olanzapine in combination for treatment of acute depressive episodes associated with bipolar i disorder 1,3
hypersensitivity to clarithromycin or any macrolide drug 41 cisapride pimozide lovastatinsimvastatin ergotaminedihydroergotamine 42 45 46 history of cholestatic jaundicehepatic dysfunction with use of clarithromycin 43 colchicine in renal or hepatic impairment 44 hypersensitivity to clarithromycin or any macrolide drug 41 cisapride pimozide lovastatinsimvastatin ergotaminedihydroergotamine 42 45 46 history of cholestatic jaundicehepatic dysfunction with use of clarithromycin 43 colchicine in renal or hepatic impairment 44 clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin erythromycin or any of the macrolide antibacterial drugs see warnings and precautions 51 concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated see drug interactions 7 there have been postmarketing reports of drug interactions when clarithromycin is coadministered with cisapride or pimozide resulting in cardiac arrhythmias qt prolongation ventricular tachycardia ventricular fibrillation and torsades de pointes clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment do not use clarithromycin tablets concomitantly with hmgcoa reductase inhibitors statins that are extensively metabolized by cyp3a4 lovastatin or simvastatin due to the increased risk of myopathy including rhabdomyolysis see warnings and precautions 54 drug interactions 7 concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated see drug interactions 7 for information about contraindications of other drugs indicated in combination with clarithromycin tablets refer to their full prescribing information contraindications section,1
rosuvastatin tablets are contraindicated in the following conditions patients with a known hypersensitivity to any component of this product hypersensitivity reactions including rash pruritus urticaria and angioedema have been reported with rosuvastatin see adverse reactions 61 patients with active liver disease which may include unexplained persistent elevations of hepatic transaminase levels see warnings and precautions 52 pregnancy see use in specific populations 81 83 lactation limited data indicate that rosuvastatin is present in human milk because statins have the potential for serious adverse reactions in nursing infants women who require rosuvastatin treatment should not breastfeed their infants see use in specific populations 82 known hypersensitivity to product components 4 active liver disease which may include unexplained persistent elevations in hepatic transaminase levels 4 pregnancy 4 81 83 lactation 4 82,1
forteo is recombinant human parathyroid hormone analog 134 rhpth134 indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture 11 increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture 12 treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture 13 forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy in postmenopausal women with osteoporosis forteo reduces the risk of vertebral and nonvertebral fractures see clinical studies 141 forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 142 forteo is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy daily dosage equivalent to 5 mg or greater of prednisone at high risk for fracture defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 143,3
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,3
fluocinonide cream usp 01 is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older 1 limitation of use treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because of the potential for the drug to suppress the hypothalamicpituitaryadrenal hpa axis 1 avoid use on the face groin or axillae 12 avoid use in perioral dermatitis or rosacea fluocinonide cream usp 01 is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older see use in specific populations 84 treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because the safety of fluocinonide cream usp 01 for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamicpituitaryadrenal hpa axis therapy should be discontinued when control of the disease is achieved if no improvement is seen within 2 weeks reassessment of the diagnosis may be necessary do not use more than half of the 120 g tube per week fluocinonide cream usp 01 should not be used in the treatment of rosacea or perioral dermatitis and should not be used on the face groin or axillae,1
adults clarithromycin extendedrelease tablets usp clarithromycin extendedrelease tablets usp are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below acute maxillary sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis or streptococcus pneumoniae communityacquired pneumonia due to haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis streptococcus pneumoniae chlamydophila pneumoniae twar or mycoplasma pneumoniae the efficacy and safety of clarithromycin extendedrelease tablets usp in treating other infections for which other formulations of clarithromycin are approved have not been established,3
clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci pneumococci and staphylococci its use should be reserved for penicillinallergic patients or other patients for whom in the judgment of the physician a penicillin is inappropriate because of the risk of colitis as described in the warning box before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives eg erythromycin anaerobes serious respiratory tract infections such as empyema anaerobic pneumonitis and lung abscess serious skin and soft tissue infections septicemia intraabdominal infections such as peritonitis and intraabdominal abscess typically resulting from anaerobic organisms resident in the normal gastrointestinal tract infections of the female pelvis and genital tract such as endometritis nongonococcal tuboovarian abscess pelvic cellulitis and postsurgical vaginal cuff infection streptococci serious respiratory tract infections serious skin and soft tissue infections staphylococci serious respiratory tract infections serious skin and soft tissue infections pneumococci serious respiratory tract infections bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin to reduce the development of drugresistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
minocycline hydrochloride capsules usp are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae mycoplasma pneumoniae chlamydia trachomatis chlamydophila psittaci chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum chlamydia trachomatis borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis klebsiella granulomatis minocycline is indicated for the treatment of infections caused by the following gramnegative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug escherichia coli enterobacter aerogenes shigella acinetobacter haemophilus influenzae klebsiella minocycline hydrochloride capsules usp are indicated for the treatment of infections caused by the following grampositive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug streptococcus pneumoniae staphylococcus aureus when penicillin is contraindicated minocycline is an alternative drug in the treatment of the following infections neisseria gonorrhoeae neisseria gonorrhoeae treponema pallidum pallidum treponema pallidum pertenue listeria monocytogenes bacillus anthracis fusobacterium fusiforme actinomyces israelii clostridium in acute intestinal amebiasis acne neisseria meningitidis oral minocycline is not indicated for the treatment of meningococcal infection mycobacterium marinum,3
zolmitriptan is contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia other significant underlying cardiovascular disease or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent use of a maoa inhibitor that is within 2 weeks see drug interactions 72 clinical pharmacology 123 known hypersensitivity to zolmitriptan angioedema and anaphylaxis seen see adverse reactions 62 history of coronary artery disease cador coronary vasospasm 4 symptomatic wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 monamine oxidase maoa inhibitor used in past 2 weeks 4 known hypersensitivity to zolmitriptan 4,1
relpax is contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5hydroxytryptamine 1 1 see drug interactions 71 hypersensitivity to relpax angioedema and anaphylaxis seen see warnings and precautions 59 recent use ie within at least 72 hours of the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir see drug interactions 72 clinical pharmacology 123 history of coronary artery disease cad or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or history or current evidence of hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 within 24 hours of treatment with another 5ht 1 4 hypersensitivity to relpax angioedema and anaphylaxis seen 4 within at least 72 hours of treatment with the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir 4,1
valacyclovir tablets usp are a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hivinfected patients reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis chickenpox limitations of use 13 the efficacy and safety of valacyclovir tablets usp have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode recurrent episodes suppressive therapy reduction of transmission sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis chickenpox see clinical studies 144 the efficacy and safety of valacyclovir tablets usp have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 2 years of age or 18 years of age with chickenpox patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection,3
11 duodenal ulcer adults omeprazole delayedrelease capsules usp are indicated for shortterm treatment of active duodenal ulcer in adults most patients heal within four weeks some patients may require an additional four weeks of therapy 12 gastric ulcer adults omeprazole delayedrelease capsules usp are indicated for shortterm treatment 4 to 8 weeks of active benign gastric ulcer in adults see clinical studies 142 13 treatment of gastroesophageal reflux disease gerd adults and pediatric patients symptomatic gerd omeprazole delayedrelease capsules usp are indicated for the treatment of heartburn and other symptoms associated with gerd in pediatric patients and adults for up to 4 weeks erosive esophagitis omeprazole delayedrelease capsules usp are indicated for the shortterm treatment 4 to 8 weeks of erosive esophagitis that has been diagnosed by endoscopy in pediatric patients and adults see clinical studies 144 the efficacy of omeprazole delayedrelease capsules usp used for longer than 8 weeks in these patients has not been established if a patient does not respond to 8 weeks of treatment an additional 4 weeks of treatment may be given if there is recurrence of erosive esophagitis or gerd symptoms eg heartburn additional 4 to 8 week courses of omeprazole may be considered 14 maintenance of healing of erosive esophagitis adults and pediatric patients omeprazole delayedrelease capsules usp are indicated to maintain healing of erosive esophagitis in pediatric patients and adults 15 pathological hypersecretory conditions adults omeprazole delayedrelease capsules usp are indicated for the longterm treatment of pathological hypersecretory conditions eg zollingerellison syndrome multiple endocrine adenomas and systemic mastocytosis in adults,3
hypertension propranolol hydrochloride tablets are indicated in the management of hypertension they may be used alone or used in combination with other antihypertensive agents particularly a thiazide diuretic propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies angina pectoris due to coronary atherosclerosis propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris atrial fibrillation propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response myocardial infarction propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable migraine propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache the efficacy of propranolol in the treatment of a migraine attack that has started has not been established and propranolol is not indicated for such use essential tremor propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor familial or essential tremor consists of involuntary rhythmic oscillatory movements usually limited to the upper limbs it is absent at rest but occurs when the limb is held in a fixed posture or position against gravity and during active movement propranolol hydrochloride tablets usp causes a reduction in the tremor amplitude but not in the tremor frequency propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with parkinsonism hypertrophic subaortic stenosis propranolol hydrochloride tablets improve nyha functional class in symptomatic patients with hypertrophic subaortic stenosis pheochromocytoma propranolol hydrochloride tablets are indicated as an adjunct to alphaadrenergic blockade to control blood pressure and reduce symptoms of catecholaminesecreting tumors,3
zyvox formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases a or b eg phenelzine isocarboxazid or within two weeks of taking any such medicinal product unless patients are monitored for potential increases in blood pressure linezolid should not be administered to patients with uncontrolled hypertension pheochromocytoma thyrotoxicosis andor patients taking any of the following types of medications directly and indirectly acting sympathomimetic agents eg pseudoephedrine vasopressive agents eg epinephrine norepinephrine dopaminergic agents eg dopamine dobutamine see precautions drug interactions unless patients are carefully observed for signs andor symptoms of serotonin syndrome linezolid should not be administered to patients with carcinoid syndrome andor patients taking any of the following medications serotonin reuptake inhibitors tricyclic antidepressants serotonin 5ht1 receptor agonists triptans meperidine or buspirone see precautions general drug interactions,1
depakene is indicated for monotherapy and adjunctive therapy of complex partial seizures sole and adjunctive therapy of simple and complex absence seizures adjunctive therapy in patients with multiple seizure types that include absence seizures 1 depakene valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures depakene valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures and adjunctively in patients with multiple seizure types which include absence seizures simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs complex absence is the term used when other signs are also present see warnings and precautions 51 because of the risk to the fetus of decreased iq neurodevelopmental disorders used treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant other medications have failed to provide adequate symptom control or are otherwise unacceptable see warnings and precautions 52 53 54 81 17 for prophylaxis of migraine headaches valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception see contraindications 4,3
spironolactone tablets are indicated in the management of primary hyperaldosteronism for establishing the diagnosis of primary hyperaldosteronism by therapeutic trial shortterm preoperative treatment of patients with primary hyperaldosteronism longterm maintenance therapy for patients with discrete aldosteroneproducing adrenal adenomas who are judged to be poor operative risks or who decline surgery longterm maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia idiopathic hyperaldosteronism edematous conditions for patients with congestive heart failure for the management of edema and sodium retention when the patient is only partially responsive to or is intolerant of other therapeutic measures spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate essential hypertension usually in combination with other drugs spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate usage in pregnancy the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developing toxemia,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of leukemias and lymphomas in adults to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
calcium salts are contraindicated in patients with ventricular fibrillation or hypercalcemia intravenous administration of calcium is contraindicated when serum calcium levels are above normal if neonates are required or expected to require treatment with calciumcontaining iv solutions including continuous calciumcontaining infusions such as parenteral nutrition ceftriaxone sodium injection is contraindicated because of the risk of precipitation of ceftriaxonecalcium a small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving calcium containing fluids and ceftriaxone in some of these cases the same intravenous infusion line was used for both calciumcontaining fluids and ceftriaxone and in some a precipitate was observed in the intravenous infusion line at least one fatality has been reported in a neonate in whom calciumcontaining fluids and ceftriaxone were administered at different time points via different intravenous lines no crystalline material was observed at autopsy in this neonate there have been no similar reports in patients other than neonates,1
hypertension propranolol hydrochloride tablets usp are indicated in the management of hypertension it may be used alone or used in combination with other antihypertensive agents particularly a thiazide diuretic propranolol hydrochloride is not indicated in the management of hypertensive emergencies angina pectoris due to coronary atherosclerosis propranolol hydrochloride tablets usp are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris atrial fibrillation propranolol hydrochloride tablets usp are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response myocardial infarction propranolol is indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable migraine propranolol is indicated for the prophylaxis of common migraine headache the efficacy of propranolol in the treatment of a migraine attack that has started has not been established and propranolol is not indicated for such use essential tremor propranolol is indicated in the management of familial or hereditary essential tremor familial or essential tremor consists of involuntary rhythmic oscillatory movements usually limited to the upper limbs it is absent at rest but occurs when the limb is held in a fixed posture or position against gravity and during active movement propranolol causes a reduction in the tremor amplitude but not in the tremor frequency propranolol is not indicated for the treatment of tremor associated with parkinsonism hypertrophic subaortic stenosis propranolol improves nyha functional class in symptomatic patients with hypertrophic subaortic stenosis pheochromocytoma propranolol is indicated as an adjunct to alphaadrenergic blockade to control blood pressure and reduce symptoms of catecholaminesecreting tumors,3
levothyroxine sodium is used for the following indications hypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiter pituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer,3
levothyroxine sodium is used for the following indications hypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiter pituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer,3
indomethacin for injection is contraindicated in neonates with proven or suspected infection that is untreated who are bleeding especially those with active intracranial hemorrhage or gastrointestinal bleeding with thrombocytopenia or coagulation defects with or who are suspected of having necrotizing enterocolitis with significant impairment of renal function with congenital heart disease in whom patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow eg pulmonary atresia severe tetralogy of fallot severe coarctation of the aorta indomethacin for injection is contraindicated in neonates with proven or suspected infection that is untreated who are bleeding especially those with active intracranial hemorrhage or gastrointestinal bleeding with thrombocytopenia or coagulation defects suspected of having necrotizing enterocolitis with significant impairment of renal function with congenital heart disease in whom patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow 4,1
tinidazole tablets is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in non pregnant adult women 14 81 tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis see clinical studies 141 tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalis g lamblia see clinical studies 142 tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolytica see clinical studies 143 144 tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilus gardnerella see use in specific populations 81 and clinical studies 145 other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicans herpes simplex to reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
tinidazole tablets is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in non pregnant adult women 14 81 tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis see clinical studies 141 tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalis g lamblia see clinical studies 142 tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolytica see clinical studies 143 144 tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilus gardnerella see use in specific populations 81 and clinical studies 145 other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicans herpes simplex to reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,3
alimta r in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic nonsquamous nsclc with no egfr or alk genomic tumor aberrations 11 in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer nsclc 11 as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous nsclc whose disease has not progressed after four cycles of platinumbased firstline chemotherapy 11 as a single agent for the treatment of patients with recurrent metastatic nonsquamous nsclc after prior chemotherapy 11 limitations of use 11 initial treatment in combination with cisplatin of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery 12 alimta r in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer nsclc as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous nsclc whose disease has not progressed after four cycles of platinumbased firstline chemotherapy as a single agent for the treatment of patients with recurrent metastatic nonsquamous nsclc after prior chemotherapy limitations of use see clinical studies 141 alimta is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery,3
upstates metolazone tablets usp are indicated for the treatment of salt and water retention including edema accompanying congestive heart failure edema accompanying renal diseases including the nephrotic syndrome and states of diminished renal function metolazone tablets usp are also indicated for the treatment of hypertension alone or in combination with other antihypertensive drugs of a different class mykrox tablets a more rapidly available form of metolazone are intended for the treatment of new patients with mild to moderate hypertension a dose titration is necessary if mykrox tablets are to be substituted for upstates metolazone tablets usp in the treatment of hypertension see package circular for mykrox tablets ucb the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy metolazone tablets usp are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy see precautions,3
kanjinti is a her2neu receptor antagonist indicated for the treatment of her2 overexpressing breast cancer 11 12 the treatment of her2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma 13 select patients for therapy based on an fdaapproved companion diagnostic for a trastuzumab product 1 21 kanjinti is indicated for adjuvant treatment of her2 overexpressing node positive or node negative erpr negative or with one high risk feature see clinical studies 141 as part of a treatment regimen consisting of doxorubicin cyclophosphamide and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multimodality anthracycline based therapy select patients for therapy based on an fdaapproved companion diagnostic for a trastuzumab product see dosage and administration 21 kanjinti is indicated in combination with paclitaxel for firstline treatment of her2overexpressing metastatic breast cancer as a single agent for treatment of her2overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease select patients for therapy based on an fdaapproved companion diagnostic for a trastuzumab product see dosage and administration 21 kanjinti is indicated in combination with cisplatin and capecitabine or 5fluorouracil for the treatment of patients with her2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease select patients for therapy based on an fdaapproved companion diagnostic for a trastuzumab product see dosage and administration 21,3
clopidogrel is a p2y 12 acute coronary syndrome for patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi clopidogrel tablets have been shown to reduce the rate of myocardial infarction mi and stroke 11 for patients with stelevation myocardial infarction stemi clopidogrel tablets have been shown to reduce the rate of mi and stroke 11 recent mi recent stroke or established peripheral arterial disease clopidogrel tablets have been shown to reduce the rate of mi and stroke 12 clopidogrel clopidogrel in patients with established peripheral arterial disease or with a history of recent myocardial infarction mi or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke,3
omeprazole delayedrelease capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm interstitial nephritis and urticaria see warnings and precautions 52 6 proton pump inhibitors ppis including omeprazole are contraindicated in patients receiving rilpivirinecontaining products see drug interactions 7 for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with omeprazole refer to the contraindications section of their package inserts patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation 4 patients receiving rilpivirinecontaining products 4 7 refer to the contraindications section of the prescribing information for clarithromycin and amoxicillin when administered in combination with omeprazole 4,0
ranitidine tablets usp is indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6 treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets usp 150 mg bid 7 treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets usp 150 mg qid 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeks concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
sumatriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke s warnings and precautions 54 peripheral vascular disease warnings and precautions 55 ischemic bowel disease warnings and precautions 55 uncontrolled hypertension warnings and precautions 58 recent use ie within 24 hours of ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide or another 5hydroxytryptamine 1 1 see drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent within 2 weeks use of an maoa inhibitor see drug interactions 72 clinical pharmacology 123 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen see warnings and precautions 59 severe hepatic impairment see use in specific populations 86 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 concurrent or recent past 2 weeks use of monoamine oxidasea inhibitor 4 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen 4 severe hepatic impairment 4,1
enoxaparin sodium injection is a low molecular weight heparin lmwh indicated for prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery knee replacement surgery or medical patients with severely restricted mobility during acute illness 11 inpatient treatment of acute dvt with or without pulmonary embolism 12 outpatient treatment of acute dvt without pulmonary embolism 12 prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction mi 13 treatment of acute stsegment elevation myocardial infarction stemi managed medically or with subsequent percutaneous coronary intervention pci 14 enoxaparin sodium injection is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 141 in patients undergoing hip replacement surgery during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness enoxaparin sodium injection is indicated for the inpatient treatment with or without pulmonary embolism the outpatient treatment without pulmonary embolism enoxaparin sodium injection is indicated for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin enoxaparin sodium injection when administered concurrently with aspirin has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute stsegment elevation myocardial infarction stemi receiving thrombolysis and being managed medically or with percutaneous coronary intervention pci,3
metoclopramide is contraindicatedmetoclopramide is contraindicated in patients with a history of tardive dyskinesia td or a dystonic reaction to metoclopramide see warnings and precautions 51 52 see warnings and precautions 51 52 when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor see warnings and precautions 55 in patients with epilepsy metoclopramide may increase the frequency and severity of seizures see adverse reactions 6 in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm see adverse reactions 6 history of td or dystonic reaction to metoclopramide 4 when stimulation of gastrointestinal motility might be dangerous 4 pheochromocytoma catecholaminereleasing paragangliomas 4 epilepsy 4 hypersensitivity to metoclopramide 4,0
estrogens should not be used in individuals with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease known or suspected estrogendependent neoplasia active deep vein thrombosis pulmonary embolism or history of these conditions active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction liver dysfunction or disease estradiol tablets usp should not be used in patients with known hypersensitivity to its ingredients estradiol tablets usp 2 mg contain fdc yellow no 5 tartrazine which may cause allergictype reactions including bronchial asthma in certain susceptible individuals although the overall incidence of fdc yellow no 5 tartrazine sensitivity in the general population is low it is frequently seen in patients who also have aspirin hypersensitivity known or suspected pregnancy there is no indication for estradiol tablets in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,1
fluocinonide cream 01 is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older 1 limitation of use treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because of the potential for the drug to suppress the hypothalamicpituitaryadrenal hpa axis 1 avoid use on the face groin or axillae 12 avoid use in perioral dermatitis or rosacea fluocinonide cream 01 is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older see use in specific populations 84 treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because the safety of fluocinonide cream 01 for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamicpituitaryadrenal hpa axis therapy should be discontinued when control of the disease is achieved if no improvement is seen within 2 weeks reassessment of the diagnosis may be necessary do not use more than half of the 120 g tube per week fluocinonide cream 01 should not be used in the treatment of rosacea or perioral dermatitis and should not be used on the face groin or axillae,1
strattera is contraindicated in patients known to be hypersensitive to atomoxetine or other constituents of the product see warnings and precautions 57 strattera should not be taken with an maoi or within 2 weeks after discontinuing an maoi treatment with an maoi should not be initiated within 2 weeks after discontinuing strattera with other drugs that affect brain monoamine concentrations there have been reports of serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability with possible rapid fluctuations of vital signs and mental status changes that include extreme agitation progressing to delirium and coma when taken in combination with an maoi some cases presented with features resembling neuroleptic malignant syndrome such reactions may occur when these drugs are given concurrently or in close proximity see drug interactions 71 in clinical trials strattera use was associated with an increased risk of mydriasis and therefore its use is not recommended in patients with narrow angle glaucoma hypersensitivity to atomoxetine or other constituents of product 41 strattera use within 2 weeks after discontinuing maoi or other drugs that affect brain monoamine concentrations 42 71 narrow angle glaucoma 43,1
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate in patients with chd or multiple risk factors for chd atorvastatin calcium tablets can be started simultaneously with diet 11 prevention of cardiovascular disease in adults in adult patients without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as age smoking hypertension low hdlc or a family history of early coronary heart disease atorvastatin calcium tablets are indicated to reduce the risk of myocardial infarction in adult patients with type 2 diabetes and without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as retinopathy albuminuria smoking or hypertension atorvastatin calcium tablets are indicated to reduce the risk of myocardial infarction in adult patients with clinically evident coronary heart disease atorvastatin calcium tablets are indicated to reduce the risk of nonfatal myocardial infarction 12 hyperlipidemia atorvastatin calcium tablets are indicated as an adjunct to diet to reduce elevated totalc ldlc apo b and tg levels and to increase hdlc in adult patients with primary hypercholesterolemia heterozygous familial and nonfamilial and mixed dyslipidemia fredrickson types iia and iib a ldlc remains 190 mgdl or b ldlc remains 160 mgdl and there is a positive family history of premature cardiovascular disease or 13 limitations of use atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons fredrickson types i and v,3
methenamine mandelate usp is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis cystitis and other chronic urinary tract infections also those neurologic diseases leading to an infected residual urine when used as recommended methenamine mandelate usp is particularly suitable for longterm therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop pathogens resistant to other antibacterial agents may respond to methenamine mandelate usp because of the nonspecific effect of formaldehyde formed in an acid urine to reduce the development of drugresistant bacteria and maintain the effectiveness of methenamine mandelate usp and other antibacterial drugs methenamine mandelate usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria prophylactic use rationale therapeutic use rationale,3
clomipramine hydrochloride is contraindicated in patients with a history of hypersensitivity to clomipramine hydrochloride or other tricyclic antidepressants monoamine oxidase inhibitors maois the use of maois intended to treat psychiatric disorders with clomipramine hydrochloride or within 14 days of stopping treatment with clomipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome the use of clomipramine hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated see warnings and dosage and administration starting clomipramine hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome see warnings and dosage and administration myocardial infarction clomipramine hydrochloride is contraindicated during the acute recovery period after a myocardial infarction,1
brevibloc esmolol hydrochloride is contraindicated in patients with severe sinus bradycardia may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52 heart block greater than first degree second or thirddegree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52 sick sinus syndrome may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52 decompensated heart failure may worsen heart failure cardiogenic shock may precipitate further cardiovascular collapse and cause cardiac arrest iv administration of cardiodepressant calciumchannel antagonists eg verapamil and brevibloc in close proximity ie while cardiac effects from the other are still present fatal cardiac arrests have occurred in patients receiving brevibloc and intravenous verapamil pulmonary hypertension may precipitate cardiorespiratory compromise hypersensitivity reactions including anaphylaxis to esmolol or any of the inactive ingredients of the product crosssensitivity between beta blockers is possible severe sinus bradycardia 4 heart block greater than first degree 4 sick sinus syndrome 4 decompensated heart failure 4 cardiogenic shock 4 coadministration of iv cardiodepressant calciumchannel antagonists eg verapamil in close proximity to brevibloc injection 4 7 pulmonary hypertension 4 known hypersensitivity to esmolol 4,1
valacyclovir hydrochloride tablets are a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hivinfected patients reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis limitations of use 13 the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode recurrent episodes suppressive therapy reduction of transmission sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis labeling describing use of valacyclovir hcl in pediatric patients with chickenpox ages 2 to 18 years is approved for glaxosmithklines valtrexr caplets however due to glaxosmithklines marketing exclusivity rights a description of that pediatric use is not approved for this valacyclovir hcl tablet product the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection labeling describing use of valacyclovir hcl in pediatric patients with chickenpox ages of 2 to 18 years is approved for glaxosmithklines valtrex r,3
nevirapine is indicated for combination antiretroviral treatment of hiv1 infection in adults and in pediatrics patients 15 days and older see clinical studies 141 142 additional important information regarding the use of nevirapine for the treatment of hiv1 infection based on serious and lifethreatening hepatotoxicity observed in controlled and uncontrolled trials nevirapine should not be initiated in adult females with cd4 3 3 see boxed warning warnings and precautions 51 see dosage and administration 24 and warnings and precautions 52 nevirapine is an nnrti indicated for combination antiretroviral treatment of hiv1 infection in adults and in pediatric patients 15 days and older 1 initiation of treatment is not recommended in the following populations unless the benefits outweigh the risks 1 51 adult females with cd4 3 adult males with cd4 3 the 14day leadin period must be strictly followed it has been demonstrated to reduce the frequency of rash 24 52,0
methylphenidate hcl extendedrelease capsules cd is contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms methylphenidate hcl extendedrelease capsules cd is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product methylphenidate hcl extendedrelease capsules cd contains sucrose therefore patients with rare hereditary problems of fructose intolerance glucosegalactose malabsorption or sucraseisomaltase insufficiency should not take this medicine methylphenidate hcl extendedrelease capsules cd is contraindicated in patients with glaucoma methylphenidate hcl extendedrelease capsules cd is contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions methylphenidate hcl extendedrelease capsules cd is contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor hypertensive crises may result methylphenidate hcl extendedrelease capsules cd is contraindicated in patients with severe hypertension angina pectoris cardiac arrhythmias heart failure recent myocardial infarction hyperthyroidism or thyrotoxicosis see warnings there is a risk of sudden blood pressure increase during surgery if surgery is planned methylphenidate hcl extendedrelease capsules cd should not be taken on the day of the surgery,1
active pathological bleeding 41 42 43 prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage see warnings and precautions 51 61 prasugrel tablets is contraindicated in patients with a history of prior transient ischemic attack tia or stroke in tritontimi 38 trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel patients with a history of tia or ischemic stroke 3 months prior to enrollment had a higher rate of stroke on prasugrel tablets 65 of which 42 were thrombotic stroke and 23 were intracranial hemorrhage ich than on clopidogrel 12 all thrombotic in patients without such a history the incidence of stroke was 09 02 ich and 10 03 ich with prasugrel tablets and clopidogrel respectively patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from tritontimi 38 patients who experience a stroke or tia while on prasugrel tablets generally should have therapy discontinued see adverse reactions 61 14 prasugrel tablets is contraindicated in patients with hypersensitivity eg anaphylaxis to prasugrel or any component of the product see adverse reactions 62,1
spironolactone tablets are indicated in the management of primary hyperaldosteronism establishing the diagnosis of primary hyperaldosteronism by therapeutic trial shortterm preoperative treatment of patients with primary hyperaldosteronism longterm maintenance therapy for patients with discrete aldosteroneproducing adrenal adenomas who are judged to be poor operative risks or who decline surgery longterm maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia idiopathic hyperaldosteronism edematous conditions congestive heart failure cirrhosis of the liver accompanied by edema andor ascites nephrotic syndrome essential hypertension usually in combination with other drugs spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate hypokalemia severe heart failure nyha class iii iv usage in pregnancy precautions pregnancy,3
hyperkalemia amiloride hcl tablets should not be used in the presence of elevated serum potassium levels greater than 55 meq per liter antikaliuretic therapy or potassium supplementation amiloride hcl tablets should not be given to patients receiving other potassiumconserving agents such as spironolactone or triamterene potassium supplementation in the form of medication potassiumcontaining salt substitutes or a potassiumrich diet should not be used with amiloride hcl tablets except in severe andor refractory cases of hypokalemia such concomitant therapy can be associated with rapid increases in serum potassium levels if potassium supplementation is used careful monitoring of the serum potassium level is necessary impaired renal function anuria acute or chronic renal insufficiency and evidence of diabetic nephropathy are contraindications to the use of amiloride hcl tablets patients with evidence of renal functional impairment blood urea nitrogen bun levels over 30 mg per 100 ml or serum creatinine levels over 15 mg per 100 ml or diabetes mellitus should not receive the drug without careful frequent and continuing monitoring of serum electrolytes creatinine and bun levels potassium retention associated with the use of an antikaliuretic agent is accentuated in the presence of renal impairment and may result in the rapid development of hyperkalemia hypersensitivity amiloride hcl tablets are contraindicated in patients who are hypersensitive to this product warnings,1
for the treatment of the following conditions steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctuate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical or thermal burns or penetration of foreign bodies steroid responsive inflammatory conditions of the external auditory meatus such as allergic otitis externa selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below adults and adolescents communityacquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis clinical studies acute exacerbations of chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis note pediatric use dosage and administration pharyngitistonsillitis streptococcus pyogenes clinical studies note s pyogenes s pyogenes uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes pediatric patients acute bacterial otitis media haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis pharyngitistonsillitis streptococcus pyogenes clinical studies note s pyogenes s pyogenes uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes,3
losartan potassium tablets usp are an angiotensin ii receptor blocker arb indicated for 11 12 13 losartan potassium tablets usp are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular cv events primarily strokes and myocardial infarction these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan losartan potassium tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy but there is evidence that this benefit does not apply to black patients see use in specific populations 86 123 losartan potassium tablets usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria urinary albumin to creatinine ratio 300 mgg in patients with type 2 diabetes and a history of hypertension in this population losartan potassium tablets usp reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease need for dialysis or renal transplantation see clinical studies 143,3
marked anxiety tension and agitation are contraindications to metadate er since the drug may aggravate these symptoms metadate er is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product metadate er contains lactose therefore patients with rare hereditary problems of galactose intolerance the lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine metadate er is contraindicated in patients with glaucoma metadate er is contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions metadate er is contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor hypertensive crises may result metadate er is contraindicated in patients with severe hypertension angina pectoris cardiac arrhythmias heart failure recent myocardial infarction hyperthyroidism or thyrotoxicosis see warnings there is a risk of sudden blood pressure increase during surgery if surgery is planned metadate er should not be taken on the day of the surgery,1
efavirenz tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity eg stevensjohnson syndrome erythema multiforme or toxic skin eruptions to any of the components of this productefavirenz tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity eg stevensjohnson syndrome erythema multiforme or toxic skin eruptions to any of the components of this product coadministration of efavirenz with elbasvir and grazoprevir is contraindicated see warnings and precautions 51 drug interactions 71 warnings and precautions 51 drug interactions 71 patients with previously demonstrated hypersensitivity eg stevensjohnson syndrome erythema multiforme or toxic skin eruptions to any of the components of this product 4 coadministration of efavirenz with elbasvirgrazoprevir 4,1
clarithromycin tablets usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below pharyngitistonsillitis due to streptococcus pyogenes s pyogenes acute maxillary sinusitis due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis streptococcus pneumoniae communityacquired pneumonia due to haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae chlamydophila pneumoniae uncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes disseminated mycobacterial infections due to mycobacterium avium mycobacterium intracellulare clarithromycin tablets usp in combination with amoxicillin and prevacid lansoprazole or prilosec omeprazole delayedrelease capsules as triple therapy are indicated for the treatment of patients with helicobacter pylori h pylori clarithromycin tablets usp in combination with prilosec omeprazole capsules or tritec ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with h pylori in patients who fail therapy susceptibility testing should be done if possible if resistance to clarithromycin is demonstrated a nonclarithromycincontaining therapy is recommended for information on development of resistance see microbiology h pylori pharyngitistonsillitis due to streptococcus pyogenes communityacquired pneumonia due to mycoplasma pneumoniae streptococcus pneumoniae chlamydophila pneumoniae acute maxillary sinusitis due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae acute otitis media due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae note clinical studies uncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes disseminated mycobacterial infections due to mycobacterium avium mycobacterium intracellulare clarithromycin tablets usp are indicated for the prevention of disseminated mycobacterium avium,3
clarithromycin tablets usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below pharyngitistonsillitis due to streptococcus pyogenes s pyogenes acute maxillary sinusitis due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae haemophilus parainfluenzae moraxella catarrhalis streptococcus pneumoniae communityacquired pneumonia due to haemophilus influenzae mycoplasma pneumoniae streptococcus pneumoniae chlamydophila pneumoniae uncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes disseminated mycobacterial infections due to mycobacterium avium mycobacterium intracellulare clarithromycin tablets usp in combination with amoxicillin and prevacid lansoprazole or prilosec omeprazole delayedrelease capsules as triple therapy are indicated for the treatment of patients with helicobacter pylori h pylori clarithromycin tablets usp in combination with prilosec omeprazole capsules or tritec ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with h pylori in patients who fail therapy susceptibility testing should be done if possible if resistance to clarithromycin is demonstrated a nonclarithromycincontaining therapy is recommended for information on development of resistance see microbiology h pylori pharyngitistonsillitis due to streptococcus pyogenes communityacquired pneumonia due to mycoplasma pneumoniae streptococcus pneumoniae chlamydophila pneumoniae acute maxillary sinusitis due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae acute otitis media due to haemophilus influenzae moraxella catarrhalis streptococcus pneumoniae note clinical studies uncomplicated skin and skin structure infections due to staphylococcus aureus streptococcus pyogenes disseminated mycobacterial infections due to mycobacterium avium mycobacterium intracellulare clarithromycin tablets usp are indicated for the prevention of disseminated mycobacterium avium,3
adenosine injection is contraindicated in patients with second or thirddegree av block except in patients with a functioning artificial pacemaker see warnings and precautions 52 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker see warnings and precautions 52 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma see warnings and precautions 53 known hypersensitivity to adenosine injection see warnings and precautions 57 second or thirddegree av block except in patients with a functioning artificial pacemaker 4 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker 4 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma 4 known hypersensitivity to adenosine injection 4,1
epinephrine should not be used in the presence of cardiac dilatation or coronary insufficiency epinephrine is contraindicated in shock during general anesthesia with halogenated hydrocarbons or cyclopropane and in individuals with organic brain damage epinephrine is also contraindicated with local anesthesia of certain areas eg fingers toes because of the danger of vasoconstriction producing sloughing of tissue also contraindicated in labor because it may delay the second stage epinephrine should not be used in those cases where vasopressor drugs may be contraindicated eg in thyrotoxicosis diabetes in obstetrics when maternal blood pressure is in excess of 13080 and in hypertension and other cardiovascular disorders,1
brisdelle is indicated for the treatment of moderate to severe vasomotor symptoms vms associated with menopause limitation of use brisdelle is not indicated for the treatment of any psychiatric condition brisdelle contains a lower dose of paroxetine than that used to treat depression obsessive compulsive disorder panic disorder generalized anxiety disorder social anxiety disorder and posttraumatic stress disorder the safety and efficacy of this lower dose of paroxetine in brisdelle have not been established for any psychiatric condition patients who require paroxetine for treatment of a psychiatric condition should discontinue brisdelle and initiate a paroxetinecontaining medication that is indicated for such use brisdelle is a selective serotonin reuptake inhibitor ssri indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause vms 1 limitation of use 1,1
mavenclad is contraindicated in patients with current malignancy see warnings and precautions 51 in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception during mavenclad dosing and for 6 months after the last dose in each treatment course may cause fetal harm see warnings and precautions 52 use in specific populations 81 83 in patients infected with the human immunodeficiency virus hiv see warnings and precautions 54 in patients with active chronic infections eg hepatitis or tuberculosis see warnings and precautions 54 in patients with a history of hypersensitivity to cladribine see warnings and precautions 58 in women intending to breastfeed on a mavenclad treatment day and for 10 days after the last dose see use in specific populations 82 patients with current malignancy 4 pregnant women and women and men of reproductive potential who do not plan to use effective contraception during mavenclad dosing and for 6 months after the last dose in each treatment course 4 83 hiv infection 4 active chronic infections eg hepatitis or tuberculosis 4 history of hypersensitivity to cladribine 4 58 women intending to breastfeed on a mavenclad treatment day and for 10 days after the last dose 4 82,1
pegasys is contraindicated in patients with known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis or stevensjohnson syndrome to alpha interferons including pegasys or any of its components autoimmune hepatitis hepatic decompensation childpugh score greater than 6 class b and c in cirrhotic patients before treatment hepatic decompensation with childpugh score greater than or equal to 6 in cirrhotic chc patients coinfected with hiv before treatment pegasys is contraindicated in neonates and infants because it contains benzyl alcohol benzyl alcohol is associated with an increased incidence of neurologic and other complications which are sometimes fatal in neonates and infants when pegasys is used in combination with other hcv antiviral drugs the contraindications applicable to those agents are applicable to combination therapies pegasys combination treatment with ribavirin is contraindicated in women who are pregnant and men whose female partners are pregnant see warnings and precautions 51 use in specific populations 81 refer to the prescribing information of the other hcv antiviral drugs including ribavirin for a list of their contraindications autoimmune hepatitis 4 hepatic decompensation in patients with cirrhosis 4 use in neonatesinfants 4 known hypersensitivity reactions such as urticaria angioedema bronchoconstriction and anaphylaxis to alpha interferons or any component of the product 4 additional contraindications for use with other hcv antiviral drugs when used in combination with other hcv antiviral drugs all contraindications also apply to pegasys combination therapy 4 ribavirin is contraindicated in pregnant women and men whose female partners are pregnant 4 81,1
the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated see warnings dosage and administration starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome see warnings dosage and administration crosssensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction,1
rabeprazole sodium delayedrelease tablets are contraindicated in patients with known hypersensitivity to rabeprazole substituted benzimidazoles or to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6 see adverse reactions 6 ppis including rabeprazole sodium delayedrelease tablets are contraindicated with rilpivirinecontaining products see drug interactions 7 for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with rabeprazole sodium delayedrelease tablets refer to the contraindications patients with a history of hypersensitivity to rabeprazole 4 patients receiving rilpivirinecontaining products 4 7 refer to the contraindications section of the prescribing information for clarithromycin and amoxicillin when administered in combination with rabeprazole sodium delayedrelease tablets 4,1
agitation marked anxiety and tension 41 known hypersensitivity to methylphenidate or product components 42 glaucoma 43 history of motor tics or a family history or diagnosis of tourettes syndrome 44 during or within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor maoi 45 focalin xr is contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms focalin xr is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product focalin xr is contraindicated in patients with glaucoma focalin xr is contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 61 focalin xr is contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor hypertensive crises may result,1
upstates metolazone tablets usp are indicated for the treatment of salt and water retention including edema accompanying congestive heart failure metolazone tablets usp are also indicated for the treatment of hypertension alone or in combination with other antihypertensive drugs of a different class mykrox tablets a more rapidly available form of metolazone are intended for the treatment of new patients with mild to moderate hypertension a dose titration is necessary if mykrox tablets are to be substituted for upstates metolazone tablets usp in the treatment of hypertension see package circular for mykrox tablets ucb usage in pregnancy the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy metolazone tablets usp are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy see precautions dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother in the absence of cardiovascular disease but which is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort which is not relieved by rest in these cases a short course of diuretics may be appropriate,3
esomeprazole magnesium delayedrelease capsules are a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 11 risk reduction of nsaidassociated gastric ulcer 12 h pylori 13 pathological hypersecretory conditions including zollingerellison syndrome 14 healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated for the shortterm treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayedrelease capsules may be considered maintenance of healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months esomeprazole magnesium delayedrelease capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 60 andor documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayedrelease capsules plus amoxicillin and clarithromycin esomeprazole magnesium delayedrelease capsules in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with h pylori h pylori h pylori see dosage and administration 2 clinical studies 14 see clinical pharmacology 124 esomeprazole magnesium delayedrelease capsules are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
do not initiate in patients with constipation 41 history of chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment 42 concomitant use of fluvoxamine 43 alosetron hydrochloride should not be initiated see warnings and precautions 51 alosetron hydrochloride is contraindicated in patients with a history of the following chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated fluvoxamine a known strong inhibitor of cyp1a2 has been shown to increase mean alosetron plasma concentrations auc approximately 6fold and prolong the halflife by approximately 3fold see drug interactions 71,1
to reduce the development of drugresistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy treatment doxycycline is indicated for the treatment of the following infections rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae doxycycline is also indicated for the treatment of infections caused by the following gramnegative microorganisms chancroid caused by haemophilus ducreyi because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline culture and susceptibility testing are recommended doxycycline is indicated for treatment of infections caused by the following gramnegative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug escherichia coli doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug upper respiratory infections caused by streptococcus pneumoniae when penicillin is contraindicated doxycycline is an alternative drug in the treatment of the following infections uncomplicated gonorrhea caused by neisseria gonorrhoeae in acute intestinal amebiasis doxycycline may be a useful adjunct to amebicides in severe acne doxycycline may be useful adjunctive therapy prophylaxis doxycycline is indicated for the prophylaxis of malaria due to plasmodium falciparum in shortterm travelers 4 months to areas with chloroquine andor pyrimethaminesulfadoxine resistant strains see dosage and administration section and information for patients subsection of the precautions section,3
itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure chf or a history of chf except for the treatment of lifethreatening or other serious infections see boxed warning warnings adverse reactions postmarketing experience clinical pharmacology special populations coadministration of a number of cyp3a4 substrates are contraindicated with itraconazole oral solution plasma concentrations increase for the following drugs levaceytlmethadol levomethadyl methadone disopyramide dofetilide dronedarone quinidine isavuconazole ergot alkaloids such as dihydroergotamine ergometrine ergonovine ergotamine methylergometrine methylergonovine irinotecan lurasidone oral midazolam pimozide triazolam felodipine nisoldipine ivabradine ranolazine eplerenone cisapride naloxegol lomitapide lovastatin simvastatin avanafil ticagrelor in addition coadministration with colchicine fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of cyp2d6 and in subjects taking strong or moderate cyp2d6 inhibitors see precautions drug interactions itraconazole oral solution is contraindicated for patients who have shown hypersensitivity to itraconazole there is limited information regarding crosshypersensitivity between itraconazole and other azole antifungal agents caution should be used when prescribing itraconazole oral solution to patients with hypersensitivity to other azoles,1
treatment with eptifibatide injection is contraindicated in patients with a history of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days severe hypertension systolic blood pressure 200 mm hg or diastolic blood pressure 110 mm hg not adequately controlled on antihypertensive therapy major surgery within the preceding 6 weeks history of stroke within 30 days or any history of hemorrhagic stroke current or planned administration of another parenteral gp iibiiia inhibitor dependency on renal dialysis hypersensitivity to eptifibatide or any component of the product hypersensitivity reactions that occurred included anaphylaxis and urticaria bleeding diathesis or bleeding within the previous 30 days 4 severe uncontrolled hypertension 4 major surgery within the preceding 6 weeks 4 stroke within 30 days or any history of hemorrhagic stroke 4 coadministration of another parenteral gp iibiiia inhibitor 4 dependency on renal dialysis 4 known hypersensitivity to any component of the product 4,1
estradiol transdermal system continuous delivery onceweekly should not be used in women with any of the following conditions undiagnosed abnormal genital bleeding known suspected or history of cancer of the breast known or suspected estrogendependent neoplasia active deep vein thrombosis pulmonary embolism or a history of these conditions active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction liver dysfunction or disease estradiol transdermal system continuous delivery onceweekly should not be used in patients with known hypersensitivity to its ingredients known or suspected pregnancy there is no indication for estradiol transdermal system continuous delivery onceweekly in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,1
amantadine hydrochloride capsules usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus amantadine hydrochloride capsules usp are also indicated in the treatment of parkinsonism and druginduced extrapyramidal reactions influenza a prophylaxis following vaccination during an influenza a outbreak amantadine hydrochloride capsules usp prophylaxis should be considered for the 2 to 4week time period required to develop an antibody response influenza a treatment there is no clinical evidence indicating that amantadine hydrochloride capsules usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules usp amantadine hydrochloride capsules usp is not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules usp parkinsons diseasesyndrome druginduced extrapyramidal reactions,3
relpax tablets should not be given to patients with ischemic heart disease eg angina pectoris history of myocardial infarction or documented silent ischemia or to patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings relpax tablets should not be given to patients with cerebrovascular syndromes including but not limited to strokes of any type as well as transient ischemic attacks see warnings relpax tablets should not be given to patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings because relpax tablets may increase blood pressure it should not be given to patients with uncontrolled hypertension see warnings relpax tablets should not be administered to patients with hemiplegic or basilar migraine relpax tablets should not be used within 24 hours of treatment with another 5ht 1 relpax tablets should not be used in patients with known hypersensitivity to eletriptan or any of its inactive ingredients relpax tablets should not be given to patients with severe hepatic impairment,1
celecoxib capsules are indicated 11 osteoarthritis for the management of the signs and symptoms of oa see clinical studies 141 12 rheumatoid arthritis for the management of the signs and symptoms of ra see clinical studies 142 13 juvenile rheumatoid arthritis for the management of the signs and symptoms of jra in patients 2 years and older see clinical studies 143 14 ankylosing spondylitis for the management of the signs and symptoms of as see clinical studies 144 15 acute pain for the management of acute pain in adults see clinical studies 145 16 primary dysmenorrhea for the management of primary dysmenorrhea see clinical studies 145,2
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy communityacquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis clinical studies acute exacerbations of chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis note pediatric use dosage and administration streptococcus pyogenes clinical studies note s pyogenes s pyogenes staphylococcus aureus streptococcus pyogenes acute bacterial otitis media haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis streptococcus pyogenes clinical studies s pyogenes s pyogenes staphylococcus aureus streptococcus pyogenes,3
tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 11 51 crohns disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohns disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnfa 12 important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnfa 12 tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 51 tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohns disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnfa tysabri should not be used in combination with immunosuppressants eg 6mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnfa see warnings and precautions 51,3
depakote sprinkle capsules are an antiepileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures adjunctive therapy in patients with multiple seizure types that include absence seizures 1 depakote sprinkle capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures depakote sprinkle capsules are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures and adjunctively in patients with multiple seizure types that include absence seizures simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs complex absence is the term used when other signs are also present because of the risk to the fetus of decreased iq neurodevelopmental disorders neural tube defects and other major congenital malformations which may occur very early in pregnancy valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable see warnings and precautions 52 53 54 81 17 for prophylaxis of migraine headaches valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception see contraindications 4,3
neoprofen is contraindicated in preterm infants with proven or suspected infection that is untreated preterm infants with congenital heart disease in whom patency of the pda is necessary for satisfactory pulmonary or systemic blood flow eg pulmonary atresia severe tetralogy of fallot severe coarctation of the aorta preterm infants who are bleeding especially those with active intracranial hemorrhage or gastrointestinal bleeding preterm infants with thrombocytopenia preterm infants with coagulation defects preterm infants with or who are suspected of having necrotizing enterocolitis preterm infants with significant impairment of renal function neoprofen is contraindicated in preterm infants with proven or suspected infection that is untreated 4 with congenital heart disease in whom patency of the pda is necessary for satisfactory pulmonary or systemic blood flow 4 with impaired renal function 4 with thrombocytopenia coagulation defects or who are bleeding 4 with or who are suspected of having necrotizing enterocolitis 4,1
parlodel bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactin secreting adenomas reduction tumor size parlodel therapy is indicated in the treatment of acromegaly parlodel therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately 12 of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with parlodel offers potential benefit before the effects of irradiation are manifested parlodel snaptabs or capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor parlodel therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy parlodel therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of parlodel therapy during treatment of more than 2 years has not been established data are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with parlodel studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in parlodeltreated patients than in levodopacarbidopatreated patients patients unresponsive to levodopa are poor candidates for parlodel therapy,3
omeprazole is a proton pump inhibitor indicated for omeprazole delayedrelease capsules are indicated for shortterm treatment of active duodenal ulcer in adults most patients heal within four weeks some patients may require an additional four weeks of therapy omeprazole delayedrelease capsules in combination with clarithromycin and amoxicillin are indicated for treatment of patients with h pylori h pylori omeprazole delayedrelease capsules in combination with clarithromycin are indicated for treatment of patients with h pylori h pylori eradication of h pylori among patients who fail therapy omeprazole delayedrelease capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see microbiology section 124 and the clarithromycin package insert microbiology section omeprazole delayedrelease capsules are indicated for shortterm treatment 48 weeks of active benign gastric ulcer in adults see clinical studies 142 symptomatic gerd erosive esophagitis the efficacy of omeprazole delayedrelease capsules used for longer than 8 weeks in these patients has not been established if a patient does not respond to 8 weeks of treatment an additional 4 weeks of treatment may be given if there is recurrence of erosive esophagitis or gerd symptoms eg heartburn additional 48 week courses of omeprazole may be considered omeprazole delayedrelease capsules are indicated to maintain healing of erosive esophagitis in pediatric patients and adults controlled studies do not extend beyond 12 months see clinical studies 144 omeprazole delayedrelease capsules are indicated for the longterm treatment of pathological hypersecretory conditions eg zollingerellison syndrome multiple endocrine adenomas and systemic mastocytosis in adults,3
zoledronic acid injection is a bisphosphonate indicated for the treatment of hypercalcemia of malignancy 11 patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy prostate cancer should have progressed after treatment with at least one hormonal therapy 12 important limitation of use the safety and efficacy of zoledronic acid injection has not been established for use in hyperparathyroidism or nontumorrelated hypercalcemia 13 zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumincorrected calcium cca of greater than or equal to 12 mgdl 30 mmoll using the formula cca in mgdlca in mgdl 08 40 gdl zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy prostate cancer should have progressed after treatment with at least one hormonal therapy the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions have not been established,3
known hypersensitivity to meloxicam or any components of the drug product 4 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 4 in the setting of cabg surgery 4 meloxicam tablets are contraindicated in the following patients known hypersensitivity eg anaphylactic reactions and serious skin reactions to meloxicam or any components of the drug product see warnings and precautions 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids severe sometimes fatal anaphylactic reactions to nsaids have been reported in such patients see warnings and precautions 57 58 in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51,1
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate in patients with chd or multiple risk factors for chd atorvastatin calcium tablets can be started simultaneously with diet atorvastatin calcium tablets are an inhibitor of hmgcoa reductase statin indicated as an adjunct therapy to diet to 11 11 11 12 12 12 12 limitations of use fredrickson in adult patients without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as age smoking hypertension low hdlc or a family history of early coronary heart disease atorvastatin calcium tablets are indicated to reduce the risk of myocardial infarction reduce the risk of stroke reduce the risk for revascularization procedures and angina in patients with type 2 diabetes and without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as retinopathy albuminuria smoking or hypertension atorvastatin calcium tablets are indicated to reduce the risk of myocardial infarction in patients with clinically evident coronary heart disease atorvastatin calcium tablets are indicated to atorvastatin calcium tablets are indicated as an adjunct to diet to reduce elevated totalc ldlc apo b and tg levels and to increase hdlc in patients with primary hypercholesterolemia heterozygous familial and nonfamilial and mixed dyslipidemia fredrickson fredrickson fredrickson atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons fredrickson,3
truxima rituximababbs is a cd20directed cytolytic antibody indicated for the treatment of adult patients with nonhodgkins lymphoma nhl 11 relapsed or refractory low grade or follicular cd20positive bcell nhl as a single agent previously untreated follicular cd20positive bcell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as singleagent maintenance therapy nonprogressing including stable disease lowgrade cd20positive bcell nhl as a single agent after firstline cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large bcell cd20positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracyclinebased chemotherapy regimens chronic lymphocytic leukemia cll 12 previously untreated and previously treated cd20positive cll in combination with fludarabine and cyclophosphamide fc truxima rituximababbs is indicated for the treatment of adult patients with relapsed or refractory lowgrade or follicular cd20positive bcell nhl as a single agent previously untreated follicular cd20positive bcell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as singleagent maintenance therapy nonprogressing including stable disease lowgrade cd20positive bcell nhl as a single agent after firstline cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large bcell cd20positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracyclinebased chemotherapy regimens truxima is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd20positive cll,3
known hypersensitivity to the product 41 marked anxiety tension or agitation 42 glaucoma 43 tics or a family history or diagnosis of tourettes syndrome 44 do not use methylphenidate hcl extendedrelease tablets in patients currently using or within 2 weeks of using an mao inhibitor 45 hypersensitivity reactions such as angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate hcl extendedrelease tablets therefore methylphenidate hcl extendedrelease tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product see adverse reactions 66 methylphenidate hcl extendedrelease tablets are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms methylphenidate hcl extendedrelease tablets are contraindicated in patients with glaucoma methylphenidate hcl extendedrelease tablets are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 64 methylphenidate hcl extendedrelease tablets are contraindicated during treatment with monoamine oxidase mao inhibitors and also within a minimum of 14 days following discontinuation of a mao inhibitor hypertensive crises may result see drug interactions 71,0
rizatriptan benzoate orally disintegrating tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51 coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 history of stroke or transient ischemic attack tia see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75 clinical pharmacology 123 hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets angioedema and anaphylaxis seen see adverse reactions 62 history of ischemic heart disease or coronary artery vasospasm 4 history of stroke or transient ischemic attack 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 hemiplegic or basilar migraine 4 maoa inhibitor used in the past 2 weeks 4 hypersensitivity to rizatriptan benzoate 4,1
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions seasonal or perennial allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,2
cosmegen is an actinomycin indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen 11 adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen 12 adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen 13 adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen 14 postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen 15 adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion 16 cosmegen is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen cosmegen is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion,3
cosmegen is an actinomycin indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen 11 adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen 12 adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen 13 adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen 14 postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen 15 adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion 16 cosmegen is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multiphase combination chemotherapy regimen cosmegen is indicated for the treatment of postmenarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen cosmegen is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion,3
when oral therapy is not feasible the intramuscular use r r control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopenia trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders the intraarticular or soft tissue administration the intralesional administration celestone soluspan injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular use r r control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopenia trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders the intraarticular or soft tissue administration the intralesional administration celestone soluspan injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
when oral therapy is not feasible the intramuscular use r r control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopenia trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders the intraarticular or soft tissue administration the intralesional administration celestone soluspan injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
etidronate disodium tablets usp are indicated for the treatment of symptomatic pagets disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury etidronate disodium tablets are not approved for the treatment of osteoporosis etidronate disodium tablets are indicated for the treatment of symptomatic pagets disease of bone etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by in addition reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients in many patients the disease process will be suppressed for a period of at least one year following cessation of therapy the upper limit of this period has not been determined the effects of the etidronate disodium treatment in patients with asymptomatic pagets disease have not been studied however etidronate disodium treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage major joints or major weightbearing bones etidronate disodium tablets are indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury etidronate disodium tablets reduce the incidence of clinically important heterotopic bone by about twothirds among those patients who form heterotopic bone etidronate disodium tablets retard the progression of immature lesions and reduces the severity by at least half followup data at least 9 months posttherapy suggests these benefits persist in total hip replacement patients in spinal cord injury patients,1
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections please note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate cream is recommended for wet oozing primary infections and greasy secondary infections such as pustular acne or infected seborrheic dermatitis if a waterwashable preparation is desired the cream is preferable gentamicin sulfate cream has been used successfully in infants over one year of age as well as in adults and children,3
clozapine tablets are an atypical antipsychotic indicated for treatmentresistant schizophrenia efficacy was established in an activecontrolled study 11 141 reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder efficacy was established in an activecontrolled study 12 142 clozapine tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment because of the risks of severe neutropenia and of seizure associated with its use clozapine tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment see warnings and precautions 51 55 the effectiveness of clozapine tablets in treatmentresistant schizophrenia was demonstrated in a 6week randomized doubleblind activecontrolled study comparing clozapine tablets and chlorpromazine in patients who had failed other antipsychotics see clinical studies 141 clozapine tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior based on history and recent clinical state suicidal behavior refers to actions by a patient that put himherself at risk for death the effectiveness of clozapine tablets in reducing the risk of recurrent suicidal behavior was demonstrated over a twoyear treatment period in the intersepttm trial see clinical studies 142,3
alprazolam extendedrelease tablets are indicated for the treatment of panic disorder with or without agoraphobia this claim is supported on the basis of two positive studies with alprazolam extendedrelease tablets conducted in patients whose diagnoses corresponded closely to the dsmiiiriv criteria for panic disorder see clinical studies panic disorder dsmiv is characterized by recurrent unexpected panic attacks ie a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 10 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 10 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushes the longerterm efficacy of alprazolam extendedrelease tablets has not been systematically evaluated thus the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient,3
verapamil hydrochloride injection is contraindicated in 1 severe hypotension or cardiogenic shock 2 second or thirddegree av block except in patients with a functioning artificial ventricular pacemaker 3 sick sinus syndrome except in patients with a functioning artificial ventricular pacemaker 4 severe congestive heart failure unless secondary to a supraventricular tachycardia amenable to verapamil therapy 5 patients receiving intravenous betaadrenergic blocking drugs eg propranolol intravenous verapamil and intravenous betaadrenergic blocking drugs should not be administered in close proximity to each other within a few hours since both may have a depressant effect on myocardial contractility and av conduction 6 patients with atrial flutter or atrial fibrillation and an accessory bypass tract eg wolff parkinsonwhite lownganonglevine syndromes are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered therefore the use of verapamil in these patients is contraindicated 7 ventricular tachycardia administration of intravenous verapamil to patients with widecomplex ventricular tachycardia qrs 012 sec can result in marked hemodynamic deterioration and ventricular fibrillation proper pretherapy diagnosis and differentiation from widecomplex supraventricular tachycardia is imperative in the emergency room setting 8 known hypersensitivity to verapamil hydrochloride,1
sumatriptan succinate injection is contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia because these patients are at a higher risk of stroke see warnings and precautions 54 history of hemiplegic or basilar migraine peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent ie within 24 hours use of ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide or another 5hydroxytryptamine 1 1 see drug interactions 71 73 concurrent administration of an maoa inhibitor or recent within 2 weeks use of an maoa inhibitor see drug interactions 72 clinical pharmacology 123 known hypersensitivity to sumatriptan see warnings and precautions 59 adverse reactions 62 severe hepatic impairment see clinical pharmacology 123 coronary artery disease or coronary vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 current or recent past 2 weeks use of monoamine oxidasea inhibitor 4 known hypersensitivity to sumatriptan 4 severe hepatic impairment 4,1
when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intramuscular use of depomedrol sterile aqueous suspension is indicated as follows allergic states dermatologic diseases endocrine disorders gastrointestinal diseases hematologic disorders miscellaneous neoplastic diseases nervous system ophthalmic diseases renal diseases respiratory diseases rheumatic disorders see warnings depomedrol is indicated as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis of osteoarthritis depomedrol is indicated for intralesional use in alopecia areata discoid lupus erythematosus keloids localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus neurodermatitis and psoriatic plaques necrobiosis lipoidica diabeticorum,3
meperidine hydrochloride tablets are contraindicated in patients with significant respiratory depression see warnings and precautions 54 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 59 concomitant use of monoamine oxidase inhibitors maois or within 14 days of having taken an maoi see drug interactions 7 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 514 hypersensitivity to meperidine or to any of other ingredients of the product eg anaphylaxis see adverse reactions 6 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 concomitant use of monoamine oxidase inhibitors maois or within 14 days of having taken an maoi 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 hypersensitivity to meperidine or to any other ingredients of the product 4,1
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,2
coadministration of prezistaritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious andor lifethreatening events narrow therapeutic index these drugs and other contraindicated drugs which may lead to reduced efficacy of darunavir are listed below due to the need for coadministration of prezista with ritonavir please refer to ritonavir prescribing information for a description of ritonavir contraindications coadministration of prezistaritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious andor lifethreatening events narrow therapeutic index these drugs and other contraindicated drugs which may lead to reduced efficacy of darunavir are listed below see drug interactions 73 alpha 1adrenoreceptor antagonist alfuzosinalpha 1adrenoreceptor antagonist alfuzosin antianginal ranolazineantianginal ranolazine antiarrhythmic dronedaroneantiarrhythmic dronedarone antigout colchicine in patients with renaland or hepatic impairmentantigout colchicine in patients with renaland or hepatic impairment antimycobacterial rifampinantimycobacterial rifampin antipsychotics lurasidone pimozideantipsychotics lurasidone pimozide ergot derivatives eg dihydroergotamine ergotamine methylergonovineergot derivatives eg dihydroergotamine ergotamine methylergonovine gi motility agent cisapridegi motility agent cisapride herbal product st johns wort hypericum perforatum hypericum perforatum hepatitis c direct acting antiviral elbasvirgrazoprevirhepatitis c direct acting antiviral elbasvirgrazoprevir lipid modifying agents lomitapide lovastatin simvastatinlipid modifying agents lomitapide lovastatin simvastatin pde5 inhibitor sildenafil when used for treatment of pulmonary arterial hypertensionpde5 inhibitor sildenafil when used for treatment of pulmonary arterial hypertension sedativeshypnotics orally administered midazolam triazolamsedativeshypnotics orally administered midazolam triazolam coadministration of prezistaritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious andor lifethreatening events narrow therapeutic index 4,1
amlodipine is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension 11 coronary artery disease 12 chronic stable angina vasospastic angina prinzmetals or variant angina angiographically documented coronary artery disease in patients without heart failure or an ejection fraction 40 amlodipine besylate tablets are indicated for the treatment of hypertension it may be used alone or in combination with other antihypertensive agents amlodipine besylate tablets are indicated for the symptomatic treatment of chronic stable angina amlodipine besylate tablets may be used alone or in combination with other antianginal agents amlodipine besylate tablets are indicated for the treatment of confirmed or suspected vasospastic angina amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents in patients with recently documented cad by angiography and without heart failure or an ejection fraction 40 amlodipine besylate tablets are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure,3
urocit r in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloride in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medication in patients with peptic ulcer disease because of its ulcerogenic potential in patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of urocit r r in patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4 patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4 patients with peptic ulcer disease 4 patients with active urinary tract infection 4 patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4,1
valacyclovir tablets usp is a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes o treatment in immunocompetent patients initial or recurrent episode o suppression in immunocompetent or hivinfected patients o reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis chickenpox limitations of use 13 the efficacy and safety of valacyclovir tablets usp have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode recurrent episodes suppressive therapy reduction of transmission sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis v chickenpox v see clinical studies 144 the efficacy and safety of valacyclovir tablets usp have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 2 years of age or 18 years of age with chickenpox patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection,3
phenylephrine hydrochloride ophthalmic solution usp 10 is contraindicated in patients with hypertension or thyrotoxicosis phenylephrine hydrochloride ophthalmic solution usp 25 should be used in these patients 41 phenylephrine hydrochloride ophthalmic solution usp 10 is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity phenylephrine hydrochloride ophthalmic solution usp 25 should be used in these patients 42 phenylephrine hydrochloride ophthalmic solution usp 10 is contraindicated in patients with hypertension or thyrotoxicosis phenylephrine hydrochloride ophthalmic solution usp 25 should be used in these patients phenylephrine hydrochloride ophthalmic solution usp 10 is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity phenylephrine hydrochloride ophthalmic solution usp 25 should be used in these patients see dosage and administration section,1
carvedilol tablets are contraindicated in the following conditions bronchial asthma or related bronchospastic conditions deaths from status asthmaticus have been reported following single doses of carvedilol tablets second or thirddegree av block sick sinus syndrome severe bradycardia unless a permanent pacemaker is in place patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy such patients should first be weaned from intravenous therapy before initiating carvedilol tablets patients with severe hepatic impairment patients with a history of a serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol bronchial asthma or related bronchospastic conditions 4 second or thirddegree av block 4 sick sinus syndrome 4 severe bradycardia unless permanent pacemaker in place 4 patients in cardiogenic shock or decompensated heart failure requiring the use of iv inotropic therapy 4 severe hepatic impairment 24 4 history of serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol 4,1
administration of sildenafil tablets to patients using nitric oxide donors such as organic nitrates or organic nitrites in any form sildenafil citrate was shown to potentiate the hypotensive effect of nitrates 41 71 122 known hypersensitivity to sildenafil or any component of tablet 42 administration with guanylate cyclase gc stimulators such as riociguat 43 consistent with its known effects on the nitric oxidecgmp pathway see clinical pharmacology 121 122 after patients have taken sildenafil citrate it is unknown when nitrates if necessary can be safely administered although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration it is unknown whether nitrates can be safely coadministered at this time point see dosage and administration 23 drug interactions 71 and clinical pharmacology 122 sildenafil tablets is contraindicated in patients with a known hypersensitivity to sildenafil as contained in sildenafil tablets 25 mg 50 mg and 100 mg and sildenafil tablets 20 mg or any component of the tablet hypersensitivity reactions have been reported including rash and urticaria see adverse reactions 61 do not use sildenafil tablets in patients who are using a gc stimulator such as riociguat pde5 inhibitors including sildenafil citrate may potentiate the hypotensive effects of gc stimulators,0
escitalopram oxalate is a selective serotonin reuptake inhibitor ssri indicated for acute and maintenance treatment of major depressive disorder mdd in adults and adolescents aged 12 to 17 years 11 acute treatment of generalized anxiety disorder gad in adults 12 escitalopram tablets usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age see clinical studies 141 a major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least five of the following nine symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation escitalopram tablets usp are indicated for the acute treatment of generalized anxiety disorder gad in adults see clinical studies 142 generalized anxiety disorder dsmiv is characterized by excessive anxiety and worry apprehensive expectation that is persistent for at least 6 months and which the person finds difficult to control it must be associated with at least 3 of the following symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension and sleep disturbance,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of bicillin cr and other antibacterial drugs bicillin cr should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy this drug is indicated in the treatment of moderately severe infections due to penicillingsusceptible microorganisms that are susceptible to serum levels common to this particular dosage form therapy should be guided by bacteriological studies including susceptibility testing and by clinical response bicillin cr is indicated in the treatment of the following in adults and pediatric patients moderately severe to severe infections of the upperrespiratory tract scarlet fever erysipelas and skin and softtissue infections due to susceptible streptococci note streptococci in groups a c g h l and m are very sensitive to penicillin g other groups including group d enterococci are resistant penicillin g sodium or potassium is recommended for streptococcal infections with bacteremia moderately severe pneumonia and otitis media due to susceptible pneumococci note severe pneumonia empyema bacteremia pericarditis meningitis peritonitis and arthritis of pneumococcal etiology are better treated with penicillin g sodium or potassium during the acute stage when high sustained serum levels are required penicillin g sodium or potassium either im or iv should be used this drug should not be used in the treatment of venereal diseases including syphilis gonorrhea yaws bejel and pinta,3
hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension use in pregnancy edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy,3
11 treatment of osteoporosis in postmenopausal women alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets usp increase bone mass and reduce the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 141 12 prevention of osteoporosis in postmenopausal women alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis see clinical studies 142 13 treatment to increase bone mass in men with osteoporosis alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 143 14 treatment of glucocorticoidinduced osteoporosis alendronate sodium tablets usp are indicated for the treatment of glucocorticoidinduced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 75 mg or greater of prednisone and who have low bone mineral density see clinical studies 144 15 treatment of pagets disease of bone alendronate sodium tablets usp are indicated for the treatment of pagets disease of bone in men and women treatment is indicated in patients with pagets disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 145 16 important limitations of use the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
prednisone tablets usp are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia 2 rheumatic disorders as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus 4 dermatologic diseases pemphigus 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers 7 respiratory diseases symptomatic sarcoidosis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults 10 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,2
norditropin is a recombinant human growth hormone indicated for pediatric 11 adult 12 norditropin somatropin rdna origin injection is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone gh norditropin somatropin rdna origin injection is indicated for the treatment of children with short stature associated with noonan syndrome norditropin somatropin rdna origin injection is indicated for the treatment of children with short stature associated with turner syndrome norditropin somatropin rdna origin injection is indicated for the treatment of children with short stature born small for gestational age sga with no catchup growth by age 24 years norditropin somatropin rdna origin injection is indicated for the replacement of endogenous gh in adults with growth hormone deficiency ghd who meet either of the following two criteria adult onset ao patients who have ghd either alone or associated with multiple hormone deficiencies hypopituitarism as a result of pituitary disease hypothalamic disease surgery radiation therapy or trauma or childhood onset co patients who were gh deficient during childhood as a result of congenital genetic acquired or idiopathic causes patients who were treated with somatropin for ghd in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for ghd adults according to current standards confirmation of the diagnosis of adult ghd in both,3
indocin is contraindicated in the following patients known hypersensitivity eg anaphylactic reactions and serious skin reactions to indomethacin or any components of the drug product see warnings and precautions 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids severe sometimes fatal anaphylactic reactions to nsaids have been reported in such patients see warnings and precautions 57 58 in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51 in patients with a history of proctitis or recent rectal bleeding known hypersensitivity to indomethacin or any components of the drug product 4 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 4 in the setting of cabg surgery 4 in patients with a history of proctitis or recent rectal bleeding 4,1
valacyclovir hydrochloride is a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hivinfected patients reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis chickenpox limitations of use 13 the efficacy and safety of valacyclovir tablets usp have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis see clinical studies 144 the efficacy and safety of valacyclovir tablets usp have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 2 years of age or 18 years of age with chickenpox patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection,3
doxycycline hyclate tablets are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis to reduce the development of drugresistant bacteria and maintain the effectiveness of doxycycline hyclate tablets usp and other antibacterial drugs doxycycline hyclate tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
prednisone tablets usp are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia 2 rheumatic disorders as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus 4 dermatologic diseases pemphigus 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers 7 respiratory diseases symptomatic sarcoidosis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults 10 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,3
tindamax is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in nonpregnant adult women 14 81 tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis see clinical studies 141 tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalis g lamblia see clinical studies 142 tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolytica see clinical studies 143 144 tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilus gardnerella see use in specific populations 81 145 other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicans herpes simplex to reduce the development of drugresistant bacteria and maintain the effectiveness of tindamax and other antibacterial drugs tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
nocdurna is contraindicated in patients with the following conditions due to an increased risk of hyponatremia hyponatremia or a history of hyponatremia see warnings and precautions 51 polydipsia concomitant use with loop diuretics see warnings and precautions 51 concomitant use with systemic or inhaled glucocorticoids see warnings and precautions 52 drug interactions 71 renal impairment with estimated glomerular filtration rate egfr below 50 mlmin173 m 2 use in specific population 86 clinical pharmacology 123 known or suspected syndrome of inappropriate antidiuretic hormone siadh secretion during illnesses that can cause fluid or electrolyte imbalance such as gastroenteritis saltwasting nephropathies or systemic infection nocdurna is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition heart failure see warnings and precautions 52 uncontrolled hypertension hyponatremia or a history of hyponatremia 4 polydipsia 4 concomitant use with loop diuretics or systemic or inhaled glucocorticoids 4 estimated glomerular filtration rate below 50 mlmin173 m 2 4 syndrome of inappropriate antidiuretic hormone secretion siadh 4 during illnesses that can cause fluid or electrolyte imbalance 4 heart failure 4 uncontrolled hypertension 4,1
ibuprofen lysine is contraindicated in preterm infants with proven or suspected infection that is untreated preterm infants with congenital heart disease in whom patency of the pda is necessary for satisfactory pulmonary or systemic blood flow eg pulmonary atresia severe tetralogy of fallot severe coarctation of the aorta preterm infants who are bleeding especially those with active intracranial hemorrhage or gastrointestinal bleeding preterm infants with thrombocytopenia preterm infants with coagulation defects preterm infants with or who are suspected of having necrotizing enterocolitis preterm infants with significant impairment of renal function ibuprofen lysine is contraindicated in preterm infants with proven or suspected infection that is untreated 4 with congential heart disease in whom patency of the pda is necessary for satisfactory pulmonary or systemic blood flow 4 with impaired renal function 4 with thrombocytopenia coagulation defects or who are bleeding 4 with or who are suspected of having necrotizing enterocolitis 4,1
naratriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 agonist ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide see drug interactions 71 72 hypersensitivity to naratriptan angioedema and anaphylaxis seen see warnings and precautions 59 severe renal or hepatic impairment see use in specific populations 86 87 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 agonist eg another triptan or an ergotaminecontaining medication 4 hypersensitivity to naratriptan angioedema and anaphylaxis seen 4 severe renal or hepatic impairment 4,1
fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder ocd 1 fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder ocd as defined in dsmiiir or dsmiv the obsessions or compulsions cause marked distress are timeconsuming or significantly interfere with social or occupational functioning obsessive compulsive disorder is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are egodystonic andor repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable the efficacy of fluvoxamine maleate tablets was established in four trials in outpatients with ocd two 10week trials in adults one 10week trial in pediatric patients ages 8 to 17 and one maintenance trial in adults see clinical studies 14,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of bicillin la and other antibacterial drugs bicillin la should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy intramuscular penicillin g benzathine is indicated in the treatment of infections due to penicillingsensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form therapy should be guided by bacteriological studies including sensitivity tests and by clinical response the following infections will usually respond to adequate dosage of intramuscular penicillin g benzathine mildtomoderate infections of the upperrespiratory tract due to susceptible streptococci venereal infections medical conditions in which penicillin g benzathine therapy is indicated as prophylaxis rheumatic fever andor chorea,3
to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antimicrobial therapy in the absence of such datalocal epidemiology and susceptibility patterns may contribute to the empiric selection of therapy cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months of age or older with the following infections when caused by susceptible isolates of the designated bacteria cefixime for oral suspension usp is a cephalosporin antibacterial drug indicated for 11 12 13 14 15 uncomplicated urinary tract infections caused by escherichia coli proteus mirabilis otitis media caused by haemophilus influenzae moraxella catarrhalis streptococcus pyogenes streptococcus pyogenes streptococcus pneumoniae s ee clinical studies 14 pharyngitis and tonsillitis caused by streptococcus pyogenes streptococcus pyogenes streptococcus pyogenes acute exacerbations of chronic bronchitis caused by streptococcus pneumoniae haemophilus influenzae uncomplicated gonorrhea cervicalurethral caused by neisseria gonorrhoeae,3
to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antimicrobial therapy in the absence of such datalocal epidemiology and susceptibility patterns may contribute to the empiric selection of therapy cefixime for oral suspension usp is a cephalosporin antibacterial drug indicated for 11 12 13 14 15 uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis otitis media caused by haemophilus influenzae moraxella catarrhalis and streptococcus pyogenes efficacy for streptococcus pyogenes in this organ system was studied in fewer than 10 infections see clinical studies 14 pharyngitis and tonsillitis caused by streptococcus pyogenes note penicillin is the usual drug of choice in the treatment of streptococcus pyogenes infections cefixime for oral suspension is generally effective in the eradication of streptococcus pyogenes from the nasopharynx however data establishing the efficacy of cefixime for oral suspension in the subsequent prevention of rheumatic fever is not available acute exacerbations of chronic bronchitis caused by streptococcus pneumoniae and haemophilus influenzae uncomplicated gonorrhea cervicalurethral caused by neisseria gonorrhoeae penicillinaseand nonpenicillinaseproducing isolates,3
diethylpropion hydrochloride is indicated in the management of exogenous obesity as a shortterm adjunct a few weeks in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index bmi of 30 kgm 2 body mass index bmi kgm 2 weight pounds height feet inches 50 53 56 59 60 63 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 the usefulness of agents of this class see clinical pharmacology,3
attention deficit disorders narcolepsy attention deficit disorders methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures psychological educational social for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms moderatetosevere distractibility short attention span hyperactivity emotional lability and impulsivity the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin nonlocalizing soft neurological signs learning disability and abnormal eeg may or may not be present and a diagnosis of central nervous system dysfunction may or may not be warranted special diagnostic considerations specific etiology of this syndrome is unknown and there is no single diagnostic test adequate diagnosis requires the use not only of medical but of special psychological educational and social resources characteristics commonly reported include chronic history of short attention span distractibility emotional lability impulsivity and moderatetosevere hyperactivity minor neurological signs and abnormal eeg learning may or may not be impaired the diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of 1 or more of these characteristics drug treatment is not indicated for all children with this syndrome stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors andor primary psychiatric disorders including psychosis appropriate educational placement is essential and psychosocial intervention is generally necessary when remedial measures alone are insufficient the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the childs symptoms,3
saizen is a recombinant human growth hormone indicated for pediatric 11 adult 12 saizen somatropin is indicated for the treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone saizen is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria adult onset patients who have growth hormone deficiency either alone or associated with multiple hormone deficiencies hypopituitarism as a result of pituitary disease hypothalamic disease surgery radiation therapy or trauma or childhood onset patients who were growth hormone deficient during childhood as a result of congenital genetic acquired or idiopathic causes patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions 1 patients with multiple other pituitary hormone deficiencies due to organic disease and 2 patients with congenitalgenetic growth hormone deficiency,3
esomeprazole magnesium delayedrelease capsules are a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 11 risk reduction of nsaidassociated gastric ulcer 12 h pylori 13 pathological hypersecretory conditions including zollingerellison syndrome 14 healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated for the shortterm treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayedrelease capsules may be considered maintenance of healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months esomeprazole magnesium delayedrelease capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 60 andor documented history of gastric ulcers controlled studies do not extend beyond 6 months triple therapy esomeprazole magnesium delayedrelease capsules plus amoxicillin and clarithromycin esomeprazole magnesium delayedrelease capsules in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with h pylori h pylori h pylori see dosage and administration 2 clinical studies 14 see clinical pharmacology 124 esomeprazole magnesium delayedrelease capsules are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
naproxen delayedrelease tablets are contraindicated in the following patients known hypersensitivity eg anaphylactic reactions and serious skin reactions to naproxen or any components of the drug product see warnings and precautions 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids severe sometimes fatal anaphylactic reactions to nsaids have been reported in such patients see warnings and precautions 57 58 in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51 known hypersensitivity to naproxen or any components of the drug product 4 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 4 in the setting of cabg surgery 4,1
flurbiprofen tablets are contraindicated in the following patients known hypersensitivity eg anaphylactic reactions and serious skin reactions to flurbiprofen or any components of the drug product see warnings and precautions 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids severe sometimes fatal anaphylactic reactions to nonsteroidal antiinflammatory drugs have been reported in such patients see warnings and precautions 57 58 in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51 known hypersensitivity to flurbiprofen or any components of the drug product 57 59 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 57 58 in the setting of cabg surgery 51,1
abilify oral tablets orallydisintegrating tablets and oral solution are indicated for the treatment of schizophrenia see clinical studies 141 acute treatment of manic and mixed episodes associated with bipolar i disorder see clinical studies 142 adjunctive treatment of major depressive disorder see clinical studies 143 irritability associated with autistic disorder see clinical studies 144 treatment of tourettes disorder see clinical studies 145 abilify injection is indicated for the treatment of agitation associated with schizophrenia or bipolar mania see clinical studies 146 abilify is an atypical antipsychotic the oral formulations are indicated for schizophrenia 141 acute treatment of manic and mixed episodes associated with bipolar i 142 adjunctive treatment of major depressive disorder 143 irritability associated with autistic disorder 144 treatment of tourettes disorder 145 the injection is indicated for agitation associated with schizophrenia or bipolar mania 146,3
dicyclomine hydrochloride is contraindicated in infants less than 6 months of age see use in specific populations 84 see use in specific populations 83 unstable cardiovascular status in acute hemorrhage myasthenia gravis see warnings and precautions 54 glaucoma see adverse reactions 63 71 obstructive uropathy see warnings and precautions 58 obstructive disease of the gastrointestinal tract see warnings and precautions 55 severe ulcerative colitis see warnings and precautions 57 reflux esophagitis infants less than 6 months of age 4 nursing mothers 4 unstable cardiovascular status in acute hemorrhage 4 myasthenia gravis 4 glaucoma 4 obstructive uropathy 4 obstructive disease of the gastrointestinal tract 4 severe ulcerative colitis 4 reflux esophagitis 4,1
venlafaxine hydrochloride extendedrelease tablets are a selective serotonin and norepinephrine reuptake inhibitor snri indicated for major depressive disorder mdd 11 social anxiety disorder sad 12 venlafaxine hydrochloride extendedrelease tablets are indicated for the treatment of major depressive disorder mdd see clinical studies 141 venlafaxine hydrochloride extendedrelease tablets are indicated for the treatment of social anxiety disorder sad also known as social phobia as defined in dsmiv social anxiety disorder dsmiv is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others exposure to the feared situation almost invariably provokes anxiety which may approach the intensity of a panic attack the feared situations are avoided or endured with intense anxiety or distress the avoidance anxious anticipation or distress in the feared situations interferes significantly with the persons normal routine occupational or academic functioning or social activities or relationships or there is a marked distress about having the phobias lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment efficacy of venlafaxine hydrochloride extendedrelease tablets in the treatment of sad was established in shortterm sad trials see clinical studies 142,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of bicillin cr and other antibacterial drugs bicillin cr should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy this drug is indicated in the treatment of moderately severe infections due to penicillingsusceptible microorganisms that are susceptible to serum levels common to this particular dosage form therapy should be guided by bacteriological studies including susceptibility testing and by clinical response bicillin cr is indicated in the treatment of the following in adults and pediatric patients moderately severe to severe infections of the upperrespiratory tract scarlet fever erysipelas and skin and softtissue infections due to susceptible streptococci note streptococci in groups a c g h l and m are very sensitive to penicillin g other groups including group d enterococci are resistant penicillin g sodium or potassium is recommended for streptococcal infections with bacteremia moderately severe pneumonia and otitis media due to susceptible streptococcus pneumoniae note severe pneumonia empyema bacteremia pericarditis meningitis peritonitis and arthritis of pneumococcal etiology are better treated with penicillin g sodium or potassium during the acute stage when high sustained serum levels are required penicillin g sodium or potassium either im or iv should be used this drug should not be used in the treatment of venereal diseases including syphilis gonorrhea yaws bejel and pinta,3
symptomatic trichomoniasis t vaginalis asymptomatic trichomoniasis t vaginalis treatment of asymptomatic sexual partners t vaginalis amebiasis in amebic liver abscess metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus anaerobic bacterial infections intraabdominal infections including peritonitis intraabdominal abscess and liver abscess caused by bacteroides b fragilis b fragilis b distasonis b ovatus b thetaiotaomicron b vulgatus clostridium eubacterium peptococcus species peptostreptococcus skin and skin structure infections caused by bacteroides b fragilis clostridium peptococcus species peptostreptococcus fusobacterium gynecologic infections including endometritis endomyometritis tuboovarian abscess and postsurgical vaginal cuff infection caused by bacteroides b fragilis clostridium peptococcus species peptostreptococcus fusobacterium bacterial septicemia caused by bacteroides b fragilis clostridium bone and joint infections as adjunctive therapy caused by bacteroides b fragilis central nervous system cns infections including meningitis and brain abscess caused by bacteroides b fragilis lower respiratory tract infections including pneumonia empyema and lung abscess caused by bacteroides b fragilis endocarditis caused by bacteroides b fragilis to reduce the development of drugresistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
hypothyroidism pituitary thyrotropin thyroidstimulating hormone tsh suppression limitations of use levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism see warnings and precautions 54 levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis levothyroxine sodium tablets are levothyroxine sodium t4 indicated for hypothyroidism as replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 1 pituitary thyrotropin thyroidstimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer 1 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis,0
nitrofurantoin macrocrystals capsules is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli enterococci staphylococcus aureus klebsiella enterobacter nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses to reduce the development of drugresistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections consequently many patients who are treated with nitrofurantoin macrocrystals capsules are predisposed to persistence or reappearance of bacteriuria urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy if persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin macrocrystals capsules other therapeutic agents with broader tissue distribution should be selected in considering the use of nitrofurantoin macrocrystals capsules lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized,1
propranolol hydrochloride tablets usp are indicated in the management of hypertension it may be used alone or used in combination with other antihypertensive agents particularly a thiazide diuretic propranolol hydrochloride tablets usp are not indicated in the management of hypertensive emergencies propranolol hydrochloride tablets usp are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris propranolol hydrochloride tablets usp are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response propranolol hydrochloride tablets usp are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable propranolol hydrochloride tablets usp are indicated for the prophylaxis of common migraine headache the efficacy of propranolol in the treatment of a migraine attack that has started has not been established and propranolol is not indicated for such use propranolol hydrochloride tablets usp are indicated in the management of familial or hereditary essential tremor familial or essential tremor consists of involuntary rhythmic oscillatory movements usually limited to the upper limbs it is absent at rest but occurs when the limb is held in a fixed posture or position against gravity and during active movement propranolol hydrochloride tablets usp cause a reduction in the tremor amplitude but not in the tremor frequency propranolol hydrochloride tablets usp are not indicated for the treatment of tremor associated with parkinsonism propranolol hydrochloride tablets usp improve nyha functional class in symptomatic patients with hypertrophic subaortic stenosis propranolol hydrochloride tablets usp are indicated as an adjunct to alphaadrenergic blockade to control blood pressure and reduce symptoms of catecholaminesecreting tumors,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of erytab r r erytab r upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae h influenzae lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes streptococcus pneumoniae listeriosis caused by listeria monocytogenes respiratory tract infections due to mycoplasma pneumoniae skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes staphylococcus aureus pertussis whooping cough caused by bordetella pertussis diphtheria infections due to corynebacterium diphtheriae erythrasma in the treatment of infections due to corynebacterium minutissimum intestinal amebiasis caused by entamoeba histolytica acute pelvic inflammatory disease caused by neisseria gonorrhoeae n gonorrhoeae erythromycins are indicated for treatment of the following infections caused by chlamydia trachomatis chlamydia trachomatis when tetracyclines are contraindicated or not tolerated erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum primary syphilis caused by treponema pallidum legionnaires disease caused by legionella pneumophila in vitro penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever treatment of streptococcus pyogenes infections of the upper respiratory tract eg tonsillitis or pharyngitis 1 penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever in patients who are allergic to penicillin and sulfonamides oral erythromycin is recommended by the american heart association in the longterm prophylaxis of streptococcal pharyngitis for the prevention of recurrent attacks of rheumatic fever 1,3
escitalopram oxalate usp is a selective serotonin reuptake inhibitor ssri indicated for acute and maintenance treatment of major depressive disorder mdd in adults and adolescents aged 12 to 17 years 11 acute treatment of generalized anxiety disorder gad in adults 12 escitalopram tablet usp is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age see clinical studies 141 a major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least five of the following nine symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation escitalopram tablet usp is indicated for the acute treatment of generalized anxiety disorder gad in adults see clinical studies 142 generalized anxiety disorder dsmiv is characterized by excessive anxiety and worry apprehensive expectation that is persistent for at least 6 months and which the person finds difficult to control it must be associated with at least 3 of the following symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension and sleep disturbance,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
41 pregnancy and premenopausal women anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer anastrozole is contraindicated in women who are or may become pregnant there are no adequate and wellcontrolled studies in pregnant women using anastrozole if anastrozole is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy see use in specific populations 81 42 hypersensitivity anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients observed reactions include anaphylaxis angioedema and urticaria see adverse reactions 62,1
dicyclomine hydrochloride is contraindicated in infants less than 6 months of age see use in specific populations 84 see use in specific populations 83 unstable cardiovascular status in acute hemorrhage myasthenia gravis see warnings and precautions 54 glaucoma see adverse reactions 63 drug interactions 71 obstructive uropathy see warnings and precautions 58 obstructive disease of the gastrointestinal tract see warnings and precautions 55 severe ulcerative colitis see warnings and precautions 57 reflux esophagitis infants less than 6 months of age 4 glaucoma 4 nursing mothers 4 obstructive uropathy 4 unstable cardiovascular status in acute hemorrhage 4 obstructive disease of the gastrointestinal tract 4 myasthenia gravis 4 severe ulcerative colitis 4 reflux esophagitis 4,1
when oral therapy is not feasible the intramuscular use r r control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopenia trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders the intraarticular or soft tissue administration the intralesional administration celestone soluspan injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
clopidogrel tablets are p2y 12 acute coronary syndrome for patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi clopidogrel tablets have been shown to reduce the rate of myocardial infarction mi and stroke 11 for patients with stelevation myocardial infarction stemi clopidogrel tablets have been shown to reduce the rate of mi and stroke 11 recent mi recent stroke or established peripheral arterial disease clopidogrel tablets have been shown to reduce the rate of mi and stroke 12 clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirin in patients with established peripheral arterial disease or with a history of recent myocardial infarction mi or recent stroke clopidogrel bisulfate tablets are indicated to reduce the rate of mi and stroke,3
bronchial asthma or related bronchospastic conditions 4 second or thirddegree av block 4 sick sinus syndrome 4 severe bradycardia unless permanent pacemaker in place 4 patients in cardiogenic shock or decompensated heart failure requiring the use of iv inotropic therapy 4 severe hepatic impairment 24 4 history of serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol 4 carvedilol tablets are contraindicated in the following conditions bronchial asthma or related bronchospastic conditions deaths from status asthmaticus have been reported following single doses of carvedilol tablets second or thirddegree av block sick sinus syndrome severe bradycardia unless a permanent pacemaker is in place patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy such patients should first be weaned from intravenous therapy before initiating carvedilol tablets patients with severe hepatic impairment patients with a history of a serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol,1
prednisone tablets usp are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia 2 rheumatic disorders as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus 4 dermatologic diseases pemphigus 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers 7 respiratory diseases symptomatic sarcoidosis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults 10 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,3
imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 11 chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll 12 chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion 13 waldenstroms macroglobulinemia wm 14 marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy 15 chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 16 imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy accelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 141 imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion imbruvica is indicated for the treatment of adult patients with waldenstroms macroglobulinemia wm imbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy accelerated approval was granted for this indication based on overall response rate see clinical studies 144 imbruvica is indicated for the treatment of adult patients with chronic graftversushost disease cgvhd after failure of one or more lines of systemic therapy,3
imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 11 chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll 12 chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion 13 waldenstroms macroglobulinemia wm 14 marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy 15 chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 16 imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy accelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 141 imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll with 17p deletion imbruvica is indicated for the treatment of adult patients with waldenstroms macroglobulinemia wm imbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anticd20based therapy accelerated approval was granted for this indication based on overall response rate see clinical studies 144 imbruvica is indicated for the treatment of adult patients with chronic graftversushost disease cgvhd after failure of one or more lines of systemic therapy,3
prednisone tablets usp are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia 2 rheumatic disorders as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus 4 dermatologic diseases pemphigus 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers 7 respiratory diseases symptomatic sarcoidosis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults 10 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,2
angioedema or a history of hereditary or idiopathic angioedema 4 hypersensitivity 4 coadministration of aliskiren with lisinopril in patients with diabetes 4 74 lisinopril is contraindicated in combination with a neprilysin inhibitor eg sacubitril do not administer lisinopril tablet usp within 36 hours of switching to or from sacubitrilvalsartan a neprilysin inhibitor see warnings and precautions 52 lisinopril is contraindicated in patients with a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema do not coadminister aliskiren with lisinopril in patients with diabetes see drug interactions 74,1
diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy chlorthalidone has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failure the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy chlorthalidone is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions,3
dicyclomine hydrochloride is contraindicated in infants less than 6 months of age see use in specific populations 84 see use in specific populations 83 unstable cardiovascular status in acute hemorrhage myasthenia gravis see warnings and precautions 54 glaucoma see adverse reactions 63 drug interactions 71 obstructive uropathy see warnings and precautions 58 obstructive disease of the gastrointestinal tract see warnings and precautions 55 severe ulcerative colitis see warnings and precautions 57 reflux esophagitis infants less than 6 months of age 4 glaucoma 4 nursing mothers 4 obstructive uropathy 4 unstable cardiovascular status in accute hemorrhage 4 obstructive disease of the gastrointestinal tract 4 myasthenia gravis 4 severe ulcerative colitis 4 reflux esophagitis 4,1
warfarin sodium is contraindicated in pregnancy warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves who are at high risk of thromboembolism see warnings and precautions 57 81 see use in specific populations 81 warfarin sodium is contraindicated in patients with hemorrhagic tendencies or blood dyscrasias recent or contemplated surgery of the central nervous system or eye or traumatic surgery resulting in large open surfaces see warnings and precautions 58 bleeding tendencies associated with active ulceration or overt bleeding of the gastrointestinal genitourinary or respiratory tract threatened abortion eclampsia and preeclampsia unsupervised patients with conditions associated with potential high level of noncompliance spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding hypersensitivity to warfarin or to any other components of this product eg anaphylaxis see adverse reactions 6 major regional or lumbar block anesthesia malignant hypertension pregnancy except in women with mechanical heart valves 4 57 81 hemorrhagic tendencies or blood dyscrasias 4 recent or contemplated surgery of the central nervous system cns or eye or traumatic surgery resulting in large open surfaces 4 58 bleeding tendencies associated with certain conditions 4 threatened abortion eclampsia and preeclampsia 4 unsupervised patients with potential high levels of noncompliance 4 spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding 4 hypersensitivity to warfarin or any component of the product 4 major regional or lumbar block anesthesia 4 malignant hypertension 4,1
quinine sulfate capsules usp 324 mg is contraindicated in patients with the following prolonged qt interval one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline who received quinine sulfate intravenously for p falciparum see warnings and precautions 53 glucose6phosphate dehydrogenase g6pd deficiency hemolysis can occur in patients with g6pd deficiency receiving quinine known hypersensitivity reactions to quinine these include but are not limited to the following see warnings and precautions 56 thrombocytopenia idiopathic thrombocytopenia purpura itp and thrombotic thrombocytopenic purpura ttp hemolytic uremic syndrome hus blackwater fever acute intravascular hemolysis hemoglobinuria and hemoglobinemia known hypersensitivity to mefloquine or quinidine crosssensitivity to quinine has been documented see warnings and precautions 56 myasthenia gravis quinine has neuromuscular blocking activity and may exacerbate muscle weakness optic neuritis quinine may exacerbate active optic neuritis see adverse reactions 6 quinine sulfate is contraindicated in patients with the following prolongation of qt interval 4 glucose6phosphate dehydrogenase g6pd deficiency 4 myasthenia gravis 4 known hypersensitivity to quinine mefloquine or quinidine 4 optic neuritis 4,1
quinine sulfate capsules usp 324 mg is contraindicated in patients with the following prolonged qt interval one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline who received quinine sulfate intravenously for p falciparum see warnings and precautions 53 glucose6phosphate dehydrogenase g6pd deficiency hemolysis can occur in patients with g6pd deficiency receiving quinine known hypersensitivity reactions to quinine these include but are not limited to the following see warnings and precautions 56 thrombocytopenia idiopathic thrombocytopenia purpura itp and thrombotic thrombocytopenic purpura ttp hemolytic uremic syndrome hus blackwater fever acute intravascular hemolysis hemoglobinuria and hemoglobinemia known hypersensitivity to mefloquine or quinidine crosssensitivity to quinine has been documented see warnings and precautions 56 myasthenia gravis quinine has neuromuscular blocking activity and may exacerbate muscle weakness optic neuritis quinine may exacerbate active optic neuritis see adverse reactions 6 quinine sulfate is contraindicated in patients with the following prolongation of qt interval 4 glucose6phosphate dehydrogenase g6pd deficiency 4 myasthenia gravis 4 known hypersensitivity to quinine mefloquine or quinidine 4 optic neuritis 4,1
matzim la diltiazem hydrochloride extendedrelease tablets are contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker patients with second or thirddegree av block except in the presence of a functioning ventricular pacemaker patients with hypotension less than 90 mm hg systolic patients who have demonstrated hypersensitivity to the drug patients with acute myocardial infarction and pulmonary sick sinus syndrome except in the presence of a functioning ventricular pacemaker 4 second or thirddegree av block except in the presence of a functioning ventricular pacemaker 4 hypotension less than 90 mm hg systolic 4 hypersensitivity to the drug 4 acute myocardial infarction and pulmonary 4,1
see also boxed warning ketorolac tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding ketorolac tromethamine should not be given to patients who have experienced asthma urticaria or allergictype reactions after taking aspirin or other nsaids severe rarely fatal anaphylacticlike reactions to nsaids have been reported in such patients see warnings anaphylactoid reactions precautions preexisting asthma ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery ketorolac tromethamine is contraindicated in the setting of coronary artery bypass graft cabg surgery see warnings ketorolac tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion see warnings ketorolac tromethamine is contraindicated in labor and delivery because through its prostaglandin synthesis inhibitory effect it may adversely affect fetal circulation and inhibit uterine contractions thus increasing the risk of uterine hemorrhage ketorolac tromethamine inhibits platelet function and is therefore contraindicated in patients with suspected or confirmed cerebrovascular bleeding hemorrhagic diathesis incomplete hemostasis and those at high risk of bleeding see warnings precautions ketorolac tromethamine is contraindicated in patients currently receiving aspirin or nsaids because of the cumulative risks of inducing serious nsaidrelated adverse events the concomitant use of ketorolac tromethamine and probenecid is contraindicated the concomitant use of ketorolac tromethamine and pentoxifylline is contraindicated,1
prednisone tablets usp are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia 2 rheumatic disorders as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus 4 dermatologic diseases pemphigus 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers 7 respiratory diseases symptomatic sarcoidosis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults 10 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,3
for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histaminemediated pruritus as a sedative when used as a premedication and following general anesthesia hydroxyzine may potentiate meperidine and barbiturates the effectiveness of hydroxyzine as an antianxiety agent for long term use that is more than 4 months has not been assessed by systematic clinical studies the physician should reassess periodically the usefulness of the drug for the individual patient,2
sumatriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke s warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide or another 5hydroxytryptamine 1 1 see drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent within 2 weeks use of an maoa inhibitor see drug interactions 72 clinical pharmacology 123 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen see warnings and precautions 59 severe hepatic impairment see use in specific populations 86 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 concurrent or recent past 2 weeks use of monoamine oxidasea inhibitor 4 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen 4 severe hepatic impairment 4,1
11 treatment of gastroesophageal reflux disease gerd healing of erosive esophagitis 12 risk reduction of nsaidassociated gastric ulcer esomeprazole magnesium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age 60 andor documented history of gastric ulcers controlled studies do not extend beyond 6 months 13 h pylori eradication to reduce the risk of duodenal ulcer recurrence triple therapy esomeprazole magnesium plus amoxicillin and clarithromycin esomeprazole magnesium in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with h pylori infection and duodenal ulcer disease active or history of within the past 5 years to eradicate h pylori eradication of h pylori has been shown to reduce the risk of duodenal ulcer recurrence see dosage and administration 2 and clinical studies 14 in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 124 and the prescribing information for clarithromycin 14 pathological hypersecretory conditions including zollingerellison syndrome esomeprazole magnesium is indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of erythrocin r r erythrocin r upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae h influenzae lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes streptococcus pneumoniae listeriosis caused by listeria monocytogenes respiratory tract infections due to mycoplasma pneumoniae skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes staphylococcus aureus pertussis whooping cough caused by bordetella pertussis diphtheria infections due to corynebacterium diphtheriae erythrasma in the treatment of infections due to corynebacterium minutissimum intestinal amebiasis caused by entamoeba histolytica acute pelvic inflammatory disease caused by neisseria gonorrhoeae n gonorrhoeae erythromycins are indicated for treatment of the following infections caused by chlamydia trachomatis chlamydia trachomatis when tetracyclines are contraindicated or not tolerated erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum primary syphilis caused by treponema pallidum legionnaires disease caused by legionella pneumophila in vitro penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever treatment of streptococcus pyogenes infections of the upper respiratory tract eg tonsillitis or pharyngitis 1 penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever in patients who are allergic to penicillin and sulfonamides oral erythromycin is recommended by the american heart association in the longterm prophylaxis of streptococcal pharyngitis for the prevention of recurrent attacks of rheumatic fever 1,3
sumatriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke s warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide or another 5hydroxytryptamine 1 1 see drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent within 2 weeks use of an maoa inhibitor see drug interactions 72 clinical pharmacology 123 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen see warnings and precautions 59 severe hepatic impairment see use in specific populations 86 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 concurrent or recent past 2 weeks use of monoamine oxidasea inhibitor 4 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen 4 severe hepatic impairment 4,1
see also boxed warning ketorolac tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding ketorolac tromethamine should not be given to patients who have experienced asthma urticaria or allergictype reactions after taking aspirin or other nsaids severe rarely fatal anaphylacticlike reactions to nsaids have been reported in such patients see warnings anaphylactoid reactions precautions preexisting asthma ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery ketorolac tromethamine is contraindicated in the setting of coronary artery bypass graft cabg surgery see warnings ketorolac tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion see warnings ketorolac tromethamine is contraindicated in labor and delivery because through its prostaglandin synthesis inhibitory effect it may adversely affect fetal circulation and inhibit uterine contractions thus increasing the risk of uterine hemorrhage ketorolac tromethamine inhibits platelet function and is therefore contraindicated in patients with suspected or confirmed cerebrovascular bleeding hemorrhagic diathesis incomplete hemostasis and those at high risk of bleeding see warnings precautions ketorolac tromethamine is contraindicated in patients currently receiving aspirin or nsaids because of the cumulative risks of inducing serious nsaidrelated adverse events the concomitant use of ketorolac tromethamine and probenecid is contraindicated the concomitant use of ketorolac tromethamine and pentoxifylline is contraindicated,1
topiramate is indicated for epilepsy initial monotherapy in patients 2 years of age with partial onset or primary generalized tonicclonic seizures 11 12 prophylaxis of migraine in patients 12 years of age and older 13 topiramate tablets and topiramate capsules are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonicclonic seizures topiramate tablets and topiramate capsules are indicated as adjunctive therapy for adults and pediatric patients 2 to 16 years of age with partial onset seizures or primary generalized tonicclonic seizures and in patients 2 years of age and older with seizures associated with lennoxgastaut syndrome topiramate tablets and topiramate capsules are indicated for patients 12 years of age and older for the prophylaxis of migraine headache,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated anorectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of erytab r r erytab r upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes streptococcus pneumoniae haemophilus influenzae h influenzae lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes streptococcus pneumoniae listeriosis caused by listeria monocytogenes respiratory tract infections due to mycoplasma pneumoniae skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes staphylococcus aureus pertussis whooping cough caused by bordetella pertussis diphtheria infections due to corynebacterium diphtheriae erythrasma in the treatment of infections due to corynebacterium minutissimum intestinal amebiasis caused by entamoeba histolytica acute pelvic inflammatory disease caused by neisseria gonorrhoeae n gonorrhoeae erythromycins are indicated for treatment of the following infections caused by chlamydia trachomatis chlamydia trachomatis when tetracyclines are contraindicated or not tolerated erythromycin is indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum primary syphilis caused by treponema pallidum legionnaires disease caused by legionella pneumophila in vitro penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever treatment of streptococcus pyogenes infections of the upper respiratory tract eg tonsillitis or pharyngitis 1 penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever in patients who are allergic to penicillin and sulfonamides oral erythromycin is recommended by the american heart association in the longterm prophylaxis of streptococcal pharyngitis for the prevention of recurrent attacks of rheumatic fever 1,3
cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohns disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 11 treatment of adults with moderately to severely active rheumatoid arthritis 12 treatment of adult patients with active psoriatic arthritis 13 treatment of adults with active ankylosing spondylitis 14 treatment of adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation 15 treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy 16 cimzia is indicated for reducing signs and symptoms of crohns disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 144 cimzia is indicated for the treatment of adults with active nonradiographic axial spondyloarthritis nraxspa with objective signs of inflammation see clinical studies 145 cimzia is indicated for the treatment of adults with moderatetosevere plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 146,3
cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohns disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 11 treatment of adults with moderately to severely active rheumatoid arthritis 12 treatment of adult patients with active psoriatic arthritis 13 treatment of adults with active ankylosing spondylitis 14 treatment of adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation 15 treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy 16 cimzia is indicated for reducing signs and symptoms of crohns disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 144 cimzia is indicated for the treatment of adults with active nonradiographic axial spondyloarthritis nraxspa with objective signs of inflammation see clinical studies 145 cimzia is indicated for the treatment of adults with moderatetosevere plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 146,3
cimzia is a tumor necrosis factor tnf blocker indicated for reducing signs and symptoms of crohns disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 11 treatment of adults with moderately to severely active rheumatoid arthritis 12 treatment of adult patients with active psoriatic arthritis 13 treatment of adults with active ankylosing spondylitis 14 treatment of adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation 15 treatment of adults with moderatetosevere plaque psoriasis who are candidates for systemic therapy or phototherapy 16 cimzia is indicated for reducing signs and symptoms of crohns disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis ra cimzia is indicated for the treatment of adult patients with active psoriatic arthritis psa cimzia is indicated for the treatment of adults with active ankylosing spondylitis as see clinical studies 144 cimzia is indicated for the treatment of adults with active nonradiographic axial spondyloarthritis nraxspa with objective signs of inflammation see clinical studies 145 cimzia is indicated for the treatment of adults with moderatetosevere plaque psoriasis pso who are candidates for systemic therapy or phototherapy see clinical studies 146,3
itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised blastomycosis pulmonary and extrapulmonary histoplasmosis including chronic cavitary pulmonary disease and disseminated nonmeningeal histoplasmosis and aspergillosis pulmonary and extrapulmonary in patients who are intolerant of or who are refractory to amphotericin b therapy specimens for fungal cultures and other relevant laboratory studies wet mount histopathology serology should be obtained before therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antiinfective therapy should be adjusted accordingly itraconazole capsules are also indicated for the treatment of the following fungal infections in nonimmunocompromised onychomycosis of the toenail with or without fingernail involvement due to dermatophytes tinea unguium and onychomycosis of the fingernail due to dermatophytes tinea unguium prior to initiating treatment appropriate nail specimens for laboratory testing koh preparation fungal culture or nail biopsy should be obtained to confirm the diagnosis of onychomycosis see clinical pharmacology special populations contraindications warnings adverse reactions postmarketing experience description of clinical studies blastomycosis histoplasmosis histoplasmosis in hivinfected patients aspergillosis onychomycosis of the toenail onychomycosis of the fingernail,3
losartan potassium tablets are an angiotensin ii receptor blocker arb indicated for treatment of hypertension to lower blood pressure in adults and children greater than 6 years old lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 11 reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy there is evidence that this benefit does not apply to black patients 12 treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension 13 losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular cv events primarily strokes and myocardial infarction these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan losartan potassium tablets may be administered with other antihypertensive agents losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy but there is evidence that this benefit does not apply to black patients see use in specific populations 86 clinical pharmacology 123 losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria urinary albumin to creatinine ratio 300 mgg in patients with type 2 diabetes and a history of hypertension in this population losartan potassium tablets reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease need for dialysis or renal transplantation see clinical studies 143,3
prevacid and prevacid solutab are contraindicated in patients with known severe hypersensitivity to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria see adverse reactions 6 proton pump inhibitors ppis including prevacid and prevacid solutab are contraindicated with rilpivirinecontaining products see drug interactions 7 see drug interactions 7 for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with prevacid or prevacid solutab refer to the contraindications contraindicated in patients with known severe hypersensitivity to any component of the prevacid or prevacid solutab formulations 4 patients receiving rilpivirinecontaining products 4 7,1
the concomitant use of monoamine oxidase inhibiting compounds is contraindicated hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations the potentiation of adverse effects can be serious or even fatal when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor as long an interval should elapse as the clinical situation will allow with a minimum of 14 days initial dosage should be low and increases should be gradual and cautiously prescribed the drug is contraindicated during the acute recovery period after a myocardial infarction patients with a known hypersensitivity to this compound should not be given the drug the possibility of crosssensitivity to other dibenzazepine compounds should be kept in mind,1
bronchial asthma or related bronchospastic conditions 4 second or thirddegree av block 4 sick sinus syndrome 4 severe bradycardia unless permanent pacemaker in place 4 patients in cardiogenic shock or decompensated heart failure requiring the use of iv inotropic therapy 4 severe hepatic impairment 24 4 history of serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol 4 carvedilol tablets are contraindicated in the following conditions bronchial asthma or related bronchospastic conditions deaths from status asthmaticus have been reported following single doses of carvedilol tablets second or thirddegree av block sick sinus syndrome severe bradycardia unless a permanent pacemaker is in place patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy such patients should first be weaned from intravenous therapy before initiating carvedilol tablets patients with severe hepatic impairment patients with a history of a serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol,1
byetta exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14 limitations of use byetta is not a substitute for insulin byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis as it would not be effective in these settings the concurrent use of byetta with prandial insulin has not been studied and cannot be recommended based on postmarketing data byetta has been associated with acute pancreatitis including fatal and nonfatal hemorrhagic or necrotizing pancreatitis byetta has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using byetta other antidiabetic therapies should be considered in patients with a history of pancreatitis byetta exenatide is a glucagonlike peptide1 glp1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 14 limitations of use 1 1 1,0
valacyclovir tablet usp is a nucleoside analogue dna polymerase inhibitor indicated for cold sores herpes labialis genital herpes initial episode recurrent episodes suppressive therapy reduction of transmission sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis chickenpox valacyclovir tablets usp are indicated for the treatment of chickenpox in immunocompetent pediatric patients 2 to 18 years of age based on efficacy data from clinical studies with oral acyclovir treatment with valacyclovir tablets usp should be initiated within 24 hours after the onset of rash see clinical studies 144 the efficacy and safety of valacyclovir tablets usp have not been established in 3,3
tinidazole is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in nonpregnant adult women 14 81 tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis see clinical studies 141 tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalis g lamblia see clinical studies 142 tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolytica see clinical studies 143 144 tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilus gardnerella see use in specific populations 81 clinical studies 145 other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicans herpes simplex to reduce the development of drugresistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
fentanyl transdermal system is contraindicated in patients who are not opioidtolerant the management of acute or intermittent pain or in patients who require opioid analgesia for a short period of time the management of postoperative pain including use after outpatient or day surgeries eg tonsillectomies the management of mild pain patients with significant respiratory depression see warnings and precautions 59 in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 59 in patients with known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 517 in patients with hypersensitivity to fentanyl eg anaphylaxis or any components of the transdermal system see adverse reactions 62 opioid nontolerant patients 4 acute or intermittent pain postoperative pain mild pain 4 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 known hypersensitivity to fentanyl or any of the components of the transdermal system 4,0
hypersensitivity to any component of this product these adverse reactions may manifest as an anaphylactic reaction urticaria facial andor tongue swelling or pruritus discontinue cyclobenzaprine hydrochloride extendedrelease capsules if a hypersensitivity reaction is suspected concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine or structurally similar tricyclic antidepressants concomitantly with mao inhibitor drugs during the acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure hyperthyroidism hypersensitivity to any component of this product 4 concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation 4 during acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure 4 hyperthyroidism 4,1
zoledronic acid injection is a bisphosphonate indicated for the treatment of hypercalcemia of malignancy 11 patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy prostate cancer should have progressed after treatment with at least one hormonal therapy 12 limitations of use zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumincorrected calcium cca of greater than or equal to 12 mgdl 30 mmoll using the formula cca in mgdl ca in mgdl 08 40 gdl patient albumin gdl zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy prostate cancer should have progressed after treatment with at least one hormonal therapy limitations of use the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions have not been established,3
metoprolol tartrate tablets usp are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents metoprolol tartrate tablets usp are indicated in the longterm treatment of angina pectoris metoprolol tartrate tablets usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol oral metoprolol tartrate tablets usp therapy can be initiated after intravenous metoprolol therapy or alternatively oral treatment can begin within 3 to 10 days of the acute event see dosage and administration contraindications warnings,3
anuria oliguria or significant impairment of renal function creatinine clearance under 60 ml per minute or clinically significant elevated serum creatinine are contraindications treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems glutathione instability the drug is contraindicated in pregnant patients at term 38 to 42 weeks gestation during labor and delivery or when the onset of labor is imminent for the same reason the drug is contraindicated in neonates under one month of age nitrofurantoin monohydratemacrocrystals is contraindicated in patients with a previous history of cholestatic jaundicehepatic dysfunction associated with nitrofurantoin nitrofurantoin monohydratemacrocrystals is also contraindicated in those patients with known hypersensitivity to nitrofurantoin,1
hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents angina pectoris metoprolol tartrate tablets are indicated in the longterm treatment of angina pectoris myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol oral metoprolol therapy can be initiated after intravenous metoprolol therapy or alternatively oral treatment can begin within 3 to 10 days of the acute event see dosage and administration contraindications and warnings,3
fluoxetine capsules are indicated for the treatment of acute and maintenance treatment of major depressive disorder see clinical studies 141 acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder ocd see clinical studies 142 acute and maintenance treatment of bingeeating and vomiting behaviors in patients with moderate to severe bulimia nervosa see clinical studies 143 acute treatment of panic disorder with or without agoraphobia see clinical studies 144 fluoxetine capsules and olanzapine in combination are indicated for the treatment of acute treatment of depressive episodes associated with bipolar i disorder treatment resistant depression major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder or the treatment of treatment resistant depression r fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for acute and maintenance treatment of major depressive disorder mdd 1 acute and maintenance treatment of obsessive compulsive disorder ocd 1 acute and maintenance treatment of bulimia nervosa 1 acute treatment of panic disorder with or without agoraphobia 1 fluoxetine capsules and olanzapine in combination for treatment of acute depressive episodes associated with bipolar i disorder 1 treatment resistant depression 1,3
procrit is contraindicated in patients with uncontrolled hypertension see warnings and precautions 54 pure red cell aplasia prca that begins after treatment with procrit or other erythropoietin protein drugs see warnings and precautions 57 serious allergic reactions to procrit see warnings and precautions 58 procrit from multidose vials contains benzyl alcohol and is contraindicated in neonates infants pregnant women and nursing mothers benzyl alcohol has been associated with serious adverse events and death particularly in pediatric patients when therapy with procrit is needed in neonates and infants use singledose vials do not admix with bacteriostatic saline containing benzyl alcohol see use in specific populations 81 83 84 uncontrolled hypertension 4 pure red cell aplasia prca that begins after treatment with procrit or other erythropoietin protein drugs 4 serious allergic reactions to procrit 4 use of the multidose vials in neonates infants pregnant women and nursing mothers 4,1
docetaxel injection is a microtubule inhibitor indicated for breast cancer bc 11 nonsmall cell lung cancer nsclc 12 castrationresistant prostate cancer crpc 13 gastric adenocarcinoma gc 14 squamous cell carcinoma of the head and neck scchn 15 docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancer docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable locally advanced or metastatic nonsmall cell lung cancer who have not previously received chemotherapy for this condition docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castrationresistant prostate cancer docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction who have not received prior chemotherapy for advanced disease docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck scchn,3
acetylcysteine solution usp is indicated as adjuvant therapy for patients with abnormal viscid or inspissated mucous secretions in such conditions as chronic bronchopulmonary disease chronic emphysema emphysema with bronchitis chronic asthmatic bronchitis tuberculosis bronchiectasis and primary amyloidosis of the lung acute bronchopulmonary disease pneumonia bronchitis tracheobronchitis pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia posttraumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies bronchograms bronchospirometry and bronchial wedge catheterization acetylcysteine solution usp administered orally is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen it is essential to initiate treatment as soon as possible after the overdose and in any case within 24 hours of ingestion,3
chenodiol is contraindicated in the presence of know hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis primary biliary cirrhosis or sclerosing cholangitits see warnings a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye radiopaque stones or gallstone complications or compelling reasons for gallbladder surgery including unremitting acute cholecystitis cholangitis biliary obstruction gallstone pancreatitis or biliary gastrointestinal fistula chenodiol may cause fetal harm when administered to a pregnant woman serious hepatic renal and adrenal lesions occurred in fetuses of female rhesus monkeys given 60 to 90 mgkgday 4 to 6 times the maximum recommended human dose mrhd from day 21 to day 45 of pregnancy hepatic lesions also occurred in neonatal baboons whose mothers had received 18 to 38 mgkg 1 to 2 times the mrhd all during pregnancy fetal malformations were not observed neither fetal liver damage nor fetal abnormalities occurred in reproduction studies in rats and hamsters no human data are available at this time chenodiol is contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus,1
fenofibrate capsules are a peroxisome proliferator receptor alpha ppari activator indicated as an adjunct to diet to reduce elevated ldlc totalc tg and apo b and to increase hdlc in adult patients with primary hypercholesterolemia or mixed dyslipidemia 11 to reduce triglycerides in adult patients with severe hypertriglyceridemia 12 important limitations of use fenofibrate at a dose equivalent to 150 mg of fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large randomized controlled trial of patients with type 2 diabetes mellitus 51 fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated lowdensity lipoprotein cholesterol ldlc total cholesterol totalc triglycerides tg and apolopoprotein b apo b and to increase highdensity lipoprotein cholesterol hdlc in adult patients with primary hypercholesterolemia or mixed dyslipidemia fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention markedly elevated levels of serum triglycerides eg 2000 mgdl may increase the risk of developing pancreatitis the effect of fenofibrate therapy on reducing this risk has not been adequately studied fenofibrate at a dose equivalent to 150 mg was not shown to reduce coronary heart disease morbidity and mortality in 2 large randomized controlled trials of patients with type 2 diabetes mellitus see warnings and precautions 51,3
heparin sodium should not be used in patients with the following conditions severe thrombocytopenia when suitable blood coagulation tests eg the whole blood clotting time partial thromboplastin time etc cannot be performed at appropriate intervals this contraindication refers to fulldose heparin there is usually no need to monitor coagulation parameters in patients receiving lowdose heparin an uncontrollable active bleeding state see warnings except when this is due to disseminated intravascular coagulation pregnancy nursing mothers and pediatric use do not administer heparin sodium injection usp porcine preserved with benzyl alcohol to neonates infants pregnant women or nursing mothers see precautions pregnancy nursing mothers and pediatric use benzyl alcohol has been associated with serious adverse events and death particularly in pediatric patients heparin sodium injection usp porcine preservative free when indicated should be used in these populations,1
methenamine mandelate usp is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis cystitis and other chronic urinary tract infections also for infected residual urine sometimes accompanying neurologic diseases when used as recommended methenamine mandelate usp is particularly suitable for longterm therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop pathogens resistant to other antibacterial agents may respond to methenamine mandelate usp because of the nonspecific effect of formaldehyde formed in an acid urine prophylactic use rationale urine is a good culture medium for many urinary pathogens inoculation by a few organisms relapse or reinfection may lead to bacteriuria in susceptible individuals thus the rationale of management in recurring urinary tract infection bacteriuria is to change the urine from a growthsupporting to a growthinhibiting medium there is a growing body of evidence that longterm administration of methenamine mandelate usp can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis therapeutic use rationale methenamine mandelate usp helps to sterilize the urine and in some situations in which underlying pathologic conditions prevent sterilization by any means it can help to suppress the bacteriuria methenamine mandelate usp should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever a thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate usp,3
dutasteride is contraindicated for use in pregnancy in animal reproduction and developmental toxicity studies dutasteride inhibited development of male fetus external genitalia therefore dutasteride may cause fetal harm when administered to a pregnant woman if dutasteride is used during pregnancy or if the patient becomes pregnant while taking dutasteride the patient should be apprised of the potential hazard to the fetus see warnings and precautions 54 use in specific populations 81 women of childbearing potential see warnings and precautions 54 81 pediatric patients see use in specific populations 84 patients with previously demonstrated clinically significant hypersensitivity eg serious skin reactions angioedema to dutasteride or other 5 alphareductase inhibitors see adverse reactions 62 4 54 81 pediatric patients 4 patients with previously demonstrated clinically significant hypersensitivity eg serious skin reactions angioedema to dutasteride or other 5 alphareductase inhibitors 4,1
symptomatic trichomoniasis t vaginalis asymptomatic trichomoniasis t vaginalis treatment of asymptomatic sexual partners t vaginalis amebiasis in amebic liver abscess metronidazole tablets usp therapy does not obviate the need for aspiration or drainage of pus anaerobic bacterial infections intraabdominal infections including peritonitis intraabdominal abscess and liver abscess caused by bacteroides b fragilis b fragilis b distasonis b ovatus b thetaiotaomicron b vulgatus clostridium eubacterium peptococcus species peptostreptococcus skin and skin structure infections caused by bacteroides b fragilis clostridium peptococcus species peptostreptococcus fusobacterium gynecologic infections including endometritis endomyometritis tuboovarian abscess and postsurgical vaginal cuff infection caused by bacteroides b fragilis clostridium peptococcus species peptostreptococcus fusobacterium bacterial septicemia caused by bacteroides b fragilis clostridium bone and joint infections as adjunctive therapy caused by bacteroides b fragilis central nervous system cns infections including meningitis and brain abscess caused by bacteroides b fragilis lower respiratory tract infections including pneumonia empyema and lung abscess caused by bacteroides b fragilis endocarditis caused by bacteroides b fragilis to reduce the development of drugresistant bacteria and maintain the effectiveness of metronidazole tablets usp and other antibacterial drugs metronidazole tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
clindamycin phosphate products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria clindamycin phosphate products are also indicated in the treatment of serious infections due to susceptible strains of streptococci pneumococci and staphylococci its use should be reserved for penicillinallergic patients or other patients for whom in the judgment of the physician a penicillin is inappropriate because of the risk of antibioticassociated pseudomembranous colitis as described in the boxed warning bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin indicated surgical procedures should be performed in conjunction with antibiotic therapy clindamycin phosphate is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below lower respiratory tract infections including pneumonia empyema and lung abscess caused by anaerobes streptococcus pneumoniae e faecalis staphylococcus aureus skin and skin structure infections caused by streptococcus pyogenes staphylococcus aureus gynecological infections including endometritis nongonococcal tuboovarian abscess pelvic cellulitis and postsurgical vaginal cuff infection caused by susceptible anaerobes intraabdominal infections including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms septicemia caused by staphylococcus aureus enterococcus faecalis bone and joint infections including acute hematogenous osteomyelitis caused by staphylococcus aureus to reduce the development of drugresistant bacteria and maintain the effectiveness of clindamycin phosphate and other antibacterial drugs clindamycin phosphate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
cymbalta r major depressive disorder mdd 11 141 generalized anxiety disorder gad 12 142 diabetic peripheral neuropathic pain dpnp 13 fibromyalgia fm 14 chronic musculoskeletal pain 15 cymbalta is indicated for the treatment of major depressive disorder mdd the efficacy of cymbalta was established in four shortterm and one maintenance trial in adults see clinical studies 141 a major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least 5 of the following 9 symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration or a suicide attempt or suicidal ideation cymbalta is indicated for the treatment of generalized anxiety disorder gad the efficacy of cymbalta was established in three shortterm trials and one maintenance trial in adults see clinical studies 142 generalized anxiety disorder is defined by the dsmiv as excessive anxiety and worry present more days than not for at least 6 months the excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning it must be associated with at least 3 of the following 6 symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension andor sleep disturbance cymbalta is indicated for the management of neuropathic pain dpnp associated with diabetic peripheral neuropathy see clinical studies 143 cymbalta is indicated for the management of fibromyalgia fm see clinical studies 144 see clinical studies 145,3
cymbalta r major depressive disorder mdd 11 141 generalized anxiety disorder gad 12 142 diabetic peripheral neuropathic pain dpnp 13 fibromyalgia fm 14 chronic musculoskeletal pain 15 cymbalta is indicated for the treatment of major depressive disorder mdd the efficacy of cymbalta was established in four shortterm and one maintenance trial in adults see clinical studies 141 a major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least 5 of the following 9 symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration or a suicide attempt or suicidal ideation cymbalta is indicated for the treatment of generalized anxiety disorder gad the efficacy of cymbalta was established in three shortterm trials and one maintenance trial in adults see clinical studies 142 generalized anxiety disorder is defined by the dsmiv as excessive anxiety and worry present more days than not for at least 6 months the excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning it must be associated with at least 3 of the following 6 symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension andor sleep disturbance cymbalta is indicated for the management of neuropathic pain dpnp associated with diabetic peripheral neuropathy see clinical studies 143 cymbalta is indicated for the management of fibromyalgia fm see clinical studies 144 see clinical studies 145,3
meropenem for injection iv is a penem antibacterial indicated for the treatment of complicated skin and skin structure infections adult patients and pediatric patients 3 months of age and older only 11 complicated intraabdominal infections adult and pediatric patients 12 bacterial meningitis pediatric patients 3 months of age and older only 13 to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection iv and other antibacterial drugs meropenem for injection iv should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria meropenem for injection iv is indicated for the treatment of complicated skin and skin structure infections csssi due to staphylococcus aureus streptococcus pyogenes streptococcus agalactiae enterococcus faecalis pseudomonas aeruginosa escherichia coli proteus mirabilis bacteroides fragilis peptostreptococcus meropenem for injection iv is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci escherichia coli klebsiella pneumoniae pseudomonas aeruginosa bacteroides fragilis b thetaiotaomicron peptostreptococcus meropenem for injection iv is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae neisseria meningitidis penicillinsusceptible isolates of streptococcus pneumoniae meropenem for injection iv has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection iv and other antibacterial drugs meropenem for injection iv should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections please note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections it is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate cream usp 01 is recommended for wet oozing primary infections and greasy secondary infections such as pustular acne or infected seborrheic dermatitis gentamicin sulfate ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin if a waterwashable preparation is desired the cream is preferable gentamicin sulfate cream usp 01 has been used successfully in infants over one year of age as well as in adults and children,3
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections please note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections it is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate cream usp 01 is recommended for wet oozing primary infections and greasy secondary infections such as pustular acne or infected seborrheic dermatitis gentamicin sulfate ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin if a waterwashable preparation is desired the cream is preferable gentamicin sulfate cream usp 01 has been used successfully in infants over one year of age as well as in adults and children,3
treatment with integrilin is contraindicated in patients with a history of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days severe hypertension systolic blood pressure 200 mm hg or diastolic blood pressure 110 mm hg not adequately controlled on antihypertensive therapy major surgery within the preceding 6 weeks history of stroke within 30 days or any history of hemorrhagic stroke current or planned administration of another parenteral gp iibiiia inhibitor dependency on renal dialysis hypersensitivity to integrilin or any component of the product hypersensitivity reactions that occurred included anaphylaxis and urticaria bleeding diathesis or bleeding within the previous 30 days 4 severe uncontrolled hypertension 4 major surgery within the preceding 6 weeks 4 stroke within 30 days or any history of hemorrhagic stroke 4 coadministration of another parenteral gp iibiiia inhibitor 4 dependency on renal dialysis 4 known hypersensitivity to any component of the product 4,1
zoladex is a gonadotropin releasing hormone gnrh agonist indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate 11 use as palliative treatment of advanced carcinoma of the prostate 12 zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2bt4 stage b2c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 21 141 zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 22 142 in controlled studies of patients with advanced prostatic cancer comparing zoladex 36 mg to orchiectomy the longterm endocrine responses and objective responses were similar between the two treatment arms additionally duration of survival was similar between the two treatment arms in a major comparative trial in controlled studies of patients with advanced prostatic cancer zoladex 108 mg implant produced pharmacodynamically similar effect in terms of suppression of serum testosterone to that achieved with zoladex 36 mg implant clinical outcome similar to that produced with the use of the zoladex 36 mg implant administered every 28 days is predicted with the zoladex 108 mg implant administered every 12 weeks the automatic safety feature of the syringe aids in the prevention of needlestick injury,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,3
to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antimicrobial therapy in the absence of such datalocal epidemiology and susceptibility patterns may contribute to the empiric selection of therapy cefixime for oral suspension usp is a cephalosporin antibacterial drug indicated for 11 12 13 14 15 uncomplicated urinary tract infections caused by escherichia coli proteus mirabilis otitis media caused by haemophilus influenzae moraxella catarrhalis streptococcus pyogenes streptococcus pyogenes streptococcus pneumoniae see clinical studies 14 pharyngitis and tonsillitis caused by streptococcus pyogenes streptococcus pyogenes streptococcus pyogenes acute exacerbations of chronic bronchitis caused by streptococcus pneumoniae haemophilus influenzae uncomplicated gonorrhea cervicalurethral caused by neisseria gonorrhoeae,3
demerol tablets and oral solution are contraindicated in patients with significant respiratory depression see warnings and precautions 54 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 59 concomitant use of monoamine oxidase inhibitors maois or within 14 days of having taken an maoi see drug interactions 7 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 514 hypersensitivity to meperidine or to any of other ingredients of the product eg anaphylaxis see adverse reactions 6 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 concomitant use of monoamine oxidase inhibitors maois or within 14 days of having taken an maoi 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 hypersensitivity to meperidine or to any other ingredients of the product 4,1
enoxaparin sodium is a low molecular weight heparin lmwh indicated for prophylaxis of deep vein thrombosis dvt in abdominal surgery hip replacement surgery knee replacement surgery or medical patients with severely restricted mobility during acute illness 11 inpatient treatment of acute dvt with or without pulmonary embolism 12 outpatient treatment of acute dvt without pulmonary embolism 12 prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction mi 13 treatment of acute stsegment elevation myocardial infarction stemi managed medically or with subsequent percutaneous coronary intervention pci 14 enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients undergoing abdominal surgery who are at risk for thromboembolic complications see clinical studies 141 in patients undergoing hip replacement surgery during and following hospitalization in patients undergoing knee replacement surgery in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness enoxaparin sodium is indicated for the inpatient treatment with or without pulmonary embolism the outpatient treatment without pulmonary embolism enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and nonqwave myocardial infarction when concurrently administered with aspirin enoxaparin sodium when administered concurrently with aspirin has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute stsegment elevation myocardial infarction stemi receiving thrombolysis and being managed medically or with percutaneous coronary intervention pci,3
gemfibrozil tablets usp are indicated as adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels types iv and v hyperlipidemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them patients who present such risk typically have serum triglycerides over 2000 mgdl and have elevations of vldlcholesterol as well as fasting chylomicrons type v hyperlipidemia subjects who consistently have total serum or plasma triglycerides below 1000 mgdl are unlikely to present a risk of pancreatitis gemfibrozil tablets usp therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mgdl who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis it is recognized that some type iv patients with triglycerides under 1000 mgdl may through dietary or alcoholic indiscretion convert to a type v pattern with massive triglyceride elevations accompanying fasting chylomicronemia but the influence of gemfibrozil tablets usp therapy on the risk of pancreatitis in such situations has not been adequately studied drug therapy is not indicated for patients with type i hyperlipoproteinemia who have elevations of chylomicrons and plasma triglycerides but who have normal levels of very low density lipoprotein vldl inspection of plasma refrigerated for 14 hours is helpful in distinguishing types i iv and v hyperlipoproteinemia reducing the risk of developing coronary heart disease only and warnings precautions clinical pharmacology in a subgroup analysis of patients in the helsinki heart study with abovemedian hdlcholesterol values at baseline greater than 464 mgdl the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups see table i,3
valsartan is an angiotensin ii receptor blocker arb indicated for treatment of hypertension 11 treatment of heart failure 12 reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction 13 valsartan tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets valsartan tablets are indicated for the treatment of heart failure nyha class ii to iv in a controlled clinical trial valsartan tablets significantly reduced hospitalizations for heart failure there is no evidence that valsartan tablets provide added benefits when they are used with an adequate dose of an ace inhibitor see clinical studies 142 in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction valsartan tablets are indicated to reduce cardiovascular mortality see clinical studies 143,3
penicillin g potassium injection usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g clinical indication infecting organism septicemia empyema pneumonia pericarditis endocarditis meningitis streptococcus pyogenes streptococcus pneumoniae staphylococcus species anthrax bacillus anthracis actinomycosis cervicofacial disease and thoracic actinomyces israelii botulism adjunctive therapy to antitoxin gas gangrene clostridium species diphtheria adjunctive therapy to antitoxin and prevention corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis severe infections of the oropharynx vincents fusobacterium listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae syphilis congenital and neurosyphilis treponema pallidum meningococcal meningitis andor septicemia neisseria meningitidis gramnegative bacillary infections bacteremias penicillin g is not the drug of choice in the treatment of gramnegative bacillary infections gramnegative bacillary organisms ie enterobacteriaceae to reduce the development of drugresistant bacteria and maintain the effectiveness of penicillin g potassium injection usp and other antibacterial drugs penicillin g potassium injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
penicillin g potassium injection usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g clinical indication infecting organism septicemia empyema pneumonia pericarditis endocarditis meningitis streptococcus pyogenes streptococcus pneumoniae staphylococcus species anthrax bacillus anthracis actinomycosis cervicofacial disease and thoracic actinomyces israelii botulism adjunctive therapy to antitoxin gas gangrene clostridium species diphtheria adjunctive therapy to antitoxin and prevention corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis severe infections of the oropharynx vincents fusobacterium listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae syphilis congenital and neurosyphilis treponema pallidum meningococcal meningitis andor septicemia neisseria meningitidis gramnegative bacillary infections bacteremias penicillin g is not the drug of choice in the treatment of gramnegative bacillary infections gramnegative bacillary organisms ie enterobacteriaceae to reduce the development of drugresistant bacteria and maintain the effectiveness of penicillin g potassium injection usp and other antibacterial drugs penicillin g potassium injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
warfarin sodium is contraindicated in patients with see warnings and precautions use in specific populations 81 use in specific populations 81 hemorrhagic tendencies or blood dyscrasias recent or contemplated surgery of the central nervous system or eye or traumatic surgery resulting in large open surfaces see warnings and precautions 57 bleeding tendencies associated with active ulceration or overt bleeding of the gastrointestinal genitourinary or respiratory tract central nervous system hemorrhage cerebral aneurysms dissecting aorta pericarditis and pericardial effusions bacterial endocarditis threatened abortion eclampsia and preeclampsia unsupervised patients with conditions associated with potential high level of noncompliance spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding hypersensitivity to warfarin or to any other components of this product eg anaphylaxis see adverse reactions 6 major regional or lumbar block anesthesia malignant hypertension pregnancy except in women with mechanical heart valves 4 56 81 hemorrhagic tendencies or blood dyscrasias recent or contemplated surgery of the central nervous system cns or eye or traumatic surgery resulting in large open surfaces 4 57 bleeding tendencies associated with certain conditions threatened abortion eclampsia and preeclampsia unsupervised patients with potential high levels of noncompliance spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding hypersensitivity to warfarin or any component of the product major regional or lumbar block anesthesia malignant hypertension,1
phentermine hydrochloride is indicated as a shortterm a few weeks adjunct in a regimen of weight reduction based on exercise behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index 30 kgm 2 2 below is a chart of body mass index bmi based on various heights and weights bmi is calculated by taking the patients weight in kilograms kg divided by the patients height in meters m squared metric conversions are as follows pounds 22 kg inches x 00254 meters body mass index bmi kgm 2 height feet inches weight 50 53 56 59 60 63 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 the limited usefulness of agents of this class see clinical pharmacology,3
history of ischemic heart disease or coronary artery vasospasm 4 history of stroke or transient ischemic attack 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht1 agonist eg another triptan or of an ergotaminecontaining medication 4 hemiplegic or basilar migraine 4 maoa inhibitor used in the past 2 weeks 4 hypersensitivity to rizatriptan benzoate 4 rizatriptan benzoate tablets is contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51 coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 history of stroke or transient ischemic attack tia see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75 123 hypersensitivity to rizatriptan benzoate angioedema and anaphylaxis seen see adverse reactions 62,1
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,3
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,2
active or past history of venous thromboembolism including deep vein thrombosis pulmonary embolism and retinal vein thrombosis 41 pregnancy women who may become pregnant and nursing mothers 42 81 83 raloxifene hydrochloride tablets usp is contraindicated in women with active or past history of venous thromboembolism vte including deep vein thrombosis pulmonary embolism and retinal vein thrombosis see warnings and precautions 51 raloxifene hydrochloride tablets usp is contraindicated in pregnancy in women who may become pregnant and in nursing mothers see use in specific populations 81 83 in rabbit studies abortion and a low rate of fetal heart anomalies ventricular septal defects occurred in rabbits at doses 01 mgkg 004 times the human dose based on surface area mgm 2 2 2 2,1
morphine sulfate extendedrelease capsules are contraindicated in patients with significant respiratory depression see warnings and pre cautions 53 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment s ee warnings and precautions 56 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days see warnings and precautions 57 drug interactions 7 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precau tions 511 hypersensitivity eg anaphylaxis to morphine see adverse reactions 62,1
simvastatin tablets usp are an hmgcoa reductase inhibitor statin indicated as an adjunctive therapy to diet to reduce the risk of total mortality by reducing chd deaths and reduce the risk of nonfatal myocardial infarction stroke and the need for revascularization procedures in patients at high risk of coronary events 11 reduce elevated totalc ldlc apo b tg and increase hdlc in patients with primary hyperlipidemia heterozygous familial and nonfamilial and mixed dyslipidemia 12 reduce elevated tg in patients with hypertriglyceridemia and reduce tg and vldlc in patients with primary dysbetalipoproteinemia 12 reduce totalc and ldlc in adult patients with homozygous familial hypercholesterolemia 12 reduce elevated totalc ldlc and apo b in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy 12 13 14 reduce the risk of total mortality by reducing chd deaths reduce the risk of nonfatal myocardial infarction and stroke reduce the need for coronary and noncoronary revascularization procedures reduce elevated total cholesterol totalc lowdensity lipoprotein cholesterol ldlc apolipoprotein b apo b and triglycerides tg and to increase highdensity lipoprotein cholesterol hdlc in patients with primary hyperlipidemia fredrickson type iia heterozygous familial and nonfamilial or mixed dyslipidemia fredrickson type iib reduce elevated tg in patients with hypertriglyceridemia fredrickson type iv hyperlipidemia reduce elevated tg and vldlc in patients with primary dysbetalipoproteinemia fredrickson type iii hyperlipidemia reduce totalc and ldlc in patients with homozygous familial hypercholesterolemia as an adjunct to other lipidlowering treatments eg ldl apheresis or if such treatments are unavailable there is a positive family history of premature cardiovascular disease cvd or two or more other cvd risk factors are present in the adolescent patient,3
important notice oxytocin injection usp synthetic is indicated for the medical rather than the elective induction of labor available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications oxytocin injection usp synthetic is indicated for the initiation or improvement of uterine contractions where this is desirable and considered suitable in order to achieve early vaginal delivery for fetal or maternal reasons it is indicated for 1 induction of labor in patients with a medical indication for the initiation of labor such as rh problems maternal diabetes preeclampsia at or near term when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated 2 stimulation or reinforcement of labor as in selected cases of uterine inertia 3 adjunctive therapy in the management of incomplete or inevitable abortion in the first trimester curettage is generally considered primary therapy in second trimester abortion oxytocin infusion will often be successful in emptying the uterus other means of therapy however may be required in such cases oxytocin injection usp synthetic is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage,3
dosage and administration urinary tract infections escherichia coli klebsiella pneumoniae enterobacter cloacae serratia marcescens proteus mirabilis providencia rettgeri morganella morganii citrobacter diversus citrobacter freundii pseudomonas aeruginosa staphylococcus epidermidis staphylococcus saprophyticus enterococcus faecalis acute uncomplicated cystitis in females escherichia coli staphylococcus saprophyticus chronic bacterial prostatitis escherichia coli proteus mirabilis lower respiratory tract infections escherichia coli klebsiella pneumoniae enterobacter cloacae proteus mirabilis pseudomonas aeruginosa haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae also moraxella catarrhalis ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to streptococcus pneumoniae acute sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis skin and skin structure infections escherichia coli klebsiella pneumoniae enterobacter cloacae proteus mirabilis proteus vulgaris providencia stuartii morganella morganii citrobacter freundii pseudomonas aeruginosa staphylococcus aureus staphylococcus epidermidis streptococcus pyogenes bone and joint infections enterobacter cloacae serratia marcescens pseudomonas aeruginosa complicated intraabdominal infections escherichia coli pseudomonas aeruginosa proteus mirabilis klebsiella pneumoniae bacteroides fragilis infectious diarrhea escherichia coli campylobacter jejuni shigella boydii shigella dysenteriae shigella flexneri shigella sonnei typhoid fever enteric fever salmonella typhi uncomplicated cervical and urethral gonorrhea neisseria gonorrhoeae pediatric patients 1 to 17 years of age complicated urinary tract infections and pyelonephritis escherichia coli note although effective in clinical trials ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls including events related to joints andor surrounding tissues see warnings precautions pediatric use adverse reactions clinical studies animal pharmacology inhalational anthrax bacillus anthracis 5 inhalational anthrax additional information pseudomonas aeruginosa,3
frova should not be given to patients with ischemic heart disease eg angina pectoris history of myocardial infarction or documented silent ischemia or to patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings frova should not be given to patients with cerebrovascular syndromes including but not limited to strokes of any type as well as transient ischemic attacks frova should not be given to patients with peripheral vascular disease including but is not limited to ischemic bowel disease see warnings frova should not be given to patients with uncontrolled hypertension see warnings frova should not be administered to patients with hemiplegic or basilar migraine frova should not be used within 24 hours of treatment with another 5ht 1 frova is contraindicated in patients who are hypersensitive to frovatriptan or any of the inactive ingredients in the tablets,1
frova should not be given to patients with ischemic heart disease eg angina pectoris history of myocardial infarction or documented silent ischemia or to patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings frova should not be given to patients with cerebrovascular syndromes including but not limited to strokes of any type as well as transient ischemic attacks frova should not be given to patients with peripheral vascular disease including but is not limited to ischemic bowel disease see warnings frova should not be given to patients with uncontrolled hypertension see warnings frova should not be administered to patients with hemiplegic or basilar migraine frova should not be used within 24 hours of treatment with another 5ht 1 frova is contraindicated in patients who are hypersensitive to frovatriptan or any of the inactive ingredients in the tablets,1
bavencio is a programmed death ligand1 pdl1 blocking antibody indicated for adults and pediatric patients 12 years and older with metastatic merkel cell carcinoma mcc a 11 patients with locally advanced or metastatic urothelial carcinoma uc who have disease progression during or following platinumcontaining chemotherapy 12 have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy a 12 firstline treatment in combination with axitinib of patients with advanced renal cell carcinoma rcc 13 143 a bavencio avelumab is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic merkel cell carcinoma mcc this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials see clinical studies 141 bavencio is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma uc who have disease progression during or following platinumcontaining chemotherapy have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy this indication is approved under accelerated approval based on tumor response rate and duration of response continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials see clinical studies 142 bavencio in combination with axitinib is indicated for the firstline treatment of patients with advanced renal cell carcinoma rcc see clinical studies 143,3
striant is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate see warnings and precautions 52 61 striant is contraindicated in women who are or may become pregnant or who are breastfeeding striant may cause fetal harm when administered to a pregnant woman striant may cause serious adverse reactions in nursing infants exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization see use in specific populations 81 83 men with carcinoma of the breast or known or suspected prostate cancer 4 52 pregnant or breastfeeding women testosterone may cause fetal harm 4 81 83,1
general active internal bleeding 41 42 recent intracranial or intraspinal surgery or serious head trauma 41 42 intracranial conditions that may increase the risk of bleeding 41 42 bleeding diathesis 41 42 current severe uncontrolled hypertension 41 42 acute ischemic stroke current intracranial hemorrhage 41 subarachnoid hemorrhage 41 acute myocardial infarction or pulmonary embolism history of recent stroke 42 do not administer activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit see warnings and precautions 51 current intracranial hemorrhage subarachnoid hemorrhage active internal bleeding recent within 3 months intracranial or intraspinal surgery or serious head trauma presence of intracranial conditions that may increase the risk of bleeding eg some neoplasms arteriovenous malformations or aneurysms bleeding diathesis current severe uncontrolled hypertension do not administer activase for treatment of ami or pe in the following situations in which the risk of bleeding is greater than the potential benefit see warnings and precautions 51 active internal bleeding history of recent stroke recent within 3 months intracranial or intraspinal surgery or serious head trauma presence of intracranial conditions that may increase the risk of bleeding eg some neoplasms arteriovenous malformations or aneurysms bleeding diathesis current severe uncontrolled hypertension,1
rizatriptan benzoate orally disintegrating tablets usp are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old limitations of use rizatriptan benzoate orally disintegrating tablets usp should only be used where a clear diagnosis of migraine has been established if a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets usp the diagnosis of migraine should be reconsidered before rizatriptan benzoate orally disintegrating tablets usp are administered to treat any subsequent attacks rizatriptan benzoate orally disintegrating tablets usp are not indicated for use in the management of hemiplegic or basilar migraine see contraindications 4 rizatriptan benzoate orally disintegrating tablets usp are not indicated for the prevention of migraine attacks safety and effectiveness of rizatriptan benzoate orally disintegrating tablets usp have not been established for cluster headache rizatriptan benzoate is a serotonin 5ht 1b1d 1 limitations of use use only after clear diagnosis of migraine has been established 1 not indicated for the prophylactic therapy of migraine 1 not indicated for the treatment of cluster headache 1,3
thyroid hormone drugs are indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis this category includes cretinism myxedema and ordinary hypothyroidism in patients of any age pediatric patients adults the elderly or state including pregnancy primary hypothyroidism resulting from functional deficiency primary atrophy partial or total absence of thyroid gland or the effects of surgery radiation or drugs with or without the presence of goiter and secondary pituitary or tertiary hypothalamic hypothyroidism see warnings as pituitary thyroidstimulating hormone tsh suppressants in the treatment or prevention of various types of euthyroid goiters including thyroid nodules subacute or chronic lymphocytic thyroiditis hashimotos and multinodular goiter as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy liothyronine sodium tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef,3
dilaudid injection is contraindicated in patients with significant respiratory depression see warnings and precautions 52 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 52 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 59 hypersensitivity to hydromorphone hydromorphone salts any other components of the product or sulfite containing medications eg anaphylaxis see warnings and precautions 513 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 known hypersensitivity to hydromorphone hydromorphone salts sulfitecontaining medications or any other components of the product 4,1
diltiazem hydrochloride injection is contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker patients with second or thirddegree av block except in the presence of functioning ventricular pacemaker patients with severe hypotension or cardiogenic shock patients who have demonstrated hypersensitivity to the drug intravenous diltiazem and intravenous betablockers should not be administered together or in close proximity within a few hours patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wpw syndrome or short pr syndrome overdosage patients with ventricular tachycardia administration of other calcium channel blockers to patients with wide complex tachycardia qrs 012 seconds has resulted in hemodynamic deterioration and ventricular fibrillation it is important that an accurate pretreatment diagnosis distinguish wide complex qrs tachycardia of supraventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection,1
buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder gad many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study with an average symptom duration of 6 months generalized anxiety disorder 30002 is described in the american psychiatric associations diagnostic and statistical manual iii 1 generalized persistent anxiety of at least 1 month continual duration manifested by symptoms from three of the four following categories 1 2 3 4 the above symptoms would not be due to another mental disorder such as a depressive disorder or schizophrenia however mild depressive symptoms are common in gad the effectiveness of buspirone hydrochloride tablets in longterm use that is for more than 3 to 4 weeks has not been demonstrated in controlled trials there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad however in a study of longterm use 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect therefore the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient,3
diltiazem hydrochloride injection is contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker patients with second or thirddegree av block except in the presence of a functioning ventricular pacemaker patients with severe hypotension or cardiogenic shock patients who have demonstrated hypersensitivity to the drug intravenous diltiazem and intravenous betablockers should not be administered together or in close proximity within a few hours patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wpw syndrome or short pr syndrome as with other agents which slow av nodal conduction and do not prolong the refractoriness of the accessory pathway eg verapamil digoxin in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially lifethreatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection as such the initial use of diltiazem hydrochloride injection should be if possible in a setting where monitoring and resuscitation capabilities including dc cardioversiondefibrillation are present see overdosage patients with ventricular tachycardia administration of other calcium channel blockers to patients with wide complex tachycardia qrs 012 seconds has resulted in hemodynamic deterioration and ventricular fibrillation it is important that an accurate pretreatment diagnosis distinguish wide complex qrs tachycardia of superventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection,1
imitrex tablets should not be given to patients with history symptoms or signs of ischemic cardiac cerebrovascular or peripheral vascular syndromes in addition patients with other significant underlying cardiovascular diseases should not receive imitrex tablets ischemic cardiac syndromes include but are not limited to angina pectoris of any type eg stable angina of effort vasospastic forms of angina such as the prinzmetal variant all forms of myocardial infarction and silent myocardial ischemia cerebrovascular syndromes include but are not limited to strokes of any type as well as transient ischemic attacks peripheral vascular disease includes but is not limited to ischemic bowel disease see warnings because imitrex tablets may increase blood pressure they should not be given to patients with uncontrolled hypertension concurrent administration of maoa inhibitors or use within 2 weeks of discontinuation of maoa inhibitor therapy is contraindicated see clinical pharmacology drug interactions and precautions drug interactions imitrex tablets should not be administered to patients with hemiplegic or basilar migraine imitrex tablets and any ergotaminecontaining or ergottype medication like dihydroergotamine or methysergide should not be used within 24 hours of each other nor should imitrex and another 5ht 1 agonist imitrex tablets are contraindicated in patients with hypersensitivity to sumatriptan or any of their components imitrex tablets are contraindicated in patients with severe hepatic impairment,1
codeine sulfate tablets are contraindicated for all children younger than 12 years of age see warnings and precautions 54 postoperative management in children younger than 18 years of age following tonsillectomy andor adenoidectomy see warnings and precautions 54 codeine sulfate tablets are also contraindicated in patients with significant respiratory depression see warnings and precautions 53 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 58 see warnings and precautions 59 drug interactions 7 see warnings and precautions 513 see adverse reactions 6 children younger than 12 years of age postoperative management in children younger than 18 years of age following tonsillectomy andor adenoidectomy 4 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 hypersensitivity to codeine 4,1
for the treatment of the following conditions steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctuate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical or thermal burns or penetration of foreign bodies steroid responsive inflammatory conditions of the external auditory meatus such as allergic otitis externa selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation,3
for the treatment of the following conditions steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctuate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical or thermal burns or penetration of foreign bodies steroid responsive inflammatory conditions of the external auditory meatus such as allergic otitis externa selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation,3
estrogens should not be used in individuals with any of the following conditions 1 undiagnosed abnormal genital bleeding 2 known suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease 3 known or suspected estrogendependent neoplasia 4 active deep vein thrombosis pulmonary embolism or history of these conditions 5 active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction 6 liver dysfunction or disease 7 estradiol tablets should not be used in patients with known hypersensitivity to its ingredients 8 known or suspected pregnancy there is no indication for estradiol in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,1
docetaxel injection is a microtubule inhibitor indicated for breast cancer bc 11 nonsmall cell lung cancer nsclc 12 castrationresistant prostate cancer crpc 13 gastric adenocarcinoma gc 14 squamous cell carcinoma of the head and neck cancer scchn 15 docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancer docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable locally advanced or metastatic nonsmall cell lung cancer who have not previously received chemotherapy for this condition docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castrationresistant prostate cancer docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction who have not received prior chemotherapy for advanced disease docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck scchn,3
docetaxel injection is a microtubule inhibitor indicated for breast cancer bc 11 nonsmall cell lung cancer nsclc 12 castrationresistant prostate cancer crpc 13 gastric adenocarcinoma gc 14 squamous cell carcinoma of the head and neck cancer scchn 15 docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancer docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable locally advanced or metastatic nonsmall cell lung cancer who have not previously received chemotherapy for this condition docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castrationresistant prostate cancer docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction who have not received prior chemotherapy for advanced disease docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck scchn,3
subsys is contraindicated in opioid nontolerant patients lifethreatening respiratory depression and death could occur at any dose in opioid nontolerant patients see indications and usage 1 51 acute or postoperative pain including headachemigraine and dental pain or in the emergency department see indications and usage 1 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 59 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 514 known hypersensitivity eg anaphylaxis to fentanyl or components of subsys see adverse reactions 62 opioid nontolerant patients 4 management of acute or postoperative pain including headachemigraine and dental pain or in emergency department 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 known hypersensitivity to fentanyl or components of subsys 4,1
sedative sedation is obtainable within an hour and in adequate dosage the duration of action is more than six hours included in the more common conditions in which the sedative action of this class of drugs is desired are anxietytension states hyperthyroidism essential hypertension nausea and vomiting of functional origin motion sickness acute labyrinthitis pylorospasm in infants chorea and cardiac failure phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract phenobarbital controls anxiety decreases muscular activity and lessens nervous excitability in hyperthyroid patients however thyrotoxic individuals occasionally react poorly to barbiturates hypnotic for the shortterm treatment of insomnia since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacology preanesthetic longterm anticonvulsant phenobarbital mephobarbital and metharbital for the treatment of generalized tonicclonic and cortical focal seizures and in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia cerebral hemorrhage meningitis tetanus and toxic reactions to strychnine or local anesthetics phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use when administered intravenously it may require 15 or more minutes before reaching peak concentrations in the brain therefore injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturateinduced depression phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative including its preoperative and postoperative use,3
voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with 11 candida 12 13 scedosporium apiospermum fusarium fusarium solani 14 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of invasive aspergillosis ia in clinical trials the majority of isolates recovered were aspergillus fumigatus there was a small number of cases of cultureproven disease due to species of aspergillus other than a fumigatus see clinical studies 141 145 microbiology 124 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of candidemia in nonneutropenic patients and the following candida infections disseminated infections in skin and infections in abdomen kidney bladder wall and wounds see clinical studies 142 145 microbiology 124 voriconazole is indicated in adults and pediatric patients 2 years of age and older for the treatment of esophageal candidiasis ec in adults and pediatric patients 2 years of age and older see clinical studies 143 145 microbiology 124 voriconazole is indicated for the treatment of serious fungal infections caused by scedosporium apiospermum asexual form of pseudallescheria boydii and fusarium spp including fusarium solani in adults and pediatric patients 2 years of age and older intolerant of or refractory to other therapy see clinical studies 144 microbiology 124 specimens for fungal culture and other relevant laboratory studies including histopathology should be obtained prior to therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly,3
almotriptan tablets usp are 5ht 1b1d acute treatment of migraine attacks in adults with a history of migraine with or without aura 11 acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura and who have migraine attacks usually lasting 4 hours or more 11 important limitations use only after a clear diagnosis of migraine has been established 12 in adolescents age 12 to 17 years efficacy of almotriptan tablets on migraineassociated symptoms was not established 12 not intended for the prophylactic therapy of migraine 12 not indicated for the treatment of cluster headache 12 adults almotriptan tablets usp are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura adolescents age 12 to 17 years almotriptan tablets usp are indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more when untreated almotriptan tablets should only be used where a clear diagnosis of migraine has been established if a patient has no response for the first migraine attack treated with almotriptan tablets the diagnosis of migraine should be reconsidered before almotriptan tablets are administered to treat any subsequent attacks in adolescents age 12 to 17 years efficacy of almotriptan tablets on migraineassociated symptoms nausea photophobia and phonophobia was not established almotriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine see contraindications 47 safety and effectiveness of almotriptan tablets have not been established for cluster headache which is present in an older predominantly male population,3
ischemic heart disease coronary artery vasospasm or other significant underlying cardiovascular disease 41 cerebrovascular syndromes eg history of stroke or tia 42 peripheral vascular disease including ischemic bowel disease 43 uncontrolled hypertension 44 do not use almotriptan tablets within 24 hours of an ergotaminecontaining or ergottype medication or of another 5ht 1 45 46 hemiplegic or basilar migraine 47 known hypersensitivity to almotriptan tablets 48 do not use almotriptan tablets in patients with ischemic heart disease angina pectoris history of myocardial infarction or documented silent ischemia or in patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings and precautions 51 do not use almotriptan tablets in patients with cerebrovascular syndromes including but not limited to stroke of any type as well as transient ischemic attacks see warnings and precautions 53 do not use almotriptan tablets in patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings and precautions 54 because almotriptan tablets may increase blood pressure do not use almotriptan tablets in patients with uncontrolled hypertension see warnings and precautions 57 do not use almotriptan tablets and ergotaminecontaining or ergotderived medications like dihydroergotamine ergotamine tartrate or methysergide within 24 hours of each other see drug interactions 71 almotriptan tablets and other 5ht 1 see warnings and precautions 51 52 do not use almotriptan tablets in patients with hemiplegic or basilar migraine almotriptan tablets are contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients,1
hydromorphone hydrochloride tablets are contraindicated in patients with significant respiratory depression see warnings and precautions 56 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 56 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 510 hypersensitivity to hydromorphone hydromorphone salts any other components of the product or sulfitecontaining medications eg anaphylaxis see warnings and precautions 514 adverse reactions 61 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 known hypersensitivity to hydromorphone hydromorphone salts or sulfitecontaining medications 4,1
spironolactone tablets are indicated in the management of primary hyperaldosteronism for establishing the diagnosis of primary hyperaldosteronism by therapeutic trial shortterm preoperative treatment of patients with primary hyperaldosteronism longterm maintenance therapy for patients with discrete aldosteroneproducing adrenal adenomas who are judged to be poor operative risks or who decline surgery longterm maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia idiopathic hyperaldosteronism edematous conditions for patients with congestive heart failure cirrhosis of the liver accompanied by edema andor ascites nephrotic syndrome essential hypertension usually in combination with other drugs spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate hypokalemia severe heart failure nyha class iii iv usage in pregnancy precautions pregnancy,3
because serious or lifethreatening hypoventilation could occur fentanyl transdermal system is contraindicated in patients who are not opioidtolerant in the management of acute pain or in patients who require opioid analgesia for a short period of time in the management of postoperative pain including use after outpatient or day surgeries eg tonsillectomies in the management of mild pain in the management of intermittent pain eg use on an as needed basis prn in situations of significant respiratory depression especially in unmonitored settings where there is a lack of resuscitative equipment in patients who have acute or severe bronchial asthma fentanyl transdermal system is contraindicated in patients who have or are suspected of having paralytic ileus,1
cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinumcontaining chemotherapy 11 in combination with docetaxel for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to receiving cyramza 12 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 13 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 400 ngml and have been treated with sorafenib 14 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with disease progression on or after platinumbased chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine,3
cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinumcontaining chemotherapy 11 in combination with docetaxel for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinumbased chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to receiving cyramza 12 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 13 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 400 ngml and have been treated with sorafenib 14 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with disease progression on or after platinumbased chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fdaapproved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine,3
potassium citrate is contraindicated in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloride in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medication in patients with peptic ulcer disease because of its ulcerogenic potential in patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate moreover the rise in urinary ph resulting from potassium citrate therapy might promote further bacterial growth in patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4 patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4 patients with peptic ulcer disease 4 patients with active urinary tract infection 4 patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4,1
indications and usage for the treatment of the following conditions steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical or thermal burns or penetration of foreign bodies steroid responsive inflammatory conditions of the external auditory meatus such as allergic otitis externa selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation,3
caspofungin acetate for injection is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for 1 candida 1 1 1 caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile neutropenic adult and pediatric patients 3 months of age and older see clinical studies 141 145 caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections intraabdominal abscesses peritonitis and pleural space infections in adult and pediatric patients 3 months of age and older see clinical studies 142 145 limitations of use caspofungin acetate for injection has not been studied in endocarditis osteomyelitis and meningitis due to candida caspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients 3 months of age and older see clinical studies 143 145 limitations of use caspofungin acetate for injection has not been approved for the treatment of oropharyngeal candidiasis opc in the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis patients with concomitant opc had higher relapse rate of the opc see clinical studies 143 caspofungin acetate for injection is indicated for the treatment of invasive aspergillosis in adult and pediatric patients 3 months of age and older who are refractory to or intolerant of other therapies see clinical studies 144 145 limitations of use caspofungin acetate for injection has not been studied as initial therapy for invasive aspergillosis,3
history of coronary artery disease cad or coronary vasospasm 4 symptomatic wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 monoamine oxidase maoa inhibitor used in past 2 weeks 4 known hypersensitivity to zolmitriptan 4 zolmitriptan orally disintegrating tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia other significant underlying cardiovascular disease or c warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent use of a maoa inhibitor that is within 2 weeks see drug interactions 72 123 known hypersensitivity to zolmitriptan angioedema and anaphylaxis seen see adverse reactions 62,1
second or thirddegree av block except in patients with a functioning artificial pacemaker 4 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker 4 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma 4 known hypersensitivity to adenosine injection 4 adenosine injection is contraindicated in patients with second or thirddegree av block except in patients with a functioning artificial pacemaker see warnings and precautions 52 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker see warnings and precautions 52 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma see warnings and precautions 53 known hypersensitivity to adenosine see warnings and precautions 57,1
fluocinolone acetonide 001 topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients 11 topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks 12 limitations of use apply the least amount to cover affected areas 13 do not use in the diaper area 13 do not use on the face axillae or groin 13 62 84 fluocinolone acetonide 001 topical oil body oil is indicated for the topical treatment of atopic dermatitis in adult patients fluocinolone acetonide 001 topical oil body oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks safety and effectiveness in pediatric patients younger than 3 months of age have not been established apply the least amount of fluocinolone acetonide 001 topical oil needed to cover the affected areas as with other corticosteroids fluocinolone acetonide 001 topical oil should be discontinued when control of disease is achieved contact the physician if no improvement is seen within 2 weeks fluocinolone acetonide 001 topical oil should not be applied to the diaper area diapers or plastic pants may constitute occlusive use fluocinolone acetonide 001 topical oil should not be used on the face axillae or groin unless directed by the physician application to intertriginous areas should be avoided due to the increased risk of local adverse reactions see adverse reactions 6 use in specific populations 84,3
verapamil is contraindicated in severe left ventricular dysfunction see warnings and precautions 51 hypotension less than 90 mm hg systolic pressure or cardiogenic shock sick sinus syndrome except in patients with a functioning artificial ventricular pacemaker second or thirddegree av block except in patients with a functioning artificial ventricular pacemaker patients with atrial flutter or atrial fibrillation and an accessory bypass tract eg wolffparkinsonwhite lownganonglevine syndromes see warnings and precautions 54 severe left ventricular dysfunction 4 hypotension 90 mmhg systolic pressure or cardiogenic shock 4 sick sinus syndrome except in patients with pacemaker 4 2nd or 3rddegree av block except in patients with pacemaker 4 atrial flutter or atrial fibrillation and an accessory bypass tract 4,1
metformin hydrochloride tablets usp is contraindicated in patients with renal disease or renal dysfunction eg as suggested by serum creatinine levels 15 mgdl males 14 mgdl females or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse shock acute myocardial infarction and septicemia see and warnings precautions known hypersensitivity to metformin hydrochloride acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma diabetic ketoacidosis should be treated with insulin metformin hydrochloride tablets usp should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials because use of such products may result in acute alteration of renal function see also precautions,1
quetiapine tablet is an atypical antipsychotic indicated for the treatment of 11 12 12 quetiapine tablet is indicated for the treatment of schizophrenia the efficacy of quetiapine tablets in schizophrenia was established in three 6week trials in adults and one 6week trial in adolescents 13 to 17 years the effectiveness of quetiapine tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials see clinical studies 141 see clinical studies 142 quetiapine tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder efficacy was established in two 8week monotherapy trials in adult patients with bipolar i and bipolar ii disorder see clinical studies 142 quetiapine tablet is indicated for the maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex efficacy was established in two maintenance trials in adults the effectiveness of quetiapine tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials see clinical studies 142 pediatric schizophrenia and bipolar i disorder are serious mental disorders however diagnosis can be challenging for pediatric schizophrenia symptom profiles can be variable and for bipolar i disorder patients may have variable patterns of periodicity of manic or mixed symptoms it is recommended that medication therapy for pediatric schizophrenia and bipolar i disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment medication treatment for both pediatric schizophrenia and bipolar i disorder is indicated as part of a total treatment program that often includes psychological educational and social interventions,3
when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intramuscular use of depomedrol sterile aqueous suspension is indicated as follows allergic states dermatologic diseases endocrine disorders gastrointestinal diseases hematologic disorders miscellaneous neoplastic diseases nervous system ophthalmic diseases renal diseases respiratory diseases rheumatic disorders see warnings depomedrol is indicated as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis of osteoarthritis depomedrol is indicated for intralesional use in alopecia areata discoid lupus erythematosus keloids localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus neurodermatitis and psoriatic plaques necrobiosis lipoidica diabeticorum,3
a large study evaluating the effect of epoprostenol on survival in nyha class iii and iv patients with congestive heart failure due to severe left ventricular systolic dysfunction was terminated after an interim analysis of 471 patients revealed a higher mortality in patients receiving epoprostenol plus conventional therapy than in those receiving conventional therapy alone the chronic use of veletri in patients with congestive heart failure due to severe left ventricular systolic dysfunction is therefore contraindicated some patients with pulmonary hypertension have developed pulmonary edema during dose initiation which may be associated with pulmonary venoocclusive disease veletri should not be used chronically in patients who develop pulmonary edema during dose initiation veletri is also contraindicated in patients with known hypersensitivity to the drug or to structurally related compounds congestive heart failure due to severe left ventricular systolic dysfunction 4 pulmonary edema 4 hypersensitivity to the drug or to structurally related compounds 4,1
nucynta tablets are contraindicated in patients with significant respiratory depression see warnings and precautions 52 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 55 known or suspected gastrointestinal obstruction including suspected paralytic ileus see warnings and precautions 510 hypersensitivity to tapentadol eg anaphylaxis angioedema or to any other ingredients of the product see adverse reactions 62 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days see drug interactions 7 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 hypersensitivity to tapentadol 4 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days 4,1
celecoxib is contraindicated in patients with known hypersensitivity to celecoxib aspirin or other nsaids in patients who have demonstrated allergictype reactions to sulfonamides in patients who have experienced asthma urticaria or allergictype reactions after taking aspirin or other nsaids severe anaphylactoid reactions to nsaids some of them fatal have been reported in such patients see warnings and precautions 57 513 for the treatment of perioperative pain in the setting of coronary artery bypass graft cabg surgery see warnings and precautions 51 in patients with active gastrointestinal bleeding see warnings and precautions 54 known hypersensitivity to celecoxib or sulfonamides 4 history of asthma urticaria or other allergictype reactions after taking aspirin or other nsaids 4 57 58 513 use during the perioperative period in the setting of coronary artery bypass graft cabg surgery 4 51 active gastrointestinal bleeding 4 54,1
risedronate sodium tablets are bisphosphonate indicated for 11 12 13 14 limitations of use 15 risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women see clinical studies 141 142 risedronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis risedronate sodium tablets are indicated for the treatment and prevention of glucocorticoidinduced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment daily dosage of greater than or equal to 75 mg of prednisone or equivalent for chronic diseases patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d risedronate sodium tablets are indicated for treatment of pagetss disease of bone in men and women the optimal duration of use has not been determined the safety and effectiveness of risedronate sodium tablets for the treatment of osteoporosis are based on clinical data of three years duration all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
mvasi is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer in combination with intravenous fluorouracilbased chemotherapy for first or secondline treatment 11 metastatic colorectal cancer in combination with fluoropyrimidineirinotecan or fluoropyrimidineoxaliplatinbased chemotherapy for secondline treatment in patients who have progressed on a firstline bevacizumab productcontaining regimen 11 limitations of use 11 unresectable locally advanced recurrent or metastatic nonsquamous nonsmall cell lung cancer in combination with carboplatin and paclitaxel for firstline treatment 12 recurrent glioblastoma in adults 13 metastatic renal cell carcinoma in combination with interferonalfa 14 persistent recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan 15 mvasi in combination with intravenous fluorouracilbased chemotherapy is indicated for the first or secondline treatment of patients with metastatic colorectal cancer mcrc mvasi in combination with fluoropyrimidineirinotecan or fluoropyrimidineoxaliplatinbased chemotherapy is indicated for the secondline treatment of patients with mcrc who have progressed on a firstline bevacizumab productcontaining regimen limitations of use s ee clinical studies 142 mvasi in combination with carboplatin and paclitaxel is indicated for the firstline treatment of patients with unresectable locally advanced recurrent or metastatic nonsquamous nonsmall cell lung cancer nsclc mvasi is indicated for the treatment of recurrent glioblastoma gbm in adults mvasi in combination with interferonalfa is indicated for the treatment of metastatic renal cell carcinoma mrcc mvasi in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for the treatment of patients with persistent recurrent or metastatic cervical cancer,3
mvasi is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer in combination with intravenous fluorouracilbased chemotherapy for first or secondline treatment 11 metastatic colorectal cancer in combination with fluoropyrimidineirinotecan or fluoropyrimidineoxaliplatinbased chemotherapy for secondline treatment in patients who have progressed on a firstline bevacizumab productcontaining regimen 11 limitations of use 11 unresectable locally advanced recurrent or metastatic nonsquamous nonsmall cell lung cancer in combination with carboplatin and paclitaxel for firstline treatment 12 recurrent glioblastoma in adults 13 metastatic renal cell carcinoma in combination with interferonalfa 14 persistent recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan 15 mvasi in combination with intravenous fluorouracilbased chemotherapy is indicated for the first or secondline treatment of patients with metastatic colorectal cancer mcrc mvasi in combination with fluoropyrimidineirinotecan or fluoropyrimidineoxaliplatinbased chemotherapy is indicated for the secondline treatment of patients with mcrc who have progressed on a firstline bevacizumab productcontaining regimen limitations of use s ee clinical studies 142 mvasi in combination with carboplatin and paclitaxel is indicated for the firstline treatment of patients with unresectable locally advanced recurrent or metastatic nonsquamous nonsmall cell lung cancer nsclc mvasi is indicated for the treatment of recurrent glioblastoma gbm in adults mvasi in combination with interferonalfa is indicated for the treatment of metastatic renal cell carcinoma mrcc mvasi in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for the treatment of patients with persistent recurrent or metastatic cervical cancer,3
moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms corynebacterium micrococcus luteus staphylococcus aureus staphylococcus epidermidis staphylococcus haemolyticus staphylococcus hominis staphylococcus warneri streptococcus pneumoniae streptococcus viridans acinetobacter lwoffii haemophilus influenza haemophilus parainfluenzae chlamydia trachomatis efficacy for this organism was studied in fewer than 10 infections moxifloxacin ophthalmic solution is a topical fluoroquinolone antiinfective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms corynebacterium micrococcus luteus staphylococcus aureus staphylococcus epidermidis staphylococcus haemolyticus staphylococcus hominis staphylococcus warneri streptococcus pneumoniae streptococcus viridans acinetobacter lwoffii haemophilus influenzae haemophilus parainfluenzae chlamydia trachomatis efficacy for this organism was studied in fewer than 10 infections 1,3
metronidazole tablets are indicated for the treatment of t vaginalis metronidazole tablets are indicated in the treatment of asymptomatic t vaginalis t vaginalis metronidazole tablets are indicated in the treatment of acute intestinal amebiasis amebic dysentery and amebic liver abscess in amebic liver abscess metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria indicated surgical procedures should be performed in conjunction with metronidazole tablets therapy in a mixed aerobic and anaerobic infection antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets intraabdominal infections bacteroides b fragilis b fragilis b distasonis b ovatus b thetaiotaomicron b vulgatus clostridium eubacterium peptococcus peptostreptococcus skin and skin structure infections bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium gynecologic infections including endometritis endomyometritis tuboovarian abscess and postsurgical vaginal cuff infection caused by bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium bacterial septicemia bacteroides b fragilis clostridium bone and joint infections bacteroides b fragilis central nervous system cns infections including meningitis and brain abscess caused by bacteroides b fragilis lower respiratory tract infections including pneumonia empyema and lung abscess caused by bacteroides b fragilis endocarditis bacteroides b fragilis to reduce the development of drugresistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
eletriptan hydrobromide is contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5hydroxytryptamine 1 1 see drug interactions 71 hypersensitivity to eletriptan hydrobromide angioedema and anaphylaxis seen see warnings and precautions 59 recent use ie within at least 72 hours of the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir see drug interactions 72 and clinical pharmacology 123 history of coronary artery disease cad or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or history or current evidence of hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 within 24 hours of treatment with another 5ht 1 4 hypersensitivity to eletriptan hydrobromide angioedema and anaphylaxis seen 4 within at least 72 hours of treatment with the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir 4,1
lamotrigine tablets is an antiepileptic drug aed indicated for epilepsy adjunctive therapy in patients 2 years of age 11 partial seizures primary generalized tonicclonic seizures generalized seizures of lennoxgastaut syndrome epilepsymonotherapy in patients 16 years of age 11 bipolar disorder in patients 18 years of age 12 adjunctive therapy lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients 2 years of age partial seizures primary generalized tonicclonic seizures generalized seizures of lennoxgastaut syndrome monotherapy lamotrigine tablets are indicated for conversion to monotherapy in adults 16 years of age with partial seizures who are receiving treatment with carbamazepine phenytoin phenobarbital primidone or valproate as the single antiepileptic drug aed safety and effectiveness of lamotrigine tablets have not been established 1 as initial monotherapy 2 for conversion to monotherapy from aeds other than carbamazepine phenytoin phenobarbital primidone or valproate or 3 for simultaneous conversion to monotherapy from 2 or more concomitant aeds lamotrigine tablets are indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in adults 18 years of age treated for acute mood episodes with standard therapy the effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established the effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebocontrolled trials in patients with bipolar i disorder as defined by dsmiv see clinical studies 142,3
pegintron is contraindicated in patients with known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis stevensjohnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product autoimmune hepatitis hepatic decompensation childpugh score greater than 6 class b and c in cirrhotic chc patients before or during treatment if pegintron is administered with ribavirin the contraindications to ribavirin also apply to this combination regimen refer to the ribavirin prescribing information for a list of contraindications for ribavirin pegintron combination treatment with ribavirin is contraindicated in women who are or may become pregnant and men whose female partners are pregnant advise pregnant women about the potential risk to a fetus see warnings and precautions 51 use in specific populations 81 83 patient counseling information 17 known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis stevensjohnson syndrome and toxic epidermal necrolysis to interferon alpha or any other product component 4 autoimmune hepatitis 4 hepatic decompensation childpugh score greater than 6 class b and c in cirrhotic chc patients before or during treatment 4 if pegintron is administered with ribavirin the contraindications to ribavirin also apply to this combination regimen 4,1
pegintron is contraindicated in patients with known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis stevensjohnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product autoimmune hepatitis hepatic decompensation childpugh score greater than 6 class b and c in cirrhotic chc patients before or during treatment if pegintron is administered with ribavirin the contraindications to ribavirin also apply to this combination regimen refer to the ribavirin prescribing information for a list of contraindications for ribavirin pegintron combination treatment with ribavirin is contraindicated in women who are or may become pregnant and men whose female partners are pregnant advise pregnant women about the potential risk to a fetus see warnings and precautions 51 use in specific populations 81 83 patient counseling information 17 known hypersensitivity reactions such as urticaria angioedema bronchoconstriction anaphylaxis stevensjohnson syndrome and toxic epidermal necrolysis to interferon alpha or any other product component 4 autoimmune hepatitis 4 hepatic decompensation childpugh score greater than 6 class b and c in cirrhotic chc patients before or during treatment 4 if pegintron is administered with ribavirin the contraindications to ribavirin also apply to this combination regimen 4,1
tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below septicemia in the pediatric patient and adult caused by p aeruginosa e coli klebsiella lower respiratory tract infections caused by p aeruginos klebsiella enterobacter serratia e coli s aureus serious centralnervoussystem infections meningitis caused by susceptible organisms intraabdominal infections including peritonitis caused by e coli klebsiella enterobacter skin bone and skinstructure infections caused by p aeruginosa proteus e coli klebsiella enterobacter s aureus complicated and recurrent urinary tract infections caused by p aeruginosa proteus e coli klebsiella enterobacter serratia s aureus providencia citrobacter aminoglycosides including tobramycin sulfate are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin if susceptibility tests show that the causative organisms are resistant to tobramycin other appropriate therapy should be instituted in patients in whom a serious lifethreatening gramnegative infection is suspected including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated treatment with tobramycin sulfate may be initiated before the results of susceptibility studies are obtained the decision to continue therapy with tobramycin should be based on the results of susceptibility studies the severity of the infection and the important additional concepts discussed in the warnings,3
glyburide tablets are contraindicated in patients with known hypersensitivity or allergy to the drug diabetic ketoacidosis with or without coma this condition should be treated with insulin type i diabetes mellitus as sole therapy the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin this warning is based on the study conducted by the university group diabetes program ugdp a longterm prospective clinical trial designed to evaluate the effectiveness of glucoselowering drugs in preventing or delaying vascular complications in patients with noninsulindependent diabetes the study involved 823 patients who were randomly assigned to one of four treatment groups diabetes ugdp reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide 15 grams per day although only one drug in the sulfonylurea class tolbutamide was included in this study it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class in view of their close similarities in mode of action and chemical structure,1
moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms corynebacterium micrococcus luteus staphylococcus aureus staphylococcus epidermidis staphylococcus haemolyticus staphylococcus hominis staphylococcus warneri streptococcus pneumoniae streptococcus viridans acinetobacter lwoffii haemophilus influenza haemophilus parainfluenzae chlamydia trachomatis efficacy for this organism was studied in fewer than 10 infections moxifloxacin ophthalmic solution is a topical fluoroquinolone antiinfective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms corynebacterium micrococcus luteus staphylococcus aureus staphylococcus epidermidis staphylococcus haemolyticus staphylococcus hominis staphylococcus warneri streptococcus pneumoniae streptococcus viridans acinetobacter lwoffii haemophilus influenzae haemophilus parainfluenzae chlamydia trachomatis efficacy for this organism was studied in fewer than 10 infections 1,3
darzalex is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy in combination with bortezomib melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are doublerefractory to a pi and an immunomodulatory agent darzalex is a cd38directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy in combination with bortezomib melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are doublerefractory to a pi and an immunomodulatory agent 1,3
ranitidine is indicated in shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeks concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
minocycline hydrochloride capsules usp are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae mycoplasma pneumoniae chlamydia trachomatis chlamydophila psittaci chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum chlamydia trachomatis borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis klebsiella granulomatis minocycline is indicated for the treatment of infections caused by the following gramnegative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug enterobacter aerogenes shigella acinetobacter haemophilus influenzae klebsiella minocycline hydrochloride capsules usp are indicated for the treatment of infections caused by the following grampositive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug streptococcus pneumoniae staphylococcus aureus when penicillin is contraindicated minocycline is an alternative drug in the treatment of the following infections neisseria gonorrhoeae neisseria gonorrhoeae treponema pallidum pallidum treponema pallidum pertenue listeria monocytogenes bacillus anthracis fusobacterium fusiforme actinomyces israelii clostridium in acute intestinal amebiasis acne neisseria meningitidis mycobacterium marinum,3
indomethacin for injection is contraindicated in neonates with proven or suspected infection that is untreated who are bleeding especially those with active intracranial hemorrhage or gastrointestinal bleeding with thrombocytopenia or coagulation defects with or who are suspected of having necrotizing enterocolitis with significant impairment of renal function with congenital heart disease in whom patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow eg pulmonary atresia severe tetralogy of fallot severe coarctation of the aorta indomethacin for injection is contraindicated in neonates with proven or suspected infection that is untreated who are bleeding especially those with active intracranial hemorrhage or gastrointestinal bleeding with thrombocytopenia or coagulation defects suspected of having necrotizing enterocolitis with significant impairment of renal function with congenital heart disease in whom patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow 4,1
metadate cd is contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms metadate cd is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product metadate cd contains sucrose therefore patients with rare hereditary problems of fructose intolerance glucosegalactose malabsorption or sucraseisomaltase insufficiency should not take this medicine metadate cd is contraindicated in patients with glaucoma metadate cd is contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions metadate cd is contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor hypertensive crises may result metadate cd is contraindicated in patients with severe hypertension angina pectoris cardiac arrhythmias heart failure recent myocardial infarction hyperthyroidism or thyrotoxicosis see warnings there is a risk of sudden blood pressure increase during surgery if surgery is planned metadate cd should not be taken on the day of the surgery,1
ranitidine is indicated in 1 shortterm treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebocontrolled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions eg zollingerellison syndrome and systemic mastocytosis 4 shortterm treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebocontrolled studies have been carried out for 1 year 6 treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily 7 treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebocontrolled trials have been carried out for 48 weeks concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis,3
indications and usage avelox tablets and iv are indicated for the treatment of adults 18 years of age with infections caused by susceptible strains of the designated microorganisms in the conditions listed below see dosage and administration precautions geriatric use acute bacterial sinusitis streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis acute bacterial exacerbation of chronic bronchitis streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae staphylococcus aureus moraxella catarrhalis community acquired pneumonia streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis staphylococcus aureus klebsiella pneumoniae mycoplasma pneumoniae chlamydia pneumoniae mdrsp multidrug resistant streptococcus pneumoniae s pneumoniae nd uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes complicated intraabdominal infections escherichia coli bacteroides fragilis streptococcus anginosus streptococcus constellatus enterococcus faecalis proteus mirabilis clostridium perfringens bacteroides thetaiotaomicron peptostreptococcus species complicated skin and skin structure infections staphylococcus aureus escherichia coli klebsiella pneumoniae enterobacter cloacae clinical studies appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin therapy with avelox may be initiated before results of these tests are known once results become available appropriate therapy should be continued to reduce the development of drugresistant bacteria and maintain the effectiveness of avelox and other antibacterial drugs avelox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
indications and usage avelox tablets and iv are indicated for the treatment of adults 18 years of age with infections caused by susceptible strains of the designated microorganisms in the conditions listed below see dosage and administration precautions geriatric use acute bacterial sinusitis streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis acute bacterial exacerbation of chronic bronchitis streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae staphylococcus aureus moraxella catarrhalis community acquired pneumonia streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis staphylococcus aureus klebsiella pneumoniae mycoplasma pneumoniae chlamydia pneumoniae mdrsp multidrug resistant streptococcus pneumoniae s pneumoniae nd uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes complicated intraabdominal infections escherichia coli bacteroides fragilis streptococcus anginosus streptococcus constellatus enterococcus faecalis proteus mirabilis clostridium perfringens bacteroides thetaiotaomicron peptostreptococcus species complicated skin and skin structure infections staphylococcus aureus escherichia coli klebsiella pneumoniae enterobacter cloacae clinical studies appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin therapy with avelox may be initiated before results of these tests are known once results become available appropriate therapy should be continued to reduce the development of drugresistant bacteria and maintain the effectiveness of avelox and other antibacterial drugs avelox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
caverject is contraindicated in men who have a known hypersensitivity to the drug see adverse reactions 61 in men who have conditions that predispose them to priapism such as sickle cell anemia or sickle cell trait multiple myeloma or leukemia see warnings and precautions 51 for the treatment of erectile dysfunction in men with fibrotic conditions of the penis such as anatomical deformation angulation cavernosal fibrosis or peyronies disease see warnings and precautions 52 in men with penile implants men who have known hypersensitivity to the drug 4 men who have conditions that predispose them to priapism such as sickle cell anemia or sickle cell trait multiple myeloma or leukemia 4 treatment of erectile dysfunction in men with fibrotic conditions of the penis such as anatomical deformation angulation cavernosal fibrosis or peyronies disease 4 men with penile implants 4,1
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11 adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastatic limitation of use 12 adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13 adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14 afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15 afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16 afinitor r afinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of use see clinical studies 142 afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib afinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgery afinitor and afinitor disperz r afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11 adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastatic limitation of use 12 adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13 adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14 afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15 afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16 afinitor r afinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of use see clinical studies 142 afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib afinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgery afinitor and afinitor disperz r afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11 adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastatic limitation of use 12 adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13 adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14 afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15 afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16 afinitor r afinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of use see clinical studies 142 afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib afinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgery afinitor and afinitor disperz r afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
afinitor is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptorpositive her2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole 11 adults with progressive neuroendocrine tumors of pancreatic origin pnet and adults with progressive welldifferentiated nonfunctional neuroendocrine tumors net of gastrointestinal gi or lung origin that are unresectable locally advanced or metastatic limitation of use 12 adults with advanced renal cell carcinoma rcc after failure of treatment with sunitinib or sorafenib 13 adults with renal angiomyolipoma and tuberous sclerosis complex tsc not requiring immediate surgery 14 afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma sega that requires therapeutic intervention but cannot be curatively resected 15 afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures 16 afinitor r afinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin pnet with unresectable locally advanced or metastatic disease afinitor is indicated for the treatment of adult patients with progressive welldifferentiated nonfunctional net of gastrointestinal gi or lung origin with unresectable locally advanced or metastatic disease limitation of use see clinical studies 142 afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib afinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc not requiring immediate surgery afinitor and afinitor disperz r afinitor disperz is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tscassociated partialonset seizures,3
fragmin is contraindicated in patients with active major bleeding patients with a history of heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombosis patients with prior hypersensitivity to dalteparin sodium eg pruritis rash anaphylactic reactions see adverse reactions 61 patients undergoing epiduralneuraxial anesthesia do not administer fragmin see boxed warning warnings and precautions 51 as a treatment for unstable angina and nonqwave mi for prolonged vte prophylaxis patients with prior hypersensitivity to heparin or pork products active major bleeding 4 history of heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombosis 4 hypersensitivity to dalteparin sodium 4 61 in patients undergoing epiduralneuraxial anesthesia do not administer fragmin 51 as a treatment for unstable angina and nonqwave mi for prolonged vte prophylaxis 4 hypersensitivity to heparin or pork products 4,1
fragmin is contraindicated in patients with active major bleeding patients with a history of heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombosis patients with prior hypersensitivity to dalteparin sodium eg pruritis rash anaphylactic reactions see adverse reactions 61 patients undergoing epiduralneuraxial anesthesia do not administer fragmin see boxed warning warnings and precautions 51 as a treatment for unstable angina and nonqwave mi for prolonged vte prophylaxis patients with prior hypersensitivity to heparin or pork products active major bleeding 4 history of heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombosis 4 hypersensitivity to dalteparin sodium 4 61 in patients undergoing epiduralneuraxial anesthesia do not administer fragmin 51 as a treatment for unstable angina and nonqwave mi for prolonged vte prophylaxis 4 hypersensitivity to heparin or pork products 4,1
sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquineresistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamidesensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections twenty mg per 100 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level,3
clindamycin injection usp is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria clindamycin injection usp products are also indicated in the treatment of serious infections due to susceptible strains of streptococci pneumococci and staphylococci its use should be reserved for penicillinallergic patients or other patients for whom in the judgment of the physician a penicillin is inappropriate because of the risk of antibioticassociated pseudomembranous colitis as described in the boxed warning bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin indicated surgical procedures should be performed in conjunction with antibiotic therapy clindamycin injection usp is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below lower respiratory tract infections including pneumonia empyema and lung abscess caused by anaerobes streptococcus pneumonia e faecalis staphylococcus aureus skin and skin structure infections caused by streptococcus pyogenes staphylococcus aureus gynecological infections including endometritis nongonococcal tuboovarian abscess caused by susceptible anaerobic organisms septicemia caused by staphylococcus aureus enterococcus faecalis bone and joint infections including acute hematogenous osteomyelitis caused by staphylococcus aureus to reduce the development of drugresistant bacteria and maintain the effectiveness of clindamycin injection usp and other antibacterial drugs clindamycin injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
euthyrox is lthyroxine t4 indicated in pediatric and adult patients for hypothyroidism as replacement in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism 1 pituitary thyrotropin thyroidstimulating hormone tsh suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer 1 limitations of use not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients 1 not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis 1 hypothyroidism euthyrox is indicated in pediatric and adult patients as a replacement therapy in primary thyroidal secondary pituitary and tertiary hypothalamic congenital or acquired hypothyroidism pituitary thyrotropin thyroidstimulating hormone tsh suppression euthyrox is indicated in pediatric and adult patients as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer limitations of use euthyrox is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodinesufficient patients as there are no clinical benefits and overtreatment with euthyrox may induce hyperthyroidism see warnings and precautions 54 euthyrox is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis,3
morphine sulfate oral solution is contraindicated in patients with significant respiratory depression see warnings and precautions 54 acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see warnings and precautions 57 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days see warnings and precautions 58 7 known or suspected gastrointestinal obstruction including paralytic ileus see warnings and precautions 512 hypersensitivity to morphine eg anaphylaxis see adverse reactions 6 significant respiratory depression 4 acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment 4 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days 4 known or suspected gastrointestinal obstruction including paralytic ileus 4 hypersensitivity to morphine 4,1
since no drug is innocuous strict attention should be paid to the indications and contraindications particularly when selecting drugs for chronic longterm use colestid granules and flavored colestid granules are indicated as adjunctive therapy to diet for the reduction of elevated serum total and lowdensity lipoprotein ldl cholesterol in patients with primary hypercholesterolemia elevated low density lipoproteins ldl cholesterol who do not respond adequately to diet generally colestid and flavored colestid have no clinically significant effect on serum triglycerides but with its use triglyceride levels may be raised in some patients therapy with lipidaltering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia treatment should begin and continue with dietary therapy see ncep guidelines according to the ncep guidelines the goal of treatment is to lower ldlc and ldlc is to be used to initiate and assess treatment response only if ldlc levels are not available should the totalc be used to monitor therapy the ncep treatment guidelines are shown below ldlcholesterol definite atherosclerotic disease coronary heart disease or peripheral vascular disease including symptomatic carotid artery disease two or more other risk factors other risk factors for coronary heart disease chd include age males 45 years females 55 years or premature menopause without estrogen replacement therapy family history of premature chd current cigarette smoking hypertension confirmed hdlc 35 mgdl 091 mmoll and diabetes mellitus subtract one risk factor if hdlc is 60 mgdl 16 mmoll initiation level goal no no 190 160 no yes 160 130 yes yes or no 130 100,3
rizatriptan benzoate tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51 coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 history of stroke or transient ischemic attack tia s warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75 clinical pharmacology 123 hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets angioedema and anaphylaxis seen see adverse reactions 62 history of ischemic heart disease or coronary artery vasospasm 4 history of stroke or transient ischemic attack 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 hemiplegic or basilar migraine 4 maoa inhibitor used in the past 2 weeks 4 hypersensitivity to rizatriptan benzoate 4,1
xgeva is a rank ligand rankl inhibitor indicated for prevention of skeletalrelated events in patients with multiple myeloma and in patients with bone metastases from solid tumors 11 treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity 12 143 treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy 13 xgeva is indicated for the prevention of skeletalrelated events in patients with multiple myeloma and in patients with bone metastases from solid tumors xgeva is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity see clinical trials 142 xgeva is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy,3
xgeva is a rank ligand rankl inhibitor indicated for prevention of skeletalrelated events in patients with multiple myeloma and in patients with bone metastases from solid tumors 11 treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity 12 143 treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy 13 xgeva is indicated for the prevention of skeletalrelated events in patients with multiple myeloma and in patients with bone metastases from solid tumors xgeva is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity see clinical trials 142 xgeva is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy,3
bentyl is contraindicated in infants less than 6 months of age see use in specific populations 84 see use in specific populations 83 unstable cardiovascular status in acute hemorrhage myasthenia gravis see warnings and precautions 54 glaucoma see adverse reactions 63 and drug interactions 71 obstructive uropathy see warnings and precautions 58 obstructive disease of the gastrointestinal tract see warnings and precautions 55 severe ulcerative colitis see warnings and precautions 57 reflux esophagitis infants less than 6 months of age 4 glaucoma 4 nursing mothers 4 obstructive uropathy 4 unstable cardiovascular status in acute hemorrhage 4 obstructive disease of the gastrointestinal tract 4 myasthenia gravis 4 severe ulcerative colitis 4 reflux esophagitis 4,1
moxatag is a penicillinclass antibacterial indicated for the treatment of tonsillitis andor pharyngitis secondary to streptococcus pyogenes 1 tonsillitis andor pharyngitis moxatag is a penicillinclass antibacterial indicated for the treatment of tonsillitis andor pharyngitis secondary to streptococcus pyogenes s pyogenes to reduce the development of drugresistant bacteria and maintain the effectiveness of moxatag and other antibacterial drugs moxatag should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
the concomitant use of tybost with atazanavir or darunavir and the following drugs is contraindicated due to the potential for serious andor lifethreatening events or loss of therapeutic effect see drug interactions 73 clinical pharmacology 123 alpha 1adrenoreceptor antagonist alfuzosin antianginal ranolazine antiarrhythmic dronedarone anticonvulsants carbamazepine phenobarbital phenytoin antigout colchicine antimycobacterial rifampin antineoplastics irinotecan these contraindications apply only to tybost coadministered with atazanavir antipsychotics lurasidone pimozide ergot derivatives dihydroergotamine ergotamine methylergonovine gi motility agent cisapride herbal products st johns wort hypericum perforatum hormonal contraceptives drospirenone ethinyl estradiol lipidmodifying agents lomitapide lovastatin simvastatin nonnucleoside reverse transcriptase inhibitor nevirapine phosphodiesterase5 pde5 inhibitor sildenafil when administered as revatio r protease inhibitor indinavir sedativehypnotics triazolam orally administered midazolam coadministration with certain drugs for which altered plasma concentrations are associated with serious andor lifethreatening events or loss of therapeutic effect 4,1
olmesartan medoxomil tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets olmesartan medoxomil tablets are an angiotensin ii receptor blocker arb indicated for the treatment of hypertension alone or with other antihypertensive agents to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1,3
sotalol hydrochloride is contraindicated in patients with sinus bradycardia sick sinus syndrome second and third degree av block unless a functioning pacemaker is present congenital or acquired long qt syndromes cardiogenic shock or decompensated heart failure serum potassium 4 meql bronchial asthma or related bronchospastic conditions hypersensitivity to sotalol for the treatment of afibafl sotalol hydrochloride is also contraindicated in patients with baseline qt interval 450 ms creatinine clearance 40 mlmin for the treatment of afibafl or ventricular arrhythmias sinus bradycardia 2 nd rd 4 congenital or acquired long qt syndrome 4 serum potassium 4 meql 4 cardiogenic shock decompensated heart failure 4 bronchial asthma or related bronchospastic conditions 4 hypersensitivity to sotalol 4 for the treatment of afibafl also contraindicated for qt interval 450 ms 4 creatine clearance 40 mlmin 4,1
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections please note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin gentamicin sulfate ointment may be used in children over one year of age as well as in adults,3
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections please note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin gentamicin sulfate ointment may be used in children over one year of age as well as in adults,3
spironolactone tablets are indicated in the management of primary hyperaldosteronism establishing the diagnosis of primary hyperaldosteronism by therapeutic trial shortterm preoperative treatment of patients with primary hyperaldosteronism longterm maintenance therapy for patients with discrete aldosteroneproducing adrenal adenomas who are judged to be poor operative risks or who decline surgery longterm maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia idiopathic hyperaldosteronism edematous conditions congestive heart failure cirrhosis of the liver accompanied by edema andor ascites nephrotic syndrome essential hypertension usually in combination with other drugs spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate hypokalemia severe heart failure nyha class iii iv usage in pregnancy precautions pregnancy,3
diazepam tablets usp are indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic in acute alcohol withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor impending or acute delirium tremens and hallucinosis diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology such as inflammation of the muscles or joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis and stiffman syndrome oral diazepam may be used adjunctively in convulsive disorders although it has not proved useful as the sole therapy the effectiveness of diazepam in longterm use that is more than 4 months has not been assessed by systematic clinical studies the physician should periodically reassess the usefulness of the drug for the individual patient,3
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate fluvastatin capsules are an hmgcoa reductase inhibitor statin indicated as an adjunctive therapy to diet to 11 11 12 12 limitations of use 13 fluvastatin capsules are indicated the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cvd is summarized below category totalc mgdl ldlc mgdl acceptable 170 110 borderline 170199 110129 high 200 130 children treated with fluvastatin in adolescence should be reevaluated in adulthood and appropriate changes made to their cholesterollowering regimen to achieve adult treatment goals in patients with clinically evident chd fluvastatin capsules are indicated to fluvastatin capsules have not been studied in conditions where the major abnormality is elevation of chylomicrons vldl or idl ie hyperlipoproteinemia types i iii iv or v,3
sumatriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke s warnings and precautions 54 peripheral vascular disease warnings and precautions 55 ischemic bowel disease warnings and precautions 55 uncontrolled hypertension warnings and precautions 58 recent use ie within 24 hours of ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide or another 5hydroxytryptamine 1 1 see drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent within 2 weeks use of an maoa inhibitor see drug interactions 72 clinical pharmacology 123 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen see warnings and precautions 59 severe hepatic impairment see use in specific populations 86 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 concurrent or recent past 2 weeks use of monoamine oxidasea inhibitor 4 hypersensitivity to sumatriptan tablets angioedema and anaphylaxis seen 4 severe hepatic impairment 4,1
enter section text here tindamax is a nitroimidazole antimicrobial indicated for trichomoniasis 11 giardiasis in patients age 3 and older 12 amebiasis in patients age 3 and older 13 bacterial vaginosis in nonpregnant adult women 14 81 tinidazole is indicated for the treatment of trichomoniasis caused by trichomonas vaginalis see clinical studies 141 tinidazole is indicated for the treatment of giardiasis caused by giardia duodenalis g lamblia see clinical studies 142 tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by entamoeba histolytica see clinical studies 143 144 tinidazole is indicated for the treatment of bacterial vaginosis formerly referred to as haemophilus gardnerella see use in specific populations 81 145 other pathogens commonly associated with vulvovaginitis such as trichomonas vaginalis chlamydia trachomatis neisseria gonorrhoeae candida albicans herpes simplex to reduce the development of drugresistant bacteria and maintain the effectiveness of tindamax and other antibacterial drugs tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
inspra is an aldosterone antagonist indicated for improving survival of stable patients with lv systolic dysfunction lvef 40 and chf after an acute myocardial infarction 12 hypertension alone or combined with other agents 13 serum potassium levels should be measured before initiating inspra therapy and inspra should not be prescribed if serum potassium is 55 meql see contraindications 4 inspra is indicated to improve survival of stable patients with left ventricular lv systolic dysfunction ejection fraction 40 and clinical evidence of congestive heart failure chf after an acute myocardial infarction mi inspra is indicated for the treatment of hypertension inspra may be used alone or in combination with other antihypertensive agents,3
clindamycin injection usp is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria clindamycin injection usp is also indicated in the treatment of serious infections due to susceptible strains of streptococci pneumococci and staphylococci its use should be reserved for penicillinallergic patients or other patients for whom in the judgment of the physician a penicillin is inappropriate because of the risk of antibioticassociated pseudomembranous colitis as described in the boxed warning bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin indicated surgical procedures should be performed in conjunction with antibiotic therapy clindamycin injection usp is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below lower respiratory tract infections including pneumonia empyema and lung abscess caused by anaerobes streptococcus pneumoniae e faecalis staphylococcus aureus skin and skin structure infections caused by streptococcus pyogenes staphylococcus aureus gynecological infections including endometritis nongonococcal tuboovarian abscess pelvic cellulitis and postsurgical vaginal cuff infection caused by susceptible anaerobes intraabdominal infections including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms septicemia caused by staphylococcus aureus enterococcus faecalis bone and joint infections including acute hematogenous osteomyelitis caused by staphylococcus aureus to reduce the development of drugresistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
zoledronic acid injection is a bisphosphonate indicated for the treatment of hypercalcemia of malignancy 11 patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy prostate cancer should have progressed after treatment with at least one hormonal therapy 12 limitations of use the safety and efficacy of zoledronic acid injection has not been established for use in hyperparathyroidism or nontumorrelated hypercalcemia 13 zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumincorrected calcium cca of greater than or equal to 12 mgdl 3 mmoll using the formula cca in mgdlca in mgdl 08 4 gdl patient albumin gdl zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy prostate cancer should have progressed after treatment with at least one hormonal therapy limitations of use the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions have not been established,3
see warnings and precautions 53 bupropion hydrochloride extendedrelease tablets xl are contraindicated in patients undergoing abrupt discontinuation of alcohol benzodiazepines barbiturates and antiepileptic drugs see warnings and precautions 53 73 the use of maois intended to treat psychiatric disorders concomitantly with bupropion hydrochloride extendedrelease tablets xl or within 14 days of discontinuing treatment with bupropion hydrochloride extendedrelease tablets xl are contraindicated there is an increased risk of hypertensive reactions when bupropion hydrochloride extendedrelease tablets xl are used concomitantly with maois the use of bupropion hydrochloride extendedrelease tablets xl within 14 days of discontinuing treatment with an maoi is also contraindicated starting bupropion hydrochloride extendedrelease tablets xl in a patient treated with reversible maois such as linezolid or intravenous methylene blue is contraindicated see dosage and administration 29 54 76 bupropion hydrochloride extendedrelease tablets xl are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extendedrelease tablets xl anaphylactoidanaphylactic reactions and stevensjohnson syndrome have been reported see warnings and precautions 58 4 53 4 53 4 53 4 76 4 58,1
meropenem for injection iv is a penem antibacterial indicated for the treatment of 11 12 13 to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection iv and other antibacterial drugs meropenem for injection iv should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria meropenem for injection iv is indicated for the treatment of complicated skin and skin structure infections csssi due to staphylococcus aureus streptococcus pyogenes streptococcus agalactiae enterococcus faecalis pseudomonas aeruginosa escherichia coli proteus mirabilis bacteroides fragilis peptostreptococcus meropenem for injection iv is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci escherichia coli klebsiella pneumoniae pseudomonas aeruginosa bacteroides fragilis b thetaiotaomicron peptostreptococcus meropenem for injection iv is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae neisseria meningitidis and penicillinsusceptible isolates of streptococcus pneumoniae meropenem for injection iv has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis to reduce the development of drugresistant bacteria and maintain the effectiveness of meropenem for injection iv and other antibacterial drugs meropenem for injectioniv should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
tolbutamide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulindependent diabetes mellitus type ii whose hyperglycemia cannot be controlled by diet alone in initiating treatment for noninsulindependent diabetes diet should be emphasized as the primary form of treatment caloric restriction and weight loss are essential in the obese diabetic patient proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia the importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible if this treatment program fails to reduce symptoms andor blood glucose the use of an oral sulfonylurea or insulin should be considered use of tolbutamide tablets must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint furthermore loss of blood glucose control on diet alone may be transient thus requiring only shortterm administration of tolbutamide tablets during maintenance programs tolbutamide tablets should be discontinued if satisfactory lowering of blood glucose is no longer achieved judgments should be based on regular clinical and laboratory evaluations in considering the use of tolbutamide tablets in asymptomatic patients it should be recognized that controlling the blood glucose in noninsulin dependent diabetes has not been definitely established to be effective in preventing the longterm cardiovascular or neural complications of diabetes,3
lexiva is contraindicated in patients with previously demonstrated clinically significant hypersensitivity eg stevensjohnson syndrome to any of the components of this product or to amprenavir when coadministered with drugs that are highly dependent on cyp3a4 for clearance and for which elevated plasma concentrations are associated with serious andor lifethreatening events table 1 table 1 drugs contraindicated with lexiva drug classdrug name clinical comment antiarrhythmics potential ritonavir antimycobacterials a may lead to loss of virologic response and possible resistance to lexiva or to the class of protease inhibitors ergot derivatives potential gi motility agents potential herbal products hypericum perforatum may lead to loss of virologic response and possible resistance to lexiva or to the class of protease inhibitors hmg coreductase inhibitors potential neuroleptic potential nonnucleoside reverse transcriptase inhibitor a may lead to loss of virologic response and possible resistance to delavirdine sedativehypnotics potential a see clinical pharmacology 123 tables 10 11 12 or 13 for magnitude of interaction when coadministered with ritonavir in patients receiving the antiarrhythmic agents flecainide and propafenone if lexiva is coadministered with ritonavir reference should be made to the full prescribing information for ritonavir for additional contraindications hypersensitivity to lexiva or amprenavir eg stevensjohnson syndrome 4 drugs highly dependent on cyp3a4 for clearance and for which elevated plasma levels may result in serious andor lifethreatening events 4 review ritonavir contraindications when used in combination 4,1
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of leukemias and lymphomas in adults to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of leukemias and lymphomas in adults to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of leukemias and lymphomas in adults to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,2
xarelto is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 11 for the treatment of deep vein thrombosis dvt 12 for the treatment of pulmonary embolism pe 13 for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months 14 for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery 15 in combination with aspirin to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad 16 xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation there are limited data on the relative effectiveness of xarelto and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is wellcontrolled see clinical studies 141 xarelto is indicated for the treatment of deep vein thrombosis dvt xarelto is indicated for the treatment of pulmonary embolism pe xarelto is indicated for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months xarelto is indicated for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery xarelto in combination with aspirin is indicated to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad,3
xarelto is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 11 for the treatment of deep vein thrombosis dvt 12 for the treatment of pulmonary embolism pe 13 for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months 14 for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery 15 in combination with aspirin to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad 16 xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation there are limited data on the relative effectiveness of xarelto and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is wellcontrolled see clinical studies 141 xarelto is indicated for the treatment of deep vein thrombosis dvt xarelto is indicated for the treatment of pulmonary embolism pe xarelto is indicated for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months xarelto is indicated for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery xarelto in combination with aspirin is indicated to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad,3
dopamine hydrochloride usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction trauma endotoxic septicemia openheart surgery renal failure and chronic cardiac decompensation as in congestive failure patients most likely to respond adequately to dopamine hydrochloride usp are those in whom physiological parameters such as urine flow myocardial function and blood pressure have not undergone profound deterioration multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride usp the better the prognosis where appropriate blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride usp poor perfusion of vital organs low cardiac output redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow in many instances the renal fraction of the total cardiac output has been found to increase increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol hypotension,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefuroxime axetil tablets usp and other antibacterial drugs cefuroxime axetil tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy note cefuroxime axetil tablets usp and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligrampermilligram basis see clinical pharmacology cefuroxime axetil tablets usp cefuroxime axetil tablets usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below pharyngitistonsillitis caused by streptococcus pyogenes acute bacterial otitis media caused by streptococcus pneumoniae haemophilus influenzae including betalactamaseproducing strains moraxella catarrhalis including betalactamaseproducing strains or streptococcus pyogenes acute bacterial maxillary sinusitis caused by streptococcus pneumoniae or haemophilus influenzae nonbetalactamaseproducing strains only see clinical studies acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by streptococcus pneumoniae haemophilus influenzae betalactamase negative strains or haemophilus parainfluenzae betalactamase negative strains see dosage and administration clinical studies uncomplicated skin and skinstructure infections caused by staphylococcus aureus including betalactamaseproducing strains or streptococcus pyogenes uncomplicated urinary tract infections caused by escherichia coli or klebsiella pneumoniae uncomplicated gonorrhea urethral and endocervical caused by penicillinaseproducing and nonpenicillinaseproducing strains of neisseria gonorrhoeae and uncomplicated gonorrhea rectal in females caused by nonpenicillinaseproducing strains of neisseria gonorrhoeae early lyme disease erythema migrans caused by borrelia burgdorferi,3
frovatriptan succinate tablets are contraindicated in patients with ischemic coronary artery disease cad eg angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 71 72 hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen see warnings and precautions 59 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of treatment with another 5ht 1 4 hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen 4,1
frovatriptan succinate tablets are contraindicated in patients with ischemic coronary artery disease cad eg angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 71 72 hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen see warnings and precautions 59 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of treatment with another 5ht 1 4 hypersensitivity to frovatriptan succinate angioedema and anaphylaxis seen 4,1
valacyclovir hydrochloride is a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hivinfected patients reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis chickenpox limitations of use 13 the efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis see clinical studies 144 the efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 2 years of age or 18 years of age with chickenpox patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection,3
micardis is an angiotensin ii receptor blocker arb indicated for treatment of hypertension 11 cardiovascular cv risk reduction in patients unable to take ace inhibitors 12 micardis is indicated for the treatment of hypertension it may be used alone or in combination with other antihypertensive agents see clinical studies 141 micardis is indicated for reduction of the risk of myocardial infarction stroke or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ace inhibitors high risk for cardiovascular events can be evidenced by a history of coronary artery disease peripheral arterial disease stroke transient ischemic attack or highrisk diabetes insulindependent or noninsulin dependent with evidence of endorgan damage see clinical studies 142 see clinical studies 142 studies of telmisartan in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ace inhibitor to which it was compared consider using the ace inhibitor first and if it is stopped for cough only consider retrying the ace inhibitor after the cough resolves use of telmisartan with an ace inhibitor is not recommended see warnings and precautions 56,3
gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure a history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51 a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4 history of mobitz type ii 2 nd rd 4 baseline qtc interval 500 msec 4 cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4 hypersensitivity to fingolimod or its excipients 4,1
gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure a history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51 a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4 history of mobitz type ii 2 nd rd 4 baseline qtc interval 500 msec 4 cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4 hypersensitivity to fingolimod or its excipients 4,1
gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure a history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51 a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4 history of mobitz type ii 2 nd rd 4 baseline qtc interval 500 msec 4 cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4 hypersensitivity to fingolimod or its excipients 4,1
gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure a history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51 a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4 history of mobitz type ii 2 nd rd 4 baseline qtc interval 500 msec 4 cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4 hypersensitivity to fingolimod or its excipients 4,0
gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure a history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51 a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4 history of mobitz type ii 2 nd rd 4 baseline qtc interval 500 msec 4 cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4 hypersensitivity to fingolimod or its excipients 4,0
entyvio is an integrin receptor antagonist indicated for adult ulcerative colitis uc 11 adult patients with moderately to severely active uc who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids inducing and maintaining clinical response inducing and maintaining clinical remission improving endoscopic appearance of the mucosa achieving corticosteroidfree remission adult crohns disease cd 12 adult patients with moderately to severely active cd who have had an inadequate response with lost response to or were intolerant to a tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids achieving clinical response achieving clinical remission achieving corticosteroidfree remission entyvio vedolizumab is indicated for inducing and maintaining clinical response inducing and maintaining clinical remission improving the endoscopic appearance of the mucosa and achieving corticosteroidfree remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids entyvio vedolizumab is indicated for achieving clinical response achieving clinical remission and achieving corticosteroidfree remission in adult patients with moderately to severely active crohns disease who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids,3
bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactinsecreting adenomas reduction tumor size bromocriptine mesylate tablets and capsules therapy is indicated in the treatment of acromegaly bromocriptine therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 50 or more in approximately 12 of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine offers potential benefit before the effects of irradiation are manifested bromocriptine mesylate tablets or capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinsons disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence andor severity of adverse reactions associated with longterm levodopa therapy such as abnormal involuntary movements eg dyskinesias and the marked swings in motor function onoff phenomenon continued efficacy of bromocriptine therapy during treatment of more than 2 years has not been established data are insufficient to evaluate potential benefit from treating newly diagnosed parkinsons disease with bromocriptine studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptinetreated patients than in levodopacarbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine therapy,3
to understand fully the indication for this product please read the entire indications and usage section of the labeling ciclopirox topical solution 8 nail lacquer as a component of a comprehensive management program is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement due to trichophyton rubrum no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis therefore the concomitant use of 8 ciclopirox topical solution and systemic antifungal agents for onychomycosis is not recommended ciclopirox topical solution 8 nail lacquer should be used only under medical supervision as described above the effectiveness and safety of ciclopirox topical solution 8 nail lacquer in the following populations has not been studied the clinical trials with use of ciclopirox topical solution 8 nail lacquer excluded patients who were pregnant or nursing planned to become pregnant had a history of immunosuppression eg extensive persistent or unusual distribution of dermatomycoses extensive seborrheic dermatitis recent or recurring herpes zoster or persistent herpes simplex were hiv seropositive received organ transplant required medication to control epilepsy were insulin dependent diabetics or had diabetic neuropathy patients with severe plantar moccasin tinea pedis were also excluded the safety and efficacy of using ciclopirox topical solution 8 nail lacquer daily for greater than 48 weeks have not been established,1
to understand fully the indication for this product please read the entire indications and usage section of the labeling ciclopirox topical solution 8 nail lacquer as a component of a comprehensive management program is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement due to trichophyton rubrum no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis therefore the concomitant use of 8 ciclopirox topical solution and systemic antifungal agents for onychomycosis is not recommended ciclopirox topical solution 8 nail lacquer should be used only under medical supervision as described above the effectiveness and safety of ciclopirox topical solution 8 nail lacquer in the following populations has not been studied the clinical trials with use of ciclopirox topical solution 8 nail lacquer excluded patients who were pregnant or nursing planned to become pregnant had a history of immunosuppression eg extensive persistent or unusual distribution of dermatomycoses extensive seborrheic dermatitis recent or recurring herpes zoster or persistent herpes simplex were hiv seropositive received organ transplant required medication to control epilepsy were insulin dependent diabetics or had diabetic neuropathy patients with severe plantar moccasin tinea pedis were also excluded the safety and efficacy of using ciclopirox topical solution 8 nail lacquer daily for greater than 48 weeks have not been established,1
hypersensitivity to any component of this product these adverse reactions may manifest as an anaphylactic reaction urticaria facial andor tongue swelling or pruritus discontinue cyclobenzaprine hydrochloride extendedrelease capsules if a hypersensitivity reaction is suspected concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine or structurally similar tricyclic antidepressants concomitantly with mao inhibitor drugs during the acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure hyperthyroidism hypersensitivity to any component of this product 4 concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation 4 during acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure 4 hyperthyroidism 4,1
levothyroxine sodium is used for the following indications hypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiter pituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic iymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer,3
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections please note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate cream is recommended for wet oozing primary infections and greasy secondary infections such as pustular acne or infected seborrheic dermatitis if a waterwashable preparation is desired the cream is preferable gentamicin sulfate cream has been used successfully in infants over one year of age as well as in adults and children,3
hypersensitivity to any component of this product these adverse reactions may manifest as an anaphylactic reaction urticaria facial andor tongue swelling or pruritus discontinue cyclobenzaprine hydrochloride extendedrelease capsules if a hypersensitivity reaction is suspected concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine or structurally similar tricyclic antidepressants concomitantly with mao inhibitor drugs during the acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure hyperthyroidism hypersensitivity to any component of this product 4 concomitant use of monoamine oxidase mao inhibitors or within 14 days after their discontinuation 4 during acute recovery phase of myocardial infarction and in patients with arrhythmias heart block or conduction disturbances or congestive heart failure 4 hyperthyroidism 4,1
metronidazole tablets usp are indicated for the treatment of t vaginalis metronidazole tablets usp are indicated in the treatment of asymptomatic t vaginalis t vaginalis metronidazole tablets usp are indicated in the treatment of acute intestinal amebiasis amebic dysentery and amebic liver abscess in amebic liver abscess metronidazole tablets usp therapy does not obviate the need for aspiration or drainage of pus metronidazole tablets usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria indicated surgical procedures should be performed in conjunction with metronidazole tablets usp therapy in a mixed aerobic and anaerobic infection antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets usp intraabdominal infections bacteroides b fragilis b fragilis b distasonis b ovatus b thetaiotaomicron b vulgatus clostridium eubacterium peptococcus peptostreptococcus skin and skin structure infections bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium gynecologic infections including endometritis endomyometritis tuboovarian abscess and postsurgical vaginal cuff infection caused by bacteroides b fragilis clostridium peptococcus peptostreptococcus fusobacterium bacterial septicemia bacteroides b fragilis clostridium bone and joint infections bacteroides b fragilis central nervous system cns infections including meningitis and brain abscess caused by bacteroides b fragilis lower respiratory tract infections including pneumonia empyema and lung abscess caused by bacteroides b fragilis endocarditis bacteroides b fragilis to reduce the development of drugresistant bacteria and maintain the effectiveness of metronidazole tablets usp and other antibacterial drugs metronidazole tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
ziprasidone hydrochloride capsules are an atypical antipsychotic in choosing among treatments prescribers should be aware of the capacity of ziprasidone hydrochloride to prolong the qt interval and may consider the use of other drugs first 53 ziprasidone hydrochloride capsules are indicated as an oral formulation for the ziprasidone hydrochloride capsules are indicated for the treatment of schizophreniaas monotherapy for the acute treatment of bipolar manic or mixed episodes and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder when deciding among the alternative treatments available for the condition needing treatment the prescriber should consider the finding of ziprasidones greater capacity to prolong the qtqtc interval compared to several other antipsychotic drugs see warnings and precautions 53 see warnings and precautions 53 schizophrenia ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia in adults see clinical studies 141 bipolar i disorder acute mixed or manic episodes and maintenance treatment as an adjunct to lithium or valproate ziprasidone hydrochloride capsules are indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar i disorder see clinical studies 142 ziprasidone hydrochloride capsules are indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar i disorder in adults see clinical studies 142,3
when coadministering ritonavir with other protease inhibitors see the full prescribing information for that protease inhibitor including contraindication information table 2 drugs that are contraindicated with ritonavir drug class drugs within class that are contraindicated with ritonavir clinical comments alpha 1 alfuzosin hcl potential for hypotension antianginal ranolazine potential for serious andor lifethreatening reactions antiarrhythmic amiodaronedronedarone flecainide propafenone potential for cardiac arrhythmias antifungal voriconazole voriconazole is contraindicated with ritonavir doses of 400 mg every 12 hours or greaterdue to the potential for loss of antifungal response antigout colchicine a potential for serious andor lifethreatening reactions in patients with renal andor hepatic impairment antipsychotics lurasidone potential for serious andor lifethreatening reactions ergot derivatives dihydroergotamine potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system gi motility agent cisapride potential for cardiac arrhythmias herbal products st johns wort hypericum perforatum may lead to loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors hmgcoa reductase inhibitors lovastatin simvastatin potential for myopathy including rhabdomyolysis pde5 inhibitor sildenafil b r potential for sildenafilassociated adverse events including visual abnormalities hypotension prolonged erection and syncope sedativehypnotics oral midazolam c prolonged or increased sedation or respiratory depression a 7 table 5 b 7 table 5 c 7 table 5 ritonavir is contraindicated in patients with known hypersensitivity to ritonavir eg toxic epidermal necrolysis stevensjohnson syndrome or any of its ingredients 4,1
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate in patients with coronary heart disease chd or at high risk of chd simvastatin tablets can be started simultaneously with diet simvastatin tablets are an hmgcoa reductase inhibitor statin indicated as an adjunctive therapy to diet to 11 12 12 12 12 13 14 in patients at high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease simvastatin tablets are indicated to simvastatin tablets are indicated to simvastatin tablets are indicated as an adjunct to diet to reduce totalc ldlc and apo b levels in adolescent boys and girls who are at least one year postmenarche 10 to 17 years of age with hefh if after an adequate trial of diet therapy the following findings are present the minimum goal of treatment in pediatric and adolescent patients is to achieve a mean ldlc 130 mgdl the optimal age at which to initiate lipidlowering therapy to decrease the risk of symptomatic adulthood cad has not been determined simvastatin tablet has not been studied in conditions where the major abnormality is elevation of chylomicrons ie hyperlipidemia fredrickson types i and v,3
do not use in patients with a known history of qt prolongation 41 do not use in patients with recent acute myocardial infarction 41 do not use in patients with uncompensated heart failure 41 do not use in combination with other drugs that have demonstrated qt prolongation 41 do not use in patients with known hypersensitivity to ziprasidone 42 because of ziprasidones doserelated prolongation of the qt interval and the known association of fatal arrhythmias with qt prolongation by some other drugs ziprasidone is contraindicated in patients with a known history of qt prolongation including congenital long qt syndrome in patients with recent acute myocardial infarction in patients with uncompensated heart failure pharmacokineticpharmacodynamic studies between ziprasidone and other drugs that prolong the qt interval have not been performed an additive effect of ziprasidone and other drugs that prolong the qt interval cannot be excluded therefore ziprasidone should not be given with dofetilide sotalol quinidine other class ia and iii antiarrhythmics mesoridazine thioridazine chlorpromazine droperidol pimozide sparfloxacin gatifloxacin moxifloxacin halofantrine mefloquine pentamidine arsenic trioxide levomethadyl acetate dolasetron mesylate probucol or tacrolimus other drugs that have demonstrated qt prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning see warnings and precautions 53 ziprasidone is contraindicated in individuals with a known hypersensitivity to the product,1
thyroid hormone drugs are indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis this category includes cretinism myxedema and ordinary hypothyroidism in patients of any age pediatric patients adults the elderly or state including pregnancy primary hypothyroidism resulting from functional deficiency primary atrophy partial or total absence of thyroid gland or the effects of surgery radiation or drugs with or without the presence of goiter and secondary pituitary or tertiary hypothalamic hypothyroidism see warnings as pituitary thyroidstimulating hormone tsh suppressants in the treatment or prevention of various types of euthyroid goiters including thyroid nodules subacute or chronic lymphocytic thyroiditis hashimotos and multinodular goiter as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy cytomel liothyronine sodium tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef,3
thyroid hormone drugs are indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis this category includes cretinism myxedema and ordinary hypothyroidism in patients of any age pediatric patients adults the elderly or state including pregnancy primary hypothyroidism resulting from functional deficiency primary atrophy partial or total absence of thyroid gland or the effects of surgery radiation or drugs with or without the presence of goiter and secondary pituitary or tertiary hypothalamic hypothyroidism see warnings as pituitary thyroidstimulating hormone tsh suppressants in the treatment or prevention of various types of euthyroid goiters including thyroid nodules subacute or chronic lymphocytic thyroiditis hashimotos and multinodular goiter as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy cytomel liothyronine sodium tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef,3
prednisolone sodium phosphate ophthalmic solution 1 or 18 is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical radiation or thermal burns or penetration of foreign bodies prednisolone sodium phosphate ophthalmic solution 1 is recommended for moderate to severe inflammations particularly when unusually rapid control is desired in stubborn cases of anterior segment eye disease systemic adrenocortical hormone therapy may be required when deeper ocular structures are involved systemic therapy is necessary,3
valacyclovir hydrochloride tablets are a nucleoside analogue dna polymerase inhibitor indicated for adult patients 11 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hivinfected patients reduction of transmission herpes zoster pediatric patients 12 cold sores herpes labialis limitations of use 13 the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients cold sores herpes labialis genital herpes initial episode recurrent episodes suppressive therapy reduction of transmission sexually transmitted diseases treatment guidelines herpes zoster cold sores herpes labialis labeling describing use of valacyclovir hcl in pediatric patients with chickenpox ages 2 to 18 years is approved for glaxosmithklines valtrexr caplets however due to glaxosmithklines marketing exclusivity rights a description of that pediatric use is not approved for this valacyclovir hcl tablet product the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hivinfected patients with a cd4 cell count 100 cellsmm 3 patients 12 years of age with cold sores herpes labialis patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection labeling describing use of valacyclovir hcl in pediatric patients with chickenpox ages of 2 to 18 years is approved for glaxosmithklines valtrex r,3
lisinopril is an angiotensin converting enzyme ace inhibitor indicated for treatment of hypertension in adults and pediatric patients 6 years of age and older 11 adjunct therapy for heart failure 12 treatment of acute myocardial infarction 13 lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes see clinical studies 141 lisinopril tablets are indicated to reduce signs and symptoms of systolic heart failure see clinical studies 142 lisinopril tablets are indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction patients should receive as appropriate the standard recommended treatments such as thrombolytics aspirin and betablockers see clinical studies 143,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy communityacquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis clinical studies acute exacerbations of chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis note pediatric use dosage and administration streptococcus pyogenes clinical studies note s pyogenes s pyogenes staphylococcus aureus streptococcus pyogenes acute bacterial otitis media haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis streptococcus pyogenes clinical studies s pyogenes s pyogenes staphylococcus aureus streptococcus pyogenes,3
calcitonin salmon nasal solution is a calcitonin indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable fracture reduction efficacy has not been demonstrated 11 limitations of use due to the possible association between malignancy and calcitoninsalmon use the need for continued therapy should be reevaluated on a periodic basis 12 54 calcitonin salmon nasal solution has not been shown to increase bone mineral density in early postmenopausal women 12 calcitonin salmon nasal solution is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause fracture reduction efficacy has not been demonstrated calcitonin salmon nasal solution should be reserved for patients for whom alternative treatments are not suitable eg patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies due to the possible association between malignancy and calcitoninsalmon use the need for continued therapy should be reevaluated on a periodic basis see warnings and precautions 54 calcitonin salmon nasal solution has not been shown to increase spinal bone mineral density in early postmenopausal women,3
tolsura is indicated for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised blastomycosis pulmonary and extrapulmonary histoplasmosis including chronic cavitary pulmonary disease and disseminated nonmeningeal histoplasmosis and aspergillosis pulmonary and extrapulmonary in patients who are intolerant of or who are refractory to amphotericin b therapy specimens for fungal cultures and other relevant laboratory studies wet mount histopathology serology should be obtained before therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly tolsura is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised 1 blastomycosis pulmonary and extrapulmonary histoplasmosis including chronic cavitary pulmonary disease and disseminated nonmeningeal histoplasmosis and aspergillosis pulmonary and extrapulmonary in patients who are intolerant of or who are refractory to amphotericin b therapy limitations of use tolsura is not indicated for the treatment of onychomycosis 1 tolsura is not 1 limitations of use tolsura is not indicated for the treatment of onychomycosis tolsura is not interchangeable or substitutable with other itraconazole products due to the differences in the dosing between tolsura and other itraconazole products therefore follow the specific dosage recommendations for tolsura see dosage and administration 2,3
tolsura is indicated for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised blastomycosis pulmonary and extrapulmonary histoplasmosis including chronic cavitary pulmonary disease and disseminated nonmeningeal histoplasmosis and aspergillosis pulmonary and extrapulmonary in patients who are intolerant of or who are refractory to amphotericin b therapy specimens for fungal cultures and other relevant laboratory studies wet mount histopathology serology should be obtained before therapy to isolate and identify causative organisms therapy may be instituted before the results of the cultures and other laboratory studies are known however once these results become available antifungal therapy should be adjusted accordingly tolsura is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and nonimmunocompromised 1 blastomycosis pulmonary and extrapulmonary histoplasmosis including chronic cavitary pulmonary disease and disseminated nonmeningeal histoplasmosis and aspergillosis pulmonary and extrapulmonary in patients who are intolerant of or who are refractory to amphotericin b therapy limitations of use tolsura is not indicated for the treatment of onychomycosis 1 tolsura is not 1 limitations of use tolsura is not indicated for the treatment of onychomycosis tolsura is not interchangeable or substitutable with other itraconazole products due to the differences in the dosing between tolsura and other itraconazole products therefore follow the specific dosage recommendations for tolsura see dosage and administration 2,3
tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with pseudomonas aeruginosa safety and efficacy have not been demonstrated in patients under the age of 6 years patients with forced expiratory volume in 1 second fev1 25 or 75 predicted or patients colonized with burkholderia cepacia see clinical studies 14 tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with pseudomonas aeruginosa 1 safety and efficacy have not been demonstrated in patients under the age of 6 years patients with forced expiratory volume in 1 second fev1 25 or 75 predicted or patients colonized with burkholderia cepacia 1,3
to reduce the development of drugresistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below adults and adolescents communityacquired pneumonia haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis clinical studies acute exacerbations of chronic bronchitis haemophilus influenzae haemophilus parainfluenzae streptococcus pneumoniae moraxella catarrhalis acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis note pediatric use dosage and administration pharyngitistonsillitis streptococcus pyogenes clinical studies note s pyogenes s pyogenes uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes pediatric patients acute bacterial otitis media haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis pharyngitistonsillitis streptococcus pyogenes clinical studies note s pyogenes s pyogenes uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes,3
morphine sulfate injection is contraindicated in patients with significant respiratory depression see warnings acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment see precautions concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days see warnings known or suspected gastrointestinal obstruction including paralytic ileus see precautions hypersensitivity to morphine eg anaphylaxis see adverse reactions because of its stimulating effect on the spinal cord morphine should not be used in convulsive states such as those occurring in status epilepticus tetanus and strychnine poisoning morphine is also contraindicated in the following conditions heart failure secondary to chronic lung disease cardiac arrhythmias increased intracranial or cerebrospinal pressure head injuries brain tumor acute alcoholism and delirium tremens the use of bisulfites is contraindicated in asthmatics bisulfites and morphine may potentiate each other preventing use by causing severe adverse reactions use with extreme caution,1
otrexup is contraindicated in the following pregnancy otrexup can cause fetal death or teratogenic effects when administered to a pregnant woman otrexup is contraindicated in pregnant women if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus see warnings and precautions 52 81 nursing mothers because of the potential for serious adverse reactions from methotrexate in breast fed infants otrexup is contraindicated in nursing mothers see use in specific populations 83 alcoholism or liver disease patients with alcoholism alcoholic liver disease or other chronic liver disease see warnings and precautions 51 immunodeficiency syndromes patients who have overt or laboratory evidence of immunodeficiency syndromes see warnings and precautions 51 preexisting blood dyscrasias patients who have preexisting blood dyscrasias such as bone marrow hypoplasia leukopenia thrombocytopenia or significant anemia see warnings and precautions 51 hypersensitivity patients with a known hypersensitivity to methotrexate severe hypersensitivity reactions have been observed with methotrexate use see warnings and precautions 51 61 62 pregnancy 4 nursing mothers 4 alcoholism or liver disease 4 immunodeficiency syndromes 4 preexisting blood dyscrasias 4 hypersensitivity to methotrexate 4,1
carvedilol tablet is contraindicated in the following conditions bronchial asthma or related bronchospastic conditions deaths from status asthmaticus have been reported following single doses of carvedilol tablet second or thirddegree av block sick sinus syndrome severe bradycardia unless a permanent pacemaker is in place patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy such patients should first be weaned from intravenous therapy before initiating carvedilol tablet patients with severe hepatic impairment patients with a history of a serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol tablet bronchial asthma or related bronchospastic conditions 4 second or thirddegree av block 4 sick sinus syndrome 4 severe bradycardia unless permanent pace maker in place 4 patients in cardiogenic shock or decompensated heart failure requiring the use of iv inotropic therapy 4 severe hepatic impairment 24 4 history of serious hypersensitivity reaction e g stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol 4,1
rizatriptan benzoate tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51 coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 history of stroke or transient ischemic attack tia see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75 123 hypersensitivity to rizatriptan benzoate angioedema and anaphylaxis seen see adverse reactions 62 history of ischemic heart disease or coronary artery vasospasm 4 history of stroke or transient ischemic attack 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 hemiplegic or basilar migraine 4 maoa inhibitor used in the past 2 weeks 4 hypersensitivity to rizatriptan benzoate 4,1
byetta is a glucagonlike peptide1 glp1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus important limitations of use not a substitute for insulin byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis 12 concurrent use with prandial insulin has not been studied and cannot be recommended 12 has not been studied in patients with a history of pancreatitis consider other antidiabetic therapies in patients with a history of pancreatitis 12 byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus byetta is not a substitute for insulin byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis as it would not be effective in these settings the concurrent use of byetta with prandial insulin has not been studied and cannot be recommended based on postmarketing data byetta has been associated with acute pancreatitis including fatal and nonfatal hemorrhagic or necrotizing pancreatitis byetta has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using byetta other antidiabetic therapies should be considered in patients with a history of pancreatitis,3
azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below azithromycin is a macrolide antibacterial indicated for mild to moderate infections caused by designated susceptible bacteria 11 12 to reduce the development of drugresistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria 13 nongonococcal urethritis and cervicitis due to chlamydia trachomatis prophylaxis of disseminated mycobacterium avium complex mac disease azithromycin tablets taken alone or in combination with rifabutin at its approved dose is indicated for the prevention of disseminated mac disease in persons with advanced hiv infection see dosage and administration 2 treatment of disseminated mac disease azithromycin tablets taken in combination with ethambutol is indicated for the treatment of disseminated mac infections in persons with advanced hiv infection see use in specific populations 84 and clinical studies 141 to reduce the development of drugresistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs azithromycin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
venlafaxine hydrochloride extendedrelease capsules usp are a serotonin and norepinephrine reuptake inhibitor snri indicated for the treatment of venlafaxine hydrochloride extendedrelease capsules usp are indicated for the treatment of major depressive disorder mdd efficacy was established in three shortterm 4 8 and 12 weeks and two longterm maintenance trials venlafaxine hydrochloride extendedrelease capsules usp are indicated for the treatment of generalized anxiety disorder gad efficacy was established in two 8week and two 26week placebocontrolled trials venlafaxine hydrochloride extendedrelease capsules usp are indicated for the treatment of social anxiety disorder sad also known as social phobia efficacy was established in four 12week and one 26week placebocontrolled trials venlafaxine hydrochloride extendedrelease capsules usp are indicated for the treatment of panic disorder pd with or without agoraphobia efficacy was established in two 12week placebocontrolled trials,3
rizatriptan benzoate tablets are contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease see warnings and precautions 51 coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 history of stroke or transient ischemic attack tia s warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor see drug interactions 75 clinical pharmacology 123 hypersensitivity to rizatriptan benzoate tablets angioedema and anaphylaxis seen see adverse reactions 62 history of ischemic heart disease or coronary artery vasospasm 4 history of stroke or transient ischemic attack 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 4 hemiplegic or basilar migraine 4 maoa inhibitor used in the past 2 weeks 4 hypersensitivity to rizatriptan benzoate tablets 4,1
indapamide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive drugs indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard see precautions diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemia edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy indapamide is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see precautions,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated anorectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies,3
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated anorectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies,3
1 males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenita or acquired hypogonadotropic hypogonadism congenital or acquired safety and efficacy of methyltestosterone in men with agerelated hypogonadism also referred to as lateonset hypogonadism have not been established androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty these patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder puberty is expected to occur spontaneously at a relatively late date brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support the potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration an xray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers see warnings 2 females androgens may be used secondarily in women with advancing inoperable metastatic skeletal mammary cancer who are 1 to 5 years postmenopausal primary goals of therapy in these women include ablation of the ovaries other methods of counteracting estrogen activity are adrenalectomy hypophysectomy andor antiestrogen therapy this treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormoneresponsive tumor judgment concerning androgen therapy should be made by an oncologist with expertise in this field,3
1 males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone primary hypogonadism congenita or acquired hypogonadotropic hypogonadism congenital or acquired safety and efficacy of methyltestosterone in men with agerelated hypogonadism also referred to as lateonset hypogonadism have not been established androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty these patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder puberty is expected to occur spontaneously at a relatively late date brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support the potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration an xray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers see warnings 2 females androgens may be used secondarily in women with advancing inoperable metastatic skeletal mammary cancer who are 1 to 5 years postmenopausal primary goals of therapy in these women include ablation of the ovaries other methods of counteracting estrogen activity are adrenalectomy hypophysectomy andor antiestrogen therapy this treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormoneresponsive tumor judgment concerning androgen therapy should be made by an oncologist with expertise in this field,3
alendronate sodium tablets usp is a bisphosphonate indicated for 11 12 13 14 15 limitations of use 16 alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 141 alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis see clinical studies 142 alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 143 alendronate sodium tablets usp are indicated for the treatment of glucocorticoidinduced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 75 mg or greater of prednisone and who have low bone mineral density see clinical studies 144 alendronate sodium tablets usp are indicated for the treatment of pagets disease of bone in men and women treatment is indicated in patients with pagets disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 145 the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis patients at lowrisk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture reevaluated periodically,3
zolmitriptan is contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia other significant underlying cardiovascular disease or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease pvd see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht1 agonist ergotaminecontaining medication or ergottype medication such as dihydroergotamine or methysergide see drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent use of a maoa inhibitor that is within 2 weeks see drug interactions 72 clinical pharmacology 123 known hypersensitivity to zolmitriptan angioedema and anaphylaxis seen see adverse reactions 62 history of coronary artery disease cad or coronary vasospasm 4 symptomatic wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht1 agonist eg another triptan or an ergotaminecontaining medication 4 monamine oxidase maoa inhibitor used in past 2 weeks 4 known hypersensitivity to zolmitriptan 4,1
levothyroxine sodium is used for the following indications hypothyroidism as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis specific indications include primary thyroidal secondary pituitary and tertiary hypothalamic hypothyroidism and subclinical hypothyroidism primary hypothyroidism may result from functional deficiency primary atrophy partial or total congenital absence of the thyroid gland or from the effects of surgery radiation or drugs with or without the presence of goiter pituitary tsh suppression in the treatment or prevention of various types of euthyroid goiters see warnings and precautions including thyroid nodules see warnings and precautions subacute or chronic lymphocytic thyroiditis hashimotos thyroiditis multinodular goiter see warnings and precautions and as an adjunct to surgery and radioiodine therapy in the management of thyrotropindependent welldifferentiated thyroid cancer contraindications levothyroxine is contraindicated in patients with untreated subclinical suppressed serum tsh level with normal t3 and t4 levels or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids see precautions levothyroxine sodium tablets usp is contraindicated in patients with hypersensitivity to any of the inactive ingredients in levothyroxine sodium tablets usp see description inactive ingredients,1
naratriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke s warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 71 72 hypersensitivity to naratriptan tablets angioedema and anaphylaxis seen see warnings and precautions 59 severe renal or hepatic impairment see use in specific populations 86 87 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 hypersensitivity to naratriptan tablets angioedema and anaphylaxis seen 4 severe renal or hepatic impairment 4,1
naratriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke s warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 see drug interactions 71 72 hypersensitivity to naratriptan tablets angioedema and anaphylaxis seen see warnings and precautions 59 severe renal or hepatic impairment see use in specific populations 86 87 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 hypersensitivity to naratriptan tablets angioedema and anaphylaxis seen 4 severe renal or hepatic impairment 4,1
lipiodol is contraindicated in patients with hypersensitivity to lipiodol hyperthyroidism traumatic injuries recent hemorrhage or bleeding hysterosalpingography lipiodol hysterosalpingography is contraindicated in pregnancy acute pelvic inflammatory disease marked cervical erosion endocervicitis and intrauterine bleeding in the immediate preor postmenstrual phase or within 30 days of curettage or conization lymphography lipiodol lymphography is contraindicated in patients with a right to left cardiac shunt advanced pulmonary disease tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction previous surgery interrupting the lymphatic system radiation therapy to the examined area selective hepatic intraarterial use patients with hcc lipiodol use is contraindicated in areas of the liver where the bile ducts are dilated unless external biliary drainage was performed before injection hypersensitivity to lipiodol hyperthyroidism traumatic injuries recent hemorrhage or bleeding lipiodol hysterosalpingography is contraindicated in lipiodol lymphography is contraindicated in lipiodol selective hepatic intraarterial injection is contraindicated in,1
prometrium capsules should not be used in women with any of the following conditions prometrium capsules should not be used in patients with known hypersensitivity to its ingredients prometrium capsules contain peanut oil and should never be used by patients allergic to peanuts undiagnosed abnormal genital bleeding known suspected or history of cancer of the breast active deep vein thrombosis pulmonary embolism or history of these conditions active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction liver dysfunction or disease known or suspected pregnancy there is no indication for prometrium capsules in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,1
prometrium capsules should not be used in women with any of the following conditions prometrium capsules should not be used in patients with known hypersensitivity to its ingredients prometrium capsules contain peanut oil and should never be used by patients allergic to peanuts undiagnosed abnormal genital bleeding known suspected or history of cancer of the breast active deep vein thrombosis pulmonary embolism or history of these conditions active or recent eg within the past year arterial thromboembolic disease eg stroke myocardial infarction liver dysfunction or disease known or suspected pregnancy there is no indication for prometrium capsules in pregnancy there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy see precautions,1
sertraline hydrochloride is contraindicated in patients taking or within 14 days of stopping maois including the maois linezolid and intravenous methylene blue because of an increased risk of serotonin syndrome see warnings and precautions 52 drug interactions 71 taking pimozide see drug interactions 71 with known hypersensitivity to sertraline eg anaphylaxis angioedema see adverse reactions 61 62 in addition to the contraindications for all sertraline hydrochloride formulations listed above sertraline hydrochloride oral solution is contraindicated in patients taking disulfiram sertraline hydrochloride oral solution contains alcohol and concomitant use of sertraline hydrochloride and disulfiram may result in a disulfiramalcohol reaction concomitant use of monoamine oxidase inhibitors maois or use within 14 days of stopping maois 4 71 concomitant use of pimozide 4 71 known hypersensitivity to sertraline or excipients 4 54 sertraline hydrochloride oral solution only concomitant use of disulfiram 4,1
docetaxel injection is a microtubule inhibitor indicated for breast cancer bc 11 nonsmall cell lung cancer nsclc 12 hormone refractory prostate cancer hrpc 13 gastric adenocarcinoma gc 14 squamous cell carcinoma of the head and neck cancer scchn 15 docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancer docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable locally advanced or metastatic nonsmall cell lung cancer who have not previously received chemotherapy for this condition docetaxel injection in combination with prednisone is indicated for the treatment of patients with androgen independent hormone refractory metastatic prostate cancer docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction who have not received prior chemotherapy for advanced disease docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck scchn,3
docetaxel injection is a microtubule inhibitor indicated for breast cancer bc 11 nonsmall cell lung cancer nsclc 12 hormone refractory prostate cancer hrpc 13 gastric adenocarcinoma gc 14 squamous cell carcinoma of the head and neck cancer scchn 15 docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable nodepositive breast cancer docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior platinumbased chemotherapy docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable locally advanced or metastatic nonsmall cell lung cancer who have not previously received chemotherapy for this condition docetaxel injection in combination with prednisone is indicated for the treatment of patients with androgen independent hormone refractory metastatic prostate cancer docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction who have not received prior chemotherapy for advanced disease docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck scchn,3
alprazolam orally disintegrating tablets are contraindicated in patients with acute narrow angle glaucoma alprazolam orally disintegrating tablets can exacerbate narrow angle closure alprazolam orally disintegrating tablets may be used in patients with open angle glaucoma who are receiving appropriate therapy alprazolam orally disintegrating tablets are contraindicated in patients treated with potent cyp3a4 inhibitors eg ketoconazole and itraconazole because these medications significantly impair the oxidative metabolism mediated by cytochrome p450 3a cyp3a and can increase alprazolam exposures see clinical pharmacology 123 warnings and precautions 58 and drug interactions 74 acute narrow angle glaucoma alprazolam can exacerbate narrow angle closure 4 concomitant use with potent cyp3a inhibitors eg ketoconazole and itraconazole can increase the serum concentration of alprazolam 4,1
invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv infection the twice daily administration of invirase in combination with ritonavir is supported by safety data from the maxcmin 1 study see table 6 table 1 in a randomized doubleblind clinical study nv14256 in zidovudineexperienced hivinfected patients invirase in combination with zalcitabine was shown to be superior to either invirase or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to aidsdefining events or death furthermore in a randomized study actg229nv14255 patients with advanced hiv infection with history of prolonged zidovudine treatment and who were given invirase 600 mg three times daily zidovudine zalcitabine experienced greater increases in cd4 cell counts as compared to those who received invirase zidovudine or zalcitabine zidovudine it should be noted that hiv treatment regimens that were used in these initial clinical studies of invirase are no longer considered standard of care saquinavir gel capsule 1000 mg twice daily coadministered with ritonavir 100 mg twice daily was studied in a heterogeneous population of 148 hivinfected patients maxcmin 1 study at baseline 42 were treatment naive and 106 were treatment experienced of which 52 had an hiv rna level 400 copiesml at baseline results showed that 91148 61 subjects achieved andor sustained an hiv rna level 400 copiesml at the completion of 48 weeks,3
invirase is contraindicated in patients with clinically significant hypersensitivity eg anaphylactic reaction stevensjohnson syndrome to saquinavir saquinavir mesylate or any of its ingredients including ritonavir inviraseritonavir should not be administered concurrently with rifampin terfenadine cisapride astemizole pimozide triazolam midazolam or ergot derivatives inhibition of cyp3a4 by saquinavir and ritonavir could result in elevated plasma concentrations of these drugs potentially causing serious or lifethreatening reactions such as cardiac arrhythmias or prolonged sedation see precautions drug interactions inviraseritonavir should not be given together with rifampin due to the risk of severe hepatocellular toxicity if the three drugs are given together see precautions drug interactions invirase when administered with ritonavir is contraindicated in patients with severe hepatic impairment inviraseritonavir should not be administered concurrently with drugs listed in table 4 table 4 drugs that are contraindicated with inviraseritonavir drug class drugs within class that are contraindicated with invirase clinical comment antiarrhythmics amiodarone bepridil flecainide propafenone quinidine potential for serious andor threatening reactions ergot derivatives dihydroergotamine ergonovine ergotamine methylergonovine potential for serious and life threatening reactions such as ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues antimycobacterial agents rifampin rifampin should not be administered in patients taking ritonavirboosted invirase part of an art regimen due to the risk of severe hepatocellular toxicity gi motility agent cisapride potential for serious andor life threatening reactions such as cardiac arrhythmias neuroleptics pimozide potential for serious andor life threatening reactions such as cardiac arrhythmias sedativehypnotics triazolam orally administered midazolam potential for serious andor life threatening reactions such as prolonged or increased sedation or respiratory depression hmgcoa reductase inhibitors lovastatin simvastatin potential for myopathy including rhabdomyolysis,1
enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,3
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,3
control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis and serum sickness bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus and severe erythema multiforme stevensjohnson syndrome primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice may be used in conjunction with synthetic mineralocorticoid analogs where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer and nonsuppurative thyroiditis to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamondblackfan anemia idiopathic thrombocytopenic purpura in adults pure red cell aplasia and selected cases of secondary thrombocytopenia diagnostic testing of adrenocortical hyperfunction trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for the palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor craniotomy or head injury sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus,2
prednisolone sodium phosphate ophthalmic solution 1 or 18 is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical radiation or thermal burns or penetration of foreign bodies prednisolone sodium phosphate ophthalmic solution 1 is recommended for moderate to severe inflammations particularly when unusually rapid control is desired in stubborn cases of anterior segment eye disease systemic adrenocortical hormone therapy may be required when deeper ocular structures are involved systemic therapy is necessary,3
prednisolone sodium phosphate ophthalmic solution 1 or 18 is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation corneal injury from chemical radiation or thermal burns or penetration of foreign bodies prednisolone sodium phosphate ophthalmic solution 1 is recommended for moderate to severe inflammations particularly when unusually rapid control is desired in stubborn cases of anterior segment eye disease systemic adrenocortical hormone therapy may be required when deeper ocular structures are involved systemic therapy is necessary,3
diazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic in acute alcohol withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor impending or acute delirium tremens and hallucinosis as an adjunct prior to endoscopic procedures if apprehension anxiety or acute stress reactions are present and to diminish the patients recall of the procedures see warnings diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology such as inflammation of the muscles or joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis stiffman syndrome and tetanus diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures diazepam is a useful premedication the im route is preferred for relief of anxiety and tension in patients who are to undergo surgical procedures intravenously prior to cardioversion for the relief of anxiety and tension and to diminish the patients recall of the procedure,2
therapy with lipidaltering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate in patients with chd or multiple risk factors for chd atorvastatin calcium tablets can be started simultaneously with diet atorvastatin calcium tablets are an inhibitor of hmgcoa reductase statin indicated as an adjunct therapy to diet to 11 11 11 12 12 12 12 in adult patients without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as age smoking hypertension low hdlc or a family history of early coronary heart disease atorvastatin calcium tablets are indicated to 1 2 3 in patients with type 2 diabetes and without clinically evident coronary heart disease but with multiple risk factors for coronary heart disease such as retinopathy albuminuria smoking or hypertension atorvastatin calcium tablets are indicated to 1 2 in patients with clinically evident coronary heart disease atorvastatin calcium tablets are indicated to 1 2 3 4 5 atorvastatin calcium tablets are indicated 1 fredrickson 2 fredrickson 3 fredrickson 4 5 1 2 1 2 atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons fredrickson,3
minocin r rocky mountain spotted fever typhus fever and the typhus group q fever rickettsialpox and tick fevers caused by rickettsiae mycoplasma pneumoniae chlamydia trachomatis chlamydophila psittaci chlamydia trachomatis chlamydia trachomatis ureaplasma urealyticum chlamydia trachomatis borrelia recurrentis haemophilus ducreyi yersinia pestis francisella tularensis vibrio cholerae campylobacter fetus brucella bartonella bacilliformis klebsiella granulomatis minocycline is indicated for the treatment of infections caused by the following gramnegative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug escherichia coli enterobacter aerogenes shigella acinetobacter haemophilus influenzae klebsiella minocin r upper respiratory tract infections caused by streptococcus pneumoniae staphylococcus aureus when penicillin is contraindicated minocycline is an alternative drug in the treatment of the following infections uncomplicated urethritis in men due to neisseria gonorrhoeae neisseria gonorrhoeae treponema pallidum pallidum treponema pallidum pertenue listeria monocytogenes bacillus anthracis fusobacterium fusiforme actinomyces israelii clostridium in acute intestinal amebiasis in severe acne oral minocycline is indicated in the treatment of asymptomatic carriers of neisseria meningitidis oral minocycline is not indicated for the treatment of meningococcal infection although no controlled clinical efficacy studies have been conducted limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by mycobacterium marinum to reduce the development of drugresistant bacteria and maintain the effectiveness of minocin ar ar,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,3
hydrocortisone tablets are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in during an exacerbation or as maintenance therapy in selected cases of pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as symptomatic sarcoidosis idiopathic thrombocytopenic purpura in adults for palliative management of to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy,3
methylphenidate hydrochloride extendedrelease capsules are contraindicated in marked anxiety tension and agitation since the drug may aggravate these symptoms methylphenidate hydrochloride extendedrelease capsules are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product methylphenidate hydrochloride extendedrelease capsules are contraindicated in patients with glaucoma methylphenidate hydrochloride extendedrelease capsules are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions methylphenidate hydrochloride extendedrelease capsules are contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor hypertensive crises may result,1
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated anorectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies,3
mekinist is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 11 21 mekinist is indicated in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 11 21 the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 12 21 the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 13 21 the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 14 21 limitations of use 15 mekinist r see dosage and administration 21 22 mekinist is indicated in combination with dabrafenib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 mekinist is indicated in combination with dabrafenib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 mekinist is indicated in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 mekinist is not indicated for treatment of patients with melanoma who have progressed on prior brafinhibitor therapy see clinical studies 145,3
mekinist is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 11 21 mekinist is indicated in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 11 21 the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 12 21 the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 13 21 the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 14 21 limitations of use 15 mekinist r see dosage and administration 21 22 mekinist is indicated in combination with dabrafenib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 mekinist is indicated in combination with dabrafenib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 mekinist is indicated in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 mekinist is not indicated for treatment of patients with melanoma who have progressed on prior brafinhibitor therapy see clinical studies 145,3
mekinist is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 11 21 mekinist is indicated in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fdaapproved test 11 21 the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection 12 21 the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test 13 21 the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options 14 21 limitations of use 15 mekinist r see dosage and administration 21 22 mekinist is indicated in combination with dabrafenib for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fdaapproved test and involvement of lymph nodes following complete resection see dosage and administration 21 23 mekinist is indicated in combination with dabrafenib for the treatment of patients with metastatic nonsmall cell lung cancer nsclc with braf v600e mutation as detected by an fdaapproved test see dosage and administration 21 24 mekinist is indicated in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer atc with braf v600e mutation and with no satisfactory locoregional treatment options see dosage and administration 21 25 mekinist is not indicated for treatment of patients with melanoma who have progressed on prior brafinhibitor therapy see clinical studies 145,3
adasuve is contraindicated in patients with the following current diagnosis or history of asthma copd or other lung disease associated with bronchospasm see warnings and precautions 51 acute respiratory symptoms or signs eg wheezing see warnings and precautions 51 current use of medications to treat airways disease such as asthma or copd see warnings and precautions 51 history of bronchospasm following adasuve treatment see warnings and precautions 51 known hypersensitivity to loxapine or amoxapine serious skin reactions have occurred with oral loxapine and amoxapine current diagnosis or history of asthma chronic obstructive pulmonary disease copd or other lung disease associated with bronchospasm 4 acute respiratory signssymptoms eg wheezing 4 current use of medications to treat airways disease such as asthma or copd 4 history of bronchospasm following adasuve treatment 4 known hypersensitivity to loxapine or amoxapine 4,1
adasuve is contraindicated in patients with the following current diagnosis or history of asthma copd or other lung disease associated with bronchospasm see warnings and precautions 51 acute respiratory symptoms or signs eg wheezing see warnings and precautions 51 current use of medications to treat airways disease such as asthma or copd see warnings and precautions 51 history of bronchospasm following adasuve treatment see warnings and precautions 51 known hypersensitivity to loxapine or amoxapine serious skin reactions have occurred with oral loxapine and amoxapine current diagnosis or history of asthma chronic obstructive pulmonary disease copd or other lung disease associated with bronchospasm 4 acute respiratory signssymptoms eg wheezing 4 current use of medications to treat airways disease such as asthma or copd 4 history of bronchospasm following adasuve treatment 4 known hypersensitivity to loxapine or amoxapine 4,1
when oral therapy is not feasible the intramuscular use control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndrome congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis acquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopenia trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy for palliative management of leukemias and lymphomas acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus the intraarticular or soft tissue administration the intralesional administration betamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,3
pamidronate disodium injection is a bisphosphonate indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases 11 patients with moderate to severe pagets disease of bone 12 osteolytic bone metastases of breast cancer or osteolytic lesions of multiple myeloma in conjunction with standard antineoplastic therapy 13 limitations of use safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions have not been established 14 pamidronate disodium injection is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases pamidronate disodium injection is indicated for the treatment of patients with moderate to severe pagets disease of bone pamidronate disodium injection is indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma see clinical studies 143 the safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions has not been established,3
pamidronate disodium injection is a bisphosphonate indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases 11 patients with moderate to severe pagets disease of bone 12 osteolytic bone metastases of breast cancer or osteolytic lesions of multiple myeloma in conjunction with standard antineoplastic therapy 13 limitations of use safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions have not been established 14 pamidronate disodium injection is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases pamidronate disodium injection is indicated for the treatment of patients with moderate to severe pagets disease of bone pamidronate disodium injection is indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma see clinical studies 143 the safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumorrelated conditions has not been established,3
soltamox is contraindicated in patients with known hypersensitivity eg angioedema serious skin reactions to tamoxifen or any other soltamox ingredient see adverse reactions 62 soltamox is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis see warnings and precautions 52 drug interactions 72 known hypersensitivity to tamoxifen or any other soltamox ingredient 4 in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis 4,1
soltamox is contraindicated in patients with known hypersensitivity eg angioedema serious skin reactions to tamoxifen or any other soltamox ingredient see adverse reactions 62 soltamox is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis see warnings and precautions 52 drug interactions 72 known hypersensitivity to tamoxifen or any other soltamox ingredient 4 in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in highrisk patients or risk reduction of invasive breast cancer after treatment of dcis 4,1
soltamox is an estrogen agonistantagonist indicated for treatment of adult patients with estrogen receptorpositive metastatic breast cancer 11 for adjuvant treatment of adult patients with early stage estrogen receptor positive breast cancer 12 to reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ dcis 13 to reduce the incidence of breast cancer in adult women at high risk 14 soltamox is indicated for the treatment of adult patients with estrogen receptorpositive metastatic breast cancer soltamox is indicated for the adjuvant treatment of adult patients with early stage estrogen receptorpositive breast cancer to reduce the occurrence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer in adult women with dcis following breast surgery and radiation soltamox is indicated to reduce the risk of invasive breast cancer see boxed warning clinical studies 143 soltamox is indicated to reduce the incidence of breast cancer in adult women at high risk for breast cancer see boxed warning clinical studies 144,3
zolmitriptan is contraindicated in patients with ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia other significant underlying cardiovascular disease or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease pvdsee warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 drug interactions 71 73 concurrent administration of a monoamine oxidase maoa inhibitor or recent use of a maoa inhibitor that is within 2 weeks see drug interactions 72 clinical pharmacology 123 known hypersensitivity to zolmitriptan tablets or zolmitriptan orally disintegrating tabletsangioedema and anaphylaxis seen see adverse reactions 62 history of coronary artery disease cad or coronary vasospasm 4 symptomatic wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht1 agonist eg another triptan or an ergotaminecontaining medication 4 monamine oxidase maoa inhibitor used in past 2 weeks 4 known hypersensitivity to zolmitriptan tablets or zolmitriptan orally disintegrating tablets 4,1
esomeprazole magnesium delayedrelease capsules are a proton pump inhibitor indicated for the following treatment of gastroesophageal reflux disease gerd 11 risk reduction of nsaidassociated gastric ulcer 12 h pylori 13 pathological hypersecretory conditions including zollingerellison syndrome 14 healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated for the shortterm treatment 4 to 8 weeks in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis for those patients who have not healed after 4 to 8 weeks of treatment an additional 4 to 8 week course of esomeprazole magnesium delayedrelease capsules may be considered maintenance of healing of erosive esophagitis esomeprazole magnesium delayedrelease capsules are indicated to maintain symptom resolution and healing of erosive esophagitis controlled studies do not extend beyond 6 months symptomatic gastroesophageal reflux disease esomeprazole magnesium delayedrelease capsules are indicated for shortterm treatment 4 to 8 weeks of heartburn and other symptoms associated with gerd in adults and children 1 year or older esomeprazole magnesium delayedrelease capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers patients are considered to be at risk due to their age triple therapy esomeprazole magnesium plus amoxicillin and clarithromycin esomeprazole magnesium in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with h pylori h pylori h pylori see dosage and administration 2 clinical studies 14 in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 124 the prescribing information for clarithromycin esomeprazole magnesium delayedrelease capsules are indicated for the longterm treatment of pathological hypersecretory conditions including zollingerellison syndrome,3
nucynta er is contraindicated in patients with significant respiratory depression acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment known or suspected gastrointestinal obstruction including paralytic ileus hypersensitivity eg anaphylaxis angioedema to tapentadol or to any other ingredients of the product see adverse reactions 62 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days see drug interactions 7 significant respiratory depression 4 acute or severe bronchial asthma 4 known or suspected paralytic ileus 4 hypersensitivity to tapentadol or to any other ingredients of the product 4 concurrent use of monoamine oxidase inhibitors maois or use of maois within the last 14 days 4,1
cephalexin capsules usp is a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria respiratory tract infection 11 otitis media 12 skin and skin structure infections 13 bone infections 14 genitourinary tract infections 15 to reduce the development of drugresistant bacteria and maintain the effectiveness of cephalexin capsules usp and other antibacterial drugs cephalexin capsules usp should be used only to treat infections that are proven or strongly suspected to be caused by bacteria 16 cephalexin capsules usp are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae streptococcus pyogenes cephalexin capsules usp are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae staphylococcus aureus streptococcus pyogenes moraxella catarrhalis cephalexin capsules usp are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following grampositive bacteria staphylococcus aureus streptococcus pyogenes cephalexin capsules usp are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus proteus mirabilis cephalexin capsules usp are indicated for the treatment of genitourinary tract infections including acute prostatitis caused by susceptible isolates of escherichia coli proteus mirabilis klebsiella pneumoniae to reduce the development of drugresistant bacteria and maintain the effectiveness of cephalexin capsules usp and other antibacterial drugs cephalexin capsules usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information is available this information should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections it is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate ointment usp 01 helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin gentamicin sulfate ointment usp 01 has been used successfully in infants over one year of age as well as in adults and children,3
primary skin infections impetigo contagiosa superficial folliculitis ecthyma furunculosis sycosis barbae and pyoderma gangrenosum secondary skin infections infectious eczematoid dermatitis pustular acne pustular psoriasis infected seborrheic dermatitis infected contact dermatitis including poison ivy infected excoriations and bacterial superinfections of fungal or viral infections note gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections it is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria good results have been obtained in the treatment of infected stasis and other skin ulcers infected superficial burns paronychia infected insect bites and stings infected lacerations and abrasions and wounds from minor surgery patients sensitive to neomycin can be treated with gentamicin sulfate although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic gentamicin sulfate ointment usp 01 helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin gentamicin sulfate ointment usp 01 has been used successfully in infants over one year of age as well as in adults and children,3
rosuvastatin is contraindicated in the following conditions patients with a known hypersensitivity to any component of this product hypersensitivity reactions including rash pruritus urticaria and angioedema have been reported with rosuvastatin see adverse reactions 61 patients with active liver disease which may include unexplained persistent elevations of hepatic transaminase levels see warnings and precautions 52 pregnancy see use in specific populations 81 83 lactation limited data indicate that rosuvastatin calcium is present in human milk because statins have the potential for serious adverse reactions in nursing infants women who require rosuvastatin calcium tablets treatment should not breastfeed their infants see use in specific populations 82 known hypersensitivity to product components 4 active liver disease which may include unexplained persistent elevations in hepatic transaminase levels 4 pregnancy 4 81 83 lactation 4 82,1
dantrolene sodium for injection is indicated along with appropriate supportive measures for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages dantrolene sodium for injection should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized ie tachycardia tachypnea central venous desaturation hypercarbia metabolic acidosis skeletal muscle rigidity increased utilization of anesthesia circuit carbon dioxide absorber cyanosis and mottling of the skin and in many cases fever dantrolene sodium for injection is also indicated preoperatively and sometimes postoperatively to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible,3
dexmethylphenidate hydrochloride tablets are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms dexmethylphenidate hydrochloride tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product hypersensitivity reactions including angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate see adverse reactions dexmethylphenidate hydrochloride tablets are contraindicated in patients with glaucoma dexmethylphenidate hydrochloride tablets are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions dexmethylphenidate hydrochloride tablets are contraindicated during treatment with monoamine oxidase inhibitors and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor hypertensive crises may result,1
cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration acute otitis media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated ano rectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime therapy may be instituted while awaiting the results of these studies once these results become available antimicrobial therapy should be adjusted accordingly to reduce the development of drugresistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets usp and other antibacterial drugs cefpodoxime proxetil tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
contraindications amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it it should not be given concomitantly with monoamine oxidase inhibitors hyperpyretic crises severe convulsions and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride a minimum of 14 days should be allowed to elapse after the former is discontinued amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia this drug is not recommended for use during the acute recovery phase following myocardial infarction,1
esmolol hydrochloride is contraindicated in patients with severe sinus bradycardia may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52 heart block greater than first degree second or thirddegree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52 sick sinus syndrome may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest see warnings and precautions 52 decompensated heart failure may worsen heart failure cardiogenic shock may precipitate further cardiovascular collapse and cause cardiac arrest iv administration of cardiodepressant calciumchannel antagonists egverapamil and esmolol hydrochloride in close proximity ie while cardiac effects from the other are still present fatal cardiac arrests have occurred in patients receiving esmolol hydrochloride and intravenous verapamil pulmonary hypertension may precipitate cardiorespiratory compromise hypersensitivity reactions including anaphylaxis to esmolol or any of the inactive ingredients of the product crosssensitivity between beta blockers is possible severe sinus bradycardia 4 heart block greater than first degree 4 sick sinus syndrome 4 decompensated heart failure 4 cardiogenic shock 4 coadministration of iv cardiodepressant calciumchannel antagonists eg verapamil in close proximity to esmolol hydrochloride 4 7 pulmonary hypertension 4 known hypersensitivity to esmolol 4,1
xarelto is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 11 for the treatment of deep vein thrombosis dvt 12 for the treatment of pulmonary embolism pe 13 for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months 14 for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery 15 in combination with aspirin to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad 16 xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation there are limited data on the relative effectiveness of xarelto and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is wellcontrolled see clinical studies 141 xarelto is indicated for the treatment of deep vein thrombosis dvt xarelto is indicated for the treatment of pulmonary embolism pe xarelto is indicated for the reduction in the risk of recurrence of dvt andor pe in patients at continued risk for recurrent dvt andor pe after completion of initial treatment lasting at least 6 months xarelto is indicated for the prophylaxis of dvt which may lead to pe in patients undergoing knee or hip replacement surgery xarelto in combination with aspirin is indicated to reduce the risk of major cardiovascular events cardiovascular cv death myocardial infarction mi and stroke in patients with chronic coronary artery disease cad or peripheral artery disease pad,3
cefpodoxime proxetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration pharyngitis andor tonsillitis streptococcus pyogenes note communityacquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated anorectal infections in women due to neisseria gonorrhoeae including penicillinaseproducing strains note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime therapy may be instituted while awaiting the results of these studies once these results become available antimicrobial therapy should be adjusted accordingly to reduce the development of drugresistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy,3
rebetol combination therapy is contraindicated in pregnancy rebetol may cause fetal harm when administered to a pregnant woman rebetol is contraindicated in women who are pregnant or planning to become pregnant if a patient becomes pregnant while taking rebetol the patient should be apprised of the potential hazard to the fetus see warnings and precautions 51 use in specific populations 81 83 men whose female partners are pregnant see use in specific populations 83 patients with known hypersensitivity reactions such as stevensjohnson syndrome toxic epidermal necrolysis and erythema multiforme to ribavirin or any component of the product patients with autoimmune hepatitis patients with hemoglobinopathies eg thalassemia major sicklecell anemia patients with creatinine clearance less than 50 mlmin see clinical pharmacology 123 when coadministered with didanosine because exposure to the active metabolite of didanosine dideoxyadenosine 5triphosphate is increased fatal hepatic failure as well as peripheral neuropathy pancreatitis and symptomatic hyperlactatemialactic acidosis has been reported in patients receiving didanosine in combination with ribavirin see drug interactions 71 pregnancy and men whose female partners are pregnant 4 51 81 83 known hypersensitivity reactions such as stevensjohnson syndrome toxic epidermal necrolysis and erythema multiforme to ribavirin or any component of the product 4 autoimmune hepatitis 4 hemoglobinopathies 4 creatinine clearance less than 50 mlmin 4 123 coadministration with didanosine 4 71,1
cymbalta r major depressive disorder mdd 11 141 generalized anxiety disorder gad 12 142 diabetic peripheral neuropathic pain dpnp 13 fibromyalgia fm 14 chronic musculoskeletal pain 15 cymbalta is indicated for the treatment of major depressive disorder mdd the efficacy of cymbalta was established in four shortterm and one maintenance trial in adults see clinical studies 141 a major depressive episode dsmiv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least 5 of the following 9 symptoms depressed mood loss of interest in usual activities significant change in weight andor appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration or a suicide attempt or suicidal ideation cymbalta is indicated for the treatment of generalized anxiety disorder gad the efficacy of cymbalta was established in three shortterm trials and one maintenance trial in adults see clinical studies 142 generalized anxiety disorder is defined by the dsmiv as excessive anxiety and worry present more days than not for at least 6 months the excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning it must be associated with at least 3 of the following 6 symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension andor sleep disturbance cymbalta is indicated for the management of neuropathic pain dpnp associated with diabetic peripheral neuropathy see clinical studies 143 cymbalta is indicated for the management of fibromyalgia fm see clinical studies 144 see clinical studies 145,3
